<SEC-DOCUMENT>0001493152-22-006353.txt : 20220309
<SEC-HEADER>0001493152-22-006353.hdr.sgml : 20220309
<ACCEPTANCE-DATETIME>20220309080102
ACCESSION NUMBER:		0001493152-22-006353
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220309
DATE AS OF CHANGE:		20220309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		22723954

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:lpcn="http://lipocine.com/20211231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_lpcn_lipocine.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001535955 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey">0001535955</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2021-12-31" id="xdx2ixbrl0058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetNoncurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0077" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationReserveCurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationReserveNoncurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2020-12-31" id="xdx2ixbrl0126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0131" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2020-12-31" id="xdx2ixbrl0180" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:LitigationSettlementExpenseOne" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0634" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateBondsandNotesMember" id="xdx2ixbrl0636" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateBondsandNotesMember" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0644" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl0645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0656" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0662" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0664" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562" id="xdx2ixbrl0731" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember" id="xdx2ixbrl0737" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578" id="xdx2ixbrl0751" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578" id="xdx2ixbrl0752" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2020-12-31" id="xdx2ixbrl0755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2020-12-31" id="xdx2ixbrl0756" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" contextRef="AsOf2021-12-31" id="xdx2ixbrl0835" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0861" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0872" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0877" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0878" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" id="xdx2ixbrl0937" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" id="xdx2ixbrl0947" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2020-12-31" id="xdx2ixbrl0950" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2020-12-31" id="xdx2ixbrl0953" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0961" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0962" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2020-12-31" id="xdx2ixbrl1001" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2019-12-31" id="xdx2ixbrl1003" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2021-12-31" id="xdx2ixbrl1005" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2020-12-31" id="xdx2ixbrl1007" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_StockIncentivePlan2014Member" format="ixt-sec:duryear" id="xdx2ixbrl1094" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1114" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1116" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl1178" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl1180" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl1182" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl1184" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1222" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1224" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1230" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1232" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1234" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1236" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1238" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1240" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lpcn-20211231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MajorCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lpcn:MajorCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OneMajorCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lpcn:OneMajorCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ComputerEquipmentAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SalesBasedRoyaltiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lpcn:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MinimumGuaranteedRoyaltiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lpcn:MinimumGuaranteedRoyaltiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lpcn:MaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CorporateBondsandNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsandNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateBondsandNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsandNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateBondsandNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsandNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateBondsandNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsandNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember78957890">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember78957953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember78958203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember78958203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember78958203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember78958203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-282012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:AbbottProductsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-28</xbrli:startDate>
        <xbrli:endDate>2012-03-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:AbbottProductsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-132021-10-14_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-13</xbrli:startDate>
        <xbrli:endDate>2021-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-312025-01-01_us-gaap_SubsequentEventMember_srt_ScenarioForecastMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-31</xbrli:startDate>
        <xbrli:endDate>2025-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-312026-01-01_us-gaap_SubsequentEventMember_srt_ScenarioForecastMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-31</xbrli:startDate>
        <xbrli:endDate>2026-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-132021-10-14_srt_MaximumMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-13</xbrli:startDate>
        <xbrli:endDate>2021-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-132021-10-14_custom_TLANDOXRMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:TLANDOXRMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-13</xbrli:startDate>
        <xbrli:endDate>2021-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-042018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-04</xbrli:startDate>
        <xbrli:endDate>2018-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-09_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-30_custom_PayrollProtectionProgramLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:PayrollProtectionProgramLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ComputerEquipmentAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ComputerEquipmentAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LabAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:LabAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LabAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:LabAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_UsFederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lpcn:UsFederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-262021-01-28_custom_January2021OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:January2021OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-26</xbrli:startDate>
        <xbrli:endDate>2021-01-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-262020-02-27_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-26</xbrli:startDate>
        <xbrli:endDate>2020-02-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-262020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassAUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-26</xbrli:startDate>
        <xbrli:endDate>2020-02-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassAUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-27_us-gaap_CommonStockMember_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassAUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassBUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassBUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_us-gaap_AdditionalPaidInCapitalMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-03-052017-03-06_custom_SalesAgreementMember_custom_CantorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:CantorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-03-05</xbrli:startDate>
        <xbrli:endDate>2017-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AtMarketOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AtMarketOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SaleAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SaleAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SaleAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SaleAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SaleAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SaleAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-11-122015-11-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-11-12</xbrli:startDate>
        <xbrli:endDate>2015-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-04-30_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-04-30_custom_TwoThousandElevenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CommonStockWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lpcn:CommonStockWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CommonStockWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lpcn:CommonStockWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-02_custom_GlobalAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:GlobalAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-02_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:GlobalAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-122022-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:GlobalAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-12</xbrli:startDate>
        <xbrli:endDate>2022-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-122023-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:GlobalAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-12</xbrli:startDate>
        <xbrli:endDate>2023-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_SpriasoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:SpriasoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:SpriasoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:SpriasoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20210101__20211231_zy4GHY3QOo3a"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--DocumentAnnualReport_c20210101__20211231_zDhWLEbrHY2e"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
<span style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal
year ended <span id="xdx_906_edei--DocumentPeriodEndDate_c20210101__20211231_zTFAgcGb95ue"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_908_edei--CurrentFiscalYearEndDate_c20210101__20211231_zfMpqwSEXjm2"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20210101__20211231_z1393n3XYsDb"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></span></ix:nonNumeric></span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentTransitionReport_c20210101__20211231_zxnvD57e5wvl"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span id="xdx_903_edei--EntityFileNumber_c20210101__20211231_zMNNV0VmnLa9"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityFileNumber">001-36357</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20210101__20211231_z8H4hBCRfA38"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName">LIPOCINE
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20210101__20211231_z8prMBcZjzFa"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20210101__20211231_zs0HpUi0gFFl"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">99-0370688</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or Other Jurisdiction of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation
    or Organization)</b></span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20210101__20211231_zpxFOdgJnSth"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1">675
                                            Arapeen Drive</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20210101__20211231_zENRJTVVkncb"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2">Suite 202</ix:nonNumeric></span>,</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20210101__20211231_zPvE43Iz6Qo9"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown">Salt
    Lake City</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20210101__20211231_zGftZ2SBa0Mc"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span></b></span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20210101__20211231_zv9u4qykVi0c"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode">84108</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of Principal Executive Offices)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--CityAreaCode_c20210101__20211231_zfNr3UGlg5u4"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:CityAreaCode">801</ix:nonNumeric></span>-<span id="xdx_904_edei--LocalPhoneNumber_c20210101__20211231_zdXd7DyG6bf5"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber">994-7383</ix:nonNumeric></span>
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Each Exchange on Which Registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--Security12bTitle_c20210101__20211231_znRhQa2DIXJb"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--TradingSymbol_c20210101__20211231_zmfBgDuzBrN5"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:TradingSymbol">LPCN</ix:nonNumeric></span></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--SecurityExchangeName_c20210101__20211231_z4JTHuM8Cdgi"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    NASDAQ Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act: None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#9744; <span><span id="xdx_908_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231_zUiqTseR1Ic2"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act.
Yes&#160;&#9744; <span id="xdx_90A_edei--EntityVoluntaryFilers_c20210101__20211231_zn4laOVxpKn1"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports) and (2) has
been subject to such filing requirements for the past 90 days. <span id="xdx_909_edei--EntityCurrentReportingStatus_c20210101__20211231_zE9kDrWPxwDb"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>:&#160;&#9746; No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;220.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_908_edei--EntityInteractiveDataCurrent_c20210101__20211231_ziOajagyrf0c"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746; No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20210101__20211231_zP1RWIAWkGE6"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntitySmallBusiness_c20210101__20211231_zYAxhbr74EKa"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20210101__20211231_zNkcQpFGytqc"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to <span style="text-decoration: underline">Section 13(a) of the Exchange Act</span>.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.&#160;<span id="xdx_909_edei--IcfrAuditorAttestationFlag_c20210101__20211231_z3hDjiHOxaa8"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#160;&#9744; <span id="xdx_901_edei--EntityShellCompany_c20210101__20211231_z70POUP3mlq1"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Shares </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the common stock held by non-affiliates of the registrant was $<span id="xdx_903_edei--EntityPublicFloat_iI_pn5n6_c20210630_z5jRfWw2mOFf" title="Entity Public Float"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">120.5</ix:nonFraction></span> million as of June 30, 2021. For purposes
of calculating the aggregate market value of shares of our common stock held by non-affiliates as set forth on the cover page of this
Annual Report on Form 10-K, we have assumed that all outstanding shares are held by non-affiliates, except for shares held by each of
our executive officers, directors and 10% or greater stockholders. However, this assumption should not be deemed to constitute an admission
that all executive officers, directors and 10% or greater stockholders are, in fact, affiliates of our company, or that there are not
other persons who may be deemed to be affiliates of our company. Further information concerning shareholdings of our officers, directors
and principal stockholders is included or incorporated by reference in Part III, Item 12 of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 7, 2022, the registrant had <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_pid_c20220307_zrxLZhNrO1o3"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-03-07" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--DocumentsIncorporatedByReferenceTextBlock_c20210101__20211231_zRoDo8ezeOzi" title="Documents Incorporated By Reference"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions
of the registrant&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part
III of this Form 10-K</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.5in; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#am_012">PART I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_001">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_002">Risk
    Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_003">Unresolved
    Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_004">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_005">Legal
    Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_006">Mine
    Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#am_013">PART II</a> </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_007">Market
    for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_008">Reserved</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_009">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_010">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#am_011">Financial
    Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_001">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_002">Controls
    and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_003">Other
    Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Item 9C.</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#abcdef_001">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">104</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"><a href="#Ha_004"><span style="font-size: 10pt"><b>PART
    III</b></span> </a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_005">Directors,
    Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">105</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_006">Executive
    Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">105</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_007">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">105</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_008">Certain
    Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">105</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_009">Principal
    Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">105</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#Ha_010">PART IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_011">Exhibits
    and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">105</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Ha_012">10-K
    Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">108</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">THIS
ANNUAL REPORT ON FORM 10-K, IN PARTICULAR &#8220;ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATION,&#8221; AND &#8220;ITEM 1. BUSINESS,&#8221; CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE
SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, that involve risks and uncertainties.
Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that
does not directly relate to any historical or current fact. Forward-looking statements may refer to such matters as products, product
benefits, pre-clinical and clinical development timelines, clinical and regulatory expectations and plans, REGULATORY DEVELOPMENTS AND
REQUIREMENTS, THE RECEIPT OF REGULATORY APPROVALS, THE EXPECTATIONS FOR AND RESULTS OF CLINICAL TRIALS, PATIENT ACCEPTANCE OF LIPOCINE&#8217;S
PRODUCTS, MANUFACTURING AND COMMERCIALIZATION OF LIPOCINE&#8217;S PRODUCTS, anticipated financial performance, future revenues or earnings,
business prospects, projected ventures, new products and services, anticipated market performance, future expectations for liquidity
and capital resources needs and similar matters. Such words as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;expect&#8221;, &#8220;continue&#8221;,
&#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;intend&#8221;, and &#8220;potential&#8221; and similar terms and expressions are
intended to identify forward looking statements. Forward-looking statements are not guarantees of future performance and our actual results
may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include,
but are not limited to, those discussed in Part I, Item 1A &#8220;Risk Factors&#8221; of this Form 10-K. Except as required by applicable
law, we assume no obligation to revise or update any forward-looking statements for any reason</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-transform: uppercase">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from the forward-looking
statements contained in this Annual Report on Form 10-K. Such risks, uncertainties and other important factors include, among others,
the risks, uncertainties and factors set forth in &#8220;Risk Factors,&#8221; and the following risks, uncertainties and factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    and our licensee&#8217;s plans to develop and commercialize any future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ongoing and planned clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of and our ability to obtain regulatory approvals or fast track or orphan drug designation, breakthrough designation or
    IND clearance for any future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of the ongoing COVID-19 pandemic on our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance and clinical utility of any future product candidates, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    competition in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    intellectual property position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of key members of management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to successfully execute our strategy; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to maintain effective internal controls.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be other factors that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed
in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;
You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of these risks and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
caution you that the risks, uncertainties and other factors referred to above may not contain all of the risks, uncertainties and other
factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that
we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in
the way expected. All forward-looking statements in this Annual Report on Form 10-K apply only as of the date made and are expressly
qualified in their entirety by the cautionary statements included in this Annual Report on Form 10-K. We undertake no obligation to publicly
update or revise any forward-looking statements to reflect subsequent events or circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0; text-align: justify; text-indent: 29.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><b><span style="font-family: Times New Roman, Times, Serif">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_012"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0%"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_001"></span>ITEM
                                            1.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BUSINESS</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lipocine
Inc. (&#8220;Lipocine&#8221; or the &#8220;Company&#8221;) was originally incorporated on June 19, 1997, under the laws of the State
of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/118% Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on applying our oral drug delivery technology for the development of pharmaceutical
products focusing on neuroendocrine and metabolic disorders. Our proprietary delivery technologies are designed to improve
patient compliance and safety through orally available treatment options. Our primary development programs are based on oral delivery
solutions for poorly bioavailable drugs. We have a portfolio of differentiated innovative product candidates that target high unmet
needs for neurological and psychiatric CNS disorders, liver diseases, and hormone supplementation for men and women.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a license agreement for the development and commercialization our product candidate, TLANDO&#174;, an oral testosterone replacement
therapy (&#8220;TRT&#8221;) comprised of testosterone undecanoate (&#8220;TU&#8221;). TLANDO is a registered trademark assigned to Antares.
On October 14, 2021, we entered into a license agreement (the &#8220;Antares License Agreement&#8221;) with Antares Pharma, Inc. (&#8220;Antares&#8221;
or our &#8220;Licensee&#8221;), pursuant to which we granted to Antares an exclusive, royalty-bearing, sublicensable right and license
to develop and commercialize, upon final approval of TLANDO from the United States Food and Drug Administration (&#8220;FDA&#8221;),
the TLANDO product for TRT in the U.S. Any FDA required post-marketing studies will also be the responsibility of our licensee,
Antares. Prior to entering into the License Agreement, on December 8, 2020, we received tentative approval from the FDA
regarding our new drug application (&#8220;NDA&#8221;) filed in February 2020 for TLANDO as a TRT in adult males for conditions associated
with a deficiency of endogenous testosterone, also known as hypogonadism. In granting tentative approval, the FDA concluded that TLANDO
has met all required quality, safety and efficacy standards necessary for approval. However, TLANDO has not received final approval and
is not eligible for final approval to market in the U.S. until the expiration of the exclusivity period previously granted to Clarus
Therapeutics, Inc. (&#8220;Clarus&#8221;) with respect to <span style="text-transform: uppercase">Jatenzo</span>&#174;, which expires
on March 27, 2022. The FDA has affirmed to Antares the acceptance of the resubmission of the NDA for TLANDO filed on January 28, 2022.
The FDA has designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March
28, 2022 under the Prescription Drug User Fee Act (PDUFA).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
pipeline candidates include: LPCN 1148 comprising a novel prodrug of testosterone, testosterone laurate (&#8220;TL&#8221;), for the management
of decompensated cirrhosis; LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic
steatohepatitis (&#8220;NASH&#8221;) which has completed phase 2 testing; LPCN 1111 (TLANDO&#174; XR), a next generation oral TRT product
comprised of testosterone tridecanoate (&#8220;TT&#8221;) with the potential for once daily dosing which has completed Phase 2 testing;
LPCN 1107, potentially the first oral hydroxy progesterone caproate (&#8220;HPC&#8221;) product indicated for the prevention of recurrent
preterm birth (&#8220;PTB&#8221;), which has completed a dose finding clinical study in pregnant women and has been granted orphan
drug designation by the FDA; and neuroactive steroids (&#8220;NAS&#8221;) including LPCN 1154 for postpartum depression (PPD) and
LPCN 2101 for epilepsy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following chart summarizes the status of our product candidate development programs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="chart_1.jpg" alt="" style="height: 334px; width: 660px" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of COVID-19 Pandemic</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ongoing COVID-19 pandemic has disrupted and may continue to disrupt our business and delay our preclinical and clinical programs and
timelines. The extent to which the COVID-19 pandemic may impact our future operating results and financial condition is uncertain. We
initiated our LPCN 1148 Phase 2 trial for the management of cirrhosis in 2021. The COVID-19 surge observed in the fourth quarter of 2021
and the first quarter of 2022 has impacted enrollment in this study. We do not yet know the full extent, if any, of any potential delays or commercial
challenges, which could prevent or delay Antares from commercially launching TLANDO. For more information regarding risks related to
the ongoing COVID-19 pandemic, please see the risk factor entitled &#8220;The ongoing outbreak of coronavirus around the world could
adversely impact our business and operating results,&#8221; in Part I. Item 1A of this Annual Report on Form 10-K. To the
extent the ongoing COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening
many of the other risks set forth under &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to become a leading biopharmaceutical company focused on applying our proprietary drug delivery technology for the development
of pharmaceutical products focusing on neuroendocrine and metabolic disorders. The key components of our strategy are to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Build
a diversified multi-asset pipeline of novel therapies.</b> We intend to employ a value-driven strategy based on our proprietary technology
platform to identify and develop product candidates for neuroendocrine and metabolic disorders including Central Nervous System
(CNS) disorders and end stage diseases such as decompensated cirrhosis. We intend to focus on product candidates that we believe are
differentiated, have attractive profiles, and address a clear unmet medical need that we can advance quickly and efficiently into late-stage
development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advance
LPCN 1148, a unique prodrug of androgen receptor agonist to manage end stage (decompensated) liver cirrhosis disease. </b>We believe
LPCN 1148, a novel prodrug of testosterone, could address a significant unmet medical need in patients with decompensated liver
cirrhosis accompanied with muscle disorder such as secondary sarcopenia. Sarcopenia in male cirrhotic patients is known to be independently
associated with poor outcomes including quality of life, increased decompensation events such as hepatic encephalopathy, increased hospital
admissions, and increased mortality rate. We believe LPCN 1148 may be eligible for an orphan drug designation. Enrollment in a multi-center
placebo-controlled phase 2 trial is currently ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Support
our licensee in commercialization of our licensed oral TRT option</b>. We believe the TRT market needs a differentiated, convenient
oral option. We have exclusively licensed rights to TLANDO to Antares for commercialization of TLANDO in the US. We plan to support our
licensee&#8217;s efforts to effectively enable the availability of TLANDO to patients in a timely manner, in addition to receiving
milestone and royalty payments associated with TLANDO commercialization as agreed to in the Antares License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Develop
partnership(s) to continue the advancement of pipeline assets</b>. We continuously strive to prioritize our resources in seeking co-development
partnerships of our pipeline assets. We currently plan to explore partnering of LPCN 1144, our candidate for treatment of non-cirrhotic
NASH, LPCN 1107, our candidate for prevention of pre-term birth, and LPCN 1111, a once-a-day therapy candidate for TRT.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LPCN
1148: Oral Product Candidate for the Management of Decompensated Cirrhosis </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating LPCN 1148 comprising testosterone laurate (TL) for the management of decompensated cirrhosis. </span>We
believe LPCN 1148 targets unmet needs for cirrhosis subjects including improvement in the quality of life of patients while on the
liver transplant waiting list, prevention or reduction in the occurrence of new decompensation events, and improvement
in post liver transplant survival, including outcomes and costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently conducting a Phase 2 POC study (NCT04874350) in male cirrhotic subjects to evaluate the therapeutic potential of LPCN 1148
for the management of sarcopenia. The ongoing Phase 2 POC study is a prospective, multi-center, randomized, placebo-controlled
study in male sarcopenic cirrhotic patients. Subjects will be randomized 1:1 to one of two arms. The treatment arm is an oral dose of
LPCN 1148, and the second arm is a matching placebo. The primary endpoint is change in skeletal muscle index at week 24 with key secondary
endpoints including change in liver frailty index, rates of breakthrough hepatic encephalopathy, and number of waitlist events,
including all-cause mortality. Total treatment is expected to be 52 weeks. We currently expect enrollment in the Phase 2 study to be
complete by the end of the second or third quarter of 2022 and top-line 24-week results by the end of 2022 or during the first
quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
outcomes of interest from the Phase 2 study include clinical outcomes such as overall survival and new decompensation events (including hepatic
encephalopathy and/or ascites occurrences),  rates of survival to transplant, rates of hospitalizations, infections, etc.,
muscle changes such as muscle mass, body composition, myosteatosis (muscle fat), functional capacity changes such as liver frailty
index (LFI), patient reported outcomes (PROs), and biochemical markers including hematocrit for anemia status, albumin,
creatinine/kidney function, etc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disease
Overview &#8211; Cirrhosis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are over</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2 million cases of cirrhosis worldwide,
 with over 500,000 people living with decompensated cirrhosis in the U.S. and nonalcoholic fatty liver disease is the most
rapidly increasing indication for liver transplant. 62% of those on the liver transplant (LT) waitlist are male. The economic burden
(approximately $812,500/transplant) is high and continues to increase. Each year about half of the approximately 17,000
people in U.S. on the LT waitlist undergo transplant, while nearly 3000 patients either die or are removed from the list because
they were &#8220;too sick to transplant.&#8221; </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liver
cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands. Cirrhotic patients typically
have a years-long silent, asymptomatic phase (compensated cirrhosis) until decreasing liver function and increasing portal pressure move
the patient into the symptomatic phase (decompensated cirrhosis). Transition to decompensated cirrhosis is marked by clinical events
including ascites, encephalopathy, jaundice, and/or variceal hemorrhage. Decompensated subjects survive on average less than 2 years.
Common causes of liver cirrhosis include alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), chronic hepatitis B and
C, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and cryptogenic.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
complications in cirrhotic patients may include: compromised liver function, portal hypertension, varices in GI tract with internal bleeding,
edema, ascites, hepatic encephalopathy, compromised immunity with post-transplant acute rejection risk, high sodium levels, increased
bilirubin, low albumin level, insulin resistance with impaired peripheral uptake of glucose, depression, accelerated muscle disorder
in the form of sarcopenia, myosteotosis, and frailty with compromised energetics, bone diseases (e.g., osteoporosis), high alkaline phosphatase
(ALP), cachexia, malnutrition, weight loss (&gt;5%), symptoms of hypogonadism such as abnormal hair distribution, anemia, sexual dysfunction,
testicular atrophy, muscle wasting, fatigue, osteoporosis, gynecomastia, inflammation with elevated cytokines, and infection risk leading
to hospital admissions and possibly death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.75pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hepatic
encephalopathy (&#8220;HE&#8221;),</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> a significant
decompensation event in patient with cirrhosis, is a brain dysfunction caused by liver insufficiency and/or portal systemic shunting.
Because the damaged liver cannot function normally (as in cirrhosis), neurotoxins such as ammonia are inadequately removed
from systemic circulation and travel to the brain, where they affect neurotransmission. This can cause episodes of HE, which may
present as alterations in consciousness, cognition, and behavior that range from minimal to severe. Overt HE occurs in 30% to 40% of
patients with cirrhosis at some point during the clinical course of their disease. As the burden of chronic liver disease and cirrhosis
is increasing, the frequency of HE is also increasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Muscle
Disorders and Cirrhosis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Muscle
disorders secondary to cirrhosis could be manifested in the form of several inter-related characteristics such as sarcopenia, myosteotosis,
and frailty impacting muscle mass, strength, quality, and function. Chronic inflammation and oxidative stress have also been reported
to accelerate muscle wasting. Muscle also plays a significant compensatory role in detoxifying ammonia, a neurotoxin and a myotoxin
implicated in precipitation of HE in cirrhosis patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcopenia
and associated frailty affect up to 70% of cirrhotic men and are a leading cause of patients being removed from the LT wait list. Due
to the lack of available organs and aging demographics of those on the waitlist, patients that do receive a transplant are &#8220;increasingly
being described as frail&#8221;. The presence of sarcopenia or frailty is associated with increased risk of hospitalization and hepatic
decompensation, a two-fold increase in waitlist mortality, poor post-transplant outcomes, and reportedly is equivalent to adding 9-10
points to the Model for End-Stage Liver Disease (MELD) score.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcopenia
is typically associated with body composition changes with decreased muscle mass and/or low skeletal muscle index. Change in one
or more of appendicular lean mass, total lean mass, fat mass, high VAT (visceral adipose tissue), waist circumference, weight,
and/or BMI are notable features. Myosteotosis (fat infiltration in muscles) is indicative of poor muscle quality. Frailty is a state
of low energetics accompanied with low physical performance/mobility probably because of poor muscle strength/function and is assessed
via various measures such as decreased gait speed, weak hand grip; slow rising from a chair, balance, isometric knee extension peak torque
or a composite measure such as liver frailty index (LFI).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reportedly,
as shown in the figure below, muscle disorder such as sarcopenia and myosteotosis in cirrhosis could be a clinically meaningful predictor
of survival and mortality with lower survival in cirrhotic patients with accompanying muscle disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="form10-k_004.jpg" alt="" style="height: 379px; width: 500px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Montano-Loza,
J Cachexia Sarcopenia Muscle. 2016 May; 7(2): 126&#8211;135</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> Muscle Disorders and Mortality</i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>
in Liver Cirrhosis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcopenia
develops in the majority of male cirrhosis patients. The main mechanisms associated with sarcopenia and decompensated cirrhosis
include a catabolic state, progressive immobility, imbalance between muscle breakdown and formation, and hormonal changes. Patients are
typically diagnosed with decompensated cirrhosis upon development of cirrhotic symptoms (e.g., jaundice, HE), and the diagnosis is
confirmed via various liver function/imaging tests (e.g., MELD score, liver biopsy, CT scan). A variety of clinical evaluations for
muscle mass, strength, and function are typically used to diagnose sarcopenia. Sarcopenia in cirrhosis also correlates with decompensation
events, particularly HE (sarcopenia is about 2-fold more prevalent in overt HE patients than those without overt HE). Notably,
low testosterone in males is associated with sarcopenia, severity of cirrhosis, and mortality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reportedly,
as shown in figure below, sarcopenia is a predictor for increased mortality in cirrhosis (about 2-fold higher compared to no sarcopenia).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_005.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tantai
et al. J. Hepatol. 2022, 76, 588&#8211;599</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reportedly,
as shown in figure below, pre transplant sarcopenia in liver cirrhosis often produces poor post-transplant outcomes with higher mortality
rates. Longer post-transplant hospitalization and rehabilitation can be demanding on the individual, both physically and financially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_006.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Englesbe
et al. J Am Coll Surg. 2010 Aug;211(2):271-8</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Myosteatosis
</i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>in cirrhosis </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myosteatosis,
fat infiltration in muscles,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> has been found
in many cirrhotic patients undergoing liver transplant evaluation, and studies have associated it with more complications and poor survival.
Myosteatosis is characteristically associated with liver steatosis in NAFLD, resulting from ectopic fat accumulation in skeletal muscle.
Myosteatosis may affect many individuals who do not meet the anthropometric criteria for sarcopenia or obesity. The accumulation of excess
fat in extramyocellular compartments is mostly pathologic. It can be defined as intramuscular (between muscle fibers) or intermuscular
(between muscle fascicles) and is associated with lower muscle function and strength, muscle atrophy, and physical disabilities.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Frailty
and cirrhosis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frailty
is a state of low energetics accompanied with low physical performance/mobility, usually as a result of poor muscle strength/function
and its presence is assessed via various measures such as decreased gait speed, weak hand grip, slow rising from a chair,
poor balance, low isometric knee extension peak torque or a composite measure such as liver frailty index (LFI).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reportedly,
as shown in figure below, frailty predicts LT waitlist mortality among outpatients with cirrhosis regardless of the MELD score.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_007.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lai
et al. Am J Transplant. 2014 Aug;14(8):1870-9</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
presence of frailty is associated with increased waitlist death/delisting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
it has also been reported, as shown in figure below, that there is a higher incidence of waitlist mortality as the frailty
worsened.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><img src="form10-k_008.jpg" alt="" style="height: 344px; width: 530px" /></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lai
et al. J Hepatol. 2020 Sep;73(3):575-581.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trajectory
of liver frailty and mortality</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no FDA approved drugs to treat secondary sarcopenia in cirrhosis. Lipocine is the only clinical-stage company pursuing decompensation
in sarcopenic cirrhotic patients, and no regulatory precedent currently exists for the approval of decompensation or sarcopenia-targeted
therapies. We believe LPCN 1148 has the potential to aid the management of decompensation events in male sarcopenic cirrhotic
patients through the following possible mechanisms of action: myo-augmentation (impact muscle mass and/or quality and/or
function) via myostatin inhibition, myosteatosis reduction, anti-catabolic effect, changes in body composition (increase lean
mass and/or reduce fat mass) and slowing muscle autophagy; inducing hepato-effective actions with improved key liver injury markers;
increase protein synthesis; improve anemia, induce immunomodulation with improvement of immuno-dysregulation, and to lower
infection rates; anti-inflammatory/antioxidant effects by lowering undesirable cytokines such as IL-1, IL-6, and TNF-&#945;;
and to improve mitochondrial function.<sup>(1)</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
  <td style="text-align: justify">Ref: <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leise.
  Mayo Clin Proc. 2014.; Hudson. Eur J Gastroenterol. 2019.; Bajaj. Clin Gastroenterol Hepatol. 2017.; Bohra. World J Gastroenterol.
  2020.; Carey, Hepatology, 2019; Sinclair, Ailment Pharmacol Ther, 2016; Lai, Am J Transplant, 2014; Montano-Loza, Clin Transl
  Gastroenterol, 2015; Kahn, Clin Transp, 2018; Montano-Loza, J Cach, Sarco, and Musc, 2016.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LPCN
1144: An Oral Prodrug of Bioidentical Testosterone Product Candidate for the Treatment of NASH</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating LPCN 1144, an oral prodrug of bioidentical testosterone comprised of TU, for the treatment of non-cirrhotic
NASH.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disease
Overview &#8211; NASH</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASH
is a more advanced state of non-alcoholic fatty liver disease (&#8220;NAFLD&#8221;) and can progress to a cirrhotic liver or liver failure,
require liver transplant, and can result in hepatocellular carcinoma/ liver cancer, and death. Progression of NASH to end stage
liver disease will soon surpass all other causes of liver failure requiring liver transplantation. Importantly, beyond these critical
conditions, NASH and NAFLD patients additionally suffer heightened cardiovascular risk and, in fact, die more frequently from cardiovascular
events than from liver disease. NAFLD/NASH is becoming more common due to its strong correlation with obesity and metabolic syndrome,
including components of metabolic syndrome such as diabetes, cardiovascular disease and high blood pressure. Twenty to thirty percent
of the U.S. population is estimated to suffer from NAFLD and fifteen to twenty percent of this group progresses to NASH, which
is a substantially large population that lacks an effective therapy. NASH is a silent killer that affects millions in the U.S. Diagnoses
have been on the rise and are expected to increase dramatically in the next decade. Approximately 50% of NASH patients are in adult males.
In men, especially with comorbidities associated with NAFLD/NASH, testosterone deficiency has been associated with an increased visceral
adipose tissue and insulin resistance, which could be factors contributing to NAFLD/NASH. There is currently no approved therapy for
the treatment of NASH although there are several drug candidates currently under development with many clinical failures to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical pathophysiologic mechanisms underlying the development and progression of NASH include reduced ability to handle lipids, increased
insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. NASH patients have an excessive accumulation
of fat in the liver resulting primarily from a caloric intake above and beyond energy needs. A healthy liver contains less than 5% fat,
but a liver in someone with NASH can contain more than 20% fat. This abnormal liver fat contributes to the progression to NASH, a liver
necro-inflammatory state that can lead to scarring, also known as fibrosis, and, for some, can progress to cirrhosis and liver failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Markers
of Liver Cell Death</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alanine
aminotransferase (&#8220;ALT&#8221;) is an enzyme that is produced in liver cells and is naturally found in the blood of healthy individuals.
In liver disease, liver cells are damaged and, as a consequence, ALT is released into the blood, increasing ALT levels above the normal
range. Physicians routinely test blood levels of ALT to monitor the health of a patient&#8217;s liver. ALT level is a clinically important
biochemical marker of the severity of liver inflammation and ongoing liver disease. Elevated levels of ALT represent general markers
of liver cell death and inflammation without regard to any specific mechanism. Aspartate aminotransferase (&#8220;AST&#8221;) is a second
enzyme found in the blood that is produced in the liver and routinely measured by physicians along with ALT. As with ALT, AST is often
elevated in liver disease and, like ALT, is considered an overall marker of liver inflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Diagnosis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
people with NASH are asymptomatic and their disease is often discovered incidentally following a liver imaging procedure, such as an
ultrasound, prescribed for other reasons or as part of an investigation for elevated liver enzymes. Once suspected clinically, a liver
biopsy is required to definitively diagnose NASH, which necessitates the joint presence of steatosis, ballooning and lobular inflammation.
Once pathologically confirmed, the severity of NAFLD and NASH is determined using the histologically validated NAFLD activity score,
which grades disease activity on a scale of 0 to 8. The NAFLD activity score is the sum of the individual scores for steatosis
(0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) but does not include a score for fibrosis. Fibrosis staging
(F0-F4) relies on the NASH CRN classification (F0 = no fibrosis; F1 = perisinusoidal or portal/periportal fibrosis (not
both); F2 = both perisinusoidal and portal/periportal fibrosis; F3 = bridging fibrosis; F4 = cirrhosis).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Histological
diagnosis remains the gold standard for assessment of NASH and fibrosis. However, given that liver biopsy is associated with risks of
pain, bleeding and other morbidity, as well as significant cost, the procedure is not practical for general patient screening. Several
non-invasive tools such as clinical risk scores and imaging techniques are increasingly used to assess potential NASH patients.
Clinical risk scores such as the NAFLD fibrosis score, Fibrosis-4 index, the Enhanced Liver Fibrosis score and vibration-controlled transient
elastography (&#8220;VCTE&#8221;), have been validated and are increasingly used. These tools have an excellent negative predictive value
and an acceptable positive predictive value for detection of advanced (&#8805; F3) fibrosis and are increasingly used in clinical settings.
 Extensive efforts are also under way to develop non-invasive means to identify patients with NAS &#8805;
4 or fibrosis &#8805; F2 without a liver biopsy. In draft guidance, the FDA encouraged sponsors to identify biochemical
or noninvasive imaging biomarkers that, once characterized and agreed by the FDA, could replace liver biopsies for patient selection
and efficacy assessment in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the validation and subsequent adoption of these new tools will result in an increase in the diagnosis and treatment rates
for NASH in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
Status</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have recently completed the <i>LiFT</i> Phase 2 clinical study in biopsy-confirmed non-cirrhotic NASH subjects. The <i>LiFT</i>
clinical study was a prospective, multi-center, randomized, double-blind, placebo-controlled multiple-arm study in biopsy-confirmed hypogonadal
and eugonadal male NASH subjects with grade F1-F3 fibrosis and a target NAFLD Activity Score &#8805; 4 with a 36-week
treatment period. The <i>LiFT </i>clinical study enrolled 56 biopsy confirmed NASH male subjects. Subjects were randomized 1:1:1 to one
of three arms (Treatment A is a twice daily oral dose of 142 mg testosterone equivalent, Treatment B is a twice daily oral dose of 142
mg testosterone equivalent formulated with 217 mg of d-alpha tocopherol equivalent, and the third arm is twice daily matching placebo).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoint of the <i>LiFT</i> clinical study was change in hepatic fat fraction via MRI-PDFF and exploratory liver fat/marker end
points post 12 weeks of treatment. Additionally, key secondary endpoints post 36 weeks of treatment included assessment of histological
change for NASH resolution and/or fibrosis improvement (biopsy) as well as liver fat data (MRI-PDFF). The <i>LiFT</i> clinical
study was not powered to assess statistical significance of any of the secondary endpoints. Other important endpoints included the following:
change in liver injury markers, anthropomorphic measurements, lipids, insulin resistance and inflammatory/fibrosis markers; as well as
patient reported outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
subjects have access to LPCN 1144 through an open label extension (&#8220;OLE&#8221;) study. The extension study will enable
the collection of additional data on LPCN 1144 for up to a total of 72 weeks of therapy, as well as data for 36 weeks of therapy for
those subjects on placebo in the LiFT study. The OLE is currently on-going and has enrolled 25 subjects. We expect topline results
from the OLE study mid-2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatments
with LPCN 1144 post 12 weeks of treatment resulted in robust liver fat reduction, assessed by MRI-PDFF, and showed improvement of liver
injury markers with no observed tolerability issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liver
biopsies were performed at baseline (&#8220;BL&#8221;) and after 36 weeks of treatment (&#8220;EOS&#8221;). Prespecified biopsy analyses
included NASH Clinical Research Network (&#8220;CRN&#8221;) scoring as well as a continuous paired (&#8220;Paired Technique&#8221;) and
digital technique (&#8220;Digital Technique-Fibronest&#8221;). All biopsy analyses were performed on the same slides and the reads for
the three techniques were done independently. Analysis sets included the NASH Resolution Set (all subjects that have BL and EOS biopsy
with NASH at BL [NAS &#8805;4 with lobular inflammation score &#8805; 1 and hepatocyte ballooning score &#8805;1 at BL] (n=37)), the Biopsy Set
(all subjects with baseline and EOS biopsies (n=44)), and the Safety Set (all randomized subjects (n=56)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
LPCN 1144 treatment arms met with statistical significance the pre-specified accelerated approval regulatory endpoint of NASH resolution
with no worsening of fibrosis based on NASH CRN scoring. Additionally, both treatment arms showed substantial improvement of the observed
NASH activity in steatosis, inflammation, and ballooning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
results from the <i>LiFT</i> clinical study are presented in the following tables and figures:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="form10-k_009.jpg" alt="" style="height: 342px; width: 670px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="form10-k_010.jpg" alt="" style="height: 337px; width: 670px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
both treatment arms, substantial reductions in markers of liver injury compared to placebo were observed post four weeks of treatment
and were sustained through EOS. Using all available Safety Set data, ALT decreased up to a mean of 23.4 U/L at EOS from all group mean
baseline of 51.5 U/L and AST decreased up to a mean of 13.3 U/L at EOS from all group mean baseline of 31.9 U/L.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positive
effects in appendicular lean mass and whole-body fat mass, an indicator overall tissue quality, based on dual-energy X-ray absorptiometry
scans were noted in both LPCN 1144 treatment arms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finding
on liver injury marker and positive effects on body composition can be seen in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_011.jpg" alt="" style="height: 272px; width: 580px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the 36 weeks of treatment, LPCN 1144 was well tolerated with an overall safety profile comparable to placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2021, the FDA granted Fast Track Designation
to LPCN 1144 as a treatment for non-cirrhotic NASH. The Fast Track program is designed to accelerate the development and expedite the
review of products, such as LPCN 1144, which are intended to treat serious diseases and for which there is an unmet medical need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had a written only response from FDA for a LPCN 1144 Type C meeting with the FDA in January 2022 to discuss the development path
forward with LPCN 1144. The FDA acknowledged that the NDA submission of LPCN 1144 would be via 505(b)2 regulatory pathway
and agreed that no additional non-clinical studies are needed to support an NDA submission. The FDA recommended to request
an end of phase 2 (EOP2) meeting. The FDA acknowledged that in the LiFT study subjects achieved improvements in
key components associated with NASH histopathology after 36-weeks of treatment with LPCN 1144 in adult males and agreed that the proposed
multicomponent primary surrogate endpoint is acceptable for seeking approval under the accelerated approval pathway. The FDA also
recommended either conducting a separate dose&#8211;ranging study prior to phase 3 or evaluating multiple doses in phase 3. The FDA
agreed that the proposed primary multicomponent surrogate endpoint, NASH resolution with no worsening of fibrosis, is acceptable
for seeking approval under the accelerated approval pathway and the FDA recommended a phase 3 trial with a study
duration of 72 weeks. The FDA has requested that Lipocine submit an updated Phase 3 protocol for FDA
feedback on the study design and our next step will be to request an end-of-phase 2 (EOP2) meeting to discuss the phase 3 and confirmatory
trial designs, including the plan for reading liver histopathology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">We are exploring the possibility
of licensing LPCN 1144 to a third party, although no licensing agreement has been entered into by the Company. No assurance can be given
that any license agreement will be completed, or, if an agreement is completed, that such an agreement would be on acceptable terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>TLANDO: An Oral Product Candidate for Testosterone
Replacement Therapy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">As previously described, under
the Antares License Agreement, we granted to Antares an exclusive, royalty-bearing, sublicensable right and license to develop and commercialize,
upon final approval of TLANDO from the FDA, our TLANDO product for TRT in the U.S. Prior to entering into the Antares License Agreement
on December 8, 2020, we received tentative approval from the FDA regarding our NDA filed in February 2020 for TLANDO as a TRT in adult
males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. In granting tentative approval,
the FDA concluded that TLANDO has met all required quality, safety and efficacy standards necessary for approval. However, TLANDO has
not received final approval and is not eligible for final approval to market in the U.S. until the expiration of the exclusivity period
previously granted to Clarus with respect to <span style="text-transform: uppercase">Jatenzo</span>&#174;, which expires on March 27,
2022. The FDA has affirmed to Antares the acceptance of the resubmission of the NDA for TLANDO. The FDA has designated the NDA as a Class
1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the PDUFA. Any FDA requirement
to conduct certain post-marketing studies will also be the responsibility of our licensee, Antares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">Proof-of-concept for TLANDO
was initially established in 2006, and subsequently TLANDO was licensed in 2009 to Solvay Pharmaceuticals, Inc. which was then acquired
by Abbott Products, Inc. (&#8220;Abbott&#8221;). Following a portfolio review associated with the spin-off of AbbVie Inc. by Abbott in
2011, the rights to TLANDO were reacquired by us. All obligations under the prior license agreement have been completed except that Lipocine
will owe Abbott a perpetual 1% royalty on net sales. Such royalties are limited to $1 million in the first two calendar years following
product launch, after which period there is not a cap on royalties and no maximum aggregate amount. If generic versions of any such product
are introduced, then royalties are reduced by 50%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">Under the Pediatric Research
Equity Act (&#8220;PREA&#8221;), if TLANDO receives full approval, under the terms of the Antares Licensing Agreement, Antares will need
to address the PREA requirement to assess the safety and effectiveness of TLANDO in pediatric patients. The FDA may also require certain
post-marketing studies to be conducted which will also be the responsibility of our licensee, Antares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">Upon execution of the Antares
License Agreement, Antares paid to us an initial payment of $11.0 million. Antares will also make additional payments of $5.0 million
to us on each of January 1, 2025, and January 1, 2026, provided that certain conditions are satisfied. We are also eligible to receive
milestone payments of up to $160.0 million in the aggregate, depending on the achievement of certain sales milestones in a single calendar
year with respect to all products licensed by Antares under the Antares License Agreement. In addition, upon commercialization, we will
receive tiered royalty payments at rates ranging from percentages in the mid-teens to up to 20% of net sales of TLANDO in the United
States, subject to certain minimum royalty obligations. Further, on October 14, 2021, we assigned our Manufacturing Agreement, dated
August 27, 2013, by and between the Company and Encap Drug Delivery (the &#8220;Manufacturing Agreement&#8221;) to Antares as part of
the Antares License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; text-indent: 31.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>LPCN 1111: A Next-Generation Long-Acting Oral
Product Candidate for TRT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">LPCN 1111: is a next-generation,
novel ester prodrug of testosterone comprised of testosterone tridecanoate (TT) which uses the proprietary delivery technology to enhance
solubility and improve systemic absorption. We completed a Phase 2b dose finding study in hypogonadal men in the third quarter of 2016.
The primary objectives of the Phase 2b clinical study were to determine the starting Phase 3 dose of LPCN 1111 along with safety and
tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal men. Good dose-response
relationship was observed over the tested dose range in the Phase 2b study. Additionally, the target Phase 3 dose met primary and secondary
end points. Overall, LPCN 1111 was well tolerated with no drug-related severe or serious adverse events reported in the Phase 2b study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">In February 2018 we had a
meeting with the FDA to discuss these pre-clinical results and to discuss the Phase 3 clinical study and path forward for LPCN 1111.
Based on the results of the FDA meeting and additional pre-clinical studies conducted after the FDA meeting, we have proposed a Phase
3 protocol for LPCN 1111 and have solicited FDA feedback. Based on initial FDA feedback, we expect the Phase 3 clinical trial design
to follow the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;)
guidelines and will include at least a three-month efficacy treatment period and a one-year safety component for approximately 100 subjects.
We are currently seeking further clarification from FDA with respect to the total subject LPCN 1111 exposure information needed for an
NDA filing. We continue to refine the Phase 3 protocol and plan to request FDA approval of the protocol once it is finalized. Additionally,
the FDA previously requested that a food effect and a phlebotomy study be completed, and that ambulatory blood pressure monitoring (&#8220;ABPM&#8221;)
be included as part of the Phase 3 clinical study. We are currently transferring the manufacturing of LPCN 1111 to a third-party contract
manufacturer and scaling up the formulation after which we anticipate the next steps in developing LPCN 1111 may be to conduct a food
effect/phlebotomy study with LPCN 1111. Under the terms of the Antares License Agreement, Antares has been granted an option to license
LPCN 1111, exercisable on or before March 31, 2022, for further development and, should LPCN 1111 receive FDA approval, commercialization.
If Antares exercises its option to license LPCN 1111, we will be entitled to an additional payment of $4.0 million, as well as development
milestone payments of up to $35.0 million in the aggregate and tiered royalty payments at rates ranging from percentages in the mid-teens
to 20% of net sales of LPCN 1111 in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>LPCN 1107: An Oral Product Candidate for the
Prevention of Preterm Birth</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">We believe LPCN 1107 has
the potential to become the first oral h<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>y</b>droxyprogesterone
caproate (&#8220;</span>HPC&#8221;) product indicated for the reduction of risk of PTB (delivery less than 37 weeks) in women with singleton
pregnancy who have a history of singleton spontaneous PTB. Prevention of PTB is a significant unmet need as approximately 11.7% of all
U.S. pregnancies result in PTB, a leading cause of neonatal mortality and morbidity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Current Status</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">We have completed a multi-dose
PK dose selection study in pregnant women. The objective of the multi-dose PK selection study was to assess HPC blood levels in order
to identify the appropriate LPCN 1107 Phase 3 dose. The multi-dose PK dose selection study was an open-label, four-period, four-treatment,
randomized, single and multiple dose PK study in pregnant women with three dose levels of LPCN 1107 and the IM HPC (Makena&#174;). The
study enrolled 12 healthy pregnant women (average age of 27 years) with a gestational age of approximately 16 to 19 weeks. Subjects received
three dose levels of LPCN 1107 (400 mg BID, 600 mg BID, or 800 mg BID) in a randomized, crossover manner during the first three treatment
periods and then received five weekly injections of HPC during the fourth treatment period. During each of the LPCN 1107 treatment periods,
subjects received a single dose of LPCN 1107 on Day 1 followed by twice daily administration from Day 2 to Day 8. Following completion
of the three LPCN 1107 treatment periods and a washout period, all subjects received five weekly injections of HPC. Results from this
study demonstrated that average steady state HPC levels (Cavg0-24) were comparable or higher for all three LPCN 1107 doses than for injectable
HPC. Additionally, HPC levels as a function of daily dose were linear for the three LPCN 1107 doses. Also, unlike the injectable HPC,
steady state exposure was achieved for all three LPCN 1107 doses within seven days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">A traditional PK/PD based
Phase 2 clinical study in the intended patient population is not expected to be required prior to entering into Phase 3. Therefore, based
on the results of our multi-dose PK study we had an End-of-Phase 2 meeting and subsequent guidance meetings with the FDA to define a
pivotal Phase 2b/3 development plan for LPCN 1107. However, these discussions will need to be updated based on recent developments with
Covis&#8217; Makena&#174;. We plan to resume our interactions with the FDA to discuss our pivotal clinical trial design and better understand
next steps to advance LPCN 1107 after completion of our on-going food-effect study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">We are exploring the possibility
of licensing LPCN 1107 to a third party, although no licensing agreement has been entered into by the Company. No assurance can be given
that any license agreement will be completed, or, if an agreement is completed, that such an agreement would be on acceptable terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">The FDA has granted orphan
drug designation to LPCN 1107 based on a major contribution to patient care. Orphan designation qualifies Lipocine for various development
incentives, including tax credits for qualified clinical testing, and a waiver of the prescription drug user fee when we file our NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Recent Competition Update</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 5, 2020, the FDA&#8217;s Center for Drug Evaluation and Research (&#8220;CDER&#8221;) proposed that Makena be withdrawn
from the market because the PROLONG trial failed to verify the clinical benefit of Makena and concluded that the available evidence does
not show Makena is effective for its approved use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CDER
issued AMAG Pharmaceuticals, the NDA holder at the time, a Notice of Opportunity for Hearing to withdraw approval of Makena, for
which AMAG Pharmaceuticals responded by requesting a hearing and providing detail on the company&#8217;s position, recognizing clinicians&#8217;
decade-long use of Makena&#8217;s treatment and the public health implications of withdrawing approval. The FDA Commissioner has recently
granted Covis a public hearing although the date of that hearing is not publicly known. During this time, Makena and the approved generics
of Makena will remain on the market until the FDA makes a final decision about these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
Makena and the approved generics of Makena are the only products approved for the prevention of recurrent preterm birth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also indicated that it intends to hold a meeting with experts in obstetrics, neonatal care, and clinical trial design to discuss
how to facilitate development of effective and safe therapies to treat preterm birth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Oral
NAS Programs for CNS Disorders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
preferred endogenous or naturally occurring NAS present in central nervous system (CNS) act as positive allosteric modulators (PAM) of
the GABA<sub>A</sub> receptor, the major biological target of the inhibitory neurotransmitter &#947;-aminobutyric acid (GABA<sub>A</sub>).
To improve oral delivery of these modulators, several synthetic NAS derivatives of endogenous GABA<sub>A</sub> receptor PAMs, have been
developed for therapeutic use in the past few decades.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe through utilization of our proprietary technology we may have the ability to enable effective oral delivery of endogenous GABA<sub>A
</sub>receptor PAMs which historically had been challenging to deliver orally as they were deemed to be not orally bioavailable. We believe
these endogenous GABA<sub>A</sub> receptor PAMs provide opportunity as a differentiated NAS for treatment of various CNS disorders via
the preferred and convenient oral route.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LPCN
1154: Product Candidate for PPD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating LPCN 1154 comprising an endogenous NAS for PPD. FDA has cleared LPCN 1154 IND (investigational new drug) application
to conduct a phase 2 study in PPD. We have completed a PK study with LPCN 1154 post oral administration in which appreciable levels were
observed with dose proportionality. We plan to conduct further PK analyses and a food effect PK study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PPD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PPD
(Postpartum depression), a type of major depressive disorder with onset either during pregnancy or within four weeks of delivery, refers
to depression persisting up to 12 months after childbirth. PPD can be clinically segmented by the severity of symptoms and presence of
a comorbidity, including epilepsy. Approximately 1 in 9 mothers suffers from PPD in the United States alone; this equates to approximately
500,000 women affected by PPD annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disease
Overview - PPD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PPD
    is distinct from the &#8220;baby blues,&#8221; a condition that affects up to 70% of all new mother&#8217;s experience; &#8220;baby
    blues&#8221; tend to be short-lived emotional conditions that do not interfere with daily activities</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms
    of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in
    appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself,
    and/or thoughts of death or suicide</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    pregnancy, levels of endogenous NAS increase considerably along with levels of progesterone; however, they drop sharply postpartum.
    It has been hypothesized that the rapid perinatal decrease in circulating levels of endogenous NASs may be involved in the development
    of PPD. The first and only approved treatment option for PPD is an injectable containing endogenous NAS.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depression
    may persist long after child delivery. Additionally, approximately 40% women relapse in subsequent pregnancies or on other occasions</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Psychiatric
    comorbidities are common in patients with epilepsy. Patients with epilepsy are at high risk for major depressive disorders and PPD.
    Reported PPD rates are higher among women with epilepsy than the general population.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Associated
Risk Factors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic:
    family history and/or previous experience of depression or other mood disorders</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physiological:
    rapid changes in sex hormones, stress hormones, and thyroid hormone levels during and after delivery</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental:
    stressful life events, changes in relationships at home and at work, and/or lack of familial support</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unmet
medical need</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately,
1 in 9 moms suffers from PPD in the United States alone, which equates to approximately 500,000 women affected by PPD annually. We believe
there is considerable unmet need within women with PPD due to lack of convenient and fast-acting oral therapies. Selective Serotonin
Reuptake Inhibitors (SSRIs) have been the traditional first-line choice for women with severe PPD requiring weeks for onset of efficacy;
therefore, a need for a faster onset of action remains a significant unmet need in treating PPD, especially in women with epilepsy risk
wherein psychiatric comorbidity is common and PPD rates are higher than the general population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Injectable
brexanolone (ZulressoTM, Sage Therapeutics) became the first FDA-approved treatment for postpartum depression. However, numerous factors
limit the utilization of injectable brexanolone such as method of administration, cost, and safety concerns. Administration of injectable
brexanolone requires a 60-hour continuous infusion in a supervised medical setting, a demanding ask for a mother with a newborn. Besides
associated privacy concerns and social stigma, hospitalization may also require separation of the mother and child for a few days, which
may be difficult to the already strained mother-infant bond and may present breast feeding challenges. Moreover, the pharmacotherapy
costs coupled with hospitalization/childcare costs limits its accessibility and affordability to women most in need of the therapy. Finally,
due to concerns about the safety of injectable ZulressoTM including excessive sedation or loss of consciousness, Zulresso has a Black
Box Warning in its label and is only available through a restricted distribution program (REMS), and sites need significant time to become
treatment ready.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the need for a convenient, at-home treatment with faster onset of action which could offer privacy and affordability, independent
of socio-economic status, for women with PPD is a significant unmet need. LPCN 1154 targets this unmet need with affordable NAS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LPCN
2101: NAS for epilepsy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating an additional NAS candidate, LPCN 2101, for women with epilepsy (&#8220;WWE&#8221;). We have completed a pre-clinical study for LPCN 2101. We plan
to file an IND with the U.S. FDA for LPCN 2101 to conduct a proof-of-concept study for the evaluation of safety, tolerability, and efficacy
in adult female subjects of childbearing age diagnosed with epilepsy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
disclosed in our development pipeline, we continue to build a diversified multi-asset pipeline of novel therapies. In 2021 and 2020,
we spent $7.7 million and $9.7 million, respectively, on research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cirrhosis
Market Overview </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decompensated
cirrhosis patients with sarcopenia exhibit significantly shorter overall survival than those without sarcopenia. There are no therapies
specifically approved for sarcopenia or decompensated cirrhosis. Currently, the only curative therapy for decompensated cirrhosis
is liver transplant; however, liver transplantation is very costly, limited by the supply of available donors, and has a high risk of
post-operative complications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xifaxan
(rifaximin) is the only FDA-approved medicine indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in
adults, a decompensation event typically associated with liver cirrhosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, there are no FDA approved drugs to treat
secondary sarcopenia in decompensated cirrhosis beyond treatment of the underlying conditions. Lipocine is the only clinical-stage
company pursuing treatment for subjects with decompensated cirrhosis with sarcopenia, however there are candidates known to
be under development for cirrhosis related indication(s).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GB
1211 (by Galecto), an oral galectin-3 inhibitor for advanced liver cirrhosis targeted for directly addressing fibrosis, is in phase 2
development being assessed in patients with moderate-to-severe cirrhosis (Child-Pugh classes B and C) and is anticipated to read out
in the second half of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AXA-1665
(by Axcella Health), an orally active mixture of 8 amino acids in specific ratios designed to maximize anabolic activity and minimize
ammonia genesis, is in a Phase 2 study in the secondary prevention of overt HE with a projected completion date of March 2023. While
AXA-1665&#8217;s studies have so far enrolled non-sarcopenic patients, Axcella could pursue cirrhotic sarcopenia with AXA-1665.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reformulated
Rifaximin SSD (by BAUSCH health) is in a phase 3 study for Reduction of Early Decompensation in Cirrhosis with time to first occurrence
of hepatic encephalopathy as the Primary endpoint. Reportedly, a new drug application (NDA) planned to be submitted 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>NASH Market Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are currently no medications
approved for the treatment of NASH. However, various therapeutics are used off-label for the treatment of NASH, including vitamin E (an
antioxidant), insulin sensitizers (e.g., metformin, pioglitazone), antihyperlipidemic agents (e.g., gemfibrozil), pentoxifylline and
ursodeoxycholic acid. There are several product candidates in Phase 3 or earlier clinical or preclinical development for the treatment
of NASH, including <i>FGF21 stimulants such as BIO89-100 (89bio), Efruxifermin (EFX; Akero Therapeutics), Pegbelfermin (Bristol Myers
Squibb/Ambrx Inc.); FGF19 Analog:Aldafermin (NGM Biopharmaceuticals); FXR Agonists: Tropifexor (Novartis), EDP-305 (Enata Pharmaceuticals),
PXL007/EYP001 (Poxel/Enyo Pharma:) Glucagon-like Peptide-1 (GLP-1) Agonist: Semaglutide (Novo Nordisk); Peroxisome Proliferator-activated
Receptor (PPAR) Regulator: Lanifibranor (Inventiva)</i><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">;</span><i>THR-&#946;
Agonis:t VK2809 (Viking Therapeutics),</i> and Resmetirom (Madrigal Pharmaceuticals).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additional pharmaceutical
and biotechnology companies with product candidates in development for the treatment of NASH include AstraZeneca plc, Boehringer Ingelheim
GmbH, Bristol-Myers Squibb Company, Conatus Pharmaceuticals Inc., CymaBay Therapeutics, Inc., Durect Corporation, Galectin Therapeutics
Inc., Galmed Pharmaceuticals Ltd., Immuron Ltd., Ionis Pharmaceuticals, Inc., Islet Sciences, Inc., Madrigal Pharmaceuticals, Inc., MediciNova,
Inc., MiNA Therapeutics, NGM Biopharmaceuticals, Inc., Novo Nordisk A/S, NuSirt Sciences Inc., Viking Therapeutics, Inc. and Zydus Pharmaceuticals
(USA) Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Testosterone Replacement Therapy Market Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The gel-based testosterone
replacement products that are currently available include AbbVie&#8217;s AndroGel&#174;, Lilly&#8217;s Axiron&#174; Topical Solution and
Endo<i>&#8217;</i>s Testim&#174; and Fortesta&#174; along with their respective authorized generics as well as the equivalent generic versions
of each. Transdermal patches include Allergan&#8217;s Androderm&#174;. Intramuscular forms of testosterone also exist although commercialized
mostly in generic forms by multiple companies and in branded form as Aveed&#174; by Endo. Additionally, Endo markets the buccal testosterone
replacement therapy Striant&#174; and the Testopel&#174; implantable testosterone pellets, which it acquired from Auxillium in 2015. Antares
Pharma, Inc. markets a sub-cutaneous weekly auto-injector testosterone therapy, Xyoste&#174;. Acerus Pharmaceuticals markets an intranasal
testosterone therapy, NATESTO&#174;. Finally, Clarus markets an oral TRT, JATENZO&#174;, which received approval in March 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, intramuscular injections
have the highest market share in the testosterone replacement market in terms of annual prescriptions. While gels are also a
widely used form of TRT, there is a risk of transference; additionally, the gels are messy to apply and have significant compliance issues
leading to high rates of discontinuance among patients. Additionally, certain intramuscular injections have the potential to cause pulmonary
embolisms as well as cause injection site reactions, scarring, pain and risk of infection in patients. We believe a safe and effective
oral therapy could potentially increase patient convenience and compliance, while eliminating the testosterone transference risk associated
with gels and injection site reaction of injectables.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has granted a therapeutic equivalence rating of AB to &#8220;generic&#8221; versions of approved products which have been approved
via a 505(b)(2) NDA. In July 2014, FDA granted the AB rating to Perrigo&#8217;s 1% testosterone gel drug product (NDA 203098) approved
in January 2013, and a BX rating to Teva&#8217;s 1% gel drug product (NDA 202763) approved in February 2012. Each are versions of AbbVie&#8217;s
AndroGel 1.0% and employed 505(b)(2) submissions citing AndroGel as their reference listed drugs. Teva&#8217;s version was found to be
bioinequivalent to AndroGel, hence the BX rating. Upsher-Smith Laboratories also received approval for a version of Endo&#8217;s Testim
(Vogelxo&#8482;; NDA 204399) in June 2014 using the same pathway. In January of 2015, the FDA determined that Vogelxo&#8482; is therapeutically
equivalent to Testim and received an AB rating. In August 2015, the FDA granted AB rating to Perrigo&#8217;s 1.62% testosterone gel drug
product (NDA 204268) which also received FDA approval in August 2015. Lilly and Acrux&#8217;s Axiron had patent expiry in February 2017.
On July 6, 2017, Acrux confirmed that a generic version of Axiron&#174; Topical Solution, 30 mg/1.5 mL (Testosterone Topical Solution,
30 mg/1.5 mL) has been launched in the United States by Perrigo Company plc. Acrux also confirmed the availability of an authorized generic
version of Axiron in the United States, through a marketing and distribution agreement between Lilly and Company and a leading authorized
generics company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
TRT Therapies in Development </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently
there has been increased interest in developing oral TRT&#8217;s therapies as well as testosterone therapies which are not considered
testosterone replacement and as such will need to achieve efficacy endpoints in addition to endpoints related to serum testosterone levels
that are required for testosterone replacement therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marius
is developing an oral TU as a testosterone replacement therapy for the treatment of hypogonadism in men as well as in the treatment of
Constitutional Delay of Growth and Puberty in adolescent boys (14-17 years of age). Marinus submitted a NDA to the FDA in January 2021
for its product, Kyzatrex&#8482;, its novel oral TU soft gelatin capsule for the treatment of hypogonadism in adult men. According to
Marius, it was assigned a PDUFA date of October 31, 2021, for KYZATREX&#174;. However, no updates have been provided by Marius post the
October 31, 2021, PDUFA date for KYZATREX&#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there remains a significant unmet need in TRT for a once-a-day convenient oral option. LPCN 1111 is targeted to meet this unmet
need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Hydroxyprogesterone
caproate, or HPC, Preterm Birth, or PTB, Market Overview </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PTB
is defined as delivery before 37 weeks of gestation. The only approved therapy for prevention of PTB in women with a prior history of
at least one preterm birth (approximately 180,000 pregnancies annually) is a weekly intramuscular injection of HPC, marketed by
Covis under the brand name Makena&#174;. The FDA granted a 7-year orphan drug exclusivity to Makena in February 2011 because the product
is intended to treat &#8220;rare diseases or conditions&#8221; defined as a condition that affects fewer than 200,000 persons in the
United States; exclusivity expired in February 2018. Generic versions of the intramuscular injection of Makena became available
during 2018. In order to protect market share, Covis also developed a subcutaneous auto-injector for Makena that received FDA approval
on February 14, 2018. Treatment with Makena is initiated in pregnant women between week 16 and week 20 of pregnancy and is continued
until up to delivery or week 37, whichever is earlier. The intramuscular injection is administered by a healthcare provider using a 21-gauge
needle into the gluteus muscle, alternating sides each week. The intramuscular injections are associated with significant pain, discomfort
and associated injection site reactions. The subcutaneous auto-injector for Makena eliminates the need to travel weekly to a healthcare
provider to have the injection administered. Covis has disclosed that the completed confirmatory trial for Makena did not demonstrate
a statistically significant difference between the treatment and placebo arms for the co-primary endpoints of reducing the risk of recurrent
preterm birth or improving neonatal mortality and morbidity. On October 29, 2019 a Meeting of the Bone, Reproductive and Urologic Drugs
Advisory Committee (&#8220;BRUDAC&#8221;) was held to consider the trial&#8217;s findings and the sNDA in the context of AMAG Pharmaceuticals&#8217;
confirmatory study obligation. While the committee discussed multiple questions, in a mixed vote on the key question, nine advisory committee
members voted to recommend that the FDA pursue withdrawal of approval for Makena and seven committee members voted to leave the product
on the market under accelerated approval and require a new confirmatory trial. Among the clinicians on the advisory committee, five of
the six who practice obstetrics voted to keep Makena on the market and generate more data. On October 5, 2020, the FDA&#8217;s CDER proposed
that Makena be withdrawn from the market because the PROLONG trial failed to verify the clinical benefit of Makena and concluded that
the available evidence does not show Makena is effective for its approved use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CDER
issued AMAG, the NDA holder at the time, a NOOH to withdraw approval of Makena, for which AMAG Pharmaceuticals responded by requesting
a hearing and providing detail on the company&#8217;s position, recognizing clinicians&#8217; decade-long use of Makena&#8217;s treatment
and the public health implications of withdrawing approval. The FDA Commissioner granted a hearing, and the process is expected to take
months. During this time, Makena and the approved generics of Makena will remain on the market until the FDA makes a final decision about
these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Neuroactive Steroids Market overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unique potential mechanism
of action (MOA) of NAS presents an opportunity to treat variety of CNS disorders. Accordingly, multiple NAS as GABA<sub>A</sub> receptor
PAMs are in active development for varied indications. Some companies engaged in development include SAGE Therapeutics, Inc., Marinus
Pharmaceuticals, Praxis Precision Medicines, and Eliem Therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Postpartum Depression</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sage Therapeutics is currently
marketing an injectable version of an endogenous neuroactive steroid, brexanolone, under tradename of ZULRESSO, as first and only FDA
approved product (approval on 03/19/2019) for treatment in postpartum depression (PPD).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">SAGE therapeutics is also
currently developing an oral synthetic derivative of an endogenous NAS, SAGE-217 (Zuranolone), a GABA<sub>A</sub> receptor PAM, and is
in phase 3 development for postpartum depression. Zuranolone (oral) received Breakthrough Therapy Designation for the treatment of MDD
in February 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Marinus Pharmaceuticals has
also reported clinical development of Ganaxolone, a synthetic GABA<sub>A</sub> receptor PAM in PPD that been studied in two Phase 2 trials,
one investigating IV +/- oral administration (Magnolia part 1 and 2) and one oral administration (Amaryllis). Additional assets of the
same MOA are indicated for MDD (PRAX-114 and ETX-155) but could be pivoted to a PPD indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drug
Delivery Technologies for Lipophilic Drug Substances </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent portfolio is directed to various types of compositions and methods for delivery of lipophilic drugs, which are drugs that are
soluble in lipids. Our licensed product, TLANDO, is an oral formulation of the lipophilic prodrug TU, utilizing our proprietary technology
for improved delivery of lipophilic therapeutic agents. As of March 7, 2022, our intellectual property patent portfolio
is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15
    issued patents in the US related to Oral TU with 2029-2030 expiration dates;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    issued patent in the US related to Oral TU with 2031 expiration date;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    U.S. patent applications related to Oral TU with potential expiration dates, if issued, in 2029;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
    U.S. patent applications related to Oral TU with potential expiration dates, if issued, in 2030;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    U.S. patent applications related to Oral TU with potential expiration dates, if issued, in 2035-2040;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    issued U.S. patents related to LPCN 1111 with expiration dates in 2035-2037;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
    U.S. patent applications related to LPCN 1111, with potential expiration dates, if issued, in 2029-2037;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7
    U.S. patents related to LPCN 1107 with expiration dates in 2031;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    U.S. patent applications related to LPCN 1107 with potential expiration dates, if issued, in 2031-2036;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    issued patent related to Oral TU in the following countries: India, Mexico, Japan, Canada and Australia that expires in 2030;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    issued patent related to Oral TU in the following countries: Australia, Canada and Japan that expires in 2024;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">1 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
    patent related to Oral TU in in the following countries: Australia, Canada, and New Zealand that expires in 2026;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">1 issued patent related to Oral TU in the following
    country: Canada that expires in 2034</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">1 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patent
    application related to Oral TU in the following countries: Europe, Brazil, and Hong Kong, that if issue, will expire in
    2030;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    patent application related to Oral TU in the following countries: China and Russia, that if issue, will expire in 2035;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    patent application related to Oral TU in the following countries: Europe and Japan, that if issue, will expire in 2037;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    patent application related to LPCN 1111 in the following countries: Europe and Japan, that if issue, will expire in 2037;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    issued patents or applications related to LPCN 1111 in the following countries: Argentina, Australia, Brazil, Canada, China,
    Europe, Israel, India, Japan, South Korea, Mexico, New Zealand, Russia, Uruguay, Paraguay, Venezuela, and South Africa, that expires
    or will expire, if issued, in 2030;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    patent application related to LPCN 1111 in the following countries: Australia, Brazil, Canada, China, Europe, India, Indonesia,
    Israel, Japan, Mexico, New Zealand, Russia, South Korea and South Africa, that, if issued, will expire in 2035;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    issued patent or application related to LPCN 1107 in the following countries: Australia, Brazil, Canada, China, Europe, Israel, India,
    Japan, South Korea, Mexico, New Zealand, Russia, and South Africa that expires, or will expire if issued, in 2032;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    patent application related to LPCN 1107 in the following countries: Australia, Brazil, China, Europe, Indonesia, Israel, Japan, Mexico,
    New Zealand, Philippines and South Africa that will expire, if issued in 2036;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    U.S. Patent applications related to LPCN 1144/1148 and one Patent Cooperation Treaty (&#8220;PCT&#8221;) application; and</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    U.S. patent related to progesterone formulations that expires in 2031.</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also hold license rights in fields other than cough and cold, to 2 U.S. patents and 1 U.S. application (and related foreign patents
and applications) that we previously assigned to Spriaso LLC, which could be possibly used with future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we have 6 U.S. patents that we plan to list in the FDA Orange Book for TLANDO that are expected to expire in 2029 and 2030. If we or
our licensee are marketing the TLANDO product at the time the patents expire and have no other issued U.S. patents covering the product,
then we will lose certain advantages that come with FDA Orange Book listing of patents and will no longer be able to prevent others in
the U.S. from practicing the inventions claimed by the 6 patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to file new patent applications in the future in an attempt to further cover to various aspects of our products and product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Item 3 &#8211; Legal Proceedings, for a discussion of intellectual property related legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Regulatory Process for Drug Development </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and manufacture of our product candidates and our research and development activities are subject to regulation by various
governmental authorities around the world. In the United States, drugs and products are subject to regulation by the FDA. There are other
comparable agencies in Europe and other parts of the world. Regulations govern, among other things, the research, development, testing,
manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval
monitoring and reporting, marketing and export and import of products. Applicable law requires licensing and registration of manufacturing
and contract research facilities, carefully controlled research and testing of products, governmental review and/or approval of results
prior to marketing therapeutic products. Additionally, adherence to good laboratory practices, or GLP, good clinical practices, or GCP,
during clinical testing and current good manufacturing practices, or cGMP, during production is required. The system of new drug approval
in the United States is generally considered to be the most rigorous in the world and is described in further detail below under &#8220;United
States Pharmaceutical Product Development Process.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>United
States Pharmaceutical Product Development Process </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug and Cosmetic Act and implementing regulations.
The testing, production, sale, and promotion of pharmaceutical products are also subject to other federal, state and local statutes and
regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign
statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United
States requirements at any time during the product development process, approval process or after approval, may subject an applicant
to administrative or judicial sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval,
a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
takes many years for a typical experimental drug to go from concept to approval. The process required by the FDA before a pharmaceutical
product may be marketed in the United States generally includes the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of preclinical
  laboratory tests and animal studies. The latter often conducted according to GLPs or other applicable regulations, as well as synthesis
  and drug formulation development leading ultimately to clinical drug supplies manufactured according to cGMPs;</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td colspan="2" style="text-align: justify"></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of
  an IND, which must be submitted to the FDA and become effective before human clinical trials may begin in the United States;</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td colspan="2" style="text-align: justify"></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance of adequate and
  well-controlled human clinical trials according to the FDA&#8217;s current GCPs, to establish the safety and efficacy of the proposed
  pharmaceutical product for its intended use;</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td colspan="2" style="text-align: justify"></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of
  an NDA for a new pharmaceutical product;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory
                                            completion of an FDA inspection of the manufacturing facility or facilities where the pharmaceutical
                                            product is produced to assess compliance with the FDA&#8217;s cGMP to assure that the facilities,
                                            methods and controls are adequate to preserve the pharmaceutical product&#8217;s identity,
                                            strength, quality and purity;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential FDA audit of the
  preclinical and clinical trial sites that generated the data in support of the NDA; and</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval of
  the NDA.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require
the expenditure of substantial resources and FDA approval is inherently uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
Studies</i>: Prior to preclinical studies, a research phase takes place which involves demonstration of target and function, design,
screening and synthesis of agonists or antagonists. Preclinical studies include laboratory evaluations of product chemistry, toxicity
and formulation, as well as animal studies to evaluate efficacy and activity, toxic effects, PKs and metabolism of the pharmaceutical
product candidate and to provide evidence of the safety, bioavailability and activity of the pharmaceutical product candidate in animals.
The conduct of the preclinical safety evaluations must comply with federal regulations and requirements including GLPs. The results of
the formal IND-enabling preclinical studies, together with manufacturing information, analytical data, any available clinical data or
literature as well as the comprehensive descriptions of proposed human clinical studies, are then submitted as part of the IND application
to the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the IND on a clinical hold within that 30-day
time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The
FDA may also impose clinical holds on a pharmaceutical product candidate at any time before or during clinical trials due to safety concerns
or non-compliance. Accordingly, we cannot be certain that submission of an IND will result in the FDA allowing clinical trials to begin,
or that, once begun, issues will not arise that suspend or terminate such clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials</i>: Clinical trials involve the administration of the pharmaceutical product candidate to healthy volunteers or patients under
the supervision of qualified investigators, generally physicians not employed by the sponsor. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and
the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA if conducted under a U.S. IND. Clinical
trials must be conducted in accordance with the FDA&#8217;s GCP requirements. Further, each clinical trial must be reviewed and approved
by an independent institutional review board, or IRB, or ethics committee at or servicing each institution at which the clinical trial
will be conducted. An IRB or ethics committee is charged with protecting the welfare and rights of trial participants and considers such
items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated
benefits. The IRB or ethics committee also approves the informed consent form that must be provided to each clinical trial subject or
his or her legal representative and must monitor the clinical trial until completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
1 Clinical Trials</i>: Phase 1 clinical trials are usually first-in-man trials, take approximately one to two years to complete and are
generally conducted on a small number of healthy human subjects to evaluate the drug&#8217;s activity, schedule and dose, PKs and pharmacodynamics.
However, in the case of life-threatening diseases, such as cancer, the initial Phase 1 testing may be done in patients with the disease.
These trials typically take longer to complete and may provide insights into drug activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
2 Clinical Trials</i>: Phase 2 clinical trials can take approximately one to three years to complete and are carried out on a relatively
small to moderate number of patients (as compared to Phase 3) in a specific indication. The pharmaceutical product is evaluated to preliminarily
assess efficacy, to identify possible adverse effects and safety risks, and to determine optimal dose, regimens, PKs, pharmacodynamics
and dose response relationships. This phase also provides additional safety data and serves to identify possible common short-term side
effects and risks in a larger group of patients. Phase 2 clinical trials sometimes include randomization of patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
3 Clinical Trials</i>: Phase 3 clinical trials take approximately two to five years to complete and involve tests on a much larger population
of patients (several hundred to several thousand patients) suffering from the targeted condition or disease. These studies usually include
randomization of patients and blinding of both patients and investigators at geographically dispersed test sites (multi-center trials).
These trials are undertaken to further evaluate dosage, clinical efficacy and safety and are intended to establish the overall risk/benefit
ratio of the product and provide an adequate basis for product labeling. Generally, two adequate and well-controlled Phase 3 clinical
trials are required by the FDA for approval of an NDA or foreign authorities for approval of marketing applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
studies, or Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience
from the treatment of patients in the intended therapeutic indication and may be required by the FDA as a condition of approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and written IND safety reports must
be submitted to the FDA and the investigators for serious and unexpected adverse events or for any finding from tests in laboratory animals
that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within
any specified period, if at all. The FDA or the sponsor or, if used, its data safety and monitoring board may suspend a clinical trial
at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health
risk. Similarly, an IRB or ethics committee can suspend or terminate approval of a clinical trial at its institution if the clinical
trial is not being conducted in accordance with the IRB&#8217;s or ethics committee&#8217;s requirements or if the pharmaceutical product
has been associated with unexpected serious harm to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the pharmaceutical product, as well as finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches
of the pharmaceutical product candidate and, among other things, must develop methods for testing the identity, strength, quality and
purity of the final pharmaceutical product. Additionally, appropriate packaging must be selected and tested, and stability studies must
be conducted to demonstrate that the pharmaceutical product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Pharmaceutical Review and Approval Process </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>New
Drug Application</i>: Upon completion of pivotal Phase 3 clinical studies, the sponsor assembles all the product development, preclinical
and clinical data along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the pharmaceutical
product, proposed labeling and other relevant information, and submits it to the FDA as part of an NDA. The submission or application
is then reviewed by the regulatory body for approval to market the product. This process typically takes eight months to one year to
complete. The FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical
data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not
satisfy the criteria for approval. If a product receives regulatory approval, the approval may be limited to specific diseases and dosages
or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require
that certain contraindications, warnings or precautions be included in the product labeling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Drug Designation </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally
a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United
States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug
for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be
requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential
orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the
regulatory review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation,
the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the
same drug for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also
block the approval of one of our products for seven years if a competitor obtains approval of the same drug as defined by the FDA or
if our drug candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
pharmaceutical products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things,
record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information,
product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with
the FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, prohibitions
on promoting pharmaceutical products for uses or in patient populations that are not described in the pharmaceutical product&#8217;s
approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities and promotional activities
involving the internet. Failure to comply with the FDA requirements can have negative consequences, including adverse publicity, enforcement
letters from the FDA, mandated corrective advertising or communications with doctors and civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also may require post-marketing testing, known as Phase 4 testing, risk evaluation and mitigation strategies and surveillance to
monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>21<sup>st
</sup>Century Cures Act</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
21<sup>st</sup> Century Cures Act (Public Law No. 144-255) was enacted on December 13, 2016. This sweeping legislation makes significant
changes to the way that FDA approves new drugs and medical devices. Among other things, the legislation calls on FDA to consider new
types of data, such as patient experience data, in its drug approval process. The legislation also permits drug manufacturers to utilize
new types of clinical trial designs in order to collect data in the drug approval process. The intent of many of the statute&#8217;s
provisions are to speed the approval of new drugs and medical devices. Whether the 21<sup>st</sup> Century Cures Act realizes these goals
will depend on the adoption of new FDA regulations, policy guidance and FDA approval practices, many of which the agency has not yet
proposed or issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Healthcare Laws and Compliance Requirements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to
the FDA, including, but not limited, to the Centers for Medicare and Medicaid Services and other divisions of the United States government,
including the U.S. Federal Communications Commission, the Department of Health and Human Services, the U.S. Department of Justice and
individual U.S. Attorney offices within the Department of Justice, and state and local governments. For example, if a drug product is
reimbursed by Medicare, Medicaid, or other federal or state healthcare programs, our Company, including our sales, marketing and scientific/educational
grant programs, among others, must comply with federal healthcare laws, including, but not limited to, the federal Anti-Kickback Statute,
false claims laws, civil monetary penalties laws, healthcare fraud and false statement provisions and data privacy and security provisions
under the Health Insurance Portability and Accountability Act, or HIPAA, the Physician Payment Sunshine Act, and any analogous state
laws. If a drug product is reimbursed by Medicare or Medicaid, pricing and rebate programs must comply with, as applicable, the Medicaid
rebate requirements of the Omnibus Budget Reconciliation Act of 1990 (&#8220;OBRA&#8221;), and the Medicare Prescription Drug Improvement
and Modernization Act of 2003. Among other things, OBRA requires drug manufacturers to pay rebates on prescription drugs to state Medicaid
programs and empowers states to negotiate rebates on pharmaceutical prices, which may result in prices for our future products that will
likely be lower than the prices we might otherwise obtain. Additionally, the Patient Protection and Affordable Care Act as amended by
the Health Care and Education Reconciliation Act of 2010 (collectively, &#8220;ACA&#8221;) substantially changes the way healthcare is
financed by both governmental and private insurers. Among other cost containment measures, ACA establishes: an annual, nondeductible
fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents; a new Medicare Part D coverage
gap discount program; and a new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. There
may continue to be additional proposals relating to the reform of the U.S. healthcare system, in the future, some of which could further
limit coverage and reimbursement of drug products. If drug products are made available to authorized users of the Federal Supply Schedule
of the General Services Administration, additional laws and requirements may apply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
to the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which
may include, for instance, applicable post-marketing requirements, including fraud and abuse, privacy and transparency laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharmaceutical
Coverage, Pricing and Reimbursement </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale
will depend in part on the availability of coverage and adequate reimbursement from third-party payers, including government health administrative
authorities, managed care providers, private health insurers and other organizations. In the United States, private health insurers and
other third-party payers often provide reimbursement for products and services based on the level at which the government (through the
Medicare or Medicaid programs) provides reimbursement for such treatments. Third-party payers are increasingly examining the medical
necessity and cost-effectiveness of medical products and services in addition to their safety and efficacy and, accordingly, significant
uncertainty exists as to the coverage and reimbursement status of newly approved therapeutics. In particular, in the United States, the
European Union and other potentially significant markets for our product candidates, government authorities and third-party payers are
increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products
and therapies, which has resulted in lower average selling prices. Further, the increased emphasis on managed healthcare in the United
States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing,
reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from
rules and practices of insurers and managed care organizations, judicial decisions and governmental laws and regulations related to Medicare,
Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. As a result, coverage and adequate third-party
reimbursement may not be available for our products to enable us to realize an appropriate return on our investment in research and product
development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payers&#8217;
drug formularies or lists of medications for which third-party payers provide coverage and reimbursement. The industry competition to
be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payers may refuse
to include a particular branded drug in their formularies or may otherwise restrict patient access to a branded drug when a less-costly
generic equivalent or other alternative is available. In addition, because each third-party payer individually approves coverage and
reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We would be required to provide
scientific and clinical support for the use of any product to each third-party payer separately with no assurance that approval would
be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products.
This process could delay the market acceptance of any of our product candidates for which we may receive approval and could have a negative
effect on our future revenues and operating results. We cannot be certain that our product candidates will be considered cost-effective.
If we are unable to obtain coverage and adequate payment levels for our product candidates from third-party payers, physicians may limit
how much or under what circumstances they will prescribe or administer them, and patients may decline to purchase them. This in turn
could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition,
and future success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States Orphan Drug Act encourages the development of orphan drugs, which are intended to treat &#8220;rare diseases or conditions&#8221;
within the meaning of this Act (i.e., those that affect fewer than 200,000 persons in the United States). The provisions of the Act are
intended to stimulate the research, development and approval of products that treat rare diseases. Orphan Drug Designation provides a
sponsor with several potential benefits: (1) sponsors may be granted seven years of marketing exclusivity after approval of the orphan-designated
indication for the drug product; (2) sponsors are granted U.S. tax incentives for clinical research; (3) the FDA&#8217;s office of orphan
products development coordinates research study design assistance for sponsors of drugs for rare diseases; and (4) grant funding can
be obtained to defray costs of qualified clinical testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Priority
Review </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Priority
Review is a designation for an NDA after it has been submitted to the FDA for review. Reviews for NDAs are designated as either &#8220;Standard&#8221;
or &#8220;Priority.&#8221; A Standard designation sets the target date for completing all aspects of a review and the FDA taking an action
on 90% of applications (i.e., approve or not approve) at 12 months after the date it was submitted for drugs considered new molecular
entities and at 10 months after the date it was submitted for drugs considered non-new molecular entities. A Priority designation sets
the target date for the FDA action on 90% of applications at eight months after submission submitted for drugs considered new molecular
entities and at 6 months after submission for drugs considered non-new molecular entities. A Priority designation is intended for those
products that address unmet medical needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accelerated
Approval </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
Approval or Subpart H Approval is a program described in the NDA regulations that is intended to make promising products for life threatening
diseases available on the basis of evidence of effect on a surrogate endpoint prior to formal demonstration of patient benefit. A surrogate
marker is a measurement intended to substitute for the clinical measurement of interest, usually prolongation of survival in oncology
that is considered likely to predict patient benefit. The approval that is granted may be considered a provisional approval with a written
commitment to complete clinical studies that formally demonstrate patient benefit.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related
Party Transaction</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2013, we entered into assignment/license and services agreements with Spriaso, an entity that is majority-owned by Mahesh V.
Patel, Gordhan Patel, John W. Higuchi, Dr. William I. Higuchi, and their affiliates. Mahesh V. Patel is our President and Chief Executive
Officer and Chairman of our Board of Directors. Mr. Higuchi is a member of our Board of Directors and Gordhan Patel and Dr. Higuchi,
former Board members, were each members of our Board of Directors at the date the license and agreements were entered into.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the assignment agreement, we assigned and transferred to Spriaso all of our rights, title and interest in our intellectual property for
the cough and cold field. In addition, Spriaso was assigned all rights and obligations under our product development agreement with a
co-development partner. In exchange, we would be entitled to receive a potential cash royalty of 20% of the net proceeds received by
Spriaso, up to a maximum of $10 million. Spriaso also granted back to us an exclusive license to such intellectual property to develop
products outside of the cough and cold field. The assignment agreement will expire upon the expiration of all of Spriaso&#8217;s payment
obligations thereunder and the expiration of all of the licensed patents thereunder. Spriaso has the right to terminate the assignment
agreement with 30 days written notice. We have the right to terminate the assignment agreement upon the complete liquidation or dissolution
of Spriaso, unless the assignment agreement is assigned to an affiliate or successor of Spriaso.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the services agreement, we agreed to provide facilities and up to 10% of the services of certain employees to Spriaso for a period of
time. The agreement to provide services expired in 2021; however, it may be extended upon written agreement of Spriaso and us.
Additionally, Spriaso filed its first NDA in 2014, and as an affiliated entity of Lipocine, it used up the one-time waiver of user fees
for a small business submitting its first human drug application to FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had 13 full time employees and we also utilize the services of consultants on a regular basis. Eight employees
are engaged in drug development activities and five are in general and administration functions and all of our employees work out of
our Salt Lake City facility. <span style="background-color: white">The Company continually evaluates the business need and opportunity
and balances in house expertise and capacity with outsourced expertise and capacity. Currently, we outsource substantial clinical trial
work to clinical research organizations and certain drug manufacturing to contract manufacturers. </span>None of our employees are represented
by labor unions or covered by collective bargaining agreements and we consider our relations with our employees to be good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive toward having a diverse team of employees and are committed to equality, inclusion and workplace diversity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is www.lipocine.com. We make available free of charge on the Investor Relations portion of our website, ir.lipocine.com,
our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or
furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the Securities and Exchange Commission. The SEC maintains an internet website that contains
reports, proxy and information statements, and other information that we file electronically, which can be found at http://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0%"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_002"></span>ITEM
                                            1A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
                                            FACTORS </b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition, results
of operations and future growth prospects. Our business could be harmed by any of these risks. The risks and uncertainties described
below are not the only ones we face. The trading price of our common stock could decline due to any of these risks, and you may lose
all or part of your investment. In assessing these risks, you should also refer to the other information contained in this Annual Report
on Form 10-K, including our consolidated financial statements and related notes. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Risk
Factors Summary</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations are subject to numerous risks, factors and uncertainties, including those outside of our control, that could cause
our actual results to be harmed, including risks regarding the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Relating to Our Business and Industry</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timelines of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the early stage of development of LPCN 1148, LPCN 1114, LPCN 1111, LPCN
1107 and neuro active steroids;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the early stage of development of our research and development programs
and processes and the risk of competition;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the regulation requirements for our product candidates;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    regulatory approval, success, and commercialization of our licensed product candidate, TLANDO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that T-replacement therapies could be found to create, or could be perceived to create, health risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    possible failure to obtain adequate healthcare reimbursement for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    in the TRT market, including the entrance of generic T-gels into the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    licensee&#8217;s ability to commercialize TLANDO may be limited;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    commercialization of our product candidates internally or through collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that we may never receive regulatory approval to market our products outside the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    stringent government regulations concerning the clinical testing of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market&#8217;s acceptance of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians
    and patients using other products may not switch to our product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that regulatory agencies could find that we have improperly promoted off-label uses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    possible failure to comply with federal and state healthcare laws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ongoing outbreak of coronavirus around the world;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain our chief executive officer and other key executives and to attract, retain and motivate qualified personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in managing the growth of the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">re-importation
    of drugs from foreign countries into the United States by our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    product liability claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    failure to comply with the Controlled Substances Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    defense and resolution of any litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cyber
    security risks;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Related to Our Dependence on Third Parties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third-party contractors and service providers for the execution of some aspects of our development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on contract research organizations or other third parties to assist us in conducting clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on suppliers for the active and inactive ingredients for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish successful collaborations for our products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Related to Ownership of Our Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    stock price&#8217;s reaction to the results and timing of clinical trials, regulatory and other decisions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our internal control over financial reporting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and expense to comply with the requirements of being a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    volatility of our share price;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in the value of our warrants outstanding from the November 2019 Offering;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility of delisting of our securities from the Nasdaq Capital Market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">anti-takeover
    provisions in our amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions of
    Delaware law and our stockholder rights plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right of the holders of the common warrants issued in the November 2019 Offering to receive the Black Scholes value of the warrants
    in the event of a fundamental transaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision not to pay dividends on our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    management and directors&#8217; ability to exert influence over our affairs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in the trading price of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    failure of securities or industry analysts to publish accurate research about our business;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Relating to Our Financial Position and Capital Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    need for and ability to obtain substantial additional capital in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    covenants in our loan agreement or our failure to comply with such covenants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to generate sufficient cash flow to satisfy our significant debt service obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    dilution to our existing stockholders from raising any additional capital;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to predict when we will generate product revenues or achieve profitability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    incurrence of significant operating losses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fluctuation in our operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    shares available for issuance to raise capital;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Relating to Our Intellectual Property</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional protection under the Drug Price Competition and Patent Term Restoration Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility of incurring substantial costs as a result of litigation or other proceedings relating to patent and other intellectual
    property rights, or our inability to protect our rights to our products and technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and expense, and any unfavorable outcomes, resulting from any claims for infringing intellectual property rights of third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    fact that we do not have patent protection for our product candidates in a significant number of countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with various procedural, document submission, fee payment and other requirements imposed by governmental patent
    agencies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that we may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their
    former employers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business and Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
timelines of our clinical trials may be impacted by numerous factors and any delays may adversely affect our ability to execute our current
business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expectations regarding the success of our product candidates, including our clinical candidates and lead compounds, and our business
are based on projections which may not be realized for many scientific, business or other reasons. We therefore cannot assure investors
that we will be able to adhere to our current schedule. We set goals that forecast the accomplishment of objectives material to our success:
selecting clinical candidates, product candidates, failures in research, the inability to identify or advance lead compounds, identifying
target patient groups or clinical candidates, the timing and completion of clinical trials, and anticipated regulatory approval. The
actual timing of these events can vary dramatically due to factors such as slow enrollment of subjects in studies, uncertainties in scale-up,
manufacturing and formulation of our compounds, failures in research, the inability to identify clinical candidates, failures in our
clinical trials, requirements for additional clinical trials and uncertainties inherent in the regulatory approval process and regulatory
submissions. Decisions by our partners or collaborators may also affect our timelines and delays in achieving manufacturing capacity.
The length of time necessary to complete clinical trials and to submit an application for marketing approval by applicable regulatory
authorities may also vary significantly based on the type, complexity and novelty of the product candidate involved, as well as other
factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LPCN
1148 is in a very early stage of development and is currently undergoing phase 2 clinical evaluation in a proof-of-concept </i></b>&#160;<b><i>study
for management of liver cirrhosis in male patients and while there are no therapies specifically approved by the FDA for sarcopenia
or cirrhosis beyond treatment of underlying conditions, there are candidates know to be under development for cirrhosis related indication(s).</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LPCN
1148 is in a very early stage of development and consequently the risk that we may fail to commercialize LPCN 1148 and related products
is high.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> This development program is susceptible
to technical failures in ongoing and future clinical studies, regulatory hurdles for further testing and/or meeting FDAs needs for NDA
filing or approval. The results of the current phase 2 clinical evaluation may not support continued development or regulatory approval.
While we believe there is a potential to gain Orphan Drug Designation for an indication or condition in male liver cirrhosis, the
FDA may not grant such designation which could adversely impact development or the commercial potential of LPCN 1148.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LPCN
1144 is in a very early stage of development and may not be further developed for a variety of reasons.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LPCN
1144 is in a very early stage of development and consequently the risk that we fail to commercialize LPCN 1144 and related products is
high. In particular, we have only recently announced topline primary and key secondary endpoint results from our Phase 2 <i>LiFT</i>
clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our results from the <i>LiFT</i> clinical study results were positive for NASH resolution with no worsening of fibrosis, these results
may not be indicative of ultimate success in a larger Phase 2/3 clinical study with required FDA endpoints and populations needed for
regulatory approval of LPCN 1144 for the treatment of NASH.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical
trials, even after achieving positive results in early-stage development. The FDA currently insists on histopathology endpoint for diagnosis
and assessment of efficacy in a pivotal trial. Accordingly, our results from our <i>LiFT</i> study may not be predictive of the results
we may obtain from further studies and trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
factors could significantly affect the prospects for LPCN 1144, including factors relating to the regulatory approval, competitive landscape
and clinical development challenges for LPCN 1144. The anticipated Phase 3 programs for an NDA filing for LPCN 1144 will be very long
and resource intensive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>LPCN 1111 is in a very early stage of development
and may not be further developed for a variety of reasons.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LPCN 1111 is in a very early
stage of development. We have completed a Phase 2a and Phase 2b study in hypogonadal men. Future studies may not have clinical results
that support continued develop and/or a path towards regulatory approval and commercialization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the active ingredient
in LPCN 1111 has only been manufactured on a small scale. Scaling up into larger batches could be challenging and our ability to procure
adequate material in a timely manner to further develop LPCN 1111 is uncertain. We also may not be able to engage a manufacturer who
can supply adequate quantities of the drug substance in compliance with cGMP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Several
factors could significantly affect the prospects for LPCN 1111, including Antares&#8217; option to license LPCN 1111 (TLANDO XR) as such
option is available to them under the Antares License Agreement, and factors relating to the regulatory approval and clinical development
challenges for LPCN 1111 discussed above. The anticipated phase 3 program for an NDA filing for LPCN 1111, however, could be very long
and expensive.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LPCN
1107 is in a very early stage of development and may not be further developed for a variety of reasons.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LPCN
1107 is in a very early stage of development and consequently the risk that we fail to commercialize LPCN 1107 and related products is
high. In particular, we have only conducted three phase 1 clinical studies with this product candidate. Two of the studies were in healthy
pregnant women and one was in healthy women. Although these studies demonstrated oral absorption of LPCN 1107 is possible, we may not
be able to match Cavg blood levels shown with the intramuscular injection comparator product over a longer duration. Furthermore, our
completed phase 1 clinical studies may not be predictive of safety concerns that may arise in pregnant women or demonstrate that LPCN
1107 has an adequate safety profile to warrant further development. The FDA may also require further preclinical studies. All of these
factors can impact the timing of and our ability to continue development of LPCN 1107.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical
trials, even after achieving positive results in early-stage development. Accordingly, our results from our Phase 1a, our Phase 1b and
our multi-dose PK dose selection studies may not be predictive of the results we may obtain from further studies and trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
traditional PK/PD based phase 2 clinical study in the intended patient population may not be required prior to entering into Phase 3.
Therefore, based on the results of our multi-dose PK study results, we had an end-of-phase 2 meeting with the FDA in the second quarter
of 2016, as well as subsequent guidance meetings to agree on a pivotal Phase 2b/3 development plan for LPCN 1107. However, these discussions
will need to be updated based on recent developments with Covis&#8217; Makena&#174;. We plan to resume our interactions with the FDA to
discuss our pivotal Phase 2b/3 clinical trial design and better understand next steps to advance LPCN 1107 after completion of our ongoing
food effect study. Once the pivotal Phase 2b/3 clinical trial is started, the anticipated Phase 2b/3 program for an NDA filing for LPCN
1107 will be very long and expensive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has concluded that Makena, based on Makena&#8217;s failed definitive PROLONG study, a competing product with the same active ingredient
and similar target indication, is ineffective and has proposed that it be withdrawn from the market, but the final decision is still
pending. It is entirely possible that any pivotal study may require a placebo-controlled trial design. Therefore, given the uncertainly
of the status of the current standard of care, Makena and its generics, Lipocine may face significant challenges in patient recruitment
for a placebo-controlled trial, be faced with significant resource investment to conduct additional trials, and face potential perceived
risk of efficacy failure in a pivotal study resulting in no further development of LPCN 1107.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>LPCN 1154 and LPCN 2101 a very early stage
of development and may not be further developed for a variety of reasons.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our oral NAS comprising programs
(LPCN 1154 and LPCN 2101) are in a very early stage of development and consequently the risk that we may fail to commercialize LPCN 1154,
LPCN 2101, and related products is high. We have not conducted clinical studies of these programs and the ultimate regulatory or technical
success of each of the neuroactive steroids under investigation in these programs is uncertain. The current limited pre-clinical results
we have observed may not be replicated in larger studies, future PK phase 2, or pivotal studies with a potential &#8220;to be marketed
formulation&#8221;. We may not be able get IND clearance in a timely manner or may be unable to further test in-clinic due to other regulatory
hurdles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, our oral NAS
product candidates may not be effective in treating PPD or WWE or may not have differentiation from competitive products on the market
or in development. We may expend significant resources before determining that these programs are not viable candidates for regulatory
approval and commercialization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
research and development programs and processes are at an early stage of development, which makes it difficult to evaluate our business
and prospects or predict if or when we will successfully commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations to date have primarily been limited to conducting research and development activities under license and collaboration agreements.
Our current portfolio consists of product candidates at various clinical stages of development in addition to our out-licensed product
TLANDO. We have never marketed or commercialized a drug product. Consequently, any predictions about our future performance may not be
as accurate as they could be if we were further along our commercialization path. In addition, as a pre-commercial stage business, we
may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical product candidates are at an early stage of development and will require significant further investment and regulatory approvals
prior to marketing and commercialization. As such, our product development processes for oral neuro active steroids, LPCN 1148, LPCN
1111, LPCN 1144, and LPCN 1107 are very risky and uncertain, and our product candidates may fail to advance beyond the current study.
Even if we obtain required financing, we cannot ensure successful product development or that we will obtain regulatory approval or successfully
commercialize any of our product candidates and generate product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>All
of our clinical candidates will be subject to extensive regulation which can be costly and time consuming, cause delays or prevent approval
of the products for commercialization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical development of oral neuro active steroids, LPCN 1148, LPCN 1111, LPCN 1144, and LPCN 1107 and any future product candidates
is subject to extensive regulations by the FDA. Product development is a very lengthy and expensive process and can vary significantly
based upon the product candidate&#8217;s novelty and complexity. Regulations are subject to change and regulatory agencies have significant
discretion in the approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
statutes and regulations govern human testing and the manufacture and sale of human therapeutic products in the United States. Such legislation
and regulation bears upon, among other things, the approval of protocols and human testing, the approval of manufacturing facilities,
safety of the product candidates, testing procedures and controlled research, review and approval of manufacturing, preclinical and clinical
data prior to marketing approval including adherence to cGMP during production and storage as well as regulation of marketing activities
including advertising and labeling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to obtain regulatory clearance for the commercial sale of any of our product candidates, we must demonstrate through preclinical
studies and clinical trials that the potential product is safe and efficacious for use in humans for each target indication. Obtaining
approval of any of our product candidates is an extensive, lengthy, expensive and uncertain process, and the FDA may delay, limit or
deny approval for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to demonstrate that the product candidate is safe and effective to the satisfaction of the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval;</span></td></tr>
</table>

<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    contract research organization that we retain to manage our clinical trials may take actions outside of our control that materially
    adversely impact our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may not find the data from preclinical studies and clinical trials sufficient to demonstrate that a particular product candidate&#8217;s
    clinical and other benefits outweigh its safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with our interpretation of data from our preclinical studies and clinical trials or may require that we conduct
    additional trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may not accept data generated at our clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    our NDA once submitted is reviewed by an Advisory Committee, the FDA may have difficulties scheduling an Advisory Committee meeting
    in a timely manner or the Advisory Committee may recommend against approval of our application or may recommend that the FDA require,
    as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and
    use restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may require development of a REMS as a condition of approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may require longer or additional duration of stability data on the clinical lots prior to initiation of further clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may identify deficiencies in the formulation or stability of our product candidates or products, or relating to our manufacturing
    processes or facilities, or in the processes and facilities of the contract manufacturing organization (&#8220;CMO&#8221;), our suppliers,
    or other third parties that may be utilized in the production supply chain of our products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to TLANDO and LPCN 1111, the FDA may not grant a three-year exclusivity as the active is a Testosterone prodrug.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: -17.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product
candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain FDA approval for their
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that current regulations relating to regulatory approval will not change or become more stringent. The FDA may
also require that we amend clinical trial protocols and/or run additional trials in order to provide additional information regarding
the safety, efficacy or equivalency of any compound for which we seek regulatory approval. Moreover, any regulatory approval of a drug
which is eventually obtained may entail limitations on the indicated uses for which that drug may be marketed. Furthermore, product approvals
may be withdrawn or limited in some way if problems occur following initial marketing or if compliance with regulatory standards is not
maintained. The FDA could become more risk averse to any side effects or set higher standards of safety and efficacy prior to reviewing
or approving a product. This could result in a product not being approved</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are substantially dependent on the success of our licensed product candidate, TLANDO, for which we received tentative approval
from the FDA and which may not receive final regulatory approval or be successfully commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TLANDO
is currently our only product candidate that has completed Phase 3 clinical trials. In October 2021, we entered into the Antares License
Agreement with Antares, pursuant to which we granted Antares an exclusive, royalty-bearing, sublicensable right and license to develop
and commercialize, upon final approval of TLANDO from the FDA, our TLANDO product with respect to TRT in the U.S. None of our other products
have been approved for sale. Therefore, at this stage, our ability to realize revenue depends on TLANDO&#8217;s successful regulatory approval and commercialization, if final approval is obtained. The commercial success of TLANDO depends almost entirely on
Antares&#8217; commercialization efforts and we have very limited ability to influence Antares&#8217; efforts, including the amount and
timing of resources they devote, if any, to the commercialization of TLANDO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 8, 2020, the FDA informed us that it granted tentative approval to TLANDO for testosterone replacement therapy in adult males
indicated for conditions associated with a deficiency or absence of endogenous testosterone<span style="background-color: white">: </span>primary
hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). In granting tentative approval, the
FDA concluded that TLANDO has met all required quality, safety and efficacy standards necessary for approval, but TLANDO has not received
final approval and is not eligible for final approval and marketing in the U.S. until the expiration of the exclusivity period previously
granted to Clarus with respect to JATENZO&#174;, which expires on March 27, 2022. Antares will not be able to market TLANDO in the U.S.
until that time. Any delay in receiving final FDA approval could adversely affect Antares&#8217;s commercialization efforts and ability
to compete with other TRT products and have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the PREA, if TLANDO receives full approval, our licensing partner, Antares, will need to address the PREA requirement to assess the safety
and effectiveness of TLANDO in pediatric patients. The FDA has also required us to conduct certain post-marketing studies including:
(i) conduct an appropriately designed label comprehension and knowledge study that assesses patient understanding of key risk messages
in the Medication Guide for TLANDO and (ii) conduct an appropriately designed one-year trial to evaluate development of adrenal insufficiency
with chronic TLANDO therapy. The timetables for these post-marketing requirements will be established at the time of full approval of
TLANDO. Antares will be responsible for any required studies after approval of TLANDO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if final regulatory approval of TLANDO is obtained, the success of TLANDO, and our ability to realize royalty revenue, will depend on
the commercialization efforts of Antares. If Antares is not able to successfully commercialize TLANDO, we may not realize any royalty
revenue under the Antares License Agreement and our business could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we seek regulatory approval of TLANDO outside the United States, such markets have requirements for approval of drug candidates
with which we must comply prior to marketing. Obtaining regulatory approval for marketing of TLANDO in one country does not ensure we
will be able to obtain regulatory approval in other countries but a failure or delay in obtaining regulatory approval in one country
may have a negative effect on the regulatory process in other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approval of TLANDO, once obtained, including the FDA&#8217;s tentative approval, may be withdrawn. Ultimately, the failure
to obtain and maintain regulatory approvals would prevent TLANDO from being marketed and would have a material adverse effect on our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
T-replacement therapies are found, or are perceived, to create health risks, our ability to realize any revenue from TLANDO and
LPCN 1111 could be materially adversely affected, and our business could be harmed. Even if our TLANDO and our LPCN
1111 are approved, physicians and patients may be deterred from prescribing and using T-replacement therapies, which could depress
demand for TLANDO and LPCN 1111 and compromise the successful commercialization of TLANDO and LPCN 1111, if final approval
is obtained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
publications have suggested potential health risks associated with T-replacement therapy, such as increased cardiovascular disease risk,
including increased risk of heart attack or stroke, fluid retention, sleep apnea, breast tenderness or enlargement, increased red blood
cells, development of clinical prostate disease, including prostate cancer, and the suppression of sperm production. These potential
health risks are described in various articles, including the following publications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    2014 publication in PLOS ONE, which found that, compared to the one year prior to beginning T-replacement therapy, the risk of heart
    attack doubled 90 days after the start of T deficiency treatment in older men regardless of their history of heart disease and was
    two to three times higher in men younger than 65 with a history of heart disease;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    2013 publication in the <i>Journal of the American Medical Association</i>, which reported that hypogonadal men receiving T-replacement
    therapy developed a 30% increase in the risk of stroke, heart attack and death; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    2013 publication in BMC Medicine, which concluded that exogenous T increased the risk of cardiovascular-related events, particularly
    in trials not funded by the pharmaceutical industry.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prompted
by these events, the FDA announced on January 31, 2014, that it will investigate the risk of stroke, heart attack, and death in men taking
FDA-approved testosterone products and that the FDA would hold a T-class Advisory Committee meeting on September 17, 2014, to discuss
this topic further. The FDA has also asked health care professionals and patients to report side effects involving prescription testosterone
products to the agency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the FDA&#8217;s announcement, the Endocrine Society, a professional medical organization, released a statement in February 2014 in support
of further studies regarding the risks and benefits of FDA-approved T-replacement products for men with age-related T deficiency. Specifically,
the Endocrine Society noted that large-scale randomized controlled trials are needed to determine the risks and benefits of T-replacement
therapy in older men. In addition, the Endocrine Society recommended that patients should be informed of the potential cardiovascular
risks in middle-aged and older men associated with T-replacement therapies. Also following the FDA&#8217;s announcement, Public Citizen,
a consumer advocacy organization, petitioned the FDA to add a &#8220;black box&#8221; warning about the increased risks of heart attacks
and other cardiovascular dangers to the product labels of all T-replacement therapies. In addition, this petition urged the FDA to delay
its decision date on approving Aveed, a long-acting T-injectable developed by Endo, which was subsequently approved by the FDA in March
2014. In July 2014, the FDA responded to the Public Citizen petition and denied the petition. Additionally, in June 2014 the FDA announced
that it would require the manufacturers of testosterone drugs to update the warning label to include blood clots including deep vein
thrombosis and pulmonary embolism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the T-class Advisory Committee meeting held on September 17, 2014, the Advisory Committee discussed (i) the identification of the appropriate
patient population for whom T-replacement therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events,
defined as non-fatal stroke, non-fatal myocardial infarction and cardiovascular death associated with T-replacement therapy. At the meeting,
16 of the 21 members of the Advisory Committee voted that the FDA should require sponsors of testosterone products to conduct a post
marketing study (e.g. observational study or controlled clinical trial) to further assess the potential cardiovascular risk. Further,
12 of these voted that such post marketing study be required only if the T-replacement therapy is also approved for age-related hypogonadism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Advisory Committee also held a meeting on September 18, 2014, to evaluate the safety and efficacy of JATENZO&#174; (previously Rextoro),
an oral TU submitted to the FDA by Clarus for the proposed indication of T-replacement therapy. 18 of the 21 members of the Advisory
Committee voted that the overall benefit/risk profile of JATENZO&#174; was not acceptable to support approval for T-replacement therapy.
The Advisory Committee agreed that an oral TU as a T-replacement therapy is promising and that it would be of great value to patients
to have an oral treatment option, but they did not believe the current JATENZO&#174; data supported approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 3, 2015, the FDA issued a safety announcement addressing the Advisory Committee&#8217;s recommendations and communicated its expectations
related to label revisions and additional clinical requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s safety assessment recommended the following label modifications/restrictions in the indicated population for T-replacement
therapy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    use of T-replacement products to men who have low testosterone caused by certain medical conditions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
    to initiating use of T-replacement products, confirm diagnosis of hypogonadism by ensuring that serum testosterone has been measured
    in the morning on at least two separate days and that these concentrations are below the normal range;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding
    cautionary language stating that the safety and efficacy of TRT products with age-related hypogonadism have not been established;
    and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding
    cautionary language stating that some studies have shown an increased risk of myocardial infarction and stroke associated with use
    of T-replacement products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the FDA stated that it will require manufacturers of approved T-replacement products to conduct a well-designed clinical trial
to more clearly address the question of whether an increased risk of heart attack or stroke exists among users of T-replacement products.
The FDA encouraged manufacturers to work together on conducting a clinical trial, although the FDA will allow manufacturers to work separately
if they so choose.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 8, 2020, the FDA tentatively approved TLANDO. As part of their approval, the FDA has required us to include certain warnings
and precautions in our labeling for TLANDO, including a &#8220;black box warning,&#8221; including warnings relating to blood pressure
increases and an indication that the safety and efficacy of TLANDO in males less than 18 years has not been established. These warnings
may deter physicians and patients from using TLANDO after it has received final approval, which could adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has also required us to conduct certain post-marketing studies to (i) assess patient understanding of key risks relating to TLANDO
and (ii) evaluate development of adrenal insufficiency with chronic TLANDO therapy. Antares is responsible for conducting these post-marketing
studies. Negative outcomes from such studies could adversely affect the ability of Antares to successfully commercialize TLANDO, which
would adversely affect our ability to realize royalty revenue under the Antares License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to obtain adequate healthcare reimbursement for our products, our revenue-generating ability will be diminished and there is
no assurance that the anticipated market for our products will be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that there could be many different applications for products successfully derived from our technologies and that the anticipated
market for products under development could continue to expand. However, due to competition from existing or new products, potential
changes to the class TRT label by the FDA and the yet to be established commercial viability of our products, no assurance can be given
that these beliefs will prove to be correct. Physicians, patients, formularies, payors or the medical community in general may not accept
or utilize any products that we or our collaborative partners may develop. Other drugs may be approved during our clinical testing which
could change the accepted treatments for the disease targeted and make our compound obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize our products with success may depend, in part, on the extent to which coverage and adequate reimbursement to
patients for the cost of such products and related treatment will be available from governmental health administration authorities, private
health coverage insurers and other organizations, as well as the ability of private payors to pay for or afford our drugs. Adequate third-party
coverage may not be available to patients to allow us to maintain price levels sufficient for us to realize an appropriate return on
our investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coverage
and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payers can be critical
to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more
established or lower cost therapeutic alternatives are already available or subsequently become available. Additionally, current manufacturers
of drug products may have agreements with payors that may limit the ability of new products to get on formulary or require a step edit
with an existing product before reimbursement or a new product will occur. Even if we obtain coverage for our products, the resulting
reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are less
likely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our
products. Payers may require a more arduous prior authorization process as a condition to payment for TRT therapy. This could adversely
affect the market for TRT products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and in many other countries, pricing and/or profitability of some or all prescription pharmaceuticals and biopharmaceuticals
are subject to varying degrees of government control. Healthcare reform and controls on healthcare spending may limit the price we charge
for any products and the amounts thereof that we can sell. In particular, in the United States, the federal government and private insurers
have changed and have considered ways to change, the manner in which healthcare services are provided. In March 2010, ACA became law
in the United States. ACA substantially changes the way healthcare is financed by both governmental and private insurers and significantly
affects the healthcare industry. The provisions of ACA of importance to our potential product candidates include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers,
    and enhanced penalties for noncompliance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated
    prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s
    outpatient drugs to be covered under Medicare Part D;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension
    of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed
    care organizations;</span></td></tr>
</table>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals
    beginning in 2014 and by adding new mandatory eligibility categories for certain individuals with specified income levels, thereby
    potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
</table>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0"></p>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    requirements to report annually certain financial arrangements with physicians, certain other healthcare professionals, and teaching
    hospitals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new requirement to annually report drug samples that manufacturers and distributors provide to licensed practitioners, pharmacies
    of hospitals and other healthcare entities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
    research, along with funding for such research.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since ACA was enacted. On August 2, 2011, the Budget Control Act of
2011, created, among other things, measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked
with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required
goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions
to Medicare payments to providers of up to 2% per fiscal year, starting in 2013. On January 2, 2013, President Obama signed into law
the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the
statute of limitations period for the government to recover overpayments to providers from three to five years. The Medicare Access and
CHIP Reauthorization Act of 2015 was signed into law on April 16, 2015 and implemented the most significant change in Medicare reimbursement
since the ACA was enacted. This 2015 law authorizes a new Medicare pay &#8211;for-performance reimbursement system for physicians, which
will reward physicians for performance on metrics related to quality of care, resource use, meaningful use of electronic medical records,
and clinical practice improvement activities. The Bipartisan Budget Act was enacted on November 2, 2015, and among provisions, restricts
the types of facilities that may receive hospital reimbursement under Medicare. These new laws may result in additional reductions in
Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that ACA will result in additional downward pressure on the reimbursement we may receive for any approved and covered product
and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar
reduction in payments from private payers. In the future, the U.S. government may institute further controls and different reimbursement
schemes and limits on Medicare and Medicaid spending or reimbursement that may affect the payments we could collect from sales of any
products in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Department of Health and Human Services Office of Inspector General issued final regulations on November 30, 2020 to eliminate safe harbor
protection under the anti-kickback statute for drug price reductions that pharmaceutical manufacturers pay to Medicare and Medicaid plan
sponsors and their pharmacy benefit managers. The proposal reflects a clear intent to substantially alter many of the current drug discount
and services compensation practices among pharmaceutical manufacturers and Medicare and Medicaid managed care organizations and their
pharmacy benefit managers. The proposal also reflects a skepticism that current drug discount and compensation practices among manufacturers
and pharmacy benefit managers are sufficiently transparent to health plans to ensure that all appropriate cost reductions and value is
passed through to health plans and reflected in lower health plans costs and lower premiums for beneficiaries. The Biden Administration
has delayed the effective date of this rule until January 1, 2023, and a lawsuit initiated by the Pharmaceutical Care Management Administration
has challenged this final rule. If the regulation becomes effective, it could result in lower prices for pharmaceutical products in general.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Centers for Medicare and Medicaid Services issued an interim final rule on November 20, 2020, that would tie prices for certain drugs
under Medicare Part B to the lowest price for those drugs available in certain countries that are members of the Organization for Economic
Co-operation and Development. This &#8220;most favored nation&#8221; drug pricing rule is also the subject of lawsuits, and a federal
court has placed an injunction on the implementation of the rule. This rule, if finalized, could also result in lower prices for pharmaceutical
products in general.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biden Administration will have the opportunity to address these regulations as well as drug pricing, health care access, and other health
care reform issues. Any further legislative or administrative action to reduce reimbursement or health benefits to beneficiaries under
the Medicare or Medicaid program could affect the payment we could collect from sale of any product in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is substantial competition in the TRT market, which may result in others discovering, developing or commercializing products before or
more successfully than us or our licensing partner.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to face significant competition for any of our product candidates, if approved. In particular, once final approval is obtained,
TLANDO would compete in the T-replacement therapies market, which is competitive and currently dominated by the sale of T-gels and T-injectables.
Receipt of future potential payments under our licensing agreement will depend, in large part, on our licensing partner&#8217;s ability
to obtain an adequate share of the market. Potential competitors in North America, Europe and elsewhere include major pharmaceutical
companies, specialty pharmaceutical companies, biotechnology firms, universities and other research institutions and government agencies.
Other pharmaceutical companies may develop oral T-replacement therapies that compete with TLANDO. For example, because TU is not a patented
compound and is commercially available to third parties, it is possible that competitors may design methods of TU administration that
would be outside the scope of the claims of either our issued patents or our patent applications. This would enable their products to
effectively compete with TLANDO, which could have a negative effect on potential payments under our licensing agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following T-replacement therapies currently on the market in the United States would compete with TLANDO:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral-T,
    such as Jatenzo;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T-gels,
    such as AndroGel (marketed by Abbvie) and Perrigo&#8217;s AB-rated 1% generic of AndroGel, Teva&#8217;s 1% generic of AndroGel, Testim
    and its generics (marketed by Endo Health Solutions, or Endo), and Fortesta and its generics (marketed by Endo);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T-injectables,
    including a subcutaneous auto-injector, XYOSTED, marketed by Antares Pharma, Inc.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Branded,
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer-acting injectables, such as Aveed (marketed
    by Endo);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T-nasals,
    such as Natesto (marketed by Acerus);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">methyl-T,
    such as Methitest (marketed by Impax) and Testred (marketed by Valeant);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transdermal
    patches, such as Androderm (marketed by Allergan);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">buccal
    patches, such as Striant (marketed by Endo);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">generic
    testosterone enanthate intra-muscular injectables;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorized
    generic and generic T-gels; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subcutaneous
    injectable pellets, such as Testopel (marketed by Endo).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2019, Clarus&#8217; product JATENZO&#174;, an oral TU product, was approved by the FDA and also received three years of marketing
exclusivity. On February 10, 2020, Clarus announced that JATENZO&#174; has been launched and is commercially available. Based on the FDA&#8217;s
tentative approval of TLANDO, the marketing of TLANDO cannot begin until after March 27, 2022, the expiration of the exclusivity period
granted to Clarus with respect to JATENZO&#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also aware of other pharmaceutical companies that have T-replacement therapies or testosterone therapies in development that may
be approved for marketing in the United States or outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on publicly available information, we believe that several other T-replacement therapies that would be competitive with TLANDO are in
varying stages of development, some of which may be approved, marketed and/or commercialized prior to TLANDO. These therapies include
T-gels, oral-T, an aromatase inhibitor, a new class of drugs called Selective Androgen Receptor Modulators and hydroalcoholic gel formulations
of DHT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the competitive landscape above, TLANDO will not be the only oral TRT to market, which may significantly affect the market acceptance
and commercial success of TLANDO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
many of our potential competitors have substantially greater financial, technical, and human resources than we do and significantly greater
experience in the discovery and development of drug candidates, obtaining FDA and other marketing approvals of products and the commercialization
of those products. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval for drugs and achieving
widespread market acceptance. Our competitors&#8217; drugs may be more effective, or more effectively marketed and sold, than our products
and may render our products obsolete or non-competitive before we can recover the expenses of developing and commercializing them. We
anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available.
Failure to successfully compete in this market would materially and negatively impact our business and operations.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if TLANDO is approved by the FDA, our licensee&#8217;s ability to commercialize TLANDO may be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
licensee partner&#8217;s ability to commercialize TLANDO, should it receive final approval, is uncertain. Our licensee&#8217;s ability
to commercially launch TLANDO is contingent upon numerous factors including, among other things, receipt of final FDA approval, the completion
of post-marketing studies, the availability of commercial launch supplies, the impact of COVID-19, commercial acceptance by patients,
the medical community, and third-party payors, and the resources that our licensee devotes to the commercialization of TLANDO.
If our licensee is unable to successfully launch TLANDO commercially at scale, our business and operations could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will not be able to successfully commercialize our product candidates without establishing sales, marketing and market access capabilities
internally or through collaborators.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a sales, marketing and market access staff. If and when any of our product candidates are commercialized, we may
not be able to find suitable sales and marketing staff and collaborators for our product candidates. The outside collaborators we work
with, including Antares under the Antares License Agreement with respect to TLANDO, may not be adequate or successful and any collaborators
could terminate or materially reduce the effort they direct to our products. The development of collaborations or an internal sales force
and marketing, market access and sales capability will require significant capital, management resources and time. The cost of establishing
such a sales force may exceed any potential product revenues and our marketing, market access and sales efforts may be unsuccessful.
If we are unable to develop an internal marketing, market access and sales capability or if we are unable to enter into a marketing and
sales arrangement with a third party on acceptable terms, we may be unable to successfully commercialize our product candidates.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive marketing approval in the United States, we may never receive regulatory approval to market our products outside the United
States, which could reduce the size of our potential markets and have a material adverse impact on our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding safety and efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
procedures vary among countries and can involve additional product candidate testing and additional administrative review periods. The
time required to obtain approvals in other countries might differ from that required to obtain FDA approval. The marketing approval process
in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. In
particular, in many countries outside of the United States, products must receive pricing and reimbursement approval before the product
can be commercialized. This can result in substantial delays in such countries. Marketing approval in one country does not ensure marketing
approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the regulatory
process in others. Failure to obtain marketing approval in other countries or any delay or setback in obtaining such approval would impair
our ability to market our products in such foreign markets. Any such impairment would reduce the size of our potential markets, which
could have an adverse impact on our business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to stringent government regulations concerning the clinical testing of our products and will continue to be subject to government
regulation of any product that receives regulatory approval. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
statutes and regulations govern human testing and the manufacture and sale of human therapeutic products in the United States and other
countries where we intend to market our products. Such legislation and regulation bears upon, among other things, the approval of clinical
study protocols and human testing of our products, the approval of manufacturing facilities, testing procedures and controlled research,
the review and approval of manufacturing, preclinical and clinical data prior to marketing approval, including adherence to cGMP during
production and storage, and marketing activities including advertising and labeling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials may be delayed or suspended at any time by us or by the FDA or by other similar regulatory authorities if it is determined at
any time that patients may be or are being exposed to unacceptable health risks, including the risk of death, or if compounds are not
manufactured under acceptable cGMP conditions or with acceptable quality. Current regulations relating to regulatory approval may change
or become more stringent. The agencies may also require additional clinical trials to be run in order to provide additional information
regarding the safety, efficacy or equivalency of any compound for which we seek regulatory approval. Moreover, any regulatory approval
of a drug which is eventually obtained may entail limitations on the indicated uses for which that drug may be marketed. Furthermore,
product approvals may be withdrawn or limited in some way if problems occur following initial marketing or if compliance with regulatory
standards is not maintained. Regulatory agencies could become more risk adverse to any side effects or set higher standards of safety
and efficacy prior to reviewing or approving a product. This could result in a product not being approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, or any future marketing collaborators or CMOs, fail to comply with applicable regulatory requirements, we may be subject to sanctions
including fines, product recalls or seizures and related publicity requirements, injunctions, total or partial suspension of production,
civil penalties, suspension or withdrawals of previously granted regulatory approvals, warning or untitled letters, refusal to approve
pending applications for marketing approval of new products or of supplements to approved applications, import or export bans or restrictions,
and criminal prosecution and penalties. Any of these penalties could delay or prevent the promotion, marketing or sale of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
successful commercialization of our product candidates and ability to generate significant revenue will depend on achieving market acceptance.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates are successfully developed and receive regulatory approval, they may not gain market acceptance among physicians,
patients, healthcare payers such as private insurers or governments and other funding parties and the medical community. The degree of
market acceptance for our products, if approved, will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any adverse side effects; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in the labeling approved by the FDA; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of alternative treatments, including a number of competitive therapies already approved or expected to be commercially launched in
    the near future; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution
    and use restrictions imposed by the FDA or agreed to by us as part of a mandatory REMS or voluntary risk management plan; </span></td></tr>
  </table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    and cost effectiveness; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our or any future collaborators&#8217; sales and marketing strategies; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to increase awareness of our products through marketing efforts; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain sufficient third-party coverage or reimbursement; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay out-of-pocket in the absence of third-party coverage. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients,
we may not generate sufficient revenue from our products and we may never become or remain profitable. In addition, our efforts to educate
the medical community and third-party payors on the benefits of our products may require significant resources and may never be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain marketing approval for our products, physicians and patients using existing products may choose not to switch to our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians
often show a reluctance to switch their patients from existing drug products even when new and potentially more effective and convenient
treatments enter the market. Also, physicians may be reluctant to switch patients if adequate reimbursement for new products is not available.
In addition, patients often acclimate to the brand or type of drug product that they are currently taking and do not want to switch unless
their physicians recommend switching products or they are required to switch drug treatments due to lack of reimbursement for existing
drug treatments and only if the new product has adequate reimbursement. The existence of either or both of physician or patient reluctance
in switching to our products would have an adverse effect on our operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found
to have improperly promoted off-label uses, we may become subject to significant liability. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our
product candidates. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies
as reflected in the product&#8217;s approved labeling. The FDA may impose further requirements or restrictions on the distribution or
use of our product candidates as part of a REMS plan, such as limiting prescribing to certain physicians or medical centers that have
undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll
in a registry. If we receive marketing approval for our product candidates, physicians may nevertheless prescribe our products to their
patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become
subject to significant liability, including potential liability under federal civil and criminal false claims acts. The federal government
has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging
in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified
promotional conduct is changed or curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws,
we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid
or other third-party payers, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217;
rights are and will be applicable to our business. We could be subject to healthcare fraud and abuse and patient privacy regulation by
both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which constrains our marketing practices, educational programs, pricing policies, and relationships
    with healthcare providers or other entities, by prohibiting, among other things, soliciting, receiving, offering or paying remuneration,
    directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an
    item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities
    from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that
    are false or fraudulent; </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    which among other things created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit
    program or making false statements relating to healthcare matters; </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act, which, among other things, requires manufacturers of drugs, devices, biologics and medical
    supplies for which payment is available under certain federal healthcare programs to report annually information related to &#8220;payments
    or other transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors)
    and teaching hospitals, and ownership and investment interests held by certain healthcare professionals and their immediate family
    members; </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which
    imposes certain requirements relating to the privacy, security, breach notification, and transmission of individually identifiable
    health information; and </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items
    or services reimbursed by any third-party payer, including commercial insurers, and state and foreign laws governing the privacy
    and security of health information in certain circumstances, many of which differ from each other in significant ways and often are
    not preempted by HIPAA, thus complicating compliance efforts. </span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of available statutory and regulatory exceptions, it is possible that some of our business
activities could be subject to challenge under one or more of such laws. To the extent that any of our product candidates is ultimately
sold in countries other than the United States, we may be subject to similar laws and regulations in those countries. If we or our operations
are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject
to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, exclusion from participating in government
healthcare programs, contractual damages, reputational harm and the curtailment or restructuring of our operations. Any penalties, damages,
fines, curtailment or restructuring of our operations could materially adversely affect our ability to operate our business and our financial
results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks
cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause
us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving
and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Department of Health and Human Services Office of Inspector General proposed new regulations on February 6, 2019 to eliminate safe harbor
protection under the anti-kickback statute for drug price reductions that pharmaceutical manufacturers pay to Medicare and Medicaid plan
sponsors and their pharmacy benefit managers. The proposal reflects a clear intent to substantially alter many of the current drug discount
and services compensation practices among pharmaceutical manufacturers and Medicare and Medicaid managed care organizations and their
pharmacy benefit managers. The proposal also reflects a skepticism that current drug discount and compensation practices among manufacturers
and pharmacy benefit managers are sufficiently transparent to health plans to ensure that all appropriate cost reductions and value is
passed through to health plans and reflected in lower health plans costs and lower premiums for beneficiaries. If the proposal is finalized,
it could result in lower prices for pharmaceutical products in general. The Biden Administration has delayed the effective date of this
rule until January 1, 2023, and a lawsuit initiated by the Pharmaceutical Care Management Administration has challenged this final rule.
If the regulation becomes effective, it could result in lower prices for pharmaceutical products in general.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biden Administration will have the opportunity to address these regulations as well as drug pricing, health care access, and other health
care reform issues. Any further legislative or administrative action to reduce reimbursement or health benefits to beneficiaries under
the Medicare or Medicaid program could affect the payment we could collect from sale of any product in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
ongoing outbreak of coronavirus around the world could adversely impact our business and operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus, SARS-CoV-2, was reported to have surfaced in Wuhan, China. Since then, SARS-CoV-2, and
the resulting disease COVID-19, has spread to multiple countries, including the United States and all of the primary markets where we
conduct business. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duration and extent of COVID-19&#8217;s impact on our business may be difficult to assess or predict. The widespread pandemic has resulted,
and may continue to result for an extended period, in significant disruption of global financial markets, reducing our ability to access
capital, which would negatively affect our liquidity. Further, quarantines or government reaction or shutdowns for COVID-19 could disrupt
our operations and harm our business, financial condition and results of operations. Our key personnel and other employees could also
be affected by COVID-19, potentially reducing their availability, and an outbreak such as COVID-19 or the procedures we take to mitigate
its effect on our workforce could reduce the efficiency of our operations or prove insufficient. We may delay or reduce certain capital
spending and certain projects until the travel and logistical impacts of COVID-19 are lifted, which will delay the completion of such
projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the conduct of clinical trials and studies required to obtain regulatory approvals for our products have been and we expect
may continue to be affected by the COVID-19 pandemic. As hospital resources are prioritized for the COVID-19 outbreak and quarantines
impede patient movement or interrupt healthcare services, clinical studies may continue to be disrupted. If we are unable to successfully
complete our clinical studies, our business and operating results will be harmed. Further, we believe that subject drop-out rates and
the number of subjects that ultimately complete clinical studies could be negatively impacted by COVID-19. Interruptions caused by COVID-19
may also limit our ability to collect data from clinical studies. If we are unable to complete or effectively collect data from clinical
studies, our business and operating results will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 outbreak is highly uncertain and subject
to change. We do not yet know the full extent of potential delays or impacts on our business or the global economy as a whole. However,
these effects have harmed our business, financial condition and results of operations in the near term and could have a continuing material
impact on our operations, sales and ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success depends on our ability to retain our chief executive officer and other key executives and to attract, retain and motivate
qualified personnel. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on Dr. Mahesh V. Patel and the other principal members of our executive team. Employment with our executives and
other employees are &#8220;at will&#8221;, meaning that there is no mandatory fixed term and their employment with us may be terminated
by us or by them for any or no reason. The loss of the services of any of our executives or other key employees might impede the achievement
of our research, development and commercialization objectives. Recruiting and retaining qualified scientific personnel, and accounting
personnel will also be critical to our success. We may not be able to attract and retain qualified personnel on acceptable terms, or
at all, given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition
for the hiring of scientific personnel from universities and research institutions. Failure to succeed in clinical trials may make it
more challenging to recruit and retain qualified scientific personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development
and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under
consulting or advisory contracts with other entities that may limit their availability to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to grow our Company, and we may encounter difficulties in managing this growth, which could disrupt our operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had 13 employees. To manage our anticipated future growth, we must continue to implement and improve our managerial,
operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our
management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial
amount of time to managing these growth activities. Due to our limited resources, we may not be able to effectively manage the expansion
of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, and give
rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The
physical expansion of our operations may lead to significant costs and may divert financial resources from other projects. If our management
is unable to effectively manage our future growth, our expenses may increase more than expected, our ability to generate revenue could
be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize
our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
legislation and actions by state and local governments may permit re-importation of drugs from foreign countries into the United States,
including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect
our operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
licensing partner may face competition for TLANDO, if final approval is received, from lower priced T-replacement therapies from foreign
countries that have placed price controls on pharmaceutical products. The Medicare Prescription Drug Improvement and Modernization Act
of 2003 contains provisions that may change U.S. importation laws and expand pharmacists&#8217; and wholesalers&#8217; ability to import
lower priced versions of an approved drug and competing products from Canada, where there are government price controls. These changes
to U.S. importation laws will not take effect unless and until the Secretary of Health and Human Services certifies that the changes
will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products
to consumers. The Secretary of Health and Human Services has not yet announced any plans to make this required certification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of federal legislative proposals have been made to implement the changes to the U.S. importation laws without any certification
and to broaden permissible imports in other ways. Even if the changes do not take effect, and other changes are not enacted, imports
from Canada and elsewhere may continue to increase due to market and political forces, and the limited enforcement resources of the FDA,
U.S. Customs and Border Protection and other government agencies. For example, Pub. L. No. 111-83, which was signed into law in October
2009, provides appropriations for the Department of Homeland Security for the 2010 fiscal year, expressly prohibits U.S. Customs and
Border Protection from using funds to prevent individuals from importing from Canada less than a 90-day supply of a prescription drug
for personal use, when the drug otherwise complies with the Federal Food, Drug, and Cosmetic Act. Further, several states and local governments
have implemented importation schemes for their citizens, and, in the absence of federal action to curtail such activities, we expect
other states and local governments to launch importation efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
importation of foreign products that compete with our products could have an adverse effect on our revenue and profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become subject to the risk of product liability claims. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater
risk if we commercialize any products. Human therapeutic products involve the risk of product liability claims and associated adverse
publicity. Currently, the principal risks we face relate to patients in our clinical trials, who may suffer unintended consequences.
Claims might be made by patients, healthcare providers or pharmaceutical companies or others. We may be sued if any product we develop
allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, to our knowledge, HPC has not been administered orally in a published clinical trial in any pregnant woman for the prevention
of PTB. We cannot be certain of the safety profile upon single oral or multiple oral administration of LPCN 1107 to the patient or the
fetus and its long term side effects on the mother as well as the child because (i) oral performance of LPCN 1107 may be substantially
different from efficacy and/or safety standpoint compared to FDA approved and commercialized intramuscular HPC, Makena, and (ii) oral
delivery of HPC could have a very different PK and/or pharmacodynamic profile that has never been experienced with non-oral administration
of HPC, thus having its own significant liability exposure independent of known safety of non-oral HPC in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required
to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management
resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our product candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to defend the related litigation; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    diversion of management&#8217;s time and our resources; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial participants or patients; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing or promotional restrictions; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenues from product sales; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any of our product candidates, if approved. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have or be able to obtain or maintain sufficient and affordable insurance coverage, and without sufficient coverage any claim
brought against us could have a materially adverse effect on our business, financial condition or results of operations. We run clinical
trials through investigators that could be negligent through no fault of our own and which could affect patients, cause potential liability
claims against us and result in delayed or stopped clinical trials. We are required in many cases by contractual obligations, to indemnify
collaborators, partners, third party contractors, clinical investigators and institutions. These indemnifications could result in a material
impact due to product liability claims against us and/or these groups. We currently carry $3.0 million in product liability insurance,
which we believe is appropriate for our clinical trials. Although we maintain such insurance, any claim that may be brought against us
could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in
excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product
liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that
exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital
to pay such amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Testosterone
is a Schedule III substance under the Controlled Substances Act and any failure to comply with this Act or its state equivalents would
have a negative impact on our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testosterone
is listed by the U.S. Drug Enforcement Agency, or DEA, as a Schedule III substance under the Controlled Substances Act of 1970. The DEA
classifies substances as Schedule I, II, III, IV or V substances, with Schedule I substances considered to present the highest risk of
substance abuse and Schedule V substances the lowest risk. Scheduled substances are subject to DEA regulations relating to manufacturing,
storage, distribution and physician prescription procedures. For example, all regular Schedule III drug prescriptions must be signed
by a physician and may not be refilled more than six months after the date of the original prescription or more than five times unless
renewed by the physician.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
must register annually with the DEA to manufacture, distribute, dispense, import, export and conduct research using controlled substances.
In addition, the DEA requires entities handling controlled substances to maintain records and file reports, follow specific labeling
and packaging requirements, and provide appropriate security measures to control against diversion of controlled substances. Failure
to follow these requirements can lead to significant civil and/or criminal penalties and possibly even lead to a revocation of a DEA
registration. Individual states also have controlled substances laws. State controlled substances laws often mirror federal law, however
because the states are separate jurisdictions, they may schedule products separately. While some states automatically schedule a drug
when the DEA does so, in other states there must be rulemaking or legislative action, which could delay commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
containing controlled substances may generate public controversy. As a result, these products may have their marketing approvals withdrawn.
State and Federal legislatures and administrative agencies may take additional action to combat a perceived misuse or overuse of such
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have to dedicate resources to the defense and resolution of litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in the United States makes it relatively easy for stockholders to sue. This can lead to frivolous lawsuits which take substantial
time, money, resources and attention or force us to settle such claims rather than seek adequate judicial remedy or dismissal of such
claims. Historically, securities class action litigation has often been brought against a company following a decline in the market price
of its securities. Biotechnology and pharmaceutical companies, including us, have experienced significant stock price volatility in recent
years, increasing the risk of such litigation. As we defend the class action lawsuits or future patent infringement actions should they
be filed, or if we are required to defend additional actions brought by other shareholders, we may be required to pay substantial litigation
costs and managerial attention and financial resources may be diverted from business operations even if the outcome is in our favor.
In addition, while our insurance carrier may cover the costs of settling claims, the Company&#8217;s capital resources are critical to
its continued operations, and the payment of litigation settlements and associated legal fees diverts these capital resources away from
our operations, even if such amounts do not have a material impact on our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2019, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit,
<i>Solomon Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint
alleges that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to
the FDA contained deficiencies and as a result the defendants&#8217; statements about our business and operations were false and misleading
and/or lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class action (for a purported
class of purchasers of the Company&#8217;s securities from March 27, 2019 through November 8, 2019), compensatory damages in an unspecified
amount, and unspecified equitable or injunctive relief. We have insurance that covers claims of this nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defendants
intend to vigorously defend themselves against these allegations, but doing so may result in substantial litigation costs and managerial
attention and financial resources may be diverted from business operations even if outcome is in favor of our current and former officers
and directors and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally
on April 2, 2019, we filed a lawsuit against Clarus in the United States District Court in Delaware alleging that Clarus&#8217;s JATENZO&#174;
product infringes six of Lipocine&#8217;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390; 6,569,463; and 6,923,988.
Clarus has answered the complaint and asserted counterclaims of non-infringement and invalidity. We answered Clarus&#8217;s counterclaims
on April 29, 2019. On February 11, 2020, we voluntarily dismissed allegations of patent infringement for expired U.S. Patent Nos. 6,569,463
and 6,923,988 in an effort to streamline the issues and associated costs for dispute. The Court held a scheduling conference on August
15, 2019, a claim construction hearing on February 11, 2020 and a summary judgment hearing on January 15, 2021. In May 2021, the Court
granted Clarus&#8217; motion for Summary Judgment, finding the asserted claims of Lipocine&#8217;s U.S. patents 9,034,858; 9,205,057;
9,480,690; and 9,757,390 invalid for failure to satisfy the written description requirement of 35 U.S.C. &#167; 112. Clarus still had
remaining claims before the Court. On July 13, 2021, we entered into a Global Agreement with Clarus which resolved all outstanding claims
of this litigation. Under the terms of the settlement, we agreed to pay Clarus $4.0 million, payable as follows: $2.5 million immediately,
$1.0 million on July 13, 2022 and $500,000 on July 13, 2023. The payment of this and other settlement payments diverts capital resources
away from our operations, which may adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cyber
security risks and the failure to maintain the integrity of company, employee or guest data could expose us to data loss, litigation
and liability, and our reputation could be significantly harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
collect and third parties collaborating on our clinical trials collect and retain large volumes of data, including personally identifiable
information regarding clinical trial participants and others, for business purposes, including for regulatory, research and development
and commercialization purposes, and our collaborators&#8217; various information technology systems enter, process, summarize and report
such data. We also maintain personally identifiable information about our employees. The integrity and protection of our Company, employee
and clinical data is critical to our business. We are subject to significant security and privacy regulations, as well as requirements
imposed by government regulation. Maintaining compliance with these evolving regulations and requirements could be difficult and may
increase our expenses. In addition, a penetrated or compromised data system or the intentional, inadvertent or negligent release or disclosure
of data could result in theft, loss or fraudulent or unlawful use of company, employee or clinical data which could harm our reputation,
disrupt our operations, or result in remedial and other costs, fines or lawsuits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Dependence on Third Parties </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may enter into license agreements and/or collaborations with third parties for the development and commercialization of our drug candidates.
If those collaborations, including, without limitation, our license arrangement with Antares for the development and commercialization
of TLANDO, are not successful, we may not be able to capitalize on the market potential of these drug candidates and may have to alter
our development and commercialization plans for our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug development programs for our product candidates will require substantial additional cash to fund expenses. We have not yet established
any collaborative arrangements relating to the development or commercialization of LPCN 1111, LPCN 1144, LPCN 1148, LPCN 1107
or our oral NAS. We have entered into the Antares License Agreement for TLANDO with respect to TRT in the U.S. We intend to continue
to develop our other product candidates in the United States without a partner although our ability to advance these product candidates
will depend on our capital resources. However, in order to commercialize our product candidates in the United States, we have partnered
with Antares with respect to TLANDO and we will likely look to establish a partnership or co-promotion arrangement with an established
pharmaceutical company that has a sales force, collaborate on the establishment of an internal sales force or build an internal sales
force on our own with respect to our other product candidates. We may also seek to enter into collaborative arrangements to develop and
commercialize our product candidates outside the United States. We will face significant competition in seeking appropriate collaborators
and these collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on
acceptable terms or in a timely manner, or at all. If that were to occur, we may have to curtail the development or delay commercialization
of our product candidates in certain geographies, reduce the scope of our sales or marketing activities, reduce the scope of our commercialization
plans, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase
our expenditures to fund development or commercialization activities either inside or outside of the United States on our own, we may
need to obtain additional capital, which may not be available to us on acceptable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we have, and if we do enter into any further such arrangements with any third parties, we will likely have limited control
over the amount and timing of resources that our partners dedicate to the development or commercialization of our product candidates.
On October 14, 2021, we entered into the Antares License Agreement with Antares, pursuant to which we granted to Antares an exclusive,
royalty-bearing, sublicensable right and license to develop and commercialize, upon final approval of TLANDO from the FDA, our TLANDO
product with respect to TRT in the U.S. The Antares License Agreement also provides Antares with an option, exercisable on or before
March 31, 2022, to license TLANDO XR. Consequently, our ability to generate any revenues from TLANDO with respect to TRT in the U.S.
depends on the efforts of Antares to commercialize TLANDO, once final FDA approval is obtained. We have very limited control over the
amount and timing of resources that Antares will dedicate to these efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenues from this and other collaborative arrangements will depend on our collaborators&#8217; abilities and efforts
to successfully perform the functions agreed to with them in these arrangements. License agreements and/or collaborations involving our
drug candidates, such as our agreement with Antares, pose numerous risks to us, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
    have significant discretion in determining the efforts and resources that they will apply to these efforts and may not perform their
    obligations as expected;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.95pt; text-indent: -14.85pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
    may de-emphasize or not pursue development and commercialization of our drug candidates or may elect not to continue or renew development
    or commercialization programs based on clinical trial results, changes in the partners&#8217; strategic focus, including as a result
    of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition
    that diverts resources or creates competing priorities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.95pt; text-indent: -14.85pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate,
    repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or drug
    candidates if the partners believe that competitive products are more likely to be successfully developed or can be commercialized
    under terms that are more economically attractive than ours;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.95pt; text-indent: -14.85pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
    may not be able to acquire and maintain supplier and manufacturer relationships necessary to successfully commercialize our products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    partner with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution
    of our product relative to other products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.95pt; text-align: justify; text-indent: -14.85pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
    may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and
    intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize
    or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property
    related proceedings;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.95pt; text-indent: -14.85pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    may arise between our partners and us that result in the delay or termination of the research, development or commercialization
    of our products or drug candidates or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.95pt; text-indent: -14.85pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreements
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable drug candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.95pt; text-indent: -14.85pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreements
    may not lead to development or commercialization of drug candidates in the most efficient manner or at all; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.95pt; text-indent: -14.85pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    a partner of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or
    commercialization program could be delayed, diminished or terminated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our license arrangements with Antares, or any future license or collaboration we may enter into, if any, are not successful, our
business, financial condition, results of operations, prospects and development and commercialization efforts may be adversely affected.
Any termination or expiration of the Antares License Agreement, or any future license or collaboration we may enter into, if any, could
adversely affect us financially or harm our business reputation, development and commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely upon third-party contractors and service providers for the execution of some aspects of our development programs. Failure of these
collaborators to provide services of a suitable quality and within acceptable timeframes may cause the delay or failure of our development
programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
outsource certain functions, tests and services to contract research organizations (&#8220;CROs&#8221;), medical institutions and collaborators;
and also outsource manufacturing to collaborators and/or contract manufacturers (&#8220;CMO&#8217;s&#8221;). We also rely on third parties
for quality assurance, clinical monitoring, clinical data management and regulatory expertise. We may also engage a CRO to run all aspects
of a clinical trial on our behalf. There is no assurance that such individuals or organizations will be able to provide the functions,
tests, drug supply or services as agreed upon or in a quality fashion. Any failure to do so could cause us to suffer significant delays
in the development of our products or processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
to our reliance on CROs or other third parties to assist us or who have historically assisted us in conducting clinical trials, we will
be unable to directly control all aspects of our clinical trials</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engaged a CRO to conduct our SOAR, DV and DF Phase 3 clinical studies for TLANDO, as well as the ABPM study for TLANDO. Additionally,
we utilized a CRO for the Phase 2 <i>LiFT</i> clinical study for LPCN 1144 and are utilizing a CRO for the on-going Phase 2 clinical
study for LPCN 1148. As a result, we have less direct control over the conduct of our clinical trials, the timing and completion of the
trials and the management of data developed through the trials than if we were relying entirely upon our own staff. Communicating with
outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside
parties, including CROs, may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
    staffing difficulties or disruptions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
    to comply with contractual obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
    regulatory compliance issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undergo
    changes in priorities or may become financially distressed;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">form
    relationships with other entities, some of which may be our competitors; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    capacity limitations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors may materially adversely affect their willingness or ability to conduct our trials in a manner acceptable to us. We may experience
unexpected cost increases that are beyond our control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the FDA requires us to comply with GCP&#8217;s for conducting, recording, and reporting the results of clinical trials to assure that
data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.
Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Problems
with the timeliness or quality of the work of a CRO may lead us to seek to terminate the relationship and use an alternative service
provider. However, making this change may be costly and may delay our trials, and contractual restrictions may make such a change difficult
or impossible. If we must replace any CRO that is conducting our clinical trials, our trials may have to be suspended until we find another
CRO that offers comparable services. The time that it takes us to find alternative organizations may cause a delay in the commercialization
of our product candidates or may cause us to incur significant expenses to replicate data that may be lost. Although we do not believe
that any CRO on which we may rely will offer services that are not available elsewhere, it may be difficult to find a replacement organization
that can conduct our trials in an acceptable manner and at an acceptable cost. Any delay in or inability to complete our clinical trials
could significantly compromise our ability to secure regulatory approval of our product candidates and preclude our ability to commercialize
them, thereby limiting or preventing our ability to generate revenue from their sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
and our licensee </i></b>&#160;<b><i>rely on a single supplier for our supply of testosterone esters, the active pharmaceutical ingredient
of TLANDO, LPCN 1111, LPCN 1148, and LPCN 1144, and the loss of this supplier could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our licensee rely on a single third-party supplier for our supply of testosterone esters, the active pharmaceutical ingredient of
TLANDO, LPCN 1111, LPCN 1148, and LPCN 1144. Since there are only a limited number of testosterone esters suppliers in the world, if
this supplier ceases to provide us with testosterone esters, we may be unable to procure testosterone esters on commercially favorable
terms and/or may not be able to obtain testosterone esters in a timely manner. Furthermore, the limited number of suppliers of testosterone
esters may provide such companies with greater opportunity to raise their prices. If we or our licensee are unable to obtain testosterone
esters in a timely manner and/or in sufficient quantities, our ability to develop, and potentially commercialize, LPCN 1111, LPCN 1148,
and LPCN 1144 may be adversely affected. In addition, any increase in price for testosterone esters will likely reduce our potential
gross margins for LPCN 1111, LPCN 1148 and LPCN 1144.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on limited suppliers for our supply of NAS, the active pharmaceutical ingredient of LPCN 1154 and LPCN 2101 and the loss of these
limited suppliers could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a limited third-party supplier for our supply NAS, the active pharmaceutical ingredient of LPCN 1154 and LPCN 2101. Since there
are only a limited number of NAS suppliers in the world, if a supplier ceases to provide us with NAS, we may be unable to procure NAS
on developmental or commercially favorable terms. Furthermore, the limited number of suppliers of NAS may provide such suppliers
with a greater opportunity to raise their prices. If we are unable to obtain NAS in a timely manner and/or in sufficient quantities,
our ability to develop NAS may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not establish successful collaborations, we may have to alter our development and commercialization plans for our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug development programs for our product candidates will require substantial additional cash to fund expenses. We have not yet established
any collaborative arrangements relating to the development or commercialization of LPCN 1148, LPCN 1114, LPCN 1111, LPCN 1107
or oral neuroactive steroids. We intend to continue to develop our product candidates in the United States without a partner
although our ability to advance these product candidates will depend on our capital resources. However, in order to commercialize our
product candidates in the United States, we will likely look to establish a partnership or co-promotion arrangement with an established
pharmaceutical company that has a sales force, collaborate on the establishment of an internal sales force or build an internal sales
force on our own. We may also seek to enter into collaborative arrangements to develop and commercialize our product candidates outside
the United States. We will face significant competition in seeking appropriate collaborators and these collaborations are complex and
time-consuming to negotiate and document. We may not be able to negotiate collaborations on acceptable terms or in a timely manner, or
at all. If that were to occur, we may have to curtail the development or delay commercialization of our product candidates in certain
geographies, reduce the scope of our sales or marketing activities, reduce the scope of our commercialization plans, or increase our
expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to
fund development or commercialization activities either inside or outside of the United States on our own, we may need to obtain additional
capital, which may not be available to us on acceptable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are successful in entering into collaborative arrangements and any of our collaborative partners does not devote sufficient time and
resources to a collaboration arrangement with us, we may not realize the potential commercial benefits of the arrangement, and our results
of operations may be materially adversely affected. In addition, if any future collaboration partner were to breach or terminate its
arrangements with us, the development and commercialization of our product candidates could be delayed, curtailed or terminated because
we may not have sufficient financial resources or capabilities to continue development and commercialization of our product candidates
on our own in such locations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price could decline significantly based on the results and timing of clinical trials, and/or regulatory and other decisions affecting
our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of clinical trials and preclinical studies of our current and potential product candidates may not be viewed favorably by us or third
parties, including the FDA or other regulatory authorities, investors, analysts and potential collaborators. The same may be true of
how we design the clinical trials of our product candidates and regulatory decisions affecting those clinical trials. Pharmaceutical
company stock prices have declined significantly when such results and decisions were unfavorable or perceived negatively or when a product
candidate did not otherwise meet expectations. The final results from our clinical development programs may be negative, may not meet
expectations or may be perceived negatively. The designs of our clinical trials (which may change significantly and be more expensive
than currently anticipated depending on our clinical results and regulatory decisions) may also be viewed negatively by third parties.
We may not be successful in completing these clinical trials on our projected timetable, if at all. In addition, we may never achieve
FDA approval for any of our product candidates, which could cause our stock price to decline significantly and have other significant
adverse effects on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not maintain effective internal controls over financial reporting in the future, the accuracy and timeliness of our financial reporting
may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually
and disclosure controls and procedures quarterly. In particular, we must perform system and process evaluation and testing of our internal
control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting,
as required by Section 404 of the Sarbanes-Oxley Act. If material weaknesses are identified in the future or we are not able to comply
with the requirements of Section 404 in a timely manner, our reported financial results could be materially misstated, we could receive
an adverse opinion regarding our internal controls over financial reporting from our accounting firm, and we could be subject to investigations
or sanctions by regulatory authorities, which would require additional financial and management resources, and the market price of our
stock could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur significant expenses in order to comply with the requirements of being a public company in the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significantly more legal, accounting and other expenses than as a private company. In addition, the Sarbanes-Oxley
Act of 2002 and rules subsequently implemented by the SEC and U.S. stock exchanges impose numerous requirements on public companies,
including requiring changes in corporate governance practices. Also, the Exchange Act requires, among other things, that we file annual,
quarterly and current reports with respect to our business and operating results. Our management and other personnel will need to devote
a substantial amount of time to compliance with these laws and regulations. These requirements have increased and will continue to increase
our legal, accounting, and financial compliance costs and have made and will continue to make some activities more time consuming and
costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
share price is expected to be volatile and may be influenced by numerous factors that are beyond our control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
low share price and low market valuation may make it difficult to raise sufficient additional cash due to the significant dilution to
current stockholders. Market prices for shares of biotechnology and biopharmaceutical companies such as ours are often volatile. The
market price of our common stock may fluctuate significantly in response to a number of factors, most of which we cannot control, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
    launch of TLANDO, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plans
    for, progress of and results from clinical trials of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of the FDA to approve our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    uncertainty in the TRT class;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    Advisory Committee meetings and related recommendations including meetings convened on the TRT class or on similar companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by the FDA that may impact on-going clinical studies related to safety or efficacy of TRT products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    approval and potential FDA required labeling language and/or Phase 4 study commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of new products, technologies, commercial relationships, acquisitions or other events by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to license our products to third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to engage with collaborators or build an internal sales force to commercialize our products should a product candidate receive FDA
    approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success or failure of other TRT products or non-testosterone based testosterone therapy products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our products, if approved, to achieve commercial success;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in stock market prices and trading volumes of similar companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions and overall fluctuations in U.S. equity markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our quarterly operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our financial guidance or securities analysts&#8217; estimates of our financial performance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of large blocks of our common stock, including sales by our executive officers, directors and significant stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussion
    of us or our stock price by the press and by online investor communities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash balance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    risks and uncertainties described in these risk factors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, the stock of other biotechnology and biopharmaceutical companies has experienced extreme price fluctuations that have been
unrelated to the operating performance of the affected companies. There can be no assurance that the market price of our shares of common
stock will not experience significant fluctuations in the future, including fluctuations that are unrelated to our performance. These
fluctuations may result due to macroeconomic and world events, national or local events, general perception of the biotechnology industry
or to a lack of liquidity. In addition, other biotechnology companies or our competitors&#8217; programs could have positive or negative
results that impact their stock prices and their results, or stock fluctuations could have a positive or negative impact on our stock
price regardless of whether such impact is direct or not.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
may not agree with our business, scientific, clinical, commercial, or financial strategy, including additional dilutive financings, and
may decide to sell their shares or vote against shareholder proposals. Such actions could materially impact our stock price. In addition,
portfolio managers of funds or large investors can change or change their view on us and decide to sell our shares. These actions could
have a material impact on our stock price. In order to complete a financing, or for other business reasons, we may elect to consolidate
our shares of common stock. Investors may not agree with these actions and may sell our shares. We may have little or no ability to impact
or alter such decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock prices of many companies in the biotechnology industry have experienced wide fluctuations that have often been unrelated to the
operating performance of the companies. Following periods of volatility in the market price of a company&#8217;s securities, securities
class action litigation often has been initiated against a company. For example, on July 1, 2016, the Company and certain of its officers
were named as defendants in a purported shareholder class action lawsuit, <i>David Lewis v. Lipocine Inc., et al</i>., filed in the United
States District Court for the District of New Jersey. This initial action was followed by additional lawsuits also filed in the District
of New Jersey. David Lewis v Lipocine Inc., et al. was ultimately settled. Additionally on November 14, 2019, the Company and certain
of its officers were named as defendants in a purported shareholder class action lawsuit, <i>Solomon Abady v. Lipocine Inc. et al</i>.,
2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. This initial action was followed by additional lawsuits
also filed in the United States District Court for the District of Utah. These current class action lawsuits and any future class action
litigation that may be initiated against us may result in us incurring substantial costs and our management&#8217;s attention may be
diverted from our operations, which could significantly harm our business. In addition, such litigation could lead to increased volatility
in our share price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
value of our warrants outstanding from the November 2019 Offering is subject to potentially material increases and decreases based on
fluctuations in the price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, we completed a public offering of common stock and warrants to purchase common stock (the &#8220;November 2019 Offering&#8221;).
Gross proceeds from the November 2019 Offering were approximately $6.0 million. In the November 2019 Offering, the Company sold (i) 10,450,000
Class A Units, with each Class A Unit consisting of one share of common stock and a common stock warrant to purchase one share of common
stock, and (ii) 1,550,000 Class B Units, with each Class B Unit consisting of one pre-funded warrant to purchase one share of a common
stock and one common stock warrant to purchase one share of common stock at a price of $0.50 per Class A Unit and $0.4999 per Class B
Unit. The pre-funded warrants were issued in lieu of common stock in order to ensure the purchaser did not exceed certain beneficial
ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price of $.0001 per share, subject to adjustment.
Additionally, the common stock warrants were immediately exercisable at an exercise price of $0.50 per share and expire on November 17,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for the common stock warrants as a derivative instrument, and changes in the fair value of the warrants are included under other
income (expense) in the Company&#8217;s statements of operations for each reporting period. As of December 31, 2021, the aggregate fair
value of the warrant liability included in the Company&#8217;s consolidated balance sheet was $796,000. We use the Black-Scholes
option pricing model to determine the fair value of the warrants. As a result, the option-pricing model requires the input of several
assumptions, including the stock price volatility, share price and risk-free interest rate. Changes in these assumptions can materially
affect the fair value estimate. While the liability may only result from a change of control at a point in time, we ultimately may incur
amounts significantly different than the carrying value of the liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to maintain our listing on the NASDAQ Capital Market, which would adversely affect the price and liquidity of our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a small capitalization pharmaceutical company, the price of our common shares has been, and is likely to continue to be, highly volatile.
Any announcements concerning us or our competitors, clinical trial results, quarterly variations in operating results, introduction of
new products, delays in the introduction of new products or changes in product pricing policies by us or our competitors, acquisition
or loss of significant customers, partners and suppliers, changes in earnings estimates or our ratings by analysts, regulatory developments,
or fluctuations in the economy or general market conditions, among other factors, could cause the market price of our common shares to
fluctuate substantially. There can be no assurance that the market price of our common shares will not decline below its current price
or that it will not experience significant fluctuations in the future, including fluctuations that are unrelated to our performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
our common stock is quoted on the NASDAQ Capital Market under the symbol &#8220;LPCN&#8221;. We must satisfy certain minimum listing
maintenance requirements to maintain the NASDAQ Capital Market quotation, including certain governance requirements and a series of financial
tests relating to stockholders&#8217; equity or net income or market value, public float, number of market makers and stockholder,
market capitalization, and maintaining a minimum bid price of $1.00 per share. For example, on January 14, 2022, we received
a notice from the Listing Qualifications Department of The NASDAQ Stock Market stating that  we are no longer in compliance with
the requirement to have a majority independent board, audit committee and compensation committee for continued listing on
The NASDAQ Capital Market under NASDAQ Listing Rule 5605. In accordance with NASDAQ Listing Rules 5605(b)(1)(A), 5605(c)(4)
and 5605(d)(4) we are entitled to a cure period to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions in our amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions of Delaware
law and our stockholder rights plan, might discourage, delay or prevent a change in control of our Company or changes in our Board of
Directors or management and, therefore, depress the trading price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may depress the
market price of our common stock by acting to discourage, delay or prevent a merger, acquisition or other change in control that stockholders
may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares of our common
stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove members of our Board of Directors
or our management. Our corporate governance documents include provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the ability of our stockholders to call and bring business before special meetings and to take action by written consent in lieu
    of a meeting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates
    for election to our Board of Directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
    blank check preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the liability of, and providing indemnification to, our directors and officers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation
Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock from engaging in certain business
combinations with us. Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware
law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium
for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on November 5, 2021, we adopted an amended and restated stockholder rights plan that would cause substantial dilution to, and substantially
increase the costs paid by, a stockholder who attempts to acquire us on terms not approved by our board. The intent of the stockholder
rights plan is to protect our stockholders&#8217; interests by encouraging anyone seeking control of our Company to negotiate with our
board. However, our stockholder rights plan could make it more difficult for a third party to acquire us without the consent of our board,
even if doing so may be beneficial to our stockholders. This plan may discourage, delay or prevent a tender offer or takeover attempt,
including offers or attempts that could result in a premium over the market price of our common stock. This plan could reduce the price
that stockholders might be willing to pay for shares of our common stock in the future. Furthermore, the anti-takeover provisions of
our stockholder rights plan may entrench management and make it more difficult to replace management even if the stockholders consider
it beneficial to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
common warrants issued in the November 2019 Offering include a right to receive the Black Scholes value of the warrants in the event
of a fundamental transaction, which payment would be senior to our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common warrants issued in the November 2019 Offering provide that, in the event of a &#8220;fundamental transaction,&#8221; including,
among other things, a merger or consolidation of the Company or sale of all or substantially all of the Company&#8217;s assets, the holders
of such warrants have the option to require the Company to pay to such holders an amount of cash equal to the Black Scholes value of
the warrants. Such amount would be payable prior to any payments to holders of our common stock. The payment of such amount could result
in common stockholders and other warrant holders not receiving any consideration if we were to liquidate, dissolve or wind up, either
voluntarily or involuntarily. In addition, the existence of such right may reduce the value of our common stock, make it harder for us
to sell shares of common stock in offerings in the future, or prevent or delay a change of control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have no current plans to pay dividends on our common stock and investors must look solely to stock appreciation for a return on their
investment in us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all future earnings
to fund the development and growth of our business. Any payment of future dividends will be at the discretion of our board of directors
and will depend on, among other things, our earnings, financial condition, capital requirements, level of indebtedness, statutory and
contractual restrictions applying to the payment of dividends and other considerations that the board of directors deems relevant. Investors
may need to rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize a return
on their investment. Investors seeking cash dividends should not purchase our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management and directors will be able to exert influence over our affairs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, our executive officers and directors beneficially owned approximately 5.3% of our common stock. These stockholders,
if they act together, may be able to influence our management and affairs and all matters requiring stockholder approval, including significant
corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control and might affect
the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock has been volatile over the past year and may continue to be volatile.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price and trading volume of our common stock has been volatile over the past year, and it may continue to be volatile. During
2021, our common stock has traded as low as $0.994 and as high as $2.28 per share. We cannot predict the price at which our common stock
will trade in the future, and it may decline. The price at which our common stock trades may fluctuate significantly and may be influenced
by many factors, including our financial results; developments generally affecting our industry; general economic, industry and market
conditions; the depth and liquidity of the market for our common stock; investor perceptions of our business; reports by industry analysts;
announcements by other market participants, including, among others, investors, our competitors, and our customers; regulatory action
affecting our business; and the impact of other &#8220;Risk Factors&#8221; discussed herein and in our Annual Report. In addition, changes
in the trading price of our common stock may be inconsistent with our operating results and outlook. The volatility of the market price
of our common stock may adversely affect investors&#8217; ability to purchase or sell shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. We currently only have limited securities and industry analysts providing research coverage of our Company and may
never obtain additional research coverage by securities and industry analysts. If no additional securities or industry analysts commence
coverage of our Company or if current securities analyst coverage of our Company ceases, the trading price for our stock could be negatively
impacted. If the analysts downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would
likely decline. If analysts cease coverage of us or fail to publish reports on us regularly, demand for our stock could decrease, which
could cause our stock price and trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Financial Position and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease
operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to raise additional capital to continue to fund our operations. Our future capital requirements may be substantial and will
depend on many factors including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">current
    and future clinical trials for our product candidates, including for oral neuroactive steroids, LPCN 1148 and LPCN 1144;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    actions of the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, size, rate of progress, results and costs of completing ongoing clinical trials and development plans with our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost, timing and outcomes of our efforts to obtain marketing approval for our product candidates in the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
    received under any current or future license agreements, strategic partnerships or collaborations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of filing, prosecuting and enforcing patent claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with commercializing our product candidates if we receive marketing approval, including the cost and timing of developing
    internal sales and marketing capabilities or entering into strategic collaborations to market and sell our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of on-going and future litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">covenants
    in the Securities Purchase Agreements entered into in the February 2020 Offering and the November 2019 Offering restricting our ability
    to enter into variable rate transactions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">funding
    additional product line expansions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing capital resources, together with interest thereon, will be sufficient to meet our projected operating requirements
through at least March 31, 2023. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available
capital resources sooner than we currently expect. While we believe we have sufficient liquidity and capital resources to fund our projected
operating requirements through at least March 31, 2023, we will need to raise additional capital at some point through the equity or
debt markets or through out-licensing activities, either before or after March 31, 2023, to support our operations, on-going clinical
study for LPCN 1148, on-going litigation, and compliance with regulatory requirements. If the Company is unsuccessful in raising additional
capital, its ability to continue as a going concern will become a risk. Further, our operating plan may change, and we may need additional
funds to meet operational needs and capital requirements for product development, regulatory compliance, and clinical trial activities
sooner than planned. In addition, our capital resources may be consumed more rapidly if we pursue additional clinical studies for our
oral neuroactive steroids, LPCN 1148, LPCN 1111, LPCN 1144, and LPCN 1107. Conversely, our capital resources could last longer
if we reduce expenses, reduce the number of activities currently contemplated under our operating plan or if we terminate or suspend
on-going clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding
may not be available to us on favorable terms, or at all. Also, market conditions and the number of authorized shares we have available
may prevent us from accessing the debt and equity capital markets, including sales of our common stock through the ATM Offering (as defined
below). If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of
our clinical studies, research and development programs or, if any of our product candidates receive approval from the FDA, commercialization
efforts. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, including
the ATM Offering, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements.
These arrangements may not be available to us or available on terms favorable to us. To the extent that we raise additional capital through
marketing and distribution arrangements, other collaborations, strategic alliances or licensing arrangements with third parties, we may
have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or grant
licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity offerings, the
ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences,
warrants or other terms that adversely affect our stockholders&#8217; rights or further complicate raising additional capital in the
future. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to
take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable, for any
reason, to raise needed capital, we will have to reduce costs, delay research and development programs, liquidate assets, dispose of
rights, commercialize products or product candidates earlier than planned or on less favorable terms than desired, or reduce or cease
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
loan agreement contains covenants which may adversely impact our business; the failure to comply with such covenants could cause our
outstanding debt to become immediately payable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, we entered into a Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Silicon Valley Bank
(&#8220;SVB&#8221;) pursuant to which SVB lent us $10.0 million. The principal borrowed under the Loan and Security Agreement bears interest
at a rate equal to the Prime Rate plus one percent per annum, which interest is payable monthly. The loan matures on June 1, 2022. In
addition, as TLANDO was not approved by the FDA by May 31, 2018, we were required to maintain $5.0 million of cash collateral at SVB
until such time as TLANDO&#8217;s approval by the FDA. However, on February 16, 2021, we and SVB amended the Loan and Security
Agreement to, among other things, remove the financial trigger and financial trigger release event provisions requiring us to maintain
a minimum cash collateral value and collateral pledge thereof. The Loan Agreement includes a number of restrictive covenants, including
restrictions on incurring additional debt, transactions with affiliates, disposing of property, business combinations or acquisitions,
paying dividends and making other distributions or payments on our capital stock, subject to limited exceptions. Collectively, these
covenants could constrain our ability to grow our business through acquisitions or engage in other transactions. In addition, the Loan
Agreement includes covenants requiring, among other things, that we provide financial statements, comply with all laws, pay all taxes
and maintain insurance. If we are not able to comply with these covenants, the amounts outstanding under the Loan Agreement could become
immediately due and payable and could have a material adverse effect on our liquidity, financial condition, operating results, business,
and prospects and cause the price of our common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to generate sufficient cash flow to satisfy our significant debt service obligations, which would adversely affect our
financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to make principal and interest payments on and to refinance our indebtedness will depend on our ability to generate cash in the
future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors
that are beyond our control. If our business does not generate sufficient cash flow from operations, in the amounts projected or at all,
or if future borrowings are not available to us under our variable funding notes in amounts sufficient to fund our other liquidity needs,
our financial condition and results of operations may be adversely affected. If we cannot generate sufficient cash flow from operations
to make scheduled principal amortization and interest payments on our debt obligations in the future, we may need to refinance all or
a portion of our indebtedness on or before maturity, sell assets, delay capital expenditures or seek additional equity. If we are unable
to refinance any of our indebtedness on commercially reasonable terms, or at all, or to affect any other action relating to our indebtedness
on satisfactory terms, or at all, our business may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a combination of private and public equity offerings, debt financings collaborations and strategic
and licensing arrangements. To the extent that we raise additional capital through the sale of common stock or securities convertible
or exchangeable into common stock, current stockholders&#8217; ownership interest in the Company will be diluted. In addition, the terms
may include liquidation or other preferences that materially adversely affect their rights as a stockholder. Debt financing, if available,
would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to
take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional
funds through collaboration, strategic alliance and licensing arrangements with third parties, we may have to relinquish valuable rights
to our product candidates, our intellectual property, future revenue streams or grant licenses on terms that are not favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
cannot predict when we will generate product revenues and may never achieve or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to become profitable depends upon our ability to generate revenue from product sales and/or licensing agreements. To date, we
have not generated any revenue from product sales of TLANDO or our other drug candidates in the current pipeline, and we do not know
when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue unless or until we obtain
marketing approval of, and begin to sell, any of our product candidates. Our ability to generate revenue depends on a number of factors,
including, but not limited to, our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    U.S. and foreign marketing approval for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercialize
    our product candidates by developing a sales force and/or entering into licensing agreements or collaborations with partners/third
    parties, either before or after obtaining marketing approval for our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve
    market acceptance of our product candidates in the medical community and with third-party payors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates are approved for commercial sale, we expect to incur significant costs as we prepare to commercialize them.
Even if we receive FDA approval for our product candidates, they may not be commercially successful drugs. We may not achieve profitability
soon after generating product sales, if ever. If we are unable to generate product revenue, we will not become profitable and may be
unable to continue operations without continued funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
the likelihood of our success must be evaluated in light of many potential challenges and variables associated with an early-stage drug
development company, many of which are outside of our control, and past operating or financial results should not be relied on as an
indication of future results. If one or more of our product candidates is approved for commercial sale and we retain commercial rights,
we anticipate incurring significant costs associated with commercializing any such approved product candidate. Therefore, even if we
are able to generate revenues from the sale of any approved product, we may never become profitable. Because of the numerous risks and
uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of expenses and when
we will be able to achieve or maintain profitability, if ever.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred significant operating losses in most years since our inception and anticipate that we will incur continued losses for the
foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have focused a significant portion of our efforts on developing TLANDO and more recently on our oral neuroactive steroids, LPCN 1148,
and LPCN 1144. We have funded our operations to date through sales of our equity securities, debt, and payments received under our license
and collaboration arrangements. We have incurred losses in most years since our inception. As of December 31, 2021, we had an accumulated
deficit of $172.7 million. Substantially all of our operating losses resulted from costs incurred in connection with our research
and development programs and from general and administrative costs associated with our operations. These losses, combined with expected
future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. We expect
our research and development expenses to significantly increase in connection with clinical trials associated with our oral neuroactive
steroids, LPCN 1148, LPCN 1111, LPCN 1144, and LPCN 1107, if initiated. As a result, we expect to continue to incur significant
operating losses for the foreseeable future as we evaluate further clinical development of our oral neuroactive steroids, LPCN
1148, LPCN 1111, LPCN 1144, and LPCN 1107 and our other programs and continued research efforts. Because of the numerous risks
and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when
we will become profitable, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operating results may fluctuate significantly, and any failure to meet financial expectations may disappoint securities analysts or investors
and result in a decline in the price of our securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a history of operating losses. Our operating results have fluctuated in the past and are likely to do so in the future. These fluctuations
could cause our share price to decline. Due to fluctuations in our operating results, we believe that period-to-period comparisons of
our results are not indicative of our future performance. It is possible that in some future quarter or quarters, our operating results
will be above or below the expectations of securities analysts or investors. In this case, the price of our securities could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited shares available for issuance to raise capital to fund our operations and grant stock-based incentive awards to employees,
directors, and consultants. If we are unable to increase the number of shares of common stock available for issuance, our business will
be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we have 100,000,000 authorized shares of common stock. As of March 07, 2022, we had 88,290,650 shares of common stock outstanding.
After taking into account the 4,438,013 shares reserved for issuance upon the exercise of outstanding options and 1,934,366 reserved
for issuance upon the exercise of outstanding warrants, as of March 07, 2022, we have a limited number of shares available for
issuance. If we are not able to obtain shareholder approval to increase the number of shares of common stock available for issuance,
including, for example, through an amendment to our certificate of incorporation or a reverse stock split, we will have limited shares
available for issuance to raise capital to fund our operations, make grants of stock-based incentive awards, or take such other actions
requiring available capital stock needed to operate our business. Delays in securing, or the failure to secure, shareholder approval
of such actions, if needed, may prevent us from executing a capital raising transaction, which may have a material adverse effect on
our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights
and technology, and we may not be able to ensure their protection.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our product
candidates, their respective formulations, methods used to manufacture them and methods of treatment, as well as successfully defending
these patents against third party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to
sell, or importing our product candidates, once commercialized, is dependent upon the extent to which we have rights under valid and
enforceable patents or trade secrets that cover these activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical, biopharmaceutical and related companies can be highly uncertain and involve complex legal and factual
questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in patents
in these fields has emerged to date in the United States. There have been changes regarding how patent laws are interpreted, and both
the United States Patent and Trademark Office (&#8220;PTO&#8221;) and Congress have enacted radical changes to the patent system. We
cannot accurately predict future changes in the interpretation of patent laws or changes to patent laws which might be enacted into law.
Those changes may materially affect our patents, our ability to obtain patents and/or the patents and applications of our collaborators
and licensors. The patent situation in these fields outside the United States is even more uncertain. Changes in either the patent laws
or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or
narrow the scope of our patent protection. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in the
patents we own or which we license or third-party patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately
protect our rights or permit us to gain or keep a competitive advantage. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may be able to make or use compounds that are the same or similar to the pharmaceutical compounds used in our product candidates
    but that are not covered by the claims of our patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Active Pharmaceutical Ingredients (&#8220;APIs&#8221;) in our licensed product TLANDO and current product candidates LPCN 1144 and
    LPCN 1107 are, or may soon become, commercially available in generic drug products, and no patent protection may be available without
    regard to formulation or method of use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to detect infringement against our owned or licensed patents, which may be especially difficult for manufacturing
    processes or formulation patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might not have been the first to make the inventions covered by our issued patents or pending patent applications or those we license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might not have been the first to file patent applications for these inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that our pending patent applications or those of our licensor will not result in issued patents;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that there are dominating patents to any of our product candidates of which we are not aware;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that there are prior public disclosures that could invalidate our patents, or parts of our patents, of which we are not
    aware;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that others may circumvent our owned or licensed patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims
    covering our products or technology similar to ours;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    laws of foreign countries may not protect our proprietary rights to the same extent as the laws of the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    claims of our owned or licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    issued patents or those of our licensor may not provide us with any competitive advantages, or may be narrowed in scope, be held
    invalid or unenforceable as a result of legal challenges by third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    licensor or licensees as the case may be, who have access to our patents, may attempt to enforce our owned or licensed patents, which
    if unsuccessful, may result in narrower scope of protection of our owned or licensed patents or our owned or licensed patents becoming
    invalid or unenforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not develop additional proprietary technologies for which we can obtain patent protection; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others may have an adverse effect on our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable.
However, trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our collaborators
and suppliers. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific
collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third
party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In
addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently
develop equivalent knowledge, methods, and know-how. If our confidential or proprietary information is divulged to or acquired by third
parties, including our competitors, our competitive position in the marketplace will be harmed and our ability to successfully penetrate
our target markets could be severely compromised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our owned or licensed patents are found to be invalid or unenforceable, or if we are otherwise unable to adequately protect our
rights, it could have a material adverse impact on our business and our ability to commercialize or license our technology and products.
Additionally, we currently do not have patent protection for our product candidates in many countries, including large territories such
as India, Russia, and China, and we will be unable to prevent patent infringement in those countries unless we can file patent applications
and obtain patents in those countries that cover our product candidates. Likewise, our United States patents covering certain technology
used in our product candidates, including TLANDO, are expected to expire on various dates from 2023 through 2037. Upon the expiration
of these patents, we will lose the right to exclude others from practicing these inventions to the extent that at those times we have
no additional issued patents to protect our product candidates, including TLANDO. Additionally, if these are our only patents listed
in the FDA Orange Book, should we have an FDA-approved and marketed product at that time, their expiration will mean that we lose certain
advantages that come with Orange Book listing of patents. The expiration of these patents could also have a similar material adverse
effect on our business, results of operations, financial condition and prospects. Moreover, if we are unable to commence or continue
any action relating to the defense of our patents, we may be unable to protect our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain additional protection under the Drug Price Competition and Patent Term Restoration Act and similar foreign legislation
by extending the patent terms and obtaining data exclusivity for our product candidates, our business may be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible
for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman
Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development
and the FDA regulatory review process. However, we may not be granted an extension because of, for example, failing to apply within applicable
deadlines, failing to apply prior to expiration of relevant patents or competitor&#8217;s prior product launch or otherwise failing to
satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we
request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our
competitors may obtain approval of competing products following our patent expiration, and our ability to generate revenues could be
materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights,
and we may be unable to protect our rights to our products and technology.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our collaborators choose to go to court to stop a third party from using the inventions claimed in our owned or licensed patents,
that third party may ask a court to rule that the patents are invalid and should not be enforced against that third party. These lawsuits
are expensive and would consume time and other resources, including financial resources, even if we were successful in stopping the infringement
of these patents. In addition, there is a risk that a court will decide that these patents are not valid or not enforceable and that
we do not have the right to stop others from using the inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is also the risk that, even if the validity of these patents is not challenged or is upheld, the court will refuse to stop the third
party on the ground that such third-party&#8217;s activities do not infringe on our owned or licensed patents. In addition, the U.S.
Supreme Court has changed some standards relating to the granting of patents and assessing the validity of patents. As a consequence,
issued patents may be found to contain invalid claims according to the newly revised standards. Some of our owned or licensed patents
may be subject to challenge and subsequent invalidation or significant narrowing of claim scope in a reexamination or other proceeding
before the USPTO, or during litigation, under the revised criteria which make it more difficult to obtain or maintain patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our in-licensed patents and applications are not currently used in our product candidates, should we develop other product candidates
that are covered by this intellectual property, we will rely on our licensor to file and prosecute patent applications and maintain patents
and otherwise protect the intellectual property we license from them. Our licensor has retained the first right, but not the obligation,
to initiate an infringement proceeding against a third-party infringer of the intellectual property licensed to us, and enforcement of
our in-licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents would also be subject
to the control or cooperation of our licensor. It is possible that our licensor&#8217;s defense activities may be less vigorous than
had we conducted the defense ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also license our patent portfolio, including U.S. and foreign patents and patent applications that cover TLANDO and our other product
candidates, to third parties for their respective products and product candidates. Under our agreements with our licensees, we have the
right, but not the obligation, to enforce our current and future licensed patents against infringers of our licensees. In certain cases,
our licensees may have primary enforcement rights and we have the obligation to cooperate. In the event of an enforcement action against
infringers of our licensees, our licensees might not have the interest or resources to successfully preserve the patents, the infringers
may countersue, and as a result our patents may be found invalid or unenforceable or of a narrower scope of coverage and leave us with
no patent protection for TLANDO and our other product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to a third-party pre-issuance submission of prior art to the PTO, or become involved in opposition, derivation, reexamination,
inter partes review, post-grant review or interference proceedings challenging our owned or licensed patent rights or the patent rights
of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our owned
or licensed patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment
to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition,
if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates and impair our ability to raise needed
capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are required to defend patent infringement actions brought by other third parties, or if we sue to protect our own patent rights or
otherwise to protect our proprietary information and to prevent its disclosure, we may be required to pay substantial litigation costs
and managerial attention and financial resources may be diverted from business operations even if the outcome is in our favor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome
in that litigation would have a material adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product
candidates and use our proprietary technologies without infringing the proprietary rights of third parties. Numerous U.S. and foreign
issued patents and pending patent applications, which are owned by third parties, exist in the fields relating to our product candidates.
As the biotechnology, pharmaceutical, and related industries expand and more patents are issued, the risk increases that others may assert
that our product or product candidates infringe the patent rights of others. Moreover, it is not always clear to industry participants,
including us, which patents cover various types of drugs, products or their formulations or methods of use. Thus, because of the large
number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent
rights encompassing our product, product candidates, technology, or methods. For example, on November 2, 2015, Clarus filed a complaint
against us in the United States District Court for the District of Delaware alleging that TLANDO will infringe the Clarus 428 Patent,
and the complaint sought damages, declaratory and injunctive relief. On October 6, 2016, United States District Court of the District
of Delaware granted our motion to dismiss the lawsuit filed by Clarus, because at the time there was no actionable infringement on Clarus&#8217;
428 patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there may be issued patents of third parties of which we are currently unaware, that are infringed or are alleged to be infringed
by our product candidates or proprietary technologies. Because some patent applications in the United States may be maintained in secrecy
until the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published
until eighteen months after filing, and because publications in the scientific literature often lag behind actual discoveries, we cannot
be certain that others have not filed patent applications for technology covered by our or our licensor&#8217;s issued patents or our
pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file,
patent applications covering our products or technology similar to ours. Any such patent application may have priority over our owned
or licensed patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies.
If another party has filed a U.S. patent application on inventions similar to those owned or licensed by us, we may have to participate
in an interference proceeding declared by the PTO to determine priority of invention in the United States. If another party has an allowed
reason to question the validity of our owned or licensed U.S. patents, the third party can request that the PTO reexamine the patent
claims, which may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential infringement claims,
interference and reexamination proceedings, we may become a party to patent opposition proceedings in the European Patent Office or post-grant
proceedings in the United States where either our patents are challenged, or we are challenging the patents of others. The costs of these
proceedings could be substantial, and it is possible that such efforts would be unsuccessful, for example if the other party had independently
arrived at the same or similar invention prior to our invention, resulting in a loss of our U.S. patent position with respect to such
inventions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property
rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. These lawsuits
are costly and could adversely affect our results of operations and divert the attention of managerial and technical personnel. There
is a risk that a court would decide that we or our commercialization partners are infringing the third party&#8217;s patents and would
order us or our partners to stop the activities covered by the patents. In addition, there is a risk that a court will order us or our
partners to pay the other party damages for having violated the other party&#8217;s patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a third-party&#8217;s patent was found to cover our product candidates, proprietary technologies or their uses, we or our collaborators
could be enjoined by a court and required to pay damages and could be unable to commercialize any one or more of our product candidates
or use our proprietary technologies unless we or they obtained a license to the patent. A license may not be available to us or our collaborators
on acceptable terms, if at all. In addition, during litigation, the patent holder could obtain a preliminary injunction or other equitable
relief which could prohibit us from making, using or selling our products, technologies or methods pending a trial on the merits, which
could be years away.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology, pharmaceutical, and
related industries generally. If a third-party claims that we or our collaborators infringe its intellectual property rights, we may
face a number of issues, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">infringement
    and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert
    our management&#8217;s attention from our core business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    damages for infringement, which we may have to pay if a court decides that the product at issue infringes on or violates the third
    party&#8217;s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the
    patent owner&#8217;s attorneys&#8217; fees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court prohibiting us from selling or licensing the product unless the third party licenses its product rights to us, which it is
    not required to do;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    a license is available from a third party, we may have to pay substantial royalties, upfront fees and/or grant cross-licenses to
    intellectual property rights for our products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">redesigning
    our products or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and
    time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material
adverse effect on our ability to raise the funds necessary to continue our operations or otherwise have a material adverse effect on
our business, results of operations, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Although
we own worldwide rights to our product candidates, we do not have patent protection for the product candidates in a significant number
of countries, and we will be unable to prevent infringement in those countries.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent portfolio related to our product candidates includes patents in the United States and other foreign countries. The covered technology
and the scope of coverage varies from country to country. For those countries where we do not have granted patents, we have no ability
to prevent the unauthorized use of our intellectual property, and third parties in those countries may be able to make, use, or sell
products identical to, or substantially similar to our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on our owned or licensed patents are due to be paid to the PTO in several stages over the lifetime of the patents. Future
maintenance fees will also need to be paid on other patents which may be issued to us. We have systems in place to remind us to pay these
fees, and we employ outside firms to remind us to pay annuity fees due to foreign patent agencies on our pending foreign patent applications.
We have even less control over our in-licensed patents and applications, for which our licensor retains responsibility. The PTO and various
foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions
during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in
accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event,
our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may rely on trade secrets and confidentiality agreements to protect our technology and know-how, especially where we do not believe
patent protection is appropriate or obtainable. However, trade secrets are difficult to protect, and we have limited control over the
protection of trade secrets used by our collaborators and suppliers. Although we use reasonable efforts to protect our trade secrets,
our employees, consultants, contractors, outside scientific collaborators, and other advisors may unintentionally or willfully disclose
our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive
and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect
trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how. If our confidential or
proprietary information is divulged to or acquired by third parties, including our competitors, our competitive position in the marketplace
will be harmed and our ability to successfully generate revenues from our product candidates, if approved by the FDA or other regulatory
authorities, could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the biotechnology, pharmaceutical and related industries, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending,
we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary
information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending
against these claims, litigation could result in substantial costs and be a distraction to management, which would adversely affect our
financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_003"></span>ITEM
    1B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNRESOLVED
    STAFF COMMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_004"></span>ITEM
    2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in a leased facility in Salt Lake City, Utah. Our lease expires on February 28, 2023. We believe that
our existing facility is suitable and adequate and that we have sufficient capacity to meet our current anticipated needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_005"></span>ITEM
    3.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGAL
    PROCEEDINGS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2019, we filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that Clarus&#8217;s
JATENZO&#174; product infringes six of Lipocine&#8217;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390; 6,569,463; and
6,923,988. However, on February 11, 2020, we voluntarily dismissed allegations of patent infringement for expired U.S. Patent
Nos. 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for dispute. Clarus answered the complaint and
asserted counterclaims of non-infringement and invalidity. We answered Clarus&#8217;s counterclaims on April 29, 2019. The Court held
a scheduling conference on August 15, 2019, a claim construction hearing on February 11, 2020, and a summary judgment hearing
on January 15, 2021. In May 2021, the Court granted Clarus&#8217; motion for summary judgment, finding the asserted claims of
Lipocine&#8217;s U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy the written description
requirement of 35 U.S.C. &#167; 112. Clarus still had remaining claims before the Court. On July 13, 2021, we entered into the Global
Agreement with Clarus which resolved all outstanding claims of this litigation as well as the on-going United States Patent and Trademark
Office (&#8220;USPTO&#8221;) Interference No. 106,128 between the parties. Under the terms of the Global Agreement, Lipocine agreed to
pay Clarus $4.0 million payable as follows: $2.5 million immediately, $1.0 million on July 13, 2022, and $500,000 on July 13,
2023. No future royalties are owing from either party. On July 15, 2021, the Court dismissed with prejudice Lipocine&#8217;s claims and
Clarus&#8217; counterclaims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2019, we and certain of our officers were named as defendants in a purported shareholder class action lawsuit, <i>Solomon
Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint alleges
that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to the FDA
contained deficiencies and as a result the defendants&#8217; statements about our business and operations were false and misleading and/or
lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class action (for a purported
class of purchasers of the Company&#8217;s securities from March 27, 2019, through November 8, 2019), compensatory damages in
an unspecified amount, and unspecified equitable or injunctive relief. We have insurance that covers claims of this nature. The retention
amount payable by us under our policy is $1.25 million. We filed a motion to dismiss this class action lawsuit on July 24, 2020. In response,
the plaintiffs filed their response to the motion to dismiss the class action lawsuit on September 22, 2020, and we filed our reply to
our motion to dismiss on October 22, 2020. A hearing on the motion to dismiss occurred on January 12, 2022. We intend to vigorously defend
ourselves against these allegations and have not recorded a liability related to this shareholder class action lawsuit as the outcome
is not probable nor can an estimate be made of loss, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2020, we filed U.S. patent application serial number 16/818,779 (the &#8220;Lipocine &#8216;779 Application&#8221;) with the
USPTO. On October 16 and November 3, 2020, we filed suggestions for interference with the USPTO requesting that a patent interference
be declared between the Lipocine &#8216;779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics, Inc.
(the &#8220;Clarus &#8216;178 Application&#8221;). Pursuant to our request, the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) at
the USPTO declared the interference on January 4, 2021, to ultimately determine, as between us and Clarus, who is entitled to
the claimed subject matter. The interference number is 106,128, and we were initially declared Senior Party. A conference call with the
PTAB was held on January 25, 2021, to discuss proposed motions. On February 1, 2021, the PTAB issued an order authorizing certain
motions and setting the schedule for the preliminary motions phase. On July 13, 2021, we entered into the Global Agreement with Clarus
to resolve interference No. 106,128 among other items. On July 26, 2021, the PTAB granted our request for adverse judgment in interference
No. 106,128 in accordance with the Global Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_006"></span>ITEM
    4.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINE
    SAFETY DISCLOSURES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_013"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_007"></span>ITEM
    5.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MARKET
    FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is quoted on The NASDAQ Capital Market under the symbol &#8220;LPCN&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 7, 2022, there were approximately 96 holders of record of our common stock. This number does not include an undetermined
number of stockholders whose stock is held in &#8220;street&#8221; or &#8220;nominee&#8221; name.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance
Graph and Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following graph shows a comparison from December 31, 2016 through December 31, 2021 of the cumulative total return for (i) our ordinary
shares, (ii) the NASDAQ Composite Index, (iii) the NASDAQ Biotechnology Index and (iv) the NYSE Pharmaceutical Index.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
graph assumes an initial investment of $100 on December 31, 2016. The comparisons in the graph are required by the SEC and are not intended
to forecast or be indicative of possible future performance of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-k_012.jpg" alt="" style="height: 470px; width: 670px" />&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing graph and table are furnished solely with this report, and are not filed with this report, and shall not be deemed incorporated
by reference into any other filing under the Securities Act of 1933, as amended, or the Securities Act, or the Securities Exchange Act
of 1934, as amended, whether made by us before or after the date hereof, regardless of any general incorporation language in any such
filing, except to the extent we specifically incorporate this material by reference into any such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain any future earnings to
finance growth and development and therefore do not anticipate paying cash dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_008"></span>ITEM
    6.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESERVED</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif"><span id="am_009"></span><span style="font-size: 10pt"><b>ITEM
    7. </b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial
statements and the related notes thereto and other financial information included elsewhere in this report.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>As
used in the discussion below, &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refers to the historical financial results of
Lipocine.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward
Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section and other parts of this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. Forward-looking
statements provide current expectations of future events based on certain assumptions and include any statement that does not directly
relate to any historical or current fact. Forward-looking statements may refer to such matters as products, product benefits, pre-clinical
and clinical development timelines, clinical and regulatory expectations and plans, anticipated financial performance, future revenues
or earnings, business prospects, projected ventures, new products and services, anticipated market performance, future expectations for
liquidity and capital resources needs and similar matters. Such words as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;expect&#8221;,
&#8220;continue&#8221;, &#8220;estimate&#8221;, &#8220;project&#8221;, and &#8220;intend&#8221; and similar terms and expressions are
intended to identify forward looking statements. Forward-looking statements are not guarantees of future performance and our actual results
may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include,
but are not limited to, those discussed in Part I, Item 1A (Risk Factors) of this Form 10-K. Except as required by applicable law, we
assume no obligation to revise or update any forward-looking statements for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview
of Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/118% Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on applying our oral drug delivery technology for the development of pharmaceutical
products focusing on neuroendocrine and metabolic  disorders. Our proprietary delivery technologies are
designed to improve patient compliance and safety through orally available treatment options. Our primary development programs are based
on oral delivery solutions for poorly bioavailable drugs. We have a portfolio of differentiated innovative product candidates
that target high unmet needs for neurological and psychiatric CNS disorders, liver diseases, and hormone supplementation
for men and women.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-indent: 27.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a license agreement for the development and commercialization our product candidate, TLANDO&#174;, an oral testosterone replacement
therapy (&#8220;TRT&#8221;) comprised of testosterone undecanoate (&#8220;TU&#8221;). TLANDO is a registered trademark assigned to Antares.
On October 14, 2021, we entered into a license agreement (the &#8220;Antares License Agreement&#8221;) with Antares Pharma, Inc. (&#8220;Antares&#8221;
or our &#8220;Licensee&#8221;), pursuant to which we granted to Antares an exclusive, royalty-bearing, sublicensable right and license
to develop and commercialize, upon final approval of TLANDO from the United States Food and Drug Administration (&#8220;FDA&#8221;),
the TLANDO product for TRT in the U.S. Any FDA required post-marketing studies will also be the responsibility of our licensee, Antares.
Prior to entering into the License Agreement, on December 8, 2020, we received tentative approval from the FDA regarding
our new drug application (&#8220;NDA&#8221;) filed in February 2020 for TLANDO as a TRT in adult males for conditions associated with
a deficiency of endogenous testosterone, also known as hypogonadism. In granting tentative approval, the FDA concluded that TLANDO has
met all required quality, safety and efficacy standards necessary for approval. However, TLANDO has not received final approval and is
not eligible for final approval to market in the U.S. until the expiration of the exclusivity period previously granted to Clarus Therapeutics,
Inc. (&#8220;Clarus&#8221;) with respect to <span style="text-transform: uppercase">Jatenzo</span>&#174;, which expires on March 27, 2022.
The FDA has affirmed to Antares the acceptance of the resubmission of the NDA for TLANDO filed on January 28, 2022. The FDA has
designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022 under
the Prescription Drug User Fee Act (PDUFA).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
pipeline candidates include: LPCN 1148 comprising a novel prodrug of testosterone, testosterone laurate (&#8220;TL&#8221;), for the management
of decompensated cirrhosis; LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic
steatohepatitis (&#8220;NASH&#8221;) which has completed phase 2 testing; LPCN 1111 (TLANDO&#174; XR), a next generation oral TRT product
comprised of testosterone tridecanoate (&#8220;TT&#8221;) with the potential for once daily dosing which has completed Phase 2 testing;
LPCN 1107, potentially the first oral hydroxy progesterone caproate (&#8220;HPC&#8221;) product indicated for the prevention of recurrent
preterm birth (&#8220;PTB&#8221;), which has completed a dose finding clinical study in pregnant women and has been granted orphan
drug designation by the FDA; and neuroactive steroids (&#8220;NAS&#8221;) including LPCN 1154 for postpartum depression (PPD) and
LPCN 2101 for epilepsy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have funded our operations primarily through the sale of equity securities, debt and convertible debt and through up-front payments,
research funding and royalty and milestone payments from our license and collaboration arrangements. We have not generated any revenues
from product sales and while we expect to generate royalties from our licensee&#8217;s sales of TLANDO, we do not expect to generate
revenue from product sales unless from our other product candidates unless and until approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses in most years since our inception. As of December 31, 2021, we had an accumulated deficit of $172.7 million.
Income and losses fluctuate year to year, primarily depending on the nature and timing of research and development occurring on our product
candidates. Our net loss was $634,000 for the year ended December 31, 2021, compared to $21.0 million for the year ended December
31, 2020. Substantially all of our operating losses resulted from expenses incurred in connection with our product candidate development
programs, our research activities and general and administrative costs, including on-going litigation, associated with our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and operating losses for the foreseeable future as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
    further development of our other product candidates, including LPCN 1148 and LPCN 1144;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    our research efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
    new products or new uses for our existing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    general and administrative support for our operations, including on-going litigation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
fund future long-term operations, including the potential commercialization of any of our product candidates, we will need to raise additional
capital. The amount and timing of future funding requirements will depend on many factors, including capital market conditions, regulatory
requirements and outcomes related to TLANDO, regulatory requirements related to our other product development programs, the timing and
results of our ongoing development efforts, the potential expansion of our current development programs, potential new development programs,
our ability to license our products to third parties, the pursuit of various potential commercial activities and strategies associated
with our development programs and related general and administrative support. We anticipate that we will seek to fund our operations
through public or private equity or debt financings or other sources, such as potential license, partnering and collaboration agreements.
We cannot be certain that anticipated additional financing will be available to us on favorable terms, in amounts sufficient to fund
our operations, or at all. Although we have previously been successful in obtaining financing through public and private equity securities
offerings and our license and collaboration agreements, there can be no assurance that we will be able to do so in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to become a leading biopharmaceutical company focused on applying our proprietary drug delivery technology for the development
of pharmaceutical products focusing on neuroendocrine and metabolic disorders. The key components of our strategy are to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Build
a diversified multi-asset pipeline of novel therapies.</b> We intend to employ a value-driven strategy based on our proprietary technology
platform to identify and develop product candidates for neuroendocrine and metabolic disorders including Central Nervous System
(CNS) disorders and end stage diseases such as decompensated cirrhosis. We intend to focus on product candidates that we believe are
differentiated, have attractive profiles, and address a clear unmet medical need that we can advance quickly and efficiently into late-stage
development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advance
LPCN 1148, a unique prodrug of androgen receptor agonist to manage end stage (decompensated) liver cirrhosis disease. </b>We believe
LPCN 1148, a novel prodrug of testosterone, could address a significant unmet medical need in patients with decompensated liver
cirrhosis accompanied with muscle disorder such as secondary sarcopenia. Sarcopenia in male cirrhotic patients is known to be independently
associated with poor outcomes including quality of life, increased decompensation events such as hepatic encephalopathy, increased hospital
admissions, and increased mortality rate. We believe LPCN 1148 may be eligible for an orphan drug designation. Enrollment in a multi-center
placebo-controlled phase 2 trial is currently ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Support
our licensee in commercialization of our licensed oral TRT option</b>. We believe the TRT market needs a differentiated, convenient
oral option. We have exclusively licensed rights to TLANDO to Antares for commercialization of TLANDO in the US. We plan to support our
licensee&#8217;s efforts to effectively enable the availability of TLANDO to patients in a timely manner, in addition to receiving
milestone and royalty payments associated with TLANDO commercialization as agreed to in the Antares License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Develop
partnership(s) to continue the advancement of pipeline assets</b>. We continuously strive to prioritize our resources in seeking co-development
partnerships of our pipeline assets. We currently plan to explore partnering of LPCN 1144, our candidate for treatment of non-cirrhotic
NASH, LPCN 1107, our candidate for prevention of pre-term birth, and LPCN 1111, a once-a-day therapy candidate for TRT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Operations Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenues from product sales and do not expect to do so until one of our product candidates receives approval
from the FDA. Revenues to date have been generated substantially from license fees, royalty and milestone payments and research support
from our licensees. Since our inception through December 31, 2021, we have generated $44.2 million in revenue under our various license
and collaboration arrangements and from government grants. We have entered into the Antares license agreement with the potential for
revenue from future milestones and royalties, but we may never generate revenues from any of our clinical or preclinical
development programs or licensed products as we may never succeed in obtaining regulatory approval or commercializing any of these product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of salaries, benefits, stock-based compensation and related personnel costs, fees paid to
external service providers such as contract research organizations and contract manufacturing organizations, contractual obligations
for clinical development, clinical sites, manufacturing and scale-up for late-stage clinical trials, formulation of clinical drug supplies,
and expenses associated with regulatory submissions. Research and development expenses also include an allocation of indirect costs,
such as those for facilities, office expense, travel, and depreciation of equipment based on the ratio of direct labor hours for research
and development personnel to total direct labor hours for all personnel. We expense research and development expenses as incurred. Since
our inception, we have spent approximately $128.5 million in research and development expenses through December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 8, 2020, we received tentative approval from the FDA regarding our NDA filed in February 2020 for TLANDO as a TRT in
adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. In granting tentative
approval, the FDA concluded that TLANDO has met all required quality, safety and efficacy standards necessary for approval. However,
TLANDO has not received final approval and is not eligible for final approval to market in the U.S. until the expiration of the exclusivity
period previously granted to Clarus with respect to <span style="text-transform: uppercase">Jatenzo</span>&#174;, which expires on March
27, 2022. On October 14, 2021, we entered into the Antares License Agreement with Antares, pursuant to which we granted to Antares an
exclusive, royalty-bearing, sublicensable right and license to develop and commercialize, upon final approval of TLANDO from the FDA,
our TLANDO product with respect to TRT in the U.S. The Antares License Agreement also provides Antares with an option, exercisable on
or before March 31, 2022, to license TLANDO XR. Under the terms of the Antares License Agreement, all future research and development
activities for TLANDO will be conducted and paid for by Antares. Any further expenditures, if needed, are subject to numerous uncertainties
regarding timing and cost to completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant costs as we develop our product candidates:  ongoing phase 2 study with LPCN
1148, LPCN 1144, LPCN 1111, LPCN  1107 and NAS including LPCN 1154 and LPCN 2101.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, the cost of clinical trials may vary significantly over the life of a project as a result of uncertainties in clinical development,
including, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of sites included in the trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    length of time required to enroll suitable subjects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    duration of subject follow-ups;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    length of time required to collect, analyze and report trial results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost, timing and outcome of regulatory review; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    changes by the FDA in clinical trial and NDA filing requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also incurred significant manufacturing costs to prepare launch supplies for TLANDO. However, any additional expenditures required
to prepare for a commercial launch of TLANDO, should it be approved, will be paid by Antares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
research and development expenditures are subject to numerous uncertainties regarding timing and cost to completion, including, among
others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and outcome of regulatory filings and FDA reviews and actions for product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third-party manufacturers for the production of satisfactory finished product for registration and launch should regulatory
    approval be obtained on any of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for future license or co-promote arrangements for our product candidates, when such arrangements will be secured, if at
    all, and to what degree such arrangements would affect our future plans and capital requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect on our product development activities of actions taken by the FDA or other regulatory authorities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change of outcome for any of these variables with respect to our product development candidates could mean a substantial change in the
costs and timing associated with these efforts, will require us to raise additional capital, and may require us to reduce operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the stage of clinical development and the significant risks and uncertainties inherent in the clinical development, manufacturing and
regulatory approval process, we are unable to estimate with any certainty the time or cost to complete the development of LPCN 1148,
LPCN 1144, LPCN 1111, LPCN 1107, NAS including LPCN 1154 and LPCN 2101 and other product candidates. Clinical development
timelines, the probability of success and development costs can differ materially from expectations and results from our clinical trials
may not be favorable. If we are successful in progressing NAS, LPCN 1148, LPCN 1111, LPCN 1144, LPCN 1107, or other product
candidates into later stage development, we will require additional capital. The amount and timing of our future research and development
expenses for these product candidates will depend on the preclinical and clinical success of both our current development activities
and potential development of new product candidates, as well as ongoing assessments of the commercial potential of such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
of Research and Development Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting on-going clinical and regulatory activities with most of our product candidates. Additionally, we incur costs for our
other research programs. The following table summarizes our research and development expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">External service provider costs:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">LPCN 1154</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,499,837</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">LPCN 1148</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">891,647</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">TLANDO</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">116,419</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,192,532</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">LPCN 1111</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">72,515</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">LPCN 1144</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,693,397</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,331,092</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">LPCN 1107</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">468,467</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,860</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total external service provider costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,766,886</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,604,999</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Internal personnel costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,157,218</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,354,530</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other research and development costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">741,455</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">788,940</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,665,559</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,748,469</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect research and development expenses to increase in the future as we complete on-going clinical studies, including the <i>LiFT</i>
Phase 2 OLE clinical study with LPCN 1144 and the Phase 2 study with LPCN 1148, and as we conduct future clinical studies with LPCN 1107
and our oral neuroactive steroids. However, if we are unable to raise additional capital, we may need to reduce research and
development expenses in order to extend our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
of General and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation related to our executive,
finance, business development, and support functions. Other general and administrative expenses include rent and utilities, travel expenses,
professional fees for auditing, tax and legal services, litigation settlement and market research and market analytics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses also include expenses for the cost of preparing, filling and prosecuting patent applications and maintaining,
enforcing and defending intellectual property-related claims, including the patent interference and patent infringement lawsuits against
Clarus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that general and administrative expenses will decrease in the future as we expect to incur decreased legal fees due to the global
settlement agreement (&#8220;Global Agreement&#8221;) with Clarus. We expect that such decreases will be offset by other increases as
we mature as a public company, including legal and consulting fees, accounting and audit fees, director fees, increased directors&#8217;
and officers&#8217; insurance premiums, fees for investor relations services and enhanced business and accounting systems, litigation
costs, professional fees and other costs. However, if we are unable to raise additional capital, we may need to further reduce general
and administrative expenses in order to extend our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
of Other Expense (Income), Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expense (income), net consists primarily of interest income earned on our cash, cash equivalents and marketable investment securities
and interest expense incurred on our outstanding Loan and Security Agreement and losses (gains) on our warrant liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Years Ended December 31, 2021 and 2020</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Variance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,140,838</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,140,838</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,665,559</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,748,469</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,082,910</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,329,776</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,247,795</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,918,019</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest and investment income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(67,700</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(75,650</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,950</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">203,292</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(183,326</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized (gain) loss on warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(355,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,892,189</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,248,079</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Litigation settlement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on extinguishment of debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(234,802</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">234,802</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized license revenue of $16.1 million during the year ended December 31, 2021, compared to no license revenue during the year ended
December 31, 2020. License revenue in 2021 primarily related to licensing fees, minimum royalties and the sale of finished goods inventory
we received in accordance with the Antares Licensing Agreement for TLANDO which was signed on October 14, 2021. Additionally,
we recognized $55,000 in license revenue in 2021 related to payments received from Spriaso under a licensing agreement in the cough and
cold field.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded research and development expenses of $7.7 million and $9.7 million, respectively, for the years ended December 31, 2021, and
2020.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The decrease in research and development expenses
during the year ended December 31, 2021 was primarily due to a $3.6 million decrease in contract research organization expense and outside
consulting costs related to the LPCN 1144 <i>LiFT</i> Phase 2 clinical study in NASH subjects, a $1.1 million decrease in costs associated
with TLANDO and a $197,000 net decrease in personnel expense which was mainly due to a decrease in bonus and stock compensation expense
offset by increases in salaries partially due to headcount increases, as well as decreases in other R&amp;D expenses of 37,000.
These decreases were offset by a $1.5 million increase in costs related to LPCN 1154, a $892,000 increase in costs associated
with LPCN 1148 and a $460,000 increase in costs for LPCN 1107.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded general and administrative expenses of $5.3 million and $8.2 million, respectively, for the years ended December 31, 2021, and
2020.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The decrease in general and administrative
expenses during the year ended December 31, 2021 was primarily due to a $2.5 million decrease in legal costs in 2021 as compared to 2020
relating to a decrease in the following legal activities: lawsuit filed against Clarus Therapeutics Inc. for patent infringement
in April 2019 and the on-going class action lawsuit defense; and, a decrease of $584,000 in personnel costs mainly due a reduction in
bonus and stock compensation expense. These decreases were offset by a $153,000 increase in corporate insurance expenses and a $10,000
increase in other general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
and Investment Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decrease in interest and investment income during the year ended December 31, 2021 was due to lower interest rates in 2021 compared to
2020, despite higher cash and marketable investment securities balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decrease in interest expense during the year ended December 31, 2021 is due to a decrease in interest expense on our Loan and
Security Agreement with SVB, mainly as a result of lower principal balances in 2021 compared to 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrealized
Loss (Gain) on Warrant Liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded a $356,000 gain and a $2.9 million loss, respectively, on warrant liability during the years ended December 31,
2021 and 2020 related to the change in the fair value of outstanding common stock warrants issued in the November 2019 Offering. The
gain in 2021 was attributable to a decrease in the value of warrants outstanding as of December 31, 2021 as compared to December 31,
2020 due to a small decrease in the number of warrants outstanding, a decrease in our stock price, and a shorter term remaining
on the outstanding warrants. The loss in 2020 was mainly attributable to an increase in the value of both warrants exercised during the
year and warrants outstanding as of December 31, 2020 as compared to December 31, 2019 due to an increase in our stock price. There were
10,000 and 10,895,970 common stock warrants from the November 2019 Offering exercised during 2021 and 2020, respectively. The warrants
are classified as a liability due to a provision contained within the warrant agreement which allows the warrant holder the option to
elect to receive an amount of cash equal to the value of the warrants as determined in accordance with the Black-Scholes option pricing
model with certain defined assumptions upon a change of control. The warrant liability will continue to fluctuate in the future based
on inputs to the Black-Scholes model including our current stock price, the remaining life of the warrants, the volatility of our stock
price, the risk-free interest rate and the number of common stock warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation
Settlement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded an expense of $4.0 million and zero, respectively, on litigation settlement during 2021 and 2020 related to the Global Agreement
with Clarus to resolve all outstanding claims in the on-going intellectual property litigation between the two companies as well as the
on-going interference proceeding between the two companies. Under the terms of the settlement, we agreed to pay Clarus $4.0 million payable
as follows: $2.5 million immediately, $1.0 million on July 13, 2022 and $500,000 on July 13, 2023. No future royalties are owing from
either party. Under the terms of the Global Agreement, Lipocine and Clarus have agreed to dismiss the Lipocine Inc. v Clarus Therapeutics,
Inc., No 19-cv-622 (WCB) litigation presently pending in the U.S. District Court for the District of Delaware. Also, both parties have
reached an agreement on the interference proceedings captioned Clarus Therapeutics, Inc. v. Lipocine Inc., Interference No. 106,128 presently
pending in the U.S. Patent and Trademark Office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, our operations have been primarily financed through sales of our equity securities, debt and payments received under our
license and collaboration arrangements. We have devoted our resources to funding research and development programs, including discovery
research, preclinical and clinical development activities. We have incurred operating losses in most years since our inception and we
expect to continue to incur operating losses into the foreseeable future as we advance clinical development of LPCN 1111, LPCN
1144, LPCN 1148, LPCN 1107, oral neuroactive steriods and any other product candidate, including continued research efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had $46.6 million of unrestricted cash, cash equivalents and marketable investment securities compared to $19.7
million at December 31, 2020. Additionally, as of December 31, 2020 we had $5.0 million of restricted cash, which was required to be
maintained as cash collateral under the SVB Loan and Security Agreement until TLANDO is approved by the FDA. However, on February
16, 2021, we amended the Loan and Security Agreement with SVB to, among other things, remove the cash collateral requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, we entered into the Antares License Agreement with Antares, pursuant to which we granted to Antares an exclusive,
royalty-bearing, sublicensable right and license to develop and commercialize, upon final approval of TLANDO from the FDA, our
TLANDO product with respect to TRT in the U.S. The Antares License Agreement also provides Antares with an option, exercisable on or
before March 31, 2022, to license TLANDO XR. Upon execution of the Antares License Agreement, Antares paid to us an initial payment
of $11.0 million. Antares has also agreed to make certain minimum royalty payments in the future and, since these future minimum
royalties are variable consideration deemed to be probable, $4 million in revenue has been recognized in 2021 for the minimum
royalties to be received in the future. In addition, Antares agreed to purchase finished goods manufactured by Lipocine in
anticipation of commercial scale-up for approximately $1 million. Antares will also make additional payments of $5.0 million to
us on each of January 1, 2025 and January 1, 2026, provided that certain conditions are satisfied. We are also eligible to receive
milestone payments of up to $160.0 million in the aggregate, depending on the achievement of certain sales milestones in a single
calendar year with respect to all products licensed by Antares under the Antares License Agreement. In addition, upon
commercialization, we will receive tiered royalty payments at rates ranging from percentages in the mid-teens to up to 20% of net
sales of TLANDO in the United States, subject to certain minimum royalty obligations. If Antares exercises its option to license
TLANDO XR, we will be entitled to an additional payment of $4.0 million, as well as development milestone payments of up to $35.0
million in the aggregate and tiered royalty payments at rates ranging from percentages in the mid-teens to 20% of net sales of
TLANDO XR in the United States. Our ability to realize benefits from the Antares License Agreement, including milestone and royalty
payments, is subject to a number of risks. We may not realize milestone or royalty payments in anticipated amounts, or at
all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 28, 2021, we completed a public offering of securities registered under an effective registration statement filed pursuant to
the Securities Act of 1933, as amended (&#8220;January 2021 Offering&#8221;). The gross proceeds from the January 2021 Offering were
approximately $28.7 million, before deducting underwriter fees and other offering expenses of $1.9 million. In the January 2021 Offering,
we sold 16,428,571 shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 21, 2020, we entered into a loan (the &#8220;Loan&#8221;) from SVB in the aggregate amount of $234,000, pursuant to the Paycheck
Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which
was in the form of a note dated April 21, 2020, originally matured on April 21, 2022, and bears interest at a rate of 1.0% per
annum, payable monthly commencing on November 21, 2020. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they
are used for qualifying expenses as described in the CARES Act. On November 2, 2020, we were notified by the Small Business Administration
that our PPP Loan had been forgiven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 27, 2020, we completed a registered direct offering of securities registered under an effective registration statement filed
pursuant to the Securities Act of 1933, as amended (&#8220;February 2020 Offering&#8221;). The gross proceeds from the February 2020
Offering were approximately $6.0 million, before deducting placement agent fees and other offering expenses of $347,000. In the February
2020 Offering, the Company sold 10,084,034 Class A Units, with each Class A Unit consisting of one share of common stock and a one-half
of one common warrant to purchase one share of common stock, at a price of $0.595 per Class A Unit. The common stock warrants were immediately
exercisable at an exercise price of $0.53 per share, subject to adjustment, and expire on February 27, 2025. By their terms, however,
the common stock warrants cannot be exercised at any time that the common stock warrant holder would beneficially own, after such exercise,
more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after giving effect to such
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, we entered into the Loan and Security Agreement with SVB pursuant to which SVB agreed to lend us $10.0 million. The
principal borrowed under the Loan and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in money rates
section of The Wall Street Journal or any successor publication representing the rate of interest per annum then in effect, plus one
percent per annum, which interest is payable monthly. Additionally on April 1, 2020, we entered into a Deferral Agreement with SVB. Under
the Deferral Agreement, principal repayments were deferred by six months and we were only required to make monthly interest payments
during the deferral period. The Loan matures on June 1, 2022. Previously, we were only required to make monthly interest payments until
December 31, 2018, following which we also made equal monthly payments of principal and interest until the signing of the Deferral Agreement.
We will also be required to pay an additional final payment at maturity equal to $650,000 (the &#8220;Final Payment Charge&#8221;). At
our option, we may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest and the Final
Payment Charge). In connection with the Loan and Security Agreement, we granted to SVB a security interest in substantially all of our
assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, as TLANDO was not approved
by the FDA by May 31, 2018, we were required to maintain $5.0 million of cash collateral at SVB until such time as TLANDO is approved
by the FDA. However, on February 16, 2021, we amended the Loan and Security Agreement with SVB to, among other things, remove
the financial trigger and financial trigger release event provisions requiring us to maintain a minimum cash collateral value and collateral
pledge thereof. While any amounts are outstanding under the Loan and Security Agreement, we are subject to a number of affirmative and
negative covenants, including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional
indebtedness and transactions with affiliates, among other customary covenants. The credit facility also includes events of default,
the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would
provide SVB, as collateral agent, with the right to exercise remedies against us and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including our cash. These events of default include, among other things,
any failure by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility,
the Company&#8217;s insolvency, a material adverse change, and one or more judgments against us in an amount greater than $100,000 individually
or in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2017, we entered into the Sales Agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) pursuant to which we may issue
and sell, from time to time, shares of our common stock having an aggregate offering price of up to the amount we have registered on
an effective registration statement pursuant to which the offering is being made. We currently have registered up to $50.0 million for
sale under the Sales Agreement, pursuant to our Registration Statement on Form S-3 (File No. 333-250072) (the &#8220;Form S-3&#8221;),
through Cantor as our sales agent. Cantor may sell our common stock by any method permitted by law deemed to be an &#8220;at the market
offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including sales made directly on or through the
NASDAQ Capital Market or any other existing trade market for our common stock, in negotiated transactions at market prices prevailing
at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. Cantor uses its commercially
reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell these shares. We
pay Cantor 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. We have also provided Cantor with
customary indemnification rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of our common stock sold under the Sales Agreement are sold and issued pursuant to our Form S-3, which was previously declared
effective by the Securities and Exchange Commission, and the related prospectus and one or more prospectus supplements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not obligated to make any sales of our common stock under the 2020 Sales Agreement. The offering of our common stock pursuant to
the 2020 Sales Agreement will terminate upon the termination of the 2020 Sales Agreement as permitted therein. We and Cantor may each
terminate the 2020 Sales Agreement at any time upon ten days&#8217; prior notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, we sold 1,811,238 shares of our common stock pursuant to our current Registration Statement on Form
S-3 (File No. 333-250072), resulting in net proceeds of approximately $3.4 million under the sales agreement which is net of $112,000
in expenses consisting of commissions paid to Cantor in connection with these sales and other offering and accounting costs. As of December
31, 2021, we had $41.2 million available for sale under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing capital resources, together with interest thereon, will be sufficient to meet our projected operating
requirements through at least March 31, 2023 which include on-going clinical studies for LPCN 1148, LPCN 1154, LPCN 2101,
 and future clinical studies for LPCN 1144, LPCN 1107 and possible other oral neuroactive
steroids, compliance with regulatory requirements, and satisfaction of our obligations under the settlement agreement with
Clarus. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources
sooner than we currently expect if additional activities are performed by us including new clinical studies for LPCN 1111, LPCN
1144, LPCN 1148, LPCN 1107 and oral neuroactive steroids. While we believe we have sufficient liquidity and capital resources
to fund our projected operating requirements through at least March 31, 2023, we will need to raise additional capital at some point
through the equity or debt markets or through additional out-licensing activities, either before or after March 31, 2023, to support
our operations. If we are unsuccessful in raising additional capital, our ability to continue as a going concern will be limited.
Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for
product development, regulatory compliance and clinical trial activities sooner than planned. In addition, our capital resources may
be consumed more rapidly if we pursue additional clinical studies for LPCN 1111, LPCN 1144, LPCN 1148, LPCN 1107 and oral neuroactive
steroids. Conversely, our capital resources could last longer if we reduce expenses, reduce the number of activities currently
contemplated under our operating plan or if we terminate, modify or suspend on-going clinical studies. We can raise capital pursuant
to the Sales Agreement but may choose not to issue common stock if our market price is too low to justify such sales in our
discretion. In addition, we currently have 5,223,779 unissued and unreserved shares available for issuance at December 31, 2021.
Without sufficient shares available for issuance, our ability to raise capital through sales of equity, including under the Sales
Agreement, is limited. There are numerous risks and uncertainties associated with the development and, subject to approval by the
FDA, commercialization of our product candidates. There are numerous risks and uncertainties impacting our ability to enter into
collaborations with third parties to participate in the development and potential commercialization of our product candidates, and
the potential benefits to us of such arrangements, including the Antares License Agreement. Licensees of our product candidates,
including Antares, may not successfully commercialize our products and, as a result, we may not receive anticipated royalty or other
payments under such arrangements. Additionally, TLANDO is not eligible for final FDA approval until March 28, 2022 and, therefore,
we do not expect to receive any royalty or milestone payments until after such time, if any such payments will be received at all.
We are unable to precisely estimate the amounts of increased capital outlays and operating expenditures associated with our
anticipated or unanticipated clinical studies and ongoing development efforts. All of these factors affect our need for additional
capital resources. To fund future operations, we will need to ultimately raise additional capital and our requirements will depend
on many factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress, results and cost of our clinical studies, preclinical testing and other related activities for all of our
    product candidates, including LPCN 1111, LPCN 1144, LPCN 1148, LPCN 1107 and oral neuroactive steriods;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products that we
    may develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timing of establishing sales, marketing and distribution capabilities, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any collaborative, licensing, settlement and other arrangements that we may establish;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of product candidates that we pursue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost, timing and outcomes of regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements
    relating to any of these types of transactions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we grow significantly in the number of employees or the scope of our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding
may not be available to us on favorable terms, or at all. Also, market conditions may prevent us from accessing the debt and equity capital
markets, including sales of our common stock through the Sales Agreement. If we are unable to obtain adequate financing when needed,
we may have to delay, reduce the scope of or suspend one or more of our clinical studies, research and development programs or, if any
of our product candidates receive approval from the FDA, commercialization efforts. We may seek to raise any necessary additional capital
through a combination of public or private equity offerings, including the Sales Agreement, debt financings, collaborations, strategic
alliances, licensing arrangements and other marketing and distribution arrangements. These arrangements may not be available to us or
available on terms favorable to us. To the extent that we raise additional capital through marketing and distribution arrangements, other
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product
candidates, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.
If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will
be diluted, and the terms of these securities may include liquidation or other preferences, warrants or other terms that adversely affect
our stockholders&#8217; rights or further complicate raising additional capital in the future. If we raise additional capital through
debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional
debt, making capital expenditures or declaring dividends. If we are unable, for any reason, to raise needed capital, we will have to
reduce costs, delay research and development programs, liquidate assets, dispose of rights, commercialize products or product candidates
earlier than planned or on less favorable terms than desired or reduce or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sources
and Uses of Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of our cash flows for the years ended December 31, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years
    ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash used in operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,411,303</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,303,098</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash provided by (used in) investing
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(43,780,397</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,892,703</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash provided by financing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,924,870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,899,254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021 and 2020, net cash used in operating activities was $4.4 million and $15.3 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities during 2021 and 2020 was primarily attributable to cash outlays to support on-going operations, including
research and development expenses and general and administrative expenses. During 2021 and 2020, we were performing activities related
to the LPCN 1144 <i>LiFT</i> Phase 2 paired biopsy clinical study. During 2021, we were also conducting a Phase 2 clinical trial with
LPCN 1148 and we entered into the Global Agreement with Clarus. During 2020, we were also performing activities around the submission
of the TLANDO NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used In/Provided by Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021, net cash used in investing activities was $43.8 million compared to cash provided by investing activities
in 2020 of $3.9 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities during 2021 was primarily the result of purchasing marketable investment securities, net, of $43.8
million. Net cash provided by investing activities in 2020 was primarily the result of utilizing marketable securities, net, of $3.9
million. There were $8,000 and zero capital expenditures for the years ended December 31, 2021, and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021, and 2020, net cash provided by financing activities was $26.9 million and $20.9 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities during 2021 was attributable to the net proceeds from the sale of 16,428,571 shares of common stock
pursuant to January 2021 Offering resulting in net proceeds of $26.8 million and $3.4 million in proceeds from the sale of 1,811,238
shares of common stock pursuant to the Sales Agreement with Cantor, offset by $3.3 million in debt principal repayments under the SVB
Loan and Security Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities during 2020 was primarily attributable to $9.0 million in proceeds from the sale of 6,576,300 shares
of commons stock pursuant to the ATM Offering, $7.7 million in proceeds from the exercise of warrants, $5.7 million in proceeds from
the sale of 10,084,034 shares of common stock pursuant to the February 2020 Offering and $234,000 in loan proceeds under the Payment
Protection Program, offset by $1.7 million in debt principal repayments under the SVB Loan and Security Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
stock option exercises provided approximately $7,000 of cash during 2021 and there were no employee stock option exercises during 2020.
Proceeds from the exercise of employee stock options vary from period to period based upon, among other factors, fluctuations in the
market price of our common stock relative to the exercise price of such options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Commitments and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Long-Term
Debt Obligations and Interest on Debt</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, we entered into a Loan and Security Agreement with SVB pursuant to which SVB agreed to lend us $10.0 million. The principal
borrowed under the Loan and Security Agreement bears interest at a rate equal to the Prime Rate plus one percent per annum, which interest
is payable monthly. The loan matures on June 1, 2022 and we are required to make equal monthly payments of principal and interest for
the remaining term of the loan beginning on November 1, 2020 although there was a principal deferment period of six months beginning
on April 1, 2020 through October 31, 2020 due to COVID-19. We will also be required to pay the $650,000 Final Payment Charge at maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
Obligations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts and issue purchase orders in the normal course of business with clinical research organizations for clinical trials
and clinical and commercial supply manufacturing and with vendors for preclinical research studies, research supplies and other services
and products for operating purposes. These contracts generally provide for termination on notice and are cancellable obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2004, we entered into an agreement to lease our facility in Salt Lake City, Utah consisting of office and laboratory space which
serves as our corporate headquarters. On January 24, 2022, we modified and extended the lease through February 28, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements
which we have prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). In preparing our financial
statements, we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting periods. We have identified the following accounting policies that we believe require application of management&#8217;s
most subjective judgments, often requiring the need to make estimates about the effect of matters that are inherently uncertain and may
change in subsequent periods. Our actual results could differ from these estimates and such differences could be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in Note 2 of our annual financial statements included in this filing,
we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09,
<i>Revenue from Contracts with Customers (Topic 606) </i>with amendments in 2015 (ASU 2015-14) and 2016 (ASU 2016-8, ASU 2016-10, ASU
2016-12 and ASU 2016-20)<i>. </i>The updated standard is a new comprehensive revenue recognition model that requires revenue to be recognized
in a manner that depicts the transfer of goods or services to a customer at an amount that reflects the consideration expected to be
received in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty
of revenue and cash flows arising from contracts with customers. We adopted this pronouncement effective January 1, 2017. We recognized
revenue of $16.1 million in 2021 under agreements with Antares Pharma, Inc. and Spriaso LLC, and no revenue in 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may provide research and development services under collaboration arrangements to advance the development of jointly owned products.
We record the expenses incurred and reimbursed on a net basis in research and development expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we do not have any active collaboration agreements except for an agreement to provide joint research and development
services through January 23, 2015. This agreement was assigned to Spriaso as is further described in Note 12 &#8220;Agreement
with Spriaso, LLC&#8221; of this form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accrued
Research and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of our accrued expenses as of each balance sheet date in our financial statements based on the facts and circumstances
known to us at that time. Our expense accruals for contract research, contract manufacturing and other contract services are based on
estimates of the fees associated with services provided by the contracting organizations. Payments under some of the contracts we have
with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones.
In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in
each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be
required to estimate these services based on other information available to us. If we underestimate or overestimate the activity or fees
associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future
periods. Subsequent changes in estimates may result in a material change in our accruals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under our Incentive
Plan to employees, nonemployees and nonemployee members of our board of directors based on the grant-date fair value of those awards.
The grant-date fair value of an award is generally recognized as compensation expense over the award&#8217;s requisite service period.
In addition, we have granted performance-based stock option awards and restricted stock grants, which vest based upon our satisfying
certain performance conditions. Potential compensation cost, measured on the grant date, related to these performance options will be
recognized only if, and when, we estimate that these options will vest, which is based on whether we consider the options&#8217; performance
conditions to be probable of attainment. Our estimates of the number of performance-based options that will vest will be revised, if
necessary, in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated based
on assumptions with respect to (i) expected volatility of our common stock price, (ii) the periods of time over which employees and members
of the board of directors are expected to hold their options prior to exercise (expected term), (iii) expected dividend yield on the
common stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes an estimate, which is made at the time
of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if
actual forfeitures differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there was $1.4 million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#8217;s stock option plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrant
Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the November 2019 public offering, we issued warrants to purchase common stock. The warrants require us to pay such holders
an amount of cash in the event of a fundamental transaction, as defined in the warrant agreement. As the cash payment is at the option
of the warrant holder, we account for the common stock warrants as a liability, which is adjusted to fair value each reporting period
as well as upon exercise of such warrants. The Company estimates the fair value of the warrant liability based on a hypothetical payout
associated with a fundamental transaction. The fair value estimate utilizes a pricing model and unobservable inputs. Unlike the fair
value of other assets and liabilities which are readily observable and therefore more easily independently corroborated, the warrants
are not actively traded, and fair value is determined based on significant judgments regarding models, unobservable inputs and valuation
methodologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, the warrant liability was $796,000 and $1.2 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
Standards Issued Not Adopted</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to Note 13 in &#8220;Notes to Consolidated Financial Statements&#8221; for a discussion of new accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_010"></span>ITEM
    7A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to various market risks, which include potential losses arising from adverse changes in market rates and prices, such as
interest rates. We do not enter into derivatives or other financial instruments for trading or speculative purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b><i>. </i>Our interest rate risk exposure results from our investment portfolio. Our primary objectives in managing our
investment portfolio are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. The securities
we hold in our investment portfolio are subject to interest rate risk. At any time, sharp changes in interest rates can affect the fair
value of the investment portfolio and its interest earnings. After a review of our marketable investment securities, we believe that
in the event of a hypothetical ten percent increase in interest rates, the resulting decrease in fair value of our marketable investment
securities would be insignificant to the consolidated financial statements. Currently, we do not hedge these interest rate exposures.
We have established policies and procedures to manage exposure to fluctuations in interest rates. We place our investments with high
quality issuers and limit the amount of credit exposure to any one issuer and do not use derivative financial instruments in our investment
portfolio. We invest in highly liquid, investment-grade securities and money market funds of various issues, types and maturities. These
securities are classified as available-for-sale and, consequently, are recorded on the balance sheet at fair value with unrealized gains
or losses reported as accumulated other comprehensive income as a separate component in stockholders&#8217; deficit unless a loss is
deemed other than temporary, in which case the loss is recognized in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally
in January 2018, we entered into the Loan and Security Agreement with SVB for $10.0 million. A one percent increase in the prime rate
would result in a $5,000 increase in interest expense, while a one percent decrease in the prime rate would result in a $5,000 decrease
in interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="am_011"></span>ITEM
    8.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
    STATEMENTS AND SUPPLEMENTAL DATA</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audited
    Financial Statements of Lipocine Inc. for the Years ended December 31, 2021 and 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Naa_001">Report
    of Independent Registered Public Accounting Firm</a> (PCAOB ID No. <span id="xdx_90F_edei--AuditorFirmId_c20210101__20211231_zZOmkL1WOJA9"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorFirmId">270</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Naa_002">Consolidated
    Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">77</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Naa_003">Consolidated
    Statements of Operations and Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Naa_004">Consolidated
    Statements of Changes in Stockholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Naa_005">Consolidated
    Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Naa_006">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">81</span></td></tr>
  </table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Naa_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lipocine
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Lipocine Inc. and subsidiaries (the Company) as of December 31, 2021 and
2020, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows
for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated
financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company
as of December 31, 2021 and 2020, and the consolidated results of its operations and its cash flows for years then ended, in conformity
with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements
that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are
material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments.
The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken
as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters
or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrant Liability</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with a November 2019 public offering, the Company issued warrants to purchase common stock. The warrants require the
Company to pay such warrant holders an amount of cash in the event of a fundamental transaction, as defined in the warrant agreement.
As the cash payment is at the option of the holder, the Company accounts for the common stock warrants as a liability, which is adjusted
to fair value each reporting period as well as upon exercise of such warrants. The Company estimates the fair value of the warrant liability
based on a hypothetical payout associated with a fundamental transaction. The fair value estimate utilizes a pricing model and unobservable
inputs. Unlike the fair value of other assets and liabilities which are readily observable and therefore more easily independently corroborated,
the warrants are not actively traded, and fair value is determined based on significant judgments regarding models, unobservable inputs
and valuation methodologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the valuation of the warrant liability as a critical audit matter because of the unobservable inputs used to estimate
fair value. The valuations involve a high degree of auditor judgment and an increased extent of effort, including the need to audit and
evaluate the appropriateness of the pricing model and inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit procedures for auditing the fair value of the warrant liability included the following procedures, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    evaluated the reasonableness of management&#8217;s valuation methodology and estimates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    developed valuation estimates, using externally sourced inputs and models, and compared to management&#8217;s recorded value and
    investigated differences.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    compared management&#8217;s assumptions utilized within management&#8217;s models to external sources.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a license agreement during 2021 that includes a license fee, guaranteed minimum royalties, ongoing sales royalties,
milestone payments and transfer of materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is required to determine the transaction price and allocate the transaction price to the performance obligations in the license agreement.
Management is also required to make estimates of when achievement of a particular milestone becomes probable. Milestone payments are
included in the transaction price when it becomes probable that such inclusion would not result in a significant revenue reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified revenue recognition as a critical audit matter because of the significant judgment by management in determining the transaction
price and allocating the transaction price to the performance obligations. This in turn led to a high degree of auditor judgment and
effort in performing procedures and evaluating audit evidence related to the judgments made by management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit procedures for auditing revenue included the following procedures, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            obtained and read the material license and royalty agreements</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            tested management&#8217;s determination of the transaction price and the allocation of the
                                            transaction price to the performance obligations </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated the reasonableness of management&#8217;s judgments and estimates</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
<span id="xdx_909_edei--AuditorName_c20210101__20211231_zzItRSG1GDkf"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorName">Tanner LLC</ix:nonNumeric></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2018</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--AuditorLocation_c20210101__20211231_zZO82OYgqlF4"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorLocation">Salt
Lake City, Utah</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
9, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Naa_002"></span>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2021 and 2020</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_z9sU3l5F1wxb" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20211231_z27TqikAEpgk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20201231_zOtBs4yCBGaf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Assets</b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzaA5_zgQ8cHz5apq6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,950,552</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,217,382</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--RestrictedCashAndCashEquivalents_i02I_pp0p0_maACzaA5_z62b0QVmqV56" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0058">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AvailableForSaleSecuritiesDebtSecuritiesCurrent_i02I_pp0p0_maACzaA5_zsnu20osKnZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable investment securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,667,405</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--InterestReceivableCurrent_i02I_pp0p0_maACzaA5_zTQMDFFTKTgb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">247,253</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">391</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzaA5_zETUHZY0YG0i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid and other current
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,514,465</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">661,258</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzaA5_maAz6A3_zuhR8z9z3Ss9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,379,675</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,329,023</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_i02I_maAz6A3_zSar3oDguQoa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable investment securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,021,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0074">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ContractWithCustomerAssetNetNoncurrent_i02I_maAz6A3_znVCmws39XY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contract asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,050,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0077">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_i02I_pp0p0_maAz6A3_zkg2ulmlHZN5" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net of accumulated depreciation of $<span id="xdx_904_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_c20211231_z2bKSB1KMsn8" title="Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,144,077</ix:nonFraction></span>
    and $<span id="xdx_905_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_c20201231_zudZOBqNOM95" title="Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,143,697</ix:nonFraction></span> respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0080">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAssetsNoncurrent_i02I_pp0p0_maAz6A3_zztizUjo5Nzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,753</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,753</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01TI_pp0p0_mtAz6A3_zhOaMMepwF08" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,482,439</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,352,776</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Liabilities and Stockholders&#8217;
    Equity</b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrentAbstract_i01B_zKDDamqt0qMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzZ8l_zCn0tKhVmiw7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,289,342</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,597,220</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzZ8l_zBPyOXrHxKIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,016,458</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,653,178</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DebtCurrent_i02I_pp0p0_maLCzZ8l_zycOd4WEb3G3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Debt - current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,310,825</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,333,333</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LitigationReserveCurrent_i02I_pp0p0_maLCzZ8l_zjREzTjGQmh6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Litigation settlement liability
    - current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LitigationReserveCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0108">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzZ8l_maLzROS_zUD4jTrAQYS5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,616,625</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,583,731</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_i01I_pp0p0_maLzROS_zF42bP8gme64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Debt - non-current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0113">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,257,075</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--WarrantsAndRightsOutstanding_i01I_pp0p0_maLzROS_zt2DyAzArS6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">795,796</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LitigationReserveNoncurrent_i01I_pp0p0_maLzROS_zaenDLBNRvyi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Litigation settlement liability
    - non-current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LitigationReserveNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0120">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_i01TI_pp0p0_maLASEzC9U_mtLzROS_zDj7pb1VAqfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,912,421</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,010,857</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_zldNLknfNJN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commitments and contingencies (notes 5, 8 and
    11)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif">-<span style="-sec-ix-hidden: xdx2ixbrl0125">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif">-<span style="-sec-ix-hidden: xdx2ixbrl0126">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquityAbstract_i01B_zW7tPwdgOzE6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; equity:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_pp0p0_maSEzvlv_z3DEtf71BoGc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred
                                            stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20211231_pdd" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share, <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20211231_pdd" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20201231_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_dc_c20211231_z8M70tijQrKb" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20211231_zbJ1Y9Nl3khd" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_dc_c20201231_z1vZJkkw5UX3" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20201231_zwBxGlkH3kmg" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0131">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0132">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzvlv_zXzNLz21FFVe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized;<span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common stock, shares issued"> <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,296,360</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_c20201231_pdd" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,041,967</ix:nonFraction></span> issued and <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,036,257</ix:nonFraction></span> outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzvlv_zPsWgC1JAxX1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">218,286,323</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">187,407,634</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--TreasuryStockValue_i02NI_pp0p0_di_msSEzvlv_z5zSmE4G08N1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Treasury stock at cost,
    <span id="xdx_906_eus-gaap--TreasuryStockShares_c20211231_pdd" title="Treasury stock, shares"><span id="xdx_901_eus-gaap--TreasuryStockShares_c20201231_pdd" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></ix:nonFraction></span></span> shares</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,712</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,712</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pp0p0_maSEzvlv_zWcZPwdYACc4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated other comprehensive
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0180">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzvlv_zhrwgF2WCksd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated deficit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">172,666,407</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">172,032,008</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_i02TI_pp0p0_maLASEzC9U_mtSEzvlv_zdipcdEWmy86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total stockholders&#8217; equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,570,018</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,341,919</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzC9U_zVYoJtypBese" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&#8217; equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,482,439</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,352,776</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Naa_003"></span>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Operations and Comprehensive Loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
Ended December 31, 2021 and 2020</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_z4QYCBj3iC65" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20210101__20211231_zhj3M0zqakEl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20200101__20201231_zhnUgBUKwIs" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_maOILzelX_zhiCndP0lP3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 16%"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,140,838</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right; width: 16%">-<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0192">&#160;</span></span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzPFk_zun3LEeBcWi7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,665,559</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,748,469</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzPFk_zx5Ta1yxf1Zc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,329,776</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,247,795</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzPFk_msOILzelX_z690bl7BpEgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,995,335</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,996,264</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzelX_maILFCOz1UZ_z68w3JKUj9a9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating income (loss)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,145,503</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">17,996,264</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income (expense)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--InvestmentIncomeInterest_i01_pp0p0_maONIEz9r1_zjTWfgu05wzc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest and investment
    income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,700</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,650</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpense_i01N_pp0p0_di_msONIEz9r1_zwJKQoZpkL56" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">203,292</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">386,618</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_pp0p0_maONIEz9r1_zQYfzmx6rmnc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on extinguishment
    of debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">234,802</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--UnrealizedGainLossOnDerivatives_i01_pp0p0_maONIEz9r1_zeg7emtdyVdj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain (loss)
    on warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">355,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,892,189</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LitigationSettlementExpense_i01N_pp0p0_di_msONIEz9r1_zqfkMSxNGeQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Litigation
    settlement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_i01T_pp0p0_mtONIEz9r1_maILFCOz1UZ_zn9P2lnuYuh2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total other expense, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,779,702</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,968,355</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_mtILFCOz1UZ_maNILzdZM_zuypf4MdQ7F5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before income tax
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">634,199</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,964,619</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_msNILzdZM_z9hbnMVIA4E1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzdZM_zkd5BrB12mX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">634,399</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,964,819</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted average common shares outstanding,</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,934,618</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,688,085</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted average common shares outstanding,
    diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,934,618</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,688,085</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Comprehensive loss:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i01_pp0p0_maCINOTzUv7_z86mLRjTAZT6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">634,399</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,964,819</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_i01_pp0p0_maCINOTzUv7_zPFBrMbMyqud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized net gain (loss)
    on available-for-sale securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_pp0p0_mtCINOTzUv7_zbtVlSkQXf29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">652,415</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,964,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Naa_004"></span>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Changes in Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
Ended December 31, 2021 and 2020</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_zO5nCvJbk9pf" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z4X7rIwHMdCe" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zpFErlPcsv71" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zQeP6sayeZm3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zuXbjTvBPaVa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Loss</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zYGNGWHp42hj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_zjTJz59Xdd57" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Accumulated</b></span></p>
                                               <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Other</b></span></p>
                    <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><b>Total</b></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b></b></span></p>
                                                                                       <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>P</b>aid-In</span></p></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>
                                                                                       <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Comprehensive</span></p></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b></b></span></p>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Stockholders&#8217;</b></span></p></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Loss</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43F_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zBucolAHTY7c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">Balances at December 31, 2019</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxdQRWB62qG9" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,649,465</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,766</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zUIjckklYy6k" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,391,969</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">151,067,189</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,287,796</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,964,819</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,964,819</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Unrealized net gain on marketable investment securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--CommonStockSoldThroughEquityOffering_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock sold through equity offering</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--CommonStockSoldThroughEquityOfferingShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkLPu3xwQQml" title="Common stock sold through equity offering, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOfferingShares" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,084,034</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,008</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,652,132</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,653,140</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueWarrantsExercises_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock issued for warrant exercises</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesWarrantsExercises_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9r0oFXS0i11" title="Common stock issued for warrant exercises, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:StockIssuedDuringPeriodSharesWarrantsExercises" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,097,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,510</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,673,366</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,674,876</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,373,182</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,373,182</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Settlement of warrant liability on warrant
    exercises</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,313,338</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,313,338</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vesting of restricted stock units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYRf6frHbjb1" title="Vesting of restricted stock units, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">628,807</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock sold through ATM offering</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znpMmOaQd1w3" title="Common stock sold through ATM offering, shares" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,576,300</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">658</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,003,710</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,004,368</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_433_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zod2qK0Mw6f9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balances at December 31, 2020</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQq860u3HX5c" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,036,257</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zbOcWecWylie" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,407,634</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">172,032,008</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,341,919</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zr9zG4ESkKSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">634,399</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">634,399</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_zp6NDYck4t1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Unrealized net loss on marketable investment securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z7OAjlwEJPMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">603,946</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">603,946</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_ze0Cpb5zlBZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Option exercises</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzTsJBr4SnC5" title="Option exercises, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,584</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,693</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,693</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--CommonStockSoldThroughEquityOffering_zRNm9tOqIyKh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock sold through equity offering</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--CommonStockSoldThroughEquityOfferingShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMF5lGAIFRGf" title="Common stock sold through equity offering, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOfferingShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,428,571</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,643</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,838,814</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,840,457</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueWarrantsExercises_zbjiYyihqlQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock issued for warrant exercises</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesWarrantsExercises_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3HYJ64lcUGl" title="Common stock issued for warrant exercises, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:StockIssuedDuringPeriodSharesWarrantsExercises" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,999</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_zFjaf20imkLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Settlement of warrant liability on warrant
    exercises</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,365</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,365</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zSXc1EpL1rlg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock sold through ATM offering</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1hdElmDFKMf" title="Common stock sold through ATM offering, shares" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,811,238</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,405,872</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,406,053</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43F_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zzYEI0clCGHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balances at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg3LZTP8k3L3" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zacdV54q7Nn6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,286,323</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">172,666,407</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,570,018</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Naa_005"></span>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
Ended December 31, 2021 and 2020</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_zR6RT1rVNu8a" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20211231_z8UrlxhJmcF" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20200101__20201231_znsiG5Wn0jf9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzbPR_maNCPBUzAEM_zXsHDIjgyPNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">634,399</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,964,819</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to cash used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i02_pp0p0_maNCPBUzbPR_maNCPBUzAEM_z3yXxGJQSH78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">380</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,554</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_i02_pp0p0_maNCPBUzbPR_maNCPBUzAEM_zcOtBINp177d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">603,946</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,373,182</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccretionExpense_i02_pp0p0_maNCPBUzbPR_maNCPBUzAEM_zr3biZtsx35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash interest expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">109,335</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_pp0p0_di_maNCPBUzbPR_msNCPBUzAEM_zQkRe426PVL1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash gain on extinguishment
    of debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">234,802</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUzbPR_maNCPBUzAEM_zI1x472gZZ9e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash loss (gain) on
    change in fair value of warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">355,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,892,189</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccretionAmortizationOfDiscountsAndPremiumsInvestments_i02N_pp0p0_di_msNCPBUzbPR_msNCPBUzAEM_z4YxPhqpgotb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of premium/discount
    on marketable investment securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">515,577</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,616</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in operating assets
    and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedInterestReceivableNet_i03N_pp0p0_di_msNCPBUzbPR_msNCPBUzAEM_zOyZ6PgykNpc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">246,862</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">16,131</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pp0p0_di_msNCPBUzbPR_msNCPBUzAEM_zpsMEOxegsPl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid and other current
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,903,207</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,371</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_pp0p0_maNCPBUzbPR_maNCPBUzAEM_z6VUV8lV4Iwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">307,878</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">414,979</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_pp0p0_maNCPBUzbPR_maNCPBUzAEM_zrpxG29sTQUl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">636,720</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,205,140</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--LitigationSettlementExpenseOne_i03_pp0p0_maNCPBUzbPR_maNCPBUzAEM_zTo9UcSZSJK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Litigation settlement liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:LitigationSettlementExpenseOne" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#160;</span></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_maCCERCzn2U_mtNCPBUzAEM_z4rvLVk7sRe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash used in operating
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,411,303</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">15,303,098</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z9ZwzJbKiO3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from investing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzZWM_z1gz6yzlNUCg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchases of fixed assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,591</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0474">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquireAvailableForSaleSecuritiesDebt_i01N_pp0p0_di_msNCPBUzZWM_z5kMcItaXQs6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchases of marketable
    investment securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,422,806</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,315,297</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_i01_pp0p0_maNCPBUzZWM_zOmFi3lUQOYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Maturities of marketable
    investment securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,650,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,208,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzZWM_maCCERCzn2U_zIuOK7MYW4Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash provided by (used
    in) investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">43,780,397</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,892,703</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceOfDebt_i01_pp0p0_maNCPBUz1ML_zjLZNb2zElll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">233,537</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RepaymentsOfDebt_i01N_pp0p0_di_msNCPBUz1ML_zH249aUeVlQ5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Debt repayments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,333,333</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,666,667</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromStockOptionsExercised_i01_pp0p0_maNCPBUz1ML_zNnerERjclyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from stock option
    exercises</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,693</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUz1ML_zqxn8j1UG0q" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from sale of common
    stock sold in equity offering</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,840,457</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,653,140</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromWarrantExercises_i01_pp0p0_maNCPBUz1ML_zeZudrUqZTE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Proceeds from exercise of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,674,876</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--NetProceedsFromSaleOfCommonStockThroughATM_i01_pp0p0_maNCPBUz1ML_zEHyYdG1mFAf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from sale
    of common stock through ATM</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:NetProceedsFromSaleOfCommonStockThroughATM" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,406,053</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:NetProceedsFromSaleOfCommonStockThroughATM" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,004,368</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUz1ML_maCCERCzn2U_zAukt6ppgljf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash provided by financing
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,924,870</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,899,254</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzn2U_zhOLFTVZsC3i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease)
    in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">21,266,830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,488,859</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash, cash equivalents
    and restricted cash at beginning of period</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,217,382</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,728,523</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash, cash equivalents
    and restricted cash at end of period</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,950,552</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,217,382</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental disclosure
    of cash flow information:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest paid</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,543</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">276,019</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income taxes paid</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental disclosure
    of non-cash investing and financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--SettlementOfWarrantLiabilityOnWarrantExercises_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Settlement of warrant liability
    on warrant exercises</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:SettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,365</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:SettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,313,338</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_i01N_pp0p0_di_z06DwadoTm6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized net gain (loss)
    on marketable investment securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--AccruedFinalPaymentChargeOnDebt_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued final payment charge
    on debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:AccruedFinalPaymentChargeOnDebt" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:AccruedFinalPaymentChargeOnDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">109,335</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">See accompanying notes to consolidated financial statements</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Naa_006"></span><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zzodVWPYejM8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zc2JX4wRB5wg">Description of Business</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lipocine
Inc. (&#8220;Lipocine&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
disorders, is engaged in research and development for the delivery of drugs using its proprietary delivery technology. The Company&#8217;s
principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its own drug candidates or it develops
drug candidates on behalf of or in collaboration with corporate partners. The Company has funded operating costs primarily through collaborative
license, milestone and research arrangements, through federal grants, through the sale of equity securities and through debt. The Company
is incorporated under the laws of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zr6o0SiZ71Q5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zBASakskuM">Summary of Significant Accounting Policies</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84B_eus-gaap--UseOfEstimates_zS3cKuhCv4aa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zbAEwo35NvGi">Use of Estimates</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates. Significant items subject to such estimates and assumptions include those related to stock-based compensation;
income tax uncertainties; the fair value of the warrant liability and the useful lives of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6nKwusyv1u4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zdlSg0YRaPO3">Cash and Cash Equivalents</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities to the Company of three months or less to be cash equivalents.
Although the Company may deposit its cash and cash equivalents with multiple financial institutions, its deposits, at times, may exceed
federally insured limits. Cash and cash equivalents were $<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zYCo3dDgpqAd"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span> million and $<span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20201231_z85VN9DcsXh5" title="Cash Equivalents, at Carrying Value"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">19.2</ix:nonFraction></span>million at December 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zYEtcgyU4CTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zjSAJGjXEmm4">Receivables</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are recorded at the invoiced amount and do not bear interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains an allowance for doubtful accounts for estimated losses. In establishing the allowance, management considers historical
losses adjusted to take into account current market conditions and their customers&#8217; financial condition, the amount of receivables
in dispute, and the current receivables aging and current payment patterns. The Company had no write-offs in 2021 and 2020 and the Company
did not record an allowance for doubtful accounts as of December 31, 2021 and 2020 as there were no accounts receivable outstanding.
The Company does not have any off-balance-sheet credit exposure related to its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zFciAEhTHFDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zkB8RqQyhKIf">Revenue Recognition</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates most of its revenue from license and royalty arrangements. At inception of each contract, the Company identifies
the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines
the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and
determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction
price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. The Company reassess its reserves for variable consideration
at each reporting date and makes adjustments, if necessary, which may affect revenue and earnings in periods in which any such changes
become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<ix:exclude><!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)
Summary of Significant Accounting Policies &#8211; (continued)</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zdWnl6qjMk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation
of Revenue</i>.&#160;In the following tables, revenues reported for the year ended December 31, 2021, under Topic 606, is disaggregated
by type of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B2_zuLyLtwvNK4d" style="display: none">Schedule of Disaggregation
of Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Type of Revenue</td><td>&#160;</td>
    <td colspan="3" id="xdx_498_20210101__20211231_zgv6ccqvmkkk">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zAi9cZjBFZw8" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%">Licensing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SalesBasedRoyaltiesMember_zPyc3OXnLh2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales-based royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_SalesBasedRoyaltiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MinimumGuaranteedRoyaltiesMember_z3rfsLxUtocc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Minimum guaranteed royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_MinimumGuaranteedRoyaltiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MaterialsMember_zhfrHuzqtVT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Materials</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_MaterialsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,035,844</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Revenue</span></td><td></td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,140,838</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zV6aKZ3IMhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Topic 606, all revenue has been recognized as point in time for the year ended December 31, 2021.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 4 for a description of the license agreement with Antares Pharma, Inc. See Note 12 for a description of the agreement with Spriaso.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Fees</i>. For distinct license performance obligations, upfront license fees are recognized when the Company satisfies the underlying
performance obligation. This generally occurs upon transfer of the right to use the Company&#8217;s licensed technology to the customer.
In addition, license arrangements may include contingent milestone payments, which are due following achievement by our licensee of specified
sales or regulatory milestones and the licensee and/or Company will fulfill its performance obligation prior to achievement of these
milestones. Because of the uncertainty of the milestone achievement, and/or the dependence on sales of our licensee, variable consideration
for contingent milestones is fully constrained and is not recognized as revenue until the milestone is achieved by our licensee, to the
extent collectability is reasonably certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Royalties.
</i>Royalties revenue consists of sales-based and minimum royalties earned under licenses agreements for our products. Performance obligations
under these licenses, which consist of the right to use the Company&#8217;s proprietary technology, are satisfied at a point in time
corresponding with delivery of the underlying technology rights to the licensee, which is generally upon transfer of the licensed technology/product
to the customer. Sales-based royalties revenue represents variable consideration under the license agreements and is recognized in the
period a customer sells products incorporating the Company&#8217;s licensed technologies/products. The Company estimates sales-based
royalties revenue earned but unpaid at each reporting period using information provided by the licensee. The Company&#8217;s license
arrangements may also provide for minimum royalties, which the Company recognizes upon the satisfaction of the underlying performance
obligation, which generally occurs with delivery of the underlying technology rights to the licensee.Sales-based and minimum royalties
are generally due within 45 days after the end of each quarter in which they are earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
assets consist of minimum royalty revenue earned in relation to the license agreement but not yet payable based on the terms of the contract.
The contract asset as of December 31, 2021 is related to the Antares License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Concentration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
major customer is considered to be one that comprises more than <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--MajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLMX5IlbMtq4"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_custom_MajorCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of the Company&#8217;s total revenues. There was one major customer
for the year ended December 31, 2021 which accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--OneMajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLHc6v70JOwc" title="Percentage of total revenue"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_custom_OneMajorCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">99.7</ix:nonFraction></span>% of total revenue. There was <span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_do_c20201001__20201231_zSySGzYwqj76" title="Total revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-10-012020-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> revenue recognized for the year ended December
31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOOkvtINXNn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(e)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zioBGwPalWU6">Property and Equipment</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost, less accumulated depreciation. Maintenance and repairs that do not extend the life or improve the
asset are expensed in the year incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is computed using the straight-line method over the estimated useful lives of the assets, which are <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zatle0IZ9bo3" title="Property, Plant and Equipment, Useful Life"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">five years</ix:nonNumeric> </span>for laboratory and office
equipment, <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zr3KRIRRrS11" title="Property, Plant and Equipment, Useful Life"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_ComputerEquipmentAndSoftwareMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">three years</ix:nonNumeric></span> for computer equipment and software, and <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zpuhAqpP7wF2" title="Property, Plant and Equipment, Useful Life"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">seven years</ix:nonNumeric></span> for furniture and fixtures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zEYltHlVqFs3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(f)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z3r5HPdRjcDj">Accounting for Impairment of Long-Lived Assets</span></i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability of assets held and used is measured by a comparison of the carrying amount of an asset to future net cash
flows (undiscounted) expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized
is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets held for sale are reported
at the lower of the carrying amount, or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zij84mfqKRbc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(g)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z1FKhGvDMhyk">Income Taxes</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is provided against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or
all of the net deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition
or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related
to unrecognized tax benefits as a component of its income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zE5k11edQWx6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(h)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_znbsB5FBIE3b">Share Based Payments</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under
the Company&#8217;s Incentive Plan to employees, nonemployees and nonemployee members of the Company&#8217;s board of directors based
on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over
the award&#8217;s requisite service period. In addition, the Company has granted performance-based stock option awards and restricted
stock units, which vest based upon the Company satisfying certain performance conditions. Potential compensation cost, measured on the
grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options or units
will vest, which is based on whether the Company considers the performance conditions to be probable of attainment. The Company&#8217;s
estimates of the number of performance-based options or units that will vest will be revised, if necessary, in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated
based on assumptions with respect to (i) expected volatility of the Company&#8217;s Common Stock price, (ii) the periods of time over
which employees, nonemployees and members of the board of directors are expected to hold their options prior to exercise (expected term),
(iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes
an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised,
if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed
in the statements of operations amounted to $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3p0_c20210101__20211231_zXhfRBKUTEzf"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">604,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20200101__20201231_zuOVQIW0WaU3" title="Stock-based compensation cost"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million for the years ended December 31, 2021 and 2020, allocated as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zxktI59KUKT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zhzSwTDBtpj3" style="display: none">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfpCgm0FOUUb" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">280,186</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfo1rTd1mKY1" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">583,212</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPBGjCR5Ba9i" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">323,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zI21cmWhk788" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">789,970</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210101__20211231_zFzE5iVkIFd" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">603,946</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200101__20201231_zNigh3TFQ4U8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,373,182</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z9I2BOotSGTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zzXAxaMeRyW2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">1,106,000</ix:nonFraction></span> stock options and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0d_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zgAtZFpGhCtb" title="Number of stock options issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,360,000</ix:nonFraction></span> stock options during the years ended December 31, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used in the determination of the fair value of stock options granted are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical
experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff
Accounting Bulletin (&#8220;SAB&#8221;) No. 107, <i>Share-Based Payment,</i> for awards with stated or implied service periods. The simplified
method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance
conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an
equivalent remaining term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Dividend</i>: The expected dividend assumption is based on management&#8217;s current expectation about the Company&#8217;s anticipated
dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>: The volatility factor is based solely on the Company&#8217;s trading history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zf9P3LTrNnc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
options granted in 2021 and 2020, the Company calculated the fair value of each option grant on the respective dates of grant using the
following weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zjfYf6O7yXqg" style="display: none">Schedule of Key Assumption of Fair Value of Stock Options Granted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zigqPgUOxEZ8"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.83</ix:nonNumeric></span>
                                            years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zCceFwzJzute"><ix:nonNumeric contextRef="From2020-01-012020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.83</ix:nonNumeric></span>
                                            years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zgcnZIUoQ6K3" title="Risk-free interest rate" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.04</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zsPoWtUlC3Y7" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.93</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20210101__20211231_zXibUT3LAfol" title="Expected dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20200101__20201231_zOXOJ72FKom6" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zAWn9JB5hgod" title="Expected volatility" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102.18</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zgGyc6uUUQN9" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.32</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zVf2XvZ0efE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Stock Compensation,</i> requires the Company to recognize compensation
expense for the portion of options that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived
from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional
adjustments to compensation expense may be required in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231_zy2xMqQDarp3" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#8217;s stock option plan. That cost is expected to be recognized over a weighted average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231_zjI6ilgBAOG2" title="Weighted average period of stock option plan"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.3</ix:nonNumeric></span> years
and will be adjusted for subsequent changes in estimated forfeitures. The weighted average fair value of share-based compensation awards
granted during the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zgMvHpcT81Ld" title="Weighted average fair value of share-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.97</ix:nonFraction></span> per share and $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zR7ykk45H38c" title="Weighted average fair value of share-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></span> per share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcxKT4huaXBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(i)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zkTH0OjI9iH2">Fair Value</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent
possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability
in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 Inputs: Quoted prices for identical instruments in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets
    that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in
    active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For
accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair
value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets
and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and 2020:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zzBGjfRbBTPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z8FOEw2Zhok1" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December 31,</b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value measurements at reporting date using</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;1&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;2&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;3&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents
    - money market funds</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,089,751</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,089,751</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0626">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Government treasury bills</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_zYGZ6JIYckGg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,515,920</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTu9YGe8OTa2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,515,920</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvtejDkIbzk" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJsvJNlBhXKf" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_CommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,385,634</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,385,634</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate
    bonds and notes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_custom_CorporateBondsandNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,787,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0636">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateBondsandNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,787,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,778,956</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,605,671</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,173,285</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_WarrantMember78957890" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">795,796</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">795,796</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231_zD0ubLHmRyY8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,574,752</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9RCmwhCsiB5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,605,671</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzR9sXtEOXHf" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,173,285</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdagisEL2M91" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">795,796</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31,</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
                                            value measurements at reporting date using</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; width: 13%"><p style="margin-top: 0pt; margin-bottom: 0pt"></p>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;1&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;2&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;3&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents - money
    market funds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zXwfULRgcUP7" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,399,585</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z966EUneKSK" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,399,585</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrgFK1UTqLe3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Kb9hlcgRl" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_zmBOCCN8FPte" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkHjiDBgeDib" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPasc9NWxJpl" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUOTmfQWyXFk" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231_zgu5OFtTpuB1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,849,577</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zF2rDLCvLyih" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,399,585</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOXN8fQ4M1B5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUUzJQw55bdb" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztRdSXKnChQb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_WarrantMember78957953" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zE6BOBMv2vt" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zjL0GunQRlLa" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z3NlU6vvX9F5" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_zvV437GzwiVi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,019,628</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8hIWi8rxM73" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,399,585</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPPwnpBFeMx6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzj9PUwJ5Ha" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zfTFu6dX2mGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value
in the balance sheets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents: Cash equivalents primarily consist of highly rated money market funds and treasury bills with original maturities to
the Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to
money market funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted
market prices or broker or dealer quotations for similar assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
bonds and notes: The Company uses a third-party pricing service to value these investments. United States bonds and notes are classified
within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets and reportable trades.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. Corporate bonds, notes
and commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids
and offers, benchmark yields and credit spreads and other observable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
liability: The warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period
with the change in fair value recorded to other income (expense) in the accompanying statements of operations until the warrants are
exercised, expire or other facts and circumstances lead the warrant liability to be reclassified to stockholders&#8217; equity. The fair
value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2021, include (i) volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z19hlJuH8rVe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) risk free interest rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI5DNwf7Eil"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.97</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
(iii) strike price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziKrn14fM53k"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numunitdecimalin" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction>,
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) fair value of common stock of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zytKZGs6mw1f"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="USDPShares">.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and (v) expected life of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4nT1d8PUND7"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.9</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2020, include (i) volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKYVGOdcAUoc" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) risk free interest rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNicT6cnU262" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.27</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
(iii) strike price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUdcRG4B97b3" title="strike price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
(iv) fair value of common stock of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ETF2od4R61" title="Fair value of common stock"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.36</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and (v) expected life of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZT52iLq6ub5" title="Expected life"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.9</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change
in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2 or Level 3 for the years ended December
31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_z1GRdyWmSHB4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(j)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z0dDnmxLUJB4">Earnings (Loss) per Share</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number
of common shares outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
earnings (loss) per share is based on the weighted average number of common shares outstanding plus, where applicable, the additional
potential common shares that would have been outstanding related to dilutive options, warrants, and unvested restricted stock units to
the extent such shares are dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zh0mh9AeFEj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the years ended December
31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zifCAHpbwzRb" style="display: none">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share attributable
    to common stock:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20211231_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">634,399</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,964,819</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted avg. common
    shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20211231_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,934,618</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20201231_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,688,085</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20210101__20211231_pdd" title="Basic loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--EarningsPerShareBasic_c20200101__20201231_pdd" title="Basic loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share attributable
    to common stock:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20211231_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">634,399</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20201231_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,964,819</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted avg. common
    shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20211231_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,934,618</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20201231_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,688,085</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_pdd" title="Diluted loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EarningsPerShareDiluted_c20200101__20201231_pdd" title="Diluted loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zLNNaS75DF84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlbm6t6zCWj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of diluted earnings per share for the years ended December 31, 2021 and 2020 does not include the following stock options
or warrants to purchase shares in the computation of diluted earnings per share because these instruments were antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPYlHuaGzPrk" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z55tnWWce096" title="Stock options" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember78958203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,551,205</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjNnM0OoExji" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember78958203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,564,458</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_znkxwLVqRfxc" title="Warrants" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember78958203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,366</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8INJK4Jt5Ok" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember78958203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,944,366</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zUeuN8yTTBha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWM5TW9qprL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(k)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zcnUAgHnyhYa">Segment Information</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a single reportable segment engaged in research and development for the delivery of drugs using its proprietary delivery technology.
Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief operating
decision maker made such decisions and assessed performance at the company level, as one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zznl6ajbLwK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(l)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zDi1AbRxBOTc">Principles of Consolidation</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and all subsidiaries. The Company eliminates all intercompany accounts
and transactions in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zDZ8A5PlqoDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span> <span style="font-family: Times New Roman, Times, Serif"><span><span id="xdx_829_z2OmmfwiPND5">Marketable Investment Securities</span></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has classified its marketable investment securities as available-for-sale securities, all of which are debt securities. These
securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated
other comprehensive income (loss) in stockholders&#8217; equity until realized. Gains and losses on investment security transactions
are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized
on an accrual basis. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale
securities by major security type and class of security at December 31, 2021 and 2020 were as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock"><p id="xdx_89D_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zYhhdupVx1y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zlKToP0umYdj" style="display: none">Schedule of Available-for-Sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding gains</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding losses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Government treasury bills</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zh6R1Pywus52" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,526,122</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTPOS7Y0GRNb" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0731">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSt0V2LJBtv2" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,202</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zWsmdF4CtClg" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,515,920</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate bonds, notes
    and commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zrh4uivRxVRj" title="Amortized Cost" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,181,099</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zECanzzZzauf" title="Gross unrealized holding gains" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zDZJJgCDoHid" title="Gross unrealized holding losses" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,814</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" title="Aggregate fair value" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,173,285</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231_zRLYhI4DOdB1" title="Amortized Cost" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,707,221</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231_zi2erJtGwXD4" title="Gross unrealized holding gains" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231_z5C2aScSAzxi" title="Gross unrealized holding losses" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231_zo674dFYIaxd" title="Aggregate fair value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,689,205</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding gains</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding losses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zcXKD0mdHj0c" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zfmwQ7Ptu2Qc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zEm8Ju10QvP4" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0752">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zy0Wl78caysi" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231_z44oKmNm6se4" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231_zCZk9GXvGfh5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231_zTTj0o4UIf0b" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zvpKNGBlTQqk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z4FqzTKuHFtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Marketable Investment
    Securities - (continued)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock"><p id="xdx_890_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zI5k2fXjS3K9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of debt securities classified as available-for-sale securities at December 31, 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zeWynuVtsOre" style="display: none">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Amortized</span></p>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cost</span></p></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due within one year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20211231_zlWpRuvdhSs5" title="Due within one year" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,680,635</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pp0p0_c20211231_zR9vYYX5gt6c" title="Due within one year" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,667,405</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due after one year through
    two years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_iI_pp0p0_c20211231_zhBdsAmY0Vq4" title="Due after one year through two years" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,026,586</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pp0p0_c20211231_ztqME1Q1iHT2" title="Due after one year through two years" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,021,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20211231_zZ2qhX8uXf0h" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,707,221</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20211231_zk9zNUdkZmm5" title="Total maturities of debt securities classified as available-for-sale securities, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,689,205</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zaPfCd0mxa4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90B_eus-gaap--ProceedsFromSaleOfHeldToMaturitySecurities_do_c20210101__20211231_zjde0BaRTh1c"><span id="xdx_900_eus-gaap--ProceedsFromSaleOfHeldToMaturitySecurities_do_c20200101__20201231_z42o0XpwT7Jj"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="From2021-01-01to2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="From2020-01-012020-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> sales of marketable investment securities during the years ended December 31, 2021 and 2020 and therefore <span id="xdx_90F_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_do_c20210101__20211231_zjfnl2ujjMfd"><span id="xdx_90B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_do_c20200101__20201231_zcP7mwHdoGTd"><ix:nonFraction name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" contextRef="From2021-01-01to2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" contextRef="From2020-01-012020-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> realized gains or
losses. Additionally, $<span id="xdx_905_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20210101__20211231_zWlE21eczHe3" title="Matured marketable investment securities"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span> million and $<span id="xdx_90C_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20200101__20201231_zFxTzOkiO8r4" title="Matured marketable investment securities"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.2</ix:nonFraction></span> million of marketable investment securities matured during the years ended December 31,
2021 and 2020, respectively. The Company determined there were <span id="xdx_903_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210101__20211231_zqpKQqt9oRmf" title="Other than temporary impairments"><span id="xdx_908_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200101__20201231_zaNOEEwscDxi" title="Other than temporary impairments"><ix:nonFraction name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" contextRef="From2021-01-01to2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" contextRef="From2020-01-012020-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> other-than-temporary impairments for the years ended December 31, 2021
and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock"><p id="xdx_806_eus-gaap--BusinessAndContractualArrangementsDisclosureTextBlock_zQRIgrnD8VS7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(4)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zz50gbaFhdGi">Contractual Agreements</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Abbott
    Products, Inc. </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 29, 2012, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products,
Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations
under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual <span id="xdx_90C_ecustom--CollaborativeArrangementRoyaltiesPercentageOfNetSales_pid_dp_uPure_c20120328__20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_z7Xdni6xm4fj" title="Percentage of net sales"><ix:nonFraction name="lpcn:CollaborativeArrangementRoyaltiesPercentageOfNetSales" contextRef="From2012-03-282012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% royalty on net sales. Such
royalties are limited to $<span id="xdx_902_eus-gaap--RoyaltyGuaranteesCommitmentsAmount_iI_pn5n6_c20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_z3JnVNsB6eNk" title="Royalties, commitment amount"><ix:nonFraction name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="AsOf2012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million in the first two calendar years following product launch, after which period there is not a cap
on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by <span id="xdx_906_ecustom--PercentageOfRoyaltiesReductionBasedUponProductLaunch_pid_dp_uPure_c20120328__20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_zfbAgOSAchO8" title="Percentage of royalties reduction based upon product launch"><ix:nonFraction name="lpcn:PercentageOfRoyaltiesReductionBasedUponProductLaunch" contextRef="From2012-03-282012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%.
The Company did not incur any royalties owed during the years ended December 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b><i>Ant<span style="font-size: 10pt">ares
    Pharma, Inc.</span></i></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, the Company entered into a license agreement (&#8220;License Agreement&#8221;) with Antares Pharma, Inc. (&#8220;Antares&#8221;)
pursuant to which the Company granted to Antares an exclusive, royalty-bearing, sublicensable right and license to develop and commercialize,
upon final approval of TLANDO&#174; from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the Company&#8217;s TLANDO product
with respect to testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone,
as indicated in NDA No. 208088, treatment of Klinefelter syndrome, and pediatric indications relating to testosterone replacement therapy
in males for conditions associated with a deficiency or absence of endogenous testosterone (the &#8220;Field&#8221;), in each case within
the United States. The Antares License Agreement also provides Antares with an option, exercisable on or before March 31, 2022, to license
TLANDO XR, the Company&#8217;s potential once-daily oral product candidate for testosterone replacement therapy. Upon execution of the
Antares License Agreement, Antares paid to the Company an initial payment of $<span id="xdx_907_ecustom--LicenseFee_pn5n6_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zlckk9NqySEk" title="License fee"><ix:nonFraction name="lpcn:LicenseFee" contextRef="From2021-10-132021-10-14_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.0</ix:nonFraction></span> million. Antares will also make additional payments
of $<span id="xdx_90A_ecustom--PotentialLicenseFeesFromALicensee_pn5n6_c20241231__20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z93vpRELylG7" title="Potential license fees from a licensee"><span id="xdx_90E_ecustom--PotentialLicenseFeesFromALicensee_pn5n6_c20251231__20260101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zz6qXdCAOoQf"><ix:nonFraction name="lpcn:PotentialLicenseFeesFromALicensee" contextRef="From2024-12-312025-01-01_us-gaap_SubsequentEventMember_srt_ScenarioForecastMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="lpcn:PotentialLicenseFeesFromALicensee" contextRef="From2025-12-312026-01-01_us-gaap_SubsequentEventMember_srt_ScenarioForecastMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></ix:nonFraction></span></span> million to the Company on each of January 1, 2025, and January 1, 2026, provided that certain conditions are satisfied. The Company
is also eligible to receive milestone payments of up to $<span id="xdx_902_ecustom--SalesMilestoneRevenueRecognized_pn5n6_c20211013__20211014__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNYLTkLwYII7" title="Sales milestone"><ix:nonFraction name="lpcn:SalesMilestoneRevenueRecognized" contextRef="From2021-10-132021-10-14_srt_MaximumMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">160.0</ix:nonFraction></span> million in the aggregate, depending on the achievement of certain sales
milestones in a single calendar year with respect to all products licensed by Antares under the Antares License Agreement. In addition,
upon commercialization, the Company will receive tiered royalty payments at rates ranging from percentages in the mid-teens to up to
<span id="xdx_90F_ecustom--PercentageOfRoyaltyPayment_dp_uPure_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHgS0fUdWDRh" title="Percentage of royalty payment"><ix:nonFraction name="lpcn:PercentageOfRoyaltyPayment" contextRef="From2021-10-132021-10-14_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of net sales of TLANDO in the United States, subject to certain minimum royalty obligations. If Antares exercises its option to license
TLANDO XR, the Company will be entitled to an additional payment of $<span id="xdx_90C_ecustom--LicenseFee_pn5n6_c20211013__20211014__dei--LegalEntityAxis__custom--TLANDOXRMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zEJYa7D8Ec5k" title="License fee"><ix:nonFraction name="lpcn:LicenseFee" contextRef="From2021-10-132021-10-14_custom_TLANDOXRMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million, as well as development milestone payments of up to
$<span id="xdx_900_ecustom--ClinicalAndDevelopmentMilestones_pn5n6_c20211013__20211014__dei--LegalEntityAxis__custom--TLANDOXRMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zji15ixhz4Q5" title="Clinical and development milestones"><ix:nonFraction name="lpcn:ClinicalAndDevelopmentMilestones" contextRef="From2021-10-132021-10-14_custom_TLANDOXRMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">35.0</ix:nonFraction> </span>million in the aggregate and tiered royalty payments at rates ranging from percentages in the mid-teens to <span id="xdx_902_ecustom--PercentageOfRoyaltyPayment_dp_uPure_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z8CEA12Zgia9"><ix:nonFraction name="lpcn:PercentageOfRoyaltyPayment" contextRef="From2021-10-132021-10-14_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of net sales of
TLANDO XR in the United States. The Company retains development and commercialization rights in the rest of the world,
and with respect to applications outside of the Field inside or outside the United States. Antares will also purchase certain existing
inventory of licensed products from the Company, subject to testing and acceptance procedures. Finally, pursuant to the terms of the
Antares License Agreement, Antares is generally responsible for expenses relating to the development (including the conduct of any clinical
trials) and commercialization of licensed products in the Field in the United States, while the Company is generally responsible for
expenses relating to development activities outside of the Field and/or the United States. The Company recognized revenue under the Antares
Licensing Agreement of $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNVnux4Z6wA4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.1</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and <span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_dc_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrZrNQFMKHZ4"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_LicenseAgreementMember" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD">zero
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during the years ended December 31, 2021 and
2020.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(4) Contractual Agreements &#8211; (continued)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Contract Research and
    Development</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing
development work on behalf of the Company as well as a number of independent contractors, primarily clinical researchers, who serve as
advisors to the Company. The Company incurred expenses of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20210101__20211231_ziao6C8HwkEj" title="Contract research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200101__20201231_z1PlNuagO9H2"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.8</ix:nonFraction></span> million under these agreements in 2021 and 2020 and has
recorded these expenses in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zQKvkvmzQZZh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(5)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zMQycos3xxMj">Loan and Security Agreement</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Silicon
Valley Bank Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, the Company entered into a Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Silicon
Valley Bank (&#8220;SVB&#8221;) pursuant to which SVB agreed to lend the Company $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zOVvC7qymxjj" title="Aggregate amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million. <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zuIBLHcQGrwa"><ix:nonNumeric contextRef="From2018-01-042018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate">The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zqAnDtOJc45l" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction></span>% as of December
31, 2021), which interest is payable monthly</ix:nonNumeric></span>. Additionally on April 1, 2020, the Company entered into a Deferral Agreement with SVB.
Under the Deferral Agreement, principal repayments were deferred by six months and the Company was only required to make monthly interest
payments. The loan matures on<span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zrDepgky15n7"> <ix:nonNumeric contextRef="From2018-01-042018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">June 1, 2022</ix:nonNumeric></span>. Previously, the Company only made monthly interest payments until December 31, 2018, following
which the Company also made equal monthly payments of principal and interest until the signing of the Deferral Agreement. The Company
will also be required to pay an additional final payment at maturity equal to $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zAl5cjBWUCIj" title="Debt instrument, balloon payment to be paid"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">650,000</ix:nonFraction></span> (the &#8220;Final Payment Charge&#8221;). The
Final Payment Charge will be due on the scheduled maturity date and to date approximately $<span id="xdx_900_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z4ahh4Ejxxki" title="Debt instrument, increase in amount"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="From2018-01-042018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">644,000</ix:nonFraction></span> has been recognized as an increase
to the principal balance with a corresponding charge to interest expense with the remaining final payment charge to be recognized over
the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and
Security Agreement (including all accrued and unpaid interest and the Final Payment Charge).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Loan and Security Agreement, the Company granted to SVB a security interest in substantially all of the Company&#8217;s
assets now owned or hereafter acquired, excluding intellectual property and certain other assets. On September 9, 2021, SVB consented
to the Antares Licensing Agreement which among other things provides Antares a license to certain intellectual property as well as assigns
Antares the TLANDO&#174; trademark. In addition, as TLANDO was not approved by the United States Food and Drug Administration (&#8220;FDA&#8221;)
prior to May 31, 2018, the Company maintained $<span id="xdx_90E_eus-gaap--CashCollateralForBorrowedSecurities_iI_pn5n6_c20210909__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zoZsDKiYAwAb" title="Cash collateral for borrowed securities"><ix:nonFraction name="us-gaap:CashCollateralForBorrowedSecurities" contextRef="AsOf2021-09-09_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million of cash collateral at SVB as required under the Loan and Security Agreement
until such time as TLANDO is approved by the FDA. However on February 16, 2021, the Company amended the Loan and Security Agreement with
SVB to, among other things, remove the financial trigger and financial trigger release event provisions requiring the Company to maintain
a minimum cash collateral value and collateral pledge thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentRestrictiveCovenants_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zfhiVxo8AJI9"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" name="us-gaap:DebtInstrumentRestrictiveCovenants">While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus <span id="xdx_90F_ecustom--DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_pid_dp_uPure_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zRrdUYO81cm8" title="Debt instrument, basis spread on interest rate for debt default"><ix:nonFraction name="lpcn:DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" contextRef="From2021-01-012021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.</ix:nonNumeric></span> These events of default include, among other things,
any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the
credit facility, the Company&#8217;s insolvency, a material adverse change, and one or more judgments against the Company in an amount
greater than $<span id="xdx_90D_ecustom--DebtInstrumentMinimumAmountConsideredForInsolvency_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zfFt52NgKSVd" title="Debt instrument, minimum amount considered for insolvency"><ix:nonFraction name="lpcn:DebtInstrumentMinimumAmountConsideredForInsolvency" contextRef="From2021-01-012021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> individually or in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(5)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Loan and Security
    Agreement &#8211; (continued)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zZFZync2fV32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
maturities of principal payments on the Loan and Security Agreement at December 31, 2021 (excluding accrued final payment fee) are as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span id="xdx_8B7_zXOhItJPNeWa" style="display: none">Schedule of Maturities of Debt</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Years
    Ending December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Amount
    (in thousands)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_c20211231_z4CAx3eujQC3" title="2022" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,667</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_iI_pn3n3_c20211231_zMLi7LLZ77n4" title="Thereafter" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0835">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_pn3n3_c20211231_z4Q9n2XBIm03" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,667</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zDhm21YfyHc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; color: #212529"><i>Payroll Protection
Program Loan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In April 2020, the Company was
granted a loan from SVB in the aggregate amount of $<span id="xdx_901_eus-gaap--ProceedsFromLoans_c20200401__20200430__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramLoanMember_zBEteoi2zFog" title="Proceeds from loans"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2020-04-012020-04-30_custom_PayrollProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233,537</ix:nonFraction></span>, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under
Division A, Title I of the CARES Act. On November 2, 2020, we were notified by the Small Business Administration that our PPP loan had
been forgiven.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_ztMfhpSvSZr7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(6)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zHdSzlYWO1M3">Property and Equipment </span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5ywfB5XUtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z8gitvPuU6x2" style="display: none">Schedule of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_zw4fy03YiD61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20201231_zytAvGVPkjs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_z0bS8UhYvnUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_ComputerEquipmentAndSoftwareMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,361</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_ComputerEquipmentAndSoftwareMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,361</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabAndOfficeEquipmentMember_z9yrBCMNiS58" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lab and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_LabAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,056,523</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_LabAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,048,932</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zzp1EOKPsOK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,404</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,404</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzck5_zV1hzCS4AUug" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,151,288</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,143,697</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzck5_zg5BiWGKy7Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less accumulated depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,144,077</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,143,697</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzck5_z5Ps2EvAZhZh" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, and equipment,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zN2zJCX47L6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zc6GOszmxQ94" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20200101__20201231_zog0NzJK8Wag" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: center; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: center; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zeWiDJPCWEKg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_zOnyqVOZpKf8">Income Taxes</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
    Tax Expense </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zcGa9p47QtYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zMBY0FkvtWgg" style="display: none">Schedule of Income Tax Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49C_20210101__20211231_zlTz3afSK8Hh" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_495_20200101__20201231_zVnKhkv2ZIFa" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_z9zVKIJhGOAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_zBXsizrDDoAe" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBz2PI_z2s2jPCO8hBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2PI_zZQdFaQud6rl" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zaCgtIGhNKoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
    Rate Reconciliation </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense was $<span id="xdx_909_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20210101__20211231_zC5JBnC5fQZ8" title="Income Tax Expense (Benefit)"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20200101__20201231_zjnNmm3H1Knc" title="Income Tax Expense (Benefit)"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></span>, respectively, for the years ended December 31, 2021 and 2020 and differed from the amounts computed by
applying the U.S. federal income tax rate of <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_z8sqATuUBu9c" title="Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20200101__20201231_zkr92eLOiJEg" title="Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></ix:nonFraction></span></span>% for 2021 and 2020, respectively, to pretax income from continuing operations as a result
of the following:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zDNtqVMSaMG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B0_zmwR53YVEyt1">Schedule of Pretax Income from Continuing Operations</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_493_20210101__20211231_zGZGNl2u19z4" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_493_20200101__20201231_zq2eT0S412ff" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz2WU_zjlUzvJdf3Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computed &#8220;expected&#8221; tax benefit</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,182</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,402,570</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz2WU_z49VUkx4ehfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">476,431</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,248,002</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz2WU_zICAVJwOmpCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local income
    taxes, net of federal income tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz2WU_zGb89FhUgTbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,697</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,209</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBz2WU_z7qkQTxm1348" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,163</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485,254</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_ecustom--IncomeTaxReconciliationOrphanDrugTaxCredits_iN_di_msITEBz2WU_zFW5mjDyNuP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orphan drug tax credit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="lpcn:IncomeTaxReconciliationOrphanDrugTaxCredits" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,025</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="lpcn:IncomeTaxReconciliationOrphanDrugTaxCredits" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,797</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_maITEBz2WU_zLtbawSs1mIe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="lpcn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">74,737</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">607,360</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBz2WU_zyfpIhRBIi0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,908</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2WU_zBWrtfoNnljk" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zk7UF82BVHMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
    Taxes &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
    Components of Deferred Taxes </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zIkyhyu3EwK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at
December 31, 2021 and 2020 are presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zxEq3CXcb5vl" style="display: none">Schedule of Deferred Tax Assets and  Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_498_20211231_zHAPPRlaNbO4" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_499_20201231_zPHOlia1PQJf" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pp0p0_maDTAGz8zG_zcum6fOthJe4" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,687,480</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,651,482</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGz8zG_zDFHMTWbdLA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,759,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,102,326</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pp0p0_maDTAGz8zG_z7UNHcZ7Jawc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee benefits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,009</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,108</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz8zG_zNcbIFbU26ye" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,935,609</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,472,003</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsOrphanDrugTaxCredit_iI_pp0p0_maDTAGz8zG_zQDQMHI2Raff" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orphan drug tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:DeferredTaxAssetsOrphanDrugTaxCredit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,186,582</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:DeferredTaxAssetsOrphanDrugTaxCredit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,168,828</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGz8zG_zpjMj48aKwW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">959</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_pp0p0_maDTAGz8zG_zVV2okVSZOR8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    deductible tempory differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">394,636</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,386</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz8zG_maDTALNzp92_zl5rGnopehDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross deferred tax
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,020,206</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,455,092</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLzUYz_zeV6Ef5TbeVk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant
    and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,871</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLzUYz_maDTLznVR_zj3oMGKtshoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross deferred tax
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,871</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0950">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLznVR_msDTALNzp92_zYza23cF6rhf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,871</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzp92_zRM26uHlpLlh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax asset/deferred
    tax liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,018,335</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,455,092</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zfpcn5UPZ2Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less
    valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,018,335</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,455,092</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_zZTNEniVMPpi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zmdZhOrpJY18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation allowance for deferred tax assets as of December 31, 2021 and 2020 was $<span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20211231_zrPjfxtAO3n2" title="Deferred Tax Assets, Valuation Allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">43.0</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20201231_z0sbYKCZyGO3" title="Deferred Tax Assets, Valuation Allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">42.5</ix:nonFraction></span> million. The net change in the
valuation allowance was an increase of $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20210101__20211231_zY6z3HPSydV9" title="Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million in 2021 and an increase of $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20200101__20201231_ztYnVZNW3c69" title="Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.2</ix:nonFraction></span> million in 2020. A valuation allowance has
been provided for the full amount of the Company&#8217;s net deferred tax assets as the Company believes it is more likely than not that
these benefits will not be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely
than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods),
projected future taxable income, and tax planning strategies in making this assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
    Taxes &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2013, the Company experienced a change in ownership, as defined by the Internal Revenue Code, as amended
(the &#8220;Code&#8221;) under Section 382. A change of ownership occurs when ownership of a company increases by more than 50 percentage
points over a three-year testing period of certain stockholders. As a result of this ownership change, we determined that our annual
limitation on the utilization of our federal net operating loss (&#8220;NOL&#8221;) and credit carryforwards is approximately $<span id="xdx_90E_ecustom--OperatingLossCarryForwardsLimitationsOnUseAmount_pn5n6_c20210101__20211231_zPh96XzZMDCl" title="Operating Loss Carry forwards Limitations On Use Amount"><ix:nonFraction name="lpcn:OperatingLossCarryForwardsLimitationsOnUseAmount" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million
per year. We will only be able to utilize $<span id="xdx_909_ecustom--OperatingLossCarryForwardsPreownershipChangeAmount_pn5n6_c20210101__20211231_zaGrT6PvdATf" title="Operating Loss Carry forwards Pre-ownership Change Amount"><ix:nonFraction name="lpcn:OperatingLossCarryForwardsPreownershipChangeAmount" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.2</ix:nonFraction></span> million of our pre-ownership change NOL carryforwards and will forgo utilizing $<span id="xdx_90F_ecustom--OperatingLossForgivePreOwnershipChangeAmount_pn5n6_c20210101__20211231_zJePv2iv7Jz8" title="Operating Loss Forgive Pre-ownership Change Amount"><ix:nonFraction name="lpcn:OperatingLossForgivePreOwnershipChangeAmount" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span> million
of our pre-ownership change NOL carryforwards and $<span id="xdx_908_ecustom--TaxCreditCarryforwardPreOwnershipChangeAmount_pn5n6_c20210101__20211231_zHRgd2N1rjla" title="Tax Credit Carryforward Pre-ownership Change Amount"><ix:nonFraction name="lpcn:TaxCreditCarryforwardPreOwnershipChangeAmount" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million of our pre-change credit carryforwards as a result of this ownership change.
We do not account for forgone NOL and credit carryovers in our deferred tax assets and only account for the NOL and credit carryforwards
that will not expire unutilized as a result of the restrictions of Code Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had NOL and research and development credit carryforwards for U.S. federal income tax reporting purposes of
approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zdMFHbHkDov6" title="Operating Loss Carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">135.6</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231_zNV0KNET0l2" title="Tax Credit Carryforward, Amount"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million, respectively. <span id="xdx_904_ecustom--OperatingLossCarryForwardsExpirationDate1_c20210101__20211231_zdEOxoh5dap1" title="Operating Loss Carry forwards Expiration Date1"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="lpcn:OperatingLossCarryForwardsExpirationDate1">Approximately $24.6 million of the NOL will expire between 2023 and 2033
and $70.8 million of the NOL will <span id="xdx_907_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zsSkhfhbNBHb" title="Tax Credit Carryforward, Description"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_StateAndLocalJurisdictionMember" name="us-gaap:TaxCreditCarryforwardDescription">expire 2034 through 2037</ix:nonNumeric></span>. Pursuant to the Tax Cuts and Jobs Act of 2017, NOL&#8217;s generated in 2018
and subsequent years have an unlimited carryforward therefore the 2020, 2019 and 2018 NOL of $40.2 million can be carried forward indefinitely.
The research and development credits will begin to <span id="xdx_909_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__custom--UsFederalMember_zrXFoocs2lxh" title="Tax Credit Carryforward, Description"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_UsFederalMember" name="us-gaap:TaxCreditCarryforwardDescription">expire in 2033 through 2041</ix:nonNumeric></span>.</ix:nonNumeric></span> We have orphan drug credit carry forwards of approximately
$<span id="xdx_909_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zaQkm90n4Gk6" title="Tax Credit Carryforward, Amount"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million which will expire if unused through 2041.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have state NOL and research and development credit carry forwards of <span id="xdx_90A_ecustom--OperatingLossCarryForwardsExpirationDate1_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zoXiQH2SUdgl" title="Operating Loss Carry forwards Expiration Date1"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_StateAndLocalJurisdictionMember" name="lpcn:OperatingLossCarryForwardsExpirationDate1">approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z5UvS31SJlR2" title="Operating Loss Carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">127.1</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkFXkrYVfsD5"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million, respectively.
None of the Company&#8217;s state NOL expires in 2022, $34.8 million expires between 2022 and 2029, and $92.3 million will expire in
2030 through 2036</ix:nonNumeric></span>. The state research and development credits <span id="xdx_905_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zTAgtOzFUc89" title="Tax Credit Carryforward, Description"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_StateAndLocalJurisdictionMember" name="us-gaap:TaxCreditCarryforwardDescription">expire in 2023 through 2035</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s federal and state income tax returns for December 31, 2018 through 2021 are open tax years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zrMt1XP2WiYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amount of total unrecognized tax contingencies, excluding interest and penalties, for the
years ended December 31, 2021 and 2020 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zhUpyaUpcY99" style="display: none">Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20210101__20211231_zUiHi3opvMJf" title="Balance, beginning of year" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="width: 1%; text-align: left"></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20200101__20201231_z6Lf5Jlzogpb" title="Balance, beginning of year" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="width: 1%; text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, end of year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20210101__20211231_zTcWff85dRF6" title="Balance, end of year" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="text-align: left"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20200101__20201231_zNkeP3FViH3k" title="Balance, end of year" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left"></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z0A0ZiZOUyqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zoWdVqtnCWg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(8)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_829_zrMQIlcP2qQj">Leases</span></span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah.
On May 6, 2014, the Company modified and extended the lease through February 28, 2018, on February 8, 2018, the Company extended the
lease through February 28, 2019, on January 2, 2019, the Company extended the lease through February 29, 2020, on February 24, 2020,
the Company extended the lease through February 28, 2021, on March 3, 2021, the Company extended the lease through February 28, 2022
and on January 24, 2022, the Company extended the lease through February 28, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(8)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
    &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zsIcid4u8rHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancelable operating leases as of December 31, 2021 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zREQlESLuq8d" style="display: none">Schedule of Future Minimum Rental Payments for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20211231_zcFQWCIVuvmk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">leases</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year ending December 31:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzkOe_zP4kZRmId3Yd" style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">341,429</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzkOe_zThOAfFeqrb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,273</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzkOe_z0Rdss1IoBm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">398,702</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_z1YlePGZxq09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s rent expense was $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_zakSzmQBalk9" title="Operating Leases, Rent Expense"><span id="xdx_902_eus-gaap--OperatingLeaseExpense_pp0p0_c20200101__20201231_zG94xE3jZ4S" title="Operating Leases, Rent Expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">330,000</ix:nonFraction></ix:nonFraction></span></span> for each of the years ended December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zY6Qg01CFlu5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zE5uXXelcg31">Stockholders&#8217; Equity</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
    of Common Stock</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 28, 2021, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#8220;January 2021 Offering&#8221;). The gross proceeds from the January 2021 Offering were
approximately $<span id="xdx_90E_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zW9MnkFTdCG3" title="Proceeds from issuance of common stock, gross"><ix:nonFraction name="lpcn:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">28.7</ix:nonFraction></span> million, before deducting underwriter fees and other offering expenses of $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_ziBD1hI17glb" title="Agent fees and other offering expenses"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million. In the January 2021 Offering,
the Company sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zVKPP6m0pEUl" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,428,571</ix:nonFraction></span> shares of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 27, 2020, the Company completed a registered direct offering of securities registered under an effective registration statement
filed pursuant to the Securities Act of 1933, as amended (&#8220;February 2020 Offering&#8221;). The gross proceeds from the February
2020 Offering were approximately $<span id="xdx_901_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_ztb5QjljijHa"><ix:nonFraction name="lpcn:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2020-02-262020-02-27_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million, before deducting placement agent fees and other offering expenses of $<span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0p0"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2020-02-262020-02-27_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">347,000</ix:nonFraction></span>. In the
February 2020 Offering, the Company sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200226__20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zaj7yaFLcPDl"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-02-262020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,084,034</ix:nonFraction></span> Class A Units at an offering price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zijSzmPaaTri"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.595</ix:nonFraction></span> per unit, with each Class A Unit consisting
of one share of its common stock and one-half of a common warrant to purchase one share of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zhcjCZWwzofe"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-02-27_us-gaap_CommonStockMember_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span>
per share of common stock. Additionally, the common stock warrants were immediately exercisable and expire on February 27, 2025. By their
terms, however, the common stock warrants cannot be exercised at any time that the common stock warrant holder would beneficially own,
after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after
giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2019, the Company completed a public offering of securities registered under an effective registration statement filed
pursuant to the Securities Act of 1933, as amended (&#8220;November 2019 Offering&#8221;). The gross proceeds from the November 2019
Offering were approximately $<span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zodRw6NPdQTe" title="Proceeds from issuance of common stock gross"><ix:nonFraction name="lpcn:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million, before deducting placement agent fees and other offering expenses of $<span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zsXx16yUPze6" title="Payment of stock issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">404,000</ix:nonFraction></span>. In the
November 2019 Offering, the Company sold (i) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z3Dng32TJHXi" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-11-172019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,450,000</ix:nonFraction></span> Class A Units, with each Class A Unit consisting of one share of its common
stock and a common warrant to purchase one share of its common stock, and (ii) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0d_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zb4P1g48fhGd" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-11-172019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,550,000</ix:nonFraction></span> Class B Units, with each Class B Unit
consisting of one pre-funded warrant to purchase one share of its common stock and a common warrant to purchase one share of its
common stock, at a price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z2BPoWiFrdAa"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per Class A Unit and $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zJMtb6Fx0qCk" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4999</ix:nonFraction></span> per Class B Unit. The pre-funded warrants, which were exercised for
common stock in December 2019, were issued in lieu of common stock in order to ensure the purchaser did not exceed certain
beneficial ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z7utscgVhyc3" title="Share issued exercise price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></span> per share,
subject to adjustment. Additionally, the common stock warrants were immediately exercisable at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zHlTDgEwjCZa" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per share,
subject to adjustment, and expire on November 17, 2024. By their terms, however, neither the pre-funded warrants nor the common
stock warrants can be exercised at any time that the pre-funded warrant holder or the common stock warrant holder would beneficially
own, after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding
after giving effect to such exercise. On the date of the November 2019 Offering, the Company allocated approximately $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z0lRkAc05yC" title="Stock issued during period value new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-11-172019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">768,000</ix:nonFraction></span> and
$<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zBdEP0chPYbf" title="Stock issued during period value new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-11-172019-11-18_us-gaap_AdditionalPaidInCapitalMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million to common stock/additional paid-in capital and warrant liability, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2017, the Company entered into the Sales Agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) pursuant to which
the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to the amount
the Company registered on an effective registration statement pursuant to which the offering is being made. The Company currently has
registered up to $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_dp_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--CantorMember_zqlIbSY3IVNk" title="Common stock sold through ATM offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2017-03-052017-03-06_custom_SalesAgreementMember_custom_CantorMember" format="ixt:numdotdecimal" decimals="-5" scale="4" unitRef="USD">50.0</ix:nonFraction></span> million for sale under the Sales Agreement, pursuant to the Registration Statement on Form S-3 (File No. 333-250072)
through Cantor as the Company&#8217;s sales agent. Cantor may sell the Company&#8217;s common stock by any method permitted by law deemed
to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or
through the Nasdaq Capital Market or any other existing trade market for our common stock, in negotiated transactions at market prices
prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. Cantor uses its
commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell these
shares. The Company pays Cantor <span id="xdx_905_ecustom--PercentageOfGrossProceedOnSaleOfShares_pid_dp_uPure_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--CantorMember_zqjNqKMF9VMa" title="Percentage of gross proceeds on sale of shares"><ix:nonFraction name="lpcn:PercentageOfGrossProceedOnSaleOfShares" contextRef="From2017-03-052017-03-06_custom_SalesAgreementMember_custom_CantorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. In addition,
the Company has also provided Cantor with customary indemnification rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of the Company&#8217;s common stock sold under the Sales Agreement are sold and issued pursuant to the Registration Statement
on Form S-3 (File No. 333-250072) (the &#8220;Form S-3&#8221;), which was previously declared effective by the Securities and Exchange
Commission, and the related prospectus and one or more prospectus supplements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not obligated to make any sales of its common stock under the Sales Agreement. The offering of common stock pursuant to the
Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. The Company and Cantor may each terminate
the Sales Agreement at any time upon ten days&#8217; prior notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had sold an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zUd8oc647D41"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,023,073</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at a weighted-average sales price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_z9eWNX9pWYVi"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-31_custom_AtMarketOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.19</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share under the Sales Agreement for aggregate
gross proceeds of $<span id="xdx_900_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zAMfashxwgPa"><ix:nonFraction name="lpcn:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">32.9</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zsPrusqolkg2"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">31.7</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting sales agent commission
and discounts and our other offering costs. During the year ended December 31, 2021, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zR9cDB9IZ9Xb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,811,238</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock pursuant to the current
Registration Statement on Form S-3 (File No. 333-250072) at a weighted-average sales price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUDKOFiS06rk"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, resulting in net proceeds of approximately
$<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_z7UDMTKarRGi"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SaleAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million under the Sales Agreement which is net
of $<span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zNABr8VpOWRb"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">112,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in expenses. During the year ended December 31,
2020, the Company sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z5arr4YaPxs1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,746,300</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock pursuant to the current
Registration Statement on Form S-3 (File No. 333-250072) at a weighted average sales price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zCyXsMMx9nl5"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.41</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, in net proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_znqZw5G2hJSa"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SaleAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million under the Sales Agreement which is net
of $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zEAlUKuwdD1i"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">148,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in expenses. Additionally, during the
year ended December 31, 2020, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_zp1Rwn8GLHih"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,830,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock pursuant to the prior
Registration Statement on Form S-3 (File No. 333-220942) at a weighted average sales price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_z9gJxtlDO2H"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.43</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share under the ATM for aggregate gross proceeds
of $<span id="xdx_90B_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTIXwN1OyWc"><ix:nonFraction name="lpcn:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.9</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million which is net of $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2J0Xw6q6aw4"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in expenses. As of December 31, 2021, the Company
had $<span id="xdx_90E_ecustom--SharesAvailableForFutureIssuance_iI_pn5n6_c20211231_z9hZAuxhy9i5"><ix:nonFraction name="lpcn:SharesAvailableForFutureIssuance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">41.2</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
available for sale under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rights
    Agreement</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2015, the Company and American Stock Transfer &amp; Trust Company, LLC, as Rights Agent, entered into a Rights Agreement.
Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock
purchase right (each a &#8220;Right&#8221; and collectively, the &#8220;Rights&#8221;) for each outstanding share of common stock of
the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered
holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred
Stock of the Company at a price of $<span id="xdx_906_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20151112__20151113_zinpP0LeUJA9"><ix:nonFraction name="lpcn:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" contextRef="From2015-11-122015-11-13" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.96</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per one-thousandth share (the &#8220;Purchase
Price&#8221;). The Rights will generally become exercisable upon the earlier to occur of (i) 10 business days following a public announcement
that a person or group of affiliated or associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days
(or such later date as may be determined by action of the board of directors prior to such time as any person or group of affiliated
or associated persons becomes an Acquiring Person) following the commencement of, or announcement of an intention to make, a tender
offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of the
outstanding common stock of the Company. Except in certain situations, a person or group of affiliated or associated persons becomes
an &#8220;Acquiring Person&#8221; upon acquiring beneficial ownership of 15% or more of the outstanding shares of common stock of the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder
to purchase from the Company, at the Right&#8217;s then current exercise price, in lieu of shares of Series A Junior Participating Preferred
Stock, common stock of the Company with a market value of twice the Purchase Price. In addition, if after any person has become an Acquiring
Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company&#8217;s assets, or assets
accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions),
proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain
transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase
Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value
of twice the Purchase Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be entitled to redeem the Rights at $<span id="xdx_906_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20210101__20211231_zKKal8jomBP5"><ix:nonFraction name="lpcn:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per Right at any time prior to the time an Acquiring Person becomes such. The
terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company&#8217;s Current Report on Form 8-K dated
November 13, 2015. The rights plan was originally set to expire on November 12, 2018; however, on November 5, 2018 our Board of Directors
approved an Amended and Restated Rights Agreement pursuant to which the expiration date was extended to November 5, 2021 and again on
November 1, 2021, the Company adopted a Second Amended and Restated Rights Agreement pursuant to which the expiration date was extended
to November 1, 2024, unless the rights are earlier redeemed or exchanged by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
    Option Plan </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2014, the board of directors adopted the 2014 Stock and Incentive Plan (&#8220;2014 Plan&#8221;) subject to shareholder
approval which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock
appreciation rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20140430__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zVR3ZnzvUmA4" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2014-04-30_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction></span>
shares are authorized for issuance under the 2014 Plan. Additionally, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pp0d_c20140430__us-gaap--AwardTypeAxis__custom--TwoThousandElevenEquityIncentivePlanMember_zRqrZ4wvZsvb" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2014-04-30_custom_TwoThousandElevenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">271,906</ix:nonFraction></span>
remaining authorized shares under the 2011 Equity Incentive Plan (&#8220;2011 Plan&#8221;) were issuable under the 2014 Plan at the
time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan was amended and restated to increase
the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20160630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zSIUskLolk5e" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,271,906</ix:nonFraction></span>
to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20160630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zhuUxM7jz5Me" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,471,906</ix:nonFraction></span>.
Additionally, upon receiving shareholder approval in June 2018, the 2014 Plan was further amended and restated to increase the
authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zP4If66TwkI1" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2018-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,471,906</ix:nonFraction></span>
to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_z4JywTCZ2xr6" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2018-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,221,906</ix:nonFraction></span>.
Finally, upon receiving shareholder approval in June 2020, the 2014 Plan was further amended and restated to increase the authorized
number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zuZR5TONn2U2" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,221,906</ix:nonFraction></span>
to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20200630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zcKSezwdNYy" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,721,906</ix:nonFraction></span>.
The board of directors, on an option-by-option basis, determines the number of shares, exercise price, term, and vesting period.
Options granted generally have a <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtYxL_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_ztYVWYepuHGf" title="Contractual life::XDX::10"><span style="-sec-ix-hidden: xdx2ixbrl1094">ten-year</span></span> contractual life. The Company issues shares of common stock upon the exercise of options
with the source of those shares of common stock being either newly issued shares or shares held in treasury. An aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zLjwTcnqTjpl" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-12-31_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,721,906</ix:nonFraction></span>
shares are authorized for issuance under the 2014 Plan, with <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pp0d_c20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zb6wwehGRM5e" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-12-31_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">857,459</ix:nonFraction></span> shares remaining available for grant as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 98; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 38.15pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zvn1ofEA7Yd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35in; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zVfkRhu46cP" style="display: none">Schedule of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    stock options</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z3VAKOe26fE6" title="Number of shares, Balance at beginning of the period (in shares)" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,564,458</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFadEzxSVBa" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.36</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJRLa9Yvm5Le" title="Number of shares, Options granted (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,105,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zC0dl8yucMQf" title="Weighted average exercise price, Options granted (in dollars per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.23</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyi4NZbVnGo2" title="Number of shares, Options exercised (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,584</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ0ATDXF4zs5" title="Weighted average exercise price, Options exercised (in dollars per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.46</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ6Af9kYGFPi" title="Number of shares, Options forfeited (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqXuUV5A1hqc" title="Weighted average exercise price, Options forfeited (in dollars per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options
    cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zarxTSJlD8Aj" title="Number of shares, Options cancelled (in shares)" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">114,169</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFOU1WPI4Qbi" title="Weighted average exercise price, Options cancelled (in dollars per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zsPdWzj2jpY8" title="Number of shares, Balance at end of the period (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,551,205</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zz6D8hKfsbCa" title="Weighted average exercise price, Balance at end of the period (in dollars per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.82</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Options exercisable at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z5nKHimJAAN2" title="Number of shares, Options exercisable (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,799,979</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z1NjUEdqJOR9" title="Weighted average exercise price, Options exercisable (in dollars per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.84</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z7eSTcRX8Bh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" continuedAt="ConU001132-01" escape="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock"><p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_gL3SBCABSBPAO-YSO_zTc02wLEcti5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about stock options outstanding and exercisable at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zY059Cv3gKy7" style="display: none">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    outstanding</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    exerciseable</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_zid0YUQ2izMc" title="Number of options outstanding, shares" style="width: 37%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,551,205</ix:nonFraction></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zNRgLFcTgUv2" title="Options outstanding, Weighted average remaining contractual life (Years)"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.66</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zWclQqwsQi0e" title="Options outstanding, Weighted average exercise price (in dollars per share)" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.82</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20211231_zl8QHZL0hcUc" title="Options outstanding, Aggregate intrinsic value" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">315,330</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231_z8xOftRC4dWc" title="Number of options exercisable" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,799,979</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_z3XcmJAzelHi" title="Options exercisable, Weighted average remaining contractual life (Years)"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.01</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_znuOcOCBJgGh" title="Options exercisable, Weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.84</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20211231_zR8R8LFJ2i62" title="Options exercisable, Aggregate intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">201,966</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z2GZ9bBYdhvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic
value of stock options exercised during the years ended December 31, 2021 and 2020 was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0d_c20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNSp3WxxZyq3" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0d_dc_c20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zc8GJXwNfIYj" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">zero</ix:nonFraction></span>. There were <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zKpk9jkKBzA1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,584</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_dc_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zb2Ho2XdRos1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:numwordsen" decimals="0" unitRef="Shares">zero</ix:nonFraction></span> stock
options exercised during the years ended December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
    Stock Warrants </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its common stock warrants under ASC 480, <i>Distinguishing Liabilities from Equity</i>, which requires any financial
instrument, other than an outstanding share, that, at inception, embodies an obligation to repurchase the issuer&#8217;s equity shares,
or is indexed to such an obligation, and requires or may require the issuer to settle the obligation by transferring assets, to be classified
as a liability. In accordance with ASC 480, the Company&#8217;s outstanding warrants from the November 2019 Offering are classified as
a liability. The liability is adjusted to fair value at each reporting period, with the changes in fair value recognized as gain (loss)
on change in fair value of warranty liability in the Company&#8217;s consolidated statements of operations. The warrants issued in the
November 2019 Offering allow the warrant holder, if certain change in control events occur, the option to receive an amount of cash equal
to the value of the warrants as determined in accordance with the Black-Scholes option pricing model with certain defined assumptions
upon a fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pp0d_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zd4rVb8mQD25" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,094,030</ix:nonFraction></span> warrants outstanding from the November 2019 Offering to purchase an equal number of shares
of common stock. The fair value of these warrants on November 18, 2019 (closing date of November 19 Offering) and December 31, 2021 and
2020 was determined using the Black-Scholes option pricing model with the following Level 3 inputs (as defined in the November 2019 Offering):</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="lpcn:ScheduleOfFairValueOfWarrantsTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zEvPtQChTJ97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zOgRmVrh1aWa" style="display: none">Schedule of Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">November
    18, 2019</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life in years</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAPsS00vHhMe" title="Expected life in years"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.88</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziJz5nOPUF3a" title="Expected life in years"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.88</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQbIwjkMQVBa" title="Expected life in years"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.88</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztByE2J85ali" title="Expected life in years"><ix:nonNumeric contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFE7FUzYtWkk" title="Risk-free interest rate" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.97</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxUaVvPT4EKk" title="Risk-free interest rate" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHDDdVxZMSj7" title="Risk-free interest rate" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.69</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLVtZmrdWk9d" title="Risk-free interest rate" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5qVPYVYF3tl" title="Dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1178">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUcidrlQPARb" title="Dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWnKfM0l9avi" title="Dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZexOWkwaMcl" title="Dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1184">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZMDXMbPRTf3" title="Volatility" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3DIpur37q6" title="Volatility" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23wXIcrdWt6" title="Volatility" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">225.93</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wW2zb4T38h" title="Volatility" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">224.47</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhB0UQxg4pM1" title="Stock price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1oeVGqZqjTa" title="Stock price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.36</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthdPsPhMgC7" title="Stock price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.39</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwmlqSCNdHEl" title="Stock price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z33CR1G6NFkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company recorded a non-cash gain of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zWb5I9PHBe5j"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">356,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the change in fair value of the November
2019 Offering warrants and during the year ended December 31, 2020, the Company recorded a non-cash loss of $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z3su5MKuW8Pf"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.9</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million from the change in fair value of the
November 2019 Offering warrants. The following table is a reconciliation of the warrant liability measured at fair value using level
3 inputs:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="lpcn:ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zmQd9RxGr5i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zDnnjBsG4VSe" style="display: none">Schedule of Reconciliation of Warrant Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20210101__20211231_zDv3a8DJ2Sil" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Warrant
    Liability</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zQr0kSlwZVDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Settlement of liabilty
    on warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="lpcn:AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,365</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value of common stock warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">355,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">795,796</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zVdQIAJDQiA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
in the February 2020 Offering, the Company issued <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0d_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zhNAomONXauj" title="Issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,042,017</ix:nonFraction></span> common stock warrants. However, the February 2020 Offering warrants do not
provide the warrant holder the option to receive an amount of cash equal to the Black-Scholes value of the warrants upon a fundamental
transaction. Therefore, the Company has not recorded a warrant liability with respect to the warrants issued in the February 2020 Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 100; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zATT6IvUm7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zLcTDu6F6Hwc" style="display: none">Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyR4LcHsJwU5" title="Warrants Outstanding, Beginning" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,944,366</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSDb4Y4tlF72" title="Weighted Average Exercise Price, Outstanding, Beginning" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.51</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z64x2BOBF334" title="Warrants, Issued" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1222">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1MmTUkNV3M" title="Weighted Average Exercise Price, Issued" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1224">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNgd5KreI3Cc" title="Warrants, Exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm0aRB4EF4Zg" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCEXNcGiL3a" title="Warrants, Expired" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYko4Z3XHmrb" title="Weighted Average Exercise Price, Expired" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pCAkuC6Eek" title="Warrants, Cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgPoWOB4IIja" title="Weighted Average Exercise Price, Cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAl4lEwjFfaa" title="Warrants, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z94BuAHnex79" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy9FdiJrqipe" title="Warrants Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,366</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvgGs2LiMhk" title="Weighted Average Exercise Price, Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.51</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zpnxRPK3jWY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zUmAD3AQQBc2" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pn5n6_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zNhRVNOMb1Gg" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">15.1</ix:nonFraction></span> million common stock warrants to purchase one share of our common stock were
exercised, respectively, resulting in proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zP4mdAcFPT3k" title="Net proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_z6cI5dNhR3Gk" title="Net proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.7</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about common stock warrants outstanding at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div id="xdx_C08_gL3SBCABSBPAO-YSO_zg5lgEUB0889" style="margin-top: 0pt; margin-bottom: 0pt"><ix:continuation continuedAt="ConU001132-02" id="ConU001132-01"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)" id="xdx_305_134_zp4BjeXkoDMb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    outstanding</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    exercisable</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjg6oSfxJWz3" title="Number of warrants exercisable, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,366</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHhEHKbHN1V5" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.00</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zymjBmDFJxw5" title="Weighted average exercise price, per share" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.51</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztmcKSO1ND52" title="Aggregate intrinsic value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">922,629</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify; background-color: white"></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-indent: -24.5pt"><span id="xdx_C04_gL3SBCABSBPAO-YSO_z7KR5F00rKa"><ix:continuation id="ConU001132-02"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_807_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z54oKRExMkTb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_z2ClBiu43Um">401(k) Plan</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2002, the Company adopted a tax qualified employee savings and retirement plan (the &#8220;401(k) Plan&#8221;) covering eligible
employees. Pursuant to the 401(k) Plan, employees may elect to reduce current compensation by a percentage of eligible compensation,
not to exceed legal limits, and contribute the amount of such reduction to the 401(k) Plan. Beginning April 1, 2014, the 401(k) Plan
was amended to require matching contributions to the 401(k) Plan by the Company on behalf of the participants of <span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20210101__20211231_zKG2l0Y0tb3h" title="Employer matching contribution percent"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span> percent Company
match on up to four percent of an employee&#8217;s compensation computed on a per pay period basis. The Company contributed $<span id="xdx_907_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20210101__20211231_zAmoxdMrCg5i"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20200101__20201231_zEOr18p7P7Ld"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, to the 401(k) Plan during the years ended December 31, 2021 and 2020</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 101; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z2nzEQHpQBa1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zMS30XGrMNWe">Commitments and Contingencies</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting
business. The Company records a liability when a particular contingency is probable and estimable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2019, the Company filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that
Clarus&#8217;s JATENZO&#174; product infringes six of Lipocine&#8217;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390;
6,569,463; and 6,923,988. However, on February 11, 2020, the Company voluntarily dismissed allegations of patent infringement
for expired U.S. Patent Nos. 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for dispute. Clarus answered
the complaint and asserted counterclaims of non-infringement and invalidity. The Company answered Clarus&#8217;s counterclaims on April
29, 2019. The Court held a scheduling conference on August 15, 2019, a claim construction hearing on February 11, 2020, and a
summary judgment hearing on January 15, 2021. In May 2021, the Court granted Clarus&#8217; motion for Summary Judgment, finding the asserted
claims of Lipocine&#8217;s U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy the written description
requirement of 35 U.S.C. &#167; 112. Clarus still had remaining claims before the Court. On July 13, 2021, the Company entered into the
Global Agreement with Clarus which resolved all outstanding claims of this litigation as well as the on-going United States Patent and
Trademark Office (&#8220;USPTO&#8221;) Interference No. 106,128 between the parties. Under the terms of the Global Agreement, the Company
agreed to pay Clarus $<span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember_zolfYP8siak5"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2019-04-012019-04-02_custom_GlobalAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million payable as follows: $<span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember_zhPzxYGF0wKc"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2019-04-012019-04-02_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million immediately, $<span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20220712__20220713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zXJz5nRAPvM5"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2022-07-122022-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million on July 13, 2022 and $<span id="xdx_90D_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20230712__20230713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z0MXT6egeGfj"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2023-07-122023-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on July 13, 2023. No future royalties are owing
from either party. On July 15, 2021, the Court dismissed with prejudice the Company&#8217;s claims and Clarus&#8217; counterclaims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2019, the Company and certain of our officers were named as defendants in a purported shareholder class action lawsuit,
<i>Solomon Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint
alleges that the defendants made false and/or misleading statements and/or failed to disclose that the Company&#8217;s filing of the
NDA for TLANDO to the FDA contained deficiencies and as a result the defendants&#8217; statements about our business and operations were
false and misleading and/or lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class
action (for a purported class of purchasers of the Company&#8217;s securities from March 27, 2019 through November 8, 2019), compensatory
damages in an unspecified amount, and unspecified equitable or injunctive relief. The Company has insurance that covers claims of this
nature. The retention amount payable by us under our policy is $<span id="xdx_907_ecustom--RetentionPayables_iI_pn4n6_c20191114_z7cJcIb3icG7"><ix:nonFraction name="lpcn:RetentionPayables" contextRef="AsOf2019-11-14" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.25</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company filed a motion to dismiss
this class action lawsuit on July 24, 2020. In response, the plaintiffs filed their response to the motion to dismiss the class action
lawsuit on September 22, 2020, and the Company filed its reply to the motion to dismiss on October 22, 2020. A hearing on the motion
to dismiss occurred on January 12, 2022. The Company intends to vigorously defend ourselves against these allegations and have
not recorded a liability related to this shareholder class action lawsuit as the outcome is not probable nor can an estimate be made
of loss, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2020, the Company filed U.S. patent application serial number 16/818,779 (the &#8220;Lipocine &#8216;779 Application&#8221;)
with the USPTO. On October 16 and November 3, 2020, the Company filed suggestions for interference with the USPTO requesting that a patent
interference be declared between the Lipocine &#8216;779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics,
Inc. (the &#8220;Clarus &#8216;178 Application&#8221;). Pursuant to our request, the Patent Trial and Appeal Board (&#8220;PTAB&#8221;)
at the USPTO declared the interference on January 4, 2021 to ultimately determine, as between the Company and Clarus, who is entitled
to the claimed subject matter. The interference number is 106,128, and we were initially declared Senior Party. A conference call with
the PTAB was held on January 25, 2021 to discuss proposed motions. On February 1, 2021, the PTAB issued an order authorizing certain
motions and setting the schedule for the preliminary motions phase. On July 13, 2021, the Company entered into the Global Agreement with
Clarus to resolve interference No. 106,128 among other items. On July 26, 2021, the PTAB granted the Company&#8217;s request for adverse
judgment in interference No. 106,128 in accordance with the Global Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond <i>Solomon Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PM, management does not currently believe that any other matter, individually
or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 102; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments
    and Contingencies (continued)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Guarantees
and Indemnifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements,
and certain services agreements, containing standard guarantee and / or indemnifications provisions. Additionally, the Company has indemnified
its directors and officers to the maximum extent permitted under the laws of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zo3WKAAapzFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(12)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_826_zMTEIN8hRRXa">Agreement with Spriaso, LLC</span></span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company has a
license and a services agreement with Spriaso, a related-party that is majority-owned by certain current and former directors of Lipocine
Inc. and their affiliates. Under the license agreement, the Company assigned and transferred to Spriaso all of the Company&#8217;s rights,
title and interest in its intellectual property to develop products for the cough and cold field. In addition, Spriaso received all rights
and obligations under the Company&#8217;s product development agreement with a third-party. In exchange, the Company will receive a royalty
of <span id="xdx_90E_ecustom--PercentageOfRoyalty_dp_uPure_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zfnlCptKG6z2" title="Percentage of royalty"><ix:nonFraction name="lpcn:PercentageOfRoyalty" contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_SpriasoLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction>
</span>percent of the net proceeds received by Spriaso, up to a maximum of $<span id="xdx_909_eus-gaap--ProceedsFromContributionsFromAffiliates_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_z9wFdO1IybP8"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_SpriasoLLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction>
</span>million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside
of the cough and cold field. <span id="xdx_90D_ecustom--AgreementDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zzMntouMJDVf" title="Agreement description"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember" name="lpcn:AgreementDescription">The
Company also agreed to continue providing up to 10 percent of the services of certain employees to Spriaso for a period of time. The
agreement to provide services expired in 2021;</ix:nonNumeric></span> however, it may be extended upon written agreement of Spriaso and the Company.
The Company did not receive any reimbursements from Spriaso for the years ended December 31, 2021 and 2020, respectively. Additionally,
during the years ended December 31, 2021 and 2020, the Company received $<span id="xdx_90C_ecustom--ProceedsFromReimbursements_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zKmZ7PQsrvs"><ix:nonFraction name="lpcn:ProceedsFromReimbursements" contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction>
</span><span>and
</span><span id="xdx_90D_ecustom--ProceedsFromReimbursements_dc_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zaj1BwXdZ8gf" title="Proceeds from reimbursements"><ix:nonFraction name="lpcn:ProceedsFromReimbursements" contextRef="From2020-01-012020-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">zero</ix:nonFraction></span><span>,
respectively, in royalty revenue from Spriaso. Spriaso filed its first NDA and as an affiliated entity of the Company, it used
up the one-time waiver for user fees for a small business submitting its first human drug application to the FDA. Spriaso is considered
a variable interest entity under the FASB ASC Topic 810-10, <i>Consolidations</i>, however the Company is not the primary beneficiary
and has therefore not consolidated Spriaso.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_800_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zitncuTzd1Y4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(13)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zMVHGEF1zYNi">Accounting Pronouncements</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
Pronouncements Issued Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, <i>Measurement of Credit Losses on Financial Instruments
</i>(&#8220;ASU 2016-13&#8221;). This standard replaces the incurred loss impairment methodology in current GAAP with a methodology that
reflects expected credit losses on instruments within its scope, including trade receivables, and requires entities to measure all expected
credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable
forecasts. The original effective date for ASU 2016-13 was for annual and interim periods beginning after December 15, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
in October 2019, the FASB issued ASU 2019-10, <i>Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective
Dates</i>, which deferred the effective date of ASU 2016-13 for certain entities, including those that are eligible to be smaller reporting
companies<i>.</i> A company&#8217;s determination about whether it is eligible for the deferral is a one-time assessment as of November
15, 2019 based on its most recent determination of its small reporting company eligibility as of the last business day of the most recently
completed second quarter. Based on this determination, the Company qualifies as a smaller reporting entity and is therefore eligible
for the deferral of adoption of ASU 2016-13, resulting in a new effective date of January 1, 2023. The Company has historically not had
credit losses on financial instruments and is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated
financial statements.</span></p>

</ix:nonNumeric><p id="xdx_81E_zbw9WVp5tIwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    9.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Ha_001"></span>CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    9A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_002"></span><span style="font-size: 10pt"><b>CONTROLS
    AND PROCEDURES </b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain &#8220;disclosure controls and procedures&#8221; within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934,
as amended, or the Exchange Act. Our disclosure controls and procedures (&#8220;Disclosure Controls&#8221;) are designed to ensure
that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Annual Report on
Form 10-K, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Our
Disclosure Controls include, without limitation, controls and procedures designed to ensure that such information is accumulated and
communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the end of the period covered by this Annual Report on Form 10-K, we evaluated the effectiveness of the design and operation of our
Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive
Officer and our Chief Financial Officer. Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have
concluded that, as of the date of their evaluation, our Disclosure Controls were effective as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Report on Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control system
was designed to provide our management and board of directors reasonable assurance regarding the reliability of financial reporting and
preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting has inherent
limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses
in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion
or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected
on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial
reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has assessed the effectiveness of internal control over financial reporting as of December 31, 2021. In making this assessment,
we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in <i>Internal Control-Integrated
Framework (2013)</i>. Based on our assessment we believe that, as of December 31, 2021, our internal control over financial reporting
is effective based on those criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the quarter ended December 31, 2021, there have been no changes in our internal control over financial reporting (as defined in Rule
13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    9B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_003"></span><span style="font-size: 10pt"><b>OTHER
    INFORMATION</b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9C.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="abcdef_001"></span>DISCLOSURE
                   REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_004"></span><span style="font-size: 10pt"><b>PART
III</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    10.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_005"></span><span style="font-size: 10pt"><b>DIRECTORS,
    EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of the information required by this item will be contained in our definitive Proxy Statement with respect to our 2022 Annual Meeting
of Stockholders, under the captions &#8220;Election of Directors,&#8221; and &#8220;Compliance with Section 16(a) of the Exchange Act&#8221;
and is incorporated into this item by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    11.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_006"></span><span style="font-size: 10pt"><b>EXECUTIVE
    COMPENSATION</b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be contained in our definitive Proxy Statement with respect to our 2022 Annual Meeting of Stockholders,
under the captions &#8220;Executive Compensation&#8221;, &#8220;Compensation Committee Interlocks and Insider Participation&#8221;, and
&#8220;Compensation Committee Report&#8221; and is incorporated into this item by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    12.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_007"></span><span style="font-size: 10pt"><b>SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT, AND RELATED STOCKHOLDER MATTERS</b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be contained in our definitive Proxy Statement with respect to our 2022 Annual Meeting of Stockholders,
under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221;
and is incorporated into this item by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_008"></span><span style="font-size: 10pt"><b>CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be contained in our definitive Proxy Statement with respect to our 2022 Annual Meeting of Stockholders
under the captions &#8220;Certain Relationships and Related Transactions&#8221; and &#8220;Independence of the Board&#8221; and is incorporated
into this item by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_009"></span><span style="font-size: 10pt"><b>PRINCIPAL
    ACCOUNTANT FEES AND SERVICES</b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be contained in our definitive Proxy Statement with respect to our 2022 Annual Meeting of Stockholders,
under the caption &#8220;Principal Accountant Fees and Services&#8221; and is incorporated into this item by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_010"></span><span style="font-size: 10pt"><b>PART
IV</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_011"></span><span style="font-size: 10pt"><b>EXHIBITS
    AND FINANCIAL STATEMENT SCHEDULES</b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The following documents are filed as part of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<i>Financial Statements.</i> The financial statements listed on the accompanying Index to Consolidated Financial Statements are filed
as part of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<i>Financial statement schedules.</i> There are no financial statements schedules included because they are either not applicable or
the required information is shown in the consolidated financial statements or the notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<i>Exhibits</i>. The following exhibits are filed or incorporated by reference as part of this Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation
    By Reference</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
    File No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex21.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger and Reorganization, dated July 24, 2013, by and among Marathon Bar Corp., Lipocine Operating Inc., and MBAR Acquisition Corp.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex32.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex33.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420415068793/v426011_ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of Series A Junior Participating Preferred Stock.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/1/2015</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">3.4</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000149315221026904/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Increase of Series A Junior Participating Preferred Stock</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">001-36357</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3.1</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">11/1/2021</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex41.htm" style="-sec-extract: exhibit">Form of Common Stock certificate</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420418057761/tv505211_ex4-1.htm" style="-sec-extract: exhibit">Second
    Amended and Restated Stockholder Rights Agreement dated as of November 1, 2021 by and between the Company and American Stock
    Transfer &amp; Trust Company, LLC</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/1/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000110465919063788/tm1922709d2_ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000110465919063788/tm1922709d2_ex4-2.htm" style="-sec-extract: exhibit">Form of Common Warrant</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000110465920025054/tm209716d3_ex4-1.htm" style="-sec-extract: exhibit">Form of Common Warrant</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/26/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="ex4-6.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registered Securities*</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex101.htm" style="-sec-extract: exhibit">Lipocine Inc. Amended and Restated 2011 Equity Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex102.htm" style="-sec-extract: exhibit">Form of Stock Option Agreement and Option Grant Notice under the 2011 Equity Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex103.htm" style="-sec-extract: exhibit">Form of Restricted Stock Award Agreement and Notice under the 2011 Equity Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420414019291/v369971_ex10-4.htm" style="-sec-extract: exhibit">Form of Restricted Stock Unit Agreement and Notice under the 2011 Equity Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2014</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420414043096/v383912_ex99-1.htm" style="-sec-extract: exhibit">Amended and Restated Lipocine Inc. 2014 Stock and Incentive Plan</a></span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-197421</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2014</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex104.htm" style="-sec-extract: exhibit">Assignment and Assumption of Lease, dated August 6, 2004, by and between Lipocine Inc. and Genta Salus LLC</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex105.htm" style="-sec-extract: exhibit">Second Lease Extension and Modification Agreement, dated June 21, 2011, by and between Lipocine Inc. and Paradigm Resources, L.C.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex106.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement by and between Lipocine Inc. and each of its directors and officers</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex108.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated May 25, 2004, by and between Lipocine Operating Inc. and Schwarz Pharma Limited (now UCB Manufacturing Ireland Ltd.)</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513301353/d562293dex109.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated April 20, 2001, by and among Lipocine Operating Inc., Elan International Services, Ltd., and Elan Pharma International Limited</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/25/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513312858/d574626dex1010.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated July 26, 2013</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/31/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513312858/d574626dex1011.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated July 26, 2013</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/31/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13+</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000119312513358469/d594155dex1012.htm" style="-sec-extract: exhibit">Manufacturing Agreement, dated August 27, 2013, by and between Lipocine Inc. and Encap Drug Delivery.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-178230</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/5/2013</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420414001003/v364771_ex10-1.htm" style="-sec-extract: exhibit">Executive Employment Agreement, dated January 7, 2014, by and between Lipocine Inc. and Dr. Mahesh V. Patel</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-55092</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/7/2014</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420414001003/v364771_ex10-2.htm" style="-sec-extract: exhibit">Amended and Restated Executive Employment Agreement, dated January 7, 2014, by and between Lipocine Inc. and Morgan Brown</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-550920</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/7/2014</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom"><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation
    By Reference</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: justify; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
    File No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420416117433/v445085_ex10-1.htm" style="-sec-extract: exhibit">Second Amended and Restated Lipocine Inc. 2014 Stock Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/9/2016</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420416099991/v437924_ex10-1.htm" style="-sec-extract: exhibit">Commercial Manufacturing Services and Supply Agreement, dated March 3, 2016, by and between Lipocine Inc. and M.W. Encap Ltd.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/9/2016</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420417012930/v460000_ex10-22.htm" style="-sec-extract: exhibit">Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated March 6, 2017, by and between Lipocine Inc. and Cantor Fitzgerald &amp; Co.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/6/2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420417012930/v460000_ex10-23.htm" style="-sec-extract: exhibit">Second Amended and Restated Executive Employment Agreement, dated March 3, 2017, by and between Lipocine Inc. and Morgan Brown</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/6/2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420417012930/v460000_ex10-24.htm" style="-sec-extract: exhibit">Executive Employment Agreement, dated March 3, 2017, by and between Lipocine Inc. and Gregory Bass.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/6/2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420418057761/tv505211_ex10-1.htm" style="-sec-extract: exhibit">Vice President Employment Agreement, dated November 5, 2018, by and between Lipocine Inc. and Nachiappan Chidambaram.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/7/18</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420418001410/tv482923_ex10-1.htm" style="-sec-extract: exhibit">Loan and Security Agreement dated January 5, 2018</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/9/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000114420418042231/tv499024_ex10-1.htm" style="-sec-extract: exhibit">Third Amended and Restated Lipocine Inc. 2014 Stock and Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/7/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000110465919063788/tm1922709d2_ex10-2.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of November 14, 2019, by and between Lipocine, Inc. and the purchasers identified on the signature pages thereto</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000110465920025054/tm209716d3_ex10-2.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of February 25, 2020, by and between Lipocine, Inc. and the purchasers identified on the signature pages thereto</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/26/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000110465921025036/tm217097d1_ex10-1.htm" style="-sec-extract: exhibit">First Amendment to Loan and Security Agreement, dated February 16, 2021, made by and among Lipocine Inc., Lipocine Operating Inc. and Silicon Valley Bank</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/18/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27***</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000149315221027756/ex10-1.htm" style="-sec-extract: exhibit">License Agreement dated October 14, 2021, by and between Lipocine, Inc. and Antares Pharma, Inc.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">10-Q</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/10/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">10.28***</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000149315221027756/ex10-2.htm" style="-sec-extract: exhibit">Amendment No. 1 to Commercial Manufacturing Services and Supply Agreement between Lipocine, Inc. and MW Encap Ltd. Dated October 13, 2021</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">10-Q</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">001-36357</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">10.2</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">11/10/2021</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1535955/000149315222006175/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Officer Employment Agreement, dated March 7, 2022, by and between Lipocine Inc. and Krista Fogarty.</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36357</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/7/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">Subsidiaries</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent
    of Tanner LLC</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification
    of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350.</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation
    By Reference</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: justify; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
    File No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded
    within the Inline XBRL document.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase
    Document</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase
    Document</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Labels Linkbase Document</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE<sup>*</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase
    Document</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    contract or compensation plan or arrangement</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Confidential treatment
    has been granted with respect to certain portions of this exhibit. Omitted portions have been submitted separately with the Securities
    and Exchange Commission.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">***</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Certain portions of this exhibit have been omitted pursuant
    to Item 601(b)(10) of Regulation S-K. The Registrant hereby undertakes to furnish to the SEC, upon request, copies of any such instruments.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    16.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="Ha_012"></span><span style="font-size: 10pt"><b>FORM
    10-K SUMMARY</b></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-indent: -49.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-indent: -49.7pt"><span style="font-family: Times New Roman, Times, Serif">None</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lipocine
    Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 9, 2022</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Mahesh V. Patel</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mahesh
                                            V. Patel, President and Chief</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Officer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer and Principal Financial Officer)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 9, 2022</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Krista Fogarty</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Krista
                                            Fogarty, Corporate Controller</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Accounting Officer)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the date indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
                                            Mahesh V. Patel</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) and Chairman of the Board</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mahesh
    V. Patel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
                                            Krista Fogarty</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">Corporate Controller (Principal Accounting Officer)</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Krista
    Fogarty</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
                                            Jeffrey A. Fink</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    A. Fink</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
                                            John Higuchi</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Higuchi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
                                            R. Dana Ono</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R.
    Dana Ono</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>ex4-6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
4.6</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXCHANGE
ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lipocine
Inc. (&ldquo;Lipocine,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us&rdquo;) has one class of securities registered under
Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of the terms of our capital stock is based upon our <U>Amended and Restated Certificate of Incorporation</U> (the &ldquo;Certificate
of Incorporation&rdquo;) and our <U>Amended and Restated Bylaws</U> (the &ldquo;Bylaws&rdquo;). The summary is not complete, and is qualified
by reference to our Certificate of Incorporation and our Bylaws, which are filed as exhibits to this Annual Report on Form 10-K and are
incorporated by reference herein. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions
of the Delaware General Corporation Law for additional information.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Shares of Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 100,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred
stock, $0.0001 par value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
may be declared by the Board of Directors upon the capital stock of the corporation, subject to the provisions of the Certificate of
Incorporation and applicable law, if any, at any regular or special meeting. Dividends may be paid in cash, in property, or in shares
of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
outstanding share of common stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders
of the corporation for their vote. Corporate actions can generally be taken by a majority of our board and/or stockholders holding a
majority of our outstanding shares, except that amendments to our Bylaws and amendments to certain articles of our Certificate of Incorporation
require the vote of at least 66 and 2/3% of the voting power of all of the then-outstanding shares of the capital stock of the Company
entitled to vote generally in the election of directors, voting together as a single class. Additionally, our stockholders do not have
cumulative voting rights in the election of directors. Accordingly, holders of a plurality of the votes cast at a meeting of stockholders
will be able to elect all of the directors then standing for election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
to Receive Liquidation Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to receive, ratably, the net assets
available to stockholders after payment of all creditors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rights
and Preferences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be
adversely affected by, the rights of the holders of our outstanding preferred stock and shares of any series of our preferred stock that
we may designate in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&rsquo;s
address is 6201 15th Avenue, Brooklyn, NY 11219. Our shares of common stock are issued in uncertificated form only, subject to limited
circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;LPCN&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
Anti-Takeover Effects</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of Delaware law, our Certificate of Incorporation and our Bylaws may have the effect of delaying, deferring or discouraging
another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging
takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board
of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited
acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an
improvement of their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delaware
Law </I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are governed by the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware
corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three
years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved
in a prescribed manner. A &ldquo;business combination&rdquo; includes mergers, asset sales or other transactions resulting in a financial
benefit to the stockholder. An &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, owns, or
within three years of the date on which it is sought to be determined whether such person is an &ldquo;interested stockholder,&rdquo;
did own, 15% or more of the corporation&rsquo;s outstanding voting stock. These provisions may have the effect of delaying, deferring
or preventing a change in our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certificate
of Incorporation and Bylaw Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes
in control of our management team, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<I>Board of directors vacancies</I>. Our Certificate of Incorporation and Bylaws authorize only our board of directors to fill vacant
directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to
be set only by a resolution adopted by our board of directors. These provisions prevent a stockholder from increasing the size of our
board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This
makes it more difficult to change the composition of our board of directors but promotes continuity of management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<I>Stockholder action; special meeting of stockholders</I>. Our Certificate of Incorporation provides that our stockholders may not take
action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling
a majority of our capital stock may not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders
called in accordance with our Bylaws. Our Bylaws further provide that special meetings of our stockholders may be called only by our
board of directors, the Chairperson of our Board of Directors, our Chief Executive Officer, or a majority of the Board of Directors,
thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal
of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<I>Advance notice requirements for stockholder proposals and director nominations</I>. Our Bylaws provide advance notice procedures for
stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors
at our annual meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder&rsquo;s
notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making
nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions
may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate of
directors or otherwise attempting to obtain control of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<I>No cumulative voting</I>. The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate
votes in the election of directors unless a corporation&rsquo;s certificate of incorporation provides otherwise. Our Certificate of Incorporation
does not provide for cumulative voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<I>Issuance of undesignated preferred stock</I>. Our Board of Directors will have the authority, without further action by the stockholders,
to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from
time to time by our Board of Directors. The existence of authorized but unissued shares of preferred stock would enable our board of
directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest
or other means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lipocine Operating Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR STYLE="clear: both">
</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors<BR>
Lipocine Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in the
registration statements (Nos. 333-250072, 333-190897, 333-240197, 333-226664, 333-214492, 333-197421 and 333-191695) on Forms S-3 and
S-8 of Lipocine Inc. of our report dated March 9, 2022 with respect to the consolidated balance sheets of Lipocine Inc. as of
December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, changes in stockholders&rsquo;
equity, and cash flows for the years then ended, and the related notes (collectively, the &ldquo;consolidated financial statements&rdquo;),
which report appears in the December 31, 2021 annual report on Form 10-K of Lipocine Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>/s/ Tanner LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Salt Lake City, Utah</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 9, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Mahesh V. Patel, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Lipocine Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March
    9, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>/s/ Mahesh V. Patel</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mahesh V. Patel, President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Mahesh V. Patel, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Lipocine Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March
    9, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>/s/ Mahesh V. Patel</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mahesh V. Patel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">In connection with the Annual
Report on Form 10-K of Lipocine Inc. (the &ldquo;Corporation&rdquo;) for the year ended December 31, 2021 as filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, Mahesh V. Patel, President and Chief Executive
Officer of the Corporation, hereby certifies, pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March
    9, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>/s/ Mahesh V. Patel</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mahesh V. Patel, President and Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">In connection with the Annual
Report on Form 10-K of Lipocine Inc. (the &ldquo;Corporation&rdquo;) for the year ended December 31, 2021 as filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, Mahesh V. Patel, Principal Financial Officer
of the Corporation, hereby certifies, pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March
    9, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>/s/ Mahesh V. Patel</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mahesh V. Patel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>chart_1.jpg
<TEXT>
begin 644 chart_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %L L\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@N.N=@SCU)%8NDOI_BB]\+Z5_:GBS4KNUEBD:V^SQQQZ>Z8Y9BH^48['H/7
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M?7=D4@F)Z;6R>/?'UQ7(>%;'3]9N/%NN00>)-?AGL#:2RW:1Q"_7"\1@!6W
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MZ?>3QF6VCU"W\K[0G7*')!X!/X&O$;'P[J^I_!'68K73YUGM?$/VJ6U5#O\
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MK^G-CKBX4_UI_P#PF/AO_H.6'_?Y:0S;HK$_X3'PW_T'+#_O\M'_  F/AO\
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M^4\>U/VV([O\!>RH]CD_^%::O_T&M._\!)/_ (NC_A6FK_\ 0:T[_P !)/\
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M_P _FC?^ TW_ ,71]A\2?\_FC?\ @--_\75O^W;7^Y+^0_QH_MVU_N2_D/\
M&CV<NP>WI]RI]A\2?\_FC?\ @--_\71]A\2?\_FC?^ TW_Q=6_[=M?[DOY#_
M !H_MVU_N2_D/\:/9R[![>GW*GV'Q)_S^:-_X#3?_%T?8?$G_/YHW_@--_\
M%U;_ +>M?[DOY#_&M*.198ED0Y5AD&DXM;HJ-2,OA9A?8?$G_/YHW_@--_\
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M_GA+_P!\&NCTRS^R6HW#]Z_S/[>@K.K)<MC?#0ESW+M%%%<AZ04444 %%%%
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M[,T[_H'V?_@.G^%']F:=_P! ^S_\!T_PH B_MS2/^@MI_P#X%)_C1_;FD?\
M06T__P "D_QJ7^S-._Z!]G_X#I_A1_9FG?\ 0/L__ =/\* (O[<TC_H+:?\
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MNU1G  "J 1S@#FKB/X52,(+G22HV_>N4;.TL1G+<\NQY[L:TO[+T[_H'6?\
MX#I_A1_9>GG_ )AUG_X#I_A0!BQVG@R(Q%)-)!B(*DW:D\%2,Y;G&U< YQM&
M,8IR0^#XS\LVDX\HP[3=*1L((Q@MCHQ&>H!QTK8_LO3STTZS_P# =/\ "C^R
M]._Z!UG_ . Z?X4 907PF--;3OM.E_9&D$K1_:UY<$'<3NR6R <YSQ3HSX5B
M\K9<:3F*59HRURC%9%4J&R6SD D5I_V7IW_0.L__  '3_"C^R]/_ .@=9_\
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M9IW_ $#[/_P'3_"C^S-._P"@?9_^ Z?X4 1?VYI'_06T_P#\"D_QH_MS2/\
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MOI__ (%)_C4G]EZ=_P! ZS_\!T_PH_LO3_\ H'6?_@.G^% $?]N:1_T%]/\
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M_P "D_QH_MS2/^@MI_\ X%)_C4O]EZ?_ - ZS_\  =/\*/[+T_\ Z!UG_P"
MZ?X4 1?VYI'_ $%M/_\  I/\:/[<TC_H+:?_ .!2?XU+_9>G_P#0.L__  '3
M_"C^S-._Z!]G_P" Z?X4 1?VYI'_ $%M/_\  I/\:/[<TC_H+:?_ .!2?XU+
M_9FG?] ^S_\  =/\*/[,T[_H'V?_ (#I_A0!%_;FD?\ 06T__P "D_QH_MS2
M/^@MI_\ X%)_C4O]F:=_T#[/_P !T_PH_LS3O^@?9_\ @.G^% $7]N:1_P!!
M;3__  *3_&C^W-(_Z"VG_P#@4G^-2_V9IW_0/L__  '3_"C^S-._Z!]G_P"
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M *_G_P#2::MNL37?^0IX?_Z_G_\ 2::@"]1110 4444 %%%% !1110 4444
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M?DT/.KV]J[OH:UO=K=(SP2LZJ[1D\C#*<$?G4NY_[[?G7*'P]>0O-<6\=O\
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M\\M$_P"^YO\ "C^T/$O_ #RT3_ON;_"CGCW"S.DHKF_[0\2_\\M$_P"^YO\
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M_P */[0\2_\ /+1/^^YO\*.>/<+,Z2BN;_M#Q+_SRT3_ +[F_P */[0\2_\
M/+1/^^YO\*.>/<+,Z2BN;_M#Q+_SRT3_ +[F_P */[0\2_\ /+1/^^YO\*.>
M/<+,Z2BN;_M#Q+_SRT3_ +[F_P */[0\2_\ /+1/^^YO\*.>/<+,Z2BN;_M#
MQ+_SRT3_ +[F_P */[0\2_\ /+1/^^YO\*.>/<+,Z2BN;_M#Q+_SRT3_ +[F
M_P */[0\2_\ /+1/^^YO\*.>/<+,Z2BN;_M#Q+_SRT3_ +[F_P */[0\2_\
M/+1/^^YO\*.>/<+,Z2BN;_M#Q+_SRT3_ +[F_P */[0\2_\ /+1/^^YO\*.>
M/<+,Z2N:\6?\??A[_L(-_P"B)*7^T/$O_/+1/^^YO\*R-8NM7GU305U!-.6(
M7KE?LS2%L^3)UW#&*%-,+'HL7^J3Z4^F1?ZI/I3ZH04444 %%%% !7.^*?\
MCZT'_K^;_P!)YJZ*N=\4_P#'UH/_ %_-_P"D\U*6S&B*BBBN4L**** "BBB@
M HHHH **** "BBB@!"=JDGH!GBL-?&&DL;C_ (_5^SH7FWV<B^6 N[YLCCCI
MZUNUS5[HM]/'XK5%3_B9Q(EME^I$>TY].:UIJ#^+^M2)N2^$WY+J&*S:[D<+
M L?FLY[+C.?RJ@?$>E+I-KJC76VRNG6.*0J?O$D $=N0<YZ5EW]IKNKZ,FDO
M816*.8DEG^TK+^[7EOE &<X Q[FJA\+:@\;Z=="WN]/;4H[PL (QL8-YJA,G
M')!'UJXTZ=O>?_#$.<NB.@N_$.G6+3)-)*7AG6V=8X6<^8R[E  '/'I3?^$E
MTG^SFOOM#^6LOD%#$PE\P]$V8W;O;%<W!X;URQ1FQ'>R0ZI#<1,TP0RPQQE!
MDGHV,"K;Z%J[W3:T8;<7_P#:"7:V7G94HL?E[2^,;B"3G&*KV=+O^/\ 7WBY
MY]C6_P"$GTPVDLX:4&)_+DADC*21G&?F5L8&.]:=M<QW=NLT>X*<C##!!'4&
ML.ST6:_U+4-2U:V2W>Y$2101RAVC5 >68#!)STY&*W;>WCM8%AB4A%]3DGW)
M[FLJB@M([FD7)[DM%%%9%A1110 4444 %%%% !1110 4444 1RS)" 7SSTP*
MB^W0>K?E3-0^Y']37*:CK[V.L"R6"*08A./,(D?>Q7Y%QSC&3[5V4J$)04I'
M#5KU(U'&)UWVZ#U;\J/MT'JWY5RS>([%#.K)<AX612@C!9BY*K@ ]R,8.#34
M\11%[A9;*[C,5RMLBB/<TCE<@8!X/M]*T^KTNYG]9K=OZ^\ZO[=!ZM^5'VZ#
MU;\JY4>)],)MAOE'GA3RF/+W-L&[G^\".,TV3Q1I\4'G,ER$+.JYC W;/OD9
M/('_ .K-'U>EW#ZQ7[?@=9]N@]6_*C[=!ZM^5<G)XACDU"UMK.)Y5DF\IYBA
M"9\LOA3_ 'ON_G5G1[N^O+>5[^S^RNLA55SU'K36&I-VU!XFLE=V.C^W0>K?
ME1]N@]6_*LVBG]4I^9/URIY&E]N@]6_*C[=!ZM^59M%'U2GYA]<J>1I?;H/5
MORH^W0>K?E6;11]4I^8?7*GD:7VZ#U;\J/MT'JWY5FUAWVOO9ZV+ 012+F$8
M\PB5_,8CY5QSMQD^U)X:FM[CCBJLMK'7?;H/5ORH^W0>K?E7&1^([@6T=Q/9
MQ"&<3B$QRDG=&&.&!'<*>13[WQ$]I:I,+5&+:?\ ;,%R #N4;>G3YNOM2^KT
MO,KZQ6O;0[#[=!ZM^5'VZ#U;\JXYO$AC:R!CMY4E.9Y8)"5B0OL4C(!.6//T
M-:MU>QV]C=W$;1RM;1LS*K@X*@G!QTZ4UAJ3$\3678W/MT'JWY4?;H/5ORKB
MAXI9K>P(M%^T3S>7<1>9Q -RKG..<EEQ5V3Q%8Q/<)(EPKP;=R^7EFW-M& #
MZ]C@TOJ](;Q%==#J/MT'JWY4?;H/5ORKD[WQ (;*ZFM[6=FMV57,D?RAMRAD
MX/W@&Z>M7H+_ .W6<TMG$1+&[1&.Y_=[74\AL9QZT_JU(3Q-9*[L;WVZ#U;\
MJ/MT'JWY5P<WBRXATRWNFLX 96E4,9&V2;#@;#C/S=B>.*Z>0R^06B13,5RJ
MNV!GT)':DL-2>UPEB:T=[&K]N@]6_*C[=!ZM^5<0OB6\DM@8K*W>?_2&)\UO
M*>.'&60XR<DX'T-7$UBZDU*SMX[6%XKRW,\6)3O0!007&, $G;1]7I>8WB*R
M['5_;H/5ORH^W0>K?E7-Z1J,^H"[$\,2-;3F'?"Y:.3 !.TD=B<'WK2IK"TW
MW(>+JIV=C2^W0>K?E1]N@]6_*LVBG]4I^8?7*GD:7VZ#U;\J/MT'JWY5FT4?
M5*?F'URIY&E]N@]6_*C[=!ZM^59M%'U2GYA]<J>1I?;H/5ORH^W0>K?E6;11
M]4I^8?7*GD:7VZ#U;\J/MT'JWY5FT4?5*?F'URIY&E]N@]6_*C[=!ZM^59M%
M'U2GYA]<J>1I?;H/5ORH^W0>K?E6;11]4I^8?7*GD:7VZ#U;\J/MT'JWY5FT
M4?5*?F'URIY&E]N@]6_*G+>0NX4$Y/'(K+HH>$I@L94\C;K$U[_D(Z!_U_/_
M .B9*U;:7SH03]X<&LK7O^0CH'_7\_\ Z)DKA47&=F>BI*4>9'?Q?ZI/I3Z9
M%_JD^E/K<04444 %%%% !7.^*?\ CZT'_K^;_P!)YJZ*N=\4_P#'WH/_ %_-
M_P"D\U*6S&B*BC!]*,'TKE+"BC!]*,'TH **,'THP?2@ JO>W:V5N)&4NS.L
M<<:]7=C@ ?YX -6,'TJO>68NS;$L5-O<).O&<E<C'X@FF(R)/$PLY[H:A:I;
MP03" 21S^8TLA0/A5VCHIR>>,5)-XKTV,/Y/GW)0Q#]U$2#YFW;S]'#<]L^A
MJQ=>'["[C9)$E4FX>X+H^&WN-K<^A''MQC%1R>&-.ENS<N+AGR"%,I*J <[0
M/[I]/RQ3T 3_ (2?2]J'=<9DD5(U^SN&?<I9648R5(4D'OBHH/%VE2RK$\DD
M,CNZJ)$(X#, Q] VQL?2GGPKIS1"-VO'&5W%[@DNJ@!5;U4;1CN.3G).1?"N
MF*3\MP08C$P,I^8889/?(#$#\.XS1H +XJTIHS*SW$<00N9)+=U7A/,QG'WB
MGS =<?E3E\4:2;J*U::1)Y)/*\N2,JR-NV@,#TRW I\WAS3[B=Y)4F96;?Y7
MFD1AL*I8+V)"@'VSZFG+X?T]-1%\L<@GWF1OG.'8LS9;UP7;'X=<"EH!3U#Q
M3%8ZS)IP@262/R@P\_;(Q?GY$VG=M7YCR./I3U\7:-)"TL4\LJJ<8BA9F(VE
M]P _AV@G/M5^72+.82B2-CYMP+ESO.2X4)^6T;<>A/K6</"-DKPJLUTMO'&Z
M&,2D%PP52"1_#M7;CW)SFGH!*OB?3A,(YG:)7F>*.0C*,%)&[/8$AORH/BG2
MED@CEDFADF(")-"R'!*A6(/\)+* ??V.&MX2TAI1(T$A !&SS#M/W^3_ -_'
M_/U%2+X:L1-#,SW<LL0QODG+,X!R Q]CTQC\:- (AXNT;)+33QQ@;C-);NL8
M&UF!W$="$?'KM^E/C\4Z3*(RDLQ+MM($+$Q_,J9?'W1EU'XT^3PSI<MOY#V[
MF/:JX\P]%C\M?R7]233T\/V"* 4E<_+EFD.6VN9!G'^T<\>@]*- ()?$#?\
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M-=%C/4?I1M']T?E753Q"A%1L<=7#.<W*]CC;;PWIUJ (Q,<-&1NDSC8Q91]
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M.V/_ #UU'_P8S_\ Q=:M%<UV697_  CMC_SUU'_P8S__ !='_".V/_/74?\
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M<^_;OP*%2F[6\OQ!U(HUO^$=L?\ GKJ/_@QG_P#BZ/\ A';'_GKJ/_@QG_\
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MB1C/OVCRY=@ P>XI^QJ6N_Z_JP>TCL:__".V/_/74?\ P8S_ /Q='_".V/\
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M_P"$=L?^>NH_^#&?_P"+K5HHNP,K_A';'_GKJ/\ X,9__BZ/^$=L?^>NH_\
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M\\U_.C^T&_YYK^='U>KV#ZU2[D/_  CMC_SUU'_P8S__ !='_".V/_/74?\
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M_A';'_GKJ/\ X,9__BZ/^$=L?^>NH_\ @QG_ /BZU:*B[+,K_A';'_GKJ/\
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M?9I_^>34>TAW0>SGV?W$5%2_9I_^>34?9I_^>34>TAW0>SGV?W$5%2_9I_\
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MU-8'B,D7^@$'!^W/_P"D\U%KZ!>Q@_\ "3:/_P _;_\ @-+_ /$T?\)-H_\
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MS'_OM^='F/\ WV_.CZNNX>T9S8\3:,.EVPQZ6TO_ ,11_P )/H__ #]OZ?\
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M/_?;\Z/,?^^WYT?5UW#VC.;_ .$FT<_\O;_^ TO_ ,31_P )/H__ #^/_P"
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MND\Q_P"^WYT>8_\ ?;\Z/JZ[A[1G-_\ "3:/_P _;_\ @-+_ /$T?\)-H_\
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M^)KI-[_WF_.C>_\ >;\Z/JZ[A[1G-_\ "3:/_P _;_\ @-+_ /$T?\)-H_\
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M_P#@-+_\372>8_\ ?;\Z/,?^^WYT?5UW#VC.;_X2;1_^?M__  &E_P#B:/\
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M _Z_G_\ 2>:M^L#Q)_Q_Z!_U_/\ ^D\U-;B>Q)1116QF%%%% !1110 4444
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M4&;(F1AP 2>#U!)Q0G?H)JWVOZ^\W(-36Z0/;WRRJ25!CEW D=1P>M3>?/\
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M[R+';;O+,5S-O8,<9/;@$Y&,4N;R*Y':_,=IY\__ #UD_P"^C1]HG_YZR?\
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M\%MQ_P#$4?\ "26'_/+4?_!;<?\ Q% &M163_P ))8?\\M1_\%MQ_P#$4?\
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MBC_A)+#_ )Y:C_X+;C_XB@1K45D_\))8?\\M1_\ !;<?_$4?\))8?\\M1_\
M!;<?_$4P-:BLG_A)+#_GEJ/_ (+;C_XBC_A)+#_GEJ/_ (+;C_XB@#6HK)_X
M22P_YY:C_P""VX_^(H_X22P_YY:C_P""VX_^(H UJ*R?^$DL/^>6H_\ @MN/
M_B*/^$DL/^>6H_\ @MN/_B* -:BLG_A)+#_GEJ/_ (+;C_XBC_A)+#_GEJ/_
M (+;C_XB@"[=VGVM4&_;M)/3-5?[''_/<_\ ?/\ ]>F?\))8?\\M1_\ !;<?
M_$4?\))8?\\M1_\ !;<?_$4U)HSE2C)W:'_V./\ GN?^^?\ Z]']CC_GN?\
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MZT9/K244 +D^M&3ZTE% "Y/K7/\ B4_Z=X?_ .O]O_1$E;]8'B3_ (_O#_\
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M?_@O>M:B@#)_M^/_ *!.M_\ @O>C^WX_^@3K?_@O>M:B@#)_M^/_ *!.M_\
M@O>C^WX_^@3K?_@O>M:B@#)_M^/_ *!.M_\ @O>C^WX_^@3K?_@O>M:B@#)_
MM^/_ *!.M_\ @O>C^WX_^@3K?_@O>M:B@#)_M^/_ *!.M_\ @O>C^WX_^@3K
M?_@O>M:BD!D_V_'_ - G6_\ P7O1_;\?_0)UO_P7O6M10!D_V_'_ - G6_\
MP7O1_;\?_0)UO_P7O6M10!D_V_'_ - G6_\ P7O1_;\?_0)UO_P7O6M10!D_
MV_'_ - G6_\ P7O1_;\?_0)UO_P7O6M10!D_V_'_ - G6_\ P7O1_;\?_0)U
MO_P7O6M10!D_V_'_ - G6_\ P7O1_;\?_0)UO_P7O6M13 R?[?C_ .@3K?\
MX+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?
M[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$Z
MW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\
MX+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?
M[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$Z
MW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\
MX+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?
M[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$Z
MW_X+WK6HH R?[?C_ .@3K?\ X+WH_M^/_H$ZW_X+WK6HH R?[?C_ .@3K?\
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M4 %%%% !1110!G:N2(XL$CYCTK N-4M+0R"YO8XC&%+[WQM#'"Y^I!K>U?\
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MK-BBL?\ LGQ7_P!!B+_P"CH_LGQ7_P!!B+_P"CHYT'*S8HK'_LGQ7_T&(O\
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M#/+&JG&"6 !STI3+&)/+,BA]N[:3SCUQZ4 /HJ**Y@FC62*>.2-CA61P03Z
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M!&&!D(W$G8QZ8Y J.7P]XD"VR6^LE"D,@EE:>1B\C*XZ'C )C(Z8VGVKL:*
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M-15Y''*Y./ESC ZUKT4 >?VF@:]<:@]EJ+W!MXO(V3+<,L9"-"QP ?O'8^"
M",G/45H6WAO6K6;S4OE>9YK>261KF3#A$V,&7'/0'@C)Z].>PHH Y74/#FI/
M>WUSI]YY)NYS(?\ 2)$Q^Y1$;C.=K*QV]&R,]*L7'AV>[\-S:?=S)=7,EP9C
M)<$NH_>;@ #G;A>, 8KHJ* .-OO"NI7UO=::LUI;6,MX]T)5R[=/D79@ ;6P
MV<GE15>[\&:I</=3+<6:M>^<]U%EMC2- 8T8<<=2#QRNWN*[JB@#B)_"%[-)
M<S?9],*W*3(+1F;RK8NJ .GR\M\A)X7);@CDG:'ABTAM-06 L+N]MC#+.S'+
M';C=QW[UNT4 <SI6C:Q97\$DMV/L\404Q"Y=P<1JH3!&.'#-O^\=V,50M_">
MMV\$L2ZLB_:'-S,\#/"3.8W4].J[C&W_  #I7:T4 <@OAW7(+A#:WT<4?VY[
MF5OM$A+AF4D;3QC&X8^A!'(I$\.:_'A3K4[QBS$?%TP;S=A#$DJ<Y8[@>HZ8
MQ7844 <U=>&9=3GTN749D)M+8I((L_/+NC8$%@6"Y3KD$_G5&W\-:_90Z?;V
MVJ*(+=X6?=/(3A5C#J,\%3M?Y3TW#&.:[.B@#D?^$8U<QP*=9N<I B.1>2C<
M^R7>WXNT9'H$[=#H:+IVLVNJ7=QJ-\DT$L:*D:.Q 8$Y;!^[D$=/3H*WJ* ,
M&Y\-0WWB5M4NRKQI%&L46!RR^8"6R,XQ)T!QZCI63;^#;JUOM&EB:U1+&"WC
MD*< M'YF_"[>=P?@[ASR0>E=I10!BW&C74L&K)]O:07L,D<4<F[;$6! ZL1C
MGL!64?"5_:6\B:;J3Q$Q*<"0HK2[P9#M0!1E%V@@<9)Z\UU]% '%R^%M<42M
M;:HZ2S>299?M+[WV1LA&=N!R5;('.,$>MN7PYJLKJW]KW()ED=]MU(N09D90
M . !$'7'3+?C74T4 <G>^'M7G@TO9>J;JT29#.9W5AN(VMD#+X"C*MPW<TP>
M%M2:2WEGO?.:"YCE2,7$B(% 8-P.,DMGISC%=?10!B^&](NM%L?LD]T9XU2)
M8P9&?:5C56QNZ L"0.@SVK)O?"VI_P!LW&I:==VT,EQ.\KA]W7[.8HW&!]Y2
M3GU&/05V%% '$P>#K^S^RPP2VC1VQD2*4@KMA?!:/R\$9W9PP8$<=>15[2?#
M%YIUM=PMJ3L\]M;Q+,6)9#&"#C&WCGCG/6NHHH Y?6/#-YJ%K8"&]0WEBDK0
MW$N[/FLN%)&22N,JPST)JO!X:UM&BB;4S';IY:N(KB0;T!C^0# V8".,CEM_
M.*["B@#EKG1?$3Z;901:NIFB*&1V=E/RCL0/GSW##FH8O#FLVT#PQ72>7E2@
M2ZDC&S?N:/ &!NY^<?-SCI77T4 <;'X7UN%))4U4_:YMHE;SW D C1<=.&RI
M&_&['/7BD_X1C6UDDG2_C65Q_P ]7+!06PGF8W<*VW?U[]:[.B@#FM9T/4]2
MM8;>"Y$,;6<MO,C7,C#+(0"" "Q!Q\Q/3/&35.70/$;?;?*U,*LJJL,?VF3$
M2_+P"!G(P0&[Y.1Z=C10!QB^&M=B$OEZ@ \S^8\@NI%S(8HUWX YVLKG9]UM
MPSC%-/A37+>T2WLM7:&,OOD5)F&26E)*D@[?OQG &#L_/M:* .(FT/Q3<PWI
MAU V[2R2B/S+J0G'F2%'  PF 4^49!'7!Q4S^%+\R,1.A07C7(!N9 7S/')U
MQ\O"N,#CH?IV-% &!H>E:IIUVQN[M)K<P*N ['#@]5&  ,=>I)[CI6_110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '0 SP# 2(  A$! Q$!_\0
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M'^M.IO\ '_P'^M !_'_P'^M.IO\ '_P'^M.H ;_'_P !_K3JC_Y:?Y_NU)0
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M_#S#_@G)_P!'_P#[$_\ XE7\"/\ YNJ_E;_X@B?V8/\ H^3X\?\ AM/AQ_\
M)]'_ !!#?LP_]'Q_'K_PVGPZ_P#D^@#^J1?^"E__  3C_P"D@'[$X]_^&JO@
M1S]1_P )T*/^'E__  3CV_\ *0#]B?Z?\-5? CIUS_R/.,Y[8Z]J_E;'_!D/
M^S!_T?)\>?K_ ,*T^'1'Y?;S1_Q!#_LP;<_\-R?'G_PVGPZZ].OV_I[9_6@#
M^LWX??MS?L6?%OQ?I'P]^$W[8/[+7Q/^(/B!K^/0?!'P_P#V@_A-XP\8Z]]B
MTRZUB^.D>&_#/BO4]>OO[/TVQN]2OS8V#^5IMK=ZF0(XB1]9=W^@_D:_E/\
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MP_I5YK>K7=POQ'\&W/V>TTNPLY+V[^52<)'O'!*YR" ?K)\*O'$/Q/\ A?\
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MX('XK> _"_\ P;U? 32]4/Q8^'VI>(_!]G\3_#7BOQ'X;U?2O$-KXIL&\/\
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MM;K2;?0+1<?;+[Q!=WEC8:0I>,2ZC>V:LP4DC^)#]I_1/C9\!?AW_P %LO\
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M,=5\0Z>%TI8K/<W]E#4=-D;=_8QUSXD?MH_M%?\ ! _X%^'/V</V@/AQJ?\
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MK''I_P *P\'8_/\ X6/C&?Q]J /ZS_\ EG_G^]3CT?\ '_T$5_)E!_P>1?\
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MIFGKI*NP*:@S8QX__P %?_VE?BK^QW_P3=_:K_:3^".IZ7H_Q5^$_@/3]?\
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MJL9-2!/](G\?_ ?ZT #_ '3^'\Q3J:_W3^'\Q3J &G[R_P# OY4ZFG[R_P#
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MV4/@1\-OV@=.^#'A#P;\1?'G@WP5X?3Q9>^(/^$.L]+\?A?%EE9"_<:_K/\
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M,NG>'SI$-[X0TNV^)6J7FL71LX(/"_PXNCXP\5"UO/L&HXO&T31[T)9LJJ^
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M]\:KB]/P=\9>(/$.NL/!_P 0#J6G)::AXJTS3M+TIM.+;8QIKN4TS]"?@/\
M\$JOBI\-/$D$/QL_X*2?M:_M:_!"\\ ^,/AOXK_9P^-=M\.)OA9XV\,>+_!^
MK^#O[-\06FA>%]-U(KIEIJPOM-SJ:@:E9V>X%00?,/A/_P $&/@O\/?$7P"T
M?Q9^TY^U5\:/V:/V3OB0/BE^S5^R;\3?%?A:^^%/PX\7V=S>7WAR\U2]LO"V
MG>+O&^G^#+R]N6\)6'B'52NDEFC5FTR_U>+4P#X)^(G_  6J_P""C-_^RY^V
ME_P4D^"'P7_98O?V,_V9OB_X_P#@CX2^&_CO6OB/#\;_ !4G@;QEH_@2\^,>
MJZ_HKKX<M;%?%'B'2BOP\;3M*U34M*-^/[6C&F_VKJG[,?MR^/M8\?\ _!&W
M]JCXH7:1Z1KOC;_@G-\6?'EVFD3W4,.F:OXD_9VUKQ).-(NAF^QI][>.-+;<
M)#L3?N.=O\N/[;?_  3<_;+\:^'_ -MK]DG]GK]D_P#;_P#AWX3_ &D/CYX@
M^(7@WX1^$_C=^SGXC_X)^ZOXGUGQ[H^L#XW:O\0+X>&OBAX*\*ZEHEG=^(-7
M^!VHZ6/[*\5V6@C^UM4(TP5_8SXM_9>LOB3^PYK7[&?C/Q)=Z;8>,_V7[C]F
M_P 4^+?#D-O]NLK?6/A=_P *WUC7_#T%_P#*+P"XN=0TM;[H^S>5)S0!_G3?
M#+0/A-XD^#?_  3O^#7[+'[('[8?[-/_  5%^/$OP6\6?"7]LOXF?M!>,?AE
M\&/B$VD:I:7OQ.\>>$QXG^*NI:!XHT'Q%H0NP?"'ASPOI>J:F;S3SI&E$LND
MZI_3/_P55_X+/?M-?L.?%'XJ^%?A=X^_8GUFV^ 'PL^'WBK5/A-J]A\9?C%\
M=OBGXBU:V%WXVMO%5E\)K'3?!W[-VAZ;9+_:.D:C\0]2U,:MI5Y8:S_Q+/[3
M_LO3/TD^+_\ P1P^ OQE_8)_9M_89UKQU\0=&N/V31\+[WX"?M$>&X]$L?C!
M\._&/PI:S&D>,M&NS8?V=9WNI6%H^GZM8J@TR0-$PSJ>F:9(GSG\9/\ @W[^
M&GQD\9_M.^*[O]L']J#P-I'[:_@CP;H_[5G@7P!=^ ])\-_&#QOX%\,G1=+\
M=7;WGA35-=T:UOKX-X@U?P9INJG2M3:[O='=TT5AIM 'EEQ_P5:_;Z_:+_:G
M7]EG]CWX5?LT>%KS6/\ @G1\#_V\+7QS\<-3\>:M%X5/Q)T&TU;5? =WI7A>
M^TW_ (2;^T-;UGP_X>TG45.E#1P=0U?5_P"T4_XE(_*/]J#_ (*]6WQ<^'/_
M  ;Z?\%-OCYX:O\ X;Z/8_M ?M1:S\7/!?PQ_MKQ%!K5_P##C0E\&"V\*:.Y
M;4+\^(M:M+,:3INH;QI&IZN!_:QB0ZJ/Z7?V:O\ @E%\/OV</VB;+]I*P^+?
MC?Q?XPM/V%/A;^PA)I>JZ-X7TS1)O _PK.D?V5XR86%C]N7Q3J0T>T.I61D.
ME$D_*2N&\$^#G_!!GX"?"#P/_P $Z? 47Q:^(/BW0_\ @G/\7OBQ\7O L7B/
M0?!\\7Q(UCXJW7VV\TOQM:+8?8K.Q\.WO.C_ -F -QDX8\ 'U_\ \$P_VGOC
MK^VK^R]X9_:O^,6@?"3P5X;^.%]?>+?@A\/_ (6^(-2\87WA7X3_ -IWMCH$
M'Q,\;O?MX?UOXD7WV9O[;L/#NFZ5I?AB_M3I#^9K/]I1:9^??_!T?J%SIG_!
M'WXOW5O)K"$_%[]F^&[7P_<WECJUY87'QF\()=V-FUC<I?&[O[/=8*"Q8EV(
M15-=7K__  2P^,W[-?@+P!\'?V!OCS\8? 7POUC_ (*1?#[]IK4_!NF>-M$\
M!>#O@;\$+VZ\1:O\</@W:&R1/$'C/X.>,GOB-*^&&GA0/%%WH32>7HZZOJ:?
MHE_P4/\ V&?!/_!1;]F37_V8?'_C/Q+X!\-Z_P",?A_XPE\3>#[?2;W6XKOX
M<^,=(\96=G]DUFUEL&L]3OM)2RU-64,L<@())*4 ?RT?L&_!+6O"G_!2?]FW
MXU_\$[?V%?\ @HA^Q]^S!\./@G\8+_\ ;?M_VHW^*&B>%OCB?^$$O#\+_#/P
M[\#_ !/\;^.+[Q/XL3Q8%;23X?U(@-=Z>^-*&F:K_:?Z$_LM_P#!2[]K#_@J
M#\<[#PK\//C%^SO_ ,$Y/ _@#Q[IMUXX_9G^(T4_Q&_X*&?$/P_X<U>SO-6T
M/Q%\/O&UEX'\/?"70O&%E;-9G4/#NF^/=6TG2[QF35&D(4_TR:7I\>F:7IVF
M12/*NFV-M8QR.>9!96XM06ST)V\_3J0,GYE^./[%'[*O[1OB?P'X\^-'P+\
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M3]]?Q_\  ?ZT #_=/X?S%.IK_=/X?S%.H :?O+_P+^5.II^\O_ OY4Z@"/\
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M)3?X_P#@/]:=3?X_^ _UH /X_P#@/]:=3?X_^ _UIU '\Z/_  =3_P#*%?\
M:5_[&CX&_P#JV?#5?;__  1$_P"41W_!/7_LU[X9?^FNOB#_ (.I_P#E"O\
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M3JGW1^/\S7X'_P#!2K_@@7^QO^VMX ^*?BOX9?#3PO\  W]K_P 0^*+OXO\
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MIJ942*#$F\N$;ZR_XC:/V#?^C2OVM_\ S#?_ ,\>@#^T)>K_ %_J:?7\7?\
MQ&U?L'_]&E_M<?G\&_\ YX]>N? /_@\2_P"">GQH^,'@+X7^)_A5\<O@1H7B
M_6)M-U3XM_%B\^%^G_#GP3;II=Y>+JGBN\T7QSJ>II8.]HMA_H.F3'^T;NS
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M/K_0T^F/T'U_H:?0 QNJ?7^HI],;JGU_J*?0 T_>7_@7\J'^Z?P_F*#]Y?\
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M1_\ +3_/]V@"2FC[S?\  ?Y4ZFC[S?\  ?Y4 .IJ?='X_P S3J:GW1^/\S0
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M<H9PQ!&5(![O3?X_^ _UK^*+1/\ @X(_X*C?#[X*?LR_\%&?VA_V5_V5H/\
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M^@7\?_ ?ZT?Q_P# ?ZT?Q_\  ?ZT?Q_\!_K0 ZH_^6G^?[M25'_RT_S_ ':
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M W_U;/AJOTJ_X)3?\HT?V#?^S3_@1_Z@6B4 ?H%_'_P'^M'\?_ ?ZT?Q_P#
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M_L!G=_Q0?CC_ ,.?XR]!V^W?YZ=* /4O!7_!3']AKXW^*M(^$_AGXJC6]?\
M&\T^BV&DZGX)\9:387<WV.[NV6[U;6]"T_3;(&SLKIO].U"+[H![EOB?X_\
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MU*G0_7^@I/\ EG_G^]0 ?\L_\_WJ<>C_ (_^@BF_\L_\_P!ZG'H_X_\ H(H
M=31T3\/_ $$TZFCHGX?^@F@!O_+/_/\ >H_Y9_Y_O4?\L_\ /]ZC_EG_ )_O
M4 *_0?7^AI],?H/K_0T^@"/_ ..4[^#_ (#_ $IO_P <IW\'_ ?Z4 -_^-TK
M]!]?Z&D_^-TK]!]?Z&@!],;JGU_J*?3&ZI]?ZB@!]1=D^I_F*EJ+LGU/\Q0
MY^@^O]#3Z8_0?7^AI] #&ZI]?ZBGTQNJ?7^HI] $79/J?YBO"_B5^S1^SG\9
M]9L_$GQ@^ ?P7^*OB&QTP:/8:Y\2OA?X,\;ZK8Z/:W5U>1Z39:IXFT/4[RRL
M/MEY=WIL8Y/+\RZOF",7D->Z=D^I_F*<_0?7^AH _F[^,_\ P:N_\$EOC?\
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M>#_'-A87)MK^\\'^)-"\2V%E=D"<6MY<Z+?:@EM=XPVUI >-VW."O:_\M/\
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M'MOX_P!8TBTM])O/B%I>L>!O!?PY\-_"[61J6N?VN-)&%&IZ2NGMK.W5P^X
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M@[4]8T>VO!8OJ=C::Y?V#W5D+U?L(O H3> N]2&:O0/@M\??@K^T;X0D\??
M7XL?#[XQ>"DO[K1G\5_#?Q1I'BS0AJUB3]LTW^UM%O;^Q-[8Y7>NYN2 "!DT
M >T5 Z1SQRQ.@='!CD3VQ@^GJ/IUS4],7J_U_J: /Y9/VO\ ]EB^_81_;)\
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M/X5S>"H?$G_#9Y\0V'_"?QP1_#HZU_8W]O\ BT7GVM;T_P#"'!O[$_X1S/\
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M@_LF? CP;\#=&^(%_I.J^,K#P<-4\C7M1T6VN[+2;J\.KZCJ+;]/L[R\"A"
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M(7Q1'_N[\]!_DU^EG_QRE7J_U_J: /S4_P"'0?\ P3X_Z(&O_AP_BC_\VU?
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M_P"&^T '_P!(>/P[4_\ X85_8V_Z-E^"_P#X;[0/_D&@#\ZQ_P %]/V/^O\
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M2TN[M[:VO-(MK7Q%XW-B#>^*V.D#4=8#8.Z[L,@'4* /Z8Z8W5/K_45^2/[
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MU/NC\?YFG4U/NC\?YF@!%ZO]?ZFGTQ>K_7^II] #'Z#Z_P!#3Z8_0?7^AI]
M$?\ \<IW\'_ ?Z4W_P".4[^#_@/]* &__&Z5^@^O]#2?_&Z5^@^O]#0 ^F-U
M3Z_U%/IC=4^O]10 ^HNR?4_S%2U%V3ZG^8H <_0?7^AI],?H/K_0T^@!C=4^
MO]13Z8W5/K_44^@!I^\O_ OY4/\ =/X?S%!^\O\ P+^5#_=/X?S% !_'_P !
M_K0_W3^'\Q1_'_P'^M#_ '3^'\Q0 ZFG[R_\"_E3J:?O+_P+^5 #JC_Y:?Y_
MNU)4?_+3_/\ =H _B*_X+B_MT^#_ !]_P4Y@_80_:(_;>^+G["'[$WP!_9XT
MWXK_ !C\4? F\\36/Q.^,OQ=\<W>DWO@GP'I:^%M/U+Q#?V5AHFL:1J*6&GZ
M;J>CJ-)\1ZMK"%VTLZ/V?P8_;&^*/[#O_! ']M']HSX8_P#!0W1O^"@&C^&-
M=G\&_LE_%BXT[Q0WQ4^"D/Q&\0:-\-_#>@_%FT^((/B#_A*_!3>(M)\9Z1X>
M\1:9_9>DM_Q*4_M7P<-, L?\%-O!GAK_ ()Z?\%QO#G_  51_:/_ &5_&7[3
M7[&OQD_9M_X5)KVN>$_A_H'Q6?X+_'#1[72-&TG5;SPIK6\6AU#PKX>M-.TG
M4=2.FJ3XOU\:1JS'3#I(^!OV8_\ @G?^T/\ MB_\$S/^"[GQ"^$W[/OC?X)_
M#?\ ;2^,_@CXR_L6?LWZ[HMMX)U36-/^"/C_ ,7?$FZ'A[PFRZ?I>B_\))8W
MVD^#M)73],TK2=7U31?[(T;4WT?3=.8 '7W/@?\ :K_X([3_ /!'[_@H;/\
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MU> /B#\6KS7=&NKW5?B=X0\(/X1N[SPK:7EEQG46T?6 5U'_ (E@.K_,-W)
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MU*G0_7^@I/\ EG_G^]0 ?\L_\_WJ<>C_ (_^@BF_\L_\_P!ZG'H_X_\ H(H
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M%X%\;^/!K-S>:QJUMI%WHU\WB#Q/@Z1_;^J@EE*FPU9PQ&ZOOOPE\%/@_P"
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M3O\ 1@=0MKLFPOM2OWTP*H>1E% 'V#\._BY_P4?C_;$^+>D^/OACJ&J?LO\
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MG^?[M25'_P M/\_W:DH ;_'_ ,!_K1_'_P !_K1_'_P'^M'\?_ ?ZT .J/\
MY:?Y_NU)4?\ RT_S_=H DIH^\W_ ?Y4ZFC[S?\!_E0 ZFI]T?C_,TZFI]T?C
M_,T (O5_K_4T^F+U?Z_U-/H 8_0?7^AI],?H/K_0UY?JWQI^#N@>)(?!NN?%
M;X<Z-XNFDBBB\+:EXV\,V/B.6:Y/RJ-&O-07426&2NV)MP^7GY<@'I__ ,<I
MW\'_  '^E1[MRHR?.I[?U^O^>]2?P?\  ?Z4 -_^-TK]!]?Z&D_^-TK]!]?Z
M&@!],;JGU_J*?4$CK&F]WV)'AY'?L!ZYZ?AP.U $]1=D^I_F*Q=)\2>'O$4<
MLWAW7=&UR.WD\J>72-3L]4A@;'2X^QW3J">>"2<#H<$C:[)]3_,4 .?H/K_0
MT^F/T'U_H:?0 QNJ?7^HI]<WJGB7PYHUU9V&L^(-$TF_U!S_ &?8ZEJVG6%]
M>_\ +OFSMKNZ62\)8D?('YX(+#%=)0 T_>7_ (%_*A_NG\/YBLG5-5TO1;?[
M?J^IV&E6@D$/VW4[NVL+8SW#8M[<W-T556;D* <D#(!"LHYWQ9\0_A_X#.EI
MXW\<>$?![:W=&PT9?%/B30O#AUG4-H_T32QK%]IYO[TYR$L=S?,/E'  !W'\
M?_ ?ZT/]T_A_,56FGBABDGFFCBBCB,DDTDJB*.%03YY)^4=#@]\=<=>:\*^-
M/"/CW28O$'@CQ7X:\9:#+<3VT6M>%]8TSQ%I/VJT8"ZM1JFC7FH:>;RR/WTW
MDJ2JG[VZ@#L*:?O+_P "_E61I^KZ5JS7B:7J6GZFUA<M8WWV&]M[PVE];_?M
M;T6S'['>#(W1N 5Q]T84'7/WE_X%_*@!U1_\M/\ /]VI*C_Y:?Y_NT -D5)0
MR.F]./?^O^??G$G\?_ ?ZTZF_P ?_ ?ZT 1B-5D\Q$"O)_K#W('KR1^(Z_6I
MJ;_'_P !_K3J /YT?^#J?_E"O^TK_P!C1\#?_5L^&J_2K_@E-_RC1_8-_P"S
M3_@1_P"H%HE?FK_P=3_\H5_VE?\ L:/@;_ZMGPU7Z5?\$IO^4:/[!O\ V:?\
M"/\ U M$H _0+^/_ (#_ %H_C_X#_6C^/_@/]:/X_P#@/]: '5'_ ,M/\_W:
MDJ/_ ):?Y_NT 24T?>;_ (#_ "IU-'WF_P" _P J '4U/NC\?YFG4U/NC\?Y
MF@ _C_X#_6A/NC\?YFC^/_@/]:$^Z/Q_F:  ?>;_ (#_ "IU-'WF_P" _P J
M=0 Q>K_7^II],7J_U_J:?0 Q.A^O]!3>S_4?S-.3H?K_ $%-[/\ 4?S- $M,
M7J_U_J:?3%ZO]?ZF@!],3H?K_04^F)T/U_H* $_^-T[^#_@/]*;_ /&Z=_!_
MP'^E 'Y8?\%1O^"4WP9_X*L^ _A1X ^,_P 0?B5X T;X/_$,_$/1IOAM_P (
MLMSK&H-:6]E)IFK'Q3X8\1I]@=8 "+!(V'S%F;*JF_\ M2_\$PO@Q^U5\;/V
M$_C9XB\5^-_ ^H_L!>/&\>?"GPGX('AF#POKLZOX0:TT3Q5:ZOH6IW_]BV"^
M$K!$CT#4M).UGY9P"/TN_P#CE*O5_K_4T ?S^_\ !5'_ (-ZOV9/^"LGQ[\)
M?M"_&GXU?'CX<>*/"/PMT?X4V&B_#"7X>0Z'/HVC>)O%WB>VU*\;Q-X'\1:I
M]O:\\67BL!J2V#):V@"=2.7_ .":W_!M_P#LM?\ !,;]J+3_ -J[X4?';X_^
M/_&FG?#_ ,3?#N/P]\1)?AD?#']D>);;2;&XNF3PMX%\.ZD+W3[/2(%1AJ!1
MLL2'VA3_ $6TQ.A^O]!0!^<_[/?_  3A^%G[.?[;O[8G[='A?QOX_P!<^(?[
M:%EX%M?'?@_Q#_PC/_"&>%1X#M1::8?"AL-!T_7P=04YU$:KJNIAG_NG#'\'
MOB]_P9V?L*_%_P"*7Q1^,7B+]J#]K#1M5^)_C_QO\2]=L--O/@['I6G:AXR\
M0:KXDU2WLC>_"YKQ;*PN]4N$4W; F$*K &OZ^/\ XW6=JNG6NL:5J6DWF]K7
M5-/OM+N2A(E^S7EN]G=8X.&VL>1D=#]0#^,S4/\ @WV\7_!;]E3QO\+_ /@B
MA_P4J^*?A[XDZ_\ $_POK'Q9N=7^,OA?PKH6KV^D6NLV*_\ "0^+/@K\.7^(
M.B:UIEG=BRTSP_I^I:5I&J(;_P#MC3-2.XK^A7[57_!/C_@JO\3O^"0W[)W[
M)_P6_:WE\#_MR_"WQ5\/-1^-WQ['QT^+WAX^-=(\-^%_B/IWB.U7XG:-HC>/
MO$JZCKNO^$=09=?TE5U$Z,TSY:QTTU\:?"7]NO\ X(@_\$!?CQ^U#^S3HWC;
M]HR#XE^*/'FGZ_\ %JWUO0+KQSI5GX@^R&]L[;P_JIO=._T);'5@W.<$<Y'7
M]MO^"?'_  6)_8M_X*9ZK\2]'_9;\0^.-9N_A-HVFZ]XM'BSPC<^'/(L-7N[
MRTM&M<WVH_;3FT).WU^4$CD ^$?VW_\ @GW_ ,%6/C5_P3 _8P_9M_9V_:W?
MX:_M@_""]\#2?'KXSGXX?%[P9_PL.#1O 'B3P]XB5_B'X8T/4?&'B<:AXIU7
M2M0+>(=-7^U#9G4V =<FQ_P4*_X)^?\ !53X]_\ !/#]B'X!?LO?M:O\*?VI
M/@QIGP^M_P!HCXL#XZ_%CP,?B1?Z+\+QX8\277_"<>%] U'Q?XS^W>.4'B G
MQ)ING-JA/]K,1JP1:_2;]GK_ (*<_LK_ +3WP=_:(^.OPJUOQ1>?#_\ 9;U_
MQMH'Q4O-6\,76EWMIJ/@+2KW6/$/]E69NF&K*EA97+H49 TF V."WY2O_P '
M:O\ P1_C\Q'\<_&0/'^[P/A3<GZ_\QSVZ]1^= 'YZ_M!_P#!>']NW_@DA^V]
M\"/V6?VV?A7I'B3]C3PG\(OACX6\3?&G0OAYX\\1?&#XR^+_  S^SEX1M_B%
MXH^'WQ.\;?$CPUX0\;C3_CEJUI_PE.MZAX;75!I5W?1ZJK:RZ!?[#_@7\=/A
M5^TE\,/#'QG^"?CCP]\0_AUXQM3=:/XD\,:SI>NZ6T]H?L>IZ8;S1+_4-/6_
MTJ^2ZTS5K'[>YT[5+6[1B[1[Z_)?]HK]E7]@S_@X>_86\(_$Q-*U*72/&&AZ
MB?@1\;_^$>TS2/BU\,EM?&NB7GB*W\*_VV-3L-&'B^[\$6WA_6!J%CJ0_LB\
MO0J@N@3X6_X("?\ !-O_ (*K?\$]_ G[2_P<_:J\?:(_P>G^'']G?LL>!O"_
MQ4M/&&A>!_B!?ZKXQU;Q'KMI:6NC:>?#=SJE[JFCZ@^H,3ND! 0&-=H!_5S3
M1T3\/_037\T'_!)O]ES_ (+C?!WX<?MIZ9_P40_:(N?BAXU\<_"^QT?]EW4'
M^,EMXX/A+X@#2?&EI=ZB+I-$T_\ X1W_ (G%YX4=;PALFR+*C% P?_P2^_9<
M_P""Y'PG_9S_ &^O"_[>'[0D_P 2/C5\1OA;_9/['_B&7XQVWC<^"/B"? OQ
M*L_[4&K#1-/'A@?\)7JO@:^_M ?VB,608J/[,^8 _I:_Y9_Y_O4?\L_\_P!Z
MOYI?^"=/[+O_  7(^&G[$O\ P4%\!_MI?M"7/C_]J/XD?#W4M/\ V./%\OQA
MM_%;^ O&7_"NO'>D65W_ ,)(-#TU?"P_X3:[\)W[7Y74@3:C5004)DM?L'?L
MO_\ !;_X>_\ !/7]N?X:_M;_ +0=QXW_ &R?B!IFO1_LH>/)/C#;>*9_!%_=
M> Q9:3CQ6NA6*^&=GB_;J'.G:D%7,IV[=E ']*+]!]?Z&GU_-)^QM^RU_P %
MPO __!,']M[X3_M,_M!W'BO]O+QW?>(9?V5?B._QDM_$4O@^UO/!OARQTE1X
MU&B!/#(3Q5:>(+_#:;(4%V#@;P1^,^L?\%4_^"U?_!"O1_A/\*_^"BWA?PW^
MTYI?Q:^)K>-O&/Q_\7:]X\^*<WP_^'>K7/ASPS#X"\/>+_#%_P"&?!_]OI9>
M$_''BW2/!NH!]6WW;:D?^)9?[: /[[__ (Y3OX/^ _TK\?\ XR?\%M_V&O@1
M^P_\!/\ @H/X^U;XH0_LZ_M':];>&_AK>Z3\.;S5/&,^I7MIXRO;8:OX6&H#
M^Q;,VO@?7BSR7[L +10I$IVR?M _\%M?V'_V:/V0/V=?VXOBAJ_Q/MO@7^U#
M)IT7PKO-$^'UUJWBF4ZMH-[XCM#K_AU;Y'T8O8:5=D[Y7P0 H)R2 ?KU_P#&
MZ5^@^O\ 0U^0'[37_!;?]AK]DG]ES]F#]KWXP:Q\3[3X._M>:/INO?!RX\/?
M#J[UKQ%>:;JWA"S\96;>(-!%]$^BEM#O;1F#.X$CE 6R2T_[77_!;#]B']B?
MX"?LP?M(?'/5_B=9_#7]KWPO;^+?@Y/X6^'MWXAUJ;2;KPKX9\8H?$&E#4(S
MHUV="\6:2QB<RYD-\BN3&-P!^O=,;JGU_J*_(;]L[_@MG^Q!^P?\*OV;OC%\
M?]6^)MEX-_:J\+?\)E\))/"GP]N_$>ISZ.- \-^(P/$%D+^(Z+=_V?XLTEBC
M/(?,=T#$1@LO[<O_  6P_8>_X)Y>$_V>?&?[1NJ?%"QT/]I[PA?^./A<?!_P
M\N_%-Q/H-CI?A?5KF3Q!;?VA8?V)>?8_%NCXL6:1B6O5+ Q_, ?KW479/J?Y
MBOR._;J_X+6_L0?\$[;_ . VG_M(ZI\3[&X_:/\ "5QXV^&P\'?#V[\4"YT:
MUGT2T8ZMB_T_^QKS?XBTWY) QY;G &6?MU_\%K_V(?\ @G9XZ^"WPZ_:0U7X
MGV/B3X\>$H/&7@"/P=\/;KQ593:1<ZI::/;'5KL:A8"QO#?7(^3&54,6.X$
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MA:>+/%,'PUMM6TNST76/L?\ PF]V?%[63-9G3@+K<Q9CI;?,3DC !^NW\?\
MP'^M'\?_  '^M?D+\1_BY_P4!TW_ (*)>'OAOX,\"^(KS]D&?Q'\/[36O%<'
MPVM=0T6WT:_\(:1=>*KA_&YM&:S-AK]Q>(Q+XTYT8#IBEU_XM_\ !0&#_@HM
M8_#G3/ 7B.7]CN3Q-HMK=^+5^'5M/HHT:Y\!6=]JEV?'/V(L"GBMKJQ#;@RD
MC2@0V#0!^O=1_P#+3_/]VOR,M_BY_P % S_P4;3X:R^!/$@_8V'B34+1O&'_
M  K>V&C?V,/AQ>:Q:77_  G7V/=D>./LNG[]V<YTK=D;@SPG\6_^"@EW_P %
M%=7^'/B'P'XB@_8]MO$_BBVT_P 6O\.;:#0YM M? EY?>'KL>-Q9AFW^+!:6
M!&XF0\,2220#]>J:/O-_P'^5?CKX(^-O_!0D?MU_$;PCXO\ AGXMN_V4?#]]
M\4Y_#&J6_P -+2PM]>T_1M"O+SP7;Z5XU^Q9O;W4=0M;33],.1_:IO<,1FO3
MOV._^"B/A+X_>.?%OP/^(^AZW\(?CYX=\4>(+*U^''C9+6T\2:O8"ZU_Q'9V
MMMI-F"MG=^#?":Z5IVM2:B5?4M04ZFBOO; !^GU-3[H_'^9IU-3[H_'^9H 1
M>K_7^II],7J_U_J:?0!^./\ P7R^-_Q^_9T_X)/?M9?%;]FF[UG1OBCH?AGP
MMI\/BOP[$9?$'@KPOXC\>^&O#WC;QAI 7!M;W2O"FJ:N1J*KOT=;EM84J=-K
M^'W_ ()F_P#!.7_@B3^W?^R=;ZA\;/\ @HUXJ^&O_!17Q9I7B>YUG2OB;\4/
M"GPVT[PKXV;4-7/AVVT"S^(=A_Q<W1G TO4-5O\ 3?&YUC4S=7YQI#+M7^^3
M_@J]^W'X<_X)Y_L8_$#]I+QS\!-<_:-^'FE:CHO@_P >?#[1;_0;* :!X[N+
MGPV-2\2-XEL]2L/^$6.M7FCZ#JRMIFJ%AK2_\2R2,,K?RYZ!_P $B_\ @WH_
MX*F?LOZ1^V1\$_BA8?L&:QXO\-S>)/B1X1\-_'CPK/HGP:\8+;79\0>'O'/P
M_P#B=>?8M%3P]>VERZKX<;P)HVL:6@UG20ND:A$Q /V,_P""'?PG_P""B'[
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MS^WI_P $Z_\ @G__ ,$]_P!NK]K3]ECX3?MT?$?X0?#KX[_"#3_C?HWQ/O\
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M_G^[4E1_\M/\_P!V@"2FC[S?\!_E3J:/O-_P'^5 #J:GW1^/\S3J:GW1^/\
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MA/\ M4:MIFC^(;_]HO1Y?&/BK6[O1_AOH.RW\-'P-?\ Q"TGP!]CU/1-(M-
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M .IJ?='X_P S3J:GW1^/\S0 ?Q_\!_K0GW1^/\S7C/[0'QO\#_LU_!'XL?M
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M ,;IW\'_  '^E #?_CE25'_\<J2@!B=#]?Z"D_Y9_P"?[U*G0_7^@I/^6?\
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MQ9;Q5D99-.;Y]I()"FO/V_9)_94P?^,8_P!GO_PR_P .3_/PN>GX#WKZ$_\
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M^,_"_ASQAX<N?MNA>*-&TGQ%HMV4,)N]'UBUM;ZSN3 <%=UC=(2"#M.,9RM
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MVFC:Z!COTP*=P*_T?O\ =/X?S%'\?_ ?ZT ?S@?L'_M8?\%F?B5_P3,_;?\
MB_\ M7? &3P3^W!\.;;XE/\ LM?#AO@Y<^%&\97&C?"72-;\$#_A"&U\GQ.=
M2^(EU?6!5=2TX:F%_LGA5R?G+_@@E_P70_:8_;@_:#^+7["?[;WPH7PW^U)\
M,;+XA^.-:\3Z!H>F^!_#GAW0O NK> _!UU\.M7\%/>:EJ:^*=.U[Q#JE]J6H
M?VDR"/\ <A/E"Q_UF/\ =/X?S%?R7?MT?\$J?V_[+_@K9\'?VO/^"9^D_"WX
M"?!C6%^'(_:FU_P1K?@WX9>./B.U[\9&\7?&P^(MNA_\)!XG_P"$P\,66D_V
ML#J9&K&PL4)SG !_6B?O+_P+^5.K^;G]O_\ 9K_X+6_$/_@J-^SG\5OV/_CI
MJG@S]@OPY=_ AOC5\/(/B_I?A:SUV'PW\1KW5_BTI\#WUD[:R?$'@@VNFE0V
M-2 ,8^4 !G[:'[-/_!;#QO\ \%:?@K\7/V9OCEJ7A7_@G?HNI? >;XH_#>'X
MOZ7X<L=7T_P]KS77Q94^!VLFU"^_M+3V6,X8C50"BX4[: /Z1?\ EI_G^[4E
M?Q>?\%P_&_\ P6[_ &*?VM=?_P""@_[/7Q,U?7/^"?\ \+]1^"UP?@%%\0=3
MN-%\7:@;:RT?Q+I7B+X8^&K*/7O^$6U+7?M;:S?V.J1G^S0-78H,FOU<_P""
M1?\ P6T^'_\ P48_8E^)O[1GCK0O^$-^)?[-'AS6/$'[3'ACP=X;UZW\(:!]
ME'C/Q+I,'P]N]<US4]1\4*_@7PK9ZEJ:OJ (U2^_LP95EV@'[R_Q_P# ?ZT?
MQ_\  ?ZU^2_[(O\ P69_8P_;:_9O_:7_ &J/@AJ?Q&NOA1^RAH_B#Q!\6I_$
M_@.ZT'6H;#PWX$U7XC:M_8&DF_D?6F'A?2;UHT#1AM3*QG*@.>T_X)_?\%9?
MV,_^"E?A#7_&/[-_CG45C\/>,O\ A!Y?#WQ)L-,\#^,=0\0?V%::R_\ PCWA
MV]UJ74=:LA8WF1?:>K*S)=KA=H( /TVJ/_EI_G^[4E1_\M/\_P!V@"2FC[S?
M\!_E3J:/O-_P'^5 #J:GW1^/\S3J:GW1^/\ ,T (O5_K_4T^F+U?Z_U-/H 8
M_0?7^AI],?H/K_0T^@"/_P".4[^#_@/]*;_\<IW\'_ ?Z4 -_P#C=*_0?7^A
MI/\ XW2OT'U_H: 'TQNJ?7^HI],;JGU_J* 'U%V3ZG^8J6HNR?4_S% #GZ#Z
M_P!#3Z8_0?7^AI] #&ZI]?ZBGTQNJ?7^HI] #3]Y?^!?RH?[I_#^8H/WE_X%
M_*A_NG\/YB@ _C_X#_6A_NG\/YBC^/\ X#_6A_NG\/YB@!U-/WE_X%_*G4T_
M>7_@7\J '5'_ ,M/\_W:DJ/_ ):?Y_NT ?S%?\%S?VL/C!\<-7N/^"17[$NL
MB'XS?$[X8^*OB?\ ME?$K2VEO;;]G?\ 9+T?0KN]\06FLW-F5:Q\6?%2QN[3
M3-*L<[FTB[&F Q'Q1IFH1_BC^R9\</'/[.__  9R_'[QK\/=0N](\2:W\2OB
M?\*XM9L;I[&^TW1?BO\ &[PS\.?$5U;72E7L[M]!\0ZK8@J0<7@*G)!'[L?M
MP?\ !MW^R=^U%\8_VF/VN$^)G[4OA[X\_&S2K_7KG0_ 'Q6TGPCX5U;Q1I'@
MRTT7P]H#6G_"+,W]BW]]I&E*UCJ.ID W=ZQ;NOYJ_L!_\&Y7Q<TG_@CU^U]^
MSS\;W\4_"_\ :U_:AT>XT&#P7XP\>Z#XQ^$?@W4?A9X]/COX.:_I-GX6_M6S
MT=_$>I6ME8>+M2L-2U'44C+.=.78$8 ^2/VJ/V*_@)_P2J^#7_!OS^W9^R/X
M8N_A_P#'O6OBI^SOX;^,_BBPU?7C<?&RQ^-/PX\/>+_&UQXM^W:EJ=A9C41<
M^*= 6PTY$TE=%\47NE*7&FZ:J_VB?\%$_C3^U?\ L^_LK>,_B?\ L6_L_P!O
M^T_^T#H^M>#[#PO\'KP:F;?7M-UCQ+8V'B/4C_8^LZ5J&/#^BW-YJ9"ZC&"U
MGTVDAOY;? G[$G_!8G]OWQ?_ ,$Q_P!DS]N[]ECP1^S_ /LQ?\$U_&'@7QE\
M1/C,GQ)T'Q3/^T3<_"#0M(\-^![;P_X=T2^U3%[J>B>'K;3-68*-+?\ X237
M=8.K:7MTO1Z_M^H _P XS_@LS_P4._X+?_'W]@'XM?#+]LW_ ()9:'^S3^SY
MKNL_#ZZ\6?%ZS'C 3^'+_2/&>CWWAVV!U?QOJEAG5=<M;/3R#IS BZ4CG);^
MV_\ X)3?\HT?V#?^S3_@1_Z@6B5^:O\ P=3_ /*%?]I7_L:/@;_ZMGPU7Z5?
M\$IO^4:/[!O_ &:?\"/_ % M$H _0+^/_@/]:_-;_@K!^TG^T]^R3^P_\3/C
MI^QY\((/CI\??"FN_#>Q\)?#.X\&>-/'\.LV7B/Q_P"&_#WBFX'A7P!?Z9XD
MO_[,\,:EJM^SZ?J(6P%J'.X;A7Z4_P ?_ ?ZT?Q_\!_K0!_GU_\ $0]_P<A_
M](H]'_\ $1?VM/\ YXU)_P 1#O\ P<A9Q_PZCT;Z?\,E?M:9_P#5C>G;]:_T
M%ZC_ .6G^?[M '^?9_Q$/?\ !R%_TBCT;_Q$O]K3_P">+1_Q$/?\'(7_ $BC
MT;_Q$O\ :T_^>+7^@O31]YO^ _RH _SZO^(A[_@Y"_Z11Z-_XB7^UI_\\6OZ
MA?\ @BK^V5^VO^V_^S#XX^*G[=O[/\/[-WQ;T#XT^(/ ^A>![7X;_$CX9PZE
MX$LO!G@+6M,\3C1_B;K.KZ]>?VAK>O\ B+3DU&QOSI1.D>6@5[/-?LE34^Z/
MQ_F: /S4_P""QW_**C_@H7_V:1\</_4+U>OX<O@A+\0/^"/G[%'PR^.-J-=U
MK]@#_@KW_P $_=8^'OQ;MA%<ZO%\%/VTK[X->+](\)>)\#+66B_$4VHX/S'2
MKWQ9@8\$Z43_ **7Q_\ @AX&_:3^"7Q5^ 'Q-AU2X^'_ ,8O 7B+X=>,;?1]
M0;2]6F\/>)M+N](U8:7J@!>QOC97;!+Y4<K@84D$#Y:\3?\ !,C]DOQO^P5H
M?_!-[QGX-UCQ/^S-X9\#:%X$T'2-8U^XN?%^CV'AJY:\\-ZWIGBQHVU"S\4>
M'[P+-I>NH-\;K@^9$S @'\;O[&'Q#^,'[0'P-_X( _\ !*NP^-/Q&_9Q_9R_
M:(^"?[17Q>^-WC'X3>(Y_!'Q ^*8\"?%OXV'2?A+I'CA"+_1M/U'_A';O^UK
M#2Q_:6J_\))IY QIVE5^S7_!/OQ#\4OV(/\ @M5\>?\ @E1X;^-WQ9_: _90
MU3]E_P ._M*^!-/^,WC.\^)7C?\ 9Z\5-JEII]YX-'C>_*ZDV@^(K*].HIIV
MI L?M?A]D4N-1U75?T!\9?\ !#/]@_QI^R_^S?\ LN2:#\4?#6D_L@W.OZG^
MS7\6O!_Q.U[PW\=OA)J_B?7;WQ-JVJ>'_B#I(1KHWVNW@OVL-5TS4],#6-AB
M%7T]37NW[#/_  3"_9G_ &!=3^)GC7X6_P#"P_B!\;/C/=:?-\6?V@/CCX[U
M?XG?&/Q[;:.O_$ITO5O%FL86RT7368E-/TO3].$FRQ&JOJ9TW3&C /P;_P"#
MD_X/:9^T)^W#_P $8?@5K$"3:?\ %_QC^UA\.9-__+"?QAX$\!:-:79([:=?
M7=IJ'4<V@&>U?RU>*/B=XS_;@_92C\&>-K"\>V_X)&?\$F/B1X#\6PW^9HM,
M^,^L?M067P4TBVY! O;'X5-X2VD9/_$FU#C&-W^E_P#M#_L'? /]I_X\?LJ?
MM&_%.Q\5W/Q(_8W\9:_XW^"\^B>([C2-%L_$/B,:/_:S>(=+6T>/6[%_^$?L
M%1&:,X#$N1@+\AZ/_P $+_V ]"\,?MR>#])\(^/]/TC_ (*':C!?_M$K;?$#
M4C<7#67C*^\>BT\$71LR?"]D/$^JW4IC"R,5PH) .X _'7X%_%OXI:!_P4B_
MX-X?A%HOQ$\:Z/\ "WQI_P $K/[8\6?#?3?%&K6/@GQ5J^D?"WQ+_9.J>(/#
M]C>C3M9U#3S9VN-0U'323]B!!'S!?+/%?Q?_ &X?B1^T!_P<V?#C]FO]H_5O
M#WCKP#=?L[:1\!CXU^+A\->%?A]:WEMK(^(6A?#W7_%.NKX0^'_BGQ%HEGJ^
MG:3?G^RL:N+$?VMI14X_>_\ :+_X(I_L@_M'Z%^R3:ZGJGQO^%WC3]BSPAI'
MP]^!/Q;^#?Q7U/P+\5?#_@31]+L](7PQ=>*["SE%_97UCID:2:B=-74R;O49
M 5&IZ@CX_P /O^"#W_!.3X?^$_VLO ,'PO\ %7BKP=^V?HW@[2_CIH?C?XC>
M*?%']JW_ (#6]O= \4Z1KM]?-XBT3QR=>U6^\8:KXM756U;4_%-U_;#N2"A
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MGO4?&/@_1M7TCXL_%CXWWVNZ=J&M:YJ>BZOI&H+X=U'PUJFE?V5?:<HU4?\
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MT3X3_#FPO].T73M8NCK6JW9UC5+W6=8U'7]4NT5M:O\ 4;[5;M]3O7&9"S(
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MYI/AVYUBY2U<:S8QV5[=":QPJLY5@P^5: /Y2?#?[%OC'7?^"R'[<'_!,_\
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M_A+/$_\ 9@\%G4M<U7[?I.H?#O3/%.E:5JM[H/\ Q5FEZ/\ VH=3_I>^$O\
MP0J_8/\ AUX _:/\&?$#1OB?^TQK/[6OAS3/"GQV^)O[1_Q/\3_$CXF>+=!\
M.O:W?A72[7Q(+[3'\,_\(W>V6EZAI.H^'$TO5DU'1]"D;5'&EZ8D?.?L^_\
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M4:/[!O\ V:?\"/\ U M$H _0+^/_ (#_ %H_C_X#_6C^/_@/]:/X_P#@/]:
M'5'_ ,M/\_W:DJ/_ ):?Y_NT 24T?>;_ (#_ "IU-'WF_P" _P J '4U/NC\
M?YFG4U/NC\?YF@ _C_X#_6A/NC\?YFOC/]N+]N#X!_\ !/?X"ZU^T-^T9X@U
M?2?!UIKFD^%-"T?PWHUYXC\7^-O&7B6XN%\.^#O"7AZQ4/?:W?FTNY0/,2PC
MTVPOM0U2984S7PC^QQ_P7/\ V</VJ_VB=%_90\4_!C]J#]DOX^^-?#-_XM^&
M/@G]JGX47'PWG^)V@Z3;F]NF\)77V_4A=WR:<+N]CL=2&G/J2V%\VEM.Z@,
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M&GX-Z/X2\8:+JG@./XF?$;Q)_:.L:S:?9=)NCI7B4?V=_P 2Z\ .>!@CGD9
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M\M/\_P!V@#^6+_AMO_@MI_T1#Q#_ .(WZI_A2?\ #;G_  6S^?\ XLAX@_\
M$;=4]_Y?_6Z5_5%31]YO^ _RH _E@_X;;_X+:?\ 1$/$/_B-^J?X5_0[^ROX
MG^*/C7]GGX1^+/C7I5SH?Q6U_P &:;J'CS2+G16\.3:?XA;*W=JV@9/]CD!0
M38')7J20:^A*:GW1^/\ ,T ?@C_P7_\  '[&WQN_9F^#/P%_:N_:9UC]DWQI
M\1/VAO!U[^RC\8-,T+Q!JT6@?M#>'([RT\/7&KWNCV L-&T06/B.\&K:CJGB
M3PJVEHRZQI.K"32V!_(_1_B+_P %*O\ @G-_P4%_X)W_  M_X*=W?[)7_!1'
MP)\=_BK#\"_V=/VD;/P-H$W[5/P7\0^)+K1]%/BOP[X@U#0--\7:+9;]7M#X
MJ9DU>/6-*-]_Q5NFZOR_]5O[7O[&/[-_[>?P:U;X"_M1?#;2_B5\.;_4K?6(
M=/N[K5=,U/0_$-G'=QZ;XC\/>(-%O-+U31-9T^.\NA'J.F:@GR75[IS;T9T?
M\_?V/?\ @@1_P3O_ &+?C5X>_:"\">$_BA\1_BYX(M/LGPW\6_'3XI>(/B;+
M\-H%M?L3-X)TV\_L_2["^:S:X1+R33;]]+:ZD_L4Z<!@ '\C'_!2#Q/9_M V
M7_!3']LG]FK0?V]?CQ)\!_C7<:8G[=_C[]JO0/@-\)?V;_$'@35='TAOA?\
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MI:C?^(7U/5RNM:$FD,=&TO3=.;^Q/]G+_@D?^RK^Q=H/Q^\7? OPUX\\>?M
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M"^W-KUH7?5+T_8-1.I:8/^)=^Z8Z;IC1@'X:?\$+)_C9\"O^"SG[8_[(VN>
M?BK^S3\))/V3O!OQ>@_9(^(7[2I_:A/P]\576K_#6TTC7KSQPEYJEA9^*M?T
M7Q'JNI:OI]AJ3+I*ZQ_9#ZOJD8TO']K?\'_ ?Z5^6'[)/_!(#]B[]B[XV?\
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M?Y_NU)4?_+3_ #_=J2@!O\?_  '^M'\?_ ?ZT?Q_\!_K1_'_ ,!_K0 ZH_\
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MZ=J6FZI;BZTO4++4[<_N_M&GW=M>0$]0!<6C./<\_@#7P7_P4*_X*1_LX_\
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MO[#4+1;S3[VTU"TE_P!7>V=U;W%O-TY6YM"4/H2.GXT 7O\ XW3OX/\ @/\
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MXV_LL^%+/Q.==TAKIM8&LV&I:<;(:&-67%[IT@W%6 !P0 ?CK_P=5WEI:_\
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M=XJ@\1^'?$,O[1?_  CWPJ\!>/SIFK6MUX-&DB\/C.PU'^Q<BY\0\:=V4<G
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MC\0!=^+?$UA+KVBC3OASLU$C3F TQ5_M8%25"_TBI]T?C_,TZFI]T?C_ #-
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M#;IMAJ.EZ6K6=BSIG3D*?CS_ ,$M/^#<+]GCPM^R'\#-._X*&_LWZ;<?M)>
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M#+IOBC0--1=(\4V$=FFN:=J0T_3/) /X@K?]K?\ :I\1_P#!-#]F3]D$^/\
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MXTS^RAXP_M?^R/\ B6:7_9?%_M>>#+#XP?LX?\'3.L?$+6O%^OS?L]_\% /
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MQX@U8:WKFIBTT/P[K=Y>KI'AX!=*TIO$M@-'&E[3O_1[_@@QJ/C#]KKX]?\
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MW_ ?Y4ZFC[S?\!_E0 ZFI]T?C_,TZFI]T?C_ #- "+U?Z_U-/IB]7^O]33Z
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M^/\ Z"* '4T=$_#_ -!-.IHZ)^'_ *": &_\L_\ /]ZC_EG_ )_O4?\ +/\
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MZFGT ,?H/K_0T^F/T'U_H:?0!'_\<IW\'_ ?Z4W_ ..4[^#_ (#_ $H ;_\
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M_P"S#\"_AE_P0A\"?\%G? O[2WQ8A_X*;3R_#?XW3?M-M\>/%.K>(O%/Q?\
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M^/\ X#_6@!U1_P#+3_/]VI*C_P"6G^?[M $E-'WF_P" _P J=31]YO\ @/\
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M_P"#BG]E[PC\(OVW/!G[,?B'XP7?Q:^!'A/X@>#M#_:*TWX&Z]XE_9L\,_M
M:/:7MIX>\$ZI\0[RQU'P\-;O]=M5T[2&U+2CX4U;4[NP3^U3_:*[ #^G"FCH
MGX?^@FOS_P#^"6OQP^)7[2G_  3L_8Z^/?Q@UN/Q)\3OBS\"/ _C?QKKEOI>
MF:3!J6OZS8_:KN[&E:+9Z?IMB-P'^@V$:JO(VDDN?Y<O^"/7_!;C]N3XO?\
M!1+Q1\)_VT/BOX9\2_LW^-],_:_T?X3,G@WPMX6O='\8_LX:]I'B6]MKG5=#
MT/2VN_[/\"F\0_VB6+?;K)LKPH /[B_^6?\ G^]1_P L_P#/]ZOX8O\ @D9_
MP7%_;I^/?[;_ ,8;_P#:U\>GQ#^R9;?LH?M+_M@> OAYX)^&7A<>*M+^'/PX
M^+%WX;\/_9/[%T73?$6MWVFZ)X?\1QZ7I_\ :>I_VP@L#G^UW*K_ $M^*_\
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M:!_:&I#[5IQL-+.D:3J^EC^QAH^J?VD%TS_1$_C_ . _UID<<:?<39^'^)-
M'^=M^WIXH_;/_:,^('_!6'X&_M(:5_P4C@^,DGBCQQIG[(7[)_[*'P?N_#O[
M+WQ(^%%EH5Y9^'OB?\9/&WAG0_M_Q/L-.\*V=IJ.K#Q%XEU7^UA>G2-'_M7^
MTAI&D_6WP<^ 7Q1\2_M)_P#!JYJVJ? [XG77AGX*?LR?$#1OBK<>(/AAXQ@T
MOX8>,?#7A465I:>-?[0T/;X6OM.\5:0#I(\1_P!E+NL[!M(')-?W*;$WLX7Y
M^.?PX_R:DH _DO\ CUXJ\3?\$QO^"[_QK_;O^.OP1^-WQ$_9._:K_9,\(_"_
MPG\6?@Q\+]?^+?\ PJSQ]X#_ .$:%SX%\5Z/X82_U'1&\1_\(BQTHXVZJ?$N
MFB,%5U5M,^9/VMC^U+^T=\$O^"<W_!2'0?\ @F-XW^$GPL_8]_;\\3_%[Q3^
MQIX%\+"_^+OQ#^ UV?#-[I/[0FJ_">S\*>&QI_BO/AVZSH%\-3U4B]LM6_M8
M:*QU4_VRE4DWHZ[N>0?T';^?UZ"IJ /Y&-)\9^(?^"L'_!9+]DO]LC]FWX(_
M'#X:_LT?L/? 'XPZ7\5?CM\;?A?X@^#I^)OB?XCZ!K-IH_PE\)Z3K=B->\4?
M\(Y>ZO\ ;M4V@Z9I?VGQ"S["VF'6/Q)_X)^_MC)X3_X(3?M=?L)Z9^R'^TA\
M3/C#^U?XZ_:/^'/[/WB'X;?!O5?'/PX^*OBCXDK8>#[NXU?QKHZ+8>&=>^$]
M]]EOM6L/$++J@TRQT'5M%9T8-I?^D7=6D%W97EB^(X;RVGM)=G87:M:DKWSC
M..WK7P__ ,$]OV!?A'_P3?\ V>?^&<?@GKGC/Q)X-;QYXQ^(PU#Q_J&EZKKH
MUCQU=VEYJ]N;K1=&TFQ-A&]FO]FH-.! )0DDX(!_$_J?[&O[4_\ P2^_:E_9
M=^+G[0WCS]MSX/\ PN\4?\$Z/A!\!]4^/'["G@/PQ\9_%7PV^+/PV\,:/=>(
MO@CXVL_%'@;XCBRT+4K^R/\ 96I:=IFF#5]4NU_L8_V-IFJ_V;I?'+]AWQE#
M_P $>?#/B/X3? ?]NJ_UG]I/_@JO\./VA_%'P[_:0\(^&/$?Q;FT^]M-:LM?
M^*%WX)^$G@;PWIWAGPKXR(_M!E\0^&M+(7J!HYTDG_0]94D'S*&'/44J?='X
M_P S0!_-)^V1\*/B5J__  <;_P#!*KXE^'_AOXSU+X9>"OV7/V@= \4>/-&\
M):[?^!?"VH7>@_%3^RM+U_Q%961T#1;V_-Y:)I>GZEJ:;GNK)@@!7'\^?PD_
M8D_:[N/^"$O[.7B71OV<?BSXE\7?LB?\%:[[]J_XC?L\:CX'U[2/B-X[^$'A
MJTN[/5]4\/>!]9LM/U#Q/>JVK6JKI_\ 9P+:1=Z\=JC364?Z--,3H?K_ $%
M'X5_L>_\%(M*_;P_;;6#X#_L%?$K1O@[X7^"8F^(O[;/QS^&&I_!OQ7X:\9?
M:[PV7P0\(VGB?PF?$'C7YM6SJJZ?XFTW2M,_XGVJL)%.F#5O#O\ @NA^SO\
MM-:9\;_^">__  4Z_93^%&L?'[Q9_P $_/B#XXO/BC\#O#$-SJ'C?QO\'_B9
M:>';3Q#=^"='6U=[[6_#EEH^KJUAIZ_VIMUBQU>-)/[*Q7](:JL:'8FSMC'^
M?UQFG_P?\!_I0!_%7_P4&_;'^*?_  7Y^'?PI_X)X_L2?L=?M7?#WPW\0OBQ
M\/O&7[5/QO\ VE_A#=?"SP1\%/!_@/5K;Q(VAMJJW_B33=8\5?;[,L5T[4E.
MIMI-EI>BKJHU=VTO4\.?%'6?^"<7_!>3_@H?^TE\4/V6_P!ICQA^S#J'[-/P
M0^%FG_''X8?!/Q1X_A\-W&D^%OA3_92VWV*PCEUK0O$-]X=_L#5;[P\^I?V1
MJ_\ 87]KA='+ZKIW]GD:(F_8@7]YZ=>@_J?\\4_&[<K89>G;\CCK_P#6H _S
M;/$G_!/#]N+QS_P3K\6?MJ>'_@3\</ >@^)_^"O]Q^W]I?[.'@[P[;6_[0OA
M;]GG_A&=8TBT^(_A;X>:W8ZIX?/CCP[>WAOM(\/7_AG4A_92C63_ &IHX(;[
M=^"WP)\&?MQ_&W]J/]H[3_ 7_!63]O2T^'7[#7Q'^#;^(/VJ-,^$O[.7AWX\
M:1\1M O;75OV<_")T7X5^"?&-[XZ\.7VK7GB'PGJ(_M32QXJT8]O^$7.J?W<
MU#&J1Q_(FP>GUZ?AS0!_G'?L;W?[3?PI_:2_86\!_P#!-GQG_P %-M9DA^+7
MA#3/V@OV+/VV/@%>:Y\'OV7_ (7FZL;'XFJ/C'XFL=.\.65CIEC_ &O8^$O$
M/@SPQX5U8Z59V6YM-UG9I.J?<GQ _9A_:)\7^(/^#M/3/#_P/^)^H77QQTSX
M.W7P=$G@C7[:#XJ?\(Y;>/=7U4?#VZO;$6/C0V%D57;X=_M%LM8@$-J(!_N-
M,:?,^WY_+QW[@]O7CZ_C4AZ/^/\ Z"* /XB?CB8/VO?^#=7X!_%GX+^$/BGX
M#_:*_P""0NB_LW?$'3[OXG_#37_AUJT/Q(_9Z\!>$+3XLZ7X4_X2:R-]K7A0
M:%>7>H'4=."Z5J>K^&]/4Y;3@H_1K_@VT\ >+?B/\%/VGO\ @IQ\7=(GTWXO
M?\%)_P!HGQA\5(8KDW+'2/A!X0U:^\,_#W0+,W-H";&PO?\ A)3I$P+KJ6CI
MH;Y 0$?IE_P4>_X)S:5_P4?^'&@_!_Q=^T;^T!\#/AG'/J]K\2O!_P $?$>D
MZ%IGQF\,ZN=(NCX9\=6^L:)JD=]I]A>Z2K:7Y:KY0N[\D/O"I]I?!7X0?#_]
MGSX2?#CX'_"C04\,_#CX4^#?#W@/P5H,<MQ<G2_#WA?3+;1-*M9+Z]9[V]NU
ML[-0U]=_-?N=[-^\) !_+I_P6=^-'[3/AC_@I#\"_AO\0=?_ &V/@I^P%K'P
M$U?^S_BI^P!\(QXO^-'Q'^-VLZLUI?\ PFU;XA6.@>)O$'@RRU*PM-(L4T_3
MCI63=V&JGESK&D?ASH'[,7[14'_!"S_@I%\$YOV;OVF]-^)6J?\ !4'X8?$'
M1OAC\1?AOXQU3XMZGX U;Q-X8N[37M6 T,GQI?+9:3>+XL\1:<NJ:4^K6E\[
ME&Y/^E1L5@N]!G'0C./\^_\ .D_Y9_Y_O4 ?RU_\%$?@A\3?%7_!3_\ X-^-
M8\'?#3QE?>#_ (<:1\:M*\;>*?#W@W7[[PW\-5N_ACX/T;1QXKU:RL?[/\,V
M8O!C3/[2_LT;K1PH'RA?QZ^#_B_XL_LD?\$FO^"C?_!&3XA?L3_M0>.?VR]0
M\1?M':OH5UX+^"VJ^*_A)\2/ WCA-*U:S^-X^)@8:?=V7AZQT&Y.EEAJVIZM
MJEAX1T;1EU36=1.EZ5_H,_\ +/\ S_>IK*GS/L^<?GGC'MZ?Y.2 ?F-_P1G\
M)>*? O\ P2K_ &"?"'C7PWK_ (/\6^&_V;?AOI>O>%O%&F:CH?B'0]0L]+ N
MM-U;2+^SL-1L;U&.&L;Z(-RN0ZCYOX*/B1^Q1^V)X4_X)S:Q^T)\*O@'\<+'
MX^_"O_@J1^U_X1TSPWI_PO\ '9\<:E\&/VF_A&/!^K^*-(\.KH(U^^\*M?\
MAVTT\>(-/']E9O1N8MEZ_P!1:FCHGX?^@F@#^+K_ ()E_L,>//V9_P#@L%^S
MWX#UOX2>,8/A9X/_ .")WP^^&?BWQAJ/@S7X? %[\2/$FL:-XC^(7A>[\0W5
ME_8 UMM<U;Q#_:^@?VG_ &H <NI&5KX*_97_ &3_ (LZ]_P5Z\ _\$7O$^GW
M%[^Q_P#\$]_VT?CM_P %"-/?_2YK&?X;^+_#_@_QA^SYX.O+1@VGBQT[Q5JU
MH2"1_:C>,O%VT  @?Z"7BS0YO$WA7Q1X8@UG6/#=QX@\/:QH4/B'P]=&PU_0
M9]8TR\LAKN@7H!^QZSIK7?V[3+[!\O4;5&.W:#7YJ?\ !/C_ ()4_"K]@7QQ
M\=_C1;?%OXU?M'_M#_M)WF@GXK?';X]^(],UWQQK.C^&Q=#P]H-L-'T[3-/L
M=.T_[7B4QY;4FLM-#D#2]/  /P6_98_:$UG_ ((M?'__ (*K?"3]K+]E']I[
MXH:C^U!^U1\0?VC/V=?BO\'O@CKOQ6\/?M'^%_'7VT>'_AP/$5D2EAKNG-=F
M-]/\0ZFVEZ5JFK^(0"C!6U7\\KO_ ()T>+_V=?\ @F3^PU+^VG^R[^V7X9UR
M']I#XW?&Z/XV?L7:[=7OQN_X)[:!\8/[(N_#ND^(?A38Z#J5]K>B:B?#FD^(
M-9&G?\(P_A/53?:2^JZ7K+#2]6_T1I%1A\R;OY?_ *_K^?%.(!7Y_P <?7\:
M /\ /[^ VC_\%&/V@/V'/^"T_P ']%U+]J7]K/\ 9'O_ -FOR_V:?B[^TI\
MKGX6_M"_%KXHV8\.7GB+0?#FDWPU+X@?$"QT[0=*U?3P-1U74\G1]!_LC2M+
MU?5/[)K+_:&LOBK^T]_P3L_X(P?M ? OX>?M@:'X<_X):^)_!_P__:IB^'_P
M;NM"^.W@G4QX#^%-GJWQ;^"G@CX@Z!JFG_$,_"N\\(ZO&OB#_A&=2TH:MK*,
MSA%U;5-,_P!!7:%"*B[%$@X'H.?U_+C&>:/+18]B+\OY_P#US_2@#^#'X?>'
M_COXDTS_ (*8_P#!1K]A_2?^"E'[1/[1GA3]EOP_\$?AI\9?VV/A5\)=#\-_
M'?1]9\9^#_\ A+/^$'^"&B_"OP1X@\:>*_@SX5TKQ9J&D#Q%IFJ:439V UC2
M=4_M+2]*'SG\!M&^(WQ;_;Z_X(O_ +1&E_\ #T+]H"T^'_Q4M]/_ &F?B]^U
M;\)?%.A_"3X2?$CQ+X7T:UNOAU\)?"NCZ!8:!X(\)^&[\78U?4M.SX8_LDZ
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M_E"_XC%O^"4__0J_M5?^&FT#_P";BG_\1C'_  2F_P"A6_:K_P##3:%_\W=
M']7M,3H?K_05_*$?^#QK_@E&N=WAG]J>/Z_"C00?U\=8I_\ Q&,?\$IO^A6_
M:K_\--H7_P W= ']7/\ \;IW\'_ ?Z5_*#_Q&+?\$I_^A5_:J_\ #3:!_P#-
MQ3O^(Q?_ ()3X_Y%;]JOT_Y)+H./I_R/6/TZ=J /ZNO_ (Y4E?R?_P#$8M_P
M2G_Z%7]JK_PTV@?_ #<4_P#XC&/^"4W_ $*W[5?_ (:;0O\ YNZ /ZNDZ'Z_
MT%)_RS_S_>K^4,_\'C7_  2C3._PQ^U/']?A1H(S_P"7T*/^(Q;_ ()3_P#0
MJ_M5?^&FT#_YN* /ZO/^6?\ G^]3CT?\?_017\GW_$8Y_P $H5^1_#G[4R'T
M/PJT#=Z]_'0/Z=*;_P 1CW_!)_\ Z%_]J7_PUF@?_-U0!_6+31T3\/\ T$U_
M)Y_Q&._\$H?^A=_:G_\ #6>'_P#YNZ/^(QW_ ()0_P#0N_M3_P#AK/#_ /\
M-W0!_6#_ ,L_\_WJ/^6?^?[U?R@?\1CW_!)_'_(O_M38SU_X55X?S],_\)W_
M /7_  IO_$8[_P $H?\ H7?VI_\ PUGA_P#^;N@#^L)^@^O]#3Z_D\_XC'_^
M"4/_ $+?[4O_ (:OP_\ _-W1_P 1C_\ P2?_ .@!^U+_ .&J\/?_ #=4 ?U?
M_P#QRG?P?\!_I7\GG_$8]_P2?_Z%_P#:E_\ #6:!_P#-U1_Q&/?\$G_^A?\
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M?_\ +3_/]VI*_D\_XC'?^"4.?^1>_:F_\-5H'3Z?\)SC/^<TW_B,=_X)0_\
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M][>W&.+BZNSX9WLY R68XSDYZU3;]@G]A_YO^,/?V8NV?^+%_# ?3_F5N/\
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M.VETV>**9&50#RC_ (8*_8@_Z,]_9A_\,5\,/_F6IG_#!/[#X9?^,//V8O\
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MH_COPSJOAN[U*R!95-_IZWAOM+8G:);5"<\BOX_/"7_! [_@J_XR\#?L\?\
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M\#_^"@__  7V_9V^,/\ P3B^#WA[X??L=_\ !,GP%K_@?XM_M'_#;PG:>#O
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MHN]9O8[#1_!'P[L=7MM?U34=3QI!U630M'U9D356*_S,_P#!OGX2^'O[*?\
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MX5_%CX3^)+KQ)>WGA_Q%=V%CJ=]87VF7GBWQ"R@:=C5$U=BNJZ7JNDZ8Y?\
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MK/X=+JRWL<>CZ%?WK7C:L=0&IV!BV>9I&JL%4?J9_P#'*25?-1T[]/\ Z_\
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M&TL-$U.PO-06R^'FK*XU+4M+ -Y8A6;!- 'S+_P74_;MU"?Q7\*_^"2W[/\
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M#)IT873(OPS^/7_!&[_@JO\  KXE?MP^ _\ @F%^T!^S[H'[(7_!1KQ3XO\
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M (%_*@!U1_\ +3_/]VI*C_Y:?Y_NT 24W^/_ (#_ %IU-_C_ . _UH /X_\
M@/\ 6G4W^/\ X#_6G4 1_P#+3_/]VI*C_P"6G^?[M24 -_C_ . _UH_C_P"
M_P!:/X_^ _UH_C_X#_6@!U1_\M/\_P!VI*C_ .6G^?[M $E-'WF_X#_*G4T?
M>;_@/\J '4U/NC\?YFG4U/NC\?YF@ _C_P" _P!:$^Z/Q_F:/X_^ _UH3[H_
M'^9H !]YO^ _RIU-'WF_X#_*G4 ,7J_U_J:?3%ZO]?ZFGT ,3H?K_04WL_U'
M\S3DZ'Z_T%-[/]1_,T 2TQ>K_7^II],7J_U_J: 'TQ.A^O\ 04^F)T/U_H*
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M'GQ;^&?[.M_^U?\ \$V?C+^S_=_M%ZOX8\.>-+_X4?&;]DKXU^*++P@/B/\
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M?RIU $?_ "T_S_=J2H_^6G^?[M24 -_C_P" _P!:/X_^ _UH_C_X#_6C^/\
MX#_6@!U1_P#+3_/]VI*C_P"6G^?[M $E-'WF_P" _P J=31]YO\ @/\ *@!U
M-3[H_'^9IU-3[H_'^9H 1>K_ %_J:?3%ZO\ 7^II] #'Z#Z_T-/IC]!]?Z&G
MT 1__'*=_!_P'^E-_P#CE._@_P" _P!* &__ !NE?H/K_0TG_P ;I7Z#Z_T-
M #Z8W5/K_44^F-U3Z_U% #ZB[)]3_,5+479/J?YB@!S]!]?Z&GTQ^@^O]#3Z
M &-U3Z_U%/IC=4^O]13Z &G[R_\  OY4/]T_A_,4'[R_\"_E0_W3^'\Q0 ?Q
M_P# ?ZT/]T_A_,4?Q_\  ?ZT/]T_A_,4 .II^\O_  +^5.II^\O_  +^5 #J
MC_Y:?Y_NU)4?_+3_ #_=H DIO\?_  '^M.IO\?\ P'^M !_'_P !_K3J;_'_
M ,!_K3J (_\ EI_G^[4E1_\ +3_/]VI* &_Q_P# ?ZT?Q_\  ?ZT?Q_\!_K1
M_'_P'^M #JC_ .6G^?[M25'_ ,M/\_W: )*:/O-_P'^5.IH^\W_ ?Y4 .IJ?
M='X_S-.IJ?='X_S- !_'_P !_K0GW1^/\S1_'_P'^M"?='X_S-  /O-_P'^5
M.IH^\W_ ?Y4Z@!B]7^O]33Z8O5_K_4T^@!B=#]?Z"F]G^H_F:<G0_7^@IO9_
MJ/YF@"6F+U?Z_P!33Z8O5_K_ %- #Z8G0_7^@I],3H?K_04 )_\ &Z=_!_P'
M^E-_^-T[^#_@/]* &_\ QRE7J_U_J:3_ ..4J]7^O]30 ^F)T/U_H*?3$Z'Z
M_P!!0 G_ ,;K\A[C_@G3\0)?^"T%E_P4\7X@^#U^&]M^QS_PS5)\-/L&NCQN
M?$'_  E>J^)!XD^VBU_X1_\ L8_;!$ S#4_,5CMV$!OUX_\ C=._@_X#_2@#
M\T?^"JO_  3QT#_@IC^RGJ?[/UYXYO/A;XUT3QMX2^*GPD^)]GI_]KS^ ?B;
MX%N9+C2-=&D"\T_^T+1[.^U/3+]!J4+H+UI(I/.B4'\\O!__  2Z_P""A_[4
M/[4G[*WQQ_X*L?M)?LW?$+P'^Q#KJ^/?@O\ "_\ 9>\&>,M#M_B3\8;3["ND
M?%+XQWOQ TZP%E?Z8MFNH'0/!@.E+J=FG]E?V2C:G_:G]'/_ ,<J2@#^4GQI
M_P &_/QT\5?L:?\ !4?]FBW^/?PGM_$/[?7[:MC^U!X(\23Z/XR_L7P%X<M/
M&ECXG_X1CQ7:BR.H7VM_8[(:=G35?2P67&T9!^I_VC?^"57[5N@?M0_ ;]OC
M_@GQ\=/@Q\-_VJOAY^S9H/[,OQ=\(?'WPOXPUSX(?'/P/X<TW2K32;C5KKP1
MCQAH=]IM[9Y4V&E$NECX?</IKZ9+_:7]!B=#]?Z"D_Y9_P"?[U '\]W[/G_!
M%KQ2_P ./^"B_B_]N'XM^%?CC^UU_P %,/!6H>!_C!XL\#^'[O1?A)\.?"UG
MX?O]'^'O@_X9:3K-G_;XT_P7?7EAJ#:IJ8_M#4_^$=\/*VE"336;4OS"U#_@
MUD^*5W_P3)T3]DX_M(_#A?VKM/\ VN/%'[1&I_M!R6'CF;0K[POXQ^%]E\(-
M6\" O9'Q=MOO"NDZ0[J<:8=2L6 SNS7]IW_+/_/]ZG'H_P"/_H(H ^$)?^"<
M'[%_BGX(? 'X%_%S]G/X0?&GP=^S?X T#P!\-+;XH>!- \8_\([IVCZ#I.B7
M5SI8UJPE^PW>IKI%G)J1CV;F7YMNYU;\L/B7_P $D/VOOA#_ ,%)-0_;=_X)
MJ_&']F7X&>"?B?\ LZ^#?V9/B9\+_B]\-_%.K6'P]\$^!;/PUI.D:[\&_#_@
MK^SM-O[_ $VQ\)>'+_2M"\0:IX8T?^V+.^35GU;2M2('](%-'1/P_P#030!_
M 1_P4N_X)H?%'_@FI_P0K^/OPC^)WQET#XM^)?C)_P %,?AC\8['QYX9TO4]
M,O;>V\8:@ED+K5[6^LK!/^$L%WI5WJ&I'3?^)6#='R"N,U^TWPZ_X)8_MX?M
M#?M4?L4_'3_@H;^T[\"_BK\"OV"+#_A*_P!G7PG\%_ WB_PO\0/BIXYO-"T6
MST?QY^T&?%']I^'[#7K#^R-'U'5['P5JFIZ9J>HZ1C2_[(35-5!_HRUOPYH'
MBBQ_LWQ+H>D^(-,\V&Z&GZYIEIJME]HM6W6UTUI?6CI]K0D!?EW(N54X8AMU
M%1(U1%VH$X'H,=.YSSW_ /U '\_'_!R!\"?&OQ#_ &#O"W[0/PST2Z\2>._V
M$/VA_A/^U[I^@64)N+O4_#'PWU9[7QU;VMFH NWT_P +ZO>^() <8TW1[X9R
M>?7;#]B?5_C_ /\ !5K]F?\ X+!^ /BKX(O_ (%VO[#W_"I]&\&16VJ77BOQ
M'_PGEQXP\8Z/XITK5[,-H!T9K'QQ8Y3^T7?=:WORLK!F_:&ZMX+RWEM;F&*X
MMYXFBN(+B(30RPD$-!.#O!&&).<CN0W.:VG:98:38VNEZ786NFZ=80P6MCI^
MGVUO96%I;VP'V:WM+6T3R[6T&#M0*%0#:%"G% '\QGA__@A!\:M'_P""<'_!
M2S]B*;XX_"N?QC^W)^U+XK^/'@SQI%H_BX>'O!6B^(?%/@SQ);Z+XJM3:C4K
MW68[3PG<QR?V:C:8)+^,XV\GT?XH?\$@/VMOAG\7/V1/VQ_V"/C[\%/A_P#M
M;_ ']D3X??L@_&'P_P#'#PQXTU;X#_'_ ,$>!?"NB:/:W6K77@P+XPT1]/U#
M2!>Z4$TQMPL?#WS:8=,==0_H^_\ CE._@_X#_2@#^7L?\$)?CM\0OV9O^"F6
MH?M _M%_#[QU_P % O\ @IGH'@_0?'?Q/TCPUKVE? GX7>%_ GB#1M6\)^!/
M NCBS/C*]T'2['2X[!]3U)5U+4AI?AX/I:MI4NIZC](?M+?\$C/BG\<?@%_P
M2!^$>D?%7P%HVK?\$W/B9^SOXZ\?:MJ>F>*)['X@6'P2\!:)X/U6T\$K9V;7
M]G?:I>:6=2TAM?\ +4*Z^:048-^^7_QNE?H/K_0T ?SI_"W_ ()9_ML_ ?\
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M_P#@DWX \=Q?&3]H3]M?]I7X??"[P[<6>D-I&DZIXQ^(_P 6O#7Q'^()\$Z
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;S-.IJ?='X_S- "+U?Z_U-/IB]7^O]33Z /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $% ;\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJEJVG)J^EW&GR3W$$<Z[&DMY-C@9YPW;/3\:
M &)KNE2:?<WZ:C:FSM7=)Y_-&R-E^\">@Q3$\0Z/)HIUE-3M&TP*6-T)1Y8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3\HSG ZYKT6B@#R&>WU'2M<T74[C16:>_P!<NKV/2T="\:&VVYSG;O\ E+D
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MEIW_ ![M_O&M%N<E3X2Y1115'.%8.MPI/<^7+"DL9095T##]:WJRM0_X^O\
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M<0K-!(DT3=)(V#*?Q%:NG_\ 'L?]XTY5G-6L8.CR:W+=%%%9DA6%JW_'[_P
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M5CQ[_O6?_HLT >AUEZA_Q\C_ '16I67J'_'R/]T4GL73^(JT445!TB !6+*
M&."6 Y..F:8EO!&H6."% '\P!(P '_O<=_?K4E% 78R.**$,(HHXPS;F\M N
MYO4XZGWI]%% !6EIW_'NW^\:S:TM._X]V_WJI;F=3X2Y1115'.%9>H?\?7_
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MM:2"++D8^<UE6:<="H)IE^BBBN4U"BBB@ HHHH **** "BBB@ HHHH ****
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M?KC)/NWM1H$5),T*T]/_ ./;_@1K,K3T_P#X]C_O&A;CJ_"6Z***HYPK*O\
M_CZ_X"*U:RK_ /X^O^ BDS2G\16HHHJ#H"BBB@ HHHH$%:>G?\>W_ C696GI
M_P#Q['_>-4MR*OPENBBBJ.<**** "BBB@ HHHH **** "BBB@ HHHH ****
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M,,$KO(6W+$NU.O?'?O110!LT444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $P <$# 2(  A$! Q$!_\0
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M/LS8;,P3'SD=,]LT >@^*O'MK9_#[4_$GAN\L=1>T* $-O0$NJD, 0>AJ?\
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MLC 44GYB$_A3/(/O5#XAW6J:FWBW2VTXVTBW"M;VEMH_F/=("#Y[3]N!V^E
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MHHH *,444 &*3%+10 8I,"EHH 0# HP*6B@!,48XI:* #%&*** $P*,"EHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML/,MXL75U:ZG%.0X&,F->1D_E0!W@Z"EI!TI: (Y_P#CWE_W#_*BW_X]HO\
M<'\J)_\ CWE_W#_*BW_X]HO]P?RH DHHHH **** "DQSFEHH Y/PN/[&UO5?
M#3<1(YOK ?\ 3"0G<H_W9-P^C+765RGC)&T[[!XF@4F3292;@*.7M7PLH_#A
M_P#@%=1'(LL:R(P9& 96!R"#T- #Z*** "BBB@ HHHH **** "BBB@ HHHH
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M!UM%(#E0000><BC- "T4F?:C- "T4F:,T +129HS0 M%)FC- "T444 %%%%
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M:%7_ )BI/)N?^?L_]^Q1Y-S_ ,_9_P"_8H P)/A_X9+EX-.-G(?X[.:2 _\
MCA%-_P"$.F@Q]A\3Z_; =%:X69?_ "(K']:Z'R;G_G[/_?L4>3<_\_9_[]B@
M#G_[)\76_P T'BBVN<=$N]-'ZE&7^5)YOCJW&6M= O/]R:6 _J&KH?)N?^?L
M_P#?L4Q(KL[M]SCYB!^['(]: .-\2>-O$GAG0+K4KWP@SK"A.^VO5E13V+#
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M7VH2SP6DH9W23S#(!F$+AX,9ZL<^W.<UUODW/_/V?^_8H\FY_P"?L_\ ?L4
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Q 9D# 2(  A$! Q$!_\0
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M, P[$=165>_#'PW=Z=8V*175I#90O;H;6X:-GB<Y='(^\K'DY[DT <F-:\5
MZ5XON))SI+V5M<211S 1ONA8/#Y74R/,T>TXX'>NQ\$:S;7EDVGRZM]NUB'=
M+>YW85V<[@A(P45@4&W@;:U[GP]8W2:7$RLEMIDJ2P6Z'";D7";AW"]0/4 ]
MJIZ%X-TSP_J=S?V;7+23*R*LLFY84:1I"J#' +LQYS0!O2NT:;DB:0Y^ZI /
MZFFV\XN(%E"E0V>&ZC!Q4M5=._X\E_WF_P#0C0!:HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ]=HHHH **** "JNG?\ 'DO^\W_H1JU573O^/)?]YO\ T(T 6J*** "BBB@
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MJ<@* ."?6@#UBBO*/$_C_P 0:5KUO;(UE;2);V4O]GE?,:^>:39(D;Y'"#N
M?>NQT#6;W7?$.LS1.@T2SD%E;X3F:9?]:^?[H)"#MD&@#IJ*** /G+XJ?\E#
MO_\ <B_] %<;79?%3_DH=_\ [D7_ * *XV@ HHHH **** /<O@G_ ,BQ?_\
M7V?_ $%:]-KS+X)_\BQ?_P#7V?\ T%:]-H X7XHKI,^C:?9ZCHCZU=7-X(K&
MR6<PAYBIY9P1@ 9S7+_#2'PS:>(-/>T\+G2M0U#39)HITNGEC;;)MDCPQ/(P
MIS[_ )]7\3[(7N@6H_L?5-0:*Y$B2Z5(%N;5@#B1,]?3'O7+_"FW\(0ZQ*EC
MJ^JWFNPP-$+;5D,<EM%N#,JIC ^8Y.": /7Z*** "BBB@ JKIW_'DO\ O-_Z
M$:M55T[_ (\E_P!YO_0C0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@#V3X&_\ 'IK7_76/_P!!->MUY)\#?^/36O\ KK'_ .@FO6Z
M"BBB@ HHHH **** *NI?\@NZ_P"N+?R-9T/^HC_W%_E6CJ7_ ""[K_KDW\C6
M=#_J(O\ <'\J 'TG7DTO7FC\* "@"@"B@ JSHO\ R!K3_KF*K=JM:-_R!K3_
M *YB@#P#XJ?\E#O_ /<B_P#0!7&UV7Q4_P"2AW_^Y%_Z *XV@ HHHH ****
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M:Z5%Y\GVGR@ETB#R0TD;21J3G.612>F*U]%UB#7=-74+5)%MI'<1,XQYBJQ
M<?[)QD>V* -&JNG?\>2_[S?^A&K55=._X\E_WF_]"- %JBBB@ HHHH ****
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M>E>LT4 >:77@9+?P_P"'["*P+ZTUO!I]QJ,1.+>)8RLDG7&[8713C.7&*O\
M@9_$T>LWUEJEM+!IEO$4AC>%4CB9965$A(Y9/*"$DYY_*N\HH CFA2=-D@RN
M<XR1_*H-,4+81J. "P'_ 'T:MU5T[_CR7_>;_P!"- %JBBB@ HHHH **** "
MBFR,5B=AU )KG[422VD,CW5T6= Q(F/4T :NK:38ZYI=QINI6ZW%G<+MDC;H
M1U_ YYS69X;\%Z'X3$YTFU9);C'FS2R-)(X'0;F).!Z4_P IO^?JZ_[_ #4"
M)_\ GZNO^_QH )/".DSC6Q<0O/\ VS@7AE<DLH7:JK_= '3'0G-/\.^&-/\
M#-O/'9-<2O<2"2:>YE,DDA "C+'T  %,\IO^?FZ_[_&E\IO^?JZ_[_-0!N45
MAB%B?^/JZ_[_ #5>TB1Y=.1I'9V#,NYCDG#$#- 'B7QF_P"1T@_Z\T_]":O.
MZ]$^,W_(Z0?]>:?^A-7G= !1110 4444 >R? W_CTUK_ *ZQ_P#H)KUNO)/@
M;_QZ:U_UUC_]!->MT %%%% !1110 4444 5=2_Y!=U_UR;^1K.A_U$7^XO\
M*M'4O^07=?\ 7)OY&LZ'_41_[@_E0 ^BBDZT +U]:*** #M5G1?^0-:?]<Q5
M;M5K1O\ D#6G_7,4 > ?%3_DH=__ +D7_H KC:[+XJ?\E#O_ /<B_P#0!7&T
M %%%% !1110![E\$_P#D6+__ *^S_P"@K7IM>9?!/_D6+_\ Z^S_ .@K7IM
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M_P @^V_ZY+_*@"Q1110 44=Z* !>HJ?1/^08O^^__H1J <D?6I]$_P"08O\
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M<PD^@R">,UU=SX.\.WFMIK5SHUG+J2$,+AHP6R.A/J1ZUN8H **** "BBB@
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M;>ROF*7DFXXB=P@PSJ-Q 8]2">0* /;T\MT#H 589!QU%4=$_P"08O\ OO\
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MGT:UOXY-0AW!X@I'*XW ,1ABN1D G&>:R?%?AUK[Q)X:U2RL(WN+;44:ZN
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M-:2-<EPLL;*2-HYZ=*]'^TP_\]5_.G2QB6%XR2 ZE2?K57^SD_OM0!=HHHH
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MYCS]W)XY)R#VH ^@L4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !WHHHH **** #O1110 4G\0^E%%  O2@?>-%% "T444 %%%% !
M1110 4444 %%%% !1110 4UNM%% #3T:I!110 GK0*** #UI/3Z444 )_>IJ
4_P"ME_"BB@"7M1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$!] 'T  #__@ '2&E297/_VP!#  ," @(" @," @(#
M P,#! 8$! 0$! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2
M$Q(0$P\0$!#_VP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" -V!5<# 1$
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M+/\ H E\
M
M
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M\
M
M
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M)4DR,I0G<?\ B4 GX
M
M
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M3P9X/> GS0:XMW23;=:SRHY0G)_^90"?0
M
M
M
M     $#53I?:J7513>I4ZJ>97()4J6E+":(T.Y,^Z-7$N/\ H"=IQCX&#FD#
M$2V8,(?A8II3+S2RRE:%%A1&749&"&ERM"%U;83J<MZ9M0DTHRF)^\M^(DKL
M.AYJ$4L^ZY$U9Q_H"V_E,^F#2I26FN43-R$FL94-45"_VS.Y]';XB+<ZO[J2
MR>X@1,[6;4QH_E5\I[)[D4G5L=15P:=+$!/( B-2T<>3=3^LGS@1+ Z7T,5K
M6-PI-<'5%>>/N%S:63LJE!L)9@T.EP<6E.-I1'Y 3OX;BH2EM)-H224I(B(B
MX$0*N0  A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q* 3^
M
M
M
M                          A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q* 3^
M
M
M
M                                            A;6E\U*Z7^6XK\("
MTZ"OFC6V_="?Q* 3^
M
M
M                                              MTPJ.02E]$--)W
M PCR]Z6WXA"%*\Q&8#WI4EQ).(42DJ(C(R/)&0#D             A;6E\U*
MZ7^6XK\("TZ"OFC6V_="?Q* 3^
M
M
M                                                    (L:U+6?3
M=&/L[,ZJ:E-40)I),),,,%%9Q@V5*/#G'H!.F5W/J":TM;>IJFD,*<3,)9*8
MJ+A6B+.VZAM2D[NG>1 AH78?378341;QB[=X+VSV?5;/C5%S FJB5")E;QGO
MATM$?<;!@M,I6T,5#-9775S;+RFO(NN:)HZ*ABDLZB'C?4V;B#-R'-TS/E-D
M]WDP");C @           !"VM+YJ5TO\MQ7X0%IT%?-&MM^Z$_B4 G\
M
M
M
M                     1?>C3[9N],I4Q<FFX);K19:F;:BAXN'/H4A].%%
MCS@F)TUY8I'55IHAUQ-JZF8O7;UI)[<DF#J3F4*T?%++B<F]@NA1@GM/E@U'
M6NT#:EZQBE.2R=T%7$4^:YI2[\>[+'E.G\K#1'LGOZ2X]0'>&[5J+/V\LI2S
M=(6VIYB52U"N4-*#VENK/]9:SWJ/RF"LSMFH            "%M:7S4KI?Y;
MBOP@+3H*^:-;;]T)_$H!/X
M
M
M                                                T(NU)X#4GJZG
M5F+N7,F-*TM3$K;B95)8:+.$*;.*5A3IN9+)$701@M':%AJJW--Z.+NV\C;
MW0FLPB:IFR9;,Z4?F!QC<5"JQETBRHT&G)GT >6W=Y]+UG;ZPN:RI=IN:-$9
MPLV@C.'C(=?0LG$8,S(^@\@B)TM.GFT]Y+01TWIFL[IN5M2:2;*0NQZ"*.A4
M$6]MPR+"BZCR8$S"< 0            A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q
M* 3^
M
M
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MM.*))=QTF(G@LL=T>HHSM"R<0E:>"BR0Y&[D
M X.HY1M3>T:=HC+)<2 :;U'V.@Z@J&9S[X25S8/W1BW(KM=B:FEMK;5G926-
MQ%P(!%.HWL?Y4#8:NZP/4/<B:^Y$F?BR@8Z9FN'B-DL[#B<;TF VDT'N<KI*
MMNO9).90G<7 NZ4 GT                      0E?LB]TY;N_4,>M]._;9
MQ<5YA%V"ZAWN<P74 8+J ,%U &"Z@#!=0!@NH P74 8+J ,%U &"Z@#!=0!@
MNH P74 8+J ,%U &"Z@#!=0!@NH P74 8+J ,%U &"Z@#!=0!@NH P74 8+J
M ,%U &"Z@#!=0!@NH P74 8+J ,%U &"Z@#!=0!@NH P74 8+J ,%U &"Z@#
M!=0!@NH P74 8+J ,%U &"Z@#!=0!@NH P74 8+J ,%U &"Z@#!=0!@NH P7
M4 8+J ,%U &"Z@#!=0!@NH P74 8+J ,%U &"Z@#!=0!@NH P74 8+J ,%U
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M#_\ 4>M]._;9Q<5YA%P[W.
M                                                      [H/^M,
M_P"-/^XF!\[H2Y4@M%J_J6MZF@7HN 8=B&5-LMFM65'N/ \6,L8N)FUGHS2<
MF&*PSN]NKBWEY+>1]O:#H"-F<XFJMEC$,9K8/ODEQR0US\73-2:4KN99XN'M
MBMS6E*^FZBZZLSIM<9B)&N.J9Y*HV&E1JP>WC"4'U'TCHX:E\.#QW^&6:U<F
M3SV1C$2W6M-J8FER:DN+*:15"*6XW)XE26E*063P1&?5Z1A->)FLY+6U_)K$
MX(F*Q&UYMY=F\-^M-=3N2:,@X:JY,IQF(BU))+;\(DN[W=\99%L>7+GP3KS"
M+XZ8LL;\2CK0K*;IQ=0Q\71\UA(6DH6)3SA9=QMN;]QH\V\8\#6\S,UGM[K\
M5-(B(M'?V9S.[OWLU!WCF]M+%SN#IJ1R%;B'HY_&TLT'A1F?^Q#6V;+Q&6:8
M9U$*1CIBI%\G>97ZR]YKI4O>AW3Q?.,A9E&O)S+II#D1;:L9(C,N.2%\.;)3
M+T,O=7+CI:G4QL1JN]UT[I7QGEL:5N+++?2F0N&RA^-(DF^LMV]1F6\9WS9,
MN6:5MRQ"]<=:8XO,;VDBR,3J;DE=Q%,W#BI95U'FD]F?0;R3-!]!ECCGJ&V'
MKUORW[Q\L\O2M7=>T_#83!FK92>3/<0[7,UBU&:AZ\EEP8&QEE(9I=11FQVU
M&.))7)&O@1=6.DQP<3Q%XOTL7EU8<-9KU+^&%576^K32_%RRJ;ESF#J>G8YY
M#,6VC"C;,]QI(_U3\HRM?B.%_5DG<-*UPYXU7M+V:TIG6=9VNDEP*<FD.=MI
MDREQZ$,RY?ML\?7@N GC9M?'%XG]*.&BM;S6W[F?Z/)9>B"HZ"BJUG4'$43$
M2U'N#",XY1D]KBKZAMP<98K$WG]/LRXB:<W;RSW47,:YD=GYU4=N9B4'.I62
M7TKV-K:;_6+'F&W$3:N.9I/>%,,5M>(LBU[4C-W-'S%UH>/;*IWGBE_*[.[E
MLX-6SYQSSQ,^FZD3W:]'_7Y?9UZ;M1-25/92MZEN%,D14[I1DWDN;!(VLEDB
M,@X;B9MBM:_F#-ABMXK7W<]/ES[YU=96JKH1;":EF[T0ING9>2-@L;\&?61!
MP^7+?%;)/?X,U,=<D4\?+"9U"ZSY=0D;=BI[GRF0NPY'$>X;ZTMN;.?DDD]^
M?(,ICB:TG):VOY-(Z,VY(A)UL;YU3<;2]4%Q(]#+-025*X<WB;_1N*27R]D;
MXL]LF";SYAC?%%,L5]F#VUK:]-X=)U23N5SB 1/F8E]$0[R1-H5!)_I$XZS2
M,L=\N;AYF)[M+UICS1$^&)Z!I9=.(G\5'TG,X1BC8:-0F>0SF.4=7OV33TC/
MZ?&3FW7]ONOQ<TUW\^RZZ;B;7K5K@DD>P;<1@O)M'@6X7_Y-E<W^Q5F=O;N5
MW.]8D\MG,8Z%53\(:S;:0P1.$1%GY7$QKCRVMQ,TF>RE\=:X>:/+$)[>VZMW
MKU3ZWE+7*E=O)3(7E0[+D:24F^HCXFHS+>,[9\F7+-*VY8A>,5,=(M,;VE"Q
M<7J8E%:QE,7(>EM4TIR:C8G\(\DS0Y^J>[B1GZ!O@G/%^6_>/ECEZ4QNO:?A
MK#=22WG;U1(ET5.()5:Q#Z52:*3CDVV3/]"2NC)$.#+&2.(U,_J]G72:=+MX
M?0BDH:IX.F)="5O$M1%0M(-,Q>:^0MWI,OKR/9IS16(OY>?;4S/+X:_:S[RU
M[:!^CWJ'F:(9$>K,6TI&URW=8)/DZ!Q\;FOAY9I+?AL=<F^9@-W*OU<6]IJ5
M7PGU62^$E$P<0I,G801DPC!'LJQQR7^XQS7XC'$9;3VGV:8ZX;S..'HJ2M=6
M=>VQ=O\ 22?R^FZ?@FTJ:EC22Y1Y/[0SZ2/J$VOQ.2G6B=017%6_3GO*6K/Z
MB#J'3C$7CK=E';,G)UE_DRV2B7$_(P71M&.C#Q'-@ZEO9CDPZR\E4.T94NL?
M4E"1M?4-4$%3TD;6HH&'41(Y7'!/E/K,<U+<3Q/ZZSJ&]ZX<,\MHVDC2YJ(J
MNN:IF=GKMP;;%5R9"U-Q#:=DGR21D9&77DN(VX7B;9+=/)YAEGPQ6(O3Q*)H
M*]^IBMKL59:2@9M"/12XA;,&ZZ@DE MI/Y6T?FP.>,V?)DG'66TX\5:1>S']
M3M,:@Y%;FGW;RU'!S.7E$&GDVC(UHB,;SSTE@5XFN:M(G+.TX9QS:>2&PMBE
M7UI*QL7.J@9A:BC%R]I=)P#!D1DV>=DE^8AUX.I3%NW?X<^7ISDB([?*,IA
M:TG*,F-T*HN5*J8<A2<?*2/J2VLTI_521GQZBZ1C,<5RSDM;7\FL3AYHK6-_
MS9[::\<_O3I=K6=56RV4VEDO=AGW6T[*7LEN/'F&N+-;/@M-O*F3'&+-$0Q?
M0C%/0-AJ_CX8R)^&CG'6C,LD2B;/&2%. G6&TIXJ/]2L.BP]QKW7ELO<-4JG
M$ BI();K<$]R*6T):(SVR/KRG(C!DRYL5M3W3EK3'>-^$=:+Y)=R9UM.$T!-
MX2!E;+IHGY.XVG#-6"-'F5O&'!QDFT\D]O=KQ,TBL<R9K WGN'&:@:HLO<^;
M(BC;<=]RE&WL&2$<//DAU</FO.:V*[#+CK&.+U<*LO)<BJ-6$!:"WLY1"R&7
M;"YJ7)[1K27](6>C 7S7MQ'3I/9-<=:XN>WEM&Z226:$<$GLD?7CI'>Y'
M            =L)_7H7_ ,='XB$3XDCRVUA_ZNU_@3_L/G)\O5=@@
M  &F%S-/FL6AKC5!=#3I>QJ90D\C%QSM+SU!'#M9QEMI1YP6[=P!;<>%OI_7
M[<6W48B1:I]/M1TLION%SJ6,*B8%9]^9[L$!K?AL[;*_MH+P0C43;VO)5-EN
M(VSAVXA/+H\BD9R1@JD(            !"VM+YJ5TO\ +<5^$!:=!7S1K;?N
MA/XE )_                      $)7[_Z5EW^ _P#U'K?3OVV<7%>81<.]
MS@
M                                 .Z#_K3/^-/^XF!HE:R&EDSUV5!
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M4<VK2_$[8/MJ>QKC<(:B^2A9GMD7F,6X&DVFV:?=7BK:B,<>S:\>BY
M         =L)_7H7_P ='XB$3XDCRVUA_P"KM?X$_P"P^<GR]5V"
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M<
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M++9?2A?.U%\Z7FLZM/2+\A@8&*2Q$-.P/:QK69&9'C!9!64Z@@
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M"G*EIZL9)"5-2<XAYK*HY&W#Q4.LE)474>.!^0:=I[J3$QY7(0@ 5;_IF_\
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MIS!RN 9_I(F*>2VVGSF9X 66BKLVSN.MUNA*[DL]6QO<3 Q:'5)+K,B,!EH
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MG,"U&)+JVDY,O3D%61  "%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
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MF=VE,WC6JPW!(DD2&VT$AMM)(;07!*"W$1>8AJR5
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M&6IV8:40;4(WYD)(L^D%5\  $+:T3QI2NEC^S<7^$!:=!7S1K;?NA/XE )_
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M +D   "%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
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MSD8X[S-II;S"UJQ$1:OB4ID>> V0J
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M,W'KA)0X9]U&-H4:5.'Y,EN\XC'><D3;2;UBDZWW2 -4
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MP0)Y6]]FXRTT\HJ#JRS<'*&I!.D%$-N2UA#2'#Q^L2?UBX&1\ 59V
M      A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q* 3^
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M/#Y(B)W64=LM9F8U,,CH683ZV.KVJ;4SZ=QD9)JSABFDC[9=-26G"+:6VC/
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MJ"21)SUXR.?+^G-6T>[3''-CM5LQ$MDS$.-%P0LTD.MC'AUB%@
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M:>]C>3#2687DH>F(M;](2&JUMR8B4:FFB4:S<0@^HC(@6ENR"H
M "%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X                      BF\
M/_2,#_@,>CP7B7-F\PC\=C-@.H!*U6+KI*$*6HY._A)%DS/9Z"&>;_;E./\
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M&6>K.#$9OU9JU32=4M+9N*<)V*==3P6LS'5,L76"0
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MBO0BWNTB9ZLU]F[\C=C'Z>E$1,4F48Y 0ZGR,M^V;:<Y\N1WUWKNYI\O8)2
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MF&VNGFQ-%:>+<05O:*-3[3!F]%QCJB4[%Q"MZW5GUF8(F=I.!
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MG+ON?)X-SY4) -GW"CZC41[QECI/-.2WNO>T<L4JF,B(B\PV5
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M2U8U$I"988A8=J$A6$,L,(2VTT@L)0@BP1$1>0:Z]E7,$@
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MR;P)G:9P0            A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q* 3^
M                (HO%NCX'"5'W)\",>CP7B7/F\L R?>+]4QV,-F3[Q?JF
M!LR?>+]4P-F3[Q?JF!LR?>+]4P-A;6<[*_5,#89J4>5)69]9I,#9D^\7ZI@;
M,GWB_5,#9D^\7ZI@;,GWB_5,#9D^\7ZI@;,GWB_5,#9D^\7ZI@;,GWB_5,#9
MD^\7ZI@;,GWB_5,#9D^\7ZI@;"-1'DDK(R_NF!L,U'DS2LS/^Z8&S)]XOU3
MV9/O%^J8&S)]XOU3 V9/O%^J8&S)]XOU3 V9/O%^J8&U-Y;R0KU3 VJ:E*/)
MDL_.DP3LR?>+]4P1LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F
M3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR
M?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3
M[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?
M>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[
MQ?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>
M+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q
M?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+
M]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?
MJF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]
M4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?J
MF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4
MP-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF
M!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P-F3[Q?JF!LR?>+]4P
M-F3[Q?JF!LR?>+]4P-N4/M'%L82K^E1^J?60B?![MD&/Z!O_  %_L/$GR[W8
M(         !\R*TNQ<R2:R:S<T56^?GL8@BAJTA8A1% 1,8D_EH/=LKW[SSO
M!;7;NDCW_P#LEV?FKR;^.3^8#4-AM,5<:A*WIN9QNH2VT)1TT8B4H@X>'>)P
MG6L'E1F1GT@B=>R:00            A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q*
M 3^                      ,2K-"%Q$/M-I5NZ2'3A\,K^6/\ ),_L4>@;
M;4T$PTHR23#>3_N@:1[5&H.P-%354BJFYTB@Y@V>'&$N)<-!]1F1[C%9O$=I
ME,4F>^F7TY4=(UG*D3RCYW+9S+W.#\(ZEPB\Y$9X^L6B=QN)1,:\O>I<"AU$
M.M4,3[A;2&347*&77L\<>4!S)I@_^H;]4-FE>29_8-^J&Q:U5'2B:A*D5S:#
M3/E-&^F7F9<J;1<5XXX#<>"([;7,VF/V"/5 TML74=*2^=PE+Q\V@X><S!!N
M0<"LR)Q]/6DND@W'C9K^2Y\DSP-AOU0V:.29_8H] ;-'),_L4>@-FG1'14KE
M<!$S69N0\+!039O1#[F$H:07%1F&_P":8T\LHGU-3V0-57*XZ&7)7FS=1&NX
M;;Y,CP:C-6XB#>^Z)[=M,?I^\%FJLG2J<IFX<@F$S29I*&1$((U&70D\]U]0
MB+1/:)3RS$=X9;%K@)?#/1LP-F'AX=)K><<+"6TEQ,SZ!.T,-5>^PZ2,U74I
M@B(M^8QK=_\ E"O/'R<L_#)H*=TQ,Y+SFE\VE[\F)M3ON@EQ/(;!<5;7#!><
M6B=]R=0L%%7;M-<>.BI70E8RZ;1L'DW8=.$KV2/!J21GE19Z2$1:)\2F:S'L
MN]4572-$R]F:U;,H:6PL2^F%86M.3=>,\$A)=)[R"9B/<B-KN;+1)-1PZ<$G
M;/N=^SC/^PE$ZA:J;J:E:P@7YE2TQAIA#PT0N$?4@L&T^@\*0HN)&1]8B)WW
M@F/E=N29_8-^J)V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S1R3/[%'H#9HY)G
M]BCT!LT<DS^Q1Z V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S1R3/[%'H#9HY)
MG]BCT!LT<DS^Q1Z V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S1R3/[%'H#9HY
M)G]BCT!LT<DS^Q1Z V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S1R3/[%'H#9H
MY)G]BCT!LT<DS^Q1Z V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S1R3/[%'H#9
MHY)G]BCT!LT<DS^Q1Z V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S1R3/[%'H#
M9HY)G]BCT!LT<DS^Q1Z V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S2AM,X_H$
M>J&S3J-^3DHT+F4J0M.XTJBFTJ(^HR,]PC\G94GY0L\-S*5+4?!*(I"E'YB(
M]X?DG4.WD6>EA'JB=FE'$P;+*XF).&AV&RRMUY1-H3YU'N"?DTZX9V63"'[;
MED5 1S&<&["NI=01^4TY(A']"?+KCXR32F%..G$?+I=#$>SRT8\AE!GU$I1D
M0F9T:=S/:42PW%0BX:)AW2VFWF5I<;6762BW&&]#@;\K[;]SBB(,XPD[9PI+
M3RQ)[XT<2+RX!#NY)G]BCT!M.CDF?V*/0&S1R3/[%'H#9HY)G]BCT!LT<DS^
MQ1Z V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S1R3/[%'H#9HY)G]BCT!LT<DS
M^Q1Z V:.29_8H] ;-'),_L4>@-FCDF?V*/0&S1R3/[%'H#9HY)G]@WZH;-."
M^T6W40[BX5#[A&IME2B)Q:2XF2>)EY0@T[$P[:SV4PZ3/J)(@T\[$5)(J+7
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M]O9L^MM32U-+^4@]D_.0T9J
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M)GX.'=C:?6TPA:BP1N+,\)3Y0&S.@YLVM)5MVU&1FF4I+=P^4H!/H
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MN)86+A=T8FI-E"D_*V36G(KD\PM3Q+;F-R<4X9\349GYQJR=(@
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M]D5PY,TIF&G4,3ILJWFRX1%MH/S'N&L3S1MG,:G3)@0
M"3-*B6G&TG>1]1@-4)X:C[)Q *4>3.DW,F?^%(SK&LD::[_TW#70E4+<NPDX
M?/9@8>J6VW5'\DE'M8$Y9U,*XN^VQ]WHJ'A+7UG%Q1)Y!N2/*5M'@L&T>/\
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M;BC5CSC11Q$
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MP3/:&Q.@"O:ZCY'6UF[A3QR>3*VDY.5LS-T\N1,,K:-O:/K(DX MIMF"H
M        "%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
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M0CXGL\.C(T5 2      #G#_UN'_\5'^Y")\2AL>Q_0-_X"_V'B3Y=SL$
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MR(MXFENKFYI[:]BU>GCY8[[;<*,U&9XWGOP.QB@N_M55'6=0R_37;%]Q,[J
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M5, F)3RANX[O)=\:LG]8Z8M2OZ(GPQF+3^J89N:329D98,N@:
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MA?4;]@'Z6Q6EF!U)2^G)M#ZE*FD$XG)12>U%2E232TU@\I7L\#R")3@"
M        $+:TOFI72_RW%?A 6G05\T:VW[H3^)0"?P
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M61Z*(R91EE7FXMYYZ A9U&,RIUU1F:H8G5$6#/B1%C MPO\ MJY]1=/(Z%
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MD2E:D_5Q 92   "%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
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MCV/Z!O\ P%_L/$GR[G8(        $(QUSKZ,:D8&W,+:8G;=/0:GHBI^4/\
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M7@[WJ'[ _)LY57@[WJ'[ _)LY57@[WJ'[ _)LY57@[WJ'[ _)LY57@[WJ'[
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MV)B'J<BD-LM31A:UJV=Q)22LF9]1 /;H*(RTCVV(R,C]R$\2Q^LH!/X
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M9**1/-$L\L1$1478V@8F,4I3[DD9-9JXF8M7]L*S^YG (
M          %MJMQ9474;:5;*52J*VL?K?HE<1/LF(W,-=>QQX+3&G)?_ +P1
M?_J,L7[6F6-RE6^VH*AM/U+-SJKGW8Z9QI\E)I%#=W%1[Y_)2E!;\9Z1>UXK
M&U(K-I[(FL)9BXU>W&^%1J1;2Q4+[)HIFFR/+<GAC+<I1=_C'E%:UF9YK+6F
M(CEJV@,U+4:U&9J4>3/RB[-W03BFX@C0>R9Y+)<<8X9 :C:,RQ?_ %%>6<G^
M)(RI'ZI:W\0G&[MB:&O2B71-1O3&63B3*4J73B61"F(J'SN,B6G>9&70-+5B
MWE2+3"#+CVPIZ1Q=,Z.;1'$]N5O'%.:TFC[QNQ*X%M6TYRSA[^[2>XC&=HB/
MTPO%IG]4O2N^-[9XY5Q:=*:D3- 6D0F6FQ&*(G9GR*<*)&2[C<D]Y<0YIWJ"
M*U\RGZT=QY9=^VLBN3*8<X=F<,J4XP9Y-EU)[*TYZ>Z(QK68M&V<QJ=,N!
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MI;,6(IZ7S2#)6T3,2TLT*P?21F1F-:3S1M6T<LZ2."H      *M_TS?^(O\
M<3'B1)#?R$^8APRZ'(          :TZ@M1NCJFW(^E;K1M.S^:,&IB)E281N
M*BT*Q\DRQDC^L$QOV:(5G2]&71F!QNC739<FFYN2]I$Y;<?A(,SS\HT$O9P"
MVM>6_6B:DM2E(6WB9?J2J!J9S-3Z52\B62W&6-G>E9XWGD%9;%@@
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M*)/"4Y));3< 1%#2J$;A6\=24D1_ZY&DQJ-*>>[UB$
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M%HMY3_8JV)69M'3UME1:8J(EC2UQ3Z?DK?<5MKQY",S&E:\L:4F=SMG8E4
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MD")AL("            $+:TOFI72_P MQ7X0%IT%?-&MM^Z$_B4 G\
M                8G6)D42QD^@QT8O#*_EC^2ZR&RADNL@ E%UEZ0#)=9 &
M4]9 &T760!DNL@#)=9 &T760!DNL@#)=9 &2ZR ,EUEZ0#)=9 &2ZR ,EUD
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M:4O)]9GD )U:2V4NJ(CXD2L"!3)=9"0R760!DNL@#)=9 &2ZR ,EUD 9+K(
MR760!DNL@#)=9 &2ZR ,EUD $HN.?]0%>4/]H?K !K,^*\^<P#E#_:'ZP :S
M/BO/G,!3:W8VMW5D!5*]C>E9D?61X 4-1*/)GD^LS "5@\I5@RZ2, VLGDU9
M/RF Y<JO9V.55L]6UN] #CDNL@#)=9 &2ZR ,EUD 9+K( R760!DNL@#)=9
M&2ZR ,EUD 9+K( R760!DNL@#)=9 &2ZR 5)>#RE>#ZR/  :S4>5*R?69@*$
MK9,C2>#+I(P%36:MZUF9^4\@*$K!8)6,^4 R760!M$18)6[JR 9+K(!53AJ^
M4K.-Q9/@ )=4CY#JDYX[*L *;1&>34 9+K( R760!DNL@#)=9 &2ZR ,EUD
MJV9<LWO+Y1?[B8\2));^0GS$."70Y          #3*XVC*_5[+DSZ:7#U*3B
M6T-$QRU2R0R51M*9A=V$J5C&>(+1.F=6R['QICMJZF/31!5!,R,E''SEU40[
MM=>\\?Z C<MAY7*99)8-$!*)?#P<,V6$-,-DA)%YB!#V             (6U
MI?-2NE_EN*_" M.@KYHUMOW0G\2@$_@                     #R1LK@9@
MI*XIDEFGAD6K>:^$36)\O-S;E'@B1;JV^4<L'-N4>")#JV^3E@YMRCP1(=6W
MR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N
M4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#J
MV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@Y
MMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(
M=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L
M'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>"
M)#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3
ME@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRC
MP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6W
MR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N
M4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#J
MV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@Y
MMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(
M=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L
M'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>"
M)#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3
ME@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRC
MP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6W
MR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N
M4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#J
MV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@Y
MMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(
M=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L
M'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>"
M)#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3
ME@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRC
MP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6W
MR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N4>")#JV^3E@YMRCP1(=6WR<L'-N
M4>")#JV^3E@*G)0DR44(G)'D.K8Y87,B(BP70,UE0        &#R>\UO)Y<V
M:V?EL[Y6J9+"IC(V"Y-1<FT9X)6UPX@,DE534]/(R-E\GG4'&1,M=-B,:9>)
M:F'"XI61?)/R& N@               (6UI?-2NE_EN*_" M.@KYHUMOW0G\
M2@$_@
M
M
M                              #2.^FF[4O2VI"(U':6YE)'X^>R\I?-
MX";&1(,B5DC+/$@6B8\2U^T_Q&O5BX5UG;7R:E_=QZ?K75!3#9)KM[IY SW&
MGS GLG IGV6#Z$M_Z[8(_2V%TQQ.IJ)IN9*U-P<CAYP42GM$I4:30;.#SM8Z
M<X!$IH!            "%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
M
M
M
M                    -(;U:D;PU)>6:Z?]&M$2MVH9<9.U-4<4RE,/!NGN
MV5GC"E>4]X)TQF92KLK-MX)ZKWJII"LF(,N7B)0RVDG'D%O-*-W'S =FT&EC
M47*=2=M&JPAY<N53B">5 SF5N9VX.+0>%(//1DCP!,:3("            $+
M:TOFI72_RW%?A 6G05\T:VW[H3^)0"?P
M
M
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M.XB(CR9@/1H*(RTCVV(RQ_[(3^)0"?P
M
M
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M:35@_K ;$:#G%.Z2K;N*XJE"3/UE )]
M
M
M                                                          !X
M)Q/9+3\&J83Z;0<NA4\7HM]+2"^M1D0"T2:Y5 5!*'9_)ZPE,5+6'BAW(M$6
M@V4N&>"2:\XSD!DB%H<0EQM:5I61*2I)Y(R/@9& Y             (6UI?-
M2NE_EN*_" M.@KYHUMOW0G\2@$_@
M
M
M                                                     "AX(LF
M^>C%MH[7QJ N _=&J)K#VSMS,'))+Y#+HE3!1D0CY3SAD"WB'CTAZ?:.NUIZ
MN[86+B(Z6R5NLHIF"?AGC2^PIAPS:4:OUL&19ZP)2]V/2N:[B*<K2RUPIVY.
MIA;&<'*6)BX9FN(ACVN3VC/?DB3C>");= @           !"VM+YJ5TO\MQ7
MX0%IT%?-&MM^Z$_B4 G\
M
M
M                                               &@M?2&_.C&^56
M7;M;;^)N#;FX#JHV;R>"_K4!&'O4X@B_5_W!;S&D)Z=]3]YK8R>N*7MWINJF
M<U/5\^BYM!*=AE(8@C>49D3AXWDG/^@)F&ZVB*P-6V6H&:SNYD:W$UQ6\P5.
M9X;9Y0TXHS-+9'_=)6 5F6R (            0MK2^:E=+_+<5^$!:=!7S1K
M;?NA/XE )_
M
M
M                                     !I8U>?4/?\ U23&BK,S&!D-
MN+;QY0E1QKZ"6N:/$?=LHR71Y 3KLFC4O;R]%4T2VG3M64%2-30<045RRH=.
MS%)3OY)1XW$KA]8(671KJ'J&^U%3675_)T2NMZ-CU2B?0[?]&IY.2)Q/D5LF
M8)F--A00            A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q* 3^
M
M
M
M                   *'@RW@/G:BZ$VT ZB*^1<6D)M'6UN+,%3N73J 8-U
M,)$+/NT.8Z"(%OW0D>I^RI::Y;)UOTF_.*EFSC9]JRV"@7#<==,NY2>2W;^(
M'+*]=C_MO<"24W5]WKG2@Y/.[F3<YO[F*(R7"PY;7)DKRF2@1+;($
M     (6UI?-2NE_EN*_" M.@KYHUMOW0G\2@$_@
M
M
M
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M^$!:=!7S1K;?NA/XE )_
M
M
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ME_\ 5YQ!-1:"ZB4DCQZ057X  0MK2^:E=+_+<5^$!:=!7S1K;?NA/XE )_
M
M
M
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M[(L31Z0:^-W9W0B-G:[[;+ (CRR_1OVW\%ZVW;V>7]P6-O\ U E,AF1%DSW
MA8G*ZHMEQ;+U5RE#C:C2M*HM!&DRXD99 0UK(K.D8W2S<^&A*HE;KKE.124H
M1%(4:CV=Q$1'Q =F@K=I'MMG=_[(3^)0"?P
M
M
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MQ\P'F%NU::D)!K E$HTT::RBZGBZECF')Q,F&5%"P,&E1&K;7T'N B-=V_%
MTG!T)1<EHZ /,/)X)J$0?7LI(C/TY!5?'6TNMJ:7G961I/!]!@-3Y]V,K354
M<]F%0S(JM[;F<2Y%O\G/XA"=M9Y/!$>"+(")M2W8Y=.MN[ U[6]/IJGW3DLE
M?C(4XB>ONMDX@LEM(,\*+R& V/T'.*=TE6W<5Q5*4F?K* 3Z
M
M
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MTS^Y%Z:/MA/:5IF>]M/S2L9BF6RV&A6^46:S(^[470@L;S!#/BWD1F0"H
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M7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
M
M
M     .B.?=AH-^(984\XTVI:&T\5F19))>4P&I%'P&EC71*9A4=:T#"RZK)/
M&/2V9PCSQP<QA5H6:4J4:#2HR,BR1[P3X87;:1Q^GW56W8:UEQYK5%(U)3\5
M&QLGBHDXE4C>)"^36ES)F1&9)+!GG>"?,;EB&CR07WCZ2JIJ@KLR&0Q<+54:
M<YE\:PE44B()6]3AJ+:,C+&,[N($Z23ISLM3U4TG>VCW+K2ZM5U=$Q$-,VX)
MO9A8&/4E1+-!$1)R2C(\EU B9152563B]LEM;H[F+KKLYI*?N.5:TOHELO>V
M64J\BT8/?QP"?'=E5=2FX;FOV:0-*5E+*4CU4HAJ0N3)HE-N0R22E;;&T1D1
MD9=&_! >S**>H&I&M6M&3VY]_)+,ZQELKB.1DLM:)+T7!FE7]*:4\-K>63!'
MMV7O0?)()$BO'-9=!,>ZD96\R+EMA)K-1(3L)VN.",P39#^E"G[Y3!-Q6:#N
MM(Z?F;%8QQSB7QS"519.[6Y:C46T:#Z.CB!.DVZ+*/@*=KRZDS:NY+JQF<PF
M#)3=B6H),/!1:25M$6").3WYP")9CKCH>*J^P<UG$K1F;4B\U4$O,BRHGF#S
MNZMQF!#4>KX]&HF3UGJQD+JG56S1 ,2-Q.\SV$-'$X/R*V\@GQV2/;6:S&^T
MJOUJ2I@W'?=*1N4W3RTEW9PK3)+<-!_XC46X#PF'1=.K9-Z1*3.#B)8S+H64
M+1.6W=A)I>3M<N3Y'Q5UYX@B?+3U,%#S/1//T<G_ /9B:WD0<F;66&U0:HS]
M0C_4,N'0"WNW&U0T?9^>6.I^DKC565&P3T;+VY+-&&BQ"S!*?T!XQLXSU[@5
MA#M05SJ"TZ3BC7[WS&C[L4;&SN'E\#,$-)*;0;RRPV^VA*=DSP6\R!/GPQ^C
M9'=J/U?WLAJ+N+*::GKL4R^VW,FDJ=B(%2$&E31J(SV"/!&1=)&![,SME14=
M*]1%?U/5=[I/4E9)HM</-)-*VR2E#)(5R;CNR1%MYZSR"/9D?8_Y5*H72U,W
MH:!AR5&S6;+B5$VG+IF?ZQ]/U@6\M<Y<I!=C^F;:30335T7TH26"2@NVSW%T
M$"WNGB=2F63?799LIC"LQ':=N8B)8)Q)*V'"4G"BST^4$>SW7G2AK7U:=R')
MMN(?IZ.;VR(B4O>YLD9\3+. (\&@&:4Y**9N-(9]%0L'5D#5T<J?HBUI0^I1
MXV5JVMZD8X'O+B!/=;]"$=3$UNW?B8T8J'5*'JG<-E<.DDM*5M'DTXZ )29K
MV5LZ6*VR9$7:A9SYP1'E#.H26RZ=2/2G+9JRV_"N3>2&IIPB4E?_  Z-QD>X
MR!,)6UA7*EM!M4%2$JH&25!5-3SYN#IY,W+8@(&)V3P^X9%@MDBW B&M6L"#
MO1+Y-0#EY[G4]'/1=5PA0LDE39;!J):>Z2LR)9$1;L@F$WD:?A\U.62S[V['
M3O\ UP)\(*8=;;['U63IK+817L4:E="2*)3DS!/NGW4U1$16.E>F:\I,VHB>
MV_AY=4TM=842E*.':2I2$F7671Y 5CRL%D*F@]5>IEN\L*7;=-6]I]B6P9K+
MN3FCZ$N.K+^\D]I/U F>S=$%0   &JNH&^&L&AKC*D%G-/$/5].E#)<3,EOF
MDS=,]Z<9($Q$('F6OW6+ 5TW:R)TS2UZJWFB>.5LO..+0V?!2S(S2DO/@%M1
MY9!4>J?7M0TFB*GG6CV60\#"(-U]UAXUK0@N)[*5&H$:A/VB^_EQM1=N8JOJ
M\HZ D+2XKD8 H1XU\JE.=O:(S,TF1[L'@$3&FP@(            0MK2^:E=
M+_+<5^$!:=!7S1K;?NA/XE )_
M
M
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M"VM+YJ5TO\MQ7X0%IT%?-&MM^Z$_B4 G\
M
M
M                         ! ^IK5U0>F:&@&9]+HN<3B9=W#2R#,DNK:S
M@UY,L8SN'J_3/I.;ZGN:3J(]Y<'&<?3@]1,;F?9Z-,6J"4:F9+-)S*:.F]/I
ME41VNIN8$6TX?66XMPK]2^F6^G6BLVB=_#3A>*]3$[KK2<!YCK
M!P6TTX9&XVE1EPR1& Y$1$6" 5       !Q4A*\;22/'#) .0      PI^\M
MM(:XS%IGZL@459$M&^U+#67++019R1>8@&M.J**T!7?G[]-WKK.2P=3T^ZJ%
M7%,190\;#++]0UEOP748)C?L@:3V,[&/!S%F,G]_HRHH9A9+1 Q\\-3.[@1I
MZ2\@+;LW]L=7UF:SI)$#9";RF+D,DV81+4MQR3&[<G!>0@42.
M  A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q* 3^
M
M
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MJA8%+AY6F':2@E'UG@A\E?)?)^^=O>K2M/VQI<!58
M          8+$62MC%7,8O!$4I"+JZ%9-AF9FG]*E!EC!'Z0&K5[H'0C+=0$
M%;ZK+7P]37"K.+Y:+3!0O+&PI9XY1]1?(R"8V[-1ME-&VFRDH6M)_IN*>2]V
M*2Q$>YL)RBH9L^+JB+H(@-RG;2U)]/K-N&JFTYR^7PU.SU11"^U"QEPBQLK+
MH46<&0$[]TR@@           !"VM+YJ5TO\ +<5^$!:=!7S1K;?NA/XE )_
M
M
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MZ:"RI1^<]^/(.;BN-S\9.\UMM</#8^'[8XTSH<SH
M                      !0^!XX@-$M&G,]K5-?F#KIN$.X2J@6[#*C22;J
MI?G]'R.UP+_""T^&[<^53JI1%*J7M%<M0TI43VWL&T39%W1JVMV, JTU[&PJ
M7.1UY'J,VBH==5K.1DG/(XROE3;Z-G.. +6;N@J            A;6E\U*Z7
M^6XK\("TZ"OFC6V_="?Q* 3^
M
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M&(]DWG#6HS/>>3,QIGS6XB\Y+^5,.*N&O)7PR 9-
M                         !K%J@T8VDO=/8:OHRK(JA:QAF^3;GDNBDP[
MCJ"X)<R9;1$"8E!B- :JD<;EER]9\XG$@3W+D$S-&T&\CO%'M<#Z03O7B&[%
MG*%MI;.AH"A;5-2]J22I')I3"/)=RL^*EJ29Y49[SR"K.             $+
M:TOFI72_RW%?A 6G05\T:VW[H3^)0"?P
M
M                                 !Q)23,TDHC,N)9 4<=::3M.N)07
M6HR(@B$;TX=NP?A;/VA"=2;@[=@_"V?M"#4FX.W8/PMG[0@U)N#MV#\+9^T(
M-2;AR;?8=/#3[:S+B25$8C4D3$L9IZNX6H*LGE*-2^(9=DA-FMYQ.$.;>?DG
MY,#?+@G'CKDWY94S1>\TUX:9UYV.RZ-6UQ/JJ@M0DW@8>;1SL6U"H?=(F4K4
M9D@L'C=P'TF#_$&#%BKCG%$ZC7L\C+]+R7O-HMY_J\$@[%_/8FIY3&7*O''U
M+)(&(2\] OK6LUD1YP1JX"^3_$U8I,8<?+:?=6OT>W-$WMV_+?*"IV1R^#AX
M"%E,(EF&:0RV7(IW)26"Z.HA\I;):UIM,^7N12M8U$._W'E/T7"?8)]@CGM\
MIY:_#MAX.$A",H6&99)7'DT$G/H$3,SY3%8CP[%MMN8Y1M*MD\EDLX,1_0ER
M,B,L&0)>0Y1*C,U'+(0S/>9\@G/^PMSV^5>6OP>X\I^BX3[!/L#GM\G+7X/<
M>4_1<)]@GV!SV^3EK\'N/*?HN$^P3[ Y[?)RU^ I3*B,E%+(4C+>1\BG)'Z
MY[?)RU^'K(B(L$0JLHAMMO.PA*<GD\%C)@B'!V&AWUH<>AVG%MGE"E)(S2?D
MSP")F.T$Q$NT$@
M     *&>"R ^:T@LO-M=^HRZ,QNM7L^E]*T+-5R262:711LF6R>]2\ M/:.R
M5"[$YIO(B+W:K+=_\76".:4\Z=-,M Z9*?F-.4!%S9^&F<042\J811OK)1%C
M<9\"W@3.TN@@         4,\;S 6MRJ:8:6IMVHY6E:#-*DJC&R,CZC+("&=
M9524[%:5[H,0U02QUQ=.11)0B+;,S/9X$1'Q =>@HC+2/;;/T0G\2@$_@
M
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M3^W"P[3JWVV&TN.?+4E)$:O.?2/(F9GM+T(B([NX$@
M                                                      #YNUX>
MKRV&J*M;B6 L:3<FF[W:\P9B(A*X>;FD\E%(26-A9]8+=M=V6%J=[(5NSI;@
M_P"+(#4-BM+UQ+Z7$IJ9S"^EN&:/F,/$DW"0[;I+)UO!Y5Z01*; 0
M  .#B$NMJ;49X41EN :?U!V+VPM2U!,ZCCJNN$W$S6+<C'D,S]2$)6M63));
M.XLGN 11J0[&S8ZW%A:ZKB3537T1'223/QL.W%SU3K*EH+)$M!IPHO( V=T'
MN*>TE6W<41$:I0D]W#Y2@$^@
M
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MMM1LJH>G4NE+I1#IAV"=5M*V2ZS\X^4XC/;B<MLM_,O:PXJX*1CKXAD8R:J
M*@
M                      (1CZMU&-ZD8&EX.C)<NUKD(I<3-C=+ET/8/!$7
M'C@!#=SKK]D,E-QJ@EEO+-4],:8AHU;<JBWHE*7'F"QLJ476"8TQDKS=D^SO
ML/3'\8D$ZAL;I?JS435E-3.*U$T9+J=FC42E$$S!N$M+C6#R9XZ<@B4U@@
M         !"VM+YJ5TO\MQ7X0%IT%?-&MM^Z$_B4 G\
M
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MV6K3],5MW>N DLHE:U.2V5PL*IPB)9LLI0:O/@A6U[6[6G:U:5KXA[A58
M
M                                          0MK2^:E=+_ "W%?A 6
MG05\T:VW[H3^)0"?P
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M#*6R(DI+ZN(^=R9KY;S>T]Y>K3'2E8K6.T+P18W$6X9M%0
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M?Y;BOP@+3H*^:-;;]T)_$H!/X
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MI745=*!GFKJ:)<D4H8+98941(?+/R"06XCZ3/&1Z^3ZOP7T_AYI]/C]4N"G
MY^)RQ;B)GM_^]M-@5=C9TF*4:DV^V2/H[87N'D?YAX_[O^GH_P -P_S_ +RI
M\6OI._L"?\0OVA_F'CON_P"C^&X?Y_WE,EG[&VVL53ZJ;MQ3S4NA5N&ZM7RG
M%F?6L]YEY!YO%\=FXZ_/FG;IP</3AXF*>Z0!RMP
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M& 1+S=C<5 Q\VO1/Z194W1TPJQ:I.:4F3*\&LG%-]&,XX FS=P%0
M   $+:TOFI72_P MQ7X0%IT%?-&MM^Z$_B4 G\
M
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MHJ10DGEC2U.(A85&RVE2MYGCRCR\V?)Q%N?+.Y=V+%3#7DI&H7W&1DT5
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MTO\ +<5^$!:=!7S1K;?NA/XE )_
M                                                      !P6M#:
M%..+)*4D9J49X(B+I,P)EKG8?58_>R^%?V]@*=<8D=*+3#0L>DR6A]U*C)Q6
MV6XR/H(>QQWTN."X7'EF?U6\P\[AN-GB,UJ:_3'C_P!)FIZ@)33=6U)6,&]$
M*C*G5#KBDK7E"390:4[)=&X]X\W)Q%LN.N*?%=_]NNF&*7M>/=B&HK3I1VI6
MD(.BZTF$QA(2"C4QS:X%W86;B2,L&?5O'1]/^H9/IV2<F.(G<:[J<3PU>)B*
MS.M.RQ6G*VNG^DDTM1DJ2X:S-43'1*"7$1)YW<HKIP''?4<_'Y.IDG\>T(X;
MA,?"UU2/*4D(0V@D-I)*2+!$DL$0X75X<@                     !3.0%
M0%,EU@*@*9+K 5 4R76 9+K 5  %,EU@*@*9+K 5                 4R7
M6 J  .*4I26$D1>8@ DH(L$1$74 ;*23LX+'#& %&V66C,VFD(,^.RDB %H;
M=3LN(2LNI19( 2AM&-E"2QN+!8P0"BV67#(W&D+,N&TDC <C2G&R:2QU8 5P
M6,8W< '!+#+9F:&D),RWX219 <C;;-.P:$FGJ,MP!R;9HV#;3L][C< (:;:+
M9;;2@NI)8 <@''922C422SU]( 24D9F22(SXGCB HXTVZ6'&TK(NA19 52E*
M4[*4D1%T$6X!5*226$D1%Y '!3#*E\HIE!J[XTED!S-)*(R,LD?$C <4-,M9
MY-I",\=E)$ J24D9JV2R?21 &RG)GLED]V< ')HQL["<=6 %5)2HL*21EY2
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M?2X23\NR9@+@   "%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
M
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MUI?-2NE_EN*_" M.@KYHUMOW0G\2@$_@
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M>D3GCNEYEEN':0PRDDH;22$I+H(BP1#S)G<NMV
M
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MN@K):1K;9+_LA/XE )_
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MNY,?.H2.0XE$&\LU(1M+VBX]0[^.^H8N*Q5QUI$3'NY^'X:V*\VM;:=!Y+L
M
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MET\31583^LHYA,:]+T*4Q!09+(U*<69$1'@@(C7EO-;>CX>W]!R"BH0\M2:
M9A"/K-*=_P#KD%60N()QM39F>%),MWE ::5%V+6R-2U%-*DC:TK=$1-8MR,=
M0U-5I0E2U9,DD1[BR8"*M1O8TK,VXL37-=2BL*S=C9')GXV'1$31;C2EH+)$
MI)G@R ;3:#G%.Z2K;N+QE4H29X_Q* 3Z
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MTG'BMJ)1DX;'EMS7CND"%AV82&:A&$[+;#:6T)ZDI+!?Z#BM.YF9=$1J'<
M
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M0&:    A;6E\U*Z7^6XK\("TZ"OFC6V_="?Q* 3^
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M0E!;*$D1%T$6 !*$),U)01&?$R+B Y
M
M                    #4W41*M?47<A;VGZ;4Q#TGVLDDHCS3RO+9WYR?#
M)C7NC3W![+-]/T/Z4>T%MU/<'LLV?^GZ(]*/:".S8_2U!:FX*FIHC4Y'2>)G
M"HE)P*I;C8)G!YVL=.< B=>R;@0            A;6E\U*Z7^6XK\("TZ"OF
MC6V_="?Q* 3^
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MD)0E)$1$DL$1%P(>(]*',        !P2\TI6PEU!JZB/> JMQMLLK<2G_$>
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MX7JEJ8D]&R*$IR00_:\!!(Y-EO.=DNH99LMLUYO>>\K4I&.O+5=QFN
M                                                          H
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MFB9G/IM(&HVI( H2-4M1+:(L8(N "_@
M#3&YE%=DDC;B5#&6WN+2,)2CT:M4H8B6D&ZW#_JDHSZ03&O=A-1TUV5^GY+%
M3F&KBD)JJ$:4Z<(PRCE7"(LF2"Z5>0#LFW0C<.YUSK81U372KR!G\T..5#*A
MF(5,.[+EMY)QEU!'QVNOJ F-2V7!            "%M:7S4KI?Y;BOP@+3H*
M^:-;;]T)_$H!/X
M     .MYYJ';6^^XE#:$FM:E'@DD7$S,(B9[03.O+5ZI^R1:8*4J.8TQ,:DF
M+L5+'U0[JX>!4XTI23P>RHCP9>4>YC_P[QN6D7B([_S>9;ZK@K,QJ9_I"V_&
MA:4_[03C[N5[1I_EKCOB/[H_B^#XG^Q\:%I3_M!./NY7M#_+7'?$?W/XO@^)
M_LB;4GV0FCKGT'[V>G2,G455-2NI@4NHA%-K80O<HTE^L>#,=_T[Z!DX;+UN
M,U%:]W+Q?U.,M.3#$]_Q_P#NVV^F&U$?9VRE/4+.ILY,XV'AB<B7G2WFM>\T
M[^K(^?\ J?%1Q?$VRUC4/4X3#T<45E*4+!PD$UR,'#-,-Y-6PVDDED^)X(<$
MS-IW:73$17M#O!(      (MJ[4?;&B:ZA[=3V8Q*)S$K;;0VA@U)ROY)&H=^
M'Z9Q&?#.:L?IAS7XK%COT[3W9?7%=T_;VEXFL*D><:ET(@ENK;1M*(C\@YL&
M"_$Y(Q8_,M<F2N*O/;PMMK;N4;>"31$^HN*>?A(9[M=Q3K9H,EXSC!C3B^#R
M\%:*98[JX<],\;HQY_4'2;EUEV>@9?,XJ;((RB'68<U-,>52N@AM'T[)'#^I
MM,1"D\37J]*([L<H'3W65(W8B+@3&Z$?,Y<ZZ^M,L<SR:2<X%]0WXCZEBS<-
MT:XXB>W=GBX6^/+S\VX^&07^L_4UW95 2^FZZBZ9<A'#6MV',\N$>-QX&/T[
MC<?!VFV2G-MIQ."V:(BMM,SH:EX^E**@:8F,Y=F,5"PYLKC'/E+,\]T8Y<^6
M,N6<E8U$^S7'2:4BLSM&-HK UC;NOIA5LZN;'SR#C$+2W O&>PV:EF9&7F+<
M._C/J.+B<,8J8XB8]W/@X:V*\VFVWOOY9&JKN/2MRG+AQM-% &9N%#F?Z7/7
M@4^G\=CX/<7I%MIXGA[9]<MM)!D],Q\MH.'I)^;N/QC,M[25'*^6I>QL\IY\
M[QQ7RUMFG+$:C>]-ZTF*<N_9&5C["5A:RI9C/*@N7'5"Q&(-+<._G9;/K+([
M^.^H8N+QQ2E(KIS\/PU\-IFUMIQ'E.P
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MMQ\2ZC 2-!0C,O@V8&&(R:803:",\G@BP0#O
M                     :LU[V2/3/;BMYU;^IIW-6YM(8I4'&(;@%+2EQ/'
M"ND@3$3+'(SLK>E*'@WHB&FL\B76T&I#*)<K:<5C<DO.">5Y>QK2:K(^47'N
M_/:?B)'+;@U"J9RJ!>1L&EDC5W>R?#.T")ENF"            $+:TOFI72_
MRW%?A 6G05\T:VW[H3^)0"?P
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M=J:1R21$1*4]VX1=!F%LV2U(QS/:"*5BW-$=UY&:X
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M\M:4^<\ *D9&62/) *@ "F2+B8"H"F2SC)9 5
M                  :<ZA=2VBZT%>15.5G1D%4=6/&;T<Q+I2B*?0L_VIXX
M@F(F4:PFO'1A!/IB(;3S.$.I/<?-EL\']9 G4MK--&I"AM1M,1TZH.G9M)X&
M4OIA38F$)VN>3(S+83PQN!$QI,@(            0MK2^:E=+_+<5^$!:=!7
MS1K;?NA/XE )_
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M;A(9*E+,DEO4HSR9F?$Q.;/?B+<V2=RBF.N.-5A?ADN
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MO\MQ7X0%IT%?-&MM^Z$_B4 G\
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MMMQ/NICB>(K$Y:Z2XVVVRVAII!)0@B2E)%N(BZ!YN]]W5X<P
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M+.<UQ2\T]U)VJ,>E%/;?:LKBE&?*MEM9(NC<0*S.VU0(
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MD R1"$MH2A!$24D1$1=! .0
M
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M9"(6ZM\OUT9(]C!\,#S>/^K\1QN2;<TQ7XB?9U\-]/Q8([QNWRG8>6[@
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M"4D22+R ,<3;RDTU&JJCEI*F*\Y<4HS(SZ]G@ R0MQ *@
M
M                                        UIK?LANF2WM93BA*GJ]Z
M'F\CB50D8T4,HR0XGB6>GB"=2QV-[*)I+A()^+;K",B%M(-:66H-1K<,OU2+
MK!/+*P=C1@JBG$JN9=F,D43)I%752+F$FA'D;!\D1JRO9Z,Y($2W7!
M      "%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
M   -3M76M-FS<7#VUMA+3J"X$R4DF(9I.VVP6=Y+QOR?4/?^D_1O61.?/.L<
M/+XWZA&">GC[V0)+[":Q=8U3IG%]YS,;>2F2M$F#9ALM*<-PLF:"2?=<-YJX
M#UK<?].^D8^7A8B]I\N".&XKCK[RSJ(^8_\ Z9[2O8LZ:A:JETUN!=">5=)X
M)SE%RR-6>P[@\D1GG)?4.3+_ (GO..:XJ169]W13Z/$6B;6W']F\LNE\'*8"
M&E<N82Q"PC26&6D\$(26"(OJ(A\M:TVF;6\R]JL16-0].!"50    %#,BXF
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MN)@&2ZR <7'&V&U/.K)"$$:E*,]Q$72 C>J;W224Q+4'(&/=AQ6>4Y#)DGT
M+2Q?B8/1++"J-BTDZLD;6RK=D!+S+G*LH=,L;:25CJR0"):KJ>X%2U1$TA1\
M(<![GKVEQ:LX66/+NP \W-"^G]J84_K 2#04NJJ6R4X>KX]N+C>54HEHX;'0
M0"T5%9RDZFFKDVC^V">=^5APS(!;?@^T1UQ/K@+K2UHJ8I*<)G4L-_ETH-!;
M2LE@!F$R@&9I OR^(SR40@T+QQP8".4Z?*'26".*W?WP%?@^T1UQ/K@,OHZC
M951$L5*Y0;G(J6:^[/)Y,!UUG0TGKF$9@YP;FPPYRB=A6-X"STY9NCZ:F:9K
M"L+>=2G"2=/:(OJ,!FS<-#-*VVX=M"N&4H(C <S(E$:5$1D9;R,@'5VE!>",
M_9D =I0?@C/V9 .QMIIHMEII*"XX26" '&6GL$ZTA>#R6TG.# <N&X@%0
M
M
M8+>"]%N[%4?$UO<FH6)7+V",D;:LN/KQN0A/%2C 8%;Z@]-.HBEH.\T!:^41
MB:H2<:I^-@L/K49[S7GIW E$EW+A:)=.UW)-;>O;12V5NS-E+Z9S[FDJ#A]K
MY)+5C<8'EM_3<5((Z1P,92SD&Y*7V$N0BX0DDRILRRDT[.[& 0N8
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M-D!D/:T-Q[7;]0@'9PW$ XDVVE1K2VDE'Q,BWF Y@
M
M        ZHF)8@X=V+B7"0TR@UK6?!*2+)F T[GG95]+4BG4=)(B;3)UR B%
MPRUMPYFE2D*,C,O)D@'B^-LTI_2,V_A3 /C;-*?TC-OX4P#XVS2G](S;^%,
M^-LTI_2,V_A3 /C;-*?TC-OX4P#XVS2G](S;^%, ^-LTI_2,V_A3 /C;-*?T
MC-OX4P#XVS2G](S;^%, ^-LTI_2,V_A3 /C;-*?TC-OX4P#XVS2G](S;^%,
M^-LTI_2,V_A3 /C;-*?TC-OX4P#XVS2G](S;^%, ^-LTI_2,V_A3 /C;-*?T
MC-OX4P#XVS2G](S;^%, ^-LTI_2,V_A3 /C;-*?TC-OX4P$W:<]6=I=4$/-G
MK:3")=<DBT)BV8AHT*02\[*NHR/!@)H
M?/ROJ-@M4O9#5V\N&DXND+:R5$Q1*5K/D8I]2\;2T]/$@6\0WVDTEE-/2R'D
MLCES$# PB";8AV$$A#:2X$1$"K$+OV4MW>^DHZD:^IN"F+$6PMI#SK1&ZPHR
MP2T*XD9'O :Q=C)G-0RJFKAV4G4S=CX:W51.2^7O.*VE<@I2C).?)L@M;LW9
M!4           !"VM+YJ5TO\MQ7X0%IT%?-&MM^Z$_B4 G\
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MAA-.0:B06,J1DS\I@/3"T/2,%$MQD+((-IYH]I"TMX-)^0!?0%,$7 @%0
M
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M6V (            0MK2^:E=+_+<5^$!:=!7S1K;?NA/XE )_
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M5YS 7@
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M2W$"=RR^TVB/339B.3-:+MM E'MF1HBHW_B74'UI4LMQ@;F4ZD6-Q A4
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M)_+GQVGB*6B\:\PMM@=.U Z<Z;BZ:H5$4MN-B51+[\6YRCSBCZ#4>\R%^/\
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MZS/I,!=@
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MJ#C&'R2>#-IPEX/Z@'H   !"VM+YJ5TO\MQ7X0%IT%?-&MM^Z$_B4 G\
M   & WRE-QY[:Z?22U$1!,5+'0QP\([&.&AM!*W*/:+>1X,\&.K@;8<>>M^(
M_;#GXJN2^*:X?,M:K/=C-LU+:*AO?ID)5'5\2HWIA&%&.;.V9YPDR,L^<^(]
MKC/\2<1;+/I9Y:>W9P</]+I7'$9IG?\ *99LKL;ND5231[VIEG=DHUTC_P!Q
MS?YA^H??_P!0W_AF#^?]Y3[1-#4I;:FH2E:.E#$ME<"V2&FFT]!=*CXF?E,>
M5GSY.)O.3+.YEUXL5,%.2D:B%JI^\=M*JG[E+T_5T#&S5K:)<*VO*R-)X/\
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MBP2TIP> %W
M        '!QQMI!N.K2A"2R:E'@B^L!Y?=J3_2T']NCV@'NU)_I:#^W1[0&"
MWRND5L[1U17LC=@(V-DL Y$,M+B$[)K(MV<'U@/F[;S7-V1>Z].\[;<V<1/Y
M.;ZV"C(2")2-M/RDYZR 9+\)[LJ?_=TBONX@$<P]I=7VJ+530=:Z@K$1T#)I
M?$M-3%3T*3<*4*D\J)9@/J'1&G6RMN)[SEHNW4GE<RV#;3$,0Z26E/\ =/H
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MGL1-TLQ3T:[$O)))J==,C41$7 BP F,
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MYB)T] K+"H>'6LS80KJ5LJWD!,MFP0
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M>GZ?DE*R>%I^G)8Q+Y=!()J'AF$;*&TET$0"X@
M                                             XFA"E$HT$:BX'C>
M0#D                   #@ZRT^G8>:0XG.<*21EGZP'(B(BP6XB 5
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M6T;-YS,IC-(8H12H]U*DMMDK/<D1%O/K,!LT
M
M
M                                   "Q5C0](7 DKE.UO3D!.Y:[O7#
M1K!.H,^O!\# 8O;O3S92T\:Y,[>VVD<DC72,E1,-"I2[@^C:XD0)W*100  "
M%M:7S4KI?Y;BOP@+3H*^:-;;]T)_$H!/X
M
M
M
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M;_';1_WHU[0#X5.F_P =M'_>C7M /A4Z;_';1_WHU[0#X5.F_P =M'_>C7M
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M+AT:^)B7?;O?F /BX=&OB8EWV[WY@#XN'1KXF)=]N]^8 ^+AT:^)B7?;O?F
M/BX=&OB8EWV[WY@#XN'1KXF)=]N]^8 ^+AT:^)B7?;O?F /BX=&OB8EWV[WY
M@#XN'1KXF)=]N]^8 ^+AT:^)B7?;O?F /BX=&OB8EWV[WY@#XN'1KXF)=]N]
M^8 ^+AT:^)B7?;O?F 5+L<6C4CS[R\M^W=_, U,T7Z1-.]R[H7UD-:6YA9G!
M4O5S\OE#3KSF(6&2H\(+!EGSF VR^+AT:^)B7?;O?F /BX=&OB8EWV[WY@#X
MN'1KXF)=]N]^8 ^+AT:^)B7?;O?F /BX=&OB8EWV[WY@#XN'1KXF)=]N]^8
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M+AT:^)B7?;O?F /BX=&OB8EWV[WY@#XN'1KXF)=]N]^8 ^+AT:^)B7?;O?F
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MG-;=H;8R>V\-#TW4,#'.3. 0^YL1"T(R@SWY+!^4!M5\7#HU/?[S$M^W>_,
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M*@S-+2,YP1GOZ3 7X
M    &DVIV%BW=>&G5]J#B'&D.Q^VXAI2D(_1'\I1%@OK ;L@
M                             #1WL?4%'0MYM2#L5 Q#"'JXB%-*=:4@
MEIVCWI,RWEY@&\0                                        #3SLI
M$-%16FZ';A(1^(7SEE9[++2EJP40G?@B,P&U%$)4FCY(E:3290#!&1E@R/8(
M!>P                                        &DE_86+<[(I8J);@X
MA;")?,26ZAI1H3^CZ5$6"^L!NV
M        -&="\#'0NJ/4N]%0,2PT_/8<VG'&E(2X65[TF98/Z@&\P
M                                            .AV#A'GVXIZ$96\S
MGDW%((U(\QGO(!W@                                         #H8
M@X2&6XY#0K+*G3VG#;;))K/K/'$P'>
M           Z8F$A(QOD8R%:?;R2MEU!++)<#P8#L2DDD24I(B+<1$7 !R
M                                       ="X*#=B$13D*RM]HC)#JF
MR-:?,?$@'>                                          .AF"@X=Q
MQZ'A&6G'CRXI""2:SZS,N(#O
M              '1&1D-+X1Z/C7T,P\.VIUUQ9X)"$EDS/R$1 -,YGV0V?U1
M/)LS8"P-07!D$A?6Q&3EISD&7%(^43.4GMF7D!;E^4WZ:]4%":EJ<C)E33,5
M+)Q)W3AIQ)HU.Q$P+V<;*B/H\H(F-)D!
M                                                    #@ZZVPVM
MYYQ+;;:34M:CP22(LF9GT$ UWM[K+H^Z>I"=V'H> *8P<@@>V(J>-ODIE3^U
M@VD$7RB+O@3I.-95A3M TQ,:QJR9M0$IE3"HB*B'#P2$)+)^<_("&G,/V0ZX
M5:HB*BL[I=J>J*28<42)JMWD#B4)/Y32#3D_]06U\IVTTZJJ U,2*.BJ<9BI
M5.Y,[VO-I+')V(F#=ZC(\9+=QP")C2:@0
M                                                   "*-1.I"WV
MFNC4U77$0\Z]%NE#2Z70R=N(C7SX(0DM_P!8)B-M<XSLAMTJ9@4UE76DVJI1
M1JC):YDE[E'6&C_ZQ;9)R18W@G3;FV-RZ0N[1,LN!0LU1'R>:M$ZPZG<9=:5
M%T*+I(%7JKVN*=MO2$UK>JX]N#E<HAUQ,0ZM1%N26<%GB9\"(!$FD;53 :K:
M5G-6RNEGY+"RR8*A&2>=)9OM[]ES=PR1< 3,:3V"
M                            &M_9#*SC:)TFUO'RR*7#Q<7#(@FW$*PI
M/*+))X/S'CZP3'EDFC"B)10.F6@))*8-I@ERAJ*B#06.4><+:4L^LS GRURD
MS4/:SLI\PD\A0F$EU?4X45',-]REV)2@SVS(NG()_P#%OR"H
M
M       #7_5)8NZM_%2*CZ5N@_1U(FLUU <&6(J,;S_1(41D:2,@3$Z:P:7;
M84A9CL@U86WH6#=AI-*Z=;)M+KAN+6LU94I2CWF9F9@F?#<S4A8B6:C;8QEK
MYU/XR50$<\TZ^Y"_*6E"B5LGOX'@%67T72TAMC0LJI26FS"RJGH!$.E9D3:$
MMMIWK5T%P,S/S@-&-(L5!W-UZ7<N[;>!Y&B8>'*5O1#*<,1<86XUIQN4>2,\
M@M,]GT+!4
M                           $(7;TL4K>*\="W;J:;1*^8RE.0TK-)*AW
MUFK)*61GQ+S= )VRK4#7E$6WL]5-37 B(9N3,RU]MQIXB,GS4@R2V23XF9F6
MX$->^Q7TS4-/::7)C.X)^!@I[.XN9RN&=(RY.$69;!D1\"/_ - 6MY8W=6:Q
M>M^^$99JGHU]%I+<9BJJCV%&2)G,4;T0J3Z229'M?6!XAV]BK9AH6B[CP4$R
M3,+"57$0\.T7!#25*)*?J("S>@%0
M               &KW9)Z<B*BTB5F4,VIQ4 VS&&DBW[*'$F?^@)KY23I3G4
M%4&G*WDVE[J7&7I%#8-)YP9)P9'Y<D!/EK!-6VJO[*]+BEQ\LBF:5VHM:3R3
M:S0>$GU&"?$-]P5
M                                    &A=L?_VHUP_\OM_B(%I_;#>F
M:S272671,WFT8U"04&TIY]]U6RAM"2R:C,^@B!5\_J[NM=WL@=61UH-/S\73
M-I8"(.&J*L#2:%S B/"FH<^DC\G$$^&Y]E;+4)8.@9?;NWTJ3!RZ"06VLRR[
M$.X[IQQ72HSW^0$,]
M                                    !@=Z;TT'82@X^X5P9JB$E\&G
M#;9;W8ET_DM-I_648)B-M+J)M5=WL@E8R^[M_P"#BJ7M)+7RB:>I')H<F1$>
M4O/EWI[CW@>&P6LZ?W(MKIQF$IL)1\7&3:(;1*85B6L95!PZBV5+0DNDDYP!
M#5>R.HROK"6I8MQ3&BZNU<FPX[,Y@N&4:XR+67Z5]P\Y/)GGB"TQN?*S]CGO
MM6-+U#-J"EMG9Y-I;553N1$=.H=LS8E2G%*RVZ?0:<_Z BT/J6"H
M                                       "U5134GK&GIC2\_A$14NF
MD.Y"Q#2BR2D++!@-(J4TZ:VM-3,QM]I\K6F9[0L4^ZY*6Y\I91$J)9YP6"P9
M%Z-P+;B?*8=)6E296/?J&XER*HYT7(K-[EIS,\?HT$1F9--9WDDL@B9VV1!
M
M                     UEH[316U/ZS:KU#QDVEJZ?GDK1!0\*@U=L)61D>
M5=& 3OMI>=:MF[M7YM$[;6U=30,E7,WB*9NQ2UIY2'+![!&G?O/B!#7R@=-?
M9"[6TG 4-0%U:%E4DEB-B'AVX8_K,SV<F9]9@G<)LT]41K5I^O78^_MS*<GU
M,G!K0B%@&=ETGSQLJSLENX@B=-F 0
M                                               #236MI(O]J-N7
M3=0T?5DAA*=IELG8671ZEFE<62L\HM)%@_K!,2\K=J.R<LH0TQ>RB&FFTDA#
M:(3"4I(L$1$2.H$]FQ&F^G-0%.TC&0FHBK954$\7&+7#OR]O90EC]5)E@MX(
ME*<QAE14!$PK.RE;K*VTF9;LF6 0UWT6:<JTTZR*L9964UET:Y4$_?FD.<&:
ML(:6I1DE6>G>"9;) @
M
M
M
M
M
M
M
M
M                           ::UEK7OW3M93JFI5I#J::P<MC7(6&CVG3
MV(I"3W.)[G@8+:A@TA[)O<BJIY,:7IG2Y.IC.).K9F$$Q%[3L,?4LB3N Y4U
MV-U277N=%U&U6>G:>T<S))8['0[L6LU%&.)+)-)[DMY@C3/=--ZY]?>@'*RJ
M"WDRHV)1&O0I0$>1DX:4*,B7O(MQX!"6P           1CJ+OM3NG2UDTN;4
MD.[%-01$W#PK6Y40^K<A!'T9/I!,1M#]B-6-WZYA)S6EXK'+H*AI=)ESEF;.
MQ?*K=01Y)/)XSDT[P)CX3I9>[E-WRM_+KE4BB(3*)KMJA3?1L+4A*C3DRZ-Y
M AG0      L5:UK3%O*:CJNK"<0\LE4O:4Z\^^X22+!9P6>)GP(NDP$3:3-3
M\)JFI6>5E*Z=7*I=+IN_+X,UN[2HEE!]RZ9?JY+HZ 3,:9[7]ZK9VP?8A*TJ
MJ$@(F(+:1#FHC=V.E9I+>22ZP0C^^VJND+44?258R6.@)U 57.&9>S$LODIH
MF59VW2,MQ[)X+'E!.DW2F9PDYED+-8!Y+L/%M)=;6G@I)EG((>L
M                   !@=Z;ST186A(NX5?1CK$KA7$,_H6]M:W%JPE)$768
M$1MDU*5##593,KJ>#:6VQ-(5N+;0LNZ2E:2,B/R[P%V             8I=&
MYE*V@H6;7$K2+7#2B3LF]$+0C:5@N@BZ3,"(VLL#>253JRCMZI)+WGI><I<F
MT,P[W"W6TH-22/J,R 6;2U?Q.I.TL#=!%.JDI1C[S':BG>4-/)K-.=KRX!,Q
MI+P(
M
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M#8;29&2M_I!;6O+%*@U*ZP-+E<4NSJ3E=.5#1M31S<O.9RG"%PJUGC*B(O\
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M$6_:69EE*\;S+H [-AK5:IZ-KO36QJ-G23E4K9@7(F8MGO-IUHOTB$YX[]Q
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M*'G-/MY7!O&9%^D0DMQ;^)] ';V;P$>2R1[@55
M
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M&6]*34C<!/B%\[+ A*M.TM6:>Z;J*!4D^H^43O J\79#C,]$4I,SR9NRG\2
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M*GL&@B7#J6HB)6,?* U$^'T-D\TA)U*8.<0)F<-&L(B&C,L'L*21E_H8*O8
M
M
M                  #5?3GI5K>T&HJZ5WI_/97%RNN(GEH*'AR5RK1;1GW>
M=W3T G?9L?64FB*BI2;R&$<0V]'P;L.VM?R4J4DR(S\@(:]Z8],-:66TYU!:
M&HYY+8R:39R.4U$0Q*Y)/+;6SG._=M;P3,]V0Z+;!53IQLVW;RKYM S&/1'O
MQ1O09*)O96K)%W6_($SM8I#IEK.5:T)SJ,?G<M7()C*$2]N#22NV$K+.\^C
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MW4?4U/5=.9?,7YS/XJ:LK@R5LH;<5DDGM=()EL:"   :\ZR-+"M3-'REN15
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M6H>&;2TTVG@E"2P1%]1 J[P
M
M
M                                              >6:2V"G,NBI3,6
M2>A(UE;#[9F>%H41DHOK(S >"DZ1IJAY%#TS24GAY7+(0L,PS"=E"<[S/SGU
M@+R
=                                    _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %O M # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK!\":,3EOM)YR<R]29_//;^_^G%?*G]K:G_T$[W_ ,"'_P :/[6U/_H)WO\
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M_N)[J VLK>7-,S+D;<'!-?0?_"/Z3_SXQ?E64H\KL7&7,KFE16;_ ,(_I/\
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M_=B_[Y/^-']MW7]V+_OD_P"- '0TV2-)HVCE17C<896&01Z$5@?VW=?W8O\
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M.,-#'$91&)&D5B2 #RI .1Z5!J&LW6HZE:Z==W=I?QV.O60COK5 B2;U8E<
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M[;&GF/%Y\ORKC.2<X''/6I;_ ,,WTNI:1<6NHAH["Z>Y?[8&ED?<I7:&R,*
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MSTC_ .^J/[%O/2/_ +ZH SZ*T/[%O/2/_OJC^Q;STC_[ZH SZ*T/[%O/2/\
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M=@?9EU!.#P>": .HHKQ^#Q3XBDU'3HO[3N;G2V\06]M;W\EL+=[N)HG:1"N
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M"SYTHHHKM.4**** "BBB@#T7X(_\E(B_Z\YO_9:^F*^9_@C_ ,E(B_Z\YO\
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M &=HW_'M<?\ 7W/_ .C&K1K.T;_CVN/^ON?_ -&-6C0 4444 %%%% !1110
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M0%U'J1U% %?^QK/^Z_\ WT:/[&L_[K_]]&I!JM@TUO$MY"SW+.L(5P=[)]X
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M!?GY<^]5H/$V@W23/;ZUI\JPKOE*7*'8N<9.#P,T 2_V-9_W7_[Z-']C6?\
M=?\ [Z-6!?6C102K=0F.X($+"08D)&0%/?@$\>E1QZMI\MD]XEW$;=&=&DW<
M!E)##Z@@\>U $?\ 8UG_ '7_ .^C1_8UG_=?_OHT]]7TZ/3_ +>]Y"+7;O\
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MU:E !1110 445F2W.L+*XBT^W:,'Y6-S@D?3;32N)NQIT5E?:M;_ .@9;?\
M@4?_ (FC[5K?_0,MO_ H_P#Q-5R/NOO%SHU:*ROM6M_] RV_\"C_ /$T?:M;
M_P"@9;?^!1_^)HY'W7WASHU:*ROM6M_] RV_\"C_ /$TGVO6LX_LVUSUQ]J_
M^QHY'W7WASHUJ*R/MNL''_$OM.>?^/O_ .QI1=ZT>FG6IXS_ ,?7_P!C1R/N
MOO#G1K45E?:M;_Z!EM_X%'_XFC[5K?\ T#+;_P "C_\ $T<C[K[PYT:M87BK
M0)?$.GP6\-RD#Q3"7<Z;@>",8R/6K'VK6_\ H&6W_@4?_B:/M6M_] RV_P#
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M@#SOX7+(+GQ*X036TUZLT=_';M;Q7!* ,$C/3;@ GN37HE%% !1110 4444
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M36CB6"#3YVN([>%%2-I"I4,0!VW$CW-:] ')Z/X"L='\4WNO0W,S37.<JP7
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M+L/_ (,%_P#B:C.LZX)1$="MA(>B'4ES^6VK^M:C'86)'VF*&>8B.'>P!))
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MH?\ OX*/MMK_ ,_,/_?P4<S[?@%EW_$H^7KW_/S8?]^7_P#BJ/+U[_GYL/\
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MA8I"1Y'&/DQP<]\C/OVK5HH Y"RT35;'5%N5MK=_LK7)C?SMIN!-(K<\?+M
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M^T,5E3RPOE^5T!W_ #;O\<5U=%% !1110 4444 %%%% !1110 4444 %%%%
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M/US]1573[265I[YV-FEQM98HF!P /O,<8R?Z5KO_ *MOH:K6RE](B551BT
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MT/V-_P#G\N?S7_"C[&__ #^7/YK_ (5R4_A#5%>9H]0^T>:(DVRS.JA%QD$
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MS*T020!D6S+HRF,D-G.>6QD=1TJ:XU/Q'%IMA-!IS32R1$SHR ,K#VSQG]*
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MECTYI-KD'$PRJJ&)W#'RM\I^7W'-6+_QA'8:I>6KV,S0V<:22SAQ@!L<A>I
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MA1_:-M_?;_OVW^% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** (;JUAO(?*G7<N01@D$$="".AIMI9062,L*M
MESN=G8LS'W)Y-6** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JC)I%E)<F=HVR6#LF\[&8=RN<$U>HH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **AMKN"\1V@?>J2-$QP1AE.".?
M>IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %J M # 2(  A$! Q$!_\0
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MQFKE !1110 4444 %%%0K=VSW;VBW$37,:AWA#@NJGH2.H% $U%%% !1110
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M[:Z24>=%*3V.,'\16B_P_P!*N+[4;J^EN;PZCI\=A<+,X^=$Z-D '<<9SZT
M<[9>*?%^E:]H%KXA;2[FWUZ*0Q?9(V1K:14W@').X<@9K&T?XA^,9-+\,Z]J
M TI],U34%T]X(HV$O+,OF9S@<@\>WOQV6B_#73M)U*WOI]3U34I;.)H+(7LX
M=;5&&"$  YQQDYI8?AMI4/AS1=$6ZNS;Z3>K>PN67<[AF;#<=,L: .SHHHH
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MCFI: LT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5Y_\)AI"Z#?C2)KB53=EI?.5%",54[5"'' X)[D5Z!0 4444 %%%% !1110
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MWX'"T\;B:<*<;+>7:RM_PQC6J2HTY2D_0WN@HHHK]'/ "BBB@ HHHH ****
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M^'KX:MAY<M6+3\SV85(S5XNX4445@6%%2P6T]RVV&)W/L*W;#PZ%(DO"&/\
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MH445^@4*%.A35*FK)'A3G*<G*6X4445L2%%%% !1110 4444 %%%% !1110
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MTJWL9[AV#M#;&W\]%8A)"AY7*\X/3-=;0 4444 %%%% !1110 4444 %%%%
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M)C6A%\O7HFGOO;U.7'5</&DXU))=CU.BFQNLL:R(<JP# CN#3J_13Q HHHH
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MC^[Y$SYP6#=SR2*KZ%H=CI_ACX:ZQ;6ACU&ZU98KBX&2[QDN"I_V< #'3\Z
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M'WD;LRGL:PKT54CYG-B:"K1\T>$CQU9?;=.N&M+]I+,,?M!FB,S$[<(3LP4
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MBBB@ HHHH **** "BBB@ HHHH **** "J\G_ "$(/^N;_P UJQ5>3_D(0?\
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M\E7N:FEZD8O)O;:021R*&!'1U-=S;SQW4"31G*L,BN CC2&)(HU"1H JJHP
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M\@8&,$YP #Q0![91WQ7D'CCX@:QI$DDEEK=M:7$%G'<-I/\ 9CW$BL5!*S2
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M_2N!KM]+.=+ML_\ /,5]3PK-^UJ0[I/\3S<RBN6++=%%%?:'D!1110 4444
M%%%% %'6KX:9HE]?$@?9X'D&?4 D?K7R6[M*[2.27<EF)[D]:^FOB,YC^'VL
ME>IAV_FP%?,E>=C7[R1Y68R]Z*"BBBN(\X*1ONGZ4M(?NF@#Z&?_ (][/_KT
MA_\ 0!4=)9W5KJMI:/87EM<$6T2%(YE+@A ""N<U))#+"<2QNA_VEQ7Q^9T:
MD<34G*+LV];:?>?HV#J0E1@HM/1?D,HHHKSCJ"NF\-3%K::$_P #9'X__JKF
M:W/#)_TJ<?[ /ZU[&0U'#'PMUNOP_P" <F-C>A(Z:BBBOT<\ **** "BBB@
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M_CR7_??_ -"-6J[CT@HHHH *AN_^/*?_ *YM_*IJAN_^/*?_ *YM_*@!\/\
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M$)O!NI(;:XN1Y8)BMV(D.&!RI )R,9X&>.*WZS/$.G7&KZ!>6%K<FVFG3:)
MQ&!D9&1R,C(R.>: .7^&-@MC8ZF%TF_L?-N!(LE[,9'G0KE2<@;2 >5[$UW=
M<EX"\+7_ (5L+ZUO+U9XI;EI+>)'=UA3L,MSD]^U=;0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5Y/^0A!_US?^:U8JO)_P A
M"#_KF_\ -: +%%%% !1110 C,J*68A5 R23@"J6E3PW%O*T,J2+YS\HV?XC3
M]2M&O;"2!&4,V"-W0X(.#['&*J0:?<2WDMU.1:ED5!';/UQGECCGK0!K5SOB
MGP7I'BRVVWT6RX48CN8^'3_$>QK7^P'_ )_+K_OY_P#6H^P'_G\NO^_G_P!:
ME**DK,F45)6DCY_\0_"OQ%HKO);0_P!HVHZ26X^<#W3K^6:XF6.2"0QS(T;C
MJKJ5(_ U];?8#_S^77_?S_ZU5;OP_97Z[;P-<#_IJ%;^8KCG@HOX78X:F7Q>
ML'8^4:,CUKZ9;X<^%G;<=+BSUX %7+3P=HE@<VEG'"?5$7/YXK-8*75F2RZ7
M62/G?1?!WB#7W L-,F:,]9I!LC'_  (_TKUWPC\)-/T>2.]UATO[Q<,L>/W4
M9^A^\?K^5=[]@_Z>[K_OL?X4OV _\_EU_P!_/_K5T4\+"&KU9U4L%3IN[U9;
M P,#I2$A5+,0 .23VJK]@/\ S^77_?S_ .M5>]TEKFSEA6[GW,.!(V5/L1CI
M72=9+I-Q#/9?N94DVNP.ULX^8U>K-LK6X%_)=W$4,!,0B$<3;LX.<DX'X5I4
M %%%% !4-W_QY3_]<V_E4U0W?_'E/_US;^5 #X?]1'_NC^5/ID/^HC_W1_*G
MT %%%% !1110!C^(?"^D^)[/[/J=L)-O^KE7AXS_ +)_R*\;\0?!W6M.=I=)
M==1M^H7A)0/H>#^'Y5[Y16-2A"IN85</3J_$M3Y&O=-OM.D,=[9W%LX.")8R
MO\ZJ9'J*^P9(HYEVR1JZ^C#(JDV@Z.YRVDV+'KDVZ?X5S/!=F<;R[M(^341I
M6"QJSL>@49)KJ-%^'?B;6V4Q:<]O"?\ EM=?NUQ]#R?P%?25O86=K_Q[VD$/
M_7.,+_*K%.."2^)E0R^*^)G ^$_A7I/A]TN[XC4+]>59UQ'&?]E?7W/Z5WU%
M%=D(1@K11W0IQ@K15@HHHJBPHHHH **** "BBB@ HHHH **** &NB2QM'(BN
MC##*PR"/0BO+/%7P<M;UY+OP_*MI*>3:R?ZIC_LGJOZCZ5ZK143IQFK21G4I
M0J*TD?*FK^%-=T*1EU#3+B)1_P M NY#_P "'%8V1ZU]AD @@C(/8UF77AO1
M+T[KG2+&5CW:!2?Y5QRP7\K.">7?RR/E#(]:L6=A>:C,(;*UFN9#P%BC+']*
M^H(O!_AN!PT>A:>K#H?LZ_X5K06T%K'Y=O#'$@_AC4*/R%)8)]6*.7/[4CPO
MPY\'=7U%TFUF0:?;=3&"&E8?3HOX_E7LVA^'],\.6 L],MEACZLW5G/JQ[FM
M.BNNG1A3V.VEAZ=+X5J%%%%:FX4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !117$W7AG7&\07U_97<4
M/G2!DD=RW'R8&W';:W4GKQCF@#MJJ2S1#5((S(@<QOA2PR>5[5R']D>,7,L7
M]HO&%@^23[0#R=WRYV\L/E^<X],5<&EZE/I]U:W&GQ3W$A7==22!=Q"KG'!.
M,@@']* .NHKA!X:\3F-8?[26*U6-=MO#)L"D2;L9VYSCC/ [8Q6KJVBZQ=SV
MDMI?!5MT)VRL<NS#:PRH ^[GD@\GMUH Z:BN-C\/^([72=-MK75 DT,DAG)D
M)0AL[>HR<9'?K56XT?Q>&:?[6ADE"J467>!\W&5*@'&0<\< C!S0!WE%<.?#
M_BJ73_L]SJK3.R,-XN/+PV\'G:G((&!TVCUJZFE>*%TSRQJH^UBZ9@[MN!A.
M< _+U!_#% '5T5PI\+^)#>_:3JW[T#<&69@-V#_#C&,GGVJUJFB^)GN]1;3=
M2\N.=5\LM,00<*,@;<*1AN1U&!0!V%%<2^B>,9)CG65$1F#D!^2-F"/N_=SG
MCKSUJ*+PYXM@L7BAUE8W$?EH%<D 8[97[V?XCF@#MY9X8=OFRI'N.%W,!D^U
M25SW]F7T81KF&+4I7MEB=I6 V,,Y(XZ'/;GBJ%AH/B&/487OM262&&&2-&CD
M(QGA1MQR>GS$^U '845PJ^%-2_LRV@6"")XPRNHNFVF0J )LA<Y&#P>>>HJT
M/#>JA=76.=8S<P%$<S%FEDR<.QQE1SC SCL: .PHKAVT?Q=#&TJ:BC,$)5!)
MELA> Q*_.>W;GFA-%\82")CJ:1YBY2:3S/+;>&&<*-Q'//X4 =Q17*:/I/B6
MWO+1M0U9Y8%@=)@7!)?=E2/E )QW/:NB^S2_\_DWY+_A0!9HJM]FE_Y_)OR7
M_"C[-+_S^3?DO^% %FJ]\ZQV%PSL%41MRQP.E)]FE_Y_)OR7_"J=_83R>1(K
M&[$,F\P2E0K\$>G49SS0!H6S*]M$R,&4H,$'(/%2U0TJUDMH9C)&D7FRF00H
M<B,'''Z9_&K] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_011.jpg
<TEXT>
begin 644 form10-k_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )6!/D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAJ&B:C/X_L]3CM]UG&JAY-ZC& >V<]_2CQ9HFH:GK>DW%G;^9% V9&WJ-OS
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %1R2.LBHB!B03RV.F/;WJ2HF
M_P"/J/\ W&_FM !NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X
M4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\
M?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY
M1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%N
MG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+1
M0!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_
MX5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?
M_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_
M^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X
M4;I_^>4?_?P_X5+10!%NG_YY1_\ ?P_X4;I_^>4?_?P_X5+10!%NG_YY1_\
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M/J/_ '&_FM $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!_#_A0!+14:M*6&Z- /4/G^E24 %%%% !12$@$ D9/2D=UC1G8X51DGVH
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M;^:T 2T45CZQXELM$O;*SN([B2>]W>4D*;L[2H.>1_>% &Q5>Q_X]%_WF_\
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M6*W0A%^S^9()&92%Y.Y1C.>E:G_"&K_8&O64U_-=7>LHXN+J557),8C7"J
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M4MI65<X,DP8\G/4U-YUQ_P ^A_[^+5BHKFYAL[:2XN'"11KN9CV% #/.N/\
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ME'S'<RC!&":]BL;1;"QAM$EFE6)0H>>0NY'NQY)]Z\@T/4_"&F(;B7Q3)_;
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M;6P7-*BBBD 4444 %%%% !1110 4444 %1-_Q]1_[C?S6I:B;_CZC_W&_FM
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M#OCKD\U?\A?[\G_?P_XT>0O]^3_OX?\ &@"6BHO(7^_)_P!_#_C1Y"_WY/\
MOX?\: .5UGPUK&K>)'O6N['[$EK)!:))$S-;LZ%6DV_==B<#GC;QW-3>"/"U
MQX6LKN">XBE$\BNJ1;B$VH%^\Y+'.,XS@=!Q72>0O]^3_OX?\:/(7^_)_P!_
M#_C0!+147D+_ 'Y/^_A_QH\A?[\G_?P_XT <YXU\-7OB>QAL[6[BMD#;F=_,
M)4@@A@JL%?&/NN".E.TK0]5M_%VH:QJ,]G<),GDVY16#PP@Y5,=.>2Q[G'8
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MOB47DM];MIXU$ZIY:QL)?.,7EE<YQLSEO7M77W=I%>P&&;?L)S\DC(?S4@T
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M\&@"6BHO/'_/.3_O@T>>/^><G_?!H EHJ+SQ_P \Y/\ O@T>>/\ GG)_WP:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1-_P ?4?\
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M#U->%UZ=\"?^1^F_Z\)/_0DJ9Q7*]!QD[K4^CZ***XSI*FE?\@>Q_P"O>/\
M]!%6ZJ:5_P @>Q_Z]X__ $$5;IR^)BCL@HHHI#"BBB@ HHHH **** "BBB@
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M^\?:KE5['_CT7_>;_P!"- #_ "I/^>[_ /?*_P"%'E2?\]W_ .^5_P *EHH
MB\J3_GN__?*_X4>5)_SW?_OE?\*EHH B\J3_ )[O_P!\K_A5/5=&M]:TNXTZ
M_)FMIT*.A4?F..".H-:-%"=M4!Y]X3U&_P! U@^"M<NW:2-=VEW; 8N8!_"2
M?XUZ8]O;GO/*D_Y[O_WRO^%8GB_PO%XGTD1+(;?4+=O.LKI?O0RCH<^A[_\
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M 4444 %%%% !1110 4444 %%%% '"_$S_CSTK_KY;_T6U>?UZ!\3/^//2O\
MKY;_ -%M7G]>Y@/X*^9Y6+_BA11178<P5T?@'_D<D_Z\IO\ T*.N<KH_ /\
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M#8_VM;WMW)]IF$:[F:#RT.2!E8PH_ UTOAQMNK^)($_X]X[\,F.@+PQLX'_
MB3]2:Z  *    . !4%I96]B)A;Q[/.E::0Y)+.W4Y/\ D  4_P"OR)_K\_\
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M')6FH2DKI"<DMV=;]HC_ -K_ +X/^%'VB/\ VO\ O@_X5+14C(OM$?\ M?\
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M+F/"D,Q(4!/O+@YW>M 'M-5['_CT7_>;_P!"-6*IV:RFV&V10-S<;<_Q'WH
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M=N?3.WC/7'%:M%% &5X<_P"0./\ KXN/_1SUJUE>'/\ D#C_ *^+C_T<]:M
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MZ>[;;;PVR[GE^4MD9(&-H)R2*LZ;J-MJVG07]HQ:"9=REE*D=B"#T(.01[4
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M[Z% $E%1^?%_SU3_ +Z%'GQ?\]4_[Z% $E%1^?%_SU3_ +Z%'GQ?\]4_[Z%
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MY?$Q1V04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5$W_'U'_N-_-:EJ"4.;F/8R@[&ZC/=?>@"
M>BHML_\ SUC_ ._9_P :-L__ #UC_P"_9_QH EHJ+;/_ ,]8_P#OV?\ &C;/
M_P ]8_\ OV?\: ):*BVS_P#/6/\ []G_ !HVS_\ /6/_ +]G_&@"6BHML_\
MSUC_ ._9_P :-L__ #UC_P"_9_QH EHJ+;/_ ,]8_P#OV?\ &C;/_P ]8_\
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M+;/_ ,]8_P#OV?\ &C;/_P ]8_\ OV?\: ):*BVS_P#/6/\ []G_ !HVS_\
M/6/_ +]G_&@"6BHML_\ SUC_ ._9_P :-L__ #UC_P"_9_QH EHJ+;/_ ,]8
M_P#OV?\ &C;/_P ]8_\ OV?\: ):*BVS_P#/6/\ []G_ !HVS_\ /6/_ +]G
M_&@"6BHML_\ SUC_ ._9_P :-L__ #UC_P"_9_QH EHJ+;/_ ,]8_P#OV?\
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M%O,+^1;HJIY>H_\ /U:_^ S?_'*/+U'_ )^K7_P&;_XY1;S"_D6Z*J>7J/\
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M_P#/U:_^ S?_ !RCR]1_Y^K7_P !F_\ CE%O,+^1;HJIY>H_\_5K_P" S?\
MQRCR]1_Y^K7_ ,!F_P#CE%O,+^1;HJIY>H_\_5K_ . S?_'*/+U'_GZM?_ 9
MO_CE%O,+^1;HJIY>H_\ /U:_^ S?_'*/+U'_ )^K7_P&;_XY1;S"_D6Z*J>7
MJ/\ S]6O_@,W_P <H\O4?^?JU_\  9O_ (Y1;S"_D&E?\@>Q_P"O>/\ ]!%6
MZALX#:V4%N7WF*-4+8QG QG':IJ):M@M@HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'7-=OM)OK*W@TD72
M7DHACD^TA/GVLV""#QA#S6]6=J>E_P!HW.F3>=Y?V&Z^T8VYW_NW3'7C[^<\
M]*.J KGQ3I$;SQ2W)$UNRQS(D;OMD. (P0OS/R,*.3UQ2OXIT>.""=KIO)G.
M%D$$A53NV_.=N$^;CYL<\5FZCX-%[97,0NT\R34O[1C,D1*!MH78P# D8SR"
M.OM5"_\  $]]9PVJZA;6\"QLKPQ6\GEAS)O,BKYOWCT);=ZC%"\_+_@@_(V(
M?&NC2)=-)+/ +>[-H?-MW!>09P$ 'S$X. .?;D5-:^+] O1(8-2C*QPM.SLK
M*NQ<;CD@ [<@$=03@XJK'X7G74&E:^C-NNI_VC&@@.\$HRLA;=@C)R#C\ZJ7
M/@*.ZTU+*34&VK;WD.Y8L$^?(),]?X2N,=_:ET'U-5O%NB+;B9[QE!E\D1M!
M()#)MW!?+*[LE>1QR.E)8>+-+U/6!IMF\LKM;)<I*L3>6R-NQ\V.#\O?Z=<B
MJ6G>$#:3V5Q)+9I-;W1N&^S6[J)?W31@$M(QS\V<^V,=ZDT3PO/H>HPSQ7T<
ML(M?L\R- 0S8D=U*G=Q_K"#D'IVJNI/0MW7B2WM?$]KHC0R%ITR9P1LC8ABB
M'W81N1]/<5M5RE[X(BO;F\OGU"X749KN.ZAF6201Q>7MV*8@^UL!<9/)W'I7
M5TEL-[A169K^L+H6D/?M$)=LD<84R!!EW5 2QX !;)-9NJ>*+G2]"CU633(Y
M(MADE$=XAPH/ 0X^=CV QZ9H Z6BLG5]:DT^2QM[:S-U>7KLL,32"-?E4LQ9
MB#C@>AY/XU8T?4XM9TBVU&%'1)TW;'^\IZ$'W!!% %ZBBB@ HK'\1ZW-H.FO
M?)9+<Q1(TDI:X6+:JC.!G[S'L/U%0W_B*:PNM/WZ9(;*]EB@6<RJ'5Y.G[OK
M@=^>/0XH6H&]16)XC\2P>'8+=I()+B6>4(L49 (7(#.<]%&X?B0.];= !111
M0 4444 %%%% !43?\?4?^XW\UJ6HF_X^H_\ <;^:T 2T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !17 ?%;7X=+T;3],?4VTUM4NTA>Z1BK10J=
MTC CD'&!_P "KF]*U+7_ !A\)K>#1+^2ZU'3KT6UX8[HQ27D*$\+(>5+*5.?
MK0!['17B.MO9W_PHU35=.O?$=E?Z/,UN\-SJ$GF02[T#(Q#?. &X)SUKNM<@
M'A'X7:S)87%W))'9R2K)<W#S.&*XSN8DX'I0!V:LKJ&1@RGH0<BEKS#1A)I7
MC?P9I,%Q*EC_ ,(\Y\D.0DCC:=Q'0GJ?QJM!XFNM,\,_$"]^TRSSIK<]I8JS
MEL.P141?0!FZ#WH ]3M[F"[A$UM/'-$20'C<,,@X(R/>GJZOG:P;!P<'.#7F
MN@6$OASQ_P"'_#T5Q*+:#P\YDB#G8\OFC<Y'3))//O6GX7/V/XF>,].BXMW^
MRWH4=%D="KG\=@- '<TT.K,RJP)7J >E>;16\_C+XA>);"_U?4K.WTCR([2V
MLKDP?>3<96V_>YZ9XKG)M9\0>%=;\=ZKIK65Q:V-U:&Z%V&,LX\I%^4J0%/.
M<\_2@#VZBO*]?^).JZ9XR6SLDMKK3$O;>TG"V<I,1DVY#39V!\MD+@\=\TV;
MQ]XHAGO[X0Z6=)L=>_LMXRC^=(A<*&!S@$;A]?:@#U:BO*8/B#XAU/X@IHE@
M^F"!=2DMI[4V\CS1P1C)E+A@H#8('H2.M,\-_$GQ/K^NVSQ:#+)HUU<20ADL
MI0(54L YG)V-RO(P,9]J /6:*X3P-XKUG6]5OK#7EMK2]A3S!IXMI(I8EW8S
MN8E9%/'S+7=T %%%% !1110 4444 %%%% !1110 4444 %%%% !43?\ 'U'_
M +C?S6I:B;_CZC_W&_FM $M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 45S?C?Q+<>%M%@O+6VAN)I[N*U59Y#&@+G&20#P
M*S-%^(MM<6&HRZU%%:2V-Z+(FT=KE+B0C($6U=S'V S0!V]%<9-X\MYM=\/0
MZ;)%+IVH_:Q<2.C+)$84R1M."I!SD$9IUY\2M!@T?5;Z%KF633K?[0]L]M+$
M[J3A2 RCY2>-W0=30!V-%<0?B-IX;3KV2:.WTRXT^6\E66&;SUV%02!MP5&[
MD]^HXK:O/&6@6$EPEQJ"J;>WCN9,(S )(<)C Y+'HHY/I0!NT5CV/B?2M2TJ
M[U&VN&,%GO\ M*R1-&\14;B&1@"#CGD5R4?CCQ-=>%KOQ+'H-G!I)LYKFU:2
MZ+2@*I*,Z8 PV!P#D9H ]%HKDO#WQ"T/6M+:;[8!<VUFES=QB"0;01R5!&6&
M<CY<U,OQ \-'3;N_EOG@ALY8XKD7%O)&\3.<)N5E! .>N,4 =/17-0>/O#=S
MI<^HQ7[-#!.MLZ>1()/-;[JB/;N)/; YIB?$+PW)IR7R7<[1R3M;I&+24RO(
MHRP$>W<<=R!@4 =117-ZOXJMX?"]KK>F7=F]O<3PI'+.'V,KN%/"@D-SCD<'
MK38_B#X8DUI=(74O],-PUKM,+A1*"1L+8V@G!QSS0!TU%<YJOB<Z3XOTO2+B
M!1:7]M/(MR6Y5X@&*X]-N3^%<QHWQ5?6?#D%]%IBI>SZM'IR6S2'[KX8/G']
MPEOPH ]*HK@_"7Q)T_6;EM-U&>.#5&O;BVBB2)PC!&.T;B"NXJ,XS6S:^.O#
MM[K TJWU#?=.[QQGRG$<CI]Y5D(VL1CH#0!T=%<)H'Q(L9?".F:IKLHAO+P3
MMY-K!))A(Y60OM4,0H &2>*TO%OB\:#X:L]7T]+:[6\N((87EEV18D/#E@#Q
MWH ZFBN+T3X@VMSH>H:CK2P626-V;1I;>4SQ3MQCRB!E\DXP!G-7_P#A/_#7
M]C2:J=0*V\<XMG5H)!*)CTC\O;NW>V* .EHKB/"_Q$LM;GN([F:.,2ZI+8Z>
M5B<>:$0,-V>C8)X..G2K>O\ CBUT_P $:AXCTI5ODM)3" VY%9Q((VY(Z D\
MCCB@#K**Y"W\:"PTI;KQ$+:.21V\M=*,MXNQ0"68JGRXSSGVI1\0]'?Q5INB
M0":==0M!<PW4<3LA#$;1PO0@YST'?% '745P_B#X@-H/CW3M DL%>RN4C,UW
MYF#"9'*+QCIN &<]Z;!\1!/\1+KPZ+)186\4I:^WDDR1*K.H7'0;P/J#0!W5
M%<S#X_\ #<UM?3F]DA2QC6:<7%M)$P1CA6"LH+ G@8!YI\WCC0[>VM9I7O%:
MZ9UB@^PS><=GWB8]NX 9')&.: .CHI%8.H8=",BEH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *Y_6M=GT_46M[=(V6#3KB^F#=]F BCTR2<_2N@K#U306U#6$N=X6"6QFL;
MD X;:^"I7@C((/7^]2=^G]:/]1JU]?ZU7Z&5I'C<WYL4N;,PS-!.]Y#$KRO$
M\?EX"JH)8,) PP,X(J[K/BB2V\-WNJ:7833-:J6=+V"6U 4 DG#H"W3' ZGJ
M*D/@S2&U>/4G21Y%LOL+QLP\N5..6&.6^4#/''X8=>^$=.N-$NM)LS)IEO=9
M$YLEC#.",$'>K#\AGWJG:^G]:_Y$QZ7_ *T_S,O7_&%UI/B*TTV.&V_?K"8D
MEW;[DN^U@C#Y5V#!^;KFMW1-2FO_ .T8;@)Y]E>26[%!@%>&0_\ ?++GWS6;
M=>"X;R61IM5OW6>.*.Z4B+]^(R2N2$^4\_PX_ \UI:)IDNG_ -H2W#(T]Y>2
M7#;"2 .%0<C^XJY]\TD!JT444#"BBB@"IJ4%S<6316CVRRDC_CYA,J$9Z%0R
M_GFN4G\#7$F@G2UN]-*RR32RO)IY;R7D8G= /,'EXSQUYP<UVU% 7.?U70+K
M4; 6CS:;<HDBF+[?8F;8H3;G[XRV<G/'!QCO6CHNE0Z'HMIIEN28K:,("0!G
MU.!P,G)Q5^BBX6"BBB@##\3:)<:]9"TC?3Q&P8-]LLS.5)& R?.NUASZ_A53
M_A&M276=/NQJ\$UM8PI%%#=6C2,"!AY-XD4;V'&XJ<<XZG/3T4+0'J<KK?@M
M=?B:2[U*XCOF41F:W+(GEK+O V;NO09SR0#VQ74(NQ%7).T8RQR3]:=10M%8
M-]0HHHH **** "BBB@ J)O\ CZC_ -QOYK4M1-_Q]1_[C?S6@"6BBFO(D8R[
MJHZ98XH =1110 4444 %%%% !1110 4444 %%%% !1110!0FT:PGUJVU>6WW
MW]M$\4,I=OD5L;L+G&3@<XS67?\ @/PWJ4]Y-=:<QEO)DGG9+B6,M(JE58;6
M&TX)'&,]\UT=% &$O@WP^OAN;P\NFHNES'=+"KN"YR&RSYW$Y Y)SQ5_5M+@
MU;0[S2ILB"Y@:!L=@RXJ]10!RJ>!]/U+PWI&G>)((KZZTZ%8TN8G>)@0 N59
M2&&0!D9I)_ >G!=#M-/$=EIFF7AO&M$0MY\@!VEF)SD$YR<D\5U=% '/Z[X)
MT#Q)?PWVJ6<DMU#&8DECNI82$SG'R,,\TWP]X:;1]9US4YYEEFU*:/8%S^[A
MC0+&A)Y)^\2?>NBHH Y[6O _ASQ!?K?ZEIHDNPFSSHYI(F9?1BC#</8YIS^"
MO#TEEJ5FVG#[/J?E_:T$KCS-@"KT;Y< #IBM^B@#F+SX>^%=0U@ZK<Z4'O3(
MDID$\B@NF-K;0P7<,#G&3WJV_@_09+6YMFL,PW5Z+^9?-?YIPP;?G=D<@<#C
MVK<HH \NT_X7ZM8^,!JJZW%';_V@U\[P"9)IE9BQB9?,\K:<X)"9-=;;^ O#
M%IJ[:I!I8CNF=I#MFD$89@0S"/=L!.3R!WKI** ,/0_!V@^&[B:XTJP\F>50
MCR-*\C;0<[078X7/88%;E%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5$W_'U'_N-_-:EJ)O^/J/_ '&_FM $M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%1SW$%L@>>:.)"<!I&"C/IS5?\ M;3?^@A:_P#?
MY?\ &FDWLA72+E%4_P"UM-_Z"%K_ -_E_P :/[6TW_H(6O\ W^7_ !I\LNP<
MR[F/XU\,-XKTFTL0\(2*^AN9%F7<KHC99<>XKD[SX6W?V>>TL+RUCL8-474=
M.M7\Q5CRI$D3%""JY.05/%>B?VMIO_00M?\ O\O^-']K:;_T$+7_ +_+_C1R
MR[!S+N<-!\/;Z*;2;BWFL=.GM#>O)]E,CCS)X]BN"Y))! )SBJ6F_#'5U75C
MJ>IV[RW^BOIC2I)-*Q<G/FL9">O4@8 [5Z-_:VF_]!"U_P"_R_XT?VMIO_00
MM?\ O\O^-'++L',NYQMMX%U&ZN-(DUJXLI$M-)GTR>.W#8=7VA2-W^RO/O6/
M:?":_'A&^L+[5H9]5EN+:2*XVL$\NW4+$C8PV, Y([G->E?VMIO_ $$+7_O\
MO^-']K:;_P!!"U_[_+_C1RR[!S+N8'A[PG]AT34[&_MK*%M1+"?[')*^Y2FW
M):0DDXS^E8EIX-\6P>%+CPK+JVE2Z4MG+:V\OD.)V4J50/SM&,CIG.*[K^UM
M-_Z"%K_W^7_&C^UM-_Z"%K_W^7_&CEEV#F7<XNY\!ZL9&FL-6CL[@>'TTJ.:
M,-N216!WCT'&/49K*C^%VJO9:ND][9K+J$]C+A9)I0GD/ELM(2QR/\BO2?[6
MTW_H(6O_ '^7_&C^UM-_Z"%K_P!_E_QHY9=@YEW/,/'?A74[9]1U"U,DB:CK
M%G<;K:*1WMDBC*ER$^?KCE.:BTWP9J6OZ'I5TEC#83Z7=W*QQ7+7$:WD<F,R
ML=WFJQ.3R37JG]K:;_T$+7_O\O\ C1_:VF_]!"U_[_+_ (T<LNP<R[G+7_@F
M6Z\"6.@6_P!CLY(+F&X81;S$-LHD8+N);GGKWJH/A]>"W,?VRWR?$W]M9P?]
M7G[G^]^E=I_:VF_]!"U_[_+_ (T?VMIO_00M?^_R_P"-'++L',NYS?Q#\'W?
MB_2;6+3KV.ROK:8ND\@) 1D9'7CU#?I6;9_#9K'Q]::S#=Q#2K>&,BSVG<9T
MB,2OZ8VG\Z[;^UM-_P"@A:_]_E_QH_M;3?\ H(6O_?Y?\:.678.9=SBK/X>W
MEM;:3$UY;DV6NS:HY /S(^_"C_:^8?E4.D?#W5[.YT>RNM1LGT;1[V2\M?+C
M87$C-N*AR> !O/3K7=_VMIO_ $$+7_O\O^-']K:;_P!!"U_[_+_C1RR[!S+N
M>91?"?4+2QT?R[FQNKBSMI[6:*=YHXI$DF:0$-&0V1NP0>#73>(_!<^J^"],
MT2R^PP/8S6\PCD1F@/EG)3&2=IZ<]JZ?^UM-_P"@A:_]_E_QH_M;3?\ H(6O
M_?Y?\:.678.9=SSQ/ACJ*6EW<QWVGV^I2:E!J,%O;P,EG$\0("[<Y^;)R?7%
M2S_#S6ITEU5M0L!K[:O%J@41O]F!C0H(_P"]C!)SUS7??VMIO_00M?\ O\O^
M-']K:;_T$+7_ +_+_C1RR[!S+N>8Z_X-U?3? >MSO,+K7)-575;-K"%LI,2@
MP%Y./O#Z<UT5YX%DN/A/%X0MYHHYO(B5Y) 2I<.KN3CU.[\ZZS^UM-_Z"%K_
M -_E_P :/[6TW_H(6O\ W^7_ !HY9=@YEW..\0^ 9[B*RM?#SV>G:>@E%S9I
MO@CE9U $A\H@L5QT/!IFD>!M6T6_\+75O>V3MIFGG3[Q9%;YT)!+1X[\=Z[3
M^UM-_P"@A:_]_E_QH_M;3?\ H(6O_?Y?\:.678.9=SDO%/@*3Q)J^J7;74<<
M=WI LHA@[HYED\Q'^@('O5+3?AQJ.G'3)HM6C6]M["\BN+H*2[W,Y#>:/H1W
M]!7=?VMIO_00M?\ O\O^-']K:;_T$+7_ +_+_C1RR[!S+N><Z9\-M8MVU&?4
M)M,OY;O3DLWCN))Y4E99 Q9V8EAD9^[C!Q@<4MQ\.-=F\-VFG_VA9O>032R0
M7;RS^98AB-JPN#N8 #&&Z\>E>B_VMIO_ $$+7_O\O^-']K:;_P!!"U_[_+_C
M1RR[!S+N6((WBMXHY)#*Z(%:0CEB!R?QJ2J?]K:;_P!!"U_[_+_C1_:VF_\
M00M?^_R_XT<LNP<R[ERBJ?\ :VF_]!"U_P"_R_XT?VMIO_00M?\ O\O^-'++
ML',NY<HI$=9$5T8,C#*L#D$>M+4C"BBB@ HHHH **** "BBB@ HHHH ****
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M** *=Y_Q]:?_ -?!_P#14E7*IWG_ !]:?_U\'_T5)5RF]D);L****0PHHHH
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M2V4,2@-\TDS-G'/KQBKX(/2@"/$_]Z/_ +Y/^-&)_P"]'_WR?\:EHH BQ/\
MWH_^^3_C1B?^]'_WR?\ &I:* (L3_P!Z/_OD_P"-&)_[T?\ WR?\:EHH BQ/
M_>C_ .^3_C1B?^]'_P!\G_&I:* (L3_WH_\ OD_XT8G_ +T?_?)_QJ6B@"+$
M_P#>C_[Y/^-&)_[T?_?)_P :EHH BQ/_ 'H_^^3_ (T8G_O1_P#?)_QJ6B@"
M+$_]Z/\ [Y/^-&)_[T?_ 'R?\:EHH BQ/_>C_P"^3_C3D\SG>5/IM&*?10 5
M$W_'U'_N-_-:EJ)O^/J/_<;^:T 2T444 %%%% !1110 4444 %%%% !1110
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M /%)=?U6Y^$J0Z;<:C=NKWAN[ZVD+S0JC.T89LY&[*<_W0?45V/A2\FE\7S
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M!K'_ *]X_P#T$5<IR^)BCL@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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M3TG_ ) UC_U[Q_\ H(JY3E\3%'9!1112&%%%% !1110 4444 %%%% !1110
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M_(TV\20!+B-IV:#<WDQ$#S>.AS535=>M]'M+:XNH+@K/-' 1$H;RV=@HW<X
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M%'ZL!^- &/X8\/7'ANREMOM[WHDD,I><*'+'EF)506)]3GI6YF?^['_WT?\
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M&\GOQ-(\RSR.(Y4E=65GW(JEB0V/FR, #I75Z=9OINFVUC"JF*WB6)"\A)(
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M<CH1ZUYUHWQ-EU+7AITMO9+)->1PQ01S%IEC;S@Q<=F7RE)'0!J](I#"B@D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J)O^/J/_ '&_FM2U$W_'U'_N-_-:
M ):\^\;W'C)[:W-CITD4$-RKLVG7NZ24"1 H;*J0I!8D#/09.,UZ#10 @)(!
M(P?3TJI9M*+8;8U(W-R7Q_$?:KE5['_CT7_>;_T(T /W3_\ /)/^^_\ ZU86
MM175C=1Z[:P R0+LN8T;)EA[]NJ]1^-=%00",$9!JH2Y7<4E='(^.#/JOPZU
M7[%!]H\^US&(279P2#P .:^9)M"UFR4/<:3?PQ,P4-+;.HW$X R1WKZGL"=
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MT_\ SR3_ +[_ /K5+10!%NG_ .>2?]]__6HW3_\ /)/^^_\ ZU2T4 1;I_\
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M\_Y^[C_OZW^->W_M!?\ (-T+_KM+_):\(KKII<J.>;?,6/M]Y_S]W'_?UO\
M&C[?>?\ /W<?]_6_QJO15V78B[+'V^\_Y^[C_OZW^->F_!."/5_$]_#J2B[B
M2S+*D_S@'>HR >]>55ZQ\ O^1MU+_KQ/_H:U,TN5E0;YD>X?\(QH7_0(LO\
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M#B-2K?4<]?;^5>GWD$%U9S6]S@PRJ4<$XR#Q7$VGPSL;75(YIK]Y85;<D!4
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MXLG./ZYKT7[;XD;II%FO^]>'^BU5;"RI2Y;H5.LIJ]C7WR_\\?\ QX4;Y?\
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M/_CPJ6B@"+?+_P \?_'A1OE_YX_^/"I:* (M\O\ SQ_\>%.1G;.Y-OXYI]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !43?\ 'U'_ +C?S6I:B;_CZC_W&_FM $M>8_$'Q5KFFO9K:?:=
M*)\\[6:$F;:4VLOW@Y.3B+Y6;U&*].HH 13N4'GD9Y&*J6;2BV 6,$;FYW8_
MB-7*KV/_ !Z+_O-_Z$: '[YO^>(_[[_^M1OF_P">(_[[_P#K5+10!S/C'PW<
M>*M)2R2ZELF259-\,F"<=C_GKBLV]\#7-UK&B7PU2Z1=,CCC,8DXEV=S[GO7
M<44 1;YO^>(_[[_^M2,9'4JT"E2,$%N"/RJ:B@#AM+DF\%ZZNA3)_P 274)&
M;3'9^()#RT!/H>2OXBNTWS?\\1_WW_\ 6JGKFBVNOZ1/IUV#LD&5=>&C<<JZ
MGL0>:\HTOXZ6]E8I9ZKIUU<WL&8Y)XBH$N#@-@G@D=?>ME"557BM>IFY*&C/
M8]\W_/$?]]__ %J-\W_/$?\ ??\ ]:L_PWKL/B7P_::Q;PR0Q7(8JDF-PPQ7
MG'TK5K)IIV9HG?4BWS?\\1_WW_\ 6HWS?\\1_P!]_P#UJEHI 1;YO^>(_P"^
M_P#ZU&^;_GB/^^__ *U2T4 1;YO^>(_[[_\ K5%<P"\MW@N;2.6)QAD=L@_I
M5JLC7O$^C>&8H9=8O5M4F8K&2C-N(Z_=!IQ3;TW$[6U)-.TFTTD.+#3H8-_W
MBK<G\>M7M\W_ #Q'_??_ -:N?TGX@>%M=U*+3M-U59[N7)2,12+G )/)4#H#
M72TY\U_?W\PC:WND6^;_ )XC_OO_ .M1OF_YXK_WW_\ 6J6HKFYM[.W>XNIX
MH($Y:25PJK]2>!4C*D&FVMK<M<0:9;13-UD0 $_CBJ]_H=MJ$HG:V,%T/NW$
M$NR0?B!S^-.7Q3X>=@JZ]I;,QP +R,DG\ZUJOFG%WNR;1:L<ZLWB'20?.A75
M;8=&C(2<#W'1OPQ5W3M=MM3++;E?.7[\,C;9$^JD9K5K/U+1K'5%!N( 95^Y
M,I*NA]F'(JN:,OB5O-?Y"LUL#7=I!?[6^R1WDH"D&51(P&<#U/4X^IJWOF_Y
MY#_OO_ZU> :E!>Q:M/#=B5KL2$-OR68YZ^]>NZ9_PED>EVJR)IC,(ESYSR!^
MG\6 >?6NBO@U2BFI+4RIUW-M-'1;YO\ GB/^^_\ ZU&^;_GB/^^__K5D?:/$
MZ]=/TQ_]VZ<?S2C^T/$2]=!MV_W;\?U2N;V3[K[T:\Z[/[C7WS?\\1_WW_\
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M_D5M(_Z\H?\ T 5J5E^&_P#D5M(_Z\H?_0!6I0 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;_OH5\P7?PN\9R7<SKH,Q!D8@B:/D9_WJ^GKNYBLK.:ZF+"*%#(^U2QP!DX
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M0^*;H?Z#X/>('H]]>QQ_^.KN->8_&%/%5S8Z6VL6]@D8ED\M+(.Y4X&=S'_
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MK&CP:C)#'"MR/,B1)1)^[/W22.-V.H&0.F36E5-6T8;A1112 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J)O^/J/_ '&_FM2U$W_'U'_N-_-: (+R]^S30P""=C-N E2+='%@=7.1
M@5Y[)XTU5]#M'M]8TY]5DU.:U2'R1MG1)MI).[Y$" DGD\CGL?364,I5@"",
M$'O6=_PCVB;0O]CZ?M!R!]F3 /KT]A0!I53LY&%L (78;FY&/[Q]ZN57L?\
MCT7_ 'F_]"- #_-?_GA)^:_XT>:__/"3\U_QJ6B@"+S7_P">$GYK_C1YK_\
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M EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G>?\?6G_\
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MY]LKRO+#YS!1N(38N-P.&(S@XIMGK^LR6DTNI&+:NOI91&VE*G;YP7:WR<J
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MHH **** "BBB@ HHHH **** "BBB@"G>?\?6G_\ 7P?_ $5)5RJ=Y_Q]:?\
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MT]/"FD)JO]HK!+YOG&X$9N)#")2,&01YV!O?'OUK:HH **** "BBB@ HHHH
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M9;>V=H81O*Y9N<=/4D=>E7F\7Z2NK'3=UQYHN1:-)]G?REF(!5"^,9((Q_\
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M+C[H!'/OCKQ0!NT50L=9L-2,'V29I!/;BYC81L%,9. <D8S[=?:K] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6O+>6<P/#*D;
MPR;P70N#\K+C (_O?I3/+U+_ )^[7_P&;_XY5RBG<5BGY>I?\_=K_P" S?\
MQRCR]2_Y^[7_ ,!F_P#CE7**.8+%/R]2_P"?NU_\!F_^.4>7J7_/W:_^ S?_
M !RKE%',%BGY>I?\_=K_ . S?_'*/+U+_G[M?_ 9O_CE7**.8+%/R]2_Y^[7
M_P !F_\ CE'EZE_S]VO_ (#-_P#'*N44<P6*?EZE_P _=K_X#-_\<H\O4O\
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M4_+U+_G[M?\ P&;_ ..4>7J7_/W:_P#@,W_QRKE%',%BGY>I?\_=K_X#-_\
M'*/+U+_G[M?_  &;_P".5<HHY@L4_+U+_G[M?_ 9O_CE'EZE_P _=K_X#-_\
M<JY11S!8I^7J7_/W:_\ @,W_ ,<H\O4O^?NU_P# 9O\ XY5RBCF"Q3\O4O\
MG[M?_ 9O_CE'EZE_S]VO_@,W_P <JY11S!8ALX#:V4%N7WF*-4W8QG QG':I
MJ**3=QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+96+!-Q;!)R>2<UH5R.@7_CJXU9(]=T?3;6P*MNEMYMS@XXXW'O774 %%%%
M!1110 4444 5[U+J2TD6RGB@N3C9)+$9%!SW4$$CMU%<6_P_N9?,E>_LC)/=
MM<W%M]B;[(Q,808B\S[PQNR2<DGCT[F:6."&2:5@D<:EF8]  ,DUQ<'CRXE\
M*ZGJDFE^5=6;1M]G:0D>3(%9)6(&0-K9; .-K>E+349+'\/X1I!TZ6_9XFT9
M-*)6$*?E)/F=3Z_=]NM(G@F5-&N+6,Z/:W;RV\L<UEIQB!:%PX\P>82P)'0$
M8R:74?$>NV7A^WU6WCT2]BDECC\R"ZD*/YDBHK*0IX^;GGM726-Y,\GV2]C"
MWJ1"27R5<PX)(&UR ">.1U%5K=_UYDZ?U]QSL/AZY?XC?VI,&^S1622/M7;'
M)=D-'O4$DY$>1^(YJYXD\.WWB$BU>]LX].+QR%6M"T\;*P.8Y-X"DXZ[<CGK
M5N7Q/I]MJ365RMU;D"0K+-;.D<FQ=S;6(YP 3[@'&:A;QAIJ:=;7LD5\B74H
MAMT-H^^9BA==J@9((!Y_/%)=/+_,;Z_UT*&G>"8].\02WZ)I<L+W4ET'EL<W
M*,^20)=^, DX.W../>M/0-#ETKP__8]Y/#=P)OCC*Q%"8CGALL<GD\C ]JB?
MQCIBZ4FI+%?RV_[SS3':2,8/+.'\P8^4@@\'GCC-1:EXVTVR2_$$5U>36=M]
MHD6"!RH4IO7+@8&X?U]*3LHV>PU=O3<R-*^&B:==:3/)JTEP]G(SW&Z''VH#
M'DAOFX\O:OKG':M*'PE<6=[8W5KJ$6^WO+N=Q+ 2'CN'WLHPPPPX /(]JL-X
MQL8=,M;^YM-1A@FC$CN;.3;""<9<XX&?TYZ4P>-+)-2UFUNK>Z@CTPH&G,+E
M9-P7 &!U)8  9)[53NG9DZ-7':7X4_LTZ(?MOF?V7'.G^JQYOF8YZ\8Q[YJE
MJ7@F74O$PU62_@,:W4%S&)+8O+%Y>W]VC[\*K8).%SDGK6_INM6NJ0W#PK/'
M);/LGAEA99(S@, 5ZG(((QG.:H?\)EI26][-<B[M19+&\R7%JZ.$=BJ,%QD@
MD$>O'-+9KR_X'_ 'O<9IGA3^SM6@OOMOF>4UZVSRL9^T2K)US_#MQ[YSQ27/
MA5KO49;B>_+0N92(@C#&]-O][;D=<A0?4TD/CG1Y;I;<K?12>>MO();.1!"[
MXV!R1A=V1CZBD7QG8PV=L]SYLUQ<&X,<=E;R2%EBDV-QC(QQG/OBELAC9O"4
MTL<*?VF1M"F4^4P\R02&1FX<#DGHV[':FGP?*(4CBU,IB-8VQ$PR I7.5<$=
M?7'J#5BZ\;:+;112B2XGA>V6[:2WMWD6*%ONR/@?*#@]>>#QQ4/_  G6G1W>
ML1W4-S!;:9Y>^Z\EV1PP7!&!ZL,=<CFFUT$NXU?!TGV-K1]10Q8<H5ML,':+
MR\D[N1C)QQVYXJ[I7AP:9J3W7VII5_>>6C;\KO;<>KE>OHH]\T3^*[*UCMY;
MFUU&"*;;F22SD58MS;5WG'&3^603C-(GB_29-5&GJUQYAN&M?--NXB$R@DIO
MQC. 33OJ+H9R>#KU-0BVZM&NG0ZD^I1P"U_>;WW%E+[\8R[$?+G\JH6GPW>.
M*]6XU*%Y+G3IK!IH[4K))O(/FR,7.]N/8?2KVL>.$C\-'4])MKES)/#!!++9
MR,C"1PH< 8+#&<#(R<#N*T8/%>GBYBLII)FFWK;R7 M72'SRN[9DYVM[9..F
M<U/3^NW^5BKZW_K?_,QM<\"W_B%$^W:G9LQM!;OFS9EB8,3YD2F3Y6((!)R?
ME&,5U.F?VB7O6OQ&L9N"+5%QD1   L1W)#'V! K-M_&.GWFEKJ-G:ZG<VSG]
MV\5C(=XQDL..@Z9]>F:GM?%.FW]W;V]F9[CSX([@210,41'!*%SCY<[3^7.*
MHFUC,U7P);:MX@?5IKVX4O);,8EED Q$6..' Y)!Z<8XY)-:>M^'8=>O-/>[
MGD%K9L\GD1LT9>0KM5MZL"-H+<=]WM2Z;XHTW5;U;:V:?=(C20220LB3JI 8
MHQ&& )'YY''-;-+HA]6<9'X'NM.GM9-(U:*!;2[GN+>.[MGN BRJ R$^:K'Y
MMS9S_%BMU='E;7[35Y[I&EALGM71(BJN69&+#+' ^3ISUZ\5K44 06<=S%;[
M;NX2>7<QWI'Y8P22!C)Z# SGG&:Y:Y\$2W7BI=8EOX75+Q+N/?;%ID"IM\H/
MOPJ=3PO4UV%%'6X=+'GU[\-);O3X+$ZK"\$=I]G_ ']H7,;;V?S(QO 5CN )
M.>%%;K>%-QG/VW_6ZM%J?^JZ;-GR=>^SK[]*Z2BA:?U_78'K_7]=SEK#P=]A
MD5OM^_;:W5MCR<?ZZ;S<_>[=,=^O'2L]/AW'!>03*=+NP+:W@F^WZ?YQS$H7
M<AWC;D <'.",UW-%"TV!N^YRWBWPE+XFDBQ>0)"()8&AN+<S("^/WBC<HWC!
M )SUII\%9M+R#^T/^/EK-MWD_=^S[/\ :YW;/PSWKJZ*%IL#U.;?PGOU=K_[
M;C.I?;]GE?\ 3OY&S.?^!9_#'>J4G@&.?1K#39=08I:Z5+IV]8L%M_EX?KQC
MR^G.<]:[&BBP=;G'77@[4-3AOIM1U6W?4)[>*WADAM2D<8CD\P$J7)8ENO(X
MZ>M:)\.W,KZO/)J7EW6I64=LTEO$4\EU5QO7+$]7R!GC'6N@HH>JL"T.'T_X
M?&T:21[RU1Y+BTG9;6T,:9@8MW<DEL\DG\ZL:MX*FOK:^AAO+13=WKW8DFM6
M:2W9D5 T3+(I5AM)SWSC'KV%%#U!:'(:AX&6^M+V-[Q)9)[Z&^0W-OYB!HXT
MCVNN1O!"G/3[WM5K3?"@LKK3+G-A;M9M.S0V-IY,<AD"C.-QY&T<]_:NEHH"
MQQ%MX#N(-:?4FU"TFF'VD(\MD7>02]!*QD^95X 48&!VJN/APPCMI&N-.FEM
MY96CMI[)I+2..0("B1F3*X*!AAL9)XP:[^BA: ]3'TNTO[&[2T\NTATNWM$1
M%MXA&K2Y.XJN3M4#'!)Z^U;%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !117+R:CK&KZQ>V>DSP6L%D0CRRIO
M+OZ8["JC!R)E)1.HHK#AUF?3M&%QX@B6WG$GE@1?-YI[%0,]?2G1>*-.EM+N
M<^?$UH-TT,L9611V.VG[.717$IQZFU17/CQEI)M_M!-PL/FB(.8CAB03QZCB
MK-IXETZ[2Z):6W:U7?,EQ&495]<>E-TIK= JD7LS7HK&T_Q/I^HW:6R">*25
M2T/GQ%!*/52>M0Q^,=)EEE16GQ$&,CF([5V]<GU]*/93VL'M(]S?HK!A\5V,
MXG58+N.6.$SK'+"5:1/5?6J^F^,+>;0DU"]C>.1I/+$<<9.]B3@)_>XH]C/L
M'M(=SIJ*HZ9JUKJT,CV^]6C;9)'*A5T/H16!>ZGK$WB>\TZRO;2VB@B60&=,
MYR!WHC3DVUM8'-)7.MHKE-,\8Q#11=ZMA&%RUMOA4E7(&<CVJ[)XMTZ."WD\
MN[9YU+K"D),@4$@L1V'!INC-.UA*K%K<WJ*QY_$VG16MK/&9KG[6"88[>,N[
M =>/:D/B?3!I:W^^78TGE+'Y9\PO_=V^M3[.?8KGCW-FBL8>)]-.ESW[-*D<
M#A)HWC(>-B<8*_C3;?Q3I]S/-"B7(DCB,RJ\)4RH.Z^M'LY]@YX]S;HKE]+\
M90W.D?;+R"5)#-Y:1Q1,V\DG 7U.!S2ZAXQMXM#N;VT@E:>&01-#-&5*,?[P
M[#_]55[&I>UB55@U>YT]%8%MK;76L6,0E,<4]JTIADA*MD$C.3T''2EC\7Z5
M+=+$&F$;R>4ER8B(F;T#4O93[#]I&U[F]16%=^+=-LY[F%UN7>V;$OEPE@@]
M2>@%;-O/'=6\<\+;HI%#HWJ#TJ7"25VAJ2;LF245AZCJ=S;>)])L(V407*R&
M0%>3@9&#2#Q;IIO%@VW(1I?)6X,)\HOZ;JI4Y-)I"=2*;3-VBL*[\6Z;9SW,
M+K<N]LV)?+A+!!ZD] *NQ:U937UO:1NS27$'VB,A>"GKFE[.=KV'SQO:YH45
MC-XGTX6+70\YU$YMU1(R7=QV [TU?%6FG3;B]?SXTMW$<T<D9#HQ/&11[.?8
M.>/<VZ*Q;+Q3IU]<P01B=6G9EB:2/:'VC)P?H:O6.IV^HR7*VY9OL\IB=BN
M6'7'K0X26Z!3B]F7**Y#5]8\0Z=]HOVBM8K**<1QP/S),I.,@@]Z-5\0:M]O
MU!=-6W6'385EG$RDER1G QTXJU1D[--?U;_-$NJD[?U_6AU]%<O=ZIKEW;QW
M>FI;6UE]E%PT]Q\VXXSM&.GUI8]4U[5=+TV;3[>" W"%YYY>5CQTP,YYQFE[
M&5KMK^O^&#VJZ?UM_F=/16-X9U6XU?23/=+&)4E:(M']U]O\0]JV:B47%\K+
MC)25T%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BN0\=MJJZ9(
M]O,D-B@0N5)\QV+8Q[ <&M+Q'8I<I'<7FIR6FG0!FFCC)4N>WS?TQ6BIZ)M[
MD.6K21NT5@^$!>?V"K7;2L&D8P&8Y?ROX<UO5,X\LG$<9<T4PHHHJ2@HHHH
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MDVLCS*\<BJP*C[H&6SD=1CV(!U]%<[<^-M$MMC>=/-"88YY)X('>.&-_N,[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_012.jpg
<TEXT>
begin 644 form10-k_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'A JT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M63_OJCR?^FLG_?52T4 1>3_TUD_[ZH\G_IK)_P!]5+10!%Y/_363_OJCR?\
MIK)_WU4M% $7D_\ 363_ +ZH\G_IK)_WU4M% $7D_P#363_OJCR?^FLG_?52
MT4 1>3_TUD_[ZH\G_IK)_P!]5+10!%Y/_363_OJCR?\ IK)_WU4M% $7D_\
M363_ +ZH\G_IK)_WU4M% $+0X4GS9.G]ZGQ$M"A/)*@FG-]P_2FP_P"HC_W1
M_*@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 16_^H7\?
MYU+45O\ ZA?Q_G4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC!@%=%G=$D Z!U4@-^(-+^OP![_UW+T$R7%O'-$VZ.10ZMZ@C(-24BJ$4*H
M4#  ' %+0P6P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 (WW#]*;#_J(_P#='\J<WW#]*;#_ *B/_='\J 'T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!%;_ZA?Q_G4M16_P#J%_'^=2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?</TIL/^HC_W
M1_*G-]P_2FP_ZB/_ '1_*@!]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4;D2'1IEBN%MY6C94E8X",> ?SK"@AWV%QIMM!-!>0S[I(7U6
M4!V9=V5E&7(YW8PO/4>O1I%'/9&&:-9(G!5D<9# ]01WJNFA:2FGQV TVT-I
M&=RPO"K*&QC.".OOUI6W P$EG6#3-7EDFN+/R+>,L;V2%]Y8@L8U^1\[EZMV
M[U/I<LIU"QN#=SR2W;7(GB>9F0!6XPA.%VD!> .O.2:W3I>GM=QW9L+4W,8
M28PKO4#H V,B@:7IXDN)!86N^Y!6=O)7,H/9CCYOQJKZ@<[=W$\=W/>QW4YN
MH[_[.D'FMY93R\[?+S@G'S9QGWQQ5K069+V%5O)[A+BPCN)/-G,F')^\,GY0
M<G@8'R\#BMH:?9+>"\%G;BZ"[?.$2[]OINQG%+:V%G8^9]DM(+?S&W/Y,83<
M?4XZFDM/Z_KU!ZEBFJX9V7NM.J*/_72_4?RH EHHHH **** "BBB@ HHHH *
M*** &HX<$CL2/RIU10?=?_?;^=2T %%%% !1110 4444 %%%% !38W$D:N.
MPS3JBMO^/:+_ '10!+1110 4444 %%%% !1110 4444 -C<21JXX# &G5%;?
M\>L/^X/Y5+0 4444 %%%% !1110 4444 -D<1QLYY"C-.J*Y_P"/:7_=-2T
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M3WX)-7-/#PW5HKVETCV)N6N)/L[X8,Q(VD#Y]QPV%STYYJNH'1&_LQ>BR-W
M+LKN$'F#S"/7;UQ1;7]G>M*MI=P3F)ML@BD#;#Z''0US5S!/-<SV<5K<"Y>_
M^TI.86"!/+QN\S& <?+C.>V,5:T!6DNX9$LY[=(+".WD$T!B^<'[HR!N YY&
M1\W!ZTE_7]?@#.CJ*/\ UTOU'\JEJ*/_ %TOU'\J ):*** "BBB@ HHHH **
M** "BBB@"*#[K_[[?SJ6HH/NO_OM_.I: "BBB@ HHHH **** "BBB@ J*V_X
M]HO]T5+45M_Q[1?[HH EHHHH **** "BBB@ HHHH **** (K;_CUA_W!_*I:
MBMO^/6'_ '!_*I: "BBB@ HHHH **** "BBB@"*Y_P"/:7_=-2U%<_\ 'M+_
M +IJ6@ HHHH **** "BBB@ HHHH *BG^ZG^^O\ZEKD]:\6FPU*6S2U601,IW
M^9UX!]/?%95JT*,>:;LC:C0J5I<M-79UE%4=(U ZII<-X8_+,F[Y<YQAB/Z5
M>JXR4HJ2V9G*+A)Q>Z"BBBJ)$;[A^E-A_P!1'_NC^5.;[A^E-A_U$?\ NC^5
M #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BM_P#4+^/\
MZEJH]S'9:;)=3$B.)&=L#)P,FJZZI=_8O.ET:]64R%5@5HF8KU#9W[0,=B>O
M'/< TZ*RK?7$O)K=+2RNIXYH8YS*OEA8U<G&[<P/\)S@&G6NMPW=Z+=;>X1'
MWB&=POERE#A@N#G\P,@$C- &G167)KUO%?&W:"<1+)Y+76%\I9-N[:>=W3OC
M&>,YIVG:Q'J,IC%M<V[>6LT?GJH\R,YPPP3Z=#@C(R* -*HH_P#72_4?RJ6H
MH_\ 72_4?RH EHHHH **** "BBB@ HHHH **** (H/NO_OM_.I:B@^Z_^^W\
MZEH **** "BBB@ HHHH **** "HK;_CVB_W14M16W_'M%_NB@"6BBB@ HHHH
M **** "BBB@ HHHH BMO^/6'_<'\JEJ*V_X]8?\ <'\JEH **** "BBB@ HH
MHH **** (KG_ (]I?]TU+45S_P >TO\ NFI: "BBHYKB&W3?/+'$G]YV"C]:
M&TM6-)O1$E%8D_BK2XW\N%Y+J3LD"%B?Z5%_:>NWG_'GI*VZ'_EI=OC_ ,=X
M-8/$T]HN_IK_ %]YNL-5M>2LO/3\_P#(Z"J]S?VEF,W-S%%[.X!/X5C_ -BZ
MK>?\A#6I%4]8[5=@_/\ ^M5FV\,:3;'=]E$S]WF.\G\#Q^E+GJR^&-O5_HK_
M )A[.C'XIW]%^KM^1 _BNS=S'8P7-[)Z0Q''YFF_:?$E[_J;.VL4/\4S[V_(
M?U%;R1I$@2-%11T"C %.H]E4E\<_NT_S8>UIQ^"'WZ_Y(Y__ (1VYN^=3U>Z
MG!ZQQ?NT_*J%[X'MFFWV]RT,;%5$>S=CH#R3^-=?44_W4_WU_G2E@Z,E[T;_
M '_YE1QM>+O&5ODK?=8@TK3QI>FPV8D,@CS\Q&,Y)/3\:N445O&*BE%;(YY2
M<I.3W844451(C?</TIL/^HC_ -T?RIS?</TIL/\ J(_]T?RH ?1110 4444
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MBB@ HHHH **** "HI_NI_OK_ #J6HIB"JX.<2+_.@"6BDR"2,\CK2T %%%%
M"-]P_2FP_P"HC_W1_*G-]P_2FP_ZB/\ W1_*@!]%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 16_P#J%_'^=2U1N1(=&F6*X6WE:-E25C@(
MQX!_.N>D'D^&]6MH/MEA<V>Z24+=M+N8KN!61B6VGAOX3GJ.3D Z^BN>U99[
M74X=2E#R62B&/:E])$5<N1GRQ\LF=R\$]N]0:7+*=0L;@W<\DMVUR)XGF9D
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MA/\ &D_M2Y?_ %.F3GT+_+6/]I87[,[^B;_),KZO4ZJWK9?J1>?XA_Y\[/\
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MJ$(WW#]*;#_J(_\ ='\J<WW#]*;#_J(_]T?RH ?1110 4444 %%%% !1110
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MW5HKVETCV)N6N)/L[X8,Q(VD#Y]QPV%STYYKJJ*$!R5S!/-<SV<5K<"Y>_\
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MT,JKYD?_ 'T/Z9J?82?P-/T_R=F5[1+XM#K**SM/U[2M4 ^Q7\$S'^ -AO\
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M07P\Q?IN[?@*ZRBM57J)6O=>>OYD.G%ZV.3_ .$@\0Z9QJV@-/&.L]@V\?\
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M 4444 16_P#J%_'^=2U%;_ZA?Q_G4M !114%[+-!87$UO%YTR1LR1_WB!P*
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M]4_[Z% %+6=&M-<T][2\3*GE7'WD/J*YW2?AYHL6FJM]$UW._P QEWLF/0
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M=PBD#)P,YR3VZ=*?$TUU+J,R2S*H_<0B,C(*CYF4-\N[<2.?[HHN!ITA4'J
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M_C4:Z+I26CVBZ99+;.VYX1 H1CZE<8)XJ]10 R**.")(H8UCC0!51!@*!T
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M:1VDNG6DEM$<QPO I1/HN,"DFT?3+F"&"?3K26&$8BCD@5EC'^R"./PJ[10
MT@+&0   , "DA_U$?^Z/Y4YON'Z4V'_41_[H_E0 ^BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** (K?_ %"_C_.I:BM_]0OX_P ZEH ****
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M6< #22;&;:"0.B@D\D=!0"UV+M%("& (Z'D4M !1110 4444 %%%% !1110
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M_P &,/\ \50!T%%<_P#\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\
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M\Q@G+$?,>!Q3);[PD_B*XUN'XEP07$ZJAC6_L71$'\";T9E4GD@'D\TZVO/
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MZ,03M"J QR%Y<,>![YSO,\+6]G)90_$33[NUN[U;F\2]U"T&1OWOM\M%.6(
M()Q@F@#7BL;S3/!0U&77)M&D=);^\>&&)V::0[@"9%88&=NT#)P #V-*36O$
MUY:7TKWYTRYTG2(;N:".&-EFG96=EDW@D(-F,*5/)YZ5:U_5?!VO75C<-\0+
M*S-DYDC2VU"T9"_9F617!(['MGBJ]W<^";YB\WQ"M?,F@%M>NFI6BF\C!)"R
M87 ^\PRFPX/6@#1U2_U:*;1K^UUB0R:A<0+%I0@B\MXB 9225,F57<VX, ,
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M@ HHHH **** (IO];!_UT/\ Z"U1ZAJ%KI5C)>7LHB@CQEL%B23@  9)))
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MD\=#6?X,OM0OEOFEN;R]TH&,V%[?6OV>:92N6RNU,J#C#;!G)ZXS0!U-%%%
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M7TL27=PL)?OC:&3):8<' !_&L[2X[V"]UG6I+OQ%-9O;06<-S+8*+O(9BSK
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MZI$ULLD>H6,4-S:%Y%5OE\L*RD$X.UAD'#'L >A;;C_GK%_W[/\ \51MN/\
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M9M[QH!M 4GA">W/:N_C"\C46SZ,IU4:@+![=;L&,,T9D5Q(5!*8QGY01S@'
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MS^9!F2/[YQ^[/]T^]/>*66-HY&A=&!5E:(D$'J"-U.F_UL'_ %T/_H+5+0!
MD4L4:QQM"B* JJL1  '0 ;J=MN/^>L7_ '[/_P 54M% $6VX_P">L7_?L_\
MQ5&VX_YZQ?\ ?L__ !5<]>7FJ6WCS2K4WR'3[N&X/V9( ,;%0@LQR2<D]-HQ
MQ@]:Y]/$FLPVMGXBFU!I+2[OY[8Z=Y48CCC7S A5L!]^8P22Q'S'@<4 >@[;
MC_GK%_W[/_Q5&VX_YZQ?]^S_ /%5QGA[5-9&H:"^H:HUY'K=C)<O T,:+;N
MC@1E0&VX<CYBQX'(YH\0:IK,FIZZNGZFUC%HM@ERL:PQN+B1@[8D+J3LP@&%
M*GD\]* .SVW'_/6+_OV?_BJBN5G^RS9DC(V'($9]/K7!MXDUFZM;[Q!#J+06
MMC>P6RZ>(8S'*C>7O+L1OW?O#C:P VC@\UZ#=?\ 'I-_US;^5 !MN/\ GK%_
MW[/_ ,54<5L\&_ROL\>]B[[(<;F/4GGD^]6:* (MMQ_SUB_[]G_XJC;<?\]8
MO^_9_P#BJEHH BVW'_/6+_OV?_BJ-MQ_SUB_[]G_ .*K)\6S:C;>&-0NM-O$
MM)[>"27S#")&PJ$X7)P#D#DAAC/'<4M5FO&\*P:H_B";2HXK,332PP1,TCE1
MC/F*PQG^$ $DC!'0@'1[;C_GK%_W[/\ \51MN/\ GK%_W[/_ ,57FVL^)/$-
MK!:&YO9]/N_[,AG*6T4+Q+<,<-]J+JQBCZ8;*C ?YB0!7>:G%<W&G(T>KG34
M0>9/<P)&QV@$G:9 RJ.^2IX';K0!=VW'_/6+_OV?_BJ-MQ_SUB_[]G_XJO/)
M_$^O/X&46MU_Q-C;SW9O6A7*VJ%MDK)C:&D 4 8QRQQQBN]TN:2YTBRGE;=)
M) CNV,9)4$F@!8%G\LXDC'SOUC/]X^]+]F?[1Y_^C^=MV>9Y/S;<YQG.<9[5
M);_ZMO\ KH__ *$:EH BVW'_ #UB_P"_9_\ BJ-MQ_SUB_[]G_XJI:#G''6@
M"+;<?\]8O^_9_P#BJ-MQ_P ]8O\ OV?_ (JN9T.YUJYU+Q)IUUJD<DUL\2V\
MJVJJD1>(,<)G) )SAF)]ZJV5UJOVCQ#9_P!O7MU9V0B"Z@+..6>.3DRQHD<8
M5R!MQ\C$%N0<8H [#;<?\]8O^_9_^*HVW'_/6+_OV?\ XJL#P7J5WJ6EW1N[
MF2X:&\DBC>>-8YS&,;?-C4+L?GH54XP2!FJ=[=ZKI7BNQB&LRWJ7 GFN;$P1
M+'!;JI*NI"[P0VU?F9MQ)X'8 ZO;<?\ /6+_ +]G_P"*J*59_,@S)']\X_=G
M^Z?>N.\(>([W5+^SEU2758'U.U:YM;>6*V%HR_*?W93,N0&'^L(SR<=AVTW^
MM@_ZZ'_T%J &O%++&T<C0NC JRM$2"#U!&ZA(I8HUCC:%$4!558B  .@ W5/
M10!%MN/^>L7_ '[/_P 51MN/^>L7_?L__%5+7,WEYJEMX\TJU-\AT^[AN#]F
M2 #&Q4(+,<DG)/3:,=CUH Z';<?\]8O^_9_^*HVW'_/6+_OV?_BJX*P\6W5Q
MK O;Z35K;3I;R>UM5CBMC:2&/> &)S-N.QCGY5S@?6?PAXCO=4O[.75)=5@?
M4[5KFUMY8K86C*-I_=E,RY 8?ZPC/)QV !VVVX_YZQ?]^S_\51MN/^>L7_?L
M_P#Q5<3XI\1W]OKMU9VYU6&QTZS2ZNY],BMGD&XM][S\C: A.$4L?PP:M_XD
MU%?% A@U:9(3=6T<"B.$V;Q.H+>=(5WI*<G"[E)RF%()H [NY6?[++F2,C8<
MXC/I]:EVW'_/6+_OV?\ XJBZ_P"/2;_KFW\JEH K16SP;_*^SQ[V+OLAQN8]
M2>>3[U)MN/\ GK%_W[/_ ,54M% $6VX_YZQ?]^S_ /%4;;C_ )ZQ?]^S_P#%
M5C^*?M$.ERWJ:]-I%O;1.[O##$[,W\.3(K#&>P&22.>QYS6]8UZQT#2]0FOK
MJSU%[>%I+2.R4VOF$KYAGF92(UP?[Z8P<%J .[VW'_/6+_OV?_BJ-MQ_SUB_
M[]G_ .*K@-8\1ZSIFM7$T]Q?PQQW\$-O:II^^TGMW**7:?8</EVQ^\7E0-I[
M]7XAU*XM;:*RTXK_ &I>DQV^1D1C^*4C^ZHY]S@=Z -3;<?\]8O^_9_^*HVW
M'_/6+_OV?_BJXFTO]3O?AW9:U>>)9M/:.U>2XN(K>$M*^<+G<A7'^RJ@DD8/
M8]9H<U]<:#83ZE$(KZ2W1KA ,;7*C(QVYH E@6?RSB2,?._6,_WC[TOV9_/\
M_P#T?SMNSS/)^;;G.,YSC/:I+?\ U;?]='_]"-2T 1;;C_GK%_W[/_Q5&VX_
MYZQ?]^S_ /%5+5:_@N;FS>&TO&LY6('GI&KLHSSM#9&<="00/0T 2;;C_GK%
M_P!^S_\ %4;;C_GK%_W[/_Q5>?)K.OO8'R]1O[C3!JDD']K6EBD]R8%3(*QI
M&5(\P%-PC(P.G\5-TCQ!K/B6XM-*AU:XLFCCNWEO%M8UFE\J7RX\I(A5"0<L
M-H.1@;>E 'H>VX_YZQ?]^S_\51MN/^>L7_?L_P#Q5<U;^*)T^&G_  DEQ'')
M<QV33.JC"LZ@CID\$BL_2]4U"6#4;._U+7;74DMX[EA/96TA2,DY:W2!7W="
M 'WL..#W .UVW'_/6+_OV?\ XJF1AQ=2;V5CL7[JX[M[FL/P7J5WJ6F79N[F
M2X,-Y)%&\\:QSF,8V^;&H78_/0JIQ@D#-;P_X^Y/^N:_S:@#.^R65Q=Z9?RW
M.V>RB=44.H!WJ =PZ]O:L7_A!O#F=23[3*;;4;N.ZN+4S*8F*$MLP1]QF))7
M/)]!Q6U<:]IFC_V5:W]T()K\B*V!1B'? XR!@=1UQUJ]%?VLU[<V<<N9[4(9
MEVD;0P)7GH<X/2@# 3PCX<M+U[K2A%I$CV[6[_V:8X X)!#$*.64C@^Y!R#B
MHKCPGI][:7L=[KM]=75VL2->220B1%C?>BJJH$ #9/W23GG/&->P\3:-J6C3
M:O:WR-I\._S)W5D";>N=P! QSGN"".M0#QCHITRXU%IKJ*WM]GF":QGCDPYP
MI$;('8$\ @$'GTH I2^%M/NX+Q;_ %N]O;FZMS:M=RS1+)'"2"R($144'')V
MY/KP,/A\(^%;+4;*_P!-LK'3;BU9B&LHXXO-4J5*28'S+SG'J :T]+\1:9K$
M\UO:2RK<P@-);W-M);RJIZ-LD56VGUQC@U)INN:;J]Q>P6-R)I;*4PW"[&78
M_IR!D<$9&1P?2@#F;SP39W&FOID'BC4[73-X>.RCDMVB3#;@F6C+E,_PEL8X
MZ<5M7^FV^KZ5;6^H:B@O(&65+RS(A:.4?QH&+8ZD8.X$$@Y%(?&&AB\%O]JF
MP9?(^T"UE^S^9G&WS]OEYW?+C=UXZ\5=U?6['0X(IKYY56:40QK#;R3.[D$@
M!8U9CP#VH R9?#]O<6JK<>(M0FO(YUGAOFFA$L+ ;<*JH(\$$@@H<Y.<\8?!
MX?TN'R))-1FGN8[S[:]Q+*F^:784&["A0 IQA0HX'OG0LO$&G:C9)=VCSRQ-
M.;<@6LH>.0'!#H5W)CN6  XSUK3H YZ;P_I,T,T37D@6744U)L2IGS%96 ''
MW<H..O7FLG2?#*&6YEU'4KE(&U2:\%@+B-H)#YA:-SP6'\)VA@,CD9SGKK2_
MMKXW MI-YMYC!+\I&UP 2.>O4<CBK- ',+X9TU;QF_M>Z-@;K[7_ &:98_($
MN[=N'R[\;_FV[]N>W:EE\.V=W>3W-_KEW>-);S6T2RM H@27&X)LC4G@ ?,6
MZ5LSZG#;ZO:::ZR&:ZCDD1@!M 3;G/.?XACBKM '/)H6GPWNFW,&J3Q&QM/L
M>P21E9XN/EDRI_N@Y7::72](BTB6);?Q#>-80@K%82- T2+V4-Y?F8';+GIW
MKH*H7>K6]GJVGZ;(DAFO_,\IE VC8NX[N<]#Q@&@"AJ.BZ7J=[=74UXRO<Z>
MVGN$E4 1L221D?>Y^GM1=Z%H]^X-S.73["]@R>: &C;;GISN^4<@BMZB@#E8
M/"NF"6234-8O-4:2T>R;[9/'CR6QE<(J@'C[W4YY)P,68=):*UN+:3Q7J<\<
ML)A7S&M@T.>-RLL0.X#NQ/Y\UT-5;+4;34?M'V67S/LT[6\ORD;9%QD<CGJ.
M1Q0!FZ/HVD:#-<-ITPAAG2-6MQ*#&"B[0P'4,5"@G/.T=ZB\/6W]DSZO \D7
MV:6^>ZMW\Q3D2 ,PQG(P^[\Q70U2L-3AU&:^BA616L[@V\F\  L%5LC!Z884
M 0:I9:?JWV+S[K;]DNDNH_+D49=,X!SGCFL[_A&M)"(WV^;[6E\;_P"V>:GG
M&0\$$XQMV?)C'W>/>NEIKNL:,[D*J@DD]A0!S<OAG2)+6YA6^FBEEOVU".XC
MF4203'NAQC&,C!!!!(.0:K:II-Q)IL5@FK3ZD;F^@>ZN+R:(>7"C!R J!%YV
M@<+DELGI6M)XITJW\/VVMWDS6EE<[/+:9#N.[[O"YZCGV')Q@U/-K^EV^NVV
MBRW874+J(RPQ%&^=1G.&QMSP>,YX- %W[5;_ //>+_OL4?:K?_GO%_WV*R[S
MQ3I%C"\LUQ*P6[^Q%8;:65S-C.P*BECQW Q2V_BC1[FS@NH[IO+GNOL:!X9$
M<39(V,C*&0\?Q 4 7I;F R0$31G#DGYAQ\IJ7[5;_P#/>+_OL52M-2AU*1O*
M5T>VNWMY4?&0RJ?0G@@@CV(Z5I4 1?:K?_GO%_WV*/M5O_SWB_[[%2T4 <U?
MZ%%?^(+;5_\ A)+Z"2VW"&"(VWEH& ##YHBQSM'4Y],4V#PQI,%^LW]HSR6D
M<TEQ%8/+'Y$4LF=S#"[SG<_#,0-QP!QC5.OZ7_;B:*+Q&U!E9O)0%MN "0Q
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M]*S[CQ9HMMJ@TZ6\(G+(A989&B1G^XK2A=BLW& S G(]16K=?\>DW_7-OY4
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M.!SR*=K#72W>OS?V5J,G]NZ5#%9JEJ[E9-KJ8Y"H(BP74DL0.3SP:[[;<?\
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MUB_[]G_XJC;<?\]8O^_9_P#BJ ,#2H+C4?%>I:S=6\T,5L/L%BDJ%24!#22
M'LS8 /<(#WK?F_UL'_70_P#H+4;;C_GK%_W[/_Q512K/YD&9(_OG'[L_W3[T
M 6J*BVW'_/6+_OV?_BJ-MQ_SUB_[]G_XJ@"6N,UO44C^(&AM]CU.2.UCG2:6
M+3;B2-3($V_.J%3T/(.!CG%==MN/^>L7_?L__%4;;C_GK%_W[/\ \50!P]W]
MKU+QK:26J:O*T37$<D=]9&*WLU*%=\4@15=F8+C+2'#'&WFLWPE%?:,^GB&T
M\0;+'39%U6WG$[1O*H78(%D.QF)5L>5\N#SU%>E;;C_GK%_W[/\ \51MN/\
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MO;O%Y5NGS,K!@"I? 3!P<,>.*Z3;<?\ /6+_ +]G_P"*HVW'_/6+_OV?_BJ
M.0UJ_CA\?:%MLM2:*TCGCEDATVX>-"ZIL^=4*D<'D' QSBH_%)?6!IMR]CK$
M5EIVJ.ETL$<J3.GEL@DC\H^84W,.5YQGMFNSVW'_ #UB_P"_9_\ BJ-MQ_SU
MB_[]G_XJ@#RRYTGQ9?>&[F0V?VVQBANS8P:A=2I=J'WA&93&[.XC.%#$,-QS
MST]&\/"[7P[IZWT"07*VZ*\:.7"X&.I53GU&.#5W;<?\]8O^_9_^*HVW'_/6
M+_OV?_BJ "W_ -6W_71__0C4M58%G\LXDC'SOUC/]X^]2[;C_GK%_P!^S_\
M%4 2U6O[R.QLI;B9)W1!RL$#S.<\<(@+'\!4FVX_YZQ?]^S_ /%4;;C_ )ZQ
M?]^S_P#%4 <3X8U2ZTWX9)Y&EZB^HV<)C6TEL9HF:4D[0 RC*Y(RPR ,Y/%1
MPZ8_A#4](NIK>\O;=-.FMYYK:V>=S<.ZR%BJ M\YW<]!@9/2NZVW'_/6+_OV
M?_BJ-MQ_SUB_[]G_ .*H Y#22=-\(0:%JVD:E,%TW?<B"$NNUF*M$"IR7 /W
M5R<#C/%9MM#;>5JD,UGXBG\+.+=(HYTNWN$F!)9D#?Z0$&(^@Z\CC)KT';<?
M\]8O^_9_^*HVW'_/6+_OV?\ XJ@#G_!RWBVVH&4W_P#9YNB=/&H&0SB+:,[O
M,_>8W[L!_FQCVK?'_'W)_P!<U_FU+MN/^>L7_?L__%4R,.+J3>RL=B_=7'=O
M<T <EXJU37-/FT%=%?<?+EGGM=BM]I2-4)C!()!(+8([XJ&3Q#J>J?VM?:#>
MB:WM([2\MX1&I$\95FDCSC(+ <=P0/>ND^R65Q=Z9?RW.V>RB=44.H!WJ =P
MZ]O:JFD>'M&T2ZU>>SN64:I)YDL;3*4C/.=@[ EF..>30!@S:SXBU'15UNR>
M^BTR[O5*+:6B27,-D 0)$1U)8LV&(*L0IX&:;?\ B"5O[ CMO$FIR6ES%<F2
M[T[35FGD9"H4/&(7VD9(;"+R.B]*Z/\ LBVBT>PTZQUR[L18QK''-!+$790N
MW#!U9&_[YX/3%4_^$5L(ELFL]>OK.YM3,WVF.2%WF:4AI"_F1LN21G@ #M@<
M4 /\1ZA<:5X!FOH-3N4E2.(_;;F%$E4,Z@LR,@53@G@H,>E<U=^(;\Z9K']F
MZU-K=C;269@U")HE=Y&F >%9(@D;#;M],;R"?3M;RPM-0T/^R[W4Y)U.S?<,
M\:R.58,"=JA>H'114VJVUCJ]@;.XN@L9DCDS'(H.4<..N>ZB@#)C\4WD,6K)
MJ6GV=G=Z>L<A!U >04DSAFE9%V $-N^4XQQNK.M_B%+>6%N]EIUG>W<VI'3@
MMKJ(DMRWEF0.)MG*X S\N1SP2,'6U/P]I6J3W<\E_+%/<&W8212IF)H6+(R@
M@C.3SN!!]*AMO"^EV\T4\FJW5S<)?_V@TLTT>7E\KR^0% "X[ #!Z8'% %74
M/&>IZ>-1<Z!%-%I;1+>,E]@G>JL1$"@WD;OXM@/'/) M)XKNHAJT.HZ?:6EY
MI\<4Q#7X\CRY,A6>5D79@JV[Y3C'&[I5J[T+2KR'5XI+QPNJ,CS[95RI554;
M>..%'7-0ZGX:TG5+N\NY+^6*XN1;D/%*G[IH'+HR@J1G+'.X$'TH SK'Q\^I
MV40L;&SN]1EOVL8TM]0\RU8JGF%_/"9V[/\ 8SGC'>DU?X@-H]W'I]U;Z3:Z
MBMO]HGCO]76WC W%56)RA,A.TGD+@8S@G%6AX2TT0L?[;OOMQO/MJWYFB,R2
M[!&2!LV8*C!4KCG@#C%B30(/-2XM?$>H6M[Y0BFNHY('>X4$L-XDC9>"S8VJ
MN,X'&  !^G^+(-38M;6S>0=,CU%'9\$ARWRD8XQMZY/6L[3?$6N:GXITU([2
MT32[O2EO&1KH[TW%<G'E<D9QC< 1SP>*OZCX?L]2G2=M<O;>8VWV6XDMYHD-
MS'G.'^3Y3DGE-I&XX-.M]!T^SN]+N;75;B%M/M!9A1)&5GB&,"3*GNH.5VF@
M#+TOQ;J%[IVE0Z?8?;M0O8IYV^VW0B6...39RZ1<DDJ  GU/&3/J/CC^S-;L
M=/N;?3XFN)(8G@?4T^UJTF "L(!W*"0"=P/!.,#E\?A/3+:UT^.QUB[LI[%9
M(XKJ&6(R,DC;F1@Z,I&<'[N1@8/6D?PAI;7C2C6KY8'N8KM[47$91YH]H#LQ
M4N<[%R"V.^,\T 6O"-S<7/\ ;OGSR2^5J]Q''YCEMB#;A1GH!Z5CZ+XLUB?1
M]"B2RCU+4=12Y<R2SBW1!')C+;4/&"!\JDYQQR2.GTNRT_2?MOD76[[7=/=2
M>9(IP[XR!C''%4M,\/Z3I7]F^1>2-_9\<T<6^5#N$K!FW8 [CC&/QH IP>,+
MS4(=-BT[2H9-2NXYI);>XO#&D(B?8_SA&+?.0!\O/4XK%L?'1TG0-,2]DM5U
M"]FNVSJVHBWCC1)F!#2X?)&54  ].P%;S>%]-2.U^QZS=V5Q;-,4N()8BY65
M][H0R,I&<8XR,#!ZY(_"^F6MG9PV&KW=G/:&417<<T;R[9&W.K>8K*P)QR03
MP.>N0"J?B';)H-CK36+R6-R\D#R6TOG;+A255%(&&5V!"OD<E>.>+_B?5+ZR
M\$S70C%KJ,R1PJJ2;O)EE94&&P,[2W7':EO?#VFZK!;PZOJ4VHI#%+'MG>-0
MY<;2[!%4;@I(!  &3QGFFZ[I:WO@V72;>_\ /N8HD,$T\J[WDC(9"QX&25&3
MB@"'7[S7K6ZAAT:*=H-/MQ=7+-#O-V 0! K$9+E0[9'.0OK5,2:YK.N:^++Q
M!=6"6)A^RVYM86C^:(.1(&3S#DGD!E/TKKXKR%X4:22.-RH+(9%.T^G!KG[K
MPU:7&IW]Y'XAO[6/4-GVJVMY8520*H7&XQF1<@8RK ^A% '(WWC:]O/LUV=5
MU'2X9=#2]6.QLDG03,S#]XS1/L3@<LR#W%=!+JNKW]\UE->W&E"PT^"ZOFTZ
MV6XFDEDW#8@*2#:-AZ*2<C! '.Q'H.B17+RHT8B:P73OL^]?+$()(&.O?'6J
MO_",V,2636>NWUI>6MLMK]LBFB:2:)>BR!T9&P><[<CG!&3D J0:PTD?AO4+
M?5)[^WFO);&622%H#("' +QD !U:, G:/XL  XKLZXX:''93>']/LYQ+86=U
M+>W-Q/,F]Y"&QP,<EY"W  &WMQ76?:K?_GO%_P!]B@ F_P!;!_UT/_H+5+56
M6Y@,D!$T9PY)^8<?*:E^U6__ #WB_P"^Q0!+147VJW_Y[Q?]]BC[5;_\]XO^
M^Q0!SUY>:I;>/-*M3?(=/NX;@_9D@ QL5""S'))R3TVC'&#UKGT\2:S#:V?B
M*;4&DM+N_GMCIWE1B..-?,"%6P'WYC!)+$?,>!Q70W^A17_B"VU?_A)+Z"2V
MW"&"(VWEH& ##YHBQSM'4Y],4V#PQI,%^LW]HSR6D<TEQ%8/+'Y$4LF=S#"[
MSG<_#,0-QP!Q@ SO#VJ:R-0T%]0U1KR/6[&2Y>!H8T6W<!' C*@-MPY'S%CP
M.1S1X@U369-3UU=/U-K&+1;!+E8UAC<7$C!VQ(74G9A ,*5/)YZ5>LO"NFV2
M%$UJ^=8[5[2S#3Q@V438R(BJ@YX7#.6(VCGKE;WPOIM\V3K-[%YEJEI>>7/&
M3>1+G D+*3GELLA4_,>>F #";Q)K-U:WWB"'46@M;&]@MET\0QF.5&\O>78C
M?N_>'&U@!M'!YKT&Z_X])O\ KFW\JYV;PQI,NH/<+J,\5K+-'<3V$<L8@FE0
M *S97>,;4X# ':,@\YW;FY@:UF FC)*$ !AZ4 6J*B^U6_\ SWB_[[%'VJW_
M .>\7_?8H EHJ+[5;_\ />+_ +[%'VJW_P">\7_?8H R?%LVHVWAC4+K3;Q+
M2>W@DE\PPB1L*A.%R< Y Y(88SQW&3XCU+6+;P=8ZI9Z@EN^+=IO]'5FD+N@
M(!/RJ,,V?E)Y&",5M:[90:YI4NGG5YK**92DK6S1;G0@@K\ZL #GL ?>LJ]\
M+PW^@V^CS>*=2^SPE<NIM0[A2"@8^3CY2HQ@#/?- $7C;4]0TD175GJ=Y XV
M>7 EFK6S?.-QN)F0B-<'^^AX.,FM7Q9/J%OX7O[O3+U+2:"WDF\PPB0X5"<+
MDX!SCDAAC/'<5-0\/0ZI;_9KOQ-J3VTD2Q7,(D@"W*@DG=B/*D@X/E[,BGZE
MH-MJ-OJ%N/$-_;0WRJDD<4T3*B!"A1 Z,%# Y..<CJ* ,K6/$&JG^P]/L5OW
MGN[%KRXET]+<S[5"#Y?/(C&2_/!/& .<CJ-!OH=3T&QO8+B:XBFA5Q+.JK(W
M'\04 !O4  9K&?PQ:M:V*+XDU!+NR1XHKU&MQ+Y3  QD>5L(^5>=N>.M;6FP
M:=I&F6^GV<D:6]N@CC!DR<#U)/)]Z +=O_JV_P"NC_\ H1J6JL%S (R#-&/G
M<\L/[QJ7[5;_ //>+_OL4 2T'...M1?:K?\ Y[Q?]]BD-U;D?\?$8]]XH YS
M0;O6I]4\1V%WJ,,\UK)$MO(;4+'&6B#?<#;BN3T+D^]9<>MZU'X+UBYDU S7
MEKJ4ELLX2)'\L2A<1J0$+X)"ALY. <]]73_#R:=J%_>IXJU&6:^'[WS/LN-P
M7:K#$(P5 X[>H-5H/!UC%8W-K)XDU&<370O%>1K8-#.'W^8NV(#.>S KCM0!
M;\&:E<ZE9WYN+Z:[2&[:.%KJ)(KE5"CB6-54(<Y(!53M*DBDL[S5E\>7VG7-
M^DUK]@6XAB6 (L9,C*.Y9C@#/S8/8"G6GAZRM7,W]NW\EU)=I=SW+7$:/<%5
MVA'"*J[,8^4 =*1= B7Q')K?_"3:@9GC\DPYMO+$>2P3_5;L GKG/J30!#I<
M^JV_C-],EUF758%LO.N_,AB06TI8; NQ00&&\[6+'"@Y]>GF_P!;!_UT/_H+
M5SGA_P .P^'7/D^)=0NH6=I)(KHVQ\UVZL[K$KLWN6[#M6]+<P&2 B:,X<D_
M,./E- %JBHOM5O\ \]XO^^Q1]JM_^>\7_?8H EKF;R\U2V\>:5:F^0Z?=PW!
M^S) !C8J$%F.23DGIM&.QZUT/VJW_P">\7_?8KG[_0HK_P 06VK_ /"27T$E
MMN$,,1MO+0, &'S1%CG:.ISZ8H I#4]0M_'=O8?VG=SPS^=YL-U9K! F%#((
M'*!I6]<,XP&)VX%-\)ZAJT>HKI_B.XU9=3FMVE6&[2T\A]K ,8F@&[C*\.<X
M/2KS^';.?44N[K7[^Y2%I'MH))XPMNS@@LK*H<D!B!N9L9]A1!X>M5EFN+KQ
M!?WMV]LUK%<S31));HW7R_+10&) .X@G@<T 1>-#J%EILVH6.NZC:SL$@MK2
MWCMF229FVIGS(F;DD9YZ UF7>N:U'K&AVUOJ&^SAO(["^N/)3_3)BC%\<?*%
M*\[<<L1_":Z.32M/GN-)FGU"68Z7DQ"292)'*;-[\99@"><C[QXJAJ7@OP?J
ME[#>3:9I:W$=R+EI$MX0TS<\.2I+ DY/N!0!TMU_QZ3?]<V_E4M5;BX@-K*J
MS1DE"  P]*E^U6__ #WB_P"^Q0!+147VJW_Y[Q?]]BC[5;_\]XO^^Q0!SWC>
M\U33M$%[IM\EJ(IHA(/(#L^Z1%P"V0!@G/RD],$8YSO&OB'4[53%HEP(#920
MO>S^6KXWNJK$-P(R0Q8]P /[PK8\1Z1;>)+);236[FR@#!G6U:']X0P9<ET8
M\$#ICWS5'4_!7A?6[0IJD-G=WC;/,U&2"#[3)M((RP0#D#!P!QQ0!%KNIZAI
MWBC3DAU.[V7%U%&]M)9JEFL3 @YG9.9">BA\DD#;U-:_BV;4;;PQ?W6FWB6D
M]O!)+YAA$C85"<+DX!R!R0PQGCN*EQX<T^YNHB^L70T^*6.9-,62(6ZM'C9C
MY-X4%0=H;;D=*??:'!>Z3>Z<?$.H1QWDLCRN)HG8(XP8EWHP5/0 9'K0!%J<
MUQ_PBL.LRZ[J&GK!9">86D=N?-.T'_EI$_.> !CK6GX:CU./P[8_VS<M<:@T
M8>=V15()YVX4 < XX SBJ/\ 8%E+I%CIEWK-U=P6D\<P,KQ*9-ARB/L105!
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M)I#U9L #H ,      5>CD22ZD*.K#8HRISW:@"Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>lpcn-20211231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaiDKbP9z5Z8qekhvWB3bWkKnykuni0s2CMk3DjmEQMD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:lpcn="http://lipocine.com/20211231" elementFormDefault="qualified" targetNamespace="http://lipocine.com/20211231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://lipocine.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
	  <link:definition>00000007 - Disclosure - Description of Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/MarketableInvestmentSecurities" id="MarketableInvestmentSecurities">
	  <link:definition>00000009 - Disclosure - Marketable Investment Securities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ContractualAgreements" id="ContractualAgreements">
	  <link:definition>00000010 - Disclosure - Contractual Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LoanAndSecurityAgreement" id="LoanAndSecurityAgreement">
	  <link:definition>00000011 - Disclosure - Loan and Security Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000012 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000013 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/Leases" id="Leases">
	  <link:definition>00000014 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000015 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/KPlan" id="KPlan">
	  <link:definition>00000016 - Disclosure - 401(k) Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000017 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/AgreementWithSpriasoLlc" id="AgreementWithSpriasoLlc">
	  <link:definition>00000018 - Disclosure - Agreement with Spriaso, LLC</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/AccountingPronouncements" id="AccountingPronouncements">
	  <link:definition>00000019 - Disclosure - Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" id="MarketableInvestmentSecuritiesTables">
	  <link:definition>00000022 - Disclosure - Marketable Investment Securities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LoanAndSecurityAgreementTables" id="LoanAndSecurityAgreementTables">
	  <link:definition>00000023 - Disclosure - Loan and Security Agreement (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000024 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000025 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000026 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000027 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails" id="ScheduleOfDisaggregationOfRevenueDetails">
	  <link:definition>00000028 - Disclosure - Schedule of Disaggregation of Revenue (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" id="ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails">
	  <link:definition>00000029 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" id="ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails">
	  <link:definition>00000031 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" id="ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
	  <link:definition>00000033 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" id="ScheduleOfAvailable-for-saleSecuritiesDetails">
	  <link:definition>00000035 - Disclosure - Schedule of Available-for-Sale Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" id="ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails">
	  <link:definition>00000036 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" id="MarketableInvestmentSecuritiesDetailsNarrative">
	  <link:definition>00000037 - Disclosure - Marketable Investment Securities (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" id="ContractualAgreementsDetailsNarrative">
	  <link:definition>00000038 - Disclosure - Contractual Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" id="ScheduleOfMaturitiesOfDebtDetails">
	  <link:definition>00000039 - Disclosure - Schedule of Maturities of Debt (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative" id="LoanAndSecurityAgreementDetailsNarrative">
	  <link:definition>00000040 - Disclosure - Loan and Security Agreement (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
	  <link:definition>00000041 - Disclosure - Schedule of Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000042 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails" id="ScheduleOfIncomeTaxExpenseDetails">
	  <link:definition>00000043 - Disclosure - Schedule of Income Tax Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails" id="ScheduleOfPretaxIncomeFromContinuingOperationsDetails">
	  <link:definition>00000044 - Disclosure - Schedule of Pretax Income from Continuing Operations (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
	  <link:definition>00000045 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" id="ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails">
	  <link:definition>00000046 - Disclosure - Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000047 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" id="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
	  <link:definition>00000048 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000049 - Disclosure - Leases (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
	  <link:definition>00000050 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" id="ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails">
	  <link:definition>00000051 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" id="ScheduleOfFairValueOfWarrantsDetails">
	  <link:definition>00000052 - Disclosure - Schedule of Fair Value of Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" id="ScheduleOfReconciliationOfWarrantLiabilityDetails">
	  <link:definition>00000053 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" id="ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails">
	  <link:definition>00000054 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000055 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/KPlanDetailsNarrative" id="KPlanDetailsNarrative">
	  <link:definition>00000056 - Disclosure - 401(k) Plan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000057 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" id="AgreementWithSpriasoLlcDetailsNarrative">
	  <link:definition>00000058 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="lpcn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lpcn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lpcn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lpcn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="lpcn_MajorCustomerMember" name="MajorCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_OneMajorCustomerMember" name="OneMajorCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SalesBasedRoyaltiesMember" name="SalesBasedRoyaltiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_MinimumGuaranteedRoyaltiesMember" name="MinimumGuaranteedRoyaltiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_MaterialsMember" name="MaterialsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_CorporateBondsandNotesMember" name="CorporateBondsandNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_CorporateBondsNotesAndCommercialPaperMember" name="CorporateBondsNotesAndCommercialPaperMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_AbbottProductsIncMember" name="AbbottProductsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_TLANDOXRMember" name="TLANDOXRMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SiliconValleyBankMember" name="SiliconValleyBankMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_PayrollProtectionProgramLoanMember" name="PayrollProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_LabAndOfficeEquipmentMember" name="LabAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_UsFederalMember" name="UsFederalMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_January2021OfferingMember" name="January2021OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_February2020OfferingMember" name="February2020OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ClassAUnitMember" name="ClassAUnitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_November2019OfferingMember" name="November2019OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ClassBUnitsMember" name="ClassBUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_CantorMember" name="CantorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SaleAgreementMember" name="SaleAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_StockIncentivePlan2014Member" name="StockIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_TwoThousandElevenEquityIncentivePlanMember" name="TwoThousandElevenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_CommonStockWarrantMember" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_GlobalAgreementMember" name="GlobalAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ClarusTherapeuticsIncMember" name="ClarusTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SpriasoLLCMember" name="SpriasoLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ServiceAgreementMember" name="ServiceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_CommonStockSoldThroughEquityOffering" name="CommonStockSoldThroughEquityOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_CommonStockSoldThroughEquityOfferingShares" name="CommonStockSoldThroughEquityOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" name="AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_LitigationSettlementExpenseOne" name="LitigationSettlementExpenseOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_NetProceedsFromSaleOfCommonStockThroughATM" name="NetProceedsFromSaleOfCommonStockThroughATM" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises" name="SettlementOfWarrantLiabilityOnWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_AccruedFinalPaymentChargeOnDebt" name="AccruedFinalPaymentChargeOnDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock" name="ScheduleOfFairValueOfWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" name="ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales" name="CollaborativeArrangementRoyaltiesPercentageOfNetSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch" name="PercentageOfRoyaltiesReductionBasedUponProductLaunch" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_LicenseFee" name="LicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_PotentialLicenseFeesFromALicensee" name="PotentialLicenseFeesFromALicensee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SalesMilestoneRevenueRecognized" name="SalesMilestoneRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_PercentageOfRoyaltyPayment" name="PercentageOfRoyaltyPayment" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ClinicalAndDevelopmentMilestones" name="ClinicalAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" name="DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency" name="DebtInstrumentMinimumAmountConsideredForInsolvency" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits" name="IncomeTaxReconciliationOrphanDrugTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_DeferredTaxAssetsOrphanDrugTaxCredit" name="DeferredTaxAssetsOrphanDrugTaxCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount" name="OperatingLossCarryForwardsLimitationsOnUseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_OperatingLossCarryForwardsPreownershipChangeAmount" name="OperatingLossCarryForwardsPreownershipChangeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_OperatingLossForgivePreOwnershipChangeAmount" name="OperatingLossForgivePreOwnershipChangeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount" name="TaxCreditCarryforwardPreOwnershipChangeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_OperatingLossCarryForwardsExpirationDate1" name="OperatingLossCarryForwardsExpirationDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" name="AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_PercentageOfGrossProceedOnSaleOfShares" name="PercentageOfGrossProceedOnSaleOfShares" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SharesAvailableForFutureIssuance" name="SharesAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" name="ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_RetentionPayables" name="RetentionPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_PercentageOfRoyalty" name="PercentageOfRoyalty" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_AgreementDescription" name="AgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ProceedsFromReimbursements" name="ProceedsFromReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_ProceedsFromCommonStockGross" name="ProceedsFromCommonStockGross" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_AccreditedInvestorsMember" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_EquityIncentivePlanMember" name="EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_AntaresLicenseAgreementMember" name="AntaresLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_DeferredFederalInsuranceContributionsActTaxPayments" name="DeferredFederalInsuranceContributionsActTaxPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_CapitalizedComputerEquipmentAndHardware" name="CapitalizedComputerEquipmentAndHardware" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_DeferredTaxAssetsPropertyPlantAndEquipmentOne" name="DeferredTaxAssetsPropertyPlantAndEquipmentOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_LicensingMember" name="LicensingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="lpcn_SharesAvailableForFutureIssuanceValue" name="SharesAvailableForFutureIssuanceValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>lpcn-20211231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lipocine.com/role/Cover" xlink:href="lpcn-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheets" xlink:href="lpcn-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:href="lpcn-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="lpcn-20211231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="lpcn-20211231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfCashFlows" xlink:href="lpcn-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/DescriptionOfBusiness" xlink:href="lpcn-20211231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreements" xlink:href="lpcn-20211231.xsd#ContractualAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreement" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipment" xlink:href="lpcn-20211231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxes" xlink:href="lpcn-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/Leases" xlink:href="lpcn-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquity" xlink:href="lpcn-20211231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/KPlan" xlink:href="lpcn-20211231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingencies" xlink:href="lpcn-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:href="lpcn-20211231.xsd#AgreementWithSpriasoLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AccountingPronouncements" xlink:href="lpcn-20211231.xsd#AccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementTables" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipmentTables" xlink:href="lpcn-20211231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxesTables" xlink:href="lpcn-20211231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesTables" xlink:href="lpcn-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityTables" xlink:href="lpcn-20211231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:href="lpcn-20211231.xsd#ContractualAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfMaturitiesOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="lpcn-20211231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxesDetailsNarrative" xlink:href="lpcn-20211231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesDetailsNarrative" xlink:href="lpcn-20211231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:href="lpcn-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/KPlanDetailsNarrative" xlink:href="lpcn-20211231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lpcn-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:href="lpcn-20211231.xsd#AgreementWithSpriasoLlcDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapContractWithCustomerAssetNetNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaapLitigationReserveCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLitigationReserveCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="loc_us-gaapLitigationReserveNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLitigationReserveNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAccretionExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LitigationSettlementExpenseOne" xlink:label="loc_lpcnLitigationSettlementExpenseOne" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_lpcnLitigationSettlementExpenseOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaapPaymentsToAcquireAvailableForSaleSecuritiesDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_NetProceedsFromSaleOfCommonStockThroughATM" xlink:label="loc_lpcnNetProceedsFromSaleOfCommonStockThroughATM" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_lpcnNetProceedsFromSaleOfCommonStockThroughATM" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - Description of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:title="00000009 - Disclosure - Marketable Investment Securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreements" xlink:title="00000010 - Disclosure - Contractual Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreement" xlink:title="00000011 - Disclosure - Loan and Security Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/Leases" xlink:title="00000014 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/KPlan" xlink:title="00000016 - Disclosure - 401(k) Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:title="00000018 - Disclosure - Agreement with Spriaso, LLC" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AccountingPronouncements" xlink:title="00000019 - Disclosure - Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:title="00000022 - Disclosure - Marketable Investment Securities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementTables" xlink:title="00000023 - Disclosure - Loan and Security Agreement (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipmentTables" xlink:title="00000024 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesTables" xlink:title="00000026 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000028 - Disclosure - Schedule of Disaggregation of Revenue (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:title="00000029 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:title="00000030 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:title="00000032 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000033 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:title="00000035 - Disclosure - Schedule of Available-for-Sale Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:title="00000036 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:title="00000037 - Disclosure - Marketable Investment Securities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:title="00000038 - Disclosure - Contractual Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:title="00000039 - Disclosure - Schedule of Maturities of Debt (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative" xlink:title="00000040 - Disclosure - Loan and Security Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:title="00000043 - Disclosure - Schedule of Income Tax Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperations" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:title="00000044 - Disclosure - Schedule of Pretax Income from Continuing Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits" xlink:label="loc_lpcnIncomeTaxReconciliationOrphanDrugTaxCredits" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_lpcnIncomeTaxReconciliationOrphanDrugTaxCredits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" xlink:label="loc_lpcnEffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_lpcnEffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000045 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DeferredTaxAssetsOrphanDrugTaxCredit" xlink:label="loc_lpcnDeferredTaxAssetsOrphanDrugTaxCredit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_lpcnDeferredTaxAssetsOrphanDrugTaxCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:title="00000046 - Disclosure - Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="00000048 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesDetailsNarrative" xlink:title="00000049 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000050 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000051 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:title="00000052 - Disclosure - Schedule of Fair Value of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:title="00000053 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000054 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000055 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/KPlanDetailsNarrative" xlink:title="00000056 - Disclosure - 401(k) Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:title="00000058 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>lpcn-20211231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lipocine.com/role/Cover" xlink:href="lpcn-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheets" xlink:href="lpcn-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:href="lpcn-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="lpcn-20211231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="lpcn-20211231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfCashFlows" xlink:href="lpcn-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/DescriptionOfBusiness" xlink:href="lpcn-20211231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreements" xlink:href="lpcn-20211231.xsd#ContractualAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreement" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipment" xlink:href="lpcn-20211231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxes" xlink:href="lpcn-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/Leases" xlink:href="lpcn-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquity" xlink:href="lpcn-20211231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/KPlan" xlink:href="lpcn-20211231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingencies" xlink:href="lpcn-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:href="lpcn-20211231.xsd#AgreementWithSpriasoLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AccountingPronouncements" xlink:href="lpcn-20211231.xsd#AccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementTables" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipmentTables" xlink:href="lpcn-20211231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxesTables" xlink:href="lpcn-20211231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesTables" xlink:href="lpcn-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityTables" xlink:href="lpcn-20211231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:href="lpcn-20211231.xsd#ContractualAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfMaturitiesOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="lpcn-20211231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxesDetailsNarrative" xlink:href="lpcn-20211231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesDetailsNarrative" xlink:href="lpcn-20211231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:href="lpcn-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/KPlanDetailsNarrative" xlink:href="lpcn-20211231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lpcn-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:href="lpcn-20211231.xsd#AgreementWithSpriasoLlcDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockSoldThroughEquityOffering" xlink:label="loc_lpcnCommonStockSoldThroughEquityOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnCommonStockSoldThroughEquityOffering_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockSoldThroughEquityOfferingShares" xlink:label="loc_lpcnCommonStockSoldThroughEquityOfferingShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnCommonStockSoldThroughEquityOfferingShares_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="loc_lpcnStockIssuedDuringPeriodValueWarrantsExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnStockIssuedDuringPeriodValueWarrantsExercises_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="loc_lpcnStockIssuedDuringPeriodSharesWarrantsExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnStockIssuedDuringPeriodSharesWarrantsExercises_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="loc_lpcnAdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnAdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - Description of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:title="00000009 - Disclosure - Marketable Investment Securities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreements" xlink:title="00000010 - Disclosure - Contractual Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreement" xlink:title="00000011 - Disclosure - Loan and Security Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/Leases" xlink:title="00000014 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/KPlan" xlink:title="00000016 - Disclosure - 401(k) Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:title="00000018 - Disclosure - Agreement with Spriaso, LLC" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/AccountingPronouncements" xlink:title="00000019 - Disclosure - Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:title="00000022 - Disclosure - Marketable Investment Securities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementTables" xlink:title="00000023 - Disclosure - Loan and Security Agreement (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipmentTables" xlink:title="00000024 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesTables" xlink:title="00000026 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000028 - Disclosure - Schedule of Disaggregation of Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesBasedRoyaltiesMember" xlink:label="loc_lpcnSalesBasedRoyaltiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_lpcnSalesBasedRoyaltiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MinimumGuaranteedRoyaltiesMember" xlink:label="loc_lpcnMinimumGuaranteedRoyaltiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_lpcnMinimumGuaranteedRoyaltiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MaterialsMember" xlink:label="loc_lpcnMaterialsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_lpcnMaterialsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:title="00000029 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:title="00000030 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaapCashAndCashEquivalentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsLineItems" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaapCommercialPaperMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapCommercialPaperMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CorporateBondsandNotesMember" xlink:label="loc_lpcnCorporateBondsandNotesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_lpcnCorporateBondsandNotesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashAndCashEquivalentsLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_410" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashAndCashEquivalentsLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_410" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:title="00000032 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000033 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MajorCustomerMember" xlink:label="loc_lpcnMajorCustomerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_lpcnMajorCustomerMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OneMajorCustomerMember" xlink:label="loc_lpcnOneMajorCustomerMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_lpcnOneMajorCustomerMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ComputerEquipmentAndSoftwareMember" xlink:label="loc_lpcnComputerEquipmentAndSoftwareMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_lpcnComputerEquipmentAndSoftwareMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharePrice_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_170" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:title="00000035 - Disclosure - Schedule of Available-for-Sale Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapMarketableSecuritiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CorporateBondsNotesAndCommercialPaperMember" xlink:label="loc_lpcnCorporateBondsNotesAndCommercialPaperMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_lpcnCorporateBondsNotesAndCommercialPaperMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaapCommercialPaperMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCommercialPaperMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:title="00000036 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:title="00000037 - Disclosure - Marketable Investment Securities (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:title="00000038 - Disclosure - Contractual Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MalpracticeInsuranceLineItems" xlink:label="loc_us-gaapMalpracticeInsuranceLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTable" xlink:label="loc_us-gaapScheduleOfMalpracticeInsuranceTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaapCollaborativeArrangementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapCollaborativeArrangementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicenseAgreementMember" xlink:label="loc_lpcnLicenseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnLicenseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AbbottProductsIncMember" xlink:label="loc_lpcnAbbottProductsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnAbbottProductsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TLANDOXRMember" xlink:label="loc_lpcnTLANDOXRMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnTLANDOXRMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:label="loc_lpcnCollaborativeArrangementRoyaltiesPercentageOfNetSales_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnCollaborativeArrangementRoyaltiesPercentageOfNetSales_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaapRoyaltyGuaranteesCommitmentsAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_us-gaapRoyaltyGuaranteesCommitmentsAmount_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:label="loc_lpcnPercentageOfRoyaltiesReductionBasedUponProductLaunch_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnPercentageOfRoyaltiesReductionBasedUponProductLaunch_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicenseFee" xlink:label="loc_lpcnLicenseFee_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnLicenseFee_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PotentialLicenseFeesFromALicensee" xlink:label="loc_lpcnPotentialLicenseFeesFromALicensee_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnPotentialLicenseFeesFromALicensee_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesMilestoneRevenueRecognized" xlink:label="loc_lpcnSalesMilestoneRevenueRecognized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnSalesMilestoneRevenueRecognized_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyaltyPayment" xlink:label="loc_lpcnPercentageOfRoyaltyPayment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnPercentageOfRoyaltyPayment_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClinicalAndDevelopmentMilestones" xlink:label="loc_lpcnClinicalAndDevelopmentMilestones_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnClinicalAndDevelopmentMilestones_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_120" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:title="00000039 - Disclosure - Schedule of Maturities of Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative" xlink:title="00000040 - Disclosure - Loan and Security Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LoanAndSecurityAgreementMember" xlink:label="loc_lpcnLoanAndSecurityAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_lpcnLoanAndSecurityAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PayrollProtectionProgramLoanMember" xlink:label="loc_lpcnPayrollProtectionProgramLoanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_lpcnPayrollProtectionProgramLoanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SiliconValleyBankMember" xlink:label="loc_lpcnSiliconValleyBankMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_lpcnSiliconValleyBankMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="loc_us-gaapCashCollateralForBorrowedSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCashCollateralForBorrowedSecurities_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="loc_us-gaapDebtInstrumentRestrictiveCovenants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentRestrictiveCovenants_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:label="loc_lpcnDebtInstrumentBasisSpreadOnInterestRateForDebtDefault_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_lpcnDebtInstrumentBasisSpreadOnInterestRateForDebtDefault_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:label="loc_lpcnDebtInstrumentMinimumAmountConsideredForInsolvency_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_lpcnDebtInstrumentMinimumAmountConsideredForInsolvency_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ComputerEquipmentAndSoftwareMember" xlink:label="loc_lpcnComputerEquipmentAndSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_lpcnComputerEquipmentAndSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LabAndOfficeEquipmentMember" xlink:label="loc_lpcnLabAndOfficeEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_lpcnLabAndOfficeEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:title="00000043 - Disclosure - Schedule of Income Tax Expense (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:title="00000044 - Disclosure - Schedule of Pretax Income from Continuing Operations (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000045 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:title="00000046 - Disclosure - Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_UsFederalMember" xlink:label="loc_lpcnUsFederalMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_lpcnUsFederalMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount" xlink:label="loc_lpcnOperatingLossCarryForwardsLimitationsOnUseAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnOperatingLossCarryForwardsLimitationsOnUseAmount_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsPreownershipChangeAmount" xlink:label="loc_lpcnOperatingLossCarryForwardsPreownershipChangeAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnOperatingLossCarryForwardsPreownershipChangeAmount_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossForgivePreOwnershipChangeAmount" xlink:label="loc_lpcnOperatingLossForgivePreOwnershipChangeAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnOperatingLossForgivePreOwnershipChangeAmount_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount" xlink:label="loc_lpcnTaxCreditCarryforwardPreOwnershipChangeAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnTaxCreditCarryforwardPreOwnershipChangeAmount_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsExpirationDate1" xlink:label="loc_lpcnOperatingLossCarryForwardsExpirationDate1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnOperatingLossCarryForwardsExpirationDate1_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription_100" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="00000048 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesDetailsNarrative" xlink:title="00000049 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000050 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000051 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:title="00000052 - Disclosure - Schedule of Fair Value of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_November2019OfferingMember" xlink:label="loc_lpcnNovember2019OfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnNovember2019OfferingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:title="00000053 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000054 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_40" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000055 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_January2021OfferingMember" xlink:label="loc_lpcnJanuary2021OfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnJanuary2021OfferingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_February2020OfferingMember" xlink:label="loc_lpcnFebruary2020OfferingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnFebruary2020OfferingMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_November2019OfferingMember" xlink:label="loc_lpcnNovember2019OfferingMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnNovember2019OfferingMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AtMarketOfferingMember" xlink:label="loc_lpcnAtMarketOfferingMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnAtMarketOfferingMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassAUnitMember" xlink:label="loc_lpcnClassAUnitMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_lpcnClassAUnitMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassBUnitsMember" xlink:label="loc_lpcnClassBUnitsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_lpcnClassBUnitsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PreFundedWarrantsMember" xlink:label="loc_lpcnPreFundedWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_lpcnPreFundedWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesAgreementMember" xlink:label="loc_lpcnSalesAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_lpcnSalesAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CantorMember" xlink:label="loc_lpcnCantorMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnCantorMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesAgreementMember" xlink:label="loc_lpcnSalesAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnSalesAgreementMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SaleAgreementMember" xlink:label="loc_lpcnSaleAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnSaleAgreementMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockWarrantMember" xlink:label="loc_lpcnCommonStockWarrantMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_lpcnCommonStockWarrantMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIncentivePlan2014Member" xlink:label="loc_lpcnStockIncentivePlan2014Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_lpcnStockIncentivePlan2014Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TwoThousandElevenEquityIncentivePlanMember" xlink:label="loc_lpcnTwoThousandElevenEquityIncentivePlanMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_lpcnTwoThousandElevenEquityIncentivePlanMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_lpcnProceedsFromIssuanceOfCommonStockGross_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_lpcnProceedsFromIssuanceOfCommonStockGross_480" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_480" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_480" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_480" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_480" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_480" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfGrossProceedOnSaleOfShares" xlink:label="loc_lpcnPercentageOfGrossProceedOnSaleOfShares_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_lpcnPercentageOfGrossProceedOnSaleOfShares_480" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_480" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SharesAvailableForFutureIssuance" xlink:label="loc_lpcnSharesAvailableForFutureIssuance_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_lpcnSharesAvailableForFutureIssuance_480" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_lpcnClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_lpcnClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_480" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_480" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_480" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_480" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_480" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_480" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_480" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_480" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_480" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_480" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_480" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/KPlanDetailsNarrative" xlink:title="00000056 - Disclosure - 401(k) Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_GlobalAgreementMember" xlink:label="loc_lpcnGlobalAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnGlobalAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClarusTherapeuticsIncMember" xlink:label="loc_lpcnClarusTherapeuticsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnClarusTherapeuticsIncMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_RetentionPayables" xlink:label="loc_lpcnRetentionPayables_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnRetentionPayables_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:title="00000058 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicenseAgreementMember" xlink:label="loc_lpcnLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ServiceAgreementMember" xlink:label="loc_lpcnServiceAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnServiceAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SpriasoLLCMember" xlink:label="loc_lpcnSpriasoLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnSpriasoLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyalty" xlink:label="loc_lpcnPercentageOfRoyalty_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_lpcnPercentageOfRoyalty_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaapProceedsFromContributionsFromAffiliates_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromContributionsFromAffiliates_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AgreementDescription" xlink:label="loc_lpcnAgreementDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_lpcnAgreementDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ProceedsFromReimbursements" xlink:label="loc_lpcnProceedsFromReimbursements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_lpcnProceedsFromReimbursements_40" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>lpcn-20211231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MajorCustomerMember" xlink:label="lpcn_MajorCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_MajorCustomerMember" xlink:to="lpcn_MajorCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_MajorCustomerMember_lbl" xml:lang="en-US">Major Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OneMajorCustomerMember" xlink:label="lpcn_OneMajorCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OneMajorCustomerMember" xlink:to="lpcn_OneMajorCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_OneMajorCustomerMember_lbl" xml:lang="en-US">One major customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ComputerEquipmentAndSoftwareMember" xlink:label="lpcn_ComputerEquipmentAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ComputerEquipmentAndSoftwareMember" xlink:to="lpcn_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Computer equipment and software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesBasedRoyaltiesMember" xlink:label="lpcn_SalesBasedRoyaltiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SalesBasedRoyaltiesMember" xlink:to="lpcn_SalesBasedRoyaltiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_SalesBasedRoyaltiesMember_lbl" xml:lang="en-US">Sales-based royalties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MinimumGuaranteedRoyaltiesMember" xlink:label="lpcn_MinimumGuaranteedRoyaltiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_MinimumGuaranteedRoyaltiesMember" xlink:to="lpcn_MinimumGuaranteedRoyaltiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_MinimumGuaranteedRoyaltiesMember_lbl" xml:lang="en-US">Minimum guaranteed royalties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MaterialsMember" xlink:label="lpcn_MaterialsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_MaterialsMember" xlink:to="lpcn_MaterialsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_MaterialsMember_lbl" xml:lang="en-US">Materials [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CorporateBondsandNotesMember" xlink:label="lpcn_CorporateBondsandNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CorporateBondsandNotesMember" xlink:to="lpcn_CorporateBondsandNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_CorporateBondsandNotesMember_lbl" xml:lang="en-US">Corporate Bonds and Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CorporateBondsNotesAndCommercialPaperMember" xlink:label="lpcn_CorporateBondsNotesAndCommercialPaperMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CorporateBondsNotesAndCommercialPaperMember" xlink:to="lpcn_CorporateBondsNotesAndCommercialPaperMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_CorporateBondsNotesAndCommercialPaperMember_lbl" xml:lang="en-US">Corporate Bonds Notes And Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AbbottProductsIncMember" xlink:label="lpcn_AbbottProductsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AbbottProductsIncMember" xlink:to="lpcn_AbbottProductsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_AbbottProductsIncMember_lbl" xml:lang="en-US">Abbott Products Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicenseAgreementMember" xlink:label="lpcn_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LicenseAgreementMember" xlink:to="lpcn_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TLANDOXRMember" xlink:label="lpcn_TLANDOXRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_TLANDOXRMember" xlink:to="lpcn_TLANDOXRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_TLANDOXRMember_lbl" xml:lang="en-US">TLANDO XR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LoanAndSecurityAgreementMember" xlink:label="lpcn_LoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LoanAndSecurityAgreementMember" xlink:to="lpcn_LoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SiliconValleyBankMember" xlink:label="lpcn_SiliconValleyBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SiliconValleyBankMember" xlink:to="lpcn_SiliconValleyBankMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_SiliconValleyBankMember_lbl" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PayrollProtectionProgramLoanMember" xlink:label="lpcn_PayrollProtectionProgramLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PayrollProtectionProgramLoanMember" xlink:to="lpcn_PayrollProtectionProgramLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_PayrollProtectionProgramLoanMember_lbl" xml:lang="en-US">Payroll Protection Program Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LabAndOfficeEquipmentMember" xlink:label="lpcn_LabAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LabAndOfficeEquipmentMember" xlink:to="lpcn_LabAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_LabAndOfficeEquipmentMember_lbl" xml:lang="en-US">Lab and office equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_UsFederalMember" xlink:label="lpcn_UsFederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_UsFederalMember" xlink:to="lpcn_UsFederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_UsFederalMember_lbl" xml:lang="en-US">Us Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_January2021OfferingMember" xlink:label="lpcn_January2021OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_January2021OfferingMember" xlink:to="lpcn_January2021OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_January2021OfferingMember_lbl" xml:lang="en-US">January 2021 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_February2020OfferingMember" xlink:label="lpcn_February2020OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_February2020OfferingMember" xlink:to="lpcn_February2020OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_February2020OfferingMember_lbl" xml:lang="en-US">February 2020 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassAUnitMember" xlink:label="lpcn_ClassAUnitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClassAUnitMember" xlink:to="lpcn_ClassAUnitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ClassAUnitMember_lbl" xml:lang="en-US">Class A Unit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_November2019OfferingMember" xlink:label="lpcn_November2019OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_November2019OfferingMember" xlink:to="lpcn_November2019OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_November2019OfferingMember_lbl" xml:lang="en-US">November 2019 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassBUnitsMember" xlink:label="lpcn_ClassBUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClassBUnitsMember" xlink:to="lpcn_ClassBUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ClassBUnitsMember_lbl" xml:lang="en-US">Class B Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PreFundedWarrantsMember" xlink:label="lpcn_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PreFundedWarrantsMember" xlink:to="lpcn_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesAgreementMember" xlink:label="lpcn_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SalesAgreementMember" xlink:to="lpcn_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CantorMember" xlink:label="lpcn_CantorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CantorMember" xlink:to="lpcn_CantorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_CantorMember_lbl" xml:lang="en-US">Cantor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AtMarketOfferingMember" xlink:label="lpcn_AtMarketOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AtMarketOfferingMember" xlink:to="lpcn_AtMarketOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_AtMarketOfferingMember_lbl" xml:lang="en-US">ATM Market Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SaleAgreementMember" xlink:label="lpcn_SaleAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SaleAgreementMember" xlink:to="lpcn_SaleAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_SaleAgreementMember_lbl" xml:lang="en-US">Sale Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIncentivePlan2014Member" xlink:label="lpcn_StockIncentivePlan2014Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_StockIncentivePlan2014Member" xlink:to="lpcn_StockIncentivePlan2014Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_StockIncentivePlan2014Member_lbl" xml:lang="en-US">Stock Incentive Plan 2014 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TwoThousandElevenEquityIncentivePlanMember" xlink:label="lpcn_TwoThousandElevenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_TwoThousandElevenEquityIncentivePlanMember" xlink:to="lpcn_TwoThousandElevenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_TwoThousandElevenEquityIncentivePlanMember_lbl" xml:lang="en-US">2011 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockWarrantMember" xlink:label="lpcn_CommonStockWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CommonStockWarrantMember" xlink:to="lpcn_CommonStockWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_CommonStockWarrantMember_lbl" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_GlobalAgreementMember" xlink:label="lpcn_GlobalAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_GlobalAgreementMember" xlink:to="lpcn_GlobalAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_GlobalAgreementMember_lbl" xml:lang="en-US">Global Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClarusTherapeuticsIncMember" xlink:label="lpcn_ClarusTherapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClarusTherapeuticsIncMember" xlink:to="lpcn_ClarusTherapeuticsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ClarusTherapeuticsIncMember_lbl" xml:lang="en-US">Clarus Therapeutics, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SpriasoLLCMember" xlink:label="lpcn_SpriasoLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SpriasoLLCMember" xlink:to="lpcn_SpriasoLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_SpriasoLLCMember_lbl" xml:lang="en-US">Spriaso LLC[Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ServiceAgreementMember" xlink:label="lpcn_ServiceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ServiceAgreementMember" xlink:to="lpcn_ServiceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ServiceAgreementMember_lbl" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated By Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent_lbl" xml:lang="en-US">Contract asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $1,144,077 and $1,143,697 respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US">Debt - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="us-gaap_LitigationReserveCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveCurrent" xlink:to="us-gaap_LitigationReserveCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xml:lang="en-US">Litigation settlement liability - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Debt - non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveNoncurrent" xlink:to="us-gaap_LitigationReserveNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveNoncurrent_lbl" xml:lang="en-US">Litigation settlement liability - non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (notes 5, 8 and 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 88,296,360 and 70,041,967 issued and 88,290,650 and 70,036,257 outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock at cost, 5,710 shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest and investment income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Unrealized gain (loss) on warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Litigation settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per share attributable to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding,</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per share attributable to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive loss:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized net gain (loss) on available-for-sale securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_lbl" xml:lang="en-US">Unrealized net loss on marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockSoldThroughEquityOffering" xlink:label="lpcn_CommonStockSoldThroughEquityOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CommonStockSoldThroughEquityOffering" xlink:to="lpcn_CommonStockSoldThroughEquityOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_CommonStockSoldThroughEquityOffering_lbl" xml:lang="en-US">Common stock sold through equity offering</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockSoldThroughEquityOfferingShares" xlink:label="lpcn_CommonStockSoldThroughEquityOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CommonStockSoldThroughEquityOfferingShares" xlink:to="lpcn_CommonStockSoldThroughEquityOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_CommonStockSoldThroughEquityOfferingShares_lbl" xml:lang="en-US">Common stock sold through equity offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="lpcn_StockIssuedDuringPeriodValueWarrantsExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="lpcn_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Common stock issued for warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="lpcn_StockIssuedDuringPeriodSharesWarrantsExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="lpcn_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Common stock issued for warrant exercises, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_lbl" xml:lang="en-US">Settlement of warrant liability on warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock sold through ATM offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock sold through ATM offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Option exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Option exercises, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Non-cash gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Non-cash loss (gain) on change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Amortization of premium/discount on marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LitigationSettlementExpenseOne" xlink:label="lpcn_LitigationSettlementExpenseOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LitigationSettlementExpenseOne" xlink:to="lpcn_LitigationSettlementExpenseOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_LitigationSettlementExpenseOne_lbl" xml:lang="en-US">Litigation settlement liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchases of marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Maturities of marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Debt repayments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from stock option exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock sold in equity offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_NetProceedsFromSaleOfCommonStockThroughATM" xlink:label="lpcn_NetProceedsFromSaleOfCommonStockThroughATM" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_NetProceedsFromSaleOfCommonStockThroughATM" xlink:to="lpcn_NetProceedsFromSaleOfCommonStockThroughATM_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_NetProceedsFromSaleOfCommonStockThroughATM_lbl" xml:lang="en-US">Net proceeds from sale of common stock through ATM</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises_lbl" xml:lang="en-US">Settlement of warrant liability on warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Unrealized net gain (loss) on marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AccruedFinalPaymentChargeOnDebt" xlink:label="lpcn_AccruedFinalPaymentChargeOnDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AccruedFinalPaymentChargeOnDebt" xlink:to="lpcn_AccruedFinalPaymentChargeOnDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_AccruedFinalPaymentChargeOnDebt_lbl" xml:lang="en-US">Accrued final payment charge on debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Description of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Marketable Investment Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="us-gaap_HealthCareOrganizationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationsAbstract" xlink:to="us-gaap_HealthCareOrganizationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationsAbstract_lbl" xml:lang="en-US">Health Care Organizations [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock" xlink:label="us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock" xlink:to="us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock_lbl" xml:lang="en-US">Contractual Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Loan and Security Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DisclosureLeasesAbstract" xlink:label="lpcn_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DisclosureLeasesAbstract" xlink:to="lpcn_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">401(k) Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Agreement with Spriaso, LLC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Accounting for Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share Based Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Key Assumption of Fair Value of Stock Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US">Schedule of Available-for-Sale Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Pretax Income from Continuing Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:label="lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:to="lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:label="lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:to="lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted avg. common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted avg. common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Percentage of total revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Stock-based compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of stock options issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period of stock option plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">strike price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair value of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Gross unrealized holding gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross unrealized holding losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Aggregate fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US">Due within one year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US">Due within one year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xml:lang="en-US">Due after one year through two years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xml:lang="en-US">Due after one year through two years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US">Total maturities of debt securities classified as available-for-sale securities, amortized cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US">Total maturities of debt securities classified as available-for-sale securities, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_lbl" xml:lang="en-US">Proceeds from Sale of Held-to-maturity Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:label="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:to="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_lbl" xml:lang="en-US">Debt and Equity Securities, Realized Gain (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Matured marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_lbl" xml:lang="en-US">Other than temporary impairments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTable" xlink:label="us-gaap_ScheduleOfMalpracticeInsuranceTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMalpracticeInsuranceTable" xlink:to="us-gaap_ScheduleOfMalpracticeInsuranceTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMalpracticeInsuranceTable_lbl" xml:lang="en-US">Schedule of Malpractice Insurance [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MalpracticeInsuranceLineItems" xlink:label="us-gaap_MalpracticeInsuranceLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeInsuranceLineItems" xlink:to="us-gaap_MalpracticeInsuranceLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MalpracticeInsuranceLineItems_lbl" xml:lang="en-US">Malpractice Insurance [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:label="lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:to="lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales_lbl" xml:lang="en-US">Percentage of net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xml:lang="en-US">Royalties, commitment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:label="lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:to="lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch_lbl" xml:lang="en-US">Percentage of royalties reduction based upon product launch</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicenseFee" xlink:label="lpcn_LicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LicenseFee" xlink:to="lpcn_LicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_LicenseFee_lbl" xml:lang="en-US">License fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PotentialLicenseFeesFromALicensee" xlink:label="lpcn_PotentialLicenseFeesFromALicensee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PotentialLicenseFeesFromALicensee" xlink:to="lpcn_PotentialLicenseFeesFromALicensee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_PotentialLicenseFeesFromALicensee_lbl" xml:lang="en-US">Potential license fees from a licensee</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesMilestoneRevenueRecognized" xlink:label="lpcn_SalesMilestoneRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SalesMilestoneRevenueRecognized" xlink:to="lpcn_SalesMilestoneRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_SalesMilestoneRevenueRecognized_lbl" xml:lang="en-US">Sales milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyaltyPayment" xlink:label="lpcn_PercentageOfRoyaltyPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PercentageOfRoyaltyPayment" xlink:to="lpcn_PercentageOfRoyaltyPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_PercentageOfRoyaltyPayment_lbl" xml:lang="en-US">Percentage of royalty payment</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClinicalAndDevelopmentMilestones" xlink:label="lpcn_ClinicalAndDevelopmentMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClinicalAndDevelopmentMilestones" xlink:to="lpcn_ClinicalAndDevelopmentMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ClinicalAndDevelopmentMilestones_lbl" xml:lang="en-US">Clinical and development milestones</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Contract research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" xlink:label="lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" xlink:to="lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Basis for Effective Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Debt instrument, balloon payment to be paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Debt instrument, increase in amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="us-gaap_CashCollateralForBorrowedSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCollateralForBorrowedSecurities" xlink:to="us-gaap_CashCollateralForBorrowedSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCollateralForBorrowedSecurities_lbl" xml:lang="en-US">Cash collateral for borrowed securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRestrictiveCovenants" xlink:to="us-gaap_DebtInstrumentRestrictiveCovenants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants_lbl" xml:lang="en-US">Debt Instrument, Restrictive Covenants</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:label="lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:to="lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_lbl" xml:lang="en-US">Debt instrument, basis spread on interest rate for debt default</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:label="lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:to="lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency_lbl" xml:lang="en-US">Debt instrument, minimum amount considered for insolvency</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Proceeds from loans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, and equipment, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Less accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">U.S. federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">State and local</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local income taxes, net of federal income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits" xlink:label="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits" xlink:to="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits_lbl" xml:lang="en-US">Orphan drug tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" xlink:label="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" xlink:to="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Other, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl" xml:lang="en-US">Employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DeferredTaxAssetsOrphanDrugTaxCredit" xlink:label="lpcn_DeferredTaxAssetsOrphanDrugTaxCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DeferredTaxAssetsOrphanDrugTaxCredit" xlink:to="lpcn_DeferredTaxAssetsOrphanDrugTaxCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_DeferredTaxAssetsOrphanDrugTaxCredit_lbl" xml:lang="en-US">Orphan drug tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US">Other deductible tempory differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total gross deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax asset/deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_2_lbl" xml:lang="en-US">Balance, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount" xlink:label="lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount" xlink:to="lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount_lbl" xml:lang="en-US">Operating Loss Carry forwards Limitations On Use Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsPreownershipChangeAmount" xlink:label="lpcn_OperatingLossCarryForwardsPreownershipChangeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OperatingLossCarryForwardsPreownershipChangeAmount" xlink:to="lpcn_OperatingLossCarryForwardsPreownershipChangeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_OperatingLossCarryForwardsPreownershipChangeAmount_lbl" xml:lang="en-US">Operating Loss Carry forwards Pre-ownership Change Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossForgivePreOwnershipChangeAmount" xlink:label="lpcn_OperatingLossForgivePreOwnershipChangeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OperatingLossForgivePreOwnershipChangeAmount" xlink:to="lpcn_OperatingLossForgivePreOwnershipChangeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_OperatingLossForgivePreOwnershipChangeAmount_lbl" xml:lang="en-US">Operating Loss Forgive Pre-ownership Change Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount" xlink:label="lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount" xlink:to="lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount_lbl" xml:lang="en-US">Tax Credit Carryforward Pre-ownership Change Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsExpirationDate1" xlink:label="lpcn_OperatingLossCarryForwardsExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OperatingLossCarryForwardsExpirationDate1" xlink:to="lpcn_OperatingLossCarryForwardsExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_OperatingLossCarryForwardsExpirationDate1_lbl" xml:lang="en-US">Operating Loss Carry forwards Expiration Date1</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Tax Credit Carryforward, Description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DisclosureLeasesAbstract" xlink:to="lpcn_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lpcn_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Future Minimum Rental Payments For Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Balance at beginning of the period (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Balance at beginning of the period (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, Options granted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options granted (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares, Options exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options exercised (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, Options forfeited (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options forfeited (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, Options cancelled (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options cancelled (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, Balance at end of the period (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Balance at end of the period (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, Options exercisable (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options exercisable (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options outstanding, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, Weighted average remaining contractual life (Years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, Weighted average exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, Aggregate intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable, Weighted average remaining contractual life (Years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options exercisable, Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options exercisable, Aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of warrants exercisable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3_lbl" xml:lang="en-US">Expected life in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3_lbl" xml:lang="en-US">Volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Stock price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Balance at December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:label="lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:to="lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_lbl" xml:lang="en-US">Settlement of liabilty on warrant exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xml:lang="en-US">Balance at December 31, 2021</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants Outstanding, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:label="lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_lbl" xml:lang="en-US">Warrants, Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Warrants, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Warrants Outstanding, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ProceedsFromIssuanceOfCommonStockGross" xlink:label="lpcn_ProceedsFromIssuanceOfCommonStockGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ProceedsFromIssuanceOfCommonStockGross" xlink:to="lpcn_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US">Proceeds from issuance of common stock gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of stock issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share issued exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfGrossProceedOnSaleOfShares" xlink:label="lpcn_PercentageOfGrossProceedOnSaleOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PercentageOfGrossProceedOnSaleOfShares" xlink:to="lpcn_PercentageOfGrossProceedOnSaleOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_PercentageOfGrossProceedOnSaleOfShares_lbl" xml:lang="en-US">Percentage of gross proceeds on sale of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SharesAvailableForFutureIssuance" xlink:label="lpcn_SharesAvailableForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SharesAvailableForFutureIssuance" xlink:to="lpcn_SharesAvailableForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_SharesAvailableForFutureIssuance_lbl" xml:lang="en-US">[custom:SharesAvailableForFutureIssuance-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US">[custom:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Net proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Employer matching contribution percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_RetentionPayables" xlink:label="lpcn_RetentionPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_RetentionPayables" xlink:to="lpcn_RetentionPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_RetentionPayables_lbl" xml:lang="en-US">[custom:RetentionPayables-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyalty" xlink:label="lpcn_PercentageOfRoyalty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PercentageOfRoyalty" xlink:to="lpcn_PercentageOfRoyalty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_PercentageOfRoyalty_lbl" xml:lang="en-US">Percentage of royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AgreementDescription" xlink:label="lpcn_AgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AgreementDescription" xlink:to="lpcn_AgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_AgreementDescription_lbl" xml:lang="en-US">Agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ProceedsFromReimbursements" xlink:label="lpcn_ProceedsFromReimbursements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ProceedsFromReimbursements" xlink:to="lpcn_ProceedsFromReimbursements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_ProceedsFromReimbursements_lbl" xml:lang="en-US">Proceeds from reimbursements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CommonStockSoldThroughEquityOffering" xlink:to="lpcn_CommonStockSoldThroughEquityOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_CommonStockSoldThroughEquityOffering_doc" xml:lang="en-US">Common stock sold through equity offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="lpcn_StockIssuedDuringPeriodValueWarrantsExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_StockIssuedDuringPeriodValueWarrantsExercises_doc" xml:lang="en-US">Common stock issued for warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_doc" xml:lang="en-US">Settlement of warrant liability on warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CommonStockSoldThroughEquityOfferingShares" xlink:to="lpcn_CommonStockSoldThroughEquityOfferingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_CommonStockSoldThroughEquityOfferingShares_doc" xml:lang="en-US">Common stock sold through equity offering, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="lpcn_StockIssuedDuringPeriodSharesWarrantsExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_StockIssuedDuringPeriodSharesWarrantsExercises_doc" xml:lang="en-US">Common stock issued for warrant exercises, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LitigationSettlementExpenseOne" xlink:to="lpcn_LitigationSettlementExpenseOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_LitigationSettlementExpenseOne_doc" xml:lang="en-US">Litigation settlement expense one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_NetProceedsFromSaleOfCommonStockThroughATM" xlink:to="lpcn_NetProceedsFromSaleOfCommonStockThroughATM_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_NetProceedsFromSaleOfCommonStockThroughATM_doc" xml:lang="en-US">Net proceeds from sale of common stock through ATM.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises_doc" xml:lang="en-US">Settlement of warrant liability on warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AccruedFinalPaymentChargeOnDebt" xlink:to="lpcn_AccruedFinalPaymentChargeOnDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_AccruedFinalPaymentChargeOnDebt_doc" xml:lang="en-US">Accrued final payment charge on debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits" xlink:to="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits_doc" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" xlink:to="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_doc" xml:lang="en-US">Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for change in warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DeferredTaxAssetsOrphanDrugTaxCredit" xlink:to="lpcn_DeferredTaxAssetsOrphanDrugTaxCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_DeferredTaxAssetsOrphanDrugTaxCredit_doc" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Orphan drug tax credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount" xlink:to="lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount_doc" xml:lang="en-US">Amount of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OperatingLossCarryForwardsPreownershipChangeAmount" xlink:to="lpcn_OperatingLossCarryForwardsPreownershipChangeAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_OperatingLossCarryForwardsPreownershipChangeAmount_doc" xml:lang="en-US">Amount of pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OperatingLossForgivePreOwnershipChangeAmount" xlink:to="lpcn_OperatingLossForgivePreOwnershipChangeAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_OperatingLossForgivePreOwnershipChangeAmount_doc" xml:lang="en-US">Amount of forgiven for pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount" xlink:to="lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount_doc" xml:lang="en-US">The amount of pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OperatingLossCarryForwardsExpirationDate1" xlink:to="lpcn_OperatingLossCarryForwardsExpirationDate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_OperatingLossCarryForwardsExpirationDate1_doc" xml:lang="en-US">The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ProceedsFromIssuanceOfCommonStockGross" xlink:to="lpcn_ProceedsFromIssuanceOfCommonStockGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ProceedsFromIssuanceOfCommonStockGross_doc" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_January2021OfferingMember" xlink:to="lpcn_January2021OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_January2021OfferingMember_doc" xml:lang="en-US">January 2021 Offering [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClassAUnitMember" xlink:to="lpcn_ClassAUnitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ClassAUnitMember_doc" xml:lang="en-US">Class A Unit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PercentageOfGrossProceedOnSaleOfShares" xlink:to="lpcn_PercentageOfGrossProceedOnSaleOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_PercentageOfGrossProceedOnSaleOfShares_doc" xml:lang="en-US">Percentage of gross proceeds on sale of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SalesAgreementMember" xlink:to="lpcn_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SalesAgreementMember_doc" xml:lang="en-US">Sales agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AtMarketOfferingMember" xlink:to="lpcn_AtMarketOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_AtMarketOfferingMember_doc" xml:lang="en-US">ATM Market Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CorporateBondsandNotesMember" xlink:to="lpcn_CorporateBondsandNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_CorporateBondsandNotesMember_doc" xml:lang="en-US">Corporate Bonds and Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ProceedsFromCommonStockGross" xlink:label="lpcn_ProceedsFromCommonStockGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ProceedsFromCommonStockGross" xlink:to="lpcn_ProceedsFromCommonStockGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ProceedsFromCommonStockGross_doc" xml:lang="en-US">Proceeds from common stock gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ComputerEquipmentAndSoftwareMember" xlink:to="lpcn_ComputerEquipmentAndSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ComputerEquipmentAndSoftwareMember_doc" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_UsFederalMember" xlink:to="lpcn_UsFederalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_UsFederalMember_doc" xml:lang="en-US">Us Federal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_February2020OfferingMember" xlink:to="lpcn_February2020OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_February2020OfferingMember_doc" xml:lang="en-US">February2020 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_November2019OfferingMember" xlink:to="lpcn_November2019OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_November2019OfferingMember_doc" xml:lang="en-US">November 2019 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClassBUnitsMember" xlink:to="lpcn_ClassBUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ClassBUnitsMember_doc" xml:lang="en-US">Class B Units [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PreFundedWarrantsMember" xlink:to="lpcn_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AccreditedInvestorsMember" xlink:label="lpcn_AccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AccreditedInvestorsMember" xlink:to="lpcn_AccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_AccreditedInvestorsMember_doc" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SaleAgreementMember" xlink:to="lpcn_SaleAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SaleAgreementMember_doc" xml:lang="en-US">Sale Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CorporateBondsNotesAndCommercialPaperMember" xlink:to="lpcn_CorporateBondsNotesAndCommercialPaperMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_CorporateBondsNotesAndCommercialPaperMember_doc" xml:lang="en-US">Corporate Bonds Notes And Commercial Paper [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_doc" xml:lang="en-US">Class of Warrant or Right, Redemption Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_StockIncentivePlan2014Member" xlink:to="lpcn_StockIncentivePlan2014Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_StockIncentivePlan2014Member_doc" xml:lang="en-US">Stock Incentive Plan 2014 [Member].</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_EquityIncentivePlanMember" xlink:label="lpcn_EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_EquityIncentivePlanMember" xlink:to="lpcn_EquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_EquityIncentivePlanMember_doc" xml:lang="en-US">Equity Incentive Plan [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_OneMajorCustomerMember" xlink:to="lpcn_OneMajorCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_OneMajorCustomerMember_doc" xml:lang="en-US">One major customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:to="lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales_doc" xml:lang="en-US">Percentage of net sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AbbottProductsIncMember" xlink:to="lpcn_AbbottProductsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_AbbottProductsIncMember_doc" xml:lang="en-US">Abbott Products Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:to="lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch_doc" xml:lang="en-US">Percentage of royalties reduction based upon product launch.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LicenseFee" xlink:to="lpcn_LicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_LicenseFee_doc" xml:lang="en-US">License fee.</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AntaresLicenseAgreementMember" xlink:label="lpcn_AntaresLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AntaresLicenseAgreementMember" xlink:to="lpcn_AntaresLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_AntaresLicenseAgreementMember_doc" xml:lang="en-US">Antares License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LicenseAgreementMember" xlink:to="lpcn_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PotentialLicenseFeesFromALicensee" xlink:to="lpcn_PotentialLicenseFeesFromALicensee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_PotentialLicenseFeesFromALicensee_doc" xml:lang="en-US">Potential license fees from a licensee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SalesMilestoneRevenueRecognized" xlink:to="lpcn_SalesMilestoneRevenueRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SalesMilestoneRevenueRecognized_doc" xml:lang="en-US">Sales milestone revenue recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PercentageOfRoyaltyPayment" xlink:to="lpcn_PercentageOfRoyaltyPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_PercentageOfRoyaltyPayment_doc" xml:lang="en-US">Percentage of royalty payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_TLANDOXRMember" xlink:to="lpcn_TLANDOXRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_TLANDOXRMember_doc" xml:lang="en-US">TLANDO XR [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClinicalAndDevelopmentMilestones" xlink:to="lpcn_ClinicalAndDevelopmentMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ClinicalAndDevelopmentMilestones_doc" xml:lang="en-US">Clinical and development milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LoanAndSecurityAgreementMember" xlink:to="lpcn_LoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_LoanAndSecurityAgreementMember_doc" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SiliconValleyBankMember" xlink:to="lpcn_SiliconValleyBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SiliconValleyBankMember_doc" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:to="lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_doc" xml:lang="en-US">Debt instrument, basis spread on interest rate for debt default.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:to="lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency_doc" xml:lang="en-US">The amount of debt instrument minimum amount considered for insolvency.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:to="lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock_doc" xml:lang="en-US">Schedule of Fair Value Of Warrants [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" xlink:to="lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_doc" xml:lang="en-US">Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DeferredFederalInsuranceContributionsActTaxPayments" xlink:label="lpcn_DeferredFederalInsuranceContributionsActTaxPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DeferredFederalInsuranceContributionsActTaxPayments" xlink:to="lpcn_DeferredFederalInsuranceContributionsActTaxPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_DeferredFederalInsuranceContributionsActTaxPayments_doc" xml:lang="en-US">This information is pertaining to the amount of deferral of FICA tax payments totaled and are included in accrued liabilities.</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CapitalizedComputerEquipmentAndHardware" xlink:label="lpcn_CapitalizedComputerEquipmentAndHardware" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CapitalizedComputerEquipmentAndHardware" xlink:to="lpcn_CapitalizedComputerEquipmentAndHardware_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_CapitalizedComputerEquipmentAndHardware_doc" xml:lang="en-US">Amount before accumulated amortization of capitalized costs for computer hardware, including but not limited to, acquired and internally developed computer hardware.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:to="lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_doc" xml:lang="en-US">Adjustment for settlement of liability on warrant exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:to="lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_doc" xml:lang="en-US">Schedule of Reconciliation of Warrant Liability [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average Exercise Price, period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average Exercise Price, issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Expired Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Cancelled Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_GlobalAgreementMember" xlink:to="lpcn_GlobalAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_GlobalAgreementMember_doc" xml:lang="en-US">Global Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ClarusTherapeuticsIncMember" xlink:to="lpcn_ClarusTherapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ClarusTherapeuticsIncMember_doc" xml:lang="en-US">Clarus Therapeutics, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_RetentionPayables" xlink:to="lpcn_RetentionPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_RetentionPayables_doc" xml:lang="en-US">Retention payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SpriasoLLCMember" xlink:to="lpcn_SpriasoLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SpriasoLLCMember_doc" xml:lang="en-US">Spriaso LLC[Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PercentageOfRoyalty" xlink:to="lpcn_PercentageOfRoyalty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_PercentageOfRoyalty_doc" xml:lang="en-US">Percentage of royalty.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_AgreementDescription" xlink:to="lpcn_AgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_AgreementDescription_doc" xml:lang="en-US">Agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ServiceAgreementMember" xlink:to="lpcn_ServiceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ServiceAgreementMember_doc" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ProceedsFromReimbursements" xlink:to="lpcn_ProceedsFromReimbursements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ProceedsFromReimbursements_doc" xml:lang="en-US">Proceeds from reimbursements.</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DeferredTaxAssetsPropertyPlantAndEquipmentOne" xlink:label="lpcn_DeferredTaxAssetsPropertyPlantAndEquipmentOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_DeferredTaxAssetsPropertyPlantAndEquipmentOne" xlink:to="lpcn_DeferredTaxAssetsPropertyPlantAndEquipmentOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_DeferredTaxAssetsPropertyPlantAndEquipmentOne_doc" xml:lang="en-US">Deferred tax assets property plant and equipment one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_MajorCustomerMember" xlink:to="lpcn_MajorCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_MajorCustomerMember_doc" xml:lang="en-US">Major Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicensingMember" xlink:label="lpcn_LicensingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LicensingMember" xlink:to="lpcn_LicensingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_LicensingMember_doc" xml:lang="en-US">Licensing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SalesBasedRoyaltiesMember" xlink:to="lpcn_SalesBasedRoyaltiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SalesBasedRoyaltiesMember_doc" xml:lang="en-US">Sales-based royalties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_MinimumGuaranteedRoyaltiesMember" xlink:to="lpcn_MinimumGuaranteedRoyaltiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_MinimumGuaranteedRoyaltiesMember_doc" xml:lang="en-US">Minimum guaranteed royalties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_MaterialsMember" xlink:to="lpcn_MaterialsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_MaterialsMember_doc" xml:lang="en-US">Materials [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_PayrollProtectionProgramLoanMember" xlink:to="lpcn_PayrollProtectionProgramLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_PayrollProtectionProgramLoanMember_doc" xml:lang="en-US">Payroll Protection Program Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_LabAndOfficeEquipmentMember" xlink:to="lpcn_LabAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_LabAndOfficeEquipmentMember_doc" xml:lang="en-US">Lab and office equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments cancelled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" xlink:to="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than option forfeited weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CantorMember" xlink:to="lpcn_CantorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_CantorMember_doc" xml:lang="en-US">Cantor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SharesAvailableForFutureIssuanceValue" xlink:label="lpcn_SharesAvailableForFutureIssuanceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SharesAvailableForFutureIssuanceValue" xlink:to="lpcn_SharesAvailableForFutureIssuanceValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SharesAvailableForFutureIssuanceValue_doc" xml:lang="en-US">Shares available for future issuance value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SharesAvailableForFutureIssuance" xlink:to="lpcn_SharesAvailableForFutureIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_SharesAvailableForFutureIssuance_doc" xml:lang="en-US">Shares available for future issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_TwoThousandElevenEquityIncentivePlanMember" xlink:to="lpcn_TwoThousandElevenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_TwoThousandElevenEquityIncentivePlanMember_doc" xml:lang="en-US">2011 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_CommonStockWarrantMember" xlink:to="lpcn_CommonStockWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lpcn_CommonStockWarrantMember_doc" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_2_lbl" xml:lang="en-US">Litigation Settlement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_lbl" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_2_lbl" xml:lang="en-US">Repayments of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_SettlementOfWarrantLiabilityOnWarrantExercises_3_lbl" xml:lang="en-US">SettlementOfWarrantLiabilityOnWarrantExercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_lbl" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits" xlink:to="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits_3_lbl" xml:lang="en-US">Income Tax Reconciliation Orphan Drug Tax Credits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" xlink:to="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_3_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Warrant Liability, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_3_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>lpcn-20211231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lipocine.com/role/Cover" xlink:href="lpcn-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheets" xlink:href="lpcn-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:href="lpcn-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="lpcn-20211231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="lpcn-20211231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfCashFlows" xlink:href="lpcn-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/DescriptionOfBusiness" xlink:href="lpcn-20211231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreements" xlink:href="lpcn-20211231.xsd#ContractualAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreement" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipment" xlink:href="lpcn-20211231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxes" xlink:href="lpcn-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/Leases" xlink:href="lpcn-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquity" xlink:href="lpcn-20211231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/KPlan" xlink:href="lpcn-20211231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingencies" xlink:href="lpcn-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:href="lpcn-20211231.xsd#AgreementWithSpriasoLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AccountingPronouncements" xlink:href="lpcn-20211231.xsd#AccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementTables" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipmentTables" xlink:href="lpcn-20211231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxesTables" xlink:href="lpcn-20211231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesTables" xlink:href="lpcn-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityTables" xlink:href="lpcn-20211231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lpcn-20211231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:href="lpcn-20211231.xsd#MarketableInvestmentSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:href="lpcn-20211231.xsd#ContractualAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfMaturitiesOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative" xlink:href="lpcn-20211231.xsd#LoanAndSecurityAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="lpcn-20211231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxesDetailsNarrative" xlink:href="lpcn-20211231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesDetailsNarrative" xlink:href="lpcn-20211231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="lpcn-20211231.xsd#ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:href="lpcn-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/KPlanDetailsNarrative" xlink:href="lpcn-20211231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lpcn-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:href="lpcn-20211231.xsd#AgreementWithSpriasoLlcDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetNetNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaapLitigationReserveCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLitigationReserveCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="loc_us-gaapLitigationReserveNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLitigationReserveNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapNetIncomeLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockSoldThroughEquityOffering" xlink:label="loc_lpcnCommonStockSoldThroughEquityOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnCommonStockSoldThroughEquityOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockSoldThroughEquityOfferingShares" xlink:label="loc_lpcnCommonStockSoldThroughEquityOfferingShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnCommonStockSoldThroughEquityOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="loc_lpcnStockIssuedDuringPeriodValueWarrantsExercises" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnStockIssuedDuringPeriodValueWarrantsExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="loc_lpcnStockIssuedDuringPeriodSharesWarrantsExercises" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnStockIssuedDuringPeriodSharesWarrantsExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="loc_lpcnAdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnAdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAccretionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LitigationSettlementExpenseOne" xlink:label="loc_lpcnLitigationSettlementExpenseOne" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_lpcnLitigationSettlementExpenseOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaapPaymentsToAcquireAvailableForSaleSecuritiesDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_NetProceedsFromSaleOfCommonStockThroughATM" xlink:label="loc_lpcnNetProceedsFromSaleOfCommonStockThroughATM" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_lpcnNetProceedsFromSaleOfCommonStockThroughATM" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="loc_lpcnSettlementOfWarrantLiabilityOnWarrantExercises" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_lpcnSettlementOfWarrantLiabilityOnWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AccruedFinalPaymentChargeOnDebt" xlink:label="loc_lpcnAccruedFinalPaymentChargeOnDebt" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_lpcnAccruedFinalPaymentChargeOnDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - Description of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:title="00000009 - Disclosure - Marketable Investment Securities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreements" xlink:title="00000010 - Disclosure - Contractual Agreements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="loc_us-gaapHealthCareOrganizationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock" xlink:label="loc_us-gaapBusinessAndContractualArrangementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationsAbstract" xlink:to="loc_us-gaapBusinessAndContractualArrangementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreement" xlink:title="00000011 - Disclosure - Loan and Security Agreement">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/Leases" xlink:title="00000014 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DisclosureLeasesAbstract" xlink:label="loc_lpcnDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lpcnDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/KPlan" xlink:title="00000016 - Disclosure - 401(k) Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:title="00000018 - Disclosure - Agreement with Spriaso, LLC">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AccountingPronouncements" xlink:title="00000019 - Disclosure - Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:title="00000022 - Disclosure - Marketable Investment Securities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaapInvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementTables" xlink:title="00000023 - Disclosure - Loan and Security Agreement (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipmentTables" xlink:title="00000024 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesTables" xlink:title="00000026 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DisclosureLeasesAbstract" xlink:label="loc_lpcnDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lpcnDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:label="loc_lpcnScheduleOfFairValueOfWarrantsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_lpcnScheduleOfFairValueOfWarrantsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:label="loc_lpcnScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_lpcnScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000028 - Disclosure - Schedule of Disaggregation of Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesBasedRoyaltiesMember" xlink:label="loc_lpcnSalesBasedRoyaltiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_lpcnSalesBasedRoyaltiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MinimumGuaranteedRoyaltiesMember" xlink:label="loc_lpcnMinimumGuaranteedRoyaltiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_lpcnMinimumGuaranteedRoyaltiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MaterialsMember" xlink:label="loc_lpcnMaterialsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_lpcnMaterialsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:title="00000029 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:title="00000030 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaapCashAndCashEquivalentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapCashAndCashEquivalentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaapCommercialPaperMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CorporateBondsandNotesMember" xlink:label="loc_lpcnCorporateBondsandNotesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_lpcnCorporateBondsandNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:title="00000032 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000033 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_MajorCustomerMember" xlink:label="loc_lpcnMajorCustomerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_lpcnMajorCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OneMajorCustomerMember" xlink:label="loc_lpcnOneMajorCustomerMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_lpcnOneMajorCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ComputerEquipmentAndSoftwareMember" xlink:label="loc_lpcnComputerEquipmentAndSoftwareMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_lpcnComputerEquipmentAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:title="00000035 - Disclosure - Schedule of Available-for-Sale Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapMarketableSecuritiesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CorporateBondsNotesAndCommercialPaperMember" xlink:label="loc_lpcnCorporateBondsNotesAndCommercialPaperMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_lpcnCorporateBondsNotesAndCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaapCommercialPaperMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:title="00000036 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:title="00000037 - Disclosure - Marketable Investment Securities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaapProceedsFromSaleOfHeldToMaturitySecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:label="loc_us-gaapDebtAndEquitySecuritiesRealizedGainLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapDebtAndEquitySecuritiesRealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" xlink:label="loc_us-gaapOtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapOtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:title="00000038 - Disclosure - Contractual Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="loc_us-gaapHealthCareOrganizationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTable" xlink:label="loc_us-gaapScheduleOfMalpracticeInsuranceTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationsAbstract" xlink:to="loc_us-gaapScheduleOfMalpracticeInsuranceTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MalpracticeInsuranceLineItems" xlink:label="loc_us-gaapMalpracticeInsuranceLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_us-gaapMalpracticeInsuranceLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaapCollaborativeArrangementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapCollaborativeArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicenseAgreementMember" xlink:label="loc_lpcnLicenseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AbbottProductsIncMember" xlink:label="loc_lpcnAbbottProductsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnAbbottProductsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TLANDOXRMember" xlink:label="loc_lpcnTLANDOXRMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnTLANDOXRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfMalpracticeInsuranceTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:label="loc_lpcnCollaborativeArrangementRoyaltiesPercentageOfNetSales" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnCollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaapRoyaltyGuaranteesCommitmentsAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_us-gaapRoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:label="loc_lpcnPercentageOfRoyaltiesReductionBasedUponProductLaunch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnPercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicenseFee" xlink:label="loc_lpcnLicenseFee" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PotentialLicenseFeesFromALicensee" xlink:label="loc_lpcnPotentialLicenseFeesFromALicensee" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnPotentialLicenseFeesFromALicensee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesMilestoneRevenueRecognized" xlink:label="loc_lpcnSalesMilestoneRevenueRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnSalesMilestoneRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyaltyPayment" xlink:label="loc_lpcnPercentageOfRoyaltyPayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnPercentageOfRoyaltyPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClinicalAndDevelopmentMilestones" xlink:label="loc_lpcnClinicalAndDevelopmentMilestones" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_lpcnClinicalAndDevelopmentMilestones" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMalpracticeInsuranceLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:title="00000039 - Disclosure - Schedule of Maturities of Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" xlink:label="loc_lpcnLongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_lpcnLongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative" xlink:title="00000040 - Disclosure - Loan and Security Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LoanAndSecurityAgreementMember" xlink:label="loc_lpcnLoanAndSecurityAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_lpcnLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PayrollProtectionProgramLoanMember" xlink:label="loc_lpcnPayrollProtectionProgramLoanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_lpcnPayrollProtectionProgramLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SiliconValleyBankMember" xlink:label="loc_lpcnSiliconValleyBankMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_lpcnSiliconValleyBankMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="loc_us-gaapCashCollateralForBorrowedSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCashCollateralForBorrowedSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="loc_us-gaapDebtInstrumentRestrictiveCovenants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentRestrictiveCovenants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:label="loc_lpcnDebtInstrumentBasisSpreadOnInterestRateForDebtDefault" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_lpcnDebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:label="loc_lpcnDebtInstrumentMinimumAmountConsideredForInsolvency" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_lpcnDebtInstrumentMinimumAmountConsideredForInsolvency" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ComputerEquipmentAndSoftwareMember" xlink:label="loc_lpcnComputerEquipmentAndSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_lpcnComputerEquipmentAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LabAndOfficeEquipmentMember" xlink:label="loc_lpcnLabAndOfficeEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_lpcnLabAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails" xlink:title="00000043 - Disclosure - Schedule of Income Tax Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails" xlink:title="00000044 - Disclosure - Schedule of Pretax Income from Continuing Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits" xlink:label="loc_lpcnIncomeTaxReconciliationOrphanDrugTaxCredits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_lpcnIncomeTaxReconciliationOrphanDrugTaxCredits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" xlink:label="loc_lpcnEffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_lpcnEffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000045 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DeferredTaxAssetsOrphanDrugTaxCredit" xlink:label="loc_lpcnDeferredTaxAssetsOrphanDrugTaxCredit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_lpcnDeferredTaxAssetsOrphanDrugTaxCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails" xlink:title="00000046 - Disclosure - Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_UsFederalMember" xlink:label="loc_lpcnUsFederalMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_lpcnUsFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount" xlink:label="loc_lpcnOperatingLossCarryForwardsLimitationsOnUseAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnOperatingLossCarryForwardsLimitationsOnUseAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsPreownershipChangeAmount" xlink:label="loc_lpcnOperatingLossCarryForwardsPreownershipChangeAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnOperatingLossCarryForwardsPreownershipChangeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossForgivePreOwnershipChangeAmount" xlink:label="loc_lpcnOperatingLossForgivePreOwnershipChangeAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnOperatingLossForgivePreOwnershipChangeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount" xlink:label="loc_lpcnTaxCreditCarryforwardPreOwnershipChangeAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnTaxCreditCarryforwardPreOwnershipChangeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_OperatingLossCarryForwardsExpirationDate1" xlink:label="loc_lpcnOperatingLossCarryForwardsExpirationDate1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_lpcnOperatingLossCarryForwardsExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="00000048 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DisclosureLeasesAbstract" xlink:label="loc_lpcnDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lpcnDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lpcnDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lpcnDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesDetailsNarrative" xlink:title="00000049 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_DisclosureLeasesAbstract" xlink:label="loc_lpcnDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lpcnDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000050 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000051 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:title="00000052 - Disclosure - Schedule of Fair Value of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_November2019OfferingMember" xlink:label="loc_lpcnNovember2019OfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnNovember2019OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:title="00000053 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:label="loc_lpcnAdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_lpcnAdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000054 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_lpcnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000055 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_January2021OfferingMember" xlink:label="loc_lpcnJanuary2021OfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnJanuary2021OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_February2020OfferingMember" xlink:label="loc_lpcnFebruary2020OfferingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnFebruary2020OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_November2019OfferingMember" xlink:label="loc_lpcnNovember2019OfferingMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnNovember2019OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AtMarketOfferingMember" xlink:label="loc_lpcnAtMarketOfferingMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_lpcnAtMarketOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassAUnitMember" xlink:label="loc_lpcnClassAUnitMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_lpcnClassAUnitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassBUnitsMember" xlink:label="loc_lpcnClassBUnitsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_lpcnClassBUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PreFundedWarrantsMember" xlink:label="loc_lpcnPreFundedWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_lpcnPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesAgreementMember" xlink:label="loc_lpcnSalesAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_lpcnSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CantorMember" xlink:label="loc_lpcnCantorMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnCantorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SalesAgreementMember" xlink:label="loc_lpcnSalesAgreementMember_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnSalesAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SaleAgreementMember" xlink:label="loc_lpcnSaleAgreementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnSaleAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_CommonStockWarrantMember" xlink:label="loc_lpcnCommonStockWarrantMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_lpcnCommonStockWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_StockIncentivePlan2014Member" xlink:label="loc_lpcnStockIncentivePlan2014Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_lpcnStockIncentivePlan2014Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_TwoThousandElevenEquityIncentivePlanMember" xlink:label="loc_lpcnTwoThousandElevenEquityIncentivePlanMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_lpcnTwoThousandElevenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_lpcnProceedsFromIssuanceOfCommonStockGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_lpcnProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfGrossProceedOnSaleOfShares" xlink:label="loc_lpcnPercentageOfGrossProceedOnSaleOfShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_lpcnPercentageOfGrossProceedOnSaleOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SharesAvailableForFutureIssuance" xlink:label="loc_lpcnSharesAvailableForFutureIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_lpcnSharesAvailableForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_lpcnClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_lpcnClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/KPlanDetailsNarrative" xlink:title="00000056 - Disclosure - 401(k) Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_GlobalAgreementMember" xlink:label="loc_lpcnGlobalAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnGlobalAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ClarusTherapeuticsIncMember" xlink:label="loc_lpcnClarusTherapeuticsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnClarusTherapeuticsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_RetentionPayables" xlink:label="loc_lpcnRetentionPayables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_lpcnRetentionPayables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:title="00000058 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_LicenseAgreementMember" xlink:label="loc_lpcnLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ServiceAgreementMember" xlink:label="loc_lpcnServiceAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_lpcnServiceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_SpriasoLLCMember" xlink:label="loc_lpcnSpriasoLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_lpcnSpriasoLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_PercentageOfRoyalty" xlink:label="loc_lpcnPercentageOfRoyalty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_lpcnPercentageOfRoyalty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaapProceedsFromContributionsFromAffiliates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromContributionsFromAffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_AgreementDescription" xlink:label="loc_lpcnAgreementDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_lpcnAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20211231.xsd#lpcn_ProceedsFromReimbursements" xlink:label="loc_lpcnProceedsFromReimbursements" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_lpcnProceedsFromReimbursements" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966026232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIPOCINE
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001535955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">99-0370688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">675
                                            Arapeen Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt
    Lake City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">994-7383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LPCN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,290,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated By Reference</a></td>
<td class="text">Portions
of the registrant&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part
III of this Form 10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Tanner LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Salt
Lake City, Utah<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129972066760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,950,552<span></span>
</td>
<td class="nump">$ 19,217,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable investment securities</a></td>
<td class="nump">41,667,405<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest income</a></td>
<td class="nump">247,253<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,514,465<span></span>
</td>
<td class="nump">661,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">46,379,675<span></span>
</td>
<td class="nump">25,329,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable investment securities</a></td>
<td class="nump">2,021,800<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract asset</a></td>
<td class="nump">4,050,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $1,144,077 and $1,143,697 respectively</a></td>
<td class="nump">7,211<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">23,753<span></span>
</td>
<td class="nump">23,753<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">52,482,439<span></span>
</td>
<td class="nump">25,352,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,289,342<span></span>
</td>
<td class="nump">1,597,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,016,458<span></span>
</td>
<td class="nump">1,653,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt - current portion</a></td>
<td class="nump">2,310,825<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement liability - current portion</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,616,625<span></span>
</td>
<td class="nump">6,583,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt - non-current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,257,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">795,796<span></span>
</td>
<td class="nump">1,170,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Litigation settlement liability - non-current portion</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,912,421<span></span>
</td>
<td class="nump">10,010,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (notes 5, 8 and 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 88,296,360 and 70,041,967 issued and 88,290,650 and 70,036,257 outstanding</a></td>
<td class="nump">8,830<span></span>
</td>
<td class="nump">7,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">218,286,323<span></span>
</td>
<td class="nump">187,407,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost, 5,710 shares</a></td>
<td class="num">(40,712)<span></span>
</td>
<td class="num">(40,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(18,016)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(172,666,407)<span></span>
</td>
<td class="num">(172,032,008)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">45,570,018<span></span>
</td>
<td class="nump">15,341,919<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 52,482,439<span></span>
</td>
<td class="nump">$ 25,352,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129972052728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)</a></td>
<td class="nump">$ 1,144,077<span></span>
</td>
<td class="nump">$ 1,143,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">88,296,360<span></span>
</td>
<td class="nump">70,041,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">70,036,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">5,710<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968725880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 16,140,838<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,665,559<span></span>
</td>
<td class="nump">9,748,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,329,776<span></span>
</td>
<td class="nump">8,247,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,995,335<span></span>
</td>
<td class="nump">17,996,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">3,145,503<span></span>
</td>
<td class="num">(17,996,264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest and investment income</a></td>
<td class="nump">67,700<span></span>
</td>
<td class="nump">75,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(203,292)<span></span>
</td>
<td class="num">(386,618)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">234,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain (loss) on warrant liability</a></td>
<td class="nump">355,890<span></span>
</td>
<td class="num">(2,892,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(3,779,702)<span></span>
</td>
<td class="num">(2,968,355)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(634,199)<span></span>
</td>
<td class="num">(20,964,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (634,399)<span></span>
</td>
<td class="num">$ (20,964,819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common stock</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding,</a></td>
<td class="nump">86,934,618<span></span>
</td>
<td class="nump">55,688,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common stock</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">86,934,618<span></span>
</td>
<td class="nump">55,688,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (634,399)<span></span>
</td>
<td class="num">$ (20,964,819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized net gain (loss) on available-for-sale securities</a></td>
<td class="num">(18,016)<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (652,415)<span></span>
</td>
<td class="num">$ (20,964,781)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968437720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 3,766<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">$ 157,391,969<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (151,067,189)<span></span>
</td>
<td class="nump">$ 6,287,796<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">37,649,465<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,964,819)<span></span>
</td>
<td class="num">(20,964,819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized net loss on marketable investment securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_CommonStockSoldThroughEquityOffering', window );">Common stock sold through equity offering</a></td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,652,132<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,653,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_CommonStockSoldThroughEquityOfferingShares', window );">Common stock sold through equity offering, shares</a></td>
<td class="nump">10,084,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_StockIssuedDuringPeriodValueWarrantsExercises', window );">Common stock issued for warrant exercises</a></td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,673,366<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,674,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Common stock issued for warrant exercises, shares</a></td>
<td class="nump">15,097,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,373,182<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,373,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises', window );">Settlement of warrant liability on warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,313,338<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,313,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">628,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold through ATM offering</a></td>
<td class="nump">$ 658<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,003,710<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,004,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold through ATM offering, shares</a></td>
<td class="nump">6,576,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 7,005<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">187,407,634<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(172,032,008)<span></span>
</td>
<td class="nump">15,341,919<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">70,036,257<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(634,399)<span></span>
</td>
<td class="num">(634,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized net loss on marketable investment securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,016)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_CommonStockSoldThroughEquityOffering', window );">Common stock sold through equity offering</a></td>
<td class="nump">$ 1,643<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,838,814<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,840,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_CommonStockSoldThroughEquityOfferingShares', window );">Common stock sold through equity offering, shares</a></td>
<td class="nump">16,428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_StockIssuedDuringPeriodValueWarrantsExercises', window );">Common stock issued for warrant exercises</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Common stock issued for warrant exercises, shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">603,946<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">603,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises', window );">Settlement of warrant liability on warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,365<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold through ATM offering</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,405,872<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,406,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold through ATM offering, shares</a></td>
<td class="nump">1,811,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,693<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 8,830<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">$ 218,286,323<span></span>
</td>
<td class="num">$ (18,016)<span></span>
</td>
<td class="num">$ (172,666,407)<span></span>
</td>
<td class="nump">$ 45,570,018<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of warrant liability on warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_CommonStockSoldThroughEquityOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock sold through equity offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_CommonStockSoldThroughEquityOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_CommonStockSoldThroughEquityOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock sold through equity offering, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_CommonStockSoldThroughEquityOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for warrant exercises, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966069928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (634,399)<span></span>
</td>
<td class="num">$ (20,964,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">603,946<span></span>
</td>
<td class="nump">1,373,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Non-cash interest expense</a></td>
<td class="nump">53,750<span></span>
</td>
<td class="nump">109,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Non-cash gain on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(234,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Non-cash loss (gain) on change in fair value of warrant liability</a></td>
<td class="num">(355,890)<span></span>
</td>
<td class="nump">2,892,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium/discount on marketable investment securities</a></td>
<td class="nump">515,577<span></span>
</td>
<td class="num">(2,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Accrued interest income</a></td>
<td class="num">(246,862)<span></span>
</td>
<td class="nump">16,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(4,903,207)<span></span>
</td>
<td class="num">(115,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(307,878)<span></span>
</td>
<td class="nump">414,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(636,720)<span></span>
</td>
<td class="nump">1,205,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_LitigationSettlementExpenseOne', window );">Litigation settlement liability</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(4,411,303)<span></span>
</td>
<td class="num">(15,303,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(7,591)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable investment securities</a></td>
<td class="num">(48,422,806)<span></span>
</td>
<td class="num">(6,315,297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities of marketable investment securities</a></td>
<td class="nump">4,650,000<span></span>
</td>
<td class="nump">10,208,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by (used in) investing activities</a></td>
<td class="num">(43,780,397)<span></span>
</td>
<td class="nump">3,892,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">233,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Debt repayments</a></td>
<td class="num">(3,333,333)<span></span>
</td>
<td class="num">(1,666,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">6,693<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock sold in equity offering</a></td>
<td class="nump">26,840,457<span></span>
</td>
<td class="nump">5,653,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">7,674,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_NetProceedsFromSaleOfCommonStockThroughATM', window );">Net proceeds from sale of common stock through ATM</a></td>
<td class="nump">3,406,053<span></span>
</td>
<td class="nump">9,004,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">26,924,870<span></span>
</td>
<td class="nump">20,899,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(21,266,830)<span></span>
</td>
<td class="nump">9,488,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">24,217,382<span></span>
</td>
<td class="nump">14,728,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">2,950,552<span></span>
</td>
<td class="nump">24,217,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">149,543<span></span>
</td>
<td class="nump">276,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_SettlementOfWarrantLiabilityOnWarrantExercises', window );">Settlement of warrant liability on warrant exercises</a></td>
<td class="nump">18,365<span></span>
</td>
<td class="nump">6,313,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized net gain (loss) on marketable investment securities</a></td>
<td class="num">(18,016)<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_AccruedFinalPaymentChargeOnDebt', window );">Accrued final payment charge on debt</a></td>
<td class="nump">$ 53,750<span></span>
</td>
<td class="nump">$ 109,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_AccruedFinalPaymentChargeOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued final payment charge on debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_AccruedFinalPaymentChargeOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_LitigationSettlementExpenseOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement expense one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_LitigationSettlementExpenseOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_NetProceedsFromSaleOfCommonStockThroughATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of common stock through ATM.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_NetProceedsFromSaleOfCommonStockThroughATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_SettlementOfWarrantLiabilityOnWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of warrant liability on warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_SettlementOfWarrantLiabilityOnWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967492200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zzodVWPYejM8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zc2JX4wRB5wg">Description of Business</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lipocine
Inc. (&#8220;Lipocine&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
disorders, is engaged in research and development for the delivery of drugs using its proprietary delivery technology. The Company&#8217;s
principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its own drug candidates or it develops
drug candidates on behalf of or in collaboration with corporate partners. The Company has funded operating costs primarily through collaborative
license, milestone and research arrangements, through federal grants, through the sale of equity securities and through debt. The Company
is incorporated under the laws of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140130056652632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zr6o0SiZ71Q5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zBASakskuM">Summary of Significant Accounting Policies</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--UseOfEstimates_zS3cKuhCv4aa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zbAEwo35NvGi">Use of Estimates</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates. Significant items subject to such estimates and assumptions include those related to stock-based compensation;
income tax uncertainties; the fair value of the warrant liability and the useful lives of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6nKwusyv1u4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zdlSg0YRaPO3">Cash and Cash Equivalents</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities to the Company of three months or less to be cash equivalents.
Although the Company may deposit its cash and cash equivalents with multiple financial institutions, its deposits, at times, may exceed
federally insured limits. Cash and cash equivalents were $<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zYCo3dDgpqAd">3.0</span> million and $<span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20201231_z85VN9DcsXh5" title="Cash Equivalents, at Carrying Value">19.2</span>million at December 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zYEtcgyU4CTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zjSAJGjXEmm4">Receivables</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are recorded at the invoiced amount and do not bear interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains an allowance for doubtful accounts for estimated losses. In establishing the allowance, management considers historical
losses adjusted to take into account current market conditions and their customers&#8217; financial condition, the amount of receivables
in dispute, and the current receivables aging and current payment patterns. The Company had no write-offs in 2021 and 2020 and the Company
did not record an allowance for doubtful accounts as of December 31, 2021 and 2020 as there were no accounts receivable outstanding.
The Company does not have any off-balance-sheet credit exposure related to its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zFciAEhTHFDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zkB8RqQyhKIf">Revenue Recognition</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates most of its revenue from license and royalty arrangements. At inception of each contract, the Company identifies
the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines
the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and
determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction
price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. The Company reassess its reserves for variable consideration
at each reporting date and makes adjustments, if necessary, which may affect revenue and earnings in periods in which any such changes
become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)
Summary of Significant Accounting Policies &#8211; (continued)</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zdWnl6qjMk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation
of Revenue</i>.&#160;In the following tables, revenues reported for the year ended December 31, 2021, under Topic 606, is disaggregated
by type of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B2_zuLyLtwvNK4d" style="display: none">Schedule of Disaggregation
of Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Type of Revenue</td><td>&#160;</td>
    <td colspan="3" id="xdx_498_20210101__20211231_zgv6ccqvmkkk">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zAi9cZjBFZw8" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%">Licensing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">11,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SalesBasedRoyaltiesMember_zPyc3OXnLh2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales-based royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,994</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MinimumGuaranteedRoyaltiesMember_z3rfsLxUtocc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Minimum guaranteed royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,050,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MaterialsMember_zhfrHuzqtVT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Materials</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,035,844</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Revenue</span></td><td/>
    <td style="text-align: left">$</td><td style="text-align: right">16,140,838</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zV6aKZ3IMhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Topic 606, all revenue has been recognized as point in time for the year ended December 31, 2021.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 4 for a description of the license agreement with Antares Pharma, Inc. See Note 12 for a description of the agreement with Spriaso.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Fees</i>. For distinct license performance obligations, upfront license fees are recognized when the Company satisfies the underlying
performance obligation. This generally occurs upon transfer of the right to use the Company&#8217;s licensed technology to the customer.
In addition, license arrangements may include contingent milestone payments, which are due following achievement by our licensee of specified
sales or regulatory milestones and the licensee and/or Company will fulfill its performance obligation prior to achievement of these
milestones. Because of the uncertainty of the milestone achievement, and/or the dependence on sales of our licensee, variable consideration
for contingent milestones is fully constrained and is not recognized as revenue until the milestone is achieved by our licensee, to the
extent collectability is reasonably certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Royalties.
</i>Royalties revenue consists of sales-based and minimum royalties earned under licenses agreements for our products. Performance obligations
under these licenses, which consist of the right to use the Company&#8217;s proprietary technology, are satisfied at a point in time
corresponding with delivery of the underlying technology rights to the licensee, which is generally upon transfer of the licensed technology/product
to the customer. Sales-based royalties revenue represents variable consideration under the license agreements and is recognized in the
period a customer sells products incorporating the Company&#8217;s licensed technologies/products. The Company estimates sales-based
royalties revenue earned but unpaid at each reporting period using information provided by the licensee. The Company&#8217;s license
arrangements may also provide for minimum royalties, which the Company recognizes upon the satisfaction of the underlying performance
obligation, which generally occurs with delivery of the underlying technology rights to the licensee.Sales-based and minimum royalties
are generally due within 45 days after the end of each quarter in which they are earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
assets consist of minimum royalty revenue earned in relation to the license agreement but not yet payable based on the terms of the contract.
The contract asset as of December 31, 2021 is related to the Antares License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Concentration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
major customer is considered to be one that comprises more than <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--MajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLMX5IlbMtq4">10</span>% of the Company&#8217;s total revenues. There was one major customer
for the year ended December 31, 2021 which accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--OneMajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLHc6v70JOwc" title="Percentage of total revenue">99.7</span>% of total revenue. There was <span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_do_c20201001__20201231_zSySGzYwqj76" title="Total revenues">no</span> revenue recognized for the year ended December
31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOOkvtINXNn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(e)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zioBGwPalWU6">Property and Equipment</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost, less accumulated depreciation. Maintenance and repairs that do not extend the life or improve the
asset are expensed in the year incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is computed using the straight-line method over the estimated useful lives of the assets, which are <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zatle0IZ9bo3" title="Property, Plant and Equipment, Useful Life">five years </span>for laboratory and office
equipment, <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zr3KRIRRrS11" title="Property, Plant and Equipment, Useful Life">three years</span> for computer equipment and software, and <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zpuhAqpP7wF2" title="Property, Plant and Equipment, Useful Life">seven years</span> for furniture and fixtures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zEYltHlVqFs3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(f)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z3r5HPdRjcDj">Accounting for Impairment of Long-Lived Assets</span></i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability of assets held and used is measured by a comparison of the carrying amount of an asset to future net cash
flows (undiscounted) expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized
is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets held for sale are reported
at the lower of the carrying amount, or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zij84mfqKRbc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(g)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z1FKhGvDMhyk">Income Taxes</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is provided against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or
all of the net deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition
or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related
to unrecognized tax benefits as a component of its income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zE5k11edQWx6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(h)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_znbsB5FBIE3b">Share Based Payments</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under
the Company&#8217;s Incentive Plan to employees, nonemployees and nonemployee members of the Company&#8217;s board of directors based
on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over
the award&#8217;s requisite service period. In addition, the Company has granted performance-based stock option awards and restricted
stock units, which vest based upon the Company satisfying certain performance conditions. Potential compensation cost, measured on the
grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options or units
will vest, which is based on whether the Company considers the performance conditions to be probable of attainment. The Company&#8217;s
estimates of the number of performance-based options or units that will vest will be revised, if necessary, in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated
based on assumptions with respect to (i) expected volatility of the Company&#8217;s Common Stock price, (ii) the periods of time over
which employees, nonemployees and members of the board of directors are expected to hold their options prior to exercise (expected term),
(iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes
an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised,
if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed
in the statements of operations amounted to $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3p0_c20210101__20211231_zXhfRBKUTEzf">604,000</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20200101__20201231_zuOVQIW0WaU3" title="Stock-based compensation cost">1.4</span> million for the years ended December 31, 2021 and 2020, allocated as follows:</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zxktI59KUKT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zhzSwTDBtpj3" style="display: none">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfpCgm0FOUUb" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">280,186</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfo1rTd1mKY1" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">583,212</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPBGjCR5Ba9i" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">323,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zI21cmWhk788" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">789,970</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210101__20211231_zFzE5iVkIFd" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">603,946</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200101__20201231_zNigh3TFQ4U8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,373,182</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_z9I2BOotSGTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zzXAxaMeRyW2">1,106,000</span> stock options and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0d_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zgAtZFpGhCtb" title="Number of stock options issued">1,360,000</span> stock options during the years ended December 31, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used in the determination of the fair value of stock options granted are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical
experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff
Accounting Bulletin (&#8220;SAB&#8221;) No. 107, <i>Share-Based Payment,</i> for awards with stated or implied service periods. The simplified
method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance
conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an
equivalent remaining term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Dividend</i>: The expected dividend assumption is based on management&#8217;s current expectation about the Company&#8217;s anticipated
dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>: The volatility factor is based solely on the Company&#8217;s trading history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zf9P3LTrNnc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
options granted in 2021 and 2020, the Company calculated the fair value of each option grant on the respective dates of grant using the
following weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zjfYf6O7yXqg" style="display: none">Schedule of Key Assumption of Fair Value of Stock Options Granted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zigqPgUOxEZ8">5.83</span>
                                            years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zCceFwzJzute">5.83</span>
                                            years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zgcnZIUoQ6K3" style="width: 12%; text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">1.04</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zsPoWtUlC3Y7" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.93</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20210101__20211231_zXibUT3LAfol" style="text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20200101__20201231_zOXOJ72FKom6" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zAWn9JB5hgod" style="text-align: right" title="Expected volatility"><span style="font-family: Times New Roman, Times, Serif">102.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zgGyc6uUUQN9" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>


<p id="xdx_8A9_zVf2XvZ0efE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Stock Compensation,</i> requires the Company to recognize compensation
expense for the portion of options that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived
from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional
adjustments to compensation expense may be required in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231_zy2xMqQDarp3" title="Unrecognized compensation cost">1.4</span> million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#8217;s stock option plan. That cost is expected to be recognized over a weighted average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231_zjI6ilgBAOG2" title="Weighted average period of stock option plan">2.3</span> years
and will be adjusted for subsequent changes in estimated forfeitures. The weighted average fair value of share-based compensation awards
granted during the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zgMvHpcT81Ld" title="Weighted average fair value of share-based compensation">0.97</span> per share and $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zR7ykk45H38c" title="Weighted average fair value of share-based compensation">0.72</span> per share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcxKT4huaXBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(i)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zkTH0OjI9iH2">Fair Value</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent
possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability
in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 Inputs: Quoted prices for identical instruments in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets
    that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in
    active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For
accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair
value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets
and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and 2020:</span></p>

<p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zzBGjfRbBTPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z8FOEw2Zhok1" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December 31,</b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value measurements at reporting date using</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;1&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;2&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;3&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents
    - money market funds</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,089,751</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,089,751</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0626">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Government treasury bills</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_zYGZ6JIYckGg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,515,920</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTu9YGe8OTa2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,515,920</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvtejDkIbzk" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJsvJNlBhXKf" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,385,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,385,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate
    bonds and notes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,787,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0636">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,787,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,778,956</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,605,671</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,173,285</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231_zD0ubLHmRyY8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,574,752</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9RCmwhCsiB5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,605,671</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzR9sXtEOXHf" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,173,285</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdagisEL2M91" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31,</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
                                            value measurements at reporting date using</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; width: 13%"><p style="margin-top: 0pt; margin-bottom: 0pt"/>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;1&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;2&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;3&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents - money
    market funds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zXwfULRgcUP7" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z966EUneKSK" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrgFK1UTqLe3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Kb9hlcgRl" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_zmBOCCN8FPte" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkHjiDBgeDib" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPasc9NWxJpl" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUOTmfQWyXFk" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231_zgu5OFtTpuB1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,849,577</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zF2rDLCvLyih" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOXN8fQ4M1B5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUUzJQw55bdb" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztRdSXKnChQb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zE6BOBMv2vt" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zjL0GunQRlLa" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z3NlU6vvX9F5" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_zvV437GzwiVi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,019,628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8hIWi8rxM73" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPPwnpBFeMx6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzj9PUwJ5Ha" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_zfTFu6dX2mGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value
in the balance sheets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents: Cash equivalents primarily consist of highly rated money market funds and treasury bills with original maturities to
the Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to
money market funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted
market prices or broker or dealer quotations for similar assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
bonds and notes: The Company uses a third-party pricing service to value these investments. United States bonds and notes are classified
within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets and reportable trades.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. Corporate bonds, notes
and commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids
and offers, benchmark yields and credit spreads and other observable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
liability: The warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period
with the change in fair value recorded to other income (expense) in the accompanying statements of operations until the warrants are
exercised, expire or other facts and circumstances lead the warrant liability to be reclassified to stockholders&#8217; equity. The fair
value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2021, include (i) volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z19hlJuH8rVe">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) risk free interest rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI5DNwf7Eil">0.97</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
(iii) strike price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziKrn14fM53k">0.50,
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) fair value of common stock of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zytKZGs6mw1f">.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and (v) expected life of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4nT1d8PUND7">2.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2020, include (i) volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKYVGOdcAUoc" title="Volatility rate">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) risk free interest rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNicT6cnU262" title="Risk free interest rate">0.27</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
(iii) strike price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUdcRG4B97b3" title="strike price">0.50</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
(iv) fair value of common stock of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ETF2od4R61" title="Fair value of common stock">1.36</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and (v) expected life of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZT52iLq6ub5" title="Expected life">3.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change
in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2 or Level 3 for the years ended December
31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_z1GRdyWmSHB4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(j)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z0dDnmxLUJB4">Earnings (Loss) per Share</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number
of common shares outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
earnings (loss) per share is based on the weighted average number of common shares outstanding plus, where applicable, the additional
potential common shares that would have been outstanding related to dilutive options, warrants, and unvested restricted stock units to
the extent such shares are dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zh0mh9AeFEj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the years ended December
31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zifCAHpbwzRb" style="display: none">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share attributable
    to common stock:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(634,399</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(20,964,819</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted avg. common
    shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">86,934,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">55,688,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--EarningsPerShareBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share attributable
    to common stock:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(634,399</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(20,964,819</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted avg. common
    shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">86,934,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">55,688,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EarningsPerShareDiluted_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p id="xdx_8AF_zLNNaS75DF84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlbm6t6zCWj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of diluted earnings per share for the years ended December 31, 2021 and 2020 does not include the following stock options
or warrants to purchase shares in the computation of diluted earnings per share because these instruments were antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPYlHuaGzPrk" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z55tnWWce096" style="width: 12%; text-align: right" title="Stock options"><span style="font-family: Times New Roman, Times, Serif">4,551,205</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjNnM0OoExji" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,564,458</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_znkxwLVqRfxc" style="text-align: right" title="Warrants"><span style="font-family: Times New Roman, Times, Serif">1,934,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8INJK4Jt5Ok" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,944,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zUeuN8yTTBha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWM5TW9qprL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(k)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zcnUAgHnyhYa">Segment Information</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a single reportable segment engaged in research and development for the delivery of drugs using its proprietary delivery technology.
Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief operating
decision maker made such decisions and assessed performance at the company level, as one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zznl6ajbLwK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(l)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zDi1AbRxBOTc">Principles of Consolidation</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and all subsidiaries. The Company eliminates all intercompany accounts
and transactions in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971815320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Investment Securities</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zDZ8A5PlqoDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span> <span style="font-family: Times New Roman, Times, Serif"><span><span id="xdx_829_z2OmmfwiPND5">Marketable Investment Securities</span></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has classified its marketable investment securities as available-for-sale securities, all of which are debt securities. These
securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated
other comprehensive income (loss) in stockholders&#8217; equity until realized. Gains and losses on investment security transactions
are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized
on an accrual basis. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale
securities by major security type and class of security at December 31, 2021 and 2020 were as follows:</span></p>

<p id="xdx_89D_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zYhhdupVx1y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zlKToP0umYdj" style="display: none">Schedule of Available-for-Sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding gains</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding losses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Government treasury bills</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zh6R1Pywus52" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,526,122</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTPOS7Y0GRNb" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0731">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSt0V2LJBtv2" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,202</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zWsmdF4CtClg" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,515,920</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate bonds, notes
    and commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zrh4uivRxVRj" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif">38,181,099</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zECanzzZzauf" style="border-bottom: Black 1pt solid; text-align: right" title="Gross unrealized holding gains"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zDZJJgCDoHid" style="border-bottom: Black 1pt solid; text-align: right" title="Gross unrealized holding losses"><span style="font-family: Times New Roman, Times, Serif">(7,814</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate fair value"><span style="font-family: Times New Roman, Times, Serif">38,173,285</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231_zRLYhI4DOdB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif">43,707,221</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231_zi2erJtGwXD4" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231_z5C2aScSAzxi" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding losses"><span style="font-family: Times New Roman, Times, Serif">(18,016</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231_zo674dFYIaxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value"><span style="font-family: Times New Roman, Times, Serif">43,689,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding gains</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding losses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zcXKD0mdHj0c" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zfmwQ7Ptu2Qc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zEm8Ju10QvP4" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0752">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zy0Wl78caysi" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231_z44oKmNm6se4" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231_zCZk9GXvGfh5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231_zTTj0o4UIf0b" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zvpKNGBlTQqk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_z4FqzTKuHFtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Marketable Investment
    Securities - (continued)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_890_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zI5k2fXjS3K9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of debt securities classified as available-for-sale securities at December 31, 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zeWynuVtsOre" style="display: none">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Amortized</span></p>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cost</span></p></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due within one year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20211231_zlWpRuvdhSs5" style="width: 14%; text-align: right" title="Due within one year"><span style="font-family: Times New Roman, Times, Serif">41,680,635</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pp0p0_c20211231_zR9vYYX5gt6c" style="width: 14%; text-align: right" title="Due within one year"><span style="font-family: Times New Roman, Times, Serif">41,667,405</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due after one year through
    two years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_iI_pp0p0_c20211231_zhBdsAmY0Vq4" style="border-bottom: Black 1pt solid; text-align: right" title="Due after one year through two years"><span style="font-family: Times New Roman, Times, Serif">2,026,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pp0p0_c20211231_ztqME1Q1iHT2" style="border-bottom: Black 1pt solid; text-align: right" title="Due after one year through two years"><span style="font-family: Times New Roman, Times, Serif">2,021,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20211231_zZ2qhX8uXf0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost"><span style="font-family: Times New Roman, Times, Serif">43,707,221</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20211231_zk9zNUdkZmm5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, fair value"><span style="font-family: Times New Roman, Times, Serif">43,689,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zaPfCd0mxa4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90B_eus-gaap--ProceedsFromSaleOfHeldToMaturitySecurities_do_c20210101__20211231_zjde0BaRTh1c"><span id="xdx_900_eus-gaap--ProceedsFromSaleOfHeldToMaturitySecurities_do_c20200101__20201231_z42o0XpwT7Jj">no</span></span> sales of marketable investment securities during the years ended December 31, 2021 and 2020 and therefore <span id="xdx_90F_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_do_c20210101__20211231_zjfnl2ujjMfd"><span id="xdx_90B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_do_c20200101__20201231_zcP7mwHdoGTd">no</span></span> realized gains or
losses. Additionally, $<span id="xdx_905_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20210101__20211231_zWlE21eczHe3" title="Matured marketable investment securities">4.7</span> million and $<span id="xdx_90C_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20200101__20201231_zFxTzOkiO8r4" title="Matured marketable investment securities">10.2</span> million of marketable investment securities matured during the years ended December 31,
2021 and 2020, respectively. The Company determined there were <span id="xdx_903_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210101__20211231_zqpKQqt9oRmf" title="Other than temporary impairments"><span id="xdx_908_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200101__20201231_zaNOEEwscDxi" title="Other than temporary impairments">no</span></span> other-than-temporary impairments for the years ended December 31, 2021
and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967427992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contractual Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationsAbstract', window );"><strong>Health Care Organizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock', window );">Contractual Agreements</a></td>
<td class="text"><p id="xdx_806_eus-gaap--BusinessAndContractualArrangementsDisclosureTextBlock_zQRIgrnD8VS7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(4)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zz50gbaFhdGi">Contractual Agreements</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Abbott
    Products, Inc. </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 29, 2012, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products,
Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations
under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual <span id="xdx_90C_ecustom--CollaborativeArrangementRoyaltiesPercentageOfNetSales_pid_dp_uPure_c20120328__20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_z7Xdni6xm4fj" title="Percentage of net sales">1</span>% royalty on net sales. Such
royalties are limited to $<span id="xdx_902_eus-gaap--RoyaltyGuaranteesCommitmentsAmount_iI_pn5n6_c20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_z3JnVNsB6eNk" title="Royalties, commitment amount">1.0</span> million in the first two calendar years following product launch, after which period there is not a cap
on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by <span id="xdx_906_ecustom--PercentageOfRoyaltiesReductionBasedUponProductLaunch_pid_dp_uPure_c20120328__20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_zfbAgOSAchO8" title="Percentage of royalties reduction based upon product launch">50</span>%.
The Company did not incur any royalties owed during the years ended December 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b><i>Ant<span style="font-size: 10pt">ares
    Pharma, Inc.</span></i></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, the Company entered into a license agreement (&#8220;License Agreement&#8221;) with Antares Pharma, Inc. (&#8220;Antares&#8221;)
pursuant to which the Company granted to Antares an exclusive, royalty-bearing, sublicensable right and license to develop and commercialize,
upon final approval of TLANDO&#174; from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the Company&#8217;s TLANDO product
with respect to testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone,
as indicated in NDA No. 208088, treatment of Klinefelter syndrome, and pediatric indications relating to testosterone replacement therapy
in males for conditions associated with a deficiency or absence of endogenous testosterone (the &#8220;Field&#8221;), in each case within
the United States. The Antares License Agreement also provides Antares with an option, exercisable on or before March 31, 2022, to license
TLANDO XR, the Company&#8217;s potential once-daily oral product candidate for testosterone replacement therapy. Upon execution of the
Antares License Agreement, Antares paid to the Company an initial payment of $<span id="xdx_907_ecustom--LicenseFee_pn5n6_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zlckk9NqySEk" title="License fee">11.0</span> million. Antares will also make additional payments
of $<span id="xdx_90A_ecustom--PotentialLicenseFeesFromALicensee_pn5n6_c20241231__20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z93vpRELylG7" title="Potential license fees from a licensee"><span id="xdx_90E_ecustom--PotentialLicenseFeesFromALicensee_pn5n6_c20251231__20260101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zz6qXdCAOoQf">5.0</span></span> million to the Company on each of January 1, 2025, and January 1, 2026, provided that certain conditions are satisfied. The Company
is also eligible to receive milestone payments of up to $<span id="xdx_902_ecustom--SalesMilestoneRevenueRecognized_pn5n6_c20211013__20211014__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNYLTkLwYII7" title="Sales milestone">160.0</span> million in the aggregate, depending on the achievement of certain sales
milestones in a single calendar year with respect to all products licensed by Antares under the Antares License Agreement. In addition,
upon commercialization, the Company will receive tiered royalty payments at rates ranging from percentages in the mid-teens to up to
<span id="xdx_90F_ecustom--PercentageOfRoyaltyPayment_dp_uPure_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHgS0fUdWDRh" title="Percentage of royalty payment">20</span>% of net sales of TLANDO in the United States, subject to certain minimum royalty obligations. If Antares exercises its option to license
TLANDO XR, the Company will be entitled to an additional payment of $<span id="xdx_90C_ecustom--LicenseFee_pn5n6_c20211013__20211014__dei--LegalEntityAxis__custom--TLANDOXRMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zEJYa7D8Ec5k" title="License fee">4.0</span> million, as well as development milestone payments of up to
$<span id="xdx_900_ecustom--ClinicalAndDevelopmentMilestones_pn5n6_c20211013__20211014__dei--LegalEntityAxis__custom--TLANDOXRMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zji15ixhz4Q5" title="Clinical and development milestones">35.0 </span>million in the aggregate and tiered royalty payments at rates ranging from percentages in the mid-teens to <span id="xdx_902_ecustom--PercentageOfRoyaltyPayment_dp_uPure_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z8CEA12Zgia9">20</span>% of net sales of
TLANDO XR in the United States. The Company retains development and commercialization rights in the rest of the world,
and with respect to applications outside of the Field inside or outside the United States. Antares will also purchase certain existing
inventory of licensed products from the Company, subject to testing and acceptance procedures. Finally, pursuant to the terms of the
Antares License Agreement, Antares is generally responsible for expenses relating to the development (including the conduct of any clinical
trials) and commercialization of licensed products in the Field in the United States, while the Company is generally responsible for
expenses relating to development activities outside of the Field and/or the United States. The Company recognized revenue under the Antares
Licensing Agreement of $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNVnux4Z6wA4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and <span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_dc_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrZrNQFMKHZ4">zero
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during the years ended December 31, 2021 and
2020.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(4) Contractual Agreements &#8211; (continued)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Contract Research and
    Development</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing
development work on behalf of the Company as well as a number of independent contractors, primarily clinical researchers, who serve as
advisors to the Company. The Company incurred expenses of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20210101__20211231_ziao6C8HwkEj" title="Contract research and development expenses">4.9</span> million and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200101__20201231_z1PlNuagO9H2">6.8</span> million under these agreements in 2021 and 2020 and has
recorded these expenses in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid health care service provider's significant business and contractual arrangements with hospitals, physicians, or other associated entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -URI http://asc.fasb.org/subtopic&amp;trid=2289226<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967482952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loan and Security Agreement</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zQKvkvmzQZZh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(5)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zMQycos3xxMj">Loan and Security Agreement</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Silicon
Valley Bank Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, the Company entered into a Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Silicon
Valley Bank (&#8220;SVB&#8221;) pursuant to which SVB agreed to lend the Company $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zOVvC7qymxjj" title="Aggregate amount">10.0</span> million. <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zuIBLHcQGrwa">The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zqAnDtOJc45l" title="Interest rate">4.25</span>% as of December
31, 2021), which interest is payable monthly</span>. Additionally on April 1, 2020, the Company entered into a Deferral Agreement with SVB.
Under the Deferral Agreement, principal repayments were deferred by six months and the Company was only required to make monthly interest
payments. The loan matures on<span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zrDepgky15n7"> June 1, 2022</span>. Previously, the Company only made monthly interest payments until December 31, 2018, following
which the Company also made equal monthly payments of principal and interest until the signing of the Deferral Agreement. The Company
will also be required to pay an additional final payment at maturity equal to $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zAl5cjBWUCIj" title="Debt instrument, balloon payment to be paid">650,000</span> (the &#8220;Final Payment Charge&#8221;). The
Final Payment Charge will be due on the scheduled maturity date and to date approximately $<span id="xdx_900_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z4ahh4Ejxxki" title="Debt instrument, increase in amount">644,000</span> has been recognized as an increase
to the principal balance with a corresponding charge to interest expense with the remaining final payment charge to be recognized over
the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and
Security Agreement (including all accrued and unpaid interest and the Final Payment Charge).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Loan and Security Agreement, the Company granted to SVB a security interest in substantially all of the Company&#8217;s
assets now owned or hereafter acquired, excluding intellectual property and certain other assets. On September 9, 2021, SVB consented
to the Antares Licensing Agreement which among other things provides Antares a license to certain intellectual property as well as assigns
Antares the TLANDO&#174; trademark. In addition, as TLANDO was not approved by the United States Food and Drug Administration (&#8220;FDA&#8221;)
prior to May 31, 2018, the Company maintained $<span id="xdx_90E_eus-gaap--CashCollateralForBorrowedSecurities_iI_pn5n6_c20210909__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zoZsDKiYAwAb" title="Cash collateral for borrowed securities">5.0</span> million of cash collateral at SVB as required under the Loan and Security Agreement
until such time as TLANDO is approved by the FDA. However on February 16, 2021, the Company amended the Loan and Security Agreement with
SVB to, among other things, remove the financial trigger and financial trigger release event provisions requiring the Company to maintain
a minimum cash collateral value and collateral pledge thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentRestrictiveCovenants_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zfhiVxo8AJI9">While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus <span id="xdx_90F_ecustom--DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_pid_dp_uPure_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zRrdUYO81cm8" title="Debt instrument, basis spread on interest rate for debt default">5.0</span>% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.</span> These events of default include, among other things,
any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the
credit facility, the Company&#8217;s insolvency, a material adverse change, and one or more judgments against the Company in an amount
greater than $<span id="xdx_90D_ecustom--DebtInstrumentMinimumAmountConsideredForInsolvency_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zfFt52NgKSVd" title="Debt instrument, minimum amount considered for insolvency">100,000</span> individually or in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(5)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Loan and Security
    Agreement &#8211; (continued)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zZFZync2fV32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
maturities of principal payments on the Loan and Security Agreement at December 31, 2021 (excluding accrued final payment fee) are as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span id="xdx_8B7_zXOhItJPNeWa" style="display: none">Schedule of Maturities of Debt</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Years
    Ending December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Amount
    (in thousands)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_c20211231_z4CAx3eujQC3" style="width: 18%; text-align: right" title="2022"><span style="font-family: Times New Roman, Times, Serif">1,667</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_iI_pn3n3_c20211231_zMLi7LLZ77n4" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0835">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_pn3n3_c20211231_z4Q9n2XBIm03" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,667</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_zDhm21YfyHc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; color: #212529"><i>Payroll Protection
Program Loan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In April 2020, the Company was
granted a loan from SVB in the aggregate amount of $<span id="xdx_901_eus-gaap--ProceedsFromLoans_c20200401__20200430__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramLoanMember_zBEteoi2zFog" title="Proceeds from loans">233,537</span>, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under
Division A, Title I of the CARES Act. On November 2, 2020, we were notified by the Small Business Administration that our PPP loan had
been forgiven.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971838376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_ztMfhpSvSZr7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(6)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zHdSzlYWO1M3">Property and Equipment </span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5ywfB5XUtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z8gitvPuU6x2" style="display: none">Schedule of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_zw4fy03YiD61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20201231_zytAvGVPkjs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_z0bS8UhYvnUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,361</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,361</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabAndOfficeEquipmentMember_z9yrBCMNiS58" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lab and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,056,523</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,048,932</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zzp1EOKPsOK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,404</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,404</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzck5_zV1hzCS4AUug" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,151,288</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,143,697</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzck5_zg5BiWGKy7Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less accumulated depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,144,077</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,143,697</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzck5_z5Ps2EvAZhZh" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, and equipment,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zN2zJCX47L6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zc6GOszmxQ94" title="Depreciation expenses">400</span> and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20200101__20201231_zog0NzJK8Wag" title="Depreciation expenses">4,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: center; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: center; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971805144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zeWiDJPCWEKg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_zOnyqVOZpKf8">Income Taxes</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
    Tax Expense </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zcGa9p47QtYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zMBY0FkvtWgg" style="display: none">Schedule of Income Tax Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49C_20210101__20211231_zlTz3afSK8Hh" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_495_20200101__20201231_zVnKhkv2ZIFa" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_z9zVKIJhGOAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_zBXsizrDDoAe" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBz2PI_z2s2jPCO8hBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2PI_zZQdFaQud6rl" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_zaCgtIGhNKoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
    Rate Reconciliation </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense was $<span id="xdx_909_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20210101__20211231_zC5JBnC5fQZ8" title="Income Tax Expense (Benefit)">200</span> and $<span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20200101__20201231_zjnNmm3H1Knc" title="Income Tax Expense (Benefit)">200</span>, respectively, for the years ended December 31, 2021 and 2020 and differed from the amounts computed by
applying the U.S. federal income tax rate of <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_z8sqATuUBu9c" title="Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20200101__20201231_zkr92eLOiJEg" title="Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent">21</span></span>% for 2021 and 2020, respectively, to pretax income from continuing operations as a result
of the following:</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zDNtqVMSaMG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B0_zmwR53YVEyt1">Schedule of Pretax Income from Continuing Operations</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_493_20210101__20211231_zGZGNl2u19z4" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_493_20200101__20201231_zq2eT0S412ff" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz2WU_zjlUzvJdf3Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computed &#8220;expected&#8221; tax benefit</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(133,182</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,402,570</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz2WU_z49VUkx4ehfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">476,431</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,248,002</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz2WU_zICAVJwOmpCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local income
    taxes, net of federal income tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">158</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">158</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz2WU_zGb89FhUgTbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97,697</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,209</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBz2WU_z7qkQTxm1348" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(352,163</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(485,254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_ecustom--IncomeTaxReconciliationOrphanDrugTaxCredits_iN_di_msITEBz2WU_zFW5mjDyNuP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orphan drug tax credit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,797</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_maITEBz2WU_zLtbawSs1mIe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(74,737</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">607,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBz2WU_zyfpIhRBIi0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(48,908</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2WU_zBWrtfoNnljk" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AA_zk7UF82BVHMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
    Taxes &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
    Components of Deferred Taxes </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zIkyhyu3EwK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at
December 31, 2021 and 2020 are presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zxEq3CXcb5vl" style="display: none">Schedule of Deferred Tax Assets and  Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_498_20211231_zHAPPRlaNbO4" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_499_20201231_zPHOlia1PQJf" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pp0p0_maDTAGz8zG_zcum6fOthJe4" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,687,480</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,651,482</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGz8zG_zDFHMTWbdLA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,759,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,102,326</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pp0p0_maDTAGz8zG_z7UNHcZ7Jawc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee benefits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">56,009</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">54,108</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz8zG_zNcbIFbU26ye" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,935,609</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,472,003</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsOrphanDrugTaxCredit_iI_pp0p0_maDTAGz8zG_zQDQMHI2Raff" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orphan drug tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,186,582</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,168,828</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGz8zG_zpjMj48aKwW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">959</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_pp0p0_maDTAGz8zG_zVV2okVSZOR8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    deductible tempory differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394,636</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,386</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz8zG_maDTALNzp92_zl5rGnopehDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross deferred tax
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,020,206</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,455,092</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLzUYz_zeV6Ef5TbeVk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant
    and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,871</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLzUYz_maDTLznVR_zj3oMGKtshoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross deferred tax
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,871</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0950">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLznVR_msDTALNzp92_zYza23cF6rhf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,871</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzp92_zRM26uHlpLlh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax asset/deferred
    tax liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,018,335</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,455,092</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zfpcn5UPZ2Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less
    valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(43,018,335</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(42,455,092</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_zZTNEniVMPpi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zmdZhOrpJY18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation allowance for deferred tax assets as of December 31, 2021 and 2020 was $<span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20211231_zrPjfxtAO3n2" title="Deferred Tax Assets, Valuation Allowance">43.0</span> million and $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20201231_z0sbYKCZyGO3" title="Deferred Tax Assets, Valuation Allowance">42.5</span> million. The net change in the
valuation allowance was an increase of $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20210101__20211231_zY6z3HPSydV9" title="Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount">0.5</span> million in 2021 and an increase of $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20200101__20201231_ztYnVZNW3c69" title="Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount">5.2</span> million in 2020. A valuation allowance has
been provided for the full amount of the Company&#8217;s net deferred tax assets as the Company believes it is more likely than not that
these benefits will not be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely
than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods),
projected future taxable income, and tax planning strategies in making this assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
    Taxes &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2013, the Company experienced a change in ownership, as defined by the Internal Revenue Code, as amended
(the &#8220;Code&#8221;) under Section 382. A change of ownership occurs when ownership of a company increases by more than 50 percentage
points over a three-year testing period of certain stockholders. As a result of this ownership change, we determined that our annual
limitation on the utilization of our federal net operating loss (&#8220;NOL&#8221;) and credit carryforwards is approximately $<span id="xdx_90E_ecustom--OperatingLossCarryForwardsLimitationsOnUseAmount_pn5n6_c20210101__20211231_zPh96XzZMDCl" title="Operating Loss Carry forwards Limitations On Use Amount">1.1</span> million
per year. We will only be able to utilize $<span id="xdx_909_ecustom--OperatingLossCarryForwardsPreownershipChangeAmount_pn5n6_c20210101__20211231_zaGrT6PvdATf" title="Operating Loss Carry forwards Pre-ownership Change Amount">20.2</span> million of our pre-ownership change NOL carryforwards and will forgo utilizing $<span id="xdx_90F_ecustom--OperatingLossForgivePreOwnershipChangeAmount_pn5n6_c20210101__20211231_zJePv2iv7Jz8" title="Operating Loss Forgive Pre-ownership Change Amount">5.5</span> million
of our pre-ownership change NOL carryforwards and $<span id="xdx_908_ecustom--TaxCreditCarryforwardPreOwnershipChangeAmount_pn5n6_c20210101__20211231_zHRgd2N1rjla" title="Tax Credit Carryforward Pre-ownership Change Amount">1.2</span> million of our pre-change credit carryforwards as a result of this ownership change.
We do not account for forgone NOL and credit carryovers in our deferred tax assets and only account for the NOL and credit carryforwards
that will not expire unutilized as a result of the restrictions of Code Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had NOL and research and development credit carryforwards for U.S. federal income tax reporting purposes of
approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zdMFHbHkDov6" title="Operating Loss Carryforwards">135.6</span> million and $<span id="xdx_906_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231_zNV0KNET0l2" title="Tax Credit Carryforward, Amount">3.5</span> million, respectively. <span id="xdx_904_ecustom--OperatingLossCarryForwardsExpirationDate1_c20210101__20211231_zdEOxoh5dap1" title="Operating Loss Carry forwards Expiration Date1">Approximately $24.6 million of the NOL will expire between 2023 and 2033
and $70.8 million of the NOL will <span id="xdx_907_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zsSkhfhbNBHb" title="Tax Credit Carryforward, Description">expire 2034 through 2037</span>. Pursuant to the Tax Cuts and Jobs Act of 2017, NOL&#8217;s generated in 2018
and subsequent years have an unlimited carryforward therefore the 2020, 2019 and 2018 NOL of $40.2 million can be carried forward indefinitely.
The research and development credits will begin to <span id="xdx_909_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__custom--UsFederalMember_zrXFoocs2lxh" title="Tax Credit Carryforward, Description">expire in 2033 through 2041</span>.</span> We have orphan drug credit carry forwards of approximately
$<span id="xdx_909_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zaQkm90n4Gk6" title="Tax Credit Carryforward, Amount">1.2</span> million which will expire if unused through 2041.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have state NOL and research and development credit carry forwards of <span id="xdx_90A_ecustom--OperatingLossCarryForwardsExpirationDate1_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zoXiQH2SUdgl" title="Operating Loss Carry forwards Expiration Date1">approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z5UvS31SJlR2" title="Operating Loss Carryforwards">127.1</span> million and $<span id="xdx_902_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkFXkrYVfsD5">1.4</span> million, respectively.
None of the Company&#8217;s state NOL expires in 2022, $34.8 million expires between 2022 and 2029, and $92.3 million will expire in
2030 through 2036</span>. The state research and development credits <span id="xdx_905_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zTAgtOzFUc89" title="Tax Credit Carryforward, Description">expire in 2023 through 2035</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s federal and state income tax returns for December 31, 2018 through 2021 are open tax years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zrMt1XP2WiYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amount of total unrecognized tax contingencies, excluding interest and penalties, for the
years ended December 31, 2021 and 2020 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zhUpyaUpcY99" style="display: none">Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20210101__20211231_zUiHi3opvMJf" style="width: 12%; text-align: right" title="Balance, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="width: 1%; text-align: left"/><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20200101__20201231_z6Lf5Jlzogpb" style="width: 12%; text-align: right" title="Balance, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="width: 1%; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, end of year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20210101__20211231_zTcWff85dRF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, end of year"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="text-align: left"/><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20200101__20201231_zNkeP3FViH3k" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, end of year"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left"/></tr>
  </table>

<p id="xdx_8AC_z0A0ZiZOUyqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971778584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zoWdVqtnCWg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(8)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_829_zrMQIlcP2qQj">Leases</span></span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah.
On May 6, 2014, the Company modified and extended the lease through February 28, 2018, on February 8, 2018, the Company extended the
lease through February 28, 2019, on January 2, 2019, the Company extended the lease through February 29, 2020, on February 24, 2020,
the Company extended the lease through February 28, 2021, on March 3, 2021, the Company extended the lease through February 28, 2022
and on January 24, 2022, the Company extended the lease through February 28, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(8)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
    &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zsIcid4u8rHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancelable operating leases as of December 31, 2021 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zREQlESLuq8d" style="display: none">Schedule of Future Minimum Rental Payments for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20211231_zcFQWCIVuvmk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">leases</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year ending December 31:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzkOe_zP4kZRmId3Yd" style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">341,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzkOe_zThOAfFeqrb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,273</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzkOe_z0Rdss1IoBm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">398,702</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_z1YlePGZxq09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s rent expense was $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_zakSzmQBalk9" title="Operating Leases, Rent Expense"><span id="xdx_902_eus-gaap--OperatingLeaseExpense_pp0p0_c20200101__20201231_zG94xE3jZ4S" title="Operating Leases, Rent Expense">330,000</span></span> for each of the years ended December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971840040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zY6Qg01CFlu5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zE5uXXelcg31">Stockholders&#8217; Equity</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
    of Common Stock</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 28, 2021, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#8220;January 2021 Offering&#8221;). The gross proceeds from the January 2021 Offering were
approximately $<span id="xdx_90E_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zW9MnkFTdCG3" title="Proceeds from issuance of common stock, gross">28.7</span> million, before deducting underwriter fees and other offering expenses of $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_ziBD1hI17glb" title="Agent fees and other offering expenses">1.9</span> million. In the January 2021 Offering,
the Company sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zVKPP6m0pEUl" title="Stock issued during period, shares, new issues">16,428,571</span> shares of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 27, 2020, the Company completed a registered direct offering of securities registered under an effective registration statement
filed pursuant to the Securities Act of 1933, as amended (&#8220;February 2020 Offering&#8221;). The gross proceeds from the February
2020 Offering were approximately $<span id="xdx_901_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_ztb5QjljijHa">6.0</span> million, before deducting placement agent fees and other offering expenses of $<span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0p0">347,000</span>. In the
February 2020 Offering, the Company sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200226__20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zaj7yaFLcPDl">10,084,034</span> Class A Units at an offering price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zijSzmPaaTri">0.595</span> per unit, with each Class A Unit consisting
of one share of its common stock and one-half of a common warrant to purchase one share of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zhcjCZWwzofe">0.53</span>
per share of common stock. Additionally, the common stock warrants were immediately exercisable and expire on February 27, 2025. By their
terms, however, the common stock warrants cannot be exercised at any time that the common stock warrant holder would beneficially own,
after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after
giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2019, the Company completed a public offering of securities registered under an effective registration statement filed
pursuant to the Securities Act of 1933, as amended (&#8220;November 2019 Offering&#8221;). The gross proceeds from the November 2019
Offering were approximately $<span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zodRw6NPdQTe" title="Proceeds from issuance of common stock gross">6.0</span> million, before deducting placement agent fees and other offering expenses of $<span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zsXx16yUPze6" title="Payment of stock issuance costs">404,000</span>. In the
November 2019 Offering, the Company sold (i) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z3Dng32TJHXi" title="Number of shares issued">10,450,000</span> Class A Units, with each Class A Unit consisting of one share of its common
stock and a common warrant to purchase one share of its common stock, and (ii) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0d_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zb4P1g48fhGd" title="Number of shares issued">1,550,000</span> Class B Units, with each Class B Unit
consisting of one pre-funded warrant to purchase one share of its common stock and a common warrant to purchase one share of its
common stock, at a price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z2BPoWiFrdAa">0.50</span> per Class A Unit and $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zJMtb6Fx0qCk" title="Share issued price per share">0.4999</span> per Class B Unit. The pre-funded warrants, which were exercised for
common stock in December 2019, were issued in lieu of common stock in order to ensure the purchaser did not exceed certain
beneficial ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z7utscgVhyc3" title="Share issued exercise price per share">.0001</span> per share,
subject to adjustment. Additionally, the common stock warrants were immediately exercisable at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zHlTDgEwjCZa" title="Warrant exercise price per share">0.50</span> per share,
subject to adjustment, and expire on November 17, 2024. By their terms, however, neither the pre-funded warrants nor the common
stock warrants can be exercised at any time that the pre-funded warrant holder or the common stock warrant holder would beneficially
own, after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding
after giving effect to such exercise. On the date of the November 2019 Offering, the Company allocated approximately $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z0lRkAc05yC" title="Stock issued during period value new issues">768,000</span> and
$<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zBdEP0chPYbf" title="Stock issued during period value new issues">4.8</span> million to common stock/additional paid-in capital and warrant liability, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2017, the Company entered into the Sales Agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) pursuant to which
the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to the amount
the Company registered on an effective registration statement pursuant to which the offering is being made. The Company currently has
registered up to $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_dp_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--CantorMember_zqlIbSY3IVNk" title="Common stock sold through ATM offering">50.0</span> million for sale under the Sales Agreement, pursuant to the Registration Statement on Form S-3 (File No. 333-250072)
through Cantor as the Company&#8217;s sales agent. Cantor may sell the Company&#8217;s common stock by any method permitted by law deemed
to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or
through the Nasdaq Capital Market or any other existing trade market for our common stock, in negotiated transactions at market prices
prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. Cantor uses its
commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell these
shares. The Company pays Cantor <span id="xdx_905_ecustom--PercentageOfGrossProceedOnSaleOfShares_pid_dp_uPure_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--CantorMember_zqjNqKMF9VMa" title="Percentage of gross proceeds on sale of shares">3.0</span>% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. In addition,
the Company has also provided Cantor with customary indemnification rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of the Company&#8217;s common stock sold under the Sales Agreement are sold and issued pursuant to the Registration Statement
on Form S-3 (File No. 333-250072) (the &#8220;Form S-3&#8221;), which was previously declared effective by the Securities and Exchange
Commission, and the related prospectus and one or more prospectus supplements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not obligated to make any sales of its common stock under the Sales Agreement. The offering of common stock pursuant to the
Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. The Company and Cantor may each terminate
the Sales Agreement at any time upon ten days&#8217; prior notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had sold an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zUd8oc647D41">15,023,073
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at a weighted-average sales price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_z9eWNX9pWYVi">2.19
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share under the Sales Agreement for aggregate
gross proceeds of $<span id="xdx_900_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zAMfashxwgPa">32.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zsPrusqolkg2">31.7
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting sales agent commission
and discounts and our other offering costs. During the year ended December 31, 2021, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zR9cDB9IZ9Xb">1,811,238
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock pursuant to the current
Registration Statement on Form S-3 (File No. 333-250072) at a weighted-average sales price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUDKOFiS06rk">1.95
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, resulting in net proceeds of approximately
$<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_z7UDMTKarRGi">3.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million under the Sales Agreement which is net
of $<span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zNABr8VpOWRb">112,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in expenses. During the year ended December 31,
2020, the Company sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z5arr4YaPxs1">3,746,300
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock pursuant to the current
Registration Statement on Form S-3 (File No. 333-250072) at a weighted average sales price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zCyXsMMx9nl5">1.41
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, in net proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_znqZw5G2hJSa">5.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million under the Sales Agreement which is net
of $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zEAlUKuwdD1i">148,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in expenses. Additionally, during the
year ended December 31, 2020, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_zp1Rwn8GLHih">2,830,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock pursuant to the prior
Registration Statement on Form S-3 (File No. 333-220942) at a weighted average sales price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_z9gJxtlDO2H">1.43
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share under the ATM for aggregate gross proceeds
of $<span id="xdx_90B_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTIXwN1OyWc">3.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million which is net of $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2J0Xw6q6aw4">165,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in expenses. As of December 31, 2021, the Company
had $<span id="xdx_90E_ecustom--SharesAvailableForFutureIssuance_iI_pn5n6_c20211231_z9hZAuxhy9i5">41.2</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
available for sale under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rights
    Agreement</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2015, the Company and American Stock Transfer &amp; Trust Company, LLC, as Rights Agent, entered into a Rights Agreement.
Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock
purchase right (each a &#8220;Right&#8221; and collectively, the &#8220;Rights&#8221;) for each outstanding share of common stock of
the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered
holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred
Stock of the Company at a price of $<span id="xdx_906_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20151112__20151113_zinpP0LeUJA9">63.96
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per one-thousandth share (the &#8220;Purchase
Price&#8221;). The Rights will generally become exercisable upon the earlier to occur of (i) 10 business days following a public announcement
that a person or group of affiliated or associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days
(or such later date as may be determined by action of the board of directors prior to such time as any person or group of affiliated
or associated persons becomes an Acquiring Person) following the commencement of, or announcement of an intention to make, a tender
offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of the
outstanding common stock of the Company. Except in certain situations, a person or group of affiliated or associated persons becomes
an &#8220;Acquiring Person&#8221; upon acquiring beneficial ownership of 15% or more of the outstanding shares of common stock of the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder
to purchase from the Company, at the Right&#8217;s then current exercise price, in lieu of shares of Series A Junior Participating Preferred
Stock, common stock of the Company with a market value of twice the Purchase Price. In addition, if after any person has become an Acquiring
Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company&#8217;s assets, or assets
accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions),
proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain
transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase
Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value
of twice the Purchase Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be entitled to redeem the Rights at $<span id="xdx_906_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20210101__20211231_zKKal8jomBP5">0.001</span> per Right at any time prior to the time an Acquiring Person becomes such. The
terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company&#8217;s Current Report on Form 8-K dated
November 13, 2015. The rights plan was originally set to expire on November 12, 2018; however, on November 5, 2018 our Board of Directors
approved an Amended and Restated Rights Agreement pursuant to which the expiration date was extended to November 5, 2021 and again on
November 1, 2021, the Company adopted a Second Amended and Restated Rights Agreement pursuant to which the expiration date was extended
to November 1, 2024, unless the rights are earlier redeemed or exchanged by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
    Option Plan </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2014, the board of directors adopted the 2014 Stock and Incentive Plan (&#8220;2014 Plan&#8221;) subject to shareholder
approval which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock
appreciation rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20140430__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zVR3ZnzvUmA4" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">1,000,000</span>
shares are authorized for issuance under the 2014 Plan. Additionally, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pp0d_c20140430__us-gaap--AwardTypeAxis__custom--TwoThousandElevenEquityIncentivePlanMember_zRqrZ4wvZsvb" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant">271,906</span>
remaining authorized shares under the 2011 Equity Incentive Plan (&#8220;2011 Plan&#8221;) were issuable under the 2014 Plan at the
time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan was amended and restated to increase
the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20160630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zSIUskLolk5e" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">1,271,906</span>
to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20160630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zhuUxM7jz5Me" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">2,471,906</span>.
Additionally, upon receiving shareholder approval in June 2018, the 2014 Plan was further amended and restated to increase the
authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zP4If66TwkI1" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">2,471,906</span>
to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_z4JywTCZ2xr6" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">3,221,906</span>.
Finally, upon receiving shareholder approval in June 2020, the 2014 Plan was further amended and restated to increase the authorized
number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zuZR5TONn2U2" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">3,221,906</span>
to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20200630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zcKSezwdNYy" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">5,721,906</span>.
The board of directors, on an option-by-option basis, determines the number of shares, exercise price, term, and vesting period.
Options granted generally have a <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtYxL_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_ztYVWYepuHGf" title="Contractual life::XDX::10"><span style="-sec-ix-hidden: xdx2ixbrl1094">ten-year</span></span> contractual life. The Company issues shares of common stock upon the exercise of options
with the source of those shares of common stock being either newly issued shares or shares held in treasury. An aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zLjwTcnqTjpl" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">5,721,906</span>
shares are authorized for issuance under the 2014 Plan, with <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pp0d_c20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zb6wwehGRM5e" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant">857,459</span> shares remaining available for grant as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 38.15pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zvn1ofEA7Yd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35in; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zVfkRhu46cP" style="display: none">Schedule of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    stock options</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z3VAKOe26fE6" style="width: 16%; text-align: right" title="Number of shares, Balance at beginning of the period (in shares)"><span style="font-family: Times New Roman, Times, Serif">3,564,458</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFadEzxSVBa" style="width: 16%; text-align: right" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">3.36</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJRLa9Yvm5Le" style="text-align: right" title="Number of shares, Options granted (in shares)"><span style="font-family: Times New Roman, Times, Serif">1,105,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zC0dl8yucMQf" style="text-align: right" title="Weighted average exercise price, Options granted (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">1.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyi4NZbVnGo2" style="text-align: right" title="Number of shares, Options exercised (in shares)"><span style="font-family: Times New Roman, Times, Serif">(4,584</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ0ATDXF4zs5" style="text-align: right" title="Weighted average exercise price, Options exercised (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">1.46</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ6Af9kYGFPi" style="text-align: right" title="Number of shares, Options forfeited (in shares)"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqXuUV5A1hqc" style="text-align: right" title="Weighted average exercise price, Options forfeited (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options
    cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zarxTSJlD8Aj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Options cancelled (in shares)"><span style="font-family: Times New Roman, Times, Serif">(114,169</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFOU1WPI4Qbi" style="text-align: right" title="Weighted average exercise price, Options cancelled (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">4.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zsPdWzj2jpY8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Balance at end of the period (in shares)"><span style="font-family: Times New Roman, Times, Serif">4,551,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zz6D8hKfsbCa" style="text-align: right" title="Weighted average exercise price, Balance at end of the period (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">2.82</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Options exercisable at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z5nKHimJAAN2" style="text-align: right" title="Number of shares, Options exercisable (in shares)"><span style="font-family: Times New Roman, Times, Serif">2,799,979</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z1NjUEdqJOR9" style="text-align: right" title="Weighted average exercise price, Options exercisable (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">3.84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_z7eSTcRX8Bh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_gL3SBCABSBPAO-YSO_zTc02wLEcti5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about stock options outstanding and exercisable at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zY059Cv3gKy7" style="display: none">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    outstanding</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    exerciseable</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_zid0YUQ2izMc" style="width: 37%; text-align: right" title="Number of options outstanding, shares"><span style="font-family: Times New Roman, Times, Serif">4,551,205</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zNRgLFcTgUv2" title="Options outstanding, Weighted average remaining contractual life (Years)">6.66</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zWclQqwsQi0e" style="width: 5%; text-align: right" title="Options outstanding, Weighted average exercise price (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">2.82</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20211231_zl8QHZL0hcUc" style="width: 5%; text-align: right" title="Options outstanding, Aggregate intrinsic value"><span style="font-family: Times New Roman, Times, Serif">315,330</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231_z8xOftRC4dWc" style="width: 5%; text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif">2,799,979</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_z3XcmJAzelHi" title="Options exercisable, Weighted average remaining contractual life (Years)">5.01</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_znuOcOCBJgGh" title="Options exercisable, Weighted average exercise price">3.84</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20211231_zR8R8LFJ2i62" title="Options exercisable, Aggregate intrinsic value">201,966</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_z2GZ9bBYdhvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic
value of stock options exercised during the years ended December 31, 2021 and 2020 was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0d_c20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNSp3WxxZyq3" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value">2,000</span> and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0d_dc_c20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zc8GJXwNfIYj" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value">zero</span>. There were <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zKpk9jkKBzA1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period">4,584</span> and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_dc_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zb2Ho2XdRos1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period">zero</span> stock
options exercised during the years ended December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
    Stock Warrants </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its common stock warrants under ASC 480, <i>Distinguishing Liabilities from Equity</i>, which requires any financial
instrument, other than an outstanding share, that, at inception, embodies an obligation to repurchase the issuer&#8217;s equity shares,
or is indexed to such an obligation, and requires or may require the issuer to settle the obligation by transferring assets, to be classified
as a liability. In accordance with ASC 480, the Company&#8217;s outstanding warrants from the November 2019 Offering are classified as
a liability. The liability is adjusted to fair value at each reporting period, with the changes in fair value recognized as gain (loss)
on change in fair value of warranty liability in the Company&#8217;s consolidated statements of operations. The warrants issued in the
November 2019 Offering allow the warrant holder, if certain change in control events occur, the option to receive an amount of cash equal
to the value of the warrants as determined in accordance with the Black-Scholes option pricing model with certain defined assumptions
upon a fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pp0d_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zd4rVb8mQD25" title="Warrants outstanding">1,094,030</span> warrants outstanding from the November 2019 Offering to purchase an equal number of shares
of common stock. The fair value of these warrants on November 18, 2019 (closing date of November 19 Offering) and December 31, 2021 and
2020 was determined using the Black-Scholes option pricing model with the following Level 3 inputs (as defined in the November 2019 Offering):</span></p>

<p id="xdx_89E_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zEvPtQChTJ97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zOgRmVrh1aWa" style="display: none">Schedule of Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">November
    18, 2019</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life in years</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAPsS00vHhMe" title="Expected life in years">2.88</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziJz5nOPUF3a" title="Expected life in years">3.88</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQbIwjkMQVBa" title="Expected life in years">4.88</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztByE2J85ali" title="Expected life in years">5.00</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFE7FUzYtWkk" style="text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">0.97</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxUaVvPT4EKk" style="text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">0.27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHDDdVxZMSj7" style="text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">1.69</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLVtZmrdWk9d" style="text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">1.63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5qVPYVYF3tl" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1178">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUcidrlQPARb" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWnKfM0l9avi" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZexOWkwaMcl" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1184">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZMDXMbPRTf3" style="text-align: right" title="Volatility"><span style="font-family: Times New Roman, Times, Serif">100.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3DIpur37q6" style="text-align: right" title="Volatility"><span style="font-family: Times New Roman, Times, Serif">100.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23wXIcrdWt6" style="text-align: right" title="Volatility"><span style="font-family: Times New Roman, Times, Serif">225.93</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wW2zb4T38h" style="text-align: right" title="Volatility"><span style="font-family: Times New Roman, Times, Serif">224.47</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhB0UQxg4pM1" style="text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">0.99</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1oeVGqZqjTa" style="text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">1.36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthdPsPhMgC7" style="text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">0.39</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwmlqSCNdHEl" style="text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">0.41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_z33CR1G6NFkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company recorded a non-cash gain of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zWb5I9PHBe5j">356,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the change in fair value of the November
2019 Offering warrants and during the year ended December 31, 2020, the Company recorded a non-cash loss of $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z3su5MKuW8Pf">2.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million from the change in fair value of the
November 2019 Offering warrants. The following table is a reconciliation of the warrant liability measured at fair value using level
3 inputs:</span></p>

<p id="xdx_897_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zmQd9RxGr5i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zDnnjBsG4VSe" style="display: none">Schedule of Reconciliation of Warrant Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20210101__20211231_zDv3a8DJ2Sil" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Warrant
    Liability</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zQr0kSlwZVDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Settlement of liabilty
    on warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value of common stock warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(355,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zVdQIAJDQiA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
in the February 2020 Offering, the Company issued <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0d_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zhNAomONXauj" title="Issued">5,042,017</span> common stock warrants. However, the February 2020 Offering warrants do not
provide the warrant holder the option to receive an amount of cash equal to the Black-Scholes value of the warrants upon a fundamental
transaction. Therefore, the Company has not recorded a warrant liability with respect to the warrants issued in the February 2020 Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
    Equity &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zATT6IvUm7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zLcTDu6F6Hwc" style="display: none">Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyR4LcHsJwU5" style="width: 14%; text-align: right" title="Warrants Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">1,944,366</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSDb4Y4tlF72" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">0.51</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z64x2BOBF334" style="text-align: right" title="Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1222">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1MmTUkNV3M" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1224">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNgd5KreI3Cc" style="text-align: right" title="Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif">(10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm0aRB4EF4Zg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCEXNcGiL3a" style="text-align: right" title="Warrants, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYko4Z3XHmrb" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pCAkuC6Eek" style="text-align: right" title="Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgPoWOB4IIja" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAl4lEwjFfaa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z94BuAHnex79" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy9FdiJrqipe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">1,934,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvgGs2LiMhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">0.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_zpnxRPK3jWY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zUmAD3AQQBc2" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised">10,000</span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pn5n6_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zNhRVNOMb1Gg" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised">15.1</span> million common stock warrants to purchase one share of our common stock were
exercised, respectively, resulting in proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zP4mdAcFPT3k" title="Net proceeds from exercise of warrants">5,000</span> and $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_z6cI5dNhR3Gk" title="Net proceeds from exercise of warrants">7.7</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about common stock warrants outstanding at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div id="xdx_C08_gL3SBCABSBPAO-YSO_zg5lgEUB0889" style="margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" id="xdx_305_134_zp4BjeXkoDMb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in" summary="xdx: Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)">
<tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    outstanding</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    exercisable</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjg6oSfxJWz3" style="text-align: right" title="Number of warrants exercisable, shares"><span style="font-family: Times New Roman, Times, Serif">1,934,366</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHhEHKbHN1V5" title="Weighted average remaining contractual life">3.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zymjBmDFJxw5" style="text-align: right" title="Weighted average exercise price, per share"><span style="font-family: Times New Roman, Times, Serif">0.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztmcKSO1ND52" style="text-align: right" title="Aggregate intrinsic value"><span style="font-family: Times New Roman, Times, Serif">922,629</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify; background-color: white"/>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-indent: -24.5pt"><span id="xdx_C04_gL3SBCABSBPAO-YSO_z7KR5F00rKa"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967488040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">401(k) Plan</a></td>
<td class="text"><p id="xdx_807_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z54oKRExMkTb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_z2ClBiu43Um">401(k) Plan</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2002, the Company adopted a tax qualified employee savings and retirement plan (the &#8220;401(k) Plan&#8221;) covering eligible
employees. Pursuant to the 401(k) Plan, employees may elect to reduce current compensation by a percentage of eligible compensation,
not to exceed legal limits, and contribute the amount of such reduction to the 401(k) Plan. Beginning April 1, 2014, the 401(k) Plan
was amended to require matching contributions to the 401(k) Plan by the Company on behalf of the participants of <span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20210101__20211231_zKG2l0Y0tb3h" title="Employer matching contribution percent">100</span> percent Company
match on up to four percent of an employee&#8217;s compensation computed on a per pay period basis. The Company contributed $<span id="xdx_907_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20210101__20211231_zAmoxdMrCg5i">81,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20200101__20201231_zEOr18p7P7Ld">67,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, to the 401(k) Plan during the years ended December 31, 2021 and 2020</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971808136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z2nzEQHpQBa1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zMS30XGrMNWe">Commitments and Contingencies</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting
business. The Company records a liability when a particular contingency is probable and estimable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2019, the Company filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that
Clarus&#8217;s JATENZO&#174; product infringes six of Lipocine&#8217;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390;
6,569,463; and 6,923,988. However, on February 11, 2020, the Company voluntarily dismissed allegations of patent infringement
for expired U.S. Patent Nos. 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for dispute. Clarus answered
the complaint and asserted counterclaims of non-infringement and invalidity. The Company answered Clarus&#8217;s counterclaims on April
29, 2019. The Court held a scheduling conference on August 15, 2019, a claim construction hearing on February 11, 2020, and a
summary judgment hearing on January 15, 2021. In May 2021, the Court granted Clarus&#8217; motion for Summary Judgment, finding the asserted
claims of Lipocine&#8217;s U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy the written description
requirement of 35 U.S.C. &#167; 112. Clarus still had remaining claims before the Court. On July 13, 2021, the Company entered into the
Global Agreement with Clarus which resolved all outstanding claims of this litigation as well as the on-going United States Patent and
Trademark Office (&#8220;USPTO&#8221;) Interference No. 106,128 between the parties. Under the terms of the Global Agreement, the Company
agreed to pay Clarus $<span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember_zolfYP8siak5">4.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million payable as follows: $<span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember_zhPzxYGF0wKc">2.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million immediately, $<span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20220712__20220713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zXJz5nRAPvM5">1.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million on July 13, 2022 and $<span id="xdx_90D_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20230712__20230713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z0MXT6egeGfj">500,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on July 13, 2023. No future royalties are owing
from either party. On July 15, 2021, the Court dismissed with prejudice the Company&#8217;s claims and Clarus&#8217; counterclaims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2019, the Company and certain of our officers were named as defendants in a purported shareholder class action lawsuit,
<i>Solomon Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint
alleges that the defendants made false and/or misleading statements and/or failed to disclose that the Company&#8217;s filing of the
NDA for TLANDO to the FDA contained deficiencies and as a result the defendants&#8217; statements about our business and operations were
false and misleading and/or lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class
action (for a purported class of purchasers of the Company&#8217;s securities from March 27, 2019 through November 8, 2019), compensatory
damages in an unspecified amount, and unspecified equitable or injunctive relief. The Company has insurance that covers claims of this
nature. The retention amount payable by us under our policy is $<span id="xdx_907_ecustom--RetentionPayables_iI_pn4n6_c20191114_z7cJcIb3icG7">1.25
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company filed a motion to dismiss
this class action lawsuit on July 24, 2020. In response, the plaintiffs filed their response to the motion to dismiss the class action
lawsuit on September 22, 2020, and the Company filed its reply to the motion to dismiss on October 22, 2020. A hearing on the motion
to dismiss occurred on January 12, 2022. The Company intends to vigorously defend ourselves against these allegations and have
not recorded a liability related to this shareholder class action lawsuit as the outcome is not probable nor can an estimate be made
of loss, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2020, the Company filed U.S. patent application serial number 16/818,779 (the &#8220;Lipocine &#8216;779 Application&#8221;)
with the USPTO. On October 16 and November 3, 2020, the Company filed suggestions for interference with the USPTO requesting that a patent
interference be declared between the Lipocine &#8216;779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics,
Inc. (the &#8220;Clarus &#8216;178 Application&#8221;). Pursuant to our request, the Patent Trial and Appeal Board (&#8220;PTAB&#8221;)
at the USPTO declared the interference on January 4, 2021 to ultimately determine, as between the Company and Clarus, who is entitled
to the claimed subject matter. The interference number is 106,128, and we were initially declared Senior Party. A conference call with
the PTAB was held on January 25, 2021 to discuss proposed motions. On February 1, 2021, the PTAB issued an order authorizing certain
motions and setting the schedule for the preliminary motions phase. On July 13, 2021, the Company entered into the Global Agreement with
Clarus to resolve interference No. 106,128 among other items. On July 26, 2021, the PTAB granted the Company&#8217;s request for adverse
judgment in interference No. 106,128 in accordance with the Global Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond <i>Solomon Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PM, management does not currently believe that any other matter, individually
or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments
    and Contingencies (continued)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Guarantees
and Indemnifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements,
and certain services agreements, containing standard guarantee and / or indemnifications provisions. Additionally, the Company has indemnified
its directors and officers to the maximum extent permitted under the laws of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971840040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreement with Spriaso, LLC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Agreement with Spriaso, LLC</a></td>
<td class="text"><p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zo3WKAAapzFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(12)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_826_zMTEIN8hRRXa">Agreement with Spriaso, LLC</span></span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company has a
license and a services agreement with Spriaso, a related-party that is majority-owned by certain current and former directors of Lipocine
Inc. and their affiliates. Under the license agreement, the Company assigned and transferred to Spriaso all of the Company&#8217;s rights,
title and interest in its intellectual property to develop products for the cough and cold field. In addition, Spriaso received all rights
and obligations under the Company&#8217;s product development agreement with a third-party. In exchange, the Company will receive a royalty
of <span id="xdx_90E_ecustom--PercentageOfRoyalty_dp_uPure_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zfnlCptKG6z2" title="Percentage of royalty">20
</span>percent of the net proceeds received by Spriaso, up to a maximum of $<span id="xdx_909_eus-gaap--ProceedsFromContributionsFromAffiliates_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_z9wFdO1IybP8">10.0
</span>million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside
of the cough and cold field. <span id="xdx_90D_ecustom--AgreementDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zzMntouMJDVf" title="Agreement description">The
Company also agreed to continue providing up to 10 percent of the services of certain employees to Spriaso for a period of time. The
agreement to provide services expired in 2021;</span> however, it may be extended upon written agreement of Spriaso and the Company.
The Company did not receive any reimbursements from Spriaso for the years ended December 31, 2021 and 2020, respectively. Additionally,
during the years ended December 31, 2021 and 2020, the Company received $<span id="xdx_90C_ecustom--ProceedsFromReimbursements_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zKmZ7PQsrvs">55,000
</span><span>and
</span><span id="xdx_90D_ecustom--ProceedsFromReimbursements_dc_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zaj1BwXdZ8gf" title="Proceeds from reimbursements">zero</span><span>,
respectively, in royalty revenue from Spriaso. Spriaso filed its first NDA and as an affiliated entity of the Company, it used
up the one-time waiver for user fees for a small business submitting its first human drug application to the FDA. Spriaso is considered
a variable interest entity under the FASB ASC Topic 810-10, <i>Consolidations</i>, however the Company is not the primary beneficiary
and has therefore not consolidated Spriaso.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129973197448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_800_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zitncuTzd1Y4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(13)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zMVHGEF1zYNi">Accounting Pronouncements</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
Pronouncements Issued Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, <i>Measurement of Credit Losses on Financial Instruments
</i>(&#8220;ASU 2016-13&#8221;). This standard replaces the incurred loss impairment methodology in current GAAP with a methodology that
reflects expected credit losses on instruments within its scope, including trade receivables, and requires entities to measure all expected
credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable
forecasts. The original effective date for ASU 2016-13 was for annual and interim periods beginning after December 15, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
in October 2019, the FASB issued ASU 2019-10, <i>Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective
Dates</i>, which deferred the effective date of ASU 2016-13 for certain entities, including those that are eligible to be smaller reporting
companies<i>.</i> A company&#8217;s determination about whether it is eligible for the deferral is a one-time assessment as of November
15, 2019 based on its most recent determination of its small reporting company eligibility as of the last business day of the most recently
completed second quarter. Based on this determination, the Company qualifies as a smaller reporting entity and is therefore eligible
for the deferral of adoption of ASU 2016-13, resulting in a new effective date of January 1, 2023. The Company has historically not had
credit losses on financial instruments and is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated
financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966053592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--UseOfEstimates_zS3cKuhCv4aa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zbAEwo35NvGi">Use of Estimates</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates. Significant items subject to such estimates and assumptions include those related to stock-based compensation;
income tax uncertainties; the fair value of the warrant liability and the useful lives of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6nKwusyv1u4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zdlSg0YRaPO3">Cash and Cash Equivalents</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities to the Company of three months or less to be cash equivalents.
Although the Company may deposit its cash and cash equivalents with multiple financial institutions, its deposits, at times, may exceed
federally insured limits. Cash and cash equivalents were $<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zYCo3dDgpqAd">3.0</span> million and $<span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20201231_z85VN9DcsXh5" title="Cash Equivalents, at Carrying Value">19.2</span>million at December 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zYEtcgyU4CTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zjSAJGjXEmm4">Receivables</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are recorded at the invoiced amount and do not bear interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains an allowance for doubtful accounts for estimated losses. In establishing the allowance, management considers historical
losses adjusted to take into account current market conditions and their customers&#8217; financial condition, the amount of receivables
in dispute, and the current receivables aging and current payment patterns. The Company had no write-offs in 2021 and 2020 and the Company
did not record an allowance for doubtful accounts as of December 31, 2021 and 2020 as there were no accounts receivable outstanding.
The Company does not have any off-balance-sheet credit exposure related to its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zFciAEhTHFDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zkB8RqQyhKIf">Revenue Recognition</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates most of its revenue from license and royalty arrangements. At inception of each contract, the Company identifies
the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines
the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and
determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction
price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. The Company reassess its reserves for variable consideration
at each reporting date and makes adjustments, if necessary, which may affect revenue and earnings in periods in which any such changes
become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)
Summary of Significant Accounting Policies &#8211; (continued)</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zdWnl6qjMk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation
of Revenue</i>.&#160;In the following tables, revenues reported for the year ended December 31, 2021, under Topic 606, is disaggregated
by type of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B2_zuLyLtwvNK4d" style="display: none">Schedule of Disaggregation
of Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Type of Revenue</td><td>&#160;</td>
    <td colspan="3" id="xdx_498_20210101__20211231_zgv6ccqvmkkk">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zAi9cZjBFZw8" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%">Licensing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">11,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SalesBasedRoyaltiesMember_zPyc3OXnLh2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales-based royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,994</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MinimumGuaranteedRoyaltiesMember_z3rfsLxUtocc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Minimum guaranteed royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,050,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MaterialsMember_zhfrHuzqtVT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Materials</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,035,844</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Revenue</span></td><td/>
    <td style="text-align: left">$</td><td style="text-align: right">16,140,838</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zV6aKZ3IMhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Topic 606, all revenue has been recognized as point in time for the year ended December 31, 2021.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 4 for a description of the license agreement with Antares Pharma, Inc. See Note 12 for a description of the agreement with Spriaso.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Fees</i>. For distinct license performance obligations, upfront license fees are recognized when the Company satisfies the underlying
performance obligation. This generally occurs upon transfer of the right to use the Company&#8217;s licensed technology to the customer.
In addition, license arrangements may include contingent milestone payments, which are due following achievement by our licensee of specified
sales or regulatory milestones and the licensee and/or Company will fulfill its performance obligation prior to achievement of these
milestones. Because of the uncertainty of the milestone achievement, and/or the dependence on sales of our licensee, variable consideration
for contingent milestones is fully constrained and is not recognized as revenue until the milestone is achieved by our licensee, to the
extent collectability is reasonably certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Royalties.
</i>Royalties revenue consists of sales-based and minimum royalties earned under licenses agreements for our products. Performance obligations
under these licenses, which consist of the right to use the Company&#8217;s proprietary technology, are satisfied at a point in time
corresponding with delivery of the underlying technology rights to the licensee, which is generally upon transfer of the licensed technology/product
to the customer. Sales-based royalties revenue represents variable consideration under the license agreements and is recognized in the
period a customer sells products incorporating the Company&#8217;s licensed technologies/products. The Company estimates sales-based
royalties revenue earned but unpaid at each reporting period using information provided by the licensee. The Company&#8217;s license
arrangements may also provide for minimum royalties, which the Company recognizes upon the satisfaction of the underlying performance
obligation, which generally occurs with delivery of the underlying technology rights to the licensee.Sales-based and minimum royalties
are generally due within 45 days after the end of each quarter in which they are earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract
Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
assets consist of minimum royalty revenue earned in relation to the license agreement but not yet payable based on the terms of the contract.
The contract asset as of December 31, 2021 is related to the Antares License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Concentration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
major customer is considered to be one that comprises more than <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--MajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLMX5IlbMtq4">10</span>% of the Company&#8217;s total revenues. There was one major customer
for the year ended December 31, 2021 which accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--OneMajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLHc6v70JOwc" title="Percentage of total revenue">99.7</span>% of total revenue. There was <span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_do_c20201001__20201231_zSySGzYwqj76" title="Total revenues">no</span> revenue recognized for the year ended December
31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOOkvtINXNn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(e)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zioBGwPalWU6">Property and Equipment</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost, less accumulated depreciation. Maintenance and repairs that do not extend the life or improve the
asset are expensed in the year incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is computed using the straight-line method over the estimated useful lives of the assets, which are <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zatle0IZ9bo3" title="Property, Plant and Equipment, Useful Life">five years </span>for laboratory and office
equipment, <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zr3KRIRRrS11" title="Property, Plant and Equipment, Useful Life">three years</span> for computer equipment and software, and <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zpuhAqpP7wF2" title="Property, Plant and Equipment, Useful Life">seven years</span> for furniture and fixtures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Accounting for Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zEYltHlVqFs3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(f)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z3r5HPdRjcDj">Accounting for Impairment of Long-Lived Assets</span></i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability of assets held and used is measured by a comparison of the carrying amount of an asset to future net cash
flows (undiscounted) expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized
is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets held for sale are reported
at the lower of the carrying amount, or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zij84mfqKRbc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(g)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z1FKhGvDMhyk">Income Taxes</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is provided against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or
all of the net deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition
or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related
to unrecognized tax benefits as a component of its income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share Based Payments</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zE5k11edQWx6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(h)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_znbsB5FBIE3b">Share Based Payments</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under
the Company&#8217;s Incentive Plan to employees, nonemployees and nonemployee members of the Company&#8217;s board of directors based
on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over
the award&#8217;s requisite service period. In addition, the Company has granted performance-based stock option awards and restricted
stock units, which vest based upon the Company satisfying certain performance conditions. Potential compensation cost, measured on the
grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options or units
will vest, which is based on whether the Company considers the performance conditions to be probable of attainment. The Company&#8217;s
estimates of the number of performance-based options or units that will vest will be revised, if necessary, in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated
based on assumptions with respect to (i) expected volatility of the Company&#8217;s Common Stock price, (ii) the periods of time over
which employees, nonemployees and members of the board of directors are expected to hold their options prior to exercise (expected term),
(iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes
an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised,
if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed
in the statements of operations amounted to $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3p0_c20210101__20211231_zXhfRBKUTEzf">604,000</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20200101__20201231_zuOVQIW0WaU3" title="Stock-based compensation cost">1.4</span> million for the years ended December 31, 2021 and 2020, allocated as follows:</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zxktI59KUKT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zhzSwTDBtpj3" style="display: none">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfpCgm0FOUUb" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">280,186</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfo1rTd1mKY1" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">583,212</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPBGjCR5Ba9i" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">323,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zI21cmWhk788" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">789,970</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210101__20211231_zFzE5iVkIFd" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">603,946</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200101__20201231_zNigh3TFQ4U8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,373,182</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_z9I2BOotSGTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zzXAxaMeRyW2">1,106,000</span> stock options and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0d_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zgAtZFpGhCtb" title="Number of stock options issued">1,360,000</span> stock options during the years ended December 31, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used in the determination of the fair value of stock options granted are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical
experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff
Accounting Bulletin (&#8220;SAB&#8221;) No. 107, <i>Share-Based Payment,</i> for awards with stated or implied service periods. The simplified
method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance
conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an
equivalent remaining term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Dividend</i>: The expected dividend assumption is based on management&#8217;s current expectation about the Company&#8217;s anticipated
dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>: The volatility factor is based solely on the Company&#8217;s trading history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zf9P3LTrNnc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
options granted in 2021 and 2020, the Company calculated the fair value of each option grant on the respective dates of grant using the
following weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zjfYf6O7yXqg" style="display: none">Schedule of Key Assumption of Fair Value of Stock Options Granted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zigqPgUOxEZ8">5.83</span>
                                            years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zCceFwzJzute">5.83</span>
                                            years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zgcnZIUoQ6K3" style="width: 12%; text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">1.04</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zsPoWtUlC3Y7" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.93</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20210101__20211231_zXibUT3LAfol" style="text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20200101__20201231_zOXOJ72FKom6" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zAWn9JB5hgod" style="text-align: right" title="Expected volatility"><span style="font-family: Times New Roman, Times, Serif">102.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zgGyc6uUUQN9" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>


<p id="xdx_8A9_zVf2XvZ0efE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Stock Compensation,</i> requires the Company to recognize compensation
expense for the portion of options that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived
from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional
adjustments to compensation expense may be required in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231_zy2xMqQDarp3" title="Unrecognized compensation cost">1.4</span> million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#8217;s stock option plan. That cost is expected to be recognized over a weighted average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231_zjI6ilgBAOG2" title="Weighted average period of stock option plan">2.3</span> years
and will be adjusted for subsequent changes in estimated forfeitures. The weighted average fair value of share-based compensation awards
granted during the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zgMvHpcT81Ld" title="Weighted average fair value of share-based compensation">0.97</span> per share and $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zR7ykk45H38c" title="Weighted average fair value of share-based compensation">0.72</span> per share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcxKT4huaXBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(i)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zkTH0OjI9iH2">Fair Value</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent
possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability
in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 Inputs: Quoted prices for identical instruments in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets
    that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in
    active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For
accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair
value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets
and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and 2020:</span></p>

<p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zzBGjfRbBTPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z8FOEw2Zhok1" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December 31,</b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value measurements at reporting date using</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;1&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;2&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;3&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents
    - money market funds</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,089,751</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,089,751</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0626">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Government treasury bills</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_zYGZ6JIYckGg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,515,920</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTu9YGe8OTa2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,515,920</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvtejDkIbzk" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJsvJNlBhXKf" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,385,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,385,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate
    bonds and notes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,787,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0636">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,787,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,778,956</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,605,671</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,173,285</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231_zD0ubLHmRyY8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,574,752</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9RCmwhCsiB5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,605,671</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzR9sXtEOXHf" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,173,285</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdagisEL2M91" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31,</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
                                            value measurements at reporting date using</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; width: 13%"><p style="margin-top: 0pt; margin-bottom: 0pt"/>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;1&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;2&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;3&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents - money
    market funds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zXwfULRgcUP7" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z966EUneKSK" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrgFK1UTqLe3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Kb9hlcgRl" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_zmBOCCN8FPte" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkHjiDBgeDib" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPasc9NWxJpl" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUOTmfQWyXFk" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231_zgu5OFtTpuB1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,849,577</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zF2rDLCvLyih" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOXN8fQ4M1B5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUUzJQw55bdb" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztRdSXKnChQb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zE6BOBMv2vt" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zjL0GunQRlLa" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z3NlU6vvX9F5" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_zvV437GzwiVi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,019,628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8hIWi8rxM73" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPPwnpBFeMx6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzj9PUwJ5Ha" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_zfTFu6dX2mGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value
in the balance sheets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents: Cash equivalents primarily consist of highly rated money market funds and treasury bills with original maturities to
the Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to
money market funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted
market prices or broker or dealer quotations for similar assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
bonds and notes: The Company uses a third-party pricing service to value these investments. United States bonds and notes are classified
within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets and reportable trades.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. Corporate bonds, notes
and commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids
and offers, benchmark yields and credit spreads and other observable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
liability: The warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period
with the change in fair value recorded to other income (expense) in the accompanying statements of operations until the warrants are
exercised, expire or other facts and circumstances lead the warrant liability to be reclassified to stockholders&#8217; equity. The fair
value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2021, include (i) volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z19hlJuH8rVe">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) risk free interest rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI5DNwf7Eil">0.97</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
(iii) strike price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziKrn14fM53k">0.50,
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) fair value of common stock of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zytKZGs6mw1f">.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and (v) expected life of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4nT1d8PUND7">2.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2020, include (i) volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKYVGOdcAUoc" title="Volatility rate">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) risk free interest rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNicT6cnU262" title="Risk free interest rate">0.27</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
(iii) strike price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUdcRG4B97b3" title="strike price">0.50</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
(iv) fair value of common stock of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ETF2od4R61" title="Fair value of common stock">1.36</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and (v) expected life of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZT52iLq6ub5" title="Expected life">3.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change
in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2 or Level 3 for the years ended December
31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_z1GRdyWmSHB4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(j)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z0dDnmxLUJB4">Earnings (Loss) per Share</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number
of common shares outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
earnings (loss) per share is based on the weighted average number of common shares outstanding plus, where applicable, the additional
potential common shares that would have been outstanding related to dilutive options, warrants, and unvested restricted stock units to
the extent such shares are dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zh0mh9AeFEj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the years ended December
31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zifCAHpbwzRb" style="display: none">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share attributable
    to common stock:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(634,399</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(20,964,819</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted avg. common
    shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">86,934,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">55,688,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--EarningsPerShareBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share attributable
    to common stock:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(634,399</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(20,964,819</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted avg. common
    shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">86,934,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">55,688,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EarningsPerShareDiluted_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p id="xdx_8AF_zLNNaS75DF84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlbm6t6zCWj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of diluted earnings per share for the years ended December 31, 2021 and 2020 does not include the following stock options
or warrants to purchase shares in the computation of diluted earnings per share because these instruments were antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPYlHuaGzPrk" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z55tnWWce096" style="width: 12%; text-align: right" title="Stock options"><span style="font-family: Times New Roman, Times, Serif">4,551,205</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjNnM0OoExji" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,564,458</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_znkxwLVqRfxc" style="text-align: right" title="Warrants"><span style="font-family: Times New Roman, Times, Serif">1,934,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8INJK4Jt5Ok" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,944,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zUeuN8yTTBha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    of Significant Accounting Policies &#8211; (continued) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWM5TW9qprL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(k)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zcnUAgHnyhYa">Segment Information</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a single reportable segment engaged in research and development for the delivery of drugs using its proprietary delivery technology.
Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief operating
decision maker made such decisions and assessed performance at the company level, as one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zznl6ajbLwK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(l)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zDi1AbRxBOTc">Principles of Consolidation</span> </i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and all subsidiaries. The Company eliminates all intercompany accounts
and transactions in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968569832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zdWnl6qjMk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation
of Revenue</i>.&#160;In the following tables, revenues reported for the year ended December 31, 2021, under Topic 606, is disaggregated
by type of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B2_zuLyLtwvNK4d" style="display: none">Schedule of Disaggregation
of Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Type of Revenue</td><td>&#160;</td>
    <td colspan="3" id="xdx_498_20210101__20211231_zgv6ccqvmkkk">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zAi9cZjBFZw8" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%">Licensing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">11,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SalesBasedRoyaltiesMember_zPyc3OXnLh2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales-based royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,994</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MinimumGuaranteedRoyaltiesMember_z3rfsLxUtocc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Minimum guaranteed royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,050,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MaterialsMember_zhfrHuzqtVT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Materials</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,035,844</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Revenue</span></td><td/>
    <td style="text-align: left">$</td><td style="text-align: right">16,140,838</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zxktI59KUKT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zhzSwTDBtpj3" style="display: none">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfpCgm0FOUUb" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">280,186</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfo1rTd1mKY1" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">583,212</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPBGjCR5Ba9i" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">323,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zI21cmWhk788" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">789,970</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210101__20211231_zFzE5iVkIFd" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">603,946</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200101__20201231_zNigh3TFQ4U8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,373,182</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumption of Fair Value of Stock Options Granted</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zf9P3LTrNnc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
options granted in 2021 and 2020, the Company calculated the fair value of each option grant on the respective dates of grant using the
following weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zjfYf6O7yXqg" style="display: none">Schedule of Key Assumption of Fair Value of Stock Options Granted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zigqPgUOxEZ8">5.83</span>
                                            years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zCceFwzJzute">5.83</span>
                                            years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zgcnZIUoQ6K3" style="width: 12%; text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">1.04</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zsPoWtUlC3Y7" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.93</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20210101__20211231_zXibUT3LAfol" style="text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20200101__20201231_zOXOJ72FKom6" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zAWn9JB5hgod" style="text-align: right" title="Expected volatility"><span style="font-family: Times New Roman, Times, Serif">102.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zgGyc6uUUQN9" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zzBGjfRbBTPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z8FOEw2Zhok1" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December 31,</b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value measurements at reporting date using</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;1&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;2&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level&#160;3&#160;inputs</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents
    - money market funds</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,089,751</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,089,751</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0626">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Government treasury bills</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_zYGZ6JIYckGg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,515,920</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTu9YGe8OTa2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,515,920</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvtejDkIbzk" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJsvJNlBhXKf" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,385,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,385,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate
    bonds and notes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,787,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0636">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,787,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#160;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,778,956</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,605,671</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,173,285</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231_zD0ubLHmRyY8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,574,752</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9RCmwhCsiB5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,605,671</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzR9sXtEOXHf" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,173,285</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdagisEL2M91" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31,</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
                                            value measurements at reporting date using</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; width: 13%"><p style="margin-top: 0pt; margin-bottom: 0pt"/>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;1&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;2&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level&#160;3&#160;inputs</b></span></td><td style="font-weight: bold; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents - money
    market funds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zXwfULRgcUP7" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z966EUneKSK" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrgFK1UTqLe3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Kb9hlcgRl" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_zmBOCCN8FPte" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkHjiDBgeDib" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPasc9NWxJpl" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUOTmfQWyXFk" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231_zgu5OFtTpuB1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,849,577</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zF2rDLCvLyih" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOXN8fQ4M1B5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUUzJQw55bdb" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztRdSXKnChQb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zE6BOBMv2vt" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zjL0GunQRlLa" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z3NlU6vvX9F5" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_zvV437GzwiVi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,019,628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8hIWi8rxM73" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,399,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPPwnpBFeMx6" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzj9PUwJ5Ha" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zh0mh9AeFEj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the years ended December
31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zifCAHpbwzRb" style="display: none">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share attributable
    to common stock:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(634,399</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(20,964,819</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted avg. common
    shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">86,934,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">55,688,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--EarningsPerShareBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share attributable
    to common stock:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(634,399</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(20,964,819</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted avg. common
    shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">86,934,618</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"><span style="font-family: Times New Roman, Times, Serif">55,688,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted loss per share
    attributable to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EarningsPerShareDiluted_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"><span style="font-family: Times New Roman, Times, Serif">(0.38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlbm6t6zCWj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of diluted earnings per share for the years ended December 31, 2021 and 2020 does not include the following stock options
or warrants to purchase shares in the computation of diluted earnings per share because these instruments were antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPYlHuaGzPrk" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z55tnWWce096" style="width: 12%; text-align: right" title="Stock options"><span style="font-family: Times New Roman, Times, Serif">4,551,205</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjNnM0OoExji" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,564,458</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_znkxwLVqRfxc" style="text-align: right" title="Warrants"><span style="font-family: Times New Roman, Times, Serif">1,934,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8INJK4Jt5Ok" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,944,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967474136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Securities</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zYhhdupVx1y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zlKToP0umYdj" style="display: none">Schedule of Available-for-Sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding gains</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding losses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Government treasury bills</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zh6R1Pywus52" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,526,122</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTPOS7Y0GRNb" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0731">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSt0V2LJBtv2" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,202</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zWsmdF4CtClg" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,515,920</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate bonds, notes
    and commercial paper</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zrh4uivRxVRj" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif">38,181,099</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zECanzzZzauf" style="border-bottom: Black 1pt solid; text-align: right" title="Gross unrealized holding gains"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zDZJJgCDoHid" style="border-bottom: Black 1pt solid; text-align: right" title="Gross unrealized holding losses"><span style="font-family: Times New Roman, Times, Serif">(7,814</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate fair value"><span style="font-family: Times New Roman, Times, Serif">38,173,285</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231_zRLYhI4DOdB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif">43,707,221</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231_zi2erJtGwXD4" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231_z5C2aScSAzxi" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding losses"><span style="font-family: Times New Roman, Times, Serif">(18,016</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231_zo674dFYIaxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value"><span style="font-family: Times New Roman, Times, Serif">43,689,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding gains</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross
    unrealized holding losses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial paper</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zcXKD0mdHj0c" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zfmwQ7Ptu2Qc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zEm8Ju10QvP4" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0752">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zy0Wl78caysi" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231_z44oKmNm6se4" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231_zCZk9GXvGfh5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231_zTTj0o4UIf0b" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zvpKNGBlTQqk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</a></td>
<td class="text"><p id="xdx_890_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zI5k2fXjS3K9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of debt securities classified as available-for-sale securities at December 31, 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zeWynuVtsOre" style="display: none">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31,
    2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Amortized</span></p>
                                                                                <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cost</span></p></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    fair value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due within one year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20211231_zlWpRuvdhSs5" style="width: 14%; text-align: right" title="Due within one year"><span style="font-family: Times New Roman, Times, Serif">41,680,635</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pp0p0_c20211231_zR9vYYX5gt6c" style="width: 14%; text-align: right" title="Due within one year"><span style="font-family: Times New Roman, Times, Serif">41,667,405</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due after one year through
    two years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_iI_pp0p0_c20211231_zhBdsAmY0Vq4" style="border-bottom: Black 1pt solid; text-align: right" title="Due after one year through two years"><span style="font-family: Times New Roman, Times, Serif">2,026,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pp0p0_c20211231_ztqME1Q1iHT2" style="border-bottom: Black 1pt solid; text-align: right" title="Due after one year through two years"><span style="font-family: Times New Roman, Times, Serif">2,021,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20211231_zZ2qhX8uXf0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost"><span style="font-family: Times New Roman, Times, Serif">43,707,221</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20211231_zk9zNUdkZmm5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, fair value"><span style="font-family: Times New Roman, Times, Serif">43,689,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967401640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Debt</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zZFZync2fV32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
maturities of principal payments on the Loan and Security Agreement at December 31, 2021 (excluding accrued final payment fee) are as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"><span id="xdx_8B7_zXOhItJPNeWa" style="display: none">Schedule of Maturities of Debt</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Years
    Ending December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Amount
    (in thousands)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_c20211231_z4CAx3eujQC3" style="width: 18%; text-align: right" title="2022"><span style="font-family: Times New Roman, Times, Serif">1,667</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_iI_pn3n3_c20211231_zMLi7LLZ77n4" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0835">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_pn3n3_c20211231_z4Q9n2XBIm03" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,667</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967395592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5ywfB5XUtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z8gitvPuU6x2" style="display: none">Schedule of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_zw4fy03YiD61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20201231_zytAvGVPkjs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_z0bS8UhYvnUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,361</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,361</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabAndOfficeEquipmentMember_z9yrBCMNiS58" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lab and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,056,523</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,048,932</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zzp1EOKPsOK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,404</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,404</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzck5_zV1hzCS4AUug" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,151,288</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,143,697</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzck5_zg5BiWGKy7Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less accumulated depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,144,077</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,143,697</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzck5_z5Ps2EvAZhZh" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, and equipment,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971003368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zcGa9p47QtYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zMBY0FkvtWgg" style="display: none">Schedule of Income Tax Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49C_20210101__20211231_zlTz3afSK8Hh" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_495_20200101__20201231_zVnKhkv2ZIFa" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_z9zVKIJhGOAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_zBXsizrDDoAe" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBz2PI_z2s2jPCO8hBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2PI_zZQdFaQud6rl" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Pretax Income from Continuing Operations</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zDNtqVMSaMG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B0_zmwR53YVEyt1">Schedule of Pretax Income from Continuing Operations</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_493_20210101__20211231_zGZGNl2u19z4" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_493_20200101__20201231_zq2eT0S412ff" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz2WU_zjlUzvJdf3Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computed &#8220;expected&#8221; tax benefit</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(133,182</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,402,570</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz2WU_z49VUkx4ehfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">476,431</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,248,002</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz2WU_zICAVJwOmpCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local income
    taxes, net of federal income tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">158</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">158</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz2WU_zGb89FhUgTbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97,697</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,209</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBz2WU_z7qkQTxm1348" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(352,163</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(485,254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_ecustom--IncomeTaxReconciliationOrphanDrugTaxCredits_iN_di_msITEBz2WU_zFW5mjDyNuP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orphan drug tax credit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,797</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_maITEBz2WU_zLtbawSs1mIe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(74,737</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">607,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBz2WU_zyfpIhRBIi0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(48,908</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2WU_zBWrtfoNnljk" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zIkyhyu3EwK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at
December 31, 2021 and 2020 are presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zxEq3CXcb5vl" style="display: none">Schedule of Deferred Tax Assets and  Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_498_20211231_zHAPPRlaNbO4" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_499_20201231_zPHOlia1PQJf" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pp0p0_maDTAGz8zG_zcum6fOthJe4" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,687,480</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,651,482</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGz8zG_zDFHMTWbdLA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,759,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,102,326</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pp0p0_maDTAGz8zG_z7UNHcZ7Jawc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee benefits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">56,009</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">54,108</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz8zG_zNcbIFbU26ye" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,935,609</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,472,003</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsOrphanDrugTaxCredit_iI_pp0p0_maDTAGz8zG_zQDQMHI2Raff" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orphan drug tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,186,582</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,168,828</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGz8zG_zpjMj48aKwW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">959</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_pp0p0_maDTAGz8zG_zVV2okVSZOR8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    deductible tempory differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394,636</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,386</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz8zG_maDTALNzp92_zl5rGnopehDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross deferred tax
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,020,206</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,455,092</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLzUYz_zeV6Ef5TbeVk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Plant
    and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,871</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLzUYz_maDTLznVR_zj3oMGKtshoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total gross deferred tax
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,871</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0950">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLznVR_msDTALNzp92_zYza23cF6rhf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,871</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzp92_zRM26uHlpLlh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax asset/deferred
    tax liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,018,335</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,455,092</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zfpcn5UPZ2Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less
    valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(43,018,335</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(42,455,092</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_zZTNEniVMPpi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zrMt1XP2WiYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amount of total unrecognized tax contingencies, excluding interest and penalties, for the
years ended December 31, 2021 and 2020 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zhUpyaUpcY99" style="display: none">Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, beginning of year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20210101__20211231_zUiHi3opvMJf" style="width: 12%; text-align: right" title="Balance, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="width: 1%; text-align: left"/><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20200101__20201231_z6Lf5Jlzogpb" style="width: 12%; text-align: right" title="Balance, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="width: 1%; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance, end of year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20210101__20211231_zTcWff85dRF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, end of year"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="text-align: left"/><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20200101__20201231_zNkeP3FViH3k" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, end of year"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left"/></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967482952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zsIcid4u8rHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancelable operating leases as of December 31, 2021 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zREQlESLuq8d" style="display: none">Schedule of Future Minimum Rental Payments for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20211231_zcFQWCIVuvmk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">leases</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year ending December 31:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzkOe_zP4kZRmId3Yd" style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">341,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzkOe_zThOAfFeqrb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,273</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzkOe_z0Rdss1IoBm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">398,702</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968434632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zvn1ofEA7Yd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35in; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zVfkRhu46cP" style="display: none">Schedule of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    stock options</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z3VAKOe26fE6" style="width: 16%; text-align: right" title="Number of shares, Balance at beginning of the period (in shares)"><span style="font-family: Times New Roman, Times, Serif">3,564,458</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFadEzxSVBa" style="width: 16%; text-align: right" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">3.36</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJRLa9Yvm5Le" style="text-align: right" title="Number of shares, Options granted (in shares)"><span style="font-family: Times New Roman, Times, Serif">1,105,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zC0dl8yucMQf" style="text-align: right" title="Weighted average exercise price, Options granted (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">1.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyi4NZbVnGo2" style="text-align: right" title="Number of shares, Options exercised (in shares)"><span style="font-family: Times New Roman, Times, Serif">(4,584</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ0ATDXF4zs5" style="text-align: right" title="Weighted average exercise price, Options exercised (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">1.46</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ6Af9kYGFPi" style="text-align: right" title="Number of shares, Options forfeited (in shares)"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqXuUV5A1hqc" style="text-align: right" title="Weighted average exercise price, Options forfeited (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options
    cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zarxTSJlD8Aj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Options cancelled (in shares)"><span style="font-family: Times New Roman, Times, Serif">(114,169</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFOU1WPI4Qbi" style="text-align: right" title="Weighted average exercise price, Options cancelled (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">4.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zsPdWzj2jpY8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Balance at end of the period (in shares)"><span style="font-family: Times New Roman, Times, Serif">4,551,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zz6D8hKfsbCa" style="text-align: right" title="Weighted average exercise price, Balance at end of the period (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">2.82</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Options exercisable at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z5nKHimJAAN2" style="text-align: right" title="Number of shares, Options exercisable (in shares)"><span style="font-family: Times New Roman, Times, Serif">2,799,979</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z1NjUEdqJOR9" style="text-align: right" title="Weighted average exercise price, Options exercisable (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">3.84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock', window );">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_gL3SBCABSBPAO-YSO_zTc02wLEcti5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about stock options outstanding and exercisable at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zY059Cv3gKy7" style="display: none">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    outstanding</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    exerciseable</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_zid0YUQ2izMc" style="width: 37%; text-align: right" title="Number of options outstanding, shares"><span style="font-family: Times New Roman, Times, Serif">4,551,205</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zNRgLFcTgUv2" title="Options outstanding, Weighted average remaining contractual life (Years)">6.66</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zWclQqwsQi0e" style="width: 5%; text-align: right" title="Options outstanding, Weighted average exercise price (in dollars per share)"><span style="font-family: Times New Roman, Times, Serif">2.82</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20211231_zl8QHZL0hcUc" style="width: 5%; text-align: right" title="Options outstanding, Aggregate intrinsic value"><span style="font-family: Times New Roman, Times, Serif">315,330</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231_z8xOftRC4dWc" style="width: 5%; text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif">2,799,979</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_z3XcmJAzelHi" title="Options exercisable, Weighted average remaining contractual life (Years)">5.01</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_znuOcOCBJgGh" title="Options exercisable, Weighted average exercise price">3.84</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20211231_zR8R8LFJ2i62" title="Options exercisable, Aggregate intrinsic value">201,966</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zp4BjeXkoDMb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in" summary="xdx: Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)">
<tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    outstanding</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    exercisable</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average remaining contractual life (Years)</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    intrinsic value</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjg6oSfxJWz3" style="text-align: right" title="Number of warrants exercisable, shares"><span style="font-family: Times New Roman, Times, Serif">1,934,366</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHhEHKbHN1V5" title="Weighted average remaining contractual life">3.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zymjBmDFJxw5" style="text-align: right" title="Weighted average exercise price, per share"><span style="font-family: Times New Roman, Times, Serif">0.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztmcKSO1ND52" style="text-align: right" title="Aggregate intrinsic value"><span style="font-family: Times New Roman, Times, Serif">922,629</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify; background-color: white"/>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock', window );">Schedule of Fair Value of Warrants</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zEvPtQChTJ97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zOgRmVrh1aWa" style="display: none">Schedule of Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2020</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">November
    18, 2019</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life in years</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAPsS00vHhMe" title="Expected life in years">2.88</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziJz5nOPUF3a" title="Expected life in years">3.88</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQbIwjkMQVBa" title="Expected life in years">4.88</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztByE2J85ali" title="Expected life in years">5.00</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFE7FUzYtWkk" style="text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">0.97</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxUaVvPT4EKk" style="text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">0.27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHDDdVxZMSj7" style="text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">1.69</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLVtZmrdWk9d" style="text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif">1.63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5qVPYVYF3tl" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1178">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUcidrlQPARb" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWnKfM0l9avi" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZexOWkwaMcl" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1184">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZMDXMbPRTf3" style="text-align: right" title="Volatility"><span style="font-family: Times New Roman, Times, Serif">100.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3DIpur37q6" style="text-align: right" title="Volatility"><span style="font-family: Times New Roman, Times, Serif">100.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23wXIcrdWt6" style="text-align: right" title="Volatility"><span style="font-family: Times New Roman, Times, Serif">225.93</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wW2zb4T38h" style="text-align: right" title="Volatility"><span style="font-family: Times New Roman, Times, Serif">224.47</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhB0UQxg4pM1" style="text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">0.99</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1oeVGqZqjTa" style="text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">1.36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthdPsPhMgC7" style="text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">0.39</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwmlqSCNdHEl" style="text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">0.41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock', window );">Schedule of Reconciliation of Warrant Liability</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zmQd9RxGr5i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zDnnjBsG4VSe" style="display: none">Schedule of Reconciliation of Warrant Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20210101__20211231_zDv3a8DJ2Sil" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Warrant
    Liability</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zQr0kSlwZVDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170,051</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Settlement of liabilty
    on warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value of common stock warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(355,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zATT6IvUm7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zLcTDu6F6Hwc" style="display: none">Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyR4LcHsJwU5" style="width: 14%; text-align: right" title="Warrants Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">1,944,366</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSDb4Y4tlF72" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">0.51</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z64x2BOBF334" style="text-align: right" title="Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1222">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1MmTUkNV3M" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1224">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNgd5KreI3Cc" style="text-align: right" title="Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif">(10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm0aRB4EF4Zg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCEXNcGiL3a" style="text-align: right" title="Warrants, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYko4Z3XHmrb" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pCAkuC6Eek" style="text-align: right" title="Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgPoWOB4IIja" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAl4lEwjFfaa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z94BuAHnex79" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy9FdiJrqipe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">1,934,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvgGs2LiMhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">0.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair Value Of Warrants [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Reconciliation of Warrant Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966130760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Disaggregation of Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 16,140,838<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lpcn_SalesBasedRoyaltiesMember', window );">Sales-based royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">54,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lpcn_MinimumGuaranteedRoyaltiesMember', window );">Minimum guaranteed royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lpcn_MaterialsMember', window );">Materials [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,035,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lpcn_SalesBasedRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lpcn_SalesBasedRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lpcn_MinimumGuaranteedRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lpcn_MinimumGuaranteedRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lpcn_MaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lpcn_MaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966373512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 603,946<span></span>
</td>
<td class="nump">$ 1,373,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">280,186<span></span>
</td>
<td class="nump">583,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 323,760<span></span>
</td>
<td class="nump">$ 789,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966373512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.04%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">102.18%<span></span>
</td>
<td class="nump">100.32%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967702936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value, Assets Measured on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 45,778,956<span></span>
</td>
<td class="nump">$ 18,849,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">46,574,752<span></span>
</td>
<td class="nump">20,019,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lpcn_CorporateBondsandNotesMember', window );">Corporate Bonds and Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">22,787,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">795,796<span></span>
</td>
<td class="nump">1,170,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">7,605,671<span></span>
</td>
<td class="nump">18,399,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">7,605,671<span></span>
</td>
<td class="nump">18,399,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Corporate Bonds and Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">38,173,285<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">38,173,285<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Corporate Bonds and Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">22,787,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">795,796<span></span>
</td>
<td class="nump">1,170,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Corporate Bonds and Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">795,796<span></span>
</td>
<td class="nump">1,170,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">2,089,751<span></span>
</td>
<td class="nump">18,399,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">2,089,751<span></span>
</td>
<td class="nump">18,399,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">5,515,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">5,515,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">15,385,634<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">15,385,634<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lpcn_CorporateBondsandNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lpcn_CorporateBondsandNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129965974168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (634,399)<span></span>
</td>
<td class="num">$ (20,964,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted avg. common shares outstanding</a></td>
<td class="nump">86,934,618<span></span>
</td>
<td class="nump">55,688,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common stock</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss</a></td>
<td class="num">$ (634,399)<span></span>
</td>
<td class="num">$ (20,964,819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted avg. common shares outstanding</a></td>
<td class="nump">86,934,618<span></span>
</td>
<td class="nump">55,688,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common stock</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967601064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Warrants</a></td>
<td class="nump">1,934,366<span></span>
</td>
<td class="nump">1,944,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Warrants</a></td>
<td class="nump">4,551,205<span></span>
</td>
<td class="nump">3,564,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967505016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents, at Carrying Value</a></td>
<td class="nump">$ 19,200,000<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 19,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,946<span></span>
</td>
<td class="nump">$ 1,373,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.18%<span></span>
</td>
<td class="nump">100.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.04%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">strike price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of stock options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,106,000<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lpcn_MajorCustomerMember', window );">Major Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lpcn_OneMajorCustomerMember', window );">One major customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lpcn_MajorCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lpcn_MajorCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lpcn_OneMajorCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lpcn_OneMajorCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968493592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Available-for-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 43,707,221<span></span>
</td>
<td class="nump">$ 449,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(18,016)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate fair value</a></td>
<td class="nump">43,689,205<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,526,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(10,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate fair value</a></td>
<td class="nump">5,515,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lpcn_CorporateBondsNotesAndCommercialPaperMember', window );">Corporate Bonds Notes And Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">38,181,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(7,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate fair value</a></td>
<td class="nump">$ 38,173,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lpcn_CorporateBondsNotesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lpcn_CorporateBondsNotesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129970938424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 41,680,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">41,667,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through two years</a></td>
<td class="nump">2,026,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through two years</a></td>
<td class="nump">2,021,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total maturities of debt securities classified as available-for-sale securities, amortized cost</a></td>
<td class="nump">43,707,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total maturities of debt securities classified as available-for-sale securities, fair value</a></td>
<td class="nump">$ 43,689,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968287608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from Sale of Held-to-maturity Securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss', window );">Debt and Equity Securities, Realized Gain (Loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Matured marketable investment securities</a></td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment', window );">Other than temporary impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an increase to the cumulative amount of credit losses recognized in earnings for an other than temporary impairment (OTTI) of a debt security held for which no such other than temporary impairment (OTTI) was previously recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL6284393-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966468856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contractual Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Oct. 14, 2021</div></th>
<th class="th"><div>Mar. 29, 2012</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeInsuranceLineItems', window );"><strong>Malpractice Insurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Contract research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Abbott Products Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeInsuranceLineItems', window );"><strong>Malpractice Insurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalties, commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch', window );">Percentage of royalties reduction based upon product launch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeInsuranceLineItems', window );"><strong>Malpractice Insurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_PercentageOfRoyaltyPayment', window );">Percentage of royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember', window );">License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeInsuranceLineItems', window );"><strong>Malpractice Insurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_SalesMilestoneRevenueRecognized', window );">Sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember', window );">License Agreement [Member] | Subsequent Event [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeInsuranceLineItems', window );"><strong>Malpractice Insurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_PotentialLicenseFeesFromALicensee', window );">Potential license fees from a licensee</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember', window );">License Agreement [Member] | TLANDO XR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeInsuranceLineItems', window );"><strong>Malpractice Insurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ClinicalAndDevelopmentMilestones', window );">Clinical and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ClinicalAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical and development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ClinicalAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties reduction based upon product launch.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_PercentageOfRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_PercentageOfRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_PotentialLicenseFeesFromALicensee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential license fees from a licensee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_PotentialLicenseFeesFromALicensee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_SalesMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_SalesMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeInsuranceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeInsuranceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lpcn_AbbottProductsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lpcn_AbbottProductsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lpcn_TLANDOXRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lpcn_TLANDOXRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129973210744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968255016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreement (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2018</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 09, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lpcn_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Debt Instrument, Interest Rate, Basis for Effective Rate</a></td>
<td class="text">The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (4.25% as of December
31, 2021), which interest is payable monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Jun.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument, balloon payment to be paid</a></td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt instrument, increase in amount</a></td>
<td class="nump">$ 644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCollateralForBorrowedSecurities', window );">Cash collateral for borrowed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRestrictiveCovenants', window );">Debt Instrument, Restrictive Covenants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault', window );">Debt instrument, basis spread on interest rate for debt default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency', window );">Debt instrument, minimum amount considered for insolvency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lpcn_PayrollProtectionProgramLoanMember', window );">Payroll Protection Program Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, basis spread on interest rate for debt default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt instrument minimum amount considered for insolvency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCollateralForBorrowedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCollateralForBorrowedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRestrictiveCovenants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of covenants that limit or prohibit certain actions or activities without the lender's prior consent within a specified period of time or until certain specified targets are achieved for example, reduction of the debt or an increase in net worth to a specified amount).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRestrictiveCovenants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lpcn_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lpcn_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=lpcn_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=lpcn_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lpcn_PayrollProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lpcn_PayrollProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966057480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">$ 1,151,288<span></span>
</td>
<td class="nump">$ 1,143,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(1,144,077)<span></span>
</td>
<td class="num">(1,143,697)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, and equipment, net</a></td>
<td class="nump">7,211<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">43,361<span></span>
</td>
<td class="nump">43,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_LabAndOfficeEquipmentMember', window );">Lab and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">1,056,523<span></span>
</td>
<td class="nump">1,048,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">$ 51,404<span></span>
</td>
<td class="nump">$ 51,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_LabAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lpcn_LabAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967500088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968210024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income Tax Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">U.S. federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State and local</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968670984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Pretax Income from Continuing Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed &#8220;expected&#8221; tax benefit</a></td>
<td class="num">$ (133,182)<span></span>
</td>
<td class="num">$ (4,402,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">476,431<span></span>
</td>
<td class="nump">4,248,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes, net of federal income tax benefit</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock expense</a></td>
<td class="nump">97,697<span></span>
</td>
<td class="nump">86,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(352,163)<span></span>
</td>
<td class="num">(485,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits', window );">Orphan drug tax credit</a></td>
<td class="num">(14,025)<span></span>
</td>
<td class="num">(4,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount', window );">Warrant liability</a></td>
<td class="num">(74,737)<span></span>
</td>
<td class="nump">607,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other, net</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(48,908)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for change in warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129967575880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,687,480<span></span>
</td>
<td class="nump">$ 1,651,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards</a></td>
<td class="nump">34,759,890<span></span>
</td>
<td class="nump">35,102,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee benefits</a></td>
<td class="nump">56,009<span></span>
</td>
<td class="nump">54,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">4,935,609<span></span>
</td>
<td class="nump">4,472,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_DeferredTaxAssetsOrphanDrugTaxCredit', window );">Orphan drug tax credits</a></td>
<td class="nump">1,186,582<span></span>
</td>
<td class="nump">1,168,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Plant and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Other deductible tempory differences</a></td>
<td class="nump">394,636<span></span>
</td>
<td class="nump">5,386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">43,020,206<span></span>
</td>
<td class="nump">42,455,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Plant and equipment</a></td>
<td class="num">(1,871)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(1,871)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(1,871)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax asset/deferred tax liability</a></td>
<td class="nump">43,018,335<span></span>
</td>
<td class="nump">42,455,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(43,018,335)<span></span>
</td>
<td class="num">(42,455,092)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_DeferredTaxAssetsOrphanDrugTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Orphan drug tax credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_DeferredTaxAssetsOrphanDrugTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129973002152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966606616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 43,018,335<span></span>
</td>
<td class="nump">$ 42,455,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount', window );">Operating Loss Carry forwards Limitations On Use Amount</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_OperatingLossCarryForwardsPreownershipChangeAmount', window );">Operating Loss Carry forwards Pre-ownership Change Amount</a></td>
<td class="nump">20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_OperatingLossForgivePreOwnershipChangeAmount', window );">Operating Loss Forgive Pre-ownership Change Amount</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount', window );">Tax Credit Carryforward Pre-ownership Change Amount</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">135,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_OperatingLossCarryForwardsExpirationDate1', window );">Operating Loss Carry forwards Expiration Date1</a></td>
<td class="text">Approximately $24.6 million of the NOL will expire between 2023 and 2033
and $70.8 million of the NOL will expire 2034 through 2037. Pursuant to the Tax Cuts and Jobs Act of 2017, NOL&#8217;s generated in 2018
and subsequent years have an unlimited carryforward therefore the 2020, 2019 and 2018 NOL of $40.2 million can be carried forward indefinitely.
The research and development credits will begin to expire in 2033 through 2041.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 127,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_OperatingLossCarryForwardsExpirationDate1', window );">Operating Loss Carry forwards Expiration Date1</a></td>
<td class="text">approximately $127.1 million and $1.4 million, respectively.
None of the Company&#8217;s state NOL expires in 2022, $34.8 million expires between 2022 and 2029, and $92.3 million will expire in
2030 through 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax Credit Carryforward, Description</a></td>
<td class="text">expire in 2023 through 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax Credit Carryforward, Description</a></td>
<td class="text">expire 2034 through 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Us Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax Credit Carryforward, Description</a></td>
<td class="text">expire in 2033 through 2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_OperatingLossCarryForwardsExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_OperatingLossCarryForwardsExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_OperatingLossCarryForwardsPreownershipChangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_OperatingLossCarryForwardsPreownershipChangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_OperatingLossForgivePreOwnershipChangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of forgiven for pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_OperatingLossForgivePreOwnershipChangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=lpcn_UsFederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=lpcn_UsFederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129973076840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Rental Payments for Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 341,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">57,273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 398,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129971002776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968314280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Balance at end of the period (in shares)</a></td>
<td class="nump">4,551,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Balance at end of the period (in dollars per share)</a></td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable (in shares)</a></td>
<td class="nump">2,799,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Balance at beginning of the period (in shares)</a></td>
<td class="nump">3,564,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Balance at beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted (in shares)</a></td>
<td class="nump">1,105,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options granted (in dollars per share)</a></td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised (in shares)</a></td>
<td class="num">(4,584)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercised (in dollars per share)</a></td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Options forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options forfeited (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, Options cancelled (in shares)</a></td>
<td class="num">(114,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options cancelled (in dollars per share)</a></td>
<td class="nump">$ 4.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Balance at end of the period (in shares)</a></td>
<td class="nump">4,551,205<span></span>
</td>
<td class="nump">3,564,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Balance at end of the period (in dollars per share)</a></td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="nump">$ 3.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable (in shares)</a></td>
<td class="nump">2,799,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968313656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, shares</a></td>
<td class="nump">4,551,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average remaining contractual life (Years)</a></td>
<td class="text">6 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate intrinsic value</a></td>
<td class="nump">$ 315,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">2,799,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted average remaining contractual life (Years)</a></td>
<td class="text">5 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted average exercise price</a></td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate intrinsic value</a></td>
<td class="nump">$ 201,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants exercisable, shares</a></td>
<td class="nump">1,934,366<span></span>
</td>
<td class="nump">1,944,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice', window );">Weighted average exercise price, per share</a></td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 922,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average Exercise Price, period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968642104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.04%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.18%<span></span>
</td>
<td class="nump">100.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember', window );">November 2019 Offering [Member] | Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">2 years 10 months 17 days<span></span>
</td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
<td class="text">4 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.63%<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
<td class="nump">1.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">224.47%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">225.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966386360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Warrant Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 1,170,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise', window );">Settlement of liabilty on warrant exercise</a></td>
<td class="num">(18,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="num">(355,890)<span></span>
</td>
<td class="nump">$ 2,892,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance at December 31, 2021</a></td>
<td class="nump">$ 795,796<span></span>
</td>
<td class="nump">$ 1,170,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for settlement of liability on warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129966477960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding, Beginning | shares</a></td>
<td class="nump">1,944,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning | $ / shares</a></td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, Issued | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants, Exercised | shares</a></td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants, Expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled', window );">Warrants, Cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Warrants, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding, Ending | shares</a></td>
<td class="nump">1,934,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending | $ / shares</a></td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Cancelled Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Expired Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option forfeited weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average Exercise Price, period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average Exercise Price, issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129957929848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2021</div></th>
<th class="th"><div>Feb. 27, 2020</div></th>
<th class="th"><div>Nov. 18, 2019</div></th>
<th class="th"><div>Mar. 06, 2017</div></th>
<th class="th"><div>Nov. 13, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Apr. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold through ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,406,053<span></span>
</td>
<td class="nump">$ 9,004,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_SharesAvailableForFutureIssuance', window );">[custom:SharesAvailableForFutureIssuance-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights', window );">[custom:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.96<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(355,890)<span></span>
</td>
<td class="nump">2,892,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">7,674,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lpcn_StockIncentivePlan2014Member', window );">Stock Incentive Plan 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,721,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lpcn_StockIncentivePlan2014Member', window );">Stock Incentive Plan 2014 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,221,906<span></span>
</td>
<td class="nump">2,471,906<span></span>
</td>
<td class="nump">1,271,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lpcn_StockIncentivePlan2014Member', window );">Stock Incentive Plan 2014 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,721,906<span></span>
</td>
<td class="nump">3,221,906<span></span>
</td>
<td class="nump">2,471,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lpcn_TwoThousandElevenEquityIncentivePlanMember', window );">2011 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,811,238<span></span>
</td>
<td class="nump">6,576,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold through ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lpcn_CommonStockWarrantMember', window );">Common Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lpcn_SalesAgreementMember', window );">Sales Agreement [Member] | Cantor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold through ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_PercentageOfGrossProceedOnSaleOfShares', window );">Percentage of gross proceeds on sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_January2021OfferingMember', window );">January 2021 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock gross</a></td>
<td class="nump">$ 28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">16,428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_February2020OfferingMember', window );">February 2020 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,042,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_February2020OfferingMember', window );">February 2020 Offering [Member] | Class A Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,084,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_February2020OfferingMember', window );">February 2020 Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember', window );">November 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember', window );">November 2019 Offering [Member] | Class A Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember', window );">November 2019 Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold through ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember', window );">November 2019 Offering [Member] | Class B Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember', window );">November 2019 Offering [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember', window );">November 2019 Offering [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold through ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_AtMarketOfferingMember', window );">ATM Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,023,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_AtMarketOfferingMember', window );">ATM Market Offering [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,811,238<span></span>
</td>
<td class="nump">3,746,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_AtMarketOfferingMember', window );">ATM Market Offering [Member] | Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_AtMarketOfferingMember', window );">ATM Market Offering [Member] | Sale Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Redemption Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_PercentageOfGrossProceedOnSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds on sale of shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_PercentageOfGrossProceedOnSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_SharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_SharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lpcn_StockIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lpcn_StockIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lpcn_TwoThousandElevenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lpcn_TwoThousandElevenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lpcn_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lpcn_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lpcn_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lpcn_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lpcn_CantorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lpcn_CantorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_January2021OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lpcn_January2021OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_February2020OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lpcn_February2020OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lpcn_ClassAUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lpcn_ClassAUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lpcn_November2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lpcn_ClassBUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lpcn_ClassBUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lpcn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lpcn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lpcn_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lpcn_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lpcn_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lpcn_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lpcn_SaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lpcn_SaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129972170296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129957917960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 13, 2023</div></th>
<th class="th"><div>Jul. 13, 2022</div></th>
<th class="th"><div>Apr. 02, 2019</div></th>
<th class="th"><div>Nov. 14, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_RetentionPayables', window );">[custom:RetentionPayables-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_GlobalAgreementMember', window );">Global Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_GlobalAgreementMember', window );">Global Agreement [Member] | Clarus Therapeutics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_GlobalAgreementMember', window );">Global Agreement [Member] | Clarus Therapeutics, Inc [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_RetentionPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_RetentionPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lpcn_GlobalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lpcn_GlobalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lpcn_ClarusTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lpcn_ClarusTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140129968490424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreement with Spriaso, LLC (Details Narrative) - Spriaso LLC[Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_PercentageOfRoyalty', window );">Percentage of royalty</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Proceeds from Contributions from Affiliates</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lpcn_ServiceAgreementMember', window );">Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_AgreementDescription', window );">Agreement description</a></td>
<td class="text">The
Company also agreed to continue providing up to 10 percent of the services of certain employees to Spriaso for a period of time. The
agreement to provide services expired in 2021;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lpcn_ProceedsFromReimbursements', window );">Proceeds from reimbursements</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_PercentageOfRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_PercentageOfRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lpcn_ProceedsFromReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lpcn_ProceedsFromReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lpcn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lpcn_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lpcn_SpriasoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lpcn_SpriasoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lpcn_ServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lpcn_ServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lpcn="http://lipocine.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lpcn-20211231.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MajorCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lpcn:MajorCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OneMajorCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lpcn:OneMajorCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SalesBasedRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lpcn:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MinimumGuaranteedRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lpcn:MinimumGuaranteedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lpcn:MaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CorporateBondsandNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsandNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateBondsandNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsandNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateBondsandNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsandNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateBondsandNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsandNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember78957890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember78957953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember78958203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember78958203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember78958203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember78958203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:CorporateBondsNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2012-03-282012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:AbbottProductsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-03-28</startDate>
            <endDate>2012-03-29</endDate>
        </period>
    </context>
    <context id="AsOf2012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:AbbottProductsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-03-29</instant>
        </period>
    </context>
    <context id="From2021-10-132021-10-14_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="From2024-12-312025-01-01_us-gaap_SubsequentEventMember_srt_ScenarioForecastMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="From2025-12-312026-01-01_us-gaap_SubsequentEventMember_srt_ScenarioForecastMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="From2021-10-132021-10-14_srt_MaximumMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="From2021-10-132021-10-14_custom_TLANDOXRMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:TLANDOXRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-05</instant>
        </period>
    </context>
    <context id="From2018-01-042018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-04</startDate>
            <endDate>2018-01-05</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-09_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-09</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">lpcn:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-04-30_custom_PayrollProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lpcn:PayrollProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LabAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:LabAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LabAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lpcn:LabAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_UsFederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lpcn:UsFederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-262021-01-28_custom_January2021OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:January2021OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-26</startDate>
            <endDate>2021-01-28</endDate>
        </period>
    </context>
    <context id="From2020-02-262020-02-27_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-26</startDate>
            <endDate>2020-02-27</endDate>
        </period>
    </context>
    <context id="From2020-02-262020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassAUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-26</startDate>
            <endDate>2020-02-27</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassAUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-27</instant>
        </period>
    </context>
    <context id="AsOf2020-02-27_us-gaap_CommonStockMember_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-27</instant>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassAUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassBUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="AsOf2019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:ClassBUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lpcn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_us-gaap_AdditionalPaidInCapitalMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="From2017-03-052017-03-06_custom_SalesAgreementMember_custom_CantorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:CantorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-05</startDate>
            <endDate>2017-03-06</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AtMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_AtMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:SaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2015-11-122015-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2015-11-12</startDate>
            <endDate>2015-11-13</endDate>
        </period>
    </context>
    <context id="AsOf2014-04-30_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-04-30</instant>
        </period>
    </context>
    <context id="AsOf2014-04-30_custom_TwoThousandElevenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-04-30</instant>
        </period>
    </context>
    <context id="AsOf2016-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="AsOf2016-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lpcn:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CommonStockWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lpcn:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CommonStockWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lpcn:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lpcn:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="From2019-04-012019-04-02_custom_GlobalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:GlobalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-02</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-04-02_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:GlobalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-02</endDate>
        </period>
    </context>
    <context id="From2022-07-122022-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:GlobalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-13</endDate>
        </period>
    </context>
    <context id="From2023-07-122023-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:GlobalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-12</startDate>
            <endDate>2023-07-13</endDate>
        </period>
    </context>
    <context id="AsOf2019-11-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2019-11-14</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_SpriasoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:SpriasoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:ServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:SpriasoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lpcn:ServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lpcn:SpriasoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-12-31">0001535955</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0077"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationReserveCurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0108"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:LitigationSettlementExpenseOne
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateBondsandNotesMember"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateBondsandNotesMember"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0664"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562"
      id="xdx2ixbrl0731"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578"
      id="xdx2ixbrl0751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <lpcn:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0835"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0861"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0872"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0877"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0878"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0937"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0947"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0950"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0953"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0961"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1001"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl1003"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1005"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1007"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2021-01-012021-12-31_custom_StockIncentivePlan2014Member"
      id="xdx2ixbrl1094">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1114"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1116"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1178"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1180"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1182"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1184"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1222"
      unitRef="Shares"
      xsi:nil="true"/>
    <lpcn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1224"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1230"
      unitRef="Shares"
      xsi:nil="true"/>
    <lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1232"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1234"
      unitRef="Shares"
      xsi:nil="true"/>
    <lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1236"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1238"
      unitRef="Shares"
      xsi:nil="true"/>
    <lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1240"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-01-01to2021-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2021-01-01to2021-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-12-31">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-12-31">001-36357</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-12-31">LIPOCINE INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-12-31">99-0370688</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-12-31">675                                             Arapeen Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-12-31">Suite 202</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-12-31">Salt     Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-12-31">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-12-31">84108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-12-31">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-12-31">994-7383</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-01-01to2021-12-31">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-01-01to2021-12-31">LPCN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-01-01to2021-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2021-01-01to2021-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2021-01-01to2021-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2021-01-01to2021-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2021-06-30" decimals="-5" unitRef="USD">120500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-03-07" decimals="INF" unitRef="Shares">88290650</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2021-01-01to2021-12-31">Portions
of the registrant&#x2019;s definitive Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part
III of this Form 10-K</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2021-01-01to2021-12-31">270</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2021-01-01to2021-12-31">Tanner LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2021-01-01to2021-12-31">Salt Lake City, Utah</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2950552</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">19217382</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">41667405</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">449992</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">247253</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">391</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1514465</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">661258</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">46379675</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">25329023</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2021800</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4050000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1144077</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1143697</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7211</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">23753</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">23753</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">52482439</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">25352776</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1289342</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1597220</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1016458</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1653178</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2310825</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3333333</us-gaap:DebtCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5616625</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">6583731</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2257075</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">795796</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1170051</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LitigationReserveNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">500000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6912421</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">10010857</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">88296360</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">70041967</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">88290650</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">70036257</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">8830</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7005</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">218286323</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">187407634</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">5710</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">5710</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">40712</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">40712</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-18016</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-172666407</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-172032008</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">45570018</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">15341919</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">52482439</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">25352776</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">16140838</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">7665559</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">9748469</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">5329776</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">8247795</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">12995335</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">17996264</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">3145503</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-17996264</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">67700</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">75650</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">203292</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">386618</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">234802</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">355890</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-2892189</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">4000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-3779702</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-2968355</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-634199</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-20964619</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-634399</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-20964819</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">86934618</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">55688085</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">86934618</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">55688085</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-634399</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-20964819</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-18016</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">38</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-652415</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-20964781</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">37649465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3766</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">157391969</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-38</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-151067189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">6287796</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-20964819</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-20964819</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">38</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">38</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <lpcn:CommonStockSoldThroughEquityOfferingShares
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10084034</lpcn:CommonStockSoldThroughEquityOfferingShares>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1008</lpcn:CommonStockSoldThroughEquityOffering>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5652132</lpcn:CommonStockSoldThroughEquityOffering>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">5653140</lpcn:CommonStockSoldThroughEquityOffering>
    <lpcn:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15097651</lpcn:StockIssuedDuringPeriodSharesWarrantsExercises>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1510</lpcn:StockIssuedDuringPeriodValueWarrantsExercises>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7673366</lpcn:StockIssuedDuringPeriodValueWarrantsExercises>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">7674876</lpcn:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1373182</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1373182</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6313338</lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">6313338</lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">628807</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">63</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-63</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6576300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">658</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">9003710</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">9004368</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">70036257</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7005</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">187407634</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-172032008</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">15341919</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-634399</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-634399</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-18016</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-18016</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">603946</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">603946</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6693</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">6693</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lpcn:CommonStockSoldThroughEquityOfferingShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16428571</lpcn:CommonStockSoldThroughEquityOfferingShares>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1643</lpcn:CommonStockSoldThroughEquityOffering>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">26838814</lpcn:CommonStockSoldThroughEquityOffering>
    <lpcn:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">26840457</lpcn:CommonStockSoldThroughEquityOffering>
    <lpcn:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10000</lpcn:StockIssuedDuringPeriodSharesWarrantsExercises>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</lpcn:StockIssuedDuringPeriodValueWarrantsExercises>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4999</lpcn:StockIssuedDuringPeriodValueWarrantsExercises>
    <lpcn:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">5000</lpcn:StockIssuedDuringPeriodValueWarrantsExercises>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18365</lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">18365</lpcn:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1811238</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">181</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3405872</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">3406053</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8830</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">218286323</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-18016</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-172666407</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">45570018</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-634399</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-20964819</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">380</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">3554</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">603946</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1373182</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">53750</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">109335</us-gaap:AccretionExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">234802</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-355890</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">2892189</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-515577</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">2616</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">246862</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-16131</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">4903207</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">115371</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-307878</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">414979</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-636720</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1205140</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <lpcn:LitigationSettlementExpenseOne
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1500000</lpcn:LitigationSettlementExpenseOne>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-4411303</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-15303098</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">7591</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">48422806</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">6315297</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">4650000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">10208000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-43780397</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">3892703</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">233537</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">3333333</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1666667</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">6693</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">26840457</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">5653140</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">5000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">7674876</us-gaap:ProceedsFromWarrantExercises>
    <lpcn:NetProceedsFromSaleOfCommonStockThroughATM
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">3406053</lpcn:NetProceedsFromSaleOfCommonStockThroughATM>
    <lpcn:NetProceedsFromSaleOfCommonStockThroughATM
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">9004368</lpcn:NetProceedsFromSaleOfCommonStockThroughATM>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">26924870</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">20899254</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-21266830</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">9488859</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24217382</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">14728523</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2950552</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24217382</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">149543</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">276019</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxesPaidNet>
    <lpcn:SettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">18365</lpcn:SettlementOfWarrantLiabilityOnWarrantExercises>
    <lpcn:SettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">6313338</lpcn:SettlementOfWarrantLiabilityOnWarrantExercises>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">18016</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-38</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <lpcn:AccruedFinalPaymentChargeOnDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">53750</lpcn:AccruedFinalPaymentChargeOnDebt>
    <lpcn:AccruedFinalPaymentChargeOnDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">109335</lpcn:AccruedFinalPaymentChargeOnDebt>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80E_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zzodVWPYejM8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(1)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_zc2JX4wRB5wg"&gt;Description of Business&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lipocine
Inc. (&#x201c;Lipocine&#x201d; or the &#x201c;Company&#x201d;), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
disorders, is engaged in research and development for the delivery of drugs using its proprietary delivery technology. The Company&#x2019;s
principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its own drug candidates or it develops
drug candidates on behalf of or in collaboration with corporate partners. The Company has funded operating costs primarily through collaborative
license, milestone and research arrangements, through federal grants, through the sale of equity securities and through debt. The Company
is incorporated under the laws of the State of Delaware.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zr6o0SiZ71Q5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82B_zBASakskuM"&gt;Summary of Significant Accounting Policies&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zS3cKuhCv4aa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zbAEwo35NvGi"&gt;Use of Estimates&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates. Significant items subject to such estimates and assumptions include those related to stock-based compensation;
income tax uncertainties; the fair value of the warrant liability and the useful lives of property and equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6nKwusyv1u4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zdlSg0YRaPO3"&gt;Cash and Cash Equivalents&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with original maturities to the Company of three months or less to be cash equivalents.
Although the Company may deposit its cash and cash equivalents with multiple financial institutions, its deposits, at times, may exceed
federally insured limits. Cash and cash equivalents were $&lt;span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zYCo3dDgpqAd"&gt;3.0&lt;/span&gt; million and $&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20201231_z85VN9DcsXh5" title="Cash Equivalents, at Carrying Value"&gt;19.2&lt;/span&gt;million at December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zYEtcgyU4CTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zjSAJGjXEmm4"&gt;Receivables&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are recorded at the invoiced amount and do not bear interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains an allowance for doubtful accounts for estimated losses. In establishing the allowance, management considers historical
losses adjusted to take into account current market conditions and their customers&#x2019; financial condition, the amount of receivables
in dispute, and the current receivables aging and current payment patterns. The Company had no write-offs in 2021 and 2020 and the Company
did not record an allowance for doubtful accounts as of December 31, 2021 and 2020 as there were no accounts receivable outstanding.
The Company does not have any off-balance-sheet credit exposure related to its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zFciAEhTHFDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(d)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zkB8RqQyhKIf"&gt;Revenue Recognition&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates most of its revenue from license and royalty arrangements. At inception of each contract, the Company identifies
the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines
the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and
determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction
price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. The Company reassess its reserves for variable consideration
at each reporting date and makes adjustments, if necessary, which may affect revenue and earnings in periods in which any such changes
become known.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)
Summary of Significant Accounting Policies &#x2013; (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zdWnl6qjMk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;.&#160;In the following tables, revenues reported for the year ended December 31, 2021, under Topic 606, is disaggregated
by type of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B2_zuLyLtwvNK4d" style="display: none"&gt;Schedule of Disaggregation
of Revenue&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Type of Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_498_20210101__20211231_zgv6ccqvmkkk"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zAi9cZjBFZw8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%"&gt;Licensing&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;11,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SalesBasedRoyaltiesMember_zPyc3OXnLh2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales-based royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MinimumGuaranteedRoyaltiesMember_z3rfsLxUtocc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Minimum guaranteed royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,050,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MaterialsMember_zhfrHuzqtVT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,035,844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,140,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zV6aKZ3IMhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Topic 606, all revenue has been recognized as point in time for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 4 for a description of the license agreement with Antares Pharma, Inc. See Note 12 for a description of the agreement with Spriaso.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
Fees&lt;/i&gt;. For distinct license performance obligations, upfront license fees are recognized when the Company satisfies the underlying
performance obligation. This generally occurs upon transfer of the right to use the Company&#x2019;s licensed technology to the customer.
In addition, license arrangements may include contingent milestone payments, which are due following achievement by our licensee of specified
sales or regulatory milestones and the licensee and/or Company will fulfill its performance obligation prior to achievement of these
milestones. Because of the uncertainty of the milestone achievement, and/or the dependence on sales of our licensee, variable consideration
for contingent milestones is fully constrained and is not recognized as revenue until the milestone is achieved by our licensee, to the
extent collectability is reasonably certain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Royalties.
&lt;/i&gt;Royalties revenue consists of sales-based and minimum royalties earned under licenses agreements for our products. Performance obligations
under these licenses, which consist of the right to use the Company&#x2019;s proprietary technology, are satisfied at a point in time
corresponding with delivery of the underlying technology rights to the licensee, which is generally upon transfer of the licensed technology/product
to the customer. Sales-based royalties revenue represents variable consideration under the license agreements and is recognized in the
period a customer sells products incorporating the Company&#x2019;s licensed technologies/products. The Company estimates sales-based
royalties revenue earned but unpaid at each reporting period using information provided by the licensee. The Company&#x2019;s license
arrangements may also provide for minimum royalties, which the Company recognizes upon the satisfaction of the underlying performance
obligation, which generally occurs with delivery of the underlying technology rights to the licensee.Sales-based and minimum royalties
are generally due within 45 days after the end of each quarter in which they are earned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
assets consist of minimum royalty revenue earned in relation to the license agreement but not yet payable based on the terms of the contract.
The contract asset as of December 31, 2021 is related to the Antares License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Concentration&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
major customer is considered to be one that comprises more than &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--MajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLMX5IlbMtq4"&gt;10&lt;/span&gt;% of the Company&#x2019;s total revenues. There was one major customer
for the year ended December 31, 2021 which accounted for &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--OneMajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLHc6v70JOwc" title="Percentage of total revenue"&gt;99.7&lt;/span&gt;% of total revenue. There was &lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_do_c20201001__20201231_zSySGzYwqj76" title="Total revenues"&gt;no&lt;/span&gt; revenue recognized for the year ended December
31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOOkvtINXNn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(e)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zioBGwPalWU6"&gt;Property and Equipment&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost, less accumulated depreciation. Maintenance and repairs that do not extend the life or improve the
asset are expensed in the year incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is computed using the straight-line method over the estimated useful lives of the assets, which are &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zatle0IZ9bo3" title="Property, Plant and Equipment, Useful Life"&gt;five years &lt;/span&gt;for laboratory and office
equipment, &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zr3KRIRRrS11" title="Property, Plant and Equipment, Useful Life"&gt;three years&lt;/span&gt; for computer equipment and software, and &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zpuhAqpP7wF2" title="Property, Plant and Equipment, Useful Life"&gt;seven years&lt;/span&gt; for furniture and fixtures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zEYltHlVqFs3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(f)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z3r5HPdRjcDj"&gt;Accounting for Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability of assets held and used is measured by a comparison of the carrying amount of an asset to future net cash
flows (undiscounted) expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized
is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets held for sale are reported
at the lower of the carrying amount, or fair value, less costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zij84mfqKRbc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(g)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z1FKhGvDMhyk"&gt;Income Taxes&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is provided against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or
all of the net deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition
or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related
to unrecognized tax benefits as a component of its income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zE5k11edQWx6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(h)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_znbsB5FBIE3b"&gt;Share Based Payments&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under
the Company&#x2019;s Incentive Plan to employees, nonemployees and nonemployee members of the Company&#x2019;s board of directors based
on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over
the award&#x2019;s requisite service period. In addition, the Company has granted performance-based stock option awards and restricted
stock units, which vest based upon the Company satisfying certain performance conditions. Potential compensation cost, measured on the
grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options or units
will vest, which is based on whether the Company considers the performance conditions to be probable of attainment. The Company&#x2019;s
estimates of the number of performance-based options or units that will vest will be revised, if necessary, in subsequent periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated
based on assumptions with respect to (i) expected volatility of the Company&#x2019;s Common Stock price, (ii) the periods of time over
which employees, nonemployees and members of the board of directors are expected to hold their options prior to exercise (expected term),
(iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes
an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised,
if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed
in the statements of operations amounted to $&lt;span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3p0_c20210101__20211231_zXhfRBKUTEzf"&gt;604,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20200101__20201231_zuOVQIW0WaU3" title="Stock-based compensation cost"&gt;1.4&lt;/span&gt; million for the years ended December 31, 2021 and 2020, allocated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zxktI59KUKT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zhzSwTDBtpj3" style="display: none"&gt;Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfpCgm0FOUUb" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;280,186&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfo1rTd1mKY1" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;583,212&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPBGjCR5Ba9i" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;323,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zI21cmWhk788" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;789,970&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210101__20211231_zFzE5iVkIFd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;603,946&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200101__20201231_zNigh3TFQ4U8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,373,182&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z9I2BOotSGTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zzXAxaMeRyW2"&gt;1,106,000&lt;/span&gt; stock options and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0d_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zgAtZFpGhCtb" title="Number of stock options issued"&gt;1,360,000&lt;/span&gt; stock options during the years ended December 31, 2021 and 2020,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Key
assumptions used in the determination of the fair value of stock options granted are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical
experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff
Accounting Bulletin (&#x201c;SAB&#x201d;) No. 107, &lt;i&gt;Share-Based Payment,&lt;/i&gt; for awards with stated or implied service periods. The simplified
method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance
conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
Interest Rate&lt;/i&gt;: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an
equivalent remaining term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Dividend&lt;/i&gt;: The expected dividend assumption is based on management&#x2019;s current expectation about the Company&#x2019;s anticipated
dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;: The volatility factor is based solely on the Company&#x2019;s trading history.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zf9P3LTrNnc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
options granted in 2021 and 2020, the Company calculated the fair value of each option grant on the respective dates of grant using the
following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zjfYf6O7yXqg" style="display: none"&gt;Schedule of Key Assumption of Fair Value of Stock Options Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zigqPgUOxEZ8"&gt;5.83&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zCceFwzJzute"&gt;5.83&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zgcnZIUoQ6K3" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zsPoWtUlC3Y7" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20210101__20211231_zXibUT3LAfol" style="text-align: right" title="Expected dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20200101__20201231_zOXOJ72FKom6" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zAWn9JB5hgod" style="text-align: right" title="Expected volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zgGyc6uUUQN9" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zVf2XvZ0efE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Stock Compensation,&lt;/i&gt; requires the Company to recognize compensation
expense for the portion of options that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived
from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional
adjustments to compensation expense may be required in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, there was $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231_zy2xMqQDarp3" title="Unrecognized compensation cost"&gt;1.4&lt;/span&gt; million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#x2019;s stock option plan. That cost is expected to be recognized over a weighted average period of &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231_zjI6ilgBAOG2" title="Weighted average period of stock option plan"&gt;2.3&lt;/span&gt; years
and will be adjusted for subsequent changes in estimated forfeitures. The weighted average fair value of share-based compensation awards
granted during the years ended December 31, 2021 and 2020 was approximately $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zgMvHpcT81Ld" title="Weighted average fair value of share-based compensation"&gt;0.97&lt;/span&gt; per share and $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zR7ykk45H38c" title="Weighted average fair value of share-based compensation"&gt;0.72&lt;/span&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcxKT4huaXBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zkTH0OjI9iH2"&gt;Fair Value&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent
possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability
in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 Inputs: Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets
    that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in
    active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For
accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair
value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets
and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zzBGjfRbBTPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z8FOEw2Zhok1" style="display: none"&gt;Schedule of Fair Value, Assets Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value measurements at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;1&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;2&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;3&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents
    - money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,089,751&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,089,751&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_zYGZ6JIYckGg" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,515,920&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTu9YGe8OTa2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,515,920&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvtejDkIbzk" style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJsvJNlBhXKf" style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,385,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,385,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,787,651&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0636"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,787,651&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0638"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,778,956&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,605,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,173,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231_zD0ubLHmRyY8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,574,752&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9RCmwhCsiB5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,605,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzR9sXtEOXHf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,173,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdagisEL2M91" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
                                            value measurements at reporting date using&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; width: 13%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"/&gt;
                                                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;1&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;2&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;3&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents - money
    market funds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zXwfULRgcUP7" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z966EUneKSK" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrgFK1UTqLe3" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Kb9hlcgRl" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_zmBOCCN8FPte" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkHjiDBgeDib" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPasc9NWxJpl" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUOTmfQWyXFk" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231_zgu5OFtTpuB1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,849,577&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zF2rDLCvLyih" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOXN8fQ4M1B5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUUzJQw55bdb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztRdSXKnChQb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zE6BOBMv2vt" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0664"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zjL0GunQRlLa" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0665"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z3NlU6vvX9F5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_zvV437GzwiVi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,019,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8hIWi8rxM73" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPPwnpBFeMx6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzj9PUwJ5Ha" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zfTFu6dX2mGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value
in the balance sheets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
equivalents: Cash equivalents primarily consist of highly rated money market funds and treasury bills with original maturities to
the Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to
money market funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted
market prices or broker or dealer quotations for similar assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Government
bonds and notes: The Company uses a third-party pricing service to value these investments. United States bonds and notes are classified
within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets and reportable trades.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate
bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. Corporate bonds, notes
and commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids
and offers, benchmark yields and credit spreads and other observable inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
liability: The warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period
with the change in fair value recorded to other income (expense) in the accompanying statements of operations until the warrants are
exercised, expire or other facts and circumstances lead the warrant liability to be reclassified to stockholders&#x2019; equity. The fair
value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2021, include (i) volatility of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z19hlJuH8rVe"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii) risk free interest rate of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI5DNwf7Eil"&gt;0.97&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
(iii) strike price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziKrn14fM53k"&gt;0.50,
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv) fair value of common stock of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zytKZGs6mw1f"&gt;.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
and (v) expected life of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4nT1d8PUND7"&gt;2.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2020, include (i) volatility of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKYVGOdcAUoc" title="Volatility rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii) risk free interest rate of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNicT6cnU262" title="Risk free interest rate"&gt;0.27&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
(iii) strike price of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUdcRG4B97b3" title="strike price"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
(iv) fair value of common stock of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ETF2od4R61" title="Fair value of common stock"&gt;1.36&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
and (v) expected life of &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZT52iLq6ub5" title="Expected life"&gt;3.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change
in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2 or Level 3 for the years ended December
31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_z1GRdyWmSHB4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(j)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z0dDnmxLUJB4"&gt;Earnings (Loss) per Share&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number
of common shares outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
earnings (loss) per share is based on the weighted average number of common shares outstanding plus, where applicable, the additional
potential common shares that would have been outstanding related to dilutive options, warrants, and unvested restricted stock units to
the extent such shares are dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zh0mh9AeFEj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the years ended December
31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zifCAHpbwzRb" style="display: none"&gt;Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic loss per share attributable
    to common stock:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(634,399&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,964,819&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted avg. common
    shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,934,618&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,688,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic loss per share
    attributable to common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EarningsPerShareBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted loss per share attributable
    to common stock:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(634,399&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,964,819&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted avg. common
    shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,934,618&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,688,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted loss per share
    attributable to common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EarningsPerShareDiluted_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zLNNaS75DF84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlbm6t6zCWj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of diluted earnings per share for the years ended December 31, 2021 and 2020 does not include the following stock options
or warrants to purchase shares in the computation of diluted earnings per share because these instruments were antidilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zPYlHuaGzPrk" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z55tnWWce096" style="width: 12%; text-align: right" title="Stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,551,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjNnM0OoExji" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,564,458&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_znkxwLVqRfxc" style="text-align: right" title="Warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8INJK4Jt5Ok" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,944,366&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zUeuN8yTTBha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWM5TW9qprL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(k)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zcnUAgHnyhYa"&gt;Segment Information&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a single reportable segment engaged in research and development for the delivery of drugs using its proprietary delivery technology.
Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief operating
decision maker made such decisions and assessed performance at the company level, as one segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zznl6ajbLwK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(l)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zDi1AbRxBOTc"&gt;Principles of Consolidation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and all subsidiaries. The Company eliminates all intercompany accounts
and transactions in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zS3cKuhCv4aa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zbAEwo35NvGi"&gt;Use of Estimates&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates. Significant items subject to such estimates and assumptions include those related to stock-based compensation;
income tax uncertainties; the fair value of the warrant liability and the useful lives of property and equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6nKwusyv1u4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zdlSg0YRaPO3"&gt;Cash and Cash Equivalents&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with original maturities to the Company of three months or less to be cash equivalents.
Although the Company may deposit its cash and cash equivalents with multiple financial institutions, its deposits, at times, may exceed
federally insured limits. Cash and cash equivalents were $&lt;span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zYCo3dDgpqAd"&gt;3.0&lt;/span&gt; million and $&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20201231_z85VN9DcsXh5" title="Cash Equivalents, at Carrying Value"&gt;19.2&lt;/span&gt;million at December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">3000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="-5" unitRef="USD">19200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zYEtcgyU4CTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zjSAJGjXEmm4"&gt;Receivables&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are recorded at the invoiced amount and do not bear interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains an allowance for doubtful accounts for estimated losses. In establishing the allowance, management considers historical
losses adjusted to take into account current market conditions and their customers&#x2019; financial condition, the amount of receivables
in dispute, and the current receivables aging and current payment patterns. The Company had no write-offs in 2021 and 2020 and the Company
did not record an allowance for doubtful accounts as of December 31, 2021 and 2020 as there were no accounts receivable outstanding.
The Company does not have any off-balance-sheet credit exposure related to its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zFciAEhTHFDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(d)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zkB8RqQyhKIf"&gt;Revenue Recognition&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates most of its revenue from license and royalty arrangements. At inception of each contract, the Company identifies
the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines
the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and
determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction
price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. The Company reassess its reserves for variable consideration
at each reporting date and makes adjustments, if necessary, which may affect revenue and earnings in periods in which any such changes
become known.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)
Summary of Significant Accounting Policies &#x2013; (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zdWnl6qjMk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;.&#160;In the following tables, revenues reported for the year ended December 31, 2021, under Topic 606, is disaggregated
by type of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B2_zuLyLtwvNK4d" style="display: none"&gt;Schedule of Disaggregation
of Revenue&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Type of Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_498_20210101__20211231_zgv6ccqvmkkk"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zAi9cZjBFZw8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%"&gt;Licensing&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;11,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SalesBasedRoyaltiesMember_zPyc3OXnLh2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales-based royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MinimumGuaranteedRoyaltiesMember_z3rfsLxUtocc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Minimum guaranteed royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,050,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MaterialsMember_zhfrHuzqtVT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,035,844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,140,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zV6aKZ3IMhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Topic 606, all revenue has been recognized as point in time for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 4 for a description of the license agreement with Antares Pharma, Inc. See Note 12 for a description of the agreement with Spriaso.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
Fees&lt;/i&gt;. For distinct license performance obligations, upfront license fees are recognized when the Company satisfies the underlying
performance obligation. This generally occurs upon transfer of the right to use the Company&#x2019;s licensed technology to the customer.
In addition, license arrangements may include contingent milestone payments, which are due following achievement by our licensee of specified
sales or regulatory milestones and the licensee and/or Company will fulfill its performance obligation prior to achievement of these
milestones. Because of the uncertainty of the milestone achievement, and/or the dependence on sales of our licensee, variable consideration
for contingent milestones is fully constrained and is not recognized as revenue until the milestone is achieved by our licensee, to the
extent collectability is reasonably certain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Royalties.
&lt;/i&gt;Royalties revenue consists of sales-based and minimum royalties earned under licenses agreements for our products. Performance obligations
under these licenses, which consist of the right to use the Company&#x2019;s proprietary technology, are satisfied at a point in time
corresponding with delivery of the underlying technology rights to the licensee, which is generally upon transfer of the licensed technology/product
to the customer. Sales-based royalties revenue represents variable consideration under the license agreements and is recognized in the
period a customer sells products incorporating the Company&#x2019;s licensed technologies/products. The Company estimates sales-based
royalties revenue earned but unpaid at each reporting period using information provided by the licensee. The Company&#x2019;s license
arrangements may also provide for minimum royalties, which the Company recognizes upon the satisfaction of the underlying performance
obligation, which generally occurs with delivery of the underlying technology rights to the licensee.Sales-based and minimum royalties
are generally due within 45 days after the end of each quarter in which they are earned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract
Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
assets consist of minimum royalty revenue earned in relation to the license agreement but not yet payable based on the terms of the contract.
The contract asset as of December 31, 2021 is related to the Antares License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Concentration&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
major customer is considered to be one that comprises more than &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--MajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLMX5IlbMtq4"&gt;10&lt;/span&gt;% of the Company&#x2019;s total revenues. There was one major customer
for the year ended December 31, 2021 which accounted for &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--OneMajorCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLHc6v70JOwc" title="Percentage of total revenue"&gt;99.7&lt;/span&gt;% of total revenue. There was &lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_do_c20201001__20201231_zSySGzYwqj76" title="Total revenues"&gt;no&lt;/span&gt; revenue recognized for the year ended December
31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zdWnl6qjMk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;.&#160;In the following tables, revenues reported for the year ended December 31, 2021, under Topic 606, is disaggregated
by type of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B2_zuLyLtwvNK4d" style="display: none"&gt;Schedule of Disaggregation
of Revenue&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Type of Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_498_20210101__20211231_zgv6ccqvmkkk"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zAi9cZjBFZw8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%"&gt;Licensing&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;11,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SalesBasedRoyaltiesMember_zPyc3OXnLh2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales-based royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MinimumGuaranteedRoyaltiesMember_z3rfsLxUtocc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Minimum guaranteed royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,050,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--MaterialsMember_zhfrHuzqtVT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,035,844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,140,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_SalesBasedRoyaltiesMember"
      decimals="0"
      unitRef="USD">54994</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_MinimumGuaranteedRoyaltiesMember"
      decimals="0"
      unitRef="USD">4050000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_MaterialsMember"
      decimals="0"
      unitRef="USD">1035844</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">16140838</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_custom_MajorCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_custom_OneMajorCustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.997</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOOkvtINXNn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(e)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zioBGwPalWU6"&gt;Property and Equipment&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost, less accumulated depreciation. Maintenance and repairs that do not extend the life or improve the
asset are expensed in the year incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is computed using the straight-line method over the estimated useful lives of the assets, which are &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zatle0IZ9bo3" title="Property, Plant and Equipment, Useful Life"&gt;five years &lt;/span&gt;for laboratory and office
equipment, &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zr3KRIRRrS11" title="Property, Plant and Equipment, Useful Life"&gt;three years&lt;/span&gt; for computer equipment and software, and &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zpuhAqpP7wF2" title="Property, Plant and Equipment, Useful Life"&gt;seven years&lt;/span&gt; for furniture and fixtures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-12-31_us-gaap_OfficeEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-12-31_custom_ComputerEquipmentAndSoftwareMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zEYltHlVqFs3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(f)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z3r5HPdRjcDj"&gt;Accounting for Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability of assets held and used is measured by a comparison of the carrying amount of an asset to future net cash
flows (undiscounted) expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized
is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets held for sale are reported
at the lower of the carrying amount, or fair value, less costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zij84mfqKRbc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(g)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z1FKhGvDMhyk"&gt;Income Taxes&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is provided against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or
all of the net deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition
or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related
to unrecognized tax benefits as a component of its income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zE5k11edQWx6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(h)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_znbsB5FBIE3b"&gt;Share Based Payments&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under
the Company&#x2019;s Incentive Plan to employees, nonemployees and nonemployee members of the Company&#x2019;s board of directors based
on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over
the award&#x2019;s requisite service period. In addition, the Company has granted performance-based stock option awards and restricted
stock units, which vest based upon the Company satisfying certain performance conditions. Potential compensation cost, measured on the
grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options or units
will vest, which is based on whether the Company considers the performance conditions to be probable of attainment. The Company&#x2019;s
estimates of the number of performance-based options or units that will vest will be revised, if necessary, in subsequent periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated
based on assumptions with respect to (i) expected volatility of the Company&#x2019;s Common Stock price, (ii) the periods of time over
which employees, nonemployees and members of the board of directors are expected to hold their options prior to exercise (expected term),
(iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes
an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised,
if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed
in the statements of operations amounted to $&lt;span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3p0_c20210101__20211231_zXhfRBKUTEzf"&gt;604,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20200101__20201231_zuOVQIW0WaU3" title="Stock-based compensation cost"&gt;1.4&lt;/span&gt; million for the years ended December 31, 2021 and 2020, allocated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zxktI59KUKT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zhzSwTDBtpj3" style="display: none"&gt;Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfpCgm0FOUUb" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;280,186&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfo1rTd1mKY1" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;583,212&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPBGjCR5Ba9i" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;323,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zI21cmWhk788" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;789,970&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210101__20211231_zFzE5iVkIFd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;603,946&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200101__20201231_zNigh3TFQ4U8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,373,182&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z9I2BOotSGTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zzXAxaMeRyW2"&gt;1,106,000&lt;/span&gt; stock options and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pp0d_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zgAtZFpGhCtb" title="Number of stock options issued"&gt;1,360,000&lt;/span&gt; stock options during the years ended December 31, 2021 and 2020,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Key
assumptions used in the determination of the fair value of stock options granted are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical
experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff
Accounting Bulletin (&#x201c;SAB&#x201d;) No. 107, &lt;i&gt;Share-Based Payment,&lt;/i&gt; for awards with stated or implied service periods. The simplified
method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance
conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
Interest Rate&lt;/i&gt;: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an
equivalent remaining term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Dividend&lt;/i&gt;: The expected dividend assumption is based on management&#x2019;s current expectation about the Company&#x2019;s anticipated
dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;: The volatility factor is based solely on the Company&#x2019;s trading history.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zf9P3LTrNnc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
options granted in 2021 and 2020, the Company calculated the fair value of each option grant on the respective dates of grant using the
following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zjfYf6O7yXqg" style="display: none"&gt;Schedule of Key Assumption of Fair Value of Stock Options Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zigqPgUOxEZ8"&gt;5.83&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zCceFwzJzute"&gt;5.83&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zgcnZIUoQ6K3" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zsPoWtUlC3Y7" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20210101__20211231_zXibUT3LAfol" style="text-align: right" title="Expected dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20200101__20201231_zOXOJ72FKom6" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zAWn9JB5hgod" style="text-align: right" title="Expected volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zgGyc6uUUQN9" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zVf2XvZ0efE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Stock Compensation,&lt;/i&gt; requires the Company to recognize compensation
expense for the portion of options that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived
from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional
adjustments to compensation expense may be required in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, there was $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231_zy2xMqQDarp3" title="Unrecognized compensation cost"&gt;1.4&lt;/span&gt; million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#x2019;s stock option plan. That cost is expected to be recognized over a weighted average period of &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231_zjI6ilgBAOG2" title="Weighted average period of stock option plan"&gt;2.3&lt;/span&gt; years
and will be adjusted for subsequent changes in estimated forfeitures. The weighted average fair value of share-based compensation awards
granted during the years ended December 31, 2021 and 2020 was approximately $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zgMvHpcT81Ld" title="Weighted average fair value of share-based compensation"&gt;0.97&lt;/span&gt; per share and $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zR7ykk45H38c" title="Weighted average fair value of share-based compensation"&gt;0.72&lt;/span&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">604000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-5"
      unitRef="USD">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zxktI59KUKT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zhzSwTDBtpj3" style="display: none"&gt;Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfpCgm0FOUUb" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;280,186&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfo1rTd1mKY1" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;583,212&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPBGjCR5Ba9i" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;323,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zI21cmWhk788" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;789,970&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210101__20211231_zFzE5iVkIFd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;603,946&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200101__20201231_zNigh3TFQ4U8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,373,182&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">280186</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">583212</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">323760</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">789970</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">603946</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1373182</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">1106000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">1360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zf9P3LTrNnc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
options granted in 2021 and 2020, the Company calculated the fair value of each option grant on the respective dates of grant using the
following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zjfYf6O7yXqg" style="display: none"&gt;Schedule of Key Assumption of Fair Value of Stock Options Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zigqPgUOxEZ8"&gt;5.83&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zCceFwzJzute"&gt;5.83&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zgcnZIUoQ6K3" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zsPoWtUlC3Y7" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20210101__20211231_zXibUT3LAfol" style="text-align: right" title="Expected dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20200101__20201231_zOXOJ72FKom6" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zAWn9JB5hgod" style="text-align: right" title="Expected volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zgGyc6uUUQN9" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-12-31">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.0104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">1.0218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Pure">1.0032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2021-01-01to2021-12-31">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcxKT4huaXBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zkTH0OjI9iH2"&gt;Fair Value&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent
possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability
in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 Inputs: Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets
    that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in
    active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For
accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair
value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets
and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zzBGjfRbBTPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z8FOEw2Zhok1" style="display: none"&gt;Schedule of Fair Value, Assets Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value measurements at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;1&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;2&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;3&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents
    - money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,089,751&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,089,751&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_zYGZ6JIYckGg" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,515,920&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTu9YGe8OTa2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,515,920&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvtejDkIbzk" style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJsvJNlBhXKf" style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,385,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,385,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,787,651&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0636"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,787,651&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0638"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,778,956&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,605,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,173,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231_zD0ubLHmRyY8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,574,752&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9RCmwhCsiB5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,605,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzR9sXtEOXHf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,173,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdagisEL2M91" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
                                            value measurements at reporting date using&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; width: 13%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"/&gt;
                                                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;1&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;2&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;3&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents - money
    market funds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zXwfULRgcUP7" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z966EUneKSK" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrgFK1UTqLe3" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Kb9hlcgRl" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_zmBOCCN8FPte" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkHjiDBgeDib" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPasc9NWxJpl" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUOTmfQWyXFk" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231_zgu5OFtTpuB1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,849,577&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zF2rDLCvLyih" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOXN8fQ4M1B5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUUzJQw55bdb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztRdSXKnChQb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zE6BOBMv2vt" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0664"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zjL0GunQRlLa" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0665"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z3NlU6vvX9F5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_zvV437GzwiVi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,019,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8hIWi8rxM73" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPPwnpBFeMx6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzj9PUwJ5Ha" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zfTFu6dX2mGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value
in the balance sheets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
equivalents: Cash equivalents primarily consist of highly rated money market funds and treasury bills with original maturities to
the Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to
money market funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted
market prices or broker or dealer quotations for similar assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Government
bonds and notes: The Company uses a third-party pricing service to value these investments. United States bonds and notes are classified
within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets and reportable trades.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate
bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. Corporate bonds, notes
and commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids
and offers, benchmark yields and credit spreads and other observable inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
liability: The warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period
with the change in fair value recorded to other income (expense) in the accompanying statements of operations until the warrants are
exercised, expire or other facts and circumstances lead the warrant liability to be reclassified to stockholders&#x2019; equity. The fair
value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2021, include (i) volatility of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z19hlJuH8rVe"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii) risk free interest rate of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI5DNwf7Eil"&gt;0.97&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
(iii) strike price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziKrn14fM53k"&gt;0.50,
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv) fair value of common stock of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zytKZGs6mw1f"&gt;.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
and (v) expected life of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4nT1d8PUND7"&gt;2.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years. The significant assumptions used in preparing
the option pricing model for valuing the warrant liability as of December 31, 2020, include (i) volatility of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKYVGOdcAUoc" title="Volatility rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii) risk free interest rate of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNicT6cnU262" title="Risk free interest rate"&gt;0.27&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
(iii) strike price of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUdcRG4B97b3" title="strike price"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
(iv) fair value of common stock of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ETF2od4R61" title="Fair value of common stock"&gt;1.36&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
and (v) expected life of &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZT52iLq6ub5" title="Expected life"&gt;3.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change
in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2 or Level 3 for the years ended December
31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zzBGjfRbBTPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z8FOEw2Zhok1" style="display: none"&gt;Schedule of Fair Value, Assets Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value measurements at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;1&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;2&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;3&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents
    - money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,089,751&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,089,751&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_zYGZ6JIYckGg" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,515,920&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTu9YGe8OTa2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,515,920&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSvtejDkIbzk" style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJsvJNlBhXKf" style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,385,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,385,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,787,651&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0636"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,787,651&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsandNotesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0638"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,778,956&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,605,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,173,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231_zD0ubLHmRyY8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,574,752&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9RCmwhCsiB5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,605,671&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzR9sXtEOXHf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,173,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdagisEL2M91" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
                                            value measurements at reporting date using&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center; width: 13%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"/&gt;
                                                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;1&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;2&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level&#160;3&#160;inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents - money
    market funds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zXwfULRgcUP7" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z966EUneKSK" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrgFK1UTqLe3" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Kb9hlcgRl" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_zmBOCCN8FPte" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkHjiDBgeDib" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPasc9NWxJpl" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUOTmfQWyXFk" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231_zgu5OFtTpuB1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,849,577&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zF2rDLCvLyih" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOXN8fQ4M1B5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUUzJQw55bdb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztRdSXKnChQb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zE6BOBMv2vt" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0664"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zjL0GunQRlLa" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0665"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z3NlU6vvX9F5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_zvV437GzwiVi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,019,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8hIWi8rxM73" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,399,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPPwnpBFeMx6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzj9PUwJ5Ha" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      unitRef="USD">2089751</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">2089751</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      unitRef="USD">5515920</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">5515920</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_CommercialPaperMember"
      decimals="0"
      unitRef="USD">15385634</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">15385634</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_custom_CorporateBondsandNotesMember"
      decimals="0"
      unitRef="USD">22787651</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateBondsandNotesMember"
      decimals="0"
      unitRef="USD">22787651</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">45778956</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">7605671</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">38173285</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember78957890"
      decimals="0"
      unitRef="USD">795796</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">795796</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">46574752</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">7605671</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">38173285</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">795796</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      unitRef="USD">18399585</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">18399585</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember"
      decimals="0"
      unitRef="USD">449992</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">449992</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">18849577</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">18399585</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">449992</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember78957953"
      decimals="0"
      unitRef="USD">1170051</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">1170051</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">20019628</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">18399585</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">449992</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">1170051</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.99</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.36</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_z1GRdyWmSHB4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(j)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z0dDnmxLUJB4"&gt;Earnings (Loss) per Share&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number
of common shares outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
earnings (loss) per share is based on the weighted average number of common shares outstanding plus, where applicable, the additional
potential common shares that would have been outstanding related to dilutive options, warrants, and unvested restricted stock units to
the extent such shares are dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zh0mh9AeFEj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the years ended December
31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zifCAHpbwzRb" style="display: none"&gt;Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic loss per share attributable
    to common stock:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(634,399&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,964,819&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted avg. common
    shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,934,618&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,688,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic loss per share
    attributable to common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EarningsPerShareBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted loss per share attributable
    to common stock:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(634,399&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,964,819&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted avg. common
    shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,934,618&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,688,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted loss per share
    attributable to common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EarningsPerShareDiluted_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zLNNaS75DF84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlbm6t6zCWj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of diluted earnings per share for the years ended December 31, 2021 and 2020 does not include the following stock options
or warrants to purchase shares in the computation of diluted earnings per share because these instruments were antidilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zPYlHuaGzPrk" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z55tnWWce096" style="width: 12%; text-align: right" title="Stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,551,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjNnM0OoExji" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,564,458&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_znkxwLVqRfxc" style="text-align: right" title="Warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8INJK4Jt5Ok" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,944,366&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zUeuN8yTTBha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
    of Significant Accounting Policies &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zh0mh9AeFEj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the years ended December
31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zifCAHpbwzRb" style="display: none"&gt;Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic loss per share attributable
    to common stock:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(634,399&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,964,819&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted avg. common
    shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,934,618&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,688,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic loss per share
    attributable to common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EarningsPerShareBasic_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted loss per share attributable
    to common stock:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(634,399&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,964,819&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted avg. common
    shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,934,618&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,688,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted loss per share
    attributable to common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EarningsPerShareDiluted_c20200101__20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-634399</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-20964819</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">86934618</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">55688085</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-634399</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-20964819</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">86934618</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">55688085</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlbm6t6zCWj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of diluted earnings per share for the years ended December 31, 2021 and 2020 does not include the following stock options
or warrants to purchase shares in the computation of diluted earnings per share because these instruments were antidilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zPYlHuaGzPrk" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z55tnWWce096" style="width: 12%; text-align: right" title="Stock options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,551,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjNnM0OoExji" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,564,458&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_znkxwLVqRfxc" style="text-align: right" title="Warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8INJK4Jt5Ok" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,944,366&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember78958203"
      decimals="INF"
      unitRef="Shares">4551205</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember78958203"
      decimals="INF"
      unitRef="Shares">3564458</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember78958203"
      decimals="INF"
      unitRef="Shares">1934366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember78958203"
      decimals="INF"
      unitRef="Shares">1944366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWM5TW9qprL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(k)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zcnUAgHnyhYa"&gt;Segment Information&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a single reportable segment engaged in research and development for the delivery of drugs using its proprietary delivery technology.
Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief operating
decision maker made such decisions and assessed performance at the company level, as one segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zznl6ajbLwK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(l)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zDi1AbRxBOTc"&gt;Principles of Consolidation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and all subsidiaries. The Company eliminates all intercompany accounts
and transactions in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80C_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zDZ8A5PlqoDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(3)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_829_z2OmmfwiPND5"&gt;Marketable Investment Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has classified its marketable investment securities as available-for-sale securities, all of which are debt securities. These
securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated
other comprehensive income (loss) in stockholders&#x2019; equity until realized. Gains and losses on investment security transactions
are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized
on an accrual basis. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale
securities by major security type and class of security at December 31, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zYhhdupVx1y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zlKToP0umYdj" style="display: none"&gt;Schedule of Available-for-Sale Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31,
    2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zh6R1Pywus52" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,526,122&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTPOS7Y0GRNb" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSt0V2LJBtv2" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,202&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zWsmdF4CtClg" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,515,920&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate bonds, notes
    and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zrh4uivRxVRj" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,181,099&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zECanzzZzauf" style="border-bottom: Black 1pt solid; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zDZJJgCDoHid" style="border-bottom: Black 1pt solid; text-align: right" title="Gross unrealized holding losses"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,814&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,173,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231_zRLYhI4DOdB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,707,221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231_zi2erJtGwXD4" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231_z5C2aScSAzxi" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding losses"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,016&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231_zo674dFYIaxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,689,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31,
    2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zcXKD0mdHj0c" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zfmwQ7Ptu2Qc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zEm8Ju10QvP4" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zy0Wl78caysi" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231_z44oKmNm6se4" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231_zCZk9GXvGfh5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231_zTTj0o4UIf0b" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0756"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zvpKNGBlTQqk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z4FqzTKuHFtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Marketable Investment
    Securities - (continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zI5k2fXjS3K9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of debt securities classified as available-for-sale securities at December 31, 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zeWynuVtsOre" style="display: none"&gt;Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31,
    2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortized&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20211231_zlWpRuvdhSs5" style="width: 14%; text-align: right" title="Due within one year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,680,635&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pp0p0_c20211231_zR9vYYX5gt6c" style="width: 14%; text-align: right" title="Due within one year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,667,405&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due after one year through
    two years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_iI_pp0p0_c20211231_zhBdsAmY0Vq4" style="border-bottom: Black 1pt solid; text-align: right" title="Due after one year through two years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,026,586&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pp0p0_c20211231_ztqME1Q1iHT2" style="border-bottom: Black 1pt solid; text-align: right" title="Due after one year through two years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,021,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20211231_zZ2qhX8uXf0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,707,221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20211231_zk9zNUdkZmm5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,689,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zaPfCd0mxa4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_90B_eus-gaap--ProceedsFromSaleOfHeldToMaturitySecurities_do_c20210101__20211231_zjde0BaRTh1c"&gt;&lt;span id="xdx_900_eus-gaap--ProceedsFromSaleOfHeldToMaturitySecurities_do_c20200101__20201231_z42o0XpwT7Jj"&gt;no&lt;/span&gt;&lt;/span&gt; sales of marketable investment securities during the years ended December 31, 2021 and 2020 and therefore &lt;span id="xdx_90F_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_do_c20210101__20211231_zjfnl2ujjMfd"&gt;&lt;span id="xdx_90B_eus-gaap--DebtAndEquitySecuritiesRealizedGainLoss_pp0p0_do_c20200101__20201231_zcP7mwHdoGTd"&gt;no&lt;/span&gt;&lt;/span&gt; realized gains or
losses. Additionally, $&lt;span id="xdx_905_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20210101__20211231_zWlE21eczHe3" title="Matured marketable investment securities"&gt;4.7&lt;/span&gt; million and $&lt;span id="xdx_90C_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20200101__20201231_zFxTzOkiO8r4" title="Matured marketable investment securities"&gt;10.2&lt;/span&gt; million of marketable investment securities matured during the years ended December 31,
2021 and 2020, respectively. The Company determined there were &lt;span id="xdx_903_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210101__20211231_zqpKQqt9oRmf" title="Other than temporary impairments"&gt;&lt;span id="xdx_908_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200101__20201231_zaNOEEwscDxi" title="Other than temporary impairments"&gt;no&lt;/span&gt;&lt;/span&gt; other-than-temporary impairments for the years ended December 31, 2021
and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89D_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zYhhdupVx1y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zlKToP0umYdj" style="display: none"&gt;Schedule of Available-for-Sale Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31,
    2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zh6R1Pywus52" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,526,122&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTPOS7Y0GRNb" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zSt0V2LJBtv2" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,202&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zWsmdF4CtClg" style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,515,920&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate bonds, notes
    and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zrh4uivRxVRj" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,181,099&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zECanzzZzauf" style="border-bottom: Black 1pt solid; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zDZJJgCDoHid" style="border-bottom: Black 1pt solid; text-align: right" title="Gross unrealized holding losses"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,814&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,173,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20211231_zRLYhI4DOdB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,707,221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pp0p0_c20211231_zi2erJtGwXD4" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20211231_z5C2aScSAzxi" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding losses"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,016&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20211231_zo674dFYIaxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,689,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31,
    2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zcXKD0mdHj0c" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zfmwQ7Ptu2Qc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zEm8Ju10QvP4" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zy0Wl78caysi" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231_z44oKmNm6se4" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdp0_c20201231_zCZk9GXvGfh5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdp0_di_c20201231_zTTj0o4UIf0b" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0756"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zvpKNGBlTQqk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;449,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562"
      decimals="0"
      unitRef="USD">5526122</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562"
      decimals="0"
      unitRef="USD">10202</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-12-31_us-gaap_USTreasurySecuritiesMember78958562"
      decimals="0"
      unitRef="USD">5515920</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember"
      decimals="0"
      unitRef="USD">38181099</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember"
      decimals="0"
      unitRef="USD">7814</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-12-31_custom_CorporateBondsNotesAndCommercialPaperMember"
      decimals="0"
      unitRef="USD">38173285</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43707221</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">18016</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43689205</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578"
      decimals="0"
      unitRef="USD">449992</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember78958578"
      decimals="0"
      unitRef="USD">449992</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">449992</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">449992</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_890_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zI5k2fXjS3K9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of debt securities classified as available-for-sale securities at December 31, 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zeWynuVtsOre" style="display: none"&gt;Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31,
    2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortized&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20211231_zlWpRuvdhSs5" style="width: 14%; text-align: right" title="Due within one year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,680,635&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pp0p0_c20211231_zR9vYYX5gt6c" style="width: 14%; text-align: right" title="Due within one year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41,667,405&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due after one year through
    two years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_iI_pp0p0_c20211231_zhBdsAmY0Vq4" style="border-bottom: Black 1pt solid; text-align: right" title="Due after one year through two years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,026,586&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pp0p0_c20211231_ztqME1Q1iHT2" style="border-bottom: Black 1pt solid; text-align: right" title="Due after one year through two years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,021,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20211231_zZ2qhX8uXf0h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,707,221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20211231_zk9zNUdkZmm5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,689,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">41680635</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">41667405</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2026586</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2021800</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43707221</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43689205</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:DebtAndEquitySecuritiesRealizedGainLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtAndEquitySecuritiesRealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesRealizedGainLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtAndEquitySecuritiesRealizedGainLoss>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      unitRef="USD">4700000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2020-01-012020-12-31"
      decimals="-5"
      unitRef="USD">10200000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment>
    <us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_806_eus-gaap--BusinessAndContractualArrangementsDisclosureTextBlock_zQRIgrnD8VS7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(4)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82B_zz50gbaFhdGi"&gt;Contractual Agreements&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Abbott
    Products, Inc. &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 29, 2012, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products,
Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations
under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual &lt;span id="xdx_90C_ecustom--CollaborativeArrangementRoyaltiesPercentageOfNetSales_pid_dp_uPure_c20120328__20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_z7Xdni6xm4fj" title="Percentage of net sales"&gt;1&lt;/span&gt;% royalty on net sales. Such
royalties are limited to $&lt;span id="xdx_902_eus-gaap--RoyaltyGuaranteesCommitmentsAmount_iI_pn5n6_c20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_z3JnVNsB6eNk" title="Royalties, commitment amount"&gt;1.0&lt;/span&gt; million in the first two calendar years following product launch, after which period there is not a cap
on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by &lt;span id="xdx_906_ecustom--PercentageOfRoyaltiesReductionBasedUponProductLaunch_pid_dp_uPure_c20120328__20120329__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember__dei--LegalEntityAxis__custom--AbbottProductsIncMember_zfbAgOSAchO8" title="Percentage of royalties reduction based upon product launch"&gt;50&lt;/span&gt;%.
The Company did not incur any royalties owed during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Ant&lt;span style="font-size: 10pt"&gt;ares
    Pharma, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 14, 2021, the Company entered into a license agreement (&#x201c;License Agreement&#x201d;) with Antares Pharma, Inc. (&#x201c;Antares&#x201d;)
pursuant to which the Company granted to Antares an exclusive, royalty-bearing, sublicensable right and license to develop and commercialize,
upon final approval of TLANDO&#xae; from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;), the Company&#x2019;s TLANDO product
with respect to testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone,
as indicated in NDA No. 208088, treatment of Klinefelter syndrome, and pediatric indications relating to testosterone replacement therapy
in males for conditions associated with a deficiency or absence of endogenous testosterone (the &#x201c;Field&#x201d;), in each case within
the United States. The Antares License Agreement also provides Antares with an option, exercisable on or before March 31, 2022, to license
TLANDO XR, the Company&#x2019;s potential once-daily oral product candidate for testosterone replacement therapy. Upon execution of the
Antares License Agreement, Antares paid to the Company an initial payment of $&lt;span id="xdx_907_ecustom--LicenseFee_pn5n6_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zlckk9NqySEk" title="License fee"&gt;11.0&lt;/span&gt; million. Antares will also make additional payments
of $&lt;span id="xdx_90A_ecustom--PotentialLicenseFeesFromALicensee_pn5n6_c20241231__20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z93vpRELylG7" title="Potential license fees from a licensee"&gt;&lt;span id="xdx_90E_ecustom--PotentialLicenseFeesFromALicensee_pn5n6_c20251231__20260101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zz6qXdCAOoQf"&gt;5.0&lt;/span&gt;&lt;/span&gt; million to the Company on each of January 1, 2025, and January 1, 2026, provided that certain conditions are satisfied. The Company
is also eligible to receive milestone payments of up to $&lt;span id="xdx_902_ecustom--SalesMilestoneRevenueRecognized_pn5n6_c20211013__20211014__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNYLTkLwYII7" title="Sales milestone"&gt;160.0&lt;/span&gt; million in the aggregate, depending on the achievement of certain sales
milestones in a single calendar year with respect to all products licensed by Antares under the Antares License Agreement. In addition,
upon commercialization, the Company will receive tiered royalty payments at rates ranging from percentages in the mid-teens to up to
&lt;span id="xdx_90F_ecustom--PercentageOfRoyaltyPayment_dp_uPure_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHgS0fUdWDRh" title="Percentage of royalty payment"&gt;20&lt;/span&gt;% of net sales of TLANDO in the United States, subject to certain minimum royalty obligations. If Antares exercises its option to license
TLANDO XR, the Company will be entitled to an additional payment of $&lt;span id="xdx_90C_ecustom--LicenseFee_pn5n6_c20211013__20211014__dei--LegalEntityAxis__custom--TLANDOXRMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zEJYa7D8Ec5k" title="License fee"&gt;4.0&lt;/span&gt; million, as well as development milestone payments of up to
$&lt;span id="xdx_900_ecustom--ClinicalAndDevelopmentMilestones_pn5n6_c20211013__20211014__dei--LegalEntityAxis__custom--TLANDOXRMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zji15ixhz4Q5" title="Clinical and development milestones"&gt;35.0 &lt;/span&gt;million in the aggregate and tiered royalty payments at rates ranging from percentages in the mid-teens to &lt;span id="xdx_902_ecustom--PercentageOfRoyaltyPayment_dp_uPure_c20211013__20211014__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z8CEA12Zgia9"&gt;20&lt;/span&gt;% of net sales of
TLANDO XR in the United States. The Company retains development and commercialization rights in the rest of the world,
and with respect to applications outside of the Field inside or outside the United States. Antares will also purchase certain existing
inventory of licensed products from the Company, subject to testing and acceptance procedures. Finally, pursuant to the terms of the
Antares License Agreement, Antares is generally responsible for expenses relating to the development (including the conduct of any clinical
trials) and commercialization of licensed products in the Field in the United States, while the Company is generally responsible for
expenses relating to development activities outside of the Field and/or the United States. The Company recognized revenue under the Antares
Licensing Agreement of $&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zNVnux4Z6wA4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16.1
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and &lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_dc_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrZrNQFMKHZ4"&gt;zero
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;during the years ended December 31, 2021 and
2020.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(4) Contractual Agreements &#x2013; (continued)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contract Research and
    Development&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing
development work on behalf of the Company as well as a number of independent contractors, primarily clinical researchers, who serve as
advisors to the Company. The Company incurred expenses of $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20210101__20211231_ziao6C8HwkEj" title="Contract research and development expenses"&gt;4.9&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200101__20201231_z1PlNuagO9H2"&gt;6.8&lt;/span&gt; million under these agreements in 2021 and 2020 and has
recorded these expenses in research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock>
    <lpcn:CollaborativeArrangementRoyaltiesPercentageOfNetSales
      contextRef="From2012-03-282012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember"
      decimals="INF"
      unitRef="Pure">0.01</lpcn:CollaborativeArrangementRoyaltiesPercentageOfNetSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="AsOf2012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember"
      decimals="-5"
      unitRef="USD">1000000.0</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <lpcn:PercentageOfRoyaltiesReductionBasedUponProductLaunch
      contextRef="From2012-03-282012-03-29_us-gaap_CollaborativeArrangementMember_custom_AbbottProductsIncMember"
      decimals="INF"
      unitRef="Pure">0.50</lpcn:PercentageOfRoyaltiesReductionBasedUponProductLaunch>
    <lpcn:LicenseFee
      contextRef="From2021-10-132021-10-14_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">11000000.0</lpcn:LicenseFee>
    <lpcn:PotentialLicenseFeesFromALicensee
      contextRef="From2024-12-312025-01-01_us-gaap_SubsequentEventMember_srt_ScenarioForecastMember_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</lpcn:PotentialLicenseFeesFromALicensee>
    <lpcn:PotentialLicenseFeesFromALicensee
      contextRef="From2025-12-312026-01-01_us-gaap_SubsequentEventMember_srt_ScenarioForecastMember_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</lpcn:PotentialLicenseFeesFromALicensee>
    <lpcn:SalesMilestoneRevenueRecognized
      contextRef="From2021-10-132021-10-14_srt_MaximumMember_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">160000000.0</lpcn:SalesMilestoneRevenueRecognized>
    <lpcn:PercentageOfRoyaltyPayment
      contextRef="From2021-10-132021-10-14_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.20</lpcn:PercentageOfRoyaltyPayment>
    <lpcn:LicenseFee
      contextRef="From2021-10-132021-10-14_custom_TLANDOXRMember_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">4000000.0</lpcn:LicenseFee>
    <lpcn:ClinicalAndDevelopmentMilestones
      contextRef="From2021-10-132021-10-14_custom_TLANDOXRMember_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">35000000.0</lpcn:ClinicalAndDevelopmentMilestones>
    <lpcn:PercentageOfRoyaltyPayment
      contextRef="From2021-10-132021-10-14_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.20</lpcn:PercentageOfRoyaltyPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">16100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      unitRef="USD">4900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2020-01-012020-12-31"
      decimals="-5"
      unitRef="USD">6800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zQKvkvmzQZZh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(5)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_zMQycos3xxMj"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Silicon
Valley Bank Loan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 5, 2018, the Company entered into a Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;) with Silicon
Valley Bank (&#x201c;SVB&#x201d;) pursuant to which SVB agreed to lend the Company $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zOVvC7qymxjj" title="Aggregate amount"&gt;10.0&lt;/span&gt; million. &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zuIBLHcQGrwa"&gt;The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zqAnDtOJc45l" title="Interest rate"&gt;4.25&lt;/span&gt;% as of December
31, 2021), which interest is payable monthly&lt;/span&gt;. Additionally on April 1, 2020, the Company entered into a Deferral Agreement with SVB.
Under the Deferral Agreement, principal repayments were deferred by six months and the Company was only required to make monthly interest
payments. The loan matures on&lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zrDepgky15n7"&gt; June 1, 2022&lt;/span&gt;. Previously, the Company only made monthly interest payments until December 31, 2018, following
which the Company also made equal monthly payments of principal and interest until the signing of the Deferral Agreement. The Company
will also be required to pay an additional final payment at maturity equal to $&lt;span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zAl5cjBWUCIj" title="Debt instrument, balloon payment to be paid"&gt;650,000&lt;/span&gt; (the &#x201c;Final Payment Charge&#x201d;). The
Final Payment Charge will be due on the scheduled maturity date and to date approximately $&lt;span id="xdx_900_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20180104__20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z4ahh4Ejxxki" title="Debt instrument, increase in amount"&gt;644,000&lt;/span&gt; has been recognized as an increase
to the principal balance with a corresponding charge to interest expense with the remaining final payment charge to be recognized over
the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and
Security Agreement (including all accrued and unpaid interest and the Final Payment Charge).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Loan and Security Agreement, the Company granted to SVB a security interest in substantially all of the Company&#x2019;s
assets now owned or hereafter acquired, excluding intellectual property and certain other assets. On September 9, 2021, SVB consented
to the Antares Licensing Agreement which among other things provides Antares a license to certain intellectual property as well as assigns
Antares the TLANDO&#xae; trademark. In addition, as TLANDO was not approved by the United States Food and Drug Administration (&#x201c;FDA&#x201d;)
prior to May 31, 2018, the Company maintained $&lt;span id="xdx_90E_eus-gaap--CashCollateralForBorrowedSecurities_iI_pn5n6_c20210909__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zoZsDKiYAwAb" title="Cash collateral for borrowed securities"&gt;5.0&lt;/span&gt; million of cash collateral at SVB as required under the Loan and Security Agreement
until such time as TLANDO is approved by the FDA. However on February 16, 2021, the Company amended the Loan and Security Agreement with
SVB to, among other things, remove the financial trigger and financial trigger release event provisions requiring the Company to maintain
a minimum cash collateral value and collateral pledge thereof.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentRestrictiveCovenants_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zfhiVxo8AJI9"&gt;While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus &lt;span id="xdx_90F_ecustom--DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_pid_dp_uPure_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zRrdUYO81cm8" title="Debt instrument, basis spread on interest rate for debt default"&gt;5.0&lt;/span&gt;% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.&lt;/span&gt; These events of default include, among other things,
any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the
credit facility, the Company&#x2019;s insolvency, a material adverse change, and one or more judgments against the Company in an amount
greater than $&lt;span id="xdx_90D_ecustom--DebtInstrumentMinimumAmountConsideredForInsolvency_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zfFt52NgKSVd" title="Debt instrument, minimum amount considered for insolvency"&gt;100,000&lt;/span&gt; individually or in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(5)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Loan and Security
    Agreement &#x2013; (continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zZFZync2fV32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
maturities of principal payments on the Loan and Security Agreement at December 31, 2021 (excluding accrued final payment fee) are as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"&gt;&lt;span id="xdx_8B7_zXOhItJPNeWa" style="display: none"&gt;Schedule of Maturities of Debt&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Years
    Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount
    (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_c20211231_z4CAx3eujQC3" style="width: 18%; text-align: right" title="2022"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,667&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_iI_pn3n3_c20211231_zMLi7LLZ77n4" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0835"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LongTermDebt_iI_pn3n3_c20211231_z4Q9n2XBIm03" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zDhm21YfyHc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; color: #212529"&gt;&lt;i&gt;Payroll Protection
Program Loan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;In April 2020, the Company was
granted a loan from SVB in the aggregate amount of $&lt;span id="xdx_901_eus-gaap--ProceedsFromLoans_c20200401__20200430__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramLoanMember_zBEteoi2zFog" title="Proceeds from loans"&gt;233,537&lt;/span&gt;, pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under
Division A, Title I of the CARES Act. On November 2, 2020, we were notified by the Small Business Administration that our PPP loan had
been forgiven.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="-5"
      unitRef="USD">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="From2018-01-042018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (4.25% as of December
31, 2021), which interest is payable monthly</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="INF"
      unitRef="Pure">0.0425</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2018-01-042018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">2022-06-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="0"
      unitRef="USD">650000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="From2018-01-042018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="0"
      unitRef="USD">644000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:CashCollateralForBorrowedSecurities
      contextRef="AsOf2021-09-09_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="-5"
      unitRef="USD">5000000.0</us-gaap:CashCollateralForBorrowedSecurities>
    <us-gaap:DebtInstrumentRestrictiveCovenants contextRef="From2021-01-012021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.</us-gaap:DebtInstrumentRestrictiveCovenants>
    <lpcn:DebtInstrumentBasisSpreadOnInterestRateForDebtDefault
      contextRef="From2021-01-012021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="INF"
      unitRef="Pure">0.050</lpcn:DebtInstrumentBasisSpreadOnInterestRateForDebtDefault>
    <lpcn:DebtInstrumentMinimumAmountConsideredForInsolvency
      contextRef="From2021-01-012021-12-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="0"
      unitRef="USD">100000</lpcn:DebtInstrumentMinimumAmountConsideredForInsolvency>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zZFZync2fV32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
maturities of principal payments on the Loan and Security Agreement at December 31, 2021 (excluding accrued final payment fee) are as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt"&gt;&lt;span id="xdx_8B7_zXOhItJPNeWa" style="display: none"&gt;Schedule of Maturities of Debt&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Years
    Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount
    (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_c20211231_z4CAx3eujQC3" style="width: 18%; text-align: right" title="2022"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,667&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths_iI_pn3n3_c20211231_zMLi7LLZ77n4" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0835"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LongTermDebt_iI_pn3n3_c20211231_z4Q9n2XBIm03" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1667000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromLoans
      contextRef="From2020-04-012020-04-30_custom_PayrollProtectionProgramLoanMember"
      decimals="0"
      unitRef="USD">233537</us-gaap:ProceedsFromLoans>
    <us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_ztMfhpSvSZr7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(6)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82E_zHdSzlYWO1M3"&gt;Property and Equipment &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5ywfB5XUtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z8gitvPuU6x2" style="display: none"&gt;Schedule of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231_zw4fy03YiD61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231_zytAvGVPkjs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_z0bS8UhYvnUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,361&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,361&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabAndOfficeEquipmentMember_z9yrBCMNiS58" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,056,523&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,048,932&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zzp1EOKPsOK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,404&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,404&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzck5_zV1hzCS4AUug" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,151,288&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,143,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzck5_zg5BiWGKy7Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,144,077&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,143,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzck5_z5Ps2EvAZhZh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zN2zJCX47L6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the years ended December 31, 2021 and 2020 was approximately $&lt;span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zc6GOszmxQ94" title="Depreciation expenses"&gt;400&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20200101__20201231_zog0NzJK8Wag" title="Depreciation expenses"&gt;4,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: center; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: center; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5ywfB5XUtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z8gitvPuU6x2" style="display: none"&gt;Schedule of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231_zw4fy03YiD61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231_zytAvGVPkjs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_z0bS8UhYvnUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,361&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,361&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabAndOfficeEquipmentMember_z9yrBCMNiS58" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,056,523&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,048,932&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zzp1EOKPsOK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,404&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,404&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzck5_zV1hzCS4AUug" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,151,288&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,143,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzck5_zg5BiWGKy7Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,144,077&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,143,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzck5_z5Ps2EvAZhZh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_ComputerEquipmentAndSoftwareMember"
      decimals="0"
      unitRef="USD">43361</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_ComputerEquipmentAndSoftwareMember"
      decimals="0"
      unitRef="USD">43361</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_LabAndOfficeEquipmentMember"
      decimals="0"
      unitRef="USD">1056523</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_LabAndOfficeEquipmentMember"
      decimals="0"
      unitRef="USD">1048932</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">51404</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">51404</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1151288</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1143697</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1144077</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1143697</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7211</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">400</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">4000</us-gaap:Depreciation>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zeWiDJPCWEKg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(7)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_823_zOnyqVOZpKf8"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
    Tax Expense &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zcGa9p47QtYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zMBY0FkvtWgg" style="display: none"&gt;Schedule of Income Tax Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20210101__20211231_zlTz3afSK8Hh" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20200101__20201231_zVnKhkv2ZIFa" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_z9zVKIJhGOAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0872"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_zBXsizrDDoAe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBz2PI_z2s2jPCO8hBe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2PI_zZQdFaQud6rl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zaCgtIGhNKoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Tax
    Rate Reconciliation &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense was $&lt;span id="xdx_909_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20210101__20211231_zC5JBnC5fQZ8" title="Income Tax Expense (Benefit)"&gt;200&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20200101__20201231_zjnNmm3H1Knc" title="Income Tax Expense (Benefit)"&gt;200&lt;/span&gt;, respectively, for the years ended December 31, 2021 and 2020 and differed from the amounts computed by
applying the U.S. federal income tax rate of &lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_z8sqATuUBu9c" title="Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20200101__20201231_zkr92eLOiJEg" title="Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"&gt;21&lt;/span&gt;&lt;/span&gt;% for 2021 and 2020, respectively, to pretax income from continuing operations as a result
of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zDNtqVMSaMG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B0_zmwR53YVEyt1"&gt;Schedule of Pretax Income from Continuing Operations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20210101__20211231_zGZGNl2u19z4" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20200101__20201231_zq2eT0S412ff" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz2WU_zjlUzvJdf3Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computed &#x201c;expected&#x201d; tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(133,182&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,402,570&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increase (reduction) in income taxes resulting
    from:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz2WU_z49VUkx4ehfi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;476,431&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,248,002&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz2WU_zICAVJwOmpCe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State and local income
    taxes, net of federal income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;158&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;158&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz2WU_zGb89FhUgTbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,209&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBz2WU_z7qkQTxm1348" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development
    tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(352,163&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(485,254&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--IncomeTaxReconciliationOrphanDrugTaxCredits_iN_di_msITEBz2WU_zFW5mjDyNuP5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Orphan drug tax credit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,797&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_maITEBz2WU_zLtbawSs1mIe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(74,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;607,360&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBz2WU_zyfpIhRBIi0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(48,908&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2WU_zBWrtfoNnljk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zk7UF82BVHMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(7)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
    Taxes &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Significant
    Components of Deferred Taxes &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zIkyhyu3EwK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at
December 31, 2021 and 2020 are presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zxEq3CXcb5vl" style="display: none"&gt;Schedule of Deferred Tax Assets and  Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20211231_zHAPPRlaNbO4" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20201231_zPHOlia1PQJf" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pp0p0_maDTAGz8zG_zcum6fOthJe4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,687,480&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,651,482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGz8zG_zDFHMTWbdLA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,759,890&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,102,326&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pp0p0_maDTAGz8zG_z7UNHcZ7Jawc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;56,009&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,108&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz8zG_zNcbIFbU26ye" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development
    tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,935,609&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,472,003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxAssetsOrphanDrugTaxCredit_iI_pp0p0_maDTAGz8zG_zQDQMHI2Raff" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Orphan drug tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,186,582&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,168,828&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGz8zG_zpjMj48aKwW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;959&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_pp0p0_maDTAGz8zG_zVV2okVSZOR8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    deductible tempory differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;394,636&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,386&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz8zG_maDTALNzp92_zl5rGnopehDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total gross deferred tax
    assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,020,206&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;42,455,092&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLzUYz_zeV6Ef5TbeVk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Plant
    and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,871&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLzUYz_maDTLznVR_zj3oMGKtshoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total gross deferred tax
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,871&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLznVR_msDTALNzp92_zYza23cF6rhf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,871&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0953"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzp92_zRM26uHlpLlh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax asset/deferred
    tax liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,018,335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;42,455,092&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zfpcn5UPZ2Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less
    valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(43,018,335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(42,455,092&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_zZTNEniVMPpi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zmdZhOrpJY18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
valuation allowance for deferred tax assets as of December 31, 2021 and 2020 was $&lt;span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20211231_zrPjfxtAO3n2" title="Deferred Tax Assets, Valuation Allowance"&gt;43.0&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20201231_z0sbYKCZyGO3" title="Deferred Tax Assets, Valuation Allowance"&gt;42.5&lt;/span&gt; million. The net change in the
valuation allowance was an increase of $&lt;span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20210101__20211231_zY6z3HPSydV9" title="Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"&gt;0.5&lt;/span&gt; million in 2021 and an increase of $&lt;span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20200101__20201231_ztYnVZNW3c69" title="Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"&gt;5.2&lt;/span&gt; million in 2020. A valuation allowance has
been provided for the full amount of the Company&#x2019;s net deferred tax assets as the Company believes it is more likely than not that
these benefits will not be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely
than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods),
projected future taxable income, and tax planning strategies in making this assessment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(7)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
    Taxes &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2013, the Company experienced a change in ownership, as defined by the Internal Revenue Code, as amended
(the &#x201c;Code&#x201d;) under Section 382. A change of ownership occurs when ownership of a company increases by more than 50 percentage
points over a three-year testing period of certain stockholders. As a result of this ownership change, we determined that our annual
limitation on the utilization of our federal net operating loss (&#x201c;NOL&#x201d;) and credit carryforwards is approximately $&lt;span id="xdx_90E_ecustom--OperatingLossCarryForwardsLimitationsOnUseAmount_pn5n6_c20210101__20211231_zPh96XzZMDCl" title="Operating Loss Carry forwards Limitations On Use Amount"&gt;1.1&lt;/span&gt; million
per year. We will only be able to utilize $&lt;span id="xdx_909_ecustom--OperatingLossCarryForwardsPreownershipChangeAmount_pn5n6_c20210101__20211231_zaGrT6PvdATf" title="Operating Loss Carry forwards Pre-ownership Change Amount"&gt;20.2&lt;/span&gt; million of our pre-ownership change NOL carryforwards and will forgo utilizing $&lt;span id="xdx_90F_ecustom--OperatingLossForgivePreOwnershipChangeAmount_pn5n6_c20210101__20211231_zJePv2iv7Jz8" title="Operating Loss Forgive Pre-ownership Change Amount"&gt;5.5&lt;/span&gt; million
of our pre-ownership change NOL carryforwards and $&lt;span id="xdx_908_ecustom--TaxCreditCarryforwardPreOwnershipChangeAmount_pn5n6_c20210101__20211231_zHRgd2N1rjla" title="Tax Credit Carryforward Pre-ownership Change Amount"&gt;1.2&lt;/span&gt; million of our pre-change credit carryforwards as a result of this ownership change.
We do not account for forgone NOL and credit carryovers in our deferred tax assets and only account for the NOL and credit carryforwards
that will not expire unutilized as a result of the restrictions of Code Section 382.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, we had NOL and research and development credit carryforwards for U.S. federal income tax reporting purposes of
approximately $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zdMFHbHkDov6" title="Operating Loss Carryforwards"&gt;135.6&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231_zNV0KNET0l2" title="Tax Credit Carryforward, Amount"&gt;3.5&lt;/span&gt; million, respectively. &lt;span id="xdx_904_ecustom--OperatingLossCarryForwardsExpirationDate1_c20210101__20211231_zdEOxoh5dap1" title="Operating Loss Carry forwards Expiration Date1"&gt;Approximately $24.6 million of the NOL will expire between 2023 and 2033
and $70.8 million of the NOL will &lt;span id="xdx_907_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zsSkhfhbNBHb" title="Tax Credit Carryforward, Description"&gt;expire 2034 through 2037&lt;/span&gt;. Pursuant to the Tax Cuts and Jobs Act of 2017, NOL&#x2019;s generated in 2018
and subsequent years have an unlimited carryforward therefore the 2020, 2019 and 2018 NOL of $40.2 million can be carried forward indefinitely.
The research and development credits will begin to &lt;span id="xdx_909_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__custom--UsFederalMember_zrXFoocs2lxh" title="Tax Credit Carryforward, Description"&gt;expire in 2033 through 2041&lt;/span&gt;.&lt;/span&gt; We have orphan drug credit carry forwards of approximately
$&lt;span id="xdx_909_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zaQkm90n4Gk6" title="Tax Credit Carryforward, Amount"&gt;1.2&lt;/span&gt; million which will expire if unused through 2041.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
also have state NOL and research and development credit carry forwards of &lt;span id="xdx_90A_ecustom--OperatingLossCarryForwardsExpirationDate1_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zoXiQH2SUdgl" title="Operating Loss Carry forwards Expiration Date1"&gt;approximately $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z5UvS31SJlR2" title="Operating Loss Carryforwards"&gt;127.1&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkFXkrYVfsD5"&gt;1.4&lt;/span&gt; million, respectively.
None of the Company&#x2019;s state NOL expires in 2022, $34.8 million expires between 2022 and 2029, and $92.3 million will expire in
2030 through 2036&lt;/span&gt;. The state research and development credits &lt;span id="xdx_905_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zTAgtOzFUc89" title="Tax Credit Carryforward, Description"&gt;expire in 2023 through 2035&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s federal and state income tax returns for December 31, 2018 through 2021 are open tax years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zrMt1XP2WiYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending amount of total unrecognized tax contingencies, excluding interest and penalties, for the
years ended December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_8BE_zhUpyaUpcY99" style="display: none"&gt;Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20210101__20211231_zUiHi3opvMJf" style="width: 12%; text-align: right" title="Balance, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"/&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20200101__20201231_z6Lf5Jlzogpb" style="width: 12%; text-align: right" title="Balance, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20210101__20211231_zTcWff85dRF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20200101__20201231_zNkeP3FViH3k" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z0A0ZiZOUyqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zcGa9p47QtYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zMBY0FkvtWgg" style="display: none"&gt;Schedule of Income Tax Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20210101__20211231_zlTz3afSK8Hh" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20200101__20201231_zVnKhkv2ZIFa" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_z9zVKIJhGOAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0872"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_maITEBz2PI_zBXsizrDDoAe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBz2PI_z2s2jPCO8hBe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2PI_zZQdFaQud6rl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zDNtqVMSaMG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B0_zmwR53YVEyt1"&gt;Schedule of Pretax Income from Continuing Operations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20210101__20211231_zGZGNl2u19z4" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20200101__20201231_zq2eT0S412ff" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz2WU_zjlUzvJdf3Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computed &#x201c;expected&#x201d; tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(133,182&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,402,570&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increase (reduction) in income taxes resulting
    from:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz2WU_z49VUkx4ehfi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;476,431&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,248,002&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz2WU_zICAVJwOmpCe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State and local income
    taxes, net of federal income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;158&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;158&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz2WU_zGb89FhUgTbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,209&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBz2WU_z7qkQTxm1348" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development
    tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(352,163&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(485,254&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--IncomeTaxReconciliationOrphanDrugTaxCredits_iN_di_msITEBz2WU_zFW5mjDyNuP5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Orphan drug tax credit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,797&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount_maITEBz2WU_zLtbawSs1mIe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(74,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;607,360&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBz2WU_zyfpIhRBIi0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(48,908&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz2WU_zBWrtfoNnljk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-133182</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-4402570</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">476431</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">4248002</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">158</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">158</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">97697</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">86209</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">352163</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">485254</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <lpcn:IncomeTaxReconciliationOrphanDrugTaxCredits
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">14025</lpcn:IncomeTaxReconciliationOrphanDrugTaxCredits>
    <lpcn:IncomeTaxReconciliationOrphanDrugTaxCredits
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">4797</lpcn:IncomeTaxReconciliationOrphanDrugTaxCredits>
    <lpcn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-74737</lpcn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount>
    <lpcn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">607360</lpcn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">21</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-48908</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zIkyhyu3EwK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at
December 31, 2021 and 2020 are presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zxEq3CXcb5vl" style="display: none"&gt;Schedule of Deferred Tax Assets and  Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20211231_zHAPPRlaNbO4" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20201231_zPHOlia1PQJf" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pp0p0_maDTAGz8zG_zcum6fOthJe4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,687,480&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,651,482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_maDTAGz8zG_zDFHMTWbdLA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,759,890&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,102,326&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pp0p0_maDTAGz8zG_z7UNHcZ7Jawc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;56,009&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,108&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz8zG_zNcbIFbU26ye" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development
    tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,935,609&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,472,003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxAssetsOrphanDrugTaxCredit_iI_pp0p0_maDTAGz8zG_zQDQMHI2Raff" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Orphan drug tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,186,582&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,168,828&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGz8zG_zpjMj48aKwW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;959&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_pp0p0_maDTAGz8zG_zVV2okVSZOR8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    deductible tempory differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;394,636&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,386&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz8zG_maDTALNzp92_zl5rGnopehDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total gross deferred tax
    assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,020,206&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;42,455,092&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLzUYz_zeV6Ef5TbeVk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Plant
    and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,871&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pp0p0_di_mtDITLzUYz_maDTLznVR_zj3oMGKtshoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total gross deferred tax
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,871&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pp0p0_di_mtDTLznVR_msDTALNzp92_zYza23cF6rhf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,871&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0953"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzp92_zRM26uHlpLlh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax asset/deferred
    tax liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,018,335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;42,455,092&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zfpcn5UPZ2Yd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less
    valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(43,018,335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(42,455,092&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_zZTNEniVMPpi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1687480</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1651482</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">34759890</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">35102326</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">56009</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">54108</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4935609</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4472003</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <lpcn:DeferredTaxAssetsOrphanDrugTaxCredit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1186582</lpcn:DeferredTaxAssetsOrphanDrugTaxCredit>
    <lpcn:DeferredTaxAssetsOrphanDrugTaxCredit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1168828</lpcn:DeferredTaxAssetsOrphanDrugTaxCredit>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">959</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">394636</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5386</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43020206</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">42455092</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1871</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1871</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1871</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43018335</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">42455092</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43018335</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">42455092</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">43000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="-5" unitRef="USD">42500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      unitRef="USD">500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2020-01-012020-12-31"
      decimals="-5"
      unitRef="USD">5200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <lpcn:OperatingLossCarryForwardsLimitationsOnUseAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      unitRef="USD">1100000</lpcn:OperatingLossCarryForwardsLimitationsOnUseAmount>
    <lpcn:OperatingLossCarryForwardsPreownershipChangeAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      unitRef="USD">20200000</lpcn:OperatingLossCarryForwardsPreownershipChangeAmount>
    <lpcn:OperatingLossForgivePreOwnershipChangeAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      unitRef="USD">5500000</lpcn:OperatingLossForgivePreOwnershipChangeAmount>
    <lpcn:TaxCreditCarryforwardPreOwnershipChangeAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      unitRef="USD">1200000</lpcn:TaxCreditCarryforwardPreOwnershipChangeAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">135600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">3500000</us-gaap:TaxCreditCarryforwardAmount>
    <lpcn:OperatingLossCarryForwardsExpirationDate1 contextRef="From2021-01-01to2021-12-31">Approximately $24.6 million of the NOL will expire between 2023 and 2033
and $70.8 million of the NOL will expire 2034 through 2037. Pursuant to the Tax Cuts and Jobs Act of 2017, NOL&#x2019;s generated in 2018
and subsequent years have an unlimited carryforward therefore the 2020, 2019 and 2018 NOL of $40.2 million can be carried forward indefinitely.
The research and development credits will begin to expire in 2033 through 2041.</lpcn:OperatingLossCarryForwardsExpirationDate1>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_StateAndLocalJurisdictionMember">expire 2034 through 2037</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_UsFederalMember">expire in 2033 through 2041</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      unitRef="USD">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <lpcn:OperatingLossCarryForwardsExpirationDate1 contextRef="From2021-01-012021-12-31_us-gaap_StateAndLocalJurisdictionMember">approximately $127.1 million and $1.4 million, respectively.
None of the Company&#x2019;s state NOL expires in 2022, $34.8 million expires between 2022 and 2029, and $92.3 million will expire in
2030 through 2036</lpcn:OperatingLossCarryForwardsExpirationDate1>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      unitRef="USD">127100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      unitRef="USD">1400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="From2021-01-012021-12-31_us-gaap_StateAndLocalJurisdictionMember">expire in 2023 through 2035</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zrMt1XP2WiYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending amount of total unrecognized tax contingencies, excluding interest and penalties, for the
years ended December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;span id="xdx_8BE_zhUpyaUpcY99" style="display: none"&gt;Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20210101__20211231_zUiHi3opvMJf" style="width: 12%; text-align: right" title="Balance, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"/&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pp0p0_c20200101__20201231_z6Lf5Jlzogpb" style="width: 12%; text-align: right" title="Balance, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20210101__20211231_zTcWff85dRF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iE_pp0p0_c20200101__20201231_zNkeP3FViH3k" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zoWdVqtnCWg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(8)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_829_zrMQIlcP2qQj"&gt;Leases&lt;/span&gt;&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah.
On May 6, 2014, the Company modified and extended the lease through February 28, 2018, on February 8, 2018, the Company extended the
lease through February 28, 2019, on January 2, 2019, the Company extended the lease through February 29, 2020, on February 24, 2020,
the Company extended the lease through February 28, 2021, on March 3, 2021, the Company extended the lease through February 28, 2022
and on January 24, 2022, the Company extended the lease through February 28, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(8)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
    &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zsIcid4u8rHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments under non-cancelable operating leases as of December 31, 2021 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zREQlESLuq8d" style="display: none"&gt;Schedule of Future Minimum Rental Payments for Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_zcFQWCIVuvmk" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzkOe_zP4kZRmId3Yd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;341,429&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzkOe_zThOAfFeqrb7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,273&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzkOe_z0Rdss1IoBm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;398,702&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z1YlePGZxq09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s rent expense was $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_zakSzmQBalk9" title="Operating Leases, Rent Expense"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseExpense_pp0p0_c20200101__20201231_zG94xE3jZ4S" title="Operating Leases, Rent Expense"&gt;330,000&lt;/span&gt;&lt;/span&gt; for each of the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zsIcid4u8rHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments under non-cancelable operating leases as of December 31, 2021 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zREQlESLuq8d" style="display: none"&gt;Schedule of Future Minimum Rental Payments for Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_zcFQWCIVuvmk" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzkOe_zP4kZRmId3Yd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;341,429&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzkOe_zThOAfFeqrb7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,273&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzkOe_z0Rdss1IoBm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;398,702&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">341429</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">57273</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">398702</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">330000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">330000</us-gaap:OperatingLeaseExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zY6Qg01CFlu5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_zE5uXXelcg31"&gt;Stockholders&#x2019; Equity&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Issuance
    of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 28, 2021, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#x201c;January 2021 Offering&#x201d;). The gross proceeds from the January 2021 Offering were
approximately $&lt;span id="xdx_90E_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zW9MnkFTdCG3" title="Proceeds from issuance of common stock, gross"&gt;28.7&lt;/span&gt; million, before deducting underwriter fees and other offering expenses of $&lt;span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_ziBD1hI17glb" title="Agent fees and other offering expenses"&gt;1.9&lt;/span&gt; million. In the January 2021 Offering,
the Company sold &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zVKPP6m0pEUl" title="Stock issued during period, shares, new issues"&gt;16,428,571&lt;/span&gt; shares of its common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 27, 2020, the Company completed a registered direct offering of securities registered under an effective registration statement
filed pursuant to the Securities Act of 1933, as amended (&#x201c;February 2020 Offering&#x201d;). The gross proceeds from the February
2020 Offering were approximately $&lt;span id="xdx_901_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_ztb5QjljijHa"&gt;6.0&lt;/span&gt; million, before deducting placement agent fees and other offering expenses of $&lt;span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0p0"&gt;347,000&lt;/span&gt;. In the
February 2020 Offering, the Company sold &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200226__20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zaj7yaFLcPDl"&gt;10,084,034&lt;/span&gt; Class A Units at an offering price of $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zijSzmPaaTri"&gt;0.595&lt;/span&gt; per unit, with each Class A Unit consisting
of one share of its common stock and one-half of a common warrant to purchase one share of common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zhcjCZWwzofe"&gt;0.53&lt;/span&gt;
per share of common stock. Additionally, the common stock warrants were immediately exercisable and expire on February 27, 2025. By their
terms, however, the common stock warrants cannot be exercised at any time that the common stock warrant holder would beneficially own,
after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after
giving effect to such exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 18, 2019, the Company completed a public offering of securities registered under an effective registration statement filed
pursuant to the Securities Act of 1933, as amended (&#x201c;November 2019 Offering&#x201d;). The gross proceeds from the November 2019
Offering were approximately $&lt;span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zodRw6NPdQTe" title="Proceeds from issuance of common stock gross"&gt;6.0&lt;/span&gt; million, before deducting placement agent fees and other offering expenses of $&lt;span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zsXx16yUPze6" title="Payment of stock issuance costs"&gt;404,000&lt;/span&gt;. In the
November 2019 Offering, the Company sold (i) &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z3Dng32TJHXi" title="Number of shares issued"&gt;10,450,000&lt;/span&gt; Class A Units, with each Class A Unit consisting of one share of its common
stock and a common warrant to purchase one share of its common stock, and (ii) &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0d_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zb4P1g48fhGd" title="Number of shares issued"&gt;1,550,000&lt;/span&gt; Class B Units, with each Class B Unit
consisting of one pre-funded warrant to purchase one share of its common stock and a common warrant to purchase one share of its
common stock, at a price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z2BPoWiFrdAa"&gt;0.50&lt;/span&gt; per Class A Unit and $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zJMtb6Fx0qCk" title="Share issued price per share"&gt;0.4999&lt;/span&gt; per Class B Unit. The pre-funded warrants, which were exercised for
common stock in December 2019, were issued in lieu of common stock in order to ensure the purchaser did not exceed certain
beneficial ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z7utscgVhyc3" title="Share issued exercise price per share"&gt;.0001&lt;/span&gt; per share,
subject to adjustment. Additionally, the common stock warrants were immediately exercisable at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zHlTDgEwjCZa" title="Warrant exercise price per share"&gt;0.50&lt;/span&gt; per share,
subject to adjustment, and expire on November 17, 2024. By their terms, however, neither the pre-funded warrants nor the common
stock warrants can be exercised at any time that the pre-funded warrant holder or the common stock warrant holder would beneficially
own, after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding
after giving effect to such exercise. On the date of the November 2019 Offering, the Company allocated approximately $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z0lRkAc05yC" title="Stock issued during period value new issues"&gt;768,000&lt;/span&gt; and
$&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zBdEP0chPYbf" title="Stock issued during period value new issues"&gt;4.8&lt;/span&gt; million to common stock/additional paid-in capital and warrant liability, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stockholders&#x2019;
    Equity &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 6, 2017, the Company entered into the Sales Agreement with Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;) pursuant to which
the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to the amount
the Company registered on an effective registration statement pursuant to which the offering is being made. The Company currently has
registered up to $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_dp_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--CantorMember_zqlIbSY3IVNk" title="Common stock sold through ATM offering"&gt;50.0&lt;/span&gt; million for sale under the Sales Agreement, pursuant to the Registration Statement on Form S-3 (File No. 333-250072)
through Cantor as the Company&#x2019;s sales agent. Cantor may sell the Company&#x2019;s common stock by any method permitted by law deemed
to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or
through the Nasdaq Capital Market or any other existing trade market for our common stock, in negotiated transactions at market prices
prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. Cantor uses its
commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell these
shares. The Company pays Cantor &lt;span id="xdx_905_ecustom--PercentageOfGrossProceedOnSaleOfShares_pid_dp_uPure_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--CantorMember_zqjNqKMF9VMa" title="Percentage of gross proceeds on sale of shares"&gt;3.0&lt;/span&gt;% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. In addition,
the Company has also provided Cantor with customary indemnification rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shares of the Company&#x2019;s common stock sold under the Sales Agreement are sold and issued pursuant to the Registration Statement
on Form S-3 (File No. 333-250072) (the &#x201c;Form S-3&#x201d;), which was previously declared effective by the Securities and Exchange
Commission, and the related prospectus and one or more prospectus supplements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is not obligated to make any sales of its common stock under the Sales Agreement. The offering of common stock pursuant to the
Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. The Company and Cantor may each terminate
the Sales Agreement at any time upon ten days&#x2019; prior notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, we had sold an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zUd8oc647D41"&gt;15,023,073
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares at a weighted-average sales price of $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_z9eWNX9pWYVi"&gt;2.19
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share under the Sales Agreement for aggregate
gross proceeds of $&lt;span id="xdx_900_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zAMfashxwgPa"&gt;32.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and net proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zsPrusqolkg2"&gt;31.7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, after deducting sales agent commission
and discounts and our other offering costs. During the year ended December 31, 2021, the Company sold &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zR9cDB9IZ9Xb"&gt;1,811,238
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock pursuant to the current
Registration Statement on Form S-3 (File No. 333-250072) at a weighted-average sales price of $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUDKOFiS06rk"&gt;1.95
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, resulting in net proceeds of approximately
$&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_z7UDMTKarRGi"&gt;3.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million under the Sales Agreement which is net
of $&lt;span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zNABr8VpOWRb"&gt;112,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in expenses. During the year ended December 31,
2020, the Company sold &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z5arr4YaPxs1"&gt;3,746,300
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock pursuant to the current
Registration Statement on Form S-3 (File No. 333-250072) at a weighted average sales price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zCyXsMMx9nl5"&gt;1.41
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, in net proceeds of approximately $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_znqZw5G2hJSa"&gt;5.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million under the Sales Agreement which is net
of $&lt;span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zEAlUKuwdD1i"&gt;148,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in expenses. Additionally, during the
year ended December 31, 2020, the Company sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_zp1Rwn8GLHih"&gt;2,830,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock pursuant to the prior
Registration Statement on Form S-3 (File No. 333-220942) at a weighted average sales price of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember_z9gJxtlDO2H"&gt;1.43
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share under the ATM for aggregate gross proceeds
of $&lt;span id="xdx_90B_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyTIXwN1OyWc"&gt;3.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million which is net of $&lt;span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SaleAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2J0Xw6q6aw4"&gt;165,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in expenses. As of December 31, 2021, the Company
had $&lt;span id="xdx_90E_ecustom--SharesAvailableForFutureIssuance_iI_pn5n6_c20211231_z9hZAuxhy9i5"&gt;41.2&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
available for sale under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Rights
    Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 13, 2015, the Company and American Stock Transfer &amp;amp; Trust Company, LLC, as Rights Agent, entered into a Rights Agreement.
Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock
purchase right (each a &#x201c;Right&#x201d; and collectively, the &#x201c;Rights&#x201d;) for each outstanding share of common stock of
the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered
holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred
Stock of the Company at a price of $&lt;span id="xdx_906_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20151112__20151113_zinpP0LeUJA9"&gt;63.96
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per one-thousandth share (the &#x201c;Purchase
Price&#x201d;). The Rights will generally become exercisable upon the earlier to occur of (i) 10 business days following a public announcement
that a person or group of affiliated or associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days
(or such later date as may be determined by action of the board of directors prior to such time as any person or group of affiliated
or associated persons becomes an Acquiring Person) following the commencement of, or announcement of an intention to make, a tender
offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of the
outstanding common stock of the Company. Except in certain situations, a person or group of affiliated or associated persons becomes
an &#x201c;Acquiring Person&#x201d; upon acquiring beneficial ownership of 15% or more of the outstanding shares of common stock of the
Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stockholders&#x2019;
    Equity &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder
to purchase from the Company, at the Right&#x2019;s then current exercise price, in lieu of shares of Series A Junior Participating Preferred
Stock, common stock of the Company with a market value of twice the Purchase Price. In addition, if after any person has become an Acquiring
Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company&#x2019;s assets, or assets
accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions),
proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain
transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase
Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value
of twice the Purchase Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will be entitled to redeem the Rights at $&lt;span id="xdx_906_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20210101__20211231_zKKal8jomBP5"&gt;0.001&lt;/span&gt; per Right at any time prior to the time an Acquiring Person becomes such. The
terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company&#x2019;s Current Report on Form 8-K dated
November 13, 2015. The rights plan was originally set to expire on November 12, 2018; however, on November 5, 2018 our Board of Directors
approved an Amended and Restated Rights Agreement pursuant to which the expiration date was extended to November 5, 2021 and again on
November 1, 2021, the Company adopted a Second Amended and Restated Rights Agreement pursuant to which the expiration date was extended
to November 1, 2024, unless the rights are earlier redeemed or exchanged by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
    Option Plan &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2014, the board of directors adopted the 2014 Stock and Incentive Plan (&#x201c;2014 Plan&#x201d;) subject to shareholder
approval which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock
appreciation rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20140430__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zVR3ZnzvUmA4" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;1,000,000&lt;/span&gt;
shares are authorized for issuance under the 2014 Plan. Additionally, &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pp0d_c20140430__us-gaap--AwardTypeAxis__custom--TwoThousandElevenEquityIncentivePlanMember_zRqrZ4wvZsvb" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"&gt;271,906&lt;/span&gt;
remaining authorized shares under the 2011 Equity Incentive Plan (&#x201c;2011 Plan&#x201d;) were issuable under the 2014 Plan at the
time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan was amended and restated to increase
the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20160630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zSIUskLolk5e" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;1,271,906&lt;/span&gt;
to &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20160630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zhuUxM7jz5Me" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;2,471,906&lt;/span&gt;.
Additionally, upon receiving shareholder approval in June 2018, the 2014 Plan was further amended and restated to increase the
authorized number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zP4If66TwkI1" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;2,471,906&lt;/span&gt;
to &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_z4JywTCZ2xr6" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;3,221,906&lt;/span&gt;.
Finally, upon receiving shareholder approval in June 2020, the 2014 Plan was further amended and restated to increase the authorized
number of shares of common stock of the Company issuable under all awards granted under the 2014 Plan from &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zuZR5TONn2U2" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;3,221,906&lt;/span&gt;
to &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20200630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zcKSezwdNYy" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;5,721,906&lt;/span&gt;.
The board of directors, on an option-by-option basis, determines the number of shares, exercise price, term, and vesting period.
Options granted generally have a &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtYxL_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_ztYVWYepuHGf" title="Contractual life::XDX::10"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1094"&gt;ten-year&lt;/span&gt;&lt;/span&gt; contractual life. The Company issues shares of common stock upon the exercise of options
with the source of those shares of common stock being either newly issued shares or shares held in treasury. An aggregate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zLjwTcnqTjpl" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;5,721,906&lt;/span&gt;
shares are authorized for issuance under the 2014 Plan, with &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pp0d_c20211231__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zb6wwehGRM5e" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"&gt;857,459&lt;/span&gt; shares remaining available for grant as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stockholders&#x2019;
    Equity &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 38.15pt; text-align: justify; text-indent: 11.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zvn1ofEA7Yd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35in; text-align: justify; text-indent: 11.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zVfkRhu46cP" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z3VAKOe26fE6" style="width: 16%; text-align: right" title="Number of shares, Balance at beginning of the period (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,564,458&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFadEzxSVBa" style="width: 16%; text-align: right" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJRLa9Yvm5Le" style="text-align: right" title="Number of shares, Options granted (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,105,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zC0dl8yucMQf" style="text-align: right" title="Weighted average exercise price, Options granted (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyi4NZbVnGo2" style="text-align: right" title="Number of shares, Options exercised (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,584&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ0ATDXF4zs5" style="text-align: right" title="Weighted average exercise price, Options exercised (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ6Af9kYGFPi" style="text-align: right" title="Number of shares, Options forfeited (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqXuUV5A1hqc" style="text-align: right" title="Weighted average exercise price, Options forfeited (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zarxTSJlD8Aj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Options cancelled (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(114,169&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFOU1WPI4Qbi" style="text-align: right" title="Weighted average exercise price, Options cancelled (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zsPdWzj2jpY8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Balance at end of the period (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,551,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zz6D8hKfsbCa" style="text-align: right" title="Weighted average exercise price, Balance at end of the period (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z5nKHimJAAN2" style="text-align: right" title="Number of shares, Options exercisable (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,799,979&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z1NjUEdqJOR9" style="text-align: right" title="Weighted average exercise price, Options exercisable (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z7eSTcRX8Bh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_gL3SBCABSBPAO-YSO_zTc02wLEcti5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about stock options outstanding and exercisable at December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zY059Cv3gKy7" style="display: none"&gt;Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    exerciseable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_zid0YUQ2izMc" style="width: 37%; text-align: right" title="Number of options outstanding, shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,551,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zNRgLFcTgUv2" title="Options outstanding, Weighted average remaining contractual life (Years)"&gt;6.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zWclQqwsQi0e" style="width: 5%; text-align: right" title="Options outstanding, Weighted average exercise price (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20211231_zl8QHZL0hcUc" style="width: 5%; text-align: right" title="Options outstanding, Aggregate intrinsic value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;315,330&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231_z8xOftRC4dWc" style="width: 5%; text-align: right" title="Number of options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,799,979&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_z3XcmJAzelHi" title="Options exercisable, Weighted average remaining contractual life (Years)"&gt;5.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_znuOcOCBJgGh" title="Options exercisable, Weighted average exercise price"&gt;3.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20211231_zR8R8LFJ2i62" title="Options exercisable, Aggregate intrinsic value"&gt;201,966&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z2GZ9bBYdhvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic
value of stock options exercised during the years ended December 31, 2021 and 2020 was $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0d_c20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNSp3WxxZyq3" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"&gt;2,000&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0d_dc_c20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zc8GJXwNfIYj" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"&gt;zero&lt;/span&gt;. There were &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zKpk9jkKBzA1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"&gt;4,584&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_dc_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zb2Ho2XdRos1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"&gt;zero&lt;/span&gt; stock
options exercised during the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stockholders&#x2019;
    Equity &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(d)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
    Stock Warrants &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its common stock warrants under ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, which requires any financial
instrument, other than an outstanding share, that, at inception, embodies an obligation to repurchase the issuer&#x2019;s equity shares,
or is indexed to such an obligation, and requires or may require the issuer to settle the obligation by transferring assets, to be classified
as a liability. In accordance with ASC 480, the Company&#x2019;s outstanding warrants from the November 2019 Offering are classified as
a liability. The liability is adjusted to fair value at each reporting period, with the changes in fair value recognized as gain (loss)
on change in fair value of warranty liability in the Company&#x2019;s consolidated statements of operations. The warrants issued in the
November 2019 Offering allow the warrant holder, if certain change in control events occur, the option to receive an amount of cash equal
to the value of the warrants as determined in accordance with the Black-Scholes option pricing model with certain defined assumptions
upon a fundamental transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, the Company had &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pp0d_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zd4rVb8mQD25" title="Warrants outstanding"&gt;1,094,030&lt;/span&gt; warrants outstanding from the November 2019 Offering to purchase an equal number of shares
of common stock. The fair value of these warrants on November 18, 2019 (closing date of November 19 Offering) and December 31, 2021 and
2020 was determined using the Black-Scholes option pricing model with the following Level 3 inputs (as defined in the November 2019 Offering):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zEvPtQChTJ97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zOgRmVrh1aWa" style="display: none"&gt;Schedule of Fair Value of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;November
    18, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAPsS00vHhMe" title="Expected life in years"&gt;2.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziJz5nOPUF3a" title="Expected life in years"&gt;3.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQbIwjkMQVBa" title="Expected life in years"&gt;4.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztByE2J85ali" title="Expected life in years"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFE7FUzYtWkk" style="text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxUaVvPT4EKk" style="text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHDDdVxZMSj7" style="text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLVtZmrdWk9d" style="text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5qVPYVYF3tl" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1178"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUcidrlQPARb" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1180"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWnKfM0l9avi" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZexOWkwaMcl" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZMDXMbPRTf3" style="text-align: right" title="Volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3DIpur37q6" style="text-align: right" title="Volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23wXIcrdWt6" style="text-align: right" title="Volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;225.93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wW2zb4T38h" style="text-align: right" title="Volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhB0UQxg4pM1" style="text-align: right" title="Stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1oeVGqZqjTa" style="text-align: right" title="Stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthdPsPhMgC7" style="text-align: right" title="Stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwmlqSCNdHEl" style="text-align: right" title="Stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z33CR1G6NFkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the Company recorded a non-cash gain of $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zWb5I9PHBe5j"&gt;356,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the change in fair value of the November
2019 Offering warrants and during the year ended December 31, 2020, the Company recorded a non-cash loss of $&lt;span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z3su5MKuW8Pf"&gt;2.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million from the change in fair value of the
November 2019 Offering warrants. The following table is a reconciliation of the warrant liability measured at fair value using level
3 inputs:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zmQd9RxGr5i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zDnnjBsG4VSe" style="display: none"&gt;Schedule of Reconciliation of Warrant Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210101__20211231_zDv3a8DJ2Sil" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zQr0kSlwZVDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Settlement of liabilty
    on warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in fair value of common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(355,890&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zVdQIAJDQiA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
in the February 2020 Offering, the Company issued &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0d_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zhNAomONXauj" title="Issued"&gt;5,042,017&lt;/span&gt; common stock warrants. However, the February 2020 Offering warrants do not
provide the warrant holder the option to receive an amount of cash equal to the Black-Scholes value of the warrants upon a fundamental
transaction. Therefore, the Company has not recorded a warrant liability with respect to the warrants issued in the February 2020 Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stockholders&#x2019;
    Equity &#x2013; (continued) &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zATT6IvUm7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zLcTDu6F6Hwc" style="display: none"&gt;Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyR4LcHsJwU5" style="width: 14%; text-align: right" title="Warrants Outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,944,366&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSDb4Y4tlF72" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.51&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z64x2BOBF334" style="text-align: right" title="Warrants, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1222"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1MmTUkNV3M" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1224"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNgd5KreI3Cc" style="text-align: right" title="Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm0aRB4EF4Zg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCEXNcGiL3a" style="text-align: right" title="Warrants, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1230"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYko4Z3XHmrb" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pCAkuC6Eek" style="text-align: right" title="Warrants, Cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1234"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgPoWOB4IIja" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1236"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAl4lEwjFfaa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1238"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z94BuAHnex79" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1240"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy9FdiJrqipe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvgGs2LiMhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zpnxRPK3jWY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2021 and 2020, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zUmAD3AQQBc2" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"&gt;10,000&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pn5n6_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zNhRVNOMb1Gg" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"&gt;15.1&lt;/span&gt; million common stock warrants to purchase one share of our common stock were
exercised, respectively, resulting in proceeds of approximately $&lt;span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zP4mdAcFPT3k" title="Net proceeds from exercise of warrants"&gt;5,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_z6cI5dNhR3Gk" title="Net proceeds from exercise of warrants"&gt;7.7&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about common stock warrants outstanding at December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C08_gL3SBCABSBPAO-YSO_zg5lgEUB0889" style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zp4BjeXkoDMb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in" summary="xdx: Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 22%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjg6oSfxJWz3" style="text-align: right" title="Number of warrants exercisable, shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHhEHKbHN1V5" title="Weighted average remaining contractual life"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zymjBmDFJxw5" style="text-align: right" title="Weighted average exercise price, per share"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztmcKSO1ND52" style="text-align: right" title="Aggregate intrinsic value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;922,629&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify; background-color: white"/&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-indent: -24.5pt"&gt;&lt;span id="xdx_C04_gL3SBCABSBPAO-YSO_z7KR5F00rKa"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <lpcn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember"
      decimals="-5"
      unitRef="USD">28700000</lpcn:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember"
      decimals="-5"
      unitRef="USD">1900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember"
      decimals="INF"
      unitRef="Shares">16428571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <lpcn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2020-02-262020-02-27_custom_February2020OfferingMember"
      decimals="-5"
      unitRef="USD">6000000.0</lpcn:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2020-02-262020-02-27_custom_February2020OfferingMember"
      decimals="0"
      unitRef="USD">347000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-02-262020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember"
      decimals="INF"
      unitRef="Shares">10084034</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.595</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-02-27_us-gaap_CommonStockMember_custom_February2020OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.53</us-gaap:SharesIssuedPricePerShare>
    <lpcn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember"
      decimals="-5"
      unitRef="USD">6000000.0</lpcn:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember"
      decimals="0"
      unitRef="USD">404000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-11-172019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="Shares">10450000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-11-172019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember"
      decimals="0"
      unitRef="Shares">1550000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.4999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-11-172019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember"
      decimals="0"
      unitRef="USD">768000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-11-172019-11-18_us-gaap_AdditionalPaidInCapitalMember_custom_November2019OfferingMember"
      decimals="-5"
      unitRef="USD">4800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2017-03-052017-03-06_custom_SalesAgreementMember_custom_CantorMember"
      decimals="-5"
      unitRef="USD">500000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lpcn:PercentageOfGrossProceedOnSaleOfShares
      contextRef="From2017-03-052017-03-06_custom_SalesAgreementMember_custom_CantorMember"
      decimals="INF"
      unitRef="Pure">0.030</lpcn:PercentageOfGrossProceedOnSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember"
      decimals="INF"
      unitRef="Shares">15023073</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-31_custom_AtMarketOfferingMember"
      decimals="INF"
      unitRef="USDPShares">2.19</us-gaap:SharesIssuedPricePerShare>
    <lpcn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember"
      decimals="-5"
      unitRef="USD">32900000</lpcn:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember"
      decimals="-5"
      unitRef="USD">31700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember"
      decimals="INF"
      unitRef="Shares">1811238</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.95</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SaleAgreementMember"
      decimals="-5"
      unitRef="USD">3400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-012021-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember"
      decimals="0"
      unitRef="USD">112000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember"
      decimals="INF"
      unitRef="Shares">3746300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.41</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SaleAgreementMember"
      decimals="-5"
      unitRef="USD">5100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2020-01-012020-12-31_custom_AtMarketOfferingMember_custom_SalesAgreementMember"
      decimals="0"
      unitRef="USD">148000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember"
      decimals="INF"
      unitRef="Shares">2830000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.43</us-gaap:SharesIssuedPricePerShare>
    <lpcn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember"
      decimals="-5"
      unitRef="USD">3900000</lpcn:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_AtMarketOfferingMember_custom_SaleAgreementMember"
      decimals="0"
      unitRef="USD">165000</us-gaap:PaymentsOfStockIssuanceCosts>
    <lpcn:SharesAvailableForFutureIssuance contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">41200000</lpcn:SharesAvailableForFutureIssuance>
    <lpcn:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="From2015-11-122015-11-13"
      decimals="INF"
      unitRef="USDPShares">63.96</lpcn:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights>
    <lpcn:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</lpcn:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2014-04-30_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2014-04-30_custom_TwoThousandElevenEquityIncentivePlanMember"
      decimals="0"
      unitRef="Shares">271906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">1271906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">2471906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2018-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">2471906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2018-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">3221906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">3221906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">5721906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">5721906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">857459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zvn1ofEA7Yd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35in; text-align: justify; text-indent: 11.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zVfkRhu46cP" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z3VAKOe26fE6" style="width: 16%; text-align: right" title="Number of shares, Balance at beginning of the period (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,564,458&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFadEzxSVBa" style="width: 16%; text-align: right" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJRLa9Yvm5Le" style="text-align: right" title="Number of shares, Options granted (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,105,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zC0dl8yucMQf" style="text-align: right" title="Weighted average exercise price, Options granted (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyi4NZbVnGo2" style="text-align: right" title="Number of shares, Options exercised (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,584&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ0ATDXF4zs5" style="text-align: right" title="Weighted average exercise price, Options exercised (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zJ6Af9kYGFPi" style="text-align: right" title="Number of shares, Options forfeited (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqXuUV5A1hqc" style="text-align: right" title="Weighted average exercise price, Options forfeited (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zarxTSJlD8Aj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Options cancelled (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(114,169&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFOU1WPI4Qbi" style="text-align: right" title="Weighted average exercise price, Options cancelled (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zsPdWzj2jpY8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Balance at end of the period (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,551,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zz6D8hKfsbCa" style="text-align: right" title="Weighted average exercise price, Balance at end of the period (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z5nKHimJAAN2" style="text-align: right" title="Number of shares, Options exercisable (in shares)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,799,979&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z1NjUEdqJOR9" style="text-align: right" title="Weighted average exercise price, Options exercisable (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">3564458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1105500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">4584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">114169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">4551205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">2799979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_gL3SBCABSBPAO-YSO_zTc02wLEcti5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about stock options outstanding and exercisable at December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zY059Cv3gKy7" style="display: none"&gt;Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    exerciseable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231_zid0YUQ2izMc" style="width: 37%; text-align: right" title="Number of options outstanding, shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,551,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zNRgLFcTgUv2" title="Options outstanding, Weighted average remaining contractual life (Years)"&gt;6.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zWclQqwsQi0e" style="width: 5%; text-align: right" title="Options outstanding, Weighted average exercise price (in dollars per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20211231_zl8QHZL0hcUc" style="width: 5%; text-align: right" title="Options outstanding, Aggregate intrinsic value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;315,330&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231_z8xOftRC4dWc" style="width: 5%; text-align: right" title="Number of options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,799,979&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_z3XcmJAzelHi" title="Options exercisable, Weighted average remaining contractual life (Years)"&gt;5.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_znuOcOCBJgGh" title="Options exercisable, Weighted average exercise price"&gt;3.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20211231_zR8R8LFJ2i62" title="Options exercisable, Aggregate intrinsic value"&gt;201,966&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zp4BjeXkoDMb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in" summary="xdx: Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average remaining contractual life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 22%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjg6oSfxJWz3" style="text-align: right" title="Number of warrants exercisable, shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHhEHKbHN1V5" title="Weighted average remaining contractual life"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zymjBmDFJxw5" style="text-align: right" title="Weighted average exercise price, per share"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztmcKSO1ND52" style="text-align: right" title="Aggregate intrinsic value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;922,629&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify; background-color: white"/&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">4551205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-12-31">P6Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">2.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">315330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">2799979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-12-31">P5Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">201966</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">4584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_custom_November2019OfferingMember"
      decimals="0"
      unitRef="Shares">1094030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <lpcn:ScheduleOfFairValueOfWarrantsTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89E_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zEvPtQChTJ97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zOgRmVrh1aWa" style="display: none"&gt;Schedule of Fair Value of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;November
    18, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAPsS00vHhMe" title="Expected life in years"&gt;2.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziJz5nOPUF3a" title="Expected life in years"&gt;3.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQbIwjkMQVBa" title="Expected life in years"&gt;4.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztByE2J85ali" title="Expected life in years"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFE7FUzYtWkk" style="text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxUaVvPT4EKk" style="text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHDDdVxZMSj7" style="text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLVtZmrdWk9d" style="text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5qVPYVYF3tl" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1178"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUcidrlQPARb" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1180"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWnKfM0l9avi" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZexOWkwaMcl" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZMDXMbPRTf3" style="text-align: right" title="Volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3DIpur37q6" style="text-align: right" title="Volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20190101__20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23wXIcrdWt6" style="text-align: right" title="Volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;225.93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wW2zb4T38h" style="text-align: right" title="Volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhB0UQxg4pM1" style="text-align: right" title="Stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1oeVGqZqjTa" style="text-align: right" title="Stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthdPsPhMgC7" style="text-align: right" title="Stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwmlqSCNdHEl" style="text-align: right" title="Stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</lpcn:ScheduleOfFairValueOfWarrantsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P2Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P3Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P4Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">1.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">1.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-012019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">2.2593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">2.2447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.99</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.36</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2019-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.39</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.41</us-gaap:SharePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-12-31_custom_November2019OfferingMember"
      decimals="0"
      unitRef="USD">356000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember"
      decimals="-5"
      unitRef="USD">2900000</us-gaap:FairValueAdjustmentOfWarrants>
    <lpcn:ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_897_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zmQd9RxGr5i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zDnnjBsG4VSe" style="display: none"&gt;Schedule of Reconciliation of Warrant Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210101__20211231_zDv3a8DJ2Sil" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zQr0kSlwZVDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,170,051&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Settlement of liabilty
    on warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in fair value of common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(355,890&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</lpcn:ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1170051</us-gaap:WarrantsAndRightsOutstanding>
    <lpcn:AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-18365</lpcn:AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-355890</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">795796</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_custom_February2020OfferingMember"
      decimals="0"
      unitRef="Shares">5042017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zATT6IvUm7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zLcTDu6F6Hwc" style="display: none"&gt;Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyR4LcHsJwU5" style="width: 14%; text-align: right" title="Warrants Outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,944,366&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSDb4Y4tlF72" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.51&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z64x2BOBF334" style="text-align: right" title="Warrants, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1222"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1MmTUkNV3M" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1224"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNgd5KreI3Cc" style="text-align: right" title="Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm0aRB4EF4Zg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCEXNcGiL3a" style="text-align: right" title="Warrants, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1230"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYko4Z3XHmrb" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pCAkuC6Eek" style="text-align: right" title="Warrants, Cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1234"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgPoWOB4IIja" style="text-align: right" title="Weighted Average Exercise Price, Cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1236"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAl4lEwjFfaa" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1238"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z94BuAHnex79" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1240"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy9FdiJrqipe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvgGs2LiMhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1944366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.51</lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.50</lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1934366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.51</lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantMember"
      decimals="-5"
      unitRef="Shares">15100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantMember"
      decimals="-5"
      unitRef="USD">7700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1934366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.51</lpcn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">922629</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_807_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z54oKRExMkTb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(10)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_821_z2ClBiu43Um"&gt;401(k) Plan&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2002, the Company adopted a tax qualified employee savings and retirement plan (the &#x201c;401(k) Plan&#x201d;) covering eligible
employees. Pursuant to the 401(k) Plan, employees may elect to reduce current compensation by a percentage of eligible compensation,
not to exceed legal limits, and contribute the amount of such reduction to the 401(k) Plan. Beginning April 1, 2014, the 401(k) Plan
was amended to require matching contributions to the 401(k) Plan by the Company on behalf of the participants of &lt;span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20210101__20211231_zKG2l0Y0tb3h" title="Employer matching contribution percent"&gt;100&lt;/span&gt; percent Company
match on up to four percent of an employee&#x2019;s compensation computed on a per pay period basis. The Company contributed $&lt;span id="xdx_907_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20210101__20211231_zAmoxdMrCg5i"&gt;81,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90B_eus-gaap--DefinedContributionPlanCostRecognized_pp0p0_c20200101__20201231_zEOr18p7P7Ld"&gt;67,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, to the 401(k) Plan during the years ended December 31, 2021 and 2020&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020 &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">81000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">67000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z2nzEQHpQBa1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(11)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_zMS30XGrMNWe"&gt;Commitments and Contingencies&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting
business. The Company records a liability when a particular contingency is probable and estimable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 2, 2019, the Company filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that
Clarus&#x2019;s JATENZO&#xae; product infringes six of Lipocine&#x2019;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390;
6,569,463; and 6,923,988. However, on February 11, 2020, the Company voluntarily dismissed allegations of patent infringement
for expired U.S. Patent Nos. 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for dispute. Clarus answered
the complaint and asserted counterclaims of non-infringement and invalidity. The Company answered Clarus&#x2019;s counterclaims on April
29, 2019. The Court held a scheduling conference on August 15, 2019, a claim construction hearing on February 11, 2020, and a
summary judgment hearing on January 15, 2021. In May 2021, the Court granted Clarus&#x2019; motion for Summary Judgment, finding the asserted
claims of Lipocine&#x2019;s U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy the written description
requirement of 35 U.S.C. &#xa7; 112. Clarus still had remaining claims before the Court. On July 13, 2021, the Company entered into the
Global Agreement with Clarus which resolved all outstanding claims of this litigation as well as the on-going United States Patent and
Trademark Office (&#x201c;USPTO&#x201d;) Interference No. 106,128 between the parties. Under the terms of the Global Agreement, the Company
agreed to pay Clarus $&lt;span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember_zolfYP8siak5"&gt;4.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million payable as follows: $&lt;span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember_zhPzxYGF0wKc"&gt;2.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million immediately, $&lt;span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20220712__20220713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zXJz5nRAPvM5"&gt;1.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million on July 13, 2022 and $&lt;span id="xdx_90D_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20230712__20230713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z0MXT6egeGfj"&gt;500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on July 13, 2023. No future royalties are owing
from either party. On July 15, 2021, the Court dismissed with prejudice the Company&#x2019;s claims and Clarus&#x2019; counterclaims.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 14, 2019, the Company and certain of our officers were named as defendants in a purported shareholder class action lawsuit,
&lt;i&gt;Solomon Abady v. Lipocine Inc. et al&lt;/i&gt;., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint
alleges that the defendants made false and/or misleading statements and/or failed to disclose that the Company&#x2019;s filing of the
NDA for TLANDO to the FDA contained deficiencies and as a result the defendants&#x2019; statements about our business and operations were
false and misleading and/or lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class
action (for a purported class of purchasers of the Company&#x2019;s securities from March 27, 2019 through November 8, 2019), compensatory
damages in an unspecified amount, and unspecified equitable or injunctive relief. The Company has insurance that covers claims of this
nature. The retention amount payable by us under our policy is $&lt;span id="xdx_907_ecustom--RetentionPayables_iI_pn4n6_c20191114_z7cJcIb3icG7"&gt;1.25
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. The Company filed a motion to dismiss
this class action lawsuit on July 24, 2020. In response, the plaintiffs filed their response to the motion to dismiss the class action
lawsuit on September 22, 2020, and the Company filed its reply to the motion to dismiss on October 22, 2020. A hearing on the motion
to dismiss occurred on January 12, 2022. The Company intends to vigorously defend ourselves against these allegations and have
not recorded a liability related to this shareholder class action lawsuit as the outcome is not probable nor can an estimate be made
of loss, if any.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 13, 2020, the Company filed U.S. patent application serial number 16/818,779 (the &#x201c;Lipocine &#x2018;779 Application&#x201d;)
with the USPTO. On October 16 and November 3, 2020, the Company filed suggestions for interference with the USPTO requesting that a patent
interference be declared between the Lipocine &#x2018;779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics,
Inc. (the &#x201c;Clarus &#x2018;178 Application&#x201d;). Pursuant to our request, the Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;)
at the USPTO declared the interference on January 4, 2021 to ultimately determine, as between the Company and Clarus, who is entitled
to the claimed subject matter. The interference number is 106,128, and we were initially declared Senior Party. A conference call with
the PTAB was held on January 25, 2021 to discuss proposed motions. On February 1, 2021, the PTAB issued an order authorizing certain
motions and setting the schedule for the preliminary motions phase. On July 13, 2021, the Company entered into the Global Agreement with
Clarus to resolve interference No. 106,128 among other items. On July 26, 2021, the PTAB granted the Company&#x2019;s request for adverse
judgment in interference No. 106,128 in accordance with the Global Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beyond &lt;i&gt;Solomon Abady v. Lipocine Inc. et al&lt;/i&gt;., 2:19-cv-00906-PM, management does not currently believe that any other matter, individually
or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LIPOCINE
INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2021 and 2020 &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(11)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Commitments
    and Contingencies (continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Guarantees
and Indemnifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements,
and certain services agreements, containing standard guarantee and / or indemnifications provisions. Additionally, the Company has indemnified
its directors and officers to the maximum extent permitted under the laws of the State of Delaware.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2019-04-012019-04-02_custom_GlobalAgreementMember"
      decimals="-5"
      unitRef="USD">4000000.0</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2019-04-012019-04-02_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember"
      decimals="-5"
      unitRef="USD">2500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2022-07-122022-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember"
      decimals="-5"
      unitRef="USD">1000000.0</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2023-07-122023-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <lpcn:RetentionPayables contextRef="AsOf2019-11-14" decimals="-4" unitRef="USD">1250000</lpcn:RetentionPayables>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zo3WKAAapzFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(12)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_826_zMTEIN8hRRXa"&gt;Agreement with Spriaso, LLC&lt;/span&gt;&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;The Company has a
license and a services agreement with Spriaso, a related-party that is majority-owned by certain current and former directors of Lipocine
Inc. and their affiliates. Under the license agreement, the Company assigned and transferred to Spriaso all of the Company&#x2019;s rights,
title and interest in its intellectual property to develop products for the cough and cold field. In addition, Spriaso received all rights
and obligations under the Company&#x2019;s product development agreement with a third-party. In exchange, the Company will receive a royalty
of &lt;span id="xdx_90E_ecustom--PercentageOfRoyalty_dp_uPure_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zfnlCptKG6z2" title="Percentage of royalty"&gt;20
&lt;/span&gt;percent of the net proceeds received by Spriaso, up to a maximum of $&lt;span id="xdx_909_eus-gaap--ProceedsFromContributionsFromAffiliates_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_z9wFdO1IybP8"&gt;10.0
&lt;/span&gt;million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside
of the cough and cold field. &lt;span id="xdx_90D_ecustom--AgreementDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zzMntouMJDVf" title="Agreement description"&gt;The
Company also agreed to continue providing up to 10 percent of the services of certain employees to Spriaso for a period of time. The
agreement to provide services expired in 2021;&lt;/span&gt; however, it may be extended upon written agreement of Spriaso and the Company.
The Company did not receive any reimbursements from Spriaso for the years ended December 31, 2021 and 2020, respectively. Additionally,
during the years ended December 31, 2021 and 2020, the Company received $&lt;span id="xdx_90C_ecustom--ProceedsFromReimbursements_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zKmZ7PQsrvs"&gt;55,000
&lt;/span&gt;&lt;span&gt;and
&lt;/span&gt;&lt;span id="xdx_90D_ecustom--ProceedsFromReimbursements_dc_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zaj1BwXdZ8gf" title="Proceeds from reimbursements"&gt;zero&lt;/span&gt;&lt;span&gt;,
respectively, in royalty revenue from Spriaso. Spriaso filed its first NDA and as an affiliated entity of the Company, it used
up the one-time waiver for user fees for a small business submitting its first human drug application to the FDA. Spriaso is considered
a variable interest entity under the FASB ASC Topic 810-10, &lt;i&gt;Consolidations&lt;/i&gt;, however the Company is not the primary beneficiary
and has therefore not consolidated Spriaso.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <lpcn:PercentageOfRoyalty
      contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_SpriasoLLCMember"
      decimals="INF"
      unitRef="Pure">0.20</lpcn:PercentageOfRoyalty>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_SpriasoLLCMember"
      decimals="-5"
      unitRef="USD">10000000.0</us-gaap:ProceedsFromContributionsFromAffiliates>
    <lpcn:AgreementDescription contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember">The
Company also agreed to continue providing up to 10 percent of the services of certain employees to Spriaso for a period of time. The
agreement to provide services expired in 2021;</lpcn:AgreementDescription>
    <lpcn:ProceedsFromReimbursements
      contextRef="From2021-01-012021-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember"
      decimals="0"
      unitRef="USD">55000</lpcn:ProceedsFromReimbursements>
    <lpcn:ProceedsFromReimbursements
      contextRef="From2020-01-012020-12-31_custom_ServiceAgreementMember_custom_SpriasoLLCMember"
      decimals="0"
      unitRef="USD">0</lpcn:ProceedsFromReimbursements>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_800_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zitncuTzd1Y4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(13)&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_zMVHGEF1zYNi"&gt;Accounting Pronouncements&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements Issued Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;i&gt;Measurement of Credit Losses on Financial Instruments
&lt;/i&gt;(&#x201c;ASU 2016-13&#x201d;). This standard replaces the incurred loss impairment methodology in current GAAP with a methodology that
reflects expected credit losses on instruments within its scope, including trade receivables, and requires entities to measure all expected
credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable
forecasts. The original effective date for ASU 2016-13 was for annual and interim periods beginning after December 15, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;However,
in October 2019, the FASB issued ASU 2019-10, &lt;i&gt;Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective
Dates&lt;/i&gt;, which deferred the effective date of ASU 2016-13 for certain entities, including those that are eligible to be smaller reporting
companies&lt;i&gt;.&lt;/i&gt; A company&#x2019;s determination about whether it is eligible for the deferral is a one-time assessment as of November
15, 2019 based on its most recent determination of its small reporting company eligibility as of the last business day of the most recently
completed second quarter. Based on this determination, the Company qualifies as a smaller reporting entity and is therefore eligible
for the deferral of adoption of ASU 2016-13, resulting in a new effective date of January 1, 2023. The Company has historically not had
credit losses on financial instruments and is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !M :50'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  ;0&E4&Z!$(^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)VU%,'1[43PI""XHWD(RNQML_I",M/OVIG&WB^@#>,S,+]]\
M ].K()2/^!Q]P$@&T]5L1Y>$"AMV( H"(*D#6IGJG'"YN?/12LK/N(<@U8?<
M([2<WX!%DEJ2A 58A97(AEXKH2)*\O&$UVK%A\\X%IA6@"-:=)2@J1M@PS(Q
M'.>QAPM@@1%&F[X+J%=BJ?Z)+1U@I^2<S)J:IJF>NI++.S3P]O3X4M:MC$LD
MG<+\*QE!QX ;=I[\VMW=;Q_8T/*VK7A7\=MMTPG.Q77[OKC^\+L(6Z_-SOQC
MX[/@T,.ONQB^ %!+ P04    "  ;0&E4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M !M :50#"WK#H 8  .<;   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9E=<^(V&(6OFU^AH3N=W9D0_ $!MDEF"(26;L+2D.S.MM,+80OPQ):H)(?D
MW_>5,#:;FM?>O=C8QCI^].%S)/EB*^236C.FR4L2<W796&N]^=AJJ6#-$JK.
MQ(9Q^&4I9$(UG,I52VTDHZ$ME,0MSW'.6PF->./JPEZ;R:L+D>HXXFPFB4J3
MA,K7:Q:+[67#;>POW$>KM3876E<7&[IB<Z8?-S,)9ZU<)8P2QE4D.)%L>=D8
MN!]';5O WO$E8EMU<$Q,519"/)F327C9< P1BUF@C02%/\]LR.+8* ''OYEH
M(W^F*7AXO%<?V\I#9194L:&(OT:A7E\V>@T2LB5-8WTOMK^SK$(=HQ>(6-G_
MR79W;[O=($&JM$BRPD"01'SWE[YD#7%0H.<<*>!E!;PW!=QC3_"S G[= NVL
M0-NVS*XJMAU&5-.K"RFV1)J[0<T<V,:TI:'Z$3?]/M<2?HV@G+X:BF<F29,\
MSD?D_;L/Y!V).+F+XA@Z15VT-#S"W-@*,KGKG9QW1,[UR)W@>JW(#0]9^+U
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M'!7U%L*IS' JGF]DH0ONS'ID00EQ'"=A$ W2[C ,LRP;27J\AQQ[(5_FN=Q
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M$GGY_U:+_&$ER@67ZO??4MBZOVOTI7[RR0#2\2OQ\ROLUI8<)O8"*=/3%.2
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M=-+=2=WB'XF35+M(6TC2/O2ZZK:]A],]9,% M"&AB=EM[Z\_)V0)L1T#K5^
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M\<8^KFE146$$].]+SM7NBUE@?S-^_1]02P,$%     @ &T!I5*BR=5N1 P
MJ0<  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RE5=]OVS80?O=?<="
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M .^7&@6]>V #^\^JB[\!4$L#!!0    ( !M :52[B#.\0P8  &4-   9
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ML9D/W+TQ)@GI&MD" 28X<Q2/R,"'7<O>C/J[EHW0=B@*8KD3VVI4_W.Z\.6
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MH+;,,V/D)L]"K2,C%WFVYE4.3I5;2"#4!L._Q@AJG3S)5]!-=RR#[E0&(V\
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M:\"(+I(Z1+8IXD@ H)C:+2GV-@LFU>]UIV(-W7/I C6E*-#VA@3=<34$7KB
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M'^-(ITR*X .@"B2A=^QS5+P AQA #N)0=GC?5!7H8;8=XN%5PBQ)+*RA>&C
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M .\76594-[1 ?=3_W?\!4$L#!!0    ( !M :50>-K]%? ,  #@'   9
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MTX;:&=#]3BE[%ER YF,Y^!=02P,$%     @ &T!I5%67#9[&"0  -A<  !D
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M,#AYF;4+5ZCX$[/3W[SW#28;JJSKE#LBC/H"KM,4W8;HT!R18^^UE_?W!JU
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M;D06[T"/J5,3<KT:OV%:> :(-%^*S]4&X51>B,^JI,?C(3"<3$=CK K(4[R
MN#6?CH/9 *[%>Y7E= @-(WZMK6;5,W1%BZ',IL$<"$X',SF9!-/9+.C/)JW,
M'G1W-_8!>.GW^@/FJM\;S9 ?(\8?9-'M[/[I99,![&GX@5[7TNA2X):G]]WS
M]_4K5_PB<J/+ /MRNW()@^>_GU<OLVK6LCF(PSR)]5?-0O$%_'+F'.4"Z\)<
M\KAZ,D]/TY'+GD$Z\W-VUZ@R>L:U:#17C(/)9! ,^Q,Y"B:@*./)S%;A\$%4
MW/K1=(J?QOSI1W&M7>BE?A74H/M=4 O%G=;7&;]7[<@+$[JI',,MD)"VT-]K
ML:%'W;-5JOSBA#;#5+:"(&\>73W2!F1M!@ _GJ@11H^+:J5-II90M2X'Z*U*
M>HC"WD<G>7F:KW8]\<4]&6*FYH#K7K#@^GFI8UR;#F"%H)\>+24N.'?7_+(K
M>D-!5*BR^4*;6@RX=(>WZ!TJ]4,1!F=% +:7WE,KL8)L&<?B<_$%'[!^\W_
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MU83*0W6#M]L8V;AAMY&&1J=;EO2M@LHJT'DNZ=VPWU@'_=?/\A]02P,$%
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MXYEOYAMGIM.-5(^Z C#DI>9"S_S*F&82ACJOH*;Z7#8@\*:4JJ8&5;4.=:.
M%BZHYF$21<.PIDSX\ZFS+=5\*EO#F8"E(KJM:ZI>%\#E9N;'_LYPS]:5L89P
M/FWH&A[ _&R6"K6P1RE8#4(S*8B"<N9?QI-%9OV=PR\&&[TG$\MD)>6C5;X7
M,S^R!0&'W%@$BL<S7 'G%@C+>-IB^GU*&[@O[]"_.N[(944U7$G^FQ6FFOEC
MGQ10TI:;>[GY!EL^ XN72Z[=+]ETOAEFS%MM9+T-1KUFHCOIR[8/>P'CZ$!
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MB!,K7-J@K />EU*:G6(3]'\#\W]02P,$%     @ &T!I5&%/-;RI!0  U X
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M?S2FES75WJ':B9%+=V^92D.W(#=<T+43E16@]9F49C6Q#OJ+[-F_4$L#!!0
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M80+T_HISM9N8!/U=./H#4$L#!!0    ( !M :53J%"L(L04  *,9   9
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M<>,3 +?BNRSCNW3&]P=7)-+LMJ1)2F5=*)=[,Q^8LE-.V7%..57<?WYOF"P
M/H\UO<N\=#Z7JFY-YG"=B@<=#_?;G9T4=?93A+L8]E"]N]W2W:[3W<=$4)]K
MWOC[5'^[^XZT':7JE8[TG(Y\RPA>.T&65&C! @LJ& \,KTF34L 7F5N+B"1U
M;KG1$5A3(B3 (,XI!_9 0-;2L8?ZI>/]USD>$B; TNR=S/DY$;1F/=3%D$_4
MKR[&9K^[LQ#J!G4/K +H617QG%%\Y9%V*V)J#;0TU.WZT1$$Z*$F[+VIX\VC
MEEX3HS>.6L"*&D(GU@.3SR 4E *6*"JH5(?C<2/!IM>NC\9MITN&G;$@&PMR
M(GU\6>CF2J^;B(7U$;CM+XM%W]\L>M2O6?1%4/\%U':<5N<@=N\@TX[HGN7[
M/8V?J' )&[3*!MOG4D]HY06Z]>647>-&,&O?\^K7V4]8;L=A-0NZ1>LUN\:-
M9 BK/IIC=FC7;CL6*VC0K6A2"?:LY4,PO[9Y*<RW"?1RIW$Y9=#XR*!M_ZT.
M0K=4W6[)AY8,O>-R":R-IK?G VSBSFXX^Z-TH?J[\1S!V@[(ZB-T"^1Q&G/;
M;[0;>B7YM _SF!L+GX:U_?9A112YA6Q:T?H)6>NW:_TB9KAM1LWU!?B2]S G
M$!VRBH?@N8@.62E";O[_G!J'=YLQ"9B4:?V[7P%8[6LA]#K[O7_=0-PYW% B
MJRO(K2M?0OTR3+/WFT56BU/R;@4&G4U@D!48Y"9Y/8GN@]7Z DPB(Y$D"6P\
M%^!1TC"-P*<#&^L(>"'J+D>M@B W?X]T:YMJZ0"TS+;Q5?)0K?2F."GUEN)1
M]VRIMSR,W#S\BZEW@^/CJ;?\BMR<=IN*A*E4)]FX>,M>S+4\)>/8,AOVSI5Q
M;)D,NSOG7\OX$?#NT8QCRX;8S8;WY"\NP"@[W--+?I-I\ ]XR(\:P U-_'E,
MQ'/UQ])@Q!-?AR3R/&;-URG5JAP<G>WD"%O^P^ZSHPD5)@CSQJME055/6FK+
MXT:#QYI9;#D3NVGMBXXSSBKD_]\5LG2).V>KD*5)[.Z$7ULA-UJ_W^S65ZA5
M.;W6R9ME7P$DR Z@\\/;\FGYI>%#=KZ^\WP$K\;Y]P(+DW^^N"=BQG2_$=%0
M0WK-KEX"(O\BD-\HOLC.R)^XTA7,+N>4!%28 ?KWD'.UN3$3E-]EAO\"4$L#
M!!0    ( !M :53:=_QNL0,   00   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;+57WV_;-A#^5PAA#RVP1"(EZT=@&T@4;"O0#D&]; _#'FCI; NA
M1(^D[79__4A9E>Q:8F(W>;%%BO?=?<>[C^)XQ\637 $H]*5DE9PX*Z76-ZXK
MLQ645%[S-53ZS8*+DBH]%$M7K@70O#8JF4L\+W1+6E3.=%S//8CIF&\4*RIX
M$$ANRI**KW? ^&[B8.?;Q.=BN5)FPIV.UW0),U"/ZP>A1VZ+DA<E5++@%1*P
MF#BW^"8E@3&H5_Q9P$X>/"-#9<[YDQE\R">.9R("!IDR$%3_;2$%Q@R2CN/?
M!M1I?1K#P^=OZ+_4Y#69.960<O97D:O5Q(D=E,.";ICZS'>_04-H9/ RSF3]
MBW;[M2%Q4+:1BI>-L8Z@+*K]/_W2).+   <#!J0Q("\U\!L#OR:ZCZRF=4\5
MG8X%WR%A5FLT\U#GIK;6;(K*;.-,"?VVT'9J.M-UD6\8(+Y MUM:,#IG<*7+
MXVI&]>P,LHTH5 $2O;L'I=_+]^@*/<[NT;N?WH]=I4,P0&[6N+O;NR,#[NXA
MNT8^_AD1C^ >\_3EYMZQN:N)M^Q)RY[4>/X WB<JGC2K^3'3OS_J9>B#@E+^
M8W'BMT[\VDDPX.2VY$(5_T&.4BY57\[V]E%M;_IN.PW\R(N(2='V,#L]"X,D
M24B[["C H TPL ;XJ^!2HDVE98#5<:XXRXMJB99:!F1?P%8\HSPW<DTSF#A:
M6B2(+3A3U+?;/XYS1'C4$AY=1ICI>>AEO <,#S)_A6,/A]]MD-7O^83"EE!H
M+['E4L"2*D +6@BTI6P#?2S"$Q:!'\8)\4;?\>A9:"FTJ TSLH;Y.$-_Z)S+
MC?AZU&^?H)R#L/5:W'J(WZZAD]9)\H,-G9RD;S0B(28#^<->I];>*[>J'?#\
MDL0')PM^[2YK$(_;3$O]4-XZG<?D51JD@3G>.3Q*S&G3&T%W"&#[*9!RL>;"
M1'#'JURBW[G2E7E;F2(J2Q!901EZH&L0+^D'W&D[#MZN(W"GJ-@NJ<_W!#Z5
M4#_&,?:29""WG?IAN_Q=T!56P NZHI- ;-? 2[HB.NV**,;!0-HZK<3QZS1%
M?/+9H7<N\DD\&@BA4U)LE])+:I]T:DF\MZM]T@D=L0O=L[6?DE-=LYVGY.#[
MU:YK9U=^:@<\O_))IX#$KH#G5WYJ1[P@V$XVB?V;^(6]D38PSWZ2NP=7-',_
MUJ6YU#N$&"RTH7<=:744^ROG?J#XNKZUS;G2=\#Z<:6OZ2#, OU^P?4!T@S,
M1;"]^$__!U!+ P04    "  ;0&E4H:?8LJ<"  !&!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6R]55MOFS 4_BL6VD,GM>66 *L2I+;9M#Y4JIIU
M>YCVX, A6#4XM0])LU\_VQ":+J1[V?8"OISS7? Y9K(1\E&5 $B>*UZKJ5,B
MKBY<5V4E5%2=BQ74>J<0LJ*HIW+IJI4$FMNDBKN!YT5N15GMI!.[=B?3B6B0
MLQKN)%%-55&YO0(N-E/'=W8+]VQ9HEEPT\F*+F$.^+"ZDWKF]B@YJZ!63-1$
M0C%U+OV+J\3$VX"O##9J;TR,DX40CV9RDT\=SP@"#AD:!*I?:[@&S@V0EO'4
M83H]I4G<'^_0/UGOVLN"*K@6_!O+L9PZB4-R*&C#\5YL/D/G9VSP,L&5?9)-
M%^LY)&L4BJI+U@HJ5K=O^MQ]A[V$P#^2$'0)@=7=$EF5,XHTG4BQ(=)$:S0S
ML%9MMA;':G,H<Y1ZE^D\3.?ZE/.& Q$%N:782(8,E)G-8(%D#MENZ9I3I5C!
M("=4D<LU99PN.)SIPCA35"/LQ9[, /6^>C]Q48LT5&[6";IJ!05'!,T@.R>A
M?TH"+_ ?YC-R\NXW%%=;['T&O<_ PH9'8&_J-2C4U83JM+5&ZYQ\?&H8;O>5
M?[]<*)2Z5GZ\01KVI*$E'1WSTH ^3BQ9340-9 M4#GV0%B2V(*:)UNG(CQ(O
M"L<3=SU /^KI1W^#O@6)7M-'\<@[0C_NZ<=_I*<%@NS9"992-,N2X$;8!36D
M9WR@1Y="-$ZB83E1+R?Z)W*B(3E^XGG#<N)>3ORFG"\"*=>=O-]RN:E+]5*,
MV:N6HX<M]Q)[2F@E)+*?.C83"H><Q(<''<9>' 3^L)6DMY+\7RL%99*L*6]@
MR$9RV"YAE'P(#NK5W;L6S1_FELHEJQ7A4.A4[SS6E2;;6[N=H%C9FW(A4-^[
M=ECJ'QU($Z#W"R%P-S&7;__K3'\!4$L#!!0    ( !M :50'&C$]P0(  %<'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;(U5VVX:,1#]E=&J#XF4
M9&$A4$6 %$+:5&I:%)3VH>J#V1U8*[YL[ &2?GUM+RR0P+8\L+[,G'-F/![W
M5MH\V1R1X$4*9?M13E1<Q;%-<Y3,7N@"E=N9:2,9N:F9Q[8PR++@)$6<-!J=
M6#*NHD$OK(W-H*<7)+C"L0&[D)*9UR$*O>I'S6BS\,#G.?F%>- KV!PG2(_%
MV+A97*%D7**R7"LP..M'U\VKFZZW#P8_.*[LSAA\)%.MG_SD2]:/&EX0"DS)
M(S#W6>(-"N&!G(SG-69447K'W?$&_5.(W<4R919OM/C),\K[T<<(,IRQA: '
MO;K#=3R7'B_5PH9_6)6VG58$Z<*2EFMGIT!R57[9RSH/.P[-SA&'9.V0O'5H
M'W%HK1U:(=!260AKQ(@->D:OP'AKA^8'(3?!VT7#E3_%"1FWRYT?#>Z9>4)B
M4X'P12W1DCLA@@FF"\.)HX63D=OFPL(W9@SS.3^%<WB<C.#DPVDO)J?!(\7I
MFF]8\B5'^)H)W&M%N85;E6&V#Q [\54$R2:"85*+.,+T EK-,T@:2?. H)O_
M=V_4R&E5"6T%O-81O&T6[1F,<$K 5 :WSPM.K[MY_74]M61<%?^N(6U7I.U
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M#XTW</LSK6DS\0356SKX"U!+ P04    "  ;0&E4SDDGA%\$  "D$0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RU6']OVS80_2J$L0$MD%DB_3.%
M;<"QTR9%TAI)NPTH^@<MT;90B51)RG: ??@=)45R8IK1BB4(;(KBNSOR'A^/
M'NV$_*$VC&FT3V*NQJV-UND[SU/!AB54M47*.+Q9"9E0#8]R[:E4,AKFH"3V
MB._WO81&O#49Y7T+.1F)3,<19PN)5)8D5#Y<L%CLQBW<>NRXB]8;;3J\R2BE
M:W;/]-=T(>')JZR$4<*XB@1'DJW&K2E^=T6Z!I"/^#-B.W701F8J2R%^F(?K
M<-SR340L9H$V)BA\;=F,Q;&Q!''\+(VV*I\&>-A^M/X^GSQ,9DD5FXGXKRC4
MFW%KV$(A6]$LUG=B=\7*"?6,O4#$*O]$NV+LH-="0::T2$HP1)!$O/BF^W(A
M#@"X>P) 2@!I"NB4@,YS0/\$H%L"NDT]]$I KRF@7P+Z30&#$C!H"AB6@&&>
MW2(=>2[G5-/)2(H=DF8T6#.-G! Y&E(8<</=>RWA;00X/9D)KB40**,QFJXE
M8\!+K=";.=,TBA7Z1*6DAEYOT1_HZ_T<O?GM[<C3X-G@O:#T<E%X(2>\?*2\
MC7Q\AHA/^A;XK#F\9X'/W?#/@6XCW,WAV *_=,-OJ6PC<F[@F%C@[]WP.0O:
MJ%,$[UO@'YK#;<%?_;)W#ZA2\854?"&YO<[)Q8A3PY<H8.B:JTQ2#JUO-S ,
M76N6J.\.)YW*22=WTCWAY(YM&<\86DF1H$>&PL;0&S3+MP239^AR'\19&/$U
MFBK%X#]$7^C>EI_"V2!W9K1\.X&5V%KBZU;Q=9WQ52%)IAB5P091'H)B;N$H
M2,T&0FP/APM$9<MW]RB<[KEO_JJ@BL0>C^L/GXY[$GRO"K[W0O!Q3)>BV-5H
M"MN;K_-=C[[=LF3)Y'?T#YHNET)KM) BS +0@VL>5*\=">Y7,?1?CT6#RLG
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MAM&023, WJ\$<+A\,'?6ZH>9R;]02P,$%     @ &T!I5,Z+T7,7 @  Q@0
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M[MHX4WDX]QY(U1X685#]FX\>6O:>-7O/.O?V\;S)K3,E)76 :\0IK&/W #1
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MGW(C65:,$ LFU4!2+%=J9@2N#=3_B#&YW>BII)Y"Q_\ 4$L#!!0    ( !M
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MEJ<=:%&[KF$KM.E!W&-IVD20UL"\WPFAGP<V0-=XKOX'4$L#!!0    ( !M
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M&WYY5.@\+!BKDY.P54DWF\^5],36\<OZ]9Q#GS7"0J":E$3Z D,MJ.:ECN^
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M/ A\QD;L=0.V6R?7%.2F.- KK%J>Z?(06S^M/QHNBZ.RW2POOSANN=P@*I+
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MH)Y'C,FW@7Y?4;P!&_X'4$L#!!0    ( !M :50'=[<@N (  /(&   9
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MXS6F1'9XCIG>67*1$J6G8N7*7"!)+"AEKN]Y S<E-'.BT*[-113R0C&:X5R
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M> =Z7FKM#AM_0/\>-/\/4$L#!!0    ( !M :50Z^$L1,0,  '(3   -
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M0 .&1%%]#NZ<1^'JG K7_V4;_0902P,$%     @ &T!I5)>*NQS     $P(
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M_OJDS>-,ZT?V7$EECP9+YU:'PZ$MEE!Q^X=>@?)[YMI4W/E-LQC:E0%>VB6
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MD7EJ0C:YWD_LLQ:9<:ZI"Q/3.-MVY9>4Z5M"GE8.<T)5NW"2)F3LVX1^Y.>
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M<',O87!P+GAM;%!+ 0(4 Q0    ( !M :50;H$0C[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    "  ;0&E4QO\R%CP#  #G"@  &
M    @(&>%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M&T!I5$SD*C]J!0  AA0  !@              ("!$!D  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !M :51@,&2L1 <  !TM   8
M          " @; >  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  ;0&E4?=5ZOY@'   E'P  &               @($J)@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ &T!I5*BR=5N1 P  J0<
M !@              ("!^"T  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+
M 0(4 Q0    ( !M :530%XMTWQ@  ')+   8              " @;\Q  !X
M;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  ;0&E434UZ;1H%
M   )#   &               @('42@  >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&UL4$L! A0#%     @ &T!I5 _)QEXP!@  8@T  !D              ("!
M)%   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  ;0&E4
MNX@SO$,&  !E#0  &0              @(&+5@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !M :50*9U-P. ,  -\&   9
M      " @05=  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ &T!I5$J!31_G!P  O1(  !D              ("!=&   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  ;0&E40Y035J$#  !D"
M&0              @(&2:   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( !M :50&TAA"M0\  /8O   9              " @6IL  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ &T!I5!XVOT5\
M P  . <  !D              ("!5GP  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  ;0&E459<-GL8)   V%P  &0
M@($)@   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !M
M:518Z!MJ+@0  /@(   9              " @0:*  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ &T!I5%HM$L.E @  TP4  !D
M         ("!:XX  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  ;0&E4(FR;7L$9   M4@  &0              @(%'D0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !M :50S07)O_P8  !84
M   9              " @3^K  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ &T!I5-(&SAN6 P  "0D  !D              ("!=;(
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  ;0&E4Y3S)
MP9 "  !^!0  &0              @(%"M@  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( !M :525/*- O0(  !(&   9
M  " @0FY  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M&T!I5&%/-;RI!0  U X  !D              ("!_;L  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  ;0&E4:%^L/6X"  !Z!0  &0
M            @('=P0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( !M :51T6FN"6P4   80   9              " @8+$  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ &T!I5,-Z)<3T @
M_PD  !D              ("!%,H  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  ;0&E4H'"6>, "  !(!P  &0              @($_
MS0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !M :50\
M?!B?V0(  !4(   9              " @3;0  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ &T!I5*)0+,L0!@  &BX  !D
M     ("!1M,  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !M :52AI]BRIP(  $8'   9              "
M@7?I  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ &T!I
M5 <:,3W! @  5P<  !D              ("!5>P  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  ;0&E4SDDGA%\$  "D$0  &0
M        @(%-[P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( !M :53.B]%S%P(  ,8$   9              " @>/S  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ &T!I5'V0QG;?!0  ZQ
M !D              ("!,?8  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  ;0&E4&8[IN P#  "1"@  &0              @(%'_
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !M :51+LU\+
M,P(  !(%   9              " @8K_  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ &T!I5.'4Z4:& @  2P<  !D
M ("!] $! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  ;
M0&E4>= ^L)D#  "$"@  &0              @(&Q! $ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !M :51IE%+?\@,  #<.   9
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M970T.2YX;6Q02P$"% ,4    "  ;0&E4"[3-,B<$   R$@  &0
M    @(',&0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M !M :53@SH(6TP,  %8-   9              " @2H> 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ &T!I5 F*6C<3!   #1,  !D
M             ("!-"(! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    "  ;0&E4!W>W(+@"  #R!@  &0              @(%^)@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !M :51RCWRF90,
M )4-   9              " @6TI 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ &T!I5.@5TWA'"@  TSX  !D              ("!
M"2T! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  ;0&E4
MS@&%;& "  "L!0  &0              @(&'-P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( !M :53L:/-GLP(  $,(   9
M      " @1XZ 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ &T!I5 R] ;Y# P  $PD  !D              ("!"#T! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  ;0&E4.OA+$3$#  !R$P
M#0              @ &"0 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !M
M:527BKL<P    !,"   +              "  =Y# 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( !M :51CUB4E_@0  *<F   /              "  <=$ 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ;0&E4$R?LNN\!  "E(@  &@
M            @ 'R20$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  ;0&E48B/G&-@!  !((@  $P              @ $93 $ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     0@!"  42   B3@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>182</ContextCount>
  <ElementCount>417</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>66</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Marketable Investment Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/MarketableInvestmentSecurities</Role>
      <ShortName>Marketable Investment Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Contractual Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ContractualAgreements</Role>
      <ShortName>Contractual Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Loan and Security Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LoanAndSecurityAgreement</Role>
      <ShortName>Loan and Security Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Agreement with Spriaso, LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/AgreementWithSpriasoLlc</Role>
      <ShortName>Agreement with Spriaso, LLC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/AccountingPronouncements</Role>
      <ShortName>Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lipocine.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Marketable Investment Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/MarketableInvestmentSecuritiesTables</Role>
      <ShortName>Marketable Investment Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/MarketableInvestmentSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Loan and Security Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LoanAndSecurityAgreementTables</Role>
      <ShortName>Loan and Security Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/LoanAndSecurityAgreement</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/PropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails</Role>
      <ShortName>Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails</Role>
      <ShortName>Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Fair Value, Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails</Role>
      <ShortName>Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails</Role>
      <ShortName>Schedule of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails</Role>
      <ShortName>Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Marketable Investment Securities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative</Role>
      <ShortName>Marketable Investment Securities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/MarketableInvestmentSecuritiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Contractual Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ContractualAgreementsDetailsNarrative</Role>
      <ShortName>Contractual Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/ContractualAgreements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails</Role>
      <ShortName>Schedule of Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Loan and Security Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative</Role>
      <ShortName>Loan and Security Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/LoanAndSecurityAgreementTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails</Role>
      <ShortName>Schedule of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of Pretax Income from Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails</Role>
      <ShortName>Schedule of Pretax Income from Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails</Role>
      <ShortName>Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails</Role>
      <ShortName>Schedule of Future Minimum Rental Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/LeasesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Fair Value of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails</Role>
      <ShortName>Schedule of Fair Value of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails</Role>
      <ShortName>Schedule of Reconciliation of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails</Role>
      <ShortName>Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/StockholdersEquityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - 401(k) Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/KPlanDetailsNarrative</Role>
      <ShortName>401(k) Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/KPlan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative</Role>
      <ShortName>Agreement with Spriaso, LLC (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/AgreementWithSpriasoLlc</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>ex4-6.htm</File>
    <File>lpcn-20211231.xsd</File>
    <File>lpcn-20211231_cal.xml</File>
    <File>lpcn-20211231_def.xml</File>
    <File>lpcn-20211231_lab.xml</File>
    <File>lpcn-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>chart_1.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>form10-k_011.jpg</File>
    <File>form10-k_012.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="667">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 182,
   "dts": {
    "calculationLink": {
     "local": [
      "lpcn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lpcn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lpcn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lpcn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lpcn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 519,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 107,
    "http://lipocine.com/20211231": 27,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 137
   },
   "keyCustom": 45,
   "keyStandard": 372,
   "memberCustom": 33,
   "memberStandard": 26,
   "nsprefix": "lpcn",
   "nsuri": "http://lipocine.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://lipocine.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Contractual Agreements",
     "role": "http://lipocine.com/role/ContractualAgreements",
     "shortName": "Contractual Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Loan and Security Agreement",
     "role": "http://lipocine.com/role/LoanAndSecurityAgreement",
     "shortName": "Loan and Security Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Property and Equipment",
     "role": "http://lipocine.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Income Taxes",
     "role": "http://lipocine.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Leases",
     "role": "http://lipocine.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://lipocine.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - 401(k) Plan",
     "role": "http://lipocine.com/role/KPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Commitments and Contingencies",
     "role": "http://lipocine.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Agreement with Spriaso, LLC",
     "role": "http://lipocine.com/role/AgreementWithSpriasoLlc",
     "shortName": "Agreement with Spriaso, LLC",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Accounting Pronouncements",
     "role": "http://lipocine.com/role/AccountingPronouncements",
     "shortName": "Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "role": "http://lipocine.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Marketable Investment Securities (Tables)",
     "role": "http://lipocine.com/role/MarketableInvestmentSecuritiesTables",
     "shortName": "Marketable Investment Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Loan and Security Agreement (Tables)",
     "role": "http://lipocine.com/role/LoanAndSecurityAgreementTables",
     "shortName": "Loan and Security Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Property and Equipment (Tables)",
     "role": "http://lipocine.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Income Taxes (Tables)",
     "role": "http://lipocine.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Leases (Tables)",
     "role": "http://lipocine.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "role": "http://lipocine.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Schedule of Disaggregation of Revenue (Details)",
     "role": "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails",
     "shortName": "Schedule of Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_us-gaap_LicenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CompensationRelatedCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)",
     "role": "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails",
     "shortName": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CompensationRelatedCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://lipocine.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CompensationRelatedCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)",
     "role": "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails",
     "shortName": "Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)",
     "role": "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
     "shortName": "Schedule of Fair Value, Assets Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)",
     "role": "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
     "shortName": "Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_us-gaap_WarrantMember78958203",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_us-gaap_WarrantMember78958203",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "role": "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Schedule of Available-for-Sale Securities (Details)",
     "role": "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
     "shortName": "Schedule of Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)",
     "role": "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails",
     "shortName": "Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Marketable Investment Securities (Details Narrative)",
     "role": "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative",
     "shortName": "Marketable Investment Securities (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-10-012020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Contractual Agreements (Details Narrative)",
     "role": "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
     "shortName": "Contractual Agreements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Maturities of Debt (Details)",
     "role": "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails",
     "shortName": "Schedule of Maturities of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Loan and Security Agreement (Details Narrative)",
     "role": "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative",
     "shortName": "Loan and Security Agreement (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Schedule of Property and Equipment (Details)",
     "role": "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Property and Equipment (Details Narrative)",
     "role": "http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative",
     "shortName": "Property and Equipment (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Income Tax Expense (Details)",
     "role": "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails",
     "shortName": "Schedule of Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Schedule of Pretax Income from Continuing Operations (Details)",
     "role": "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails",
     "shortName": "Schedule of Pretax Income from Continuing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details)",
     "role": "http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails",
     "shortName": "Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Income Taxes (Details Narrative)",
     "role": "http://lipocine.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)",
     "role": "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
     "shortName": "Schedule of Future Minimum Rental Payments for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Leases (Details Narrative)",
     "role": "http://lipocine.com/role/LeasesDetailsNarrative",
     "shortName": "Leases (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Schedule of Stock Option Activity (Details)",
     "role": "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)",
     "role": "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
     "shortName": "Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CompensationRelatedCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - Schedule of Fair Value of Warrants (Details)",
     "role": "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
     "shortName": "Schedule of Fair Value of Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "lpcn:ScheduleOfFairValueOfWarrantsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-11-172019-11-18_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)",
     "role": "http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails",
     "shortName": "Schedule of Reconciliation of Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "lpcn:ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "lpcn:AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)",
     "role": "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
     "shortName": "Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "role": "http://lipocine.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "lpcn:SharesAvailableForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - 401(k) Plan (Details Narrative)",
     "role": "http://lipocine.com/role/KPlanDetailsNarrative",
     "shortName": "401(k) Plan (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-11-14",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "lpcn:RetentionPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-11-14",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "lpcn:RetentionPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_SpriasoLLCMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "lpcn:PercentageOfRoyalty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)",
     "role": "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
     "shortName": "Agreement with Spriaso, LLC (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_custom_LicenseAgreementMember_custom_SpriasoLLCMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "lpcn:PercentageOfRoyalty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://lipocine.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Description of Business",
     "role": "http://lipocine.com/role/DescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://lipocine.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Marketable Investment Securities",
     "role": "http://lipocine.com/role/MarketableInvestmentSecurities",
     "shortName": "Marketable Investment Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 66,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r602",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r602",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r602",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r602",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r602",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "lpcn_AbbottProductsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abbott Products Inc [Member]",
        "label": "Abbott Products Inc [Member]"
       }
      }
     },
     "localname": "AbbottProductsIncMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_AccruedFinalPaymentChargeOnDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued final payment charge on debt.",
        "label": "Accrued final payment charge on debt"
       }
      }
     },
     "localname": "AccruedFinalPaymentChargeOnDebt",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for settlement of liability on warrant exercised.",
        "label": "Settlement of liabilty on warrant exercise"
       }
      }
     },
     "localname": "AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of warrant liability on warrant exercises.",
        "label": "Settlement of warrant liability on warrant exercises"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_AgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement description.",
        "label": "Agreement description"
       }
      }
     },
     "localname": "AgreementDescription",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "lpcn_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Market Offering [Member]",
        "label": "ATM Market Offering [Member]"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_CantorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cantor [Member]",
        "label": "Cantor [Member]"
       }
      }
     },
     "localname": "CantorMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_ClarusTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clarus Therapeutics, Inc [Member]",
        "label": "Clarus Therapeutics, Inc [Member]"
       }
      }
     },
     "localname": "ClarusTherapeuticsIncMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_ClassAUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Unit [Member]",
        "label": "Class A Unit [Member]"
       }
      }
     },
     "localname": "ClassAUnitMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_ClassBUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Units [Member]",
        "label": "Class B Units [Member]"
       }
      }
     },
     "localname": "ClassBUnitsMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Redemption Price of Warrants or Rights",
        "label": "[custom:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights]"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "lpcn_ClinicalAndDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and development milestones.",
        "label": "Clinical and development milestones"
       }
      }
     },
     "localname": "ClinicalAndDevelopmentMilestones",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_CollaborativeArrangementRoyaltiesPercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net sales",
        "label": "Percentage of net sales"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesPercentageOfNetSales",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "lpcn_CommonStockSoldThroughEquityOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sold through equity offering.",
        "label": "Common stock sold through equity offering"
       }
      }
     },
     "localname": "CommonStockSoldThroughEquityOffering",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_CommonStockSoldThroughEquityOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sold through equity offering, shares.",
        "label": "Common stock sold through equity offering, shares"
       }
      }
     },
     "localname": "CommonStockSoldThroughEquityOfferingShares",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "lpcn_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrant [Member]",
        "label": "Common Stock Warrant [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software [Member]",
        "label": "Computer equipment and software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_CorporateBondsNotesAndCommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Notes And Commercial Paper [Member]",
        "label": "Corporate Bonds Notes And Commercial Paper [Member]"
       }
      }
     },
     "localname": "CorporateBondsNotesAndCommercialPaperMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_CorporateBondsandNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds and Notes [Member]",
        "label": "Corporate Bonds and Notes [Member]"
       }
      }
     },
     "localname": "CorporateBondsandNotesMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, basis spread on interest rate for debt default.",
        "label": "Debt instrument, basis spread on interest rate for debt default"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnInterestRateForDebtDefault",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "lpcn_DebtInstrumentMinimumAmountConsideredForInsolvency": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt instrument minimum amount considered for insolvency.",
        "label": "Debt instrument, minimum amount considered for insolvency"
       }
      }
     },
     "localname": "DebtInstrumentMinimumAmountConsideredForInsolvency",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_DeferredTaxAssetsOrphanDrugTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Orphan drug tax credit",
        "label": "Orphan drug tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsOrphanDrugTaxCredit",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Future Minimum Rental Payments For Operating Leases"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://lipocine.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lpcn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for change in warrant liability.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Warrant Liability, Amount",
        "verboseLabel": "Warrant liability"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_February2020OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February2020 Offering [Member]",
        "label": "February 2020 Offering [Member]"
       }
      }
     },
     "localname": "February2020OfferingMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_GlobalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Agreement [Member]",
        "label": "Global Agreement [Member]"
       }
      }
     },
     "localname": "GlobalAgreementMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_IncomeTaxReconciliationOrphanDrugTaxCredits": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.",
        "label": "Income Tax Reconciliation Orphan Drug Tax Credits",
        "negatedLabel": "Orphan drug tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOrphanDrugTaxCredits",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_January2021OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2021 Offering [Member].",
        "label": "January 2021 Offering [Member]"
       }
      }
     },
     "localname": "January2021OfferingMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_LabAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab and office equipment [Member]",
        "label": "Lab and office equipment [Member]"
       }
      }
     },
     "localname": "LabAndOfficeEquipmentMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_LicenseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fee.",
        "label": "License fee"
       }
      }
     },
     "localname": "LicenseFee",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_LitigationSettlementExpenseOne": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement expense one.",
        "label": "Litigation settlement liability"
       }
      }
     },
     "localname": "LitigationSettlementExpenseOne",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan And Security Agreement [Member]",
        "label": "Loan And Security Agreement [Member]"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterFifteenMonths",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_MajorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Customer [Member]",
        "label": "Major Customer [Member]"
       }
      }
     },
     "localname": "MajorCustomerMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_MaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Materials [Member]",
        "label": "Materials [Member]"
       }
      }
     },
     "localname": "MaterialsMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_MinimumGuaranteedRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum guaranteed royalties [Member]",
        "label": "Minimum guaranteed royalties [Member]"
       }
      }
     },
     "localname": "MinimumGuaranteedRoyaltiesMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_NetProceedsFromSaleOfCommonStockThroughATM": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from sale of common stock through ATM.",
        "label": "Net proceeds from sale of common stock through ATM"
       }
      }
     },
     "localname": "NetProceedsFromSaleOfCommonStockThroughATM",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_November2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November 2019 Offering [Member]",
        "label": "November 2019 Offering [Member]"
       }
      }
     },
     "localname": "November2019OfferingMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_OneMajorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One major customer [Member]",
        "label": "One major customer [Member]"
       }
      }
     },
     "localname": "OneMajorCustomerMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_OperatingLossCarryForwardsExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.",
        "label": "Operating Loss Carry forwards Expiration Date1"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationDate1",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "lpcn_OperatingLossCarryForwardsLimitationsOnUseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carry forwards Limitations On Use Amount"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsLimitationsOnUseAmount",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_OperatingLossCarryForwardsPreownershipChangeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carry forwards Pre-ownership Change Amount"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsPreownershipChangeAmount",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_OperatingLossForgivePreOwnershipChangeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of forgiven for pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Forgive Pre-ownership Change Amount"
       }
      }
     },
     "localname": "OperatingLossForgivePreOwnershipChangeAmount",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_PayrollProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll Protection Program Loan [Member]",
        "label": "Payroll Protection Program Loan [Member]"
       }
      }
     },
     "localname": "PayrollProtectionProgramLoanMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_PercentageOfGrossProceedOnSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross proceeds on sale of shares",
        "label": "Percentage of gross proceeds on sale of shares"
       }
      }
     },
     "localname": "PercentageOfGrossProceedOnSaleOfShares",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "lpcn_PercentageOfRoyaltiesReductionBasedUponProductLaunch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties reduction based upon product launch.",
        "label": "Percentage of royalties reduction based upon product launch"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesReductionBasedUponProductLaunch",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "lpcn_PercentageOfRoyalty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty.",
        "label": "Percentage of royalty"
       }
      }
     },
     "localname": "PercentageOfRoyalty",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "lpcn_PercentageOfRoyaltyPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payment.",
        "label": "Percentage of royalty payment"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPayment",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "lpcn_PotentialLicenseFeesFromALicensee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential license fees from a licensee.",
        "label": "Potential license fees from a licensee"
       }
      }
     },
     "localname": "PotentialLicenseFeesFromALicensee",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrants [Member]",
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_ProceedsFromReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from reimbursements.",
        "label": "Proceeds from reimbursements"
       }
      }
     },
     "localname": "ProceedsFromReimbursements",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_RetentionPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retention payables.",
        "label": "[custom:RetentionPayables-0]"
       }
      }
     },
     "localname": "RetentionPayables",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_SaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Agreement [Member]",
        "label": "Sale Agreement [Member]"
       }
      }
     },
     "localname": "SaleAgreementMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement [Member].",
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_SalesBasedRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based royalties [Member]",
        "label": "Sales-based royalties [Member]"
       }
      }
     },
     "localname": "SalesBasedRoyaltiesMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_SalesMilestoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone revenue recognized.",
        "label": "Sales milestone"
       }
      }
     },
     "localname": "SalesMilestoneRevenueRecognized",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_ScheduleOfFairValueOfWarrantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Fair Value Of Warrants [Table Text Block]",
        "label": "Schedule of Fair Value of Warrants"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfWarrantsTableTextBlock",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lpcn_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Reconciliation of Warrant Liability [Table Text Block]",
        "label": "Schedule of Reconciliation of Warrant Liability"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lpcn_ServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Agreement [Member]",
        "label": "Service Agreement [Member]"
       }
      }
     },
     "localname": "ServiceAgreementMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_SettlementOfWarrantLiabilityOnWarrantExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of warrant liability on warrant exercises.",
        "label": "SettlementOfWarrantLiabilityOnWarrantExercises",
        "verboseLabel": "Settlement of warrant liability on warrant exercises"
       }
      }
     },
     "localname": "SettlementOfWarrantLiabilityOnWarrantExercises",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Cancelled Weighted Average Exercise Price",
        "label": "Weighted Average Exercise Price, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Exercise Price",
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Expired Weighted Average Exercise Price",
        "label": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option forfeited weighted average exercise price.",
        "label": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionForfeitedWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average Exercise Price, period",
        "label": "Weighted average exercise price, per share",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lpcn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments cancelled.",
        "label": "Warrants, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lpcn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average Exercise Price, issued.",
        "label": "Weighted Average Exercise Price, Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lpcn_SharesAvailableForFutureIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares available for future issuance.",
        "label": "[custom:SharesAvailableForFutureIssuance-0]"
       }
      }
     },
     "localname": "SharesAvailableForFutureIssuance",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank [Member]",
        "label": "Silicon Valley Bank [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_SpriasoLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spriaso LLC[Member]",
        "label": "Spriaso LLC[Member]"
       }
      }
     },
     "localname": "SpriasoLLCMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_StockIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2014 [Member].",
        "label": "Stock Incentive Plan 2014 [Member]"
       }
      }
     },
     "localname": "StockIncentivePlan2014Member",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for warrant exercises, shares.",
        "label": "Common stock issued for warrant exercises, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "lpcn_StockIssuedDuringPeriodValueWarrantsExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for warrant exercises.",
        "label": "Common stock issued for warrant exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_TLANDOXRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TLANDO XR [Member]",
        "label": "TLANDO XR [Member]"
       }
      }
     },
     "localname": "TLANDOXRMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_TaxCreditCarryforwardPreOwnershipChangeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of pre-change credit carryforwards as a result of this ownership change, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Pre-ownership Change Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardPreOwnershipChangeAmount",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lpcn_TwoThousandElevenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2011 Equity Incentive Plan [Member]",
        "label": "2011 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandElevenEquityIncentivePlanMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "lpcn_UsFederalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Us Federal [Member]",
        "label": "Us Federal [Member]"
       }
      }
     },
     "localname": "UsFederalMember",
     "nsuri": "http://lipocine.com/20211231",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r184",
      "r329",
      "r332",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r260",
      "r298",
      "r350",
      "r352",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r519",
      "r568",
      "r571",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r260",
      "r298",
      "r350",
      "r352",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r519",
      "r568",
      "r571",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r184",
      "r329",
      "r332",
      "r570"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r182",
      "r329",
      "r331",
      "r521",
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r182",
      "r329",
      "r331",
      "r521",
      "r567",
      "r569"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r260",
      "r298",
      "r340",
      "r350",
      "r352",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r519",
      "r568",
      "r571",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r260",
      "r298",
      "r340",
      "r350",
      "r352",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r519",
      "r568",
      "r571",
      "r588",
      "r589"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r119",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r119",
      "r124",
      "r351"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r119",
      "r124",
      "r241",
      "r351",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r486"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium/discount on marketable investment securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r233",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Non-cash interest expense"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r228"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical",
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r49",
      "r50",
      "r51",
      "r556",
      "r576",
      "r579"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r58",
      "r59",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r48",
      "r51",
      "r58",
      "r59",
      "r60",
      "r107",
      "r108",
      "r109",
      "r441",
      "r572",
      "r573",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r389",
      "r486"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r385",
      "r386",
      "r387",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r354",
      "r356",
      "r392",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r356",
      "r381",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation cost"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Warrants"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r165",
      "r174",
      "r180",
      "r210",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r438",
      "r442",
      "r458",
      "r484",
      "r486",
      "r529",
      "r553"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r45",
      "r99",
      "r210",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r438",
      "r442",
      "r458",
      "r484",
      "r486"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r195",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Due after one year through two years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r199",
      "r201",
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through two years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r199",
      "r202",
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Total maturities of debt securities classified as available-for-sale securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r199",
      "r202",
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Total maturities of debt securities classified as available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r199",
      "r200",
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r192",
      "r196",
      "r219",
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Aggregate fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r194",
      "r219"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Marketable investment securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r194",
      "r219"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "verboseLabel": "Marketable investment securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid health care service provider's significant business and contractual arrangements with hospitals, physicians, or other associated entities.",
        "label": "Contractual Agreements"
       }
      }
     },
     "localname": "BusinessAndContractualArrangementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r26",
      "r88"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r81",
      "r88",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r462"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCollateralForBorrowedSecurities": {
     "auth_ref": [
      "r535",
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.",
        "label": "Cash collateral for borrowed securities"
       }
      }
     },
     "localname": "CashCollateralForBorrowedSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r96",
      "r99",
      "r130",
      "r131",
      "r136",
      "r139",
      "r141",
      "r147",
      "r148",
      "r149",
      "r210",
      "r246",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r296",
      "r297",
      "r300",
      "r304",
      "r458",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrant exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r240",
      "r536",
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (notes 5, 8 and 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r243",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r486"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 88,296,360 and 70,041,967 issued and 88,290,650 and 70,036,257 outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r338",
      "r339",
      "r353",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "401(k) Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Share Based Payments"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r65",
      "r539",
      "r563"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r184",
      "r456",
      "r457",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r184",
      "r456",
      "r457",
      "r580",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r184",
      "r456",
      "r457",
      "r580",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r155",
      "r156",
      "r184",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Percentage of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r184",
      "r456",
      "r457",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r318",
      "r319",
      "r330"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r154",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.",
        "label": "Debt and Equity Securities, Realized Gain (Loss)"
       }
      }
     },
     "localname": "DebtAndEquitySecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt - current portion"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r274",
      "r281",
      "r282",
      "r284",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Loan and Security Agreement"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r98",
      "r105",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r287",
      "r288",
      "r289",
      "r290",
      "r473",
      "r530",
      "r532",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r257",
      "r287",
      "r288",
      "r471",
      "r473",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Aggregate amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt instrument, increase in amount"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "auth_ref": [
      "r38",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.",
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r38",
      "r286",
      "r471",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r39",
      "r260",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40",
      "r98",
      "r105",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r287",
      "r288",
      "r289",
      "r290",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt instrument, balloon payment to be paid"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRestrictiveCovenants": {
     "auth_ref": [
      "r104",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of covenants that limit or prohibit certain actions or activities without the lender's prior consent within a specified period of time or until certain specified targets are achieved for example, reduction of the debt or an increase in net worth to a specified amount).",
        "label": "Debt Instrument, Restrictive Covenants"
       }
      }
     },
     "localname": "DebtInstrumentRestrictiveCovenants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Schedule of Available-for-Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r100",
      "r418",
      "r428",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r13",
      "r14",
      "r408",
      "r531",
      "r551"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax asset/deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r414",
      "r416",
      "r417"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Other deductible tempory differences"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r414",
      "r416",
      "r417"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Employee benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r399",
      "r411"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/KPlanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Employer matching contribution percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/KPlanDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r86",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expenses"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r86",
      "r226"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r127",
      "r130",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r451",
      "r452",
      "r540",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic loss per share attributable to common stock"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r130",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r451",
      "r452",
      "r540",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted loss per share attributable to common stock"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r101",
      "r401",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period of stock option plan"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r58",
      "r59",
      "r60",
      "r107",
      "r108",
      "r109",
      "r113",
      "r121",
      "r123",
      "r146",
      "r211",
      "r311",
      "r313",
      "r385",
      "r386",
      "r387",
      "r421",
      "r422",
      "r450",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r572",
      "r573",
      "r574",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r86",
      "r294"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Non-cash loss (gain) on change in fair value of warrant liability",
        "terseLabel": "Fair Value Adjustment of Warrants",
        "verboseLabel": "Change in fair value of common stock warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails",
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r454",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r272",
      "r341",
      "r342",
      "r347",
      "r348",
      "r454",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r341",
      "r342",
      "r347",
      "r348",
      "r454",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r454",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r100",
      "r400"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "U.S. federal"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r207",
      "r208",
      "r209",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r283",
      "r309",
      "r447",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r86",
      "r291",
      "r292"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on extinguishment of debt",
        "negatedLabel": "Non-cash gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organizations [Abstract]"
       }
      }
     },
     "localname": "HealthCareOrganizationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r225",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Accounting for Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r165",
      "r173",
      "r176",
      "r179",
      "r181",
      "r526",
      "r537",
      "r542",
      "r565"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r230",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r402",
      "r406",
      "r413",
      "r426",
      "r432",
      "r434",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r122",
      "r123",
      "r164",
      "r400",
      "r427",
      "r433",
      "r566"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails",
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r397",
      "r398",
      "r406",
      "r407",
      "r412",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Computed \u201cexpected\u201d tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Stock expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State and local income taxes, net of federal income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPretaxIncomeFromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Accrued interest income"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r61",
      "r163",
      "r470",
      "r472",
      "r541"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r80",
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Accrued interest income"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r69",
      "r162"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest and investment income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r527",
      "r548",
      "r581",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Marketable Investment Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r99",
      "r175",
      "r210",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r439",
      "r442",
      "r443",
      "r458",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r99",
      "r210",
      "r458",
      "r486",
      "r533",
      "r558"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r99",
      "r210",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r439",
      "r442",
      "r443",
      "r458",
      "r484",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r32",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r32",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r41",
      "r240",
      "r242"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Litigation settlement liability - current portion"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveNoncurrent": {
     "auth_ref": [
      "r41",
      "r240"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.",
        "label": "Litigation settlement liability - non-current portion"
       }
      }
     },
     "localname": "LitigationReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "negatedLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r12",
      "r271",
      "r285",
      "r287",
      "r288",
      "r532",
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r105",
      "r245",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Debt - non-current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeInsuranceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Malpractice Insurance [Line Items]"
       }
      }
     },
     "localname": "MalpracticeInsuranceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r84",
      "r87"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r52",
      "r54",
      "r60",
      "r64",
      "r87",
      "r99",
      "r112",
      "r116",
      "r117",
      "r118",
      "r119",
      "r122",
      "r123",
      "r137",
      "r165",
      "r173",
      "r176",
      "r179",
      "r181",
      "r210",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r452",
      "r458",
      "r538",
      "r562"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r127",
      "r128",
      "r138",
      "r141",
      "r165",
      "r173",
      "r176",
      "r179",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r129",
      "r132",
      "r133",
      "r134",
      "r135",
      "r138",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r110",
      "r111",
      "r114",
      "r115",
      "r124",
      "r125",
      "r126",
      "r190",
      "r191",
      "r212",
      "r213",
      "r333",
      "r334",
      "r335",
      "r336",
      "r388",
      "r423",
      "r424",
      "r425",
      "r449",
      "r459",
      "r460",
      "r461",
      "r478",
      "r522",
      "r523",
      "r524",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r173",
      "r176",
      "r179",
      "r181"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r295",
      "r445",
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "auth_ref": [
      "r295",
      "r445",
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different types of options indexed to an issuer's equity along with the different attributes of those options.",
        "label": "Option Indexed to Issuer's Equity, Equity [Table]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Option Indexed to Issuer's Equity [Line Items]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTable": {
     "auth_ref": [
      "r295",
      "r445",
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Freestanding contracts issued by an Entity that are indexed to, and potentially settled in, an Entity's own stock by the different attributes of these freestanding contracts, including the strike price, number of shares, and settlement dates.",
        "label": "Option Indexed to Issuer's Equity [Table]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r295",
      "r445",
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/DescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r46",
      "r47",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "negatedLabel": "Unrealized net gain (loss) on marketable investment securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r49"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized net gain (loss) on available-for-sale securities",
        "verboseLabel": "Unrealized net loss on marketable investment securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an increase to the cumulative amount of credit losses recognized in earnings for an other than temporary impairment (OTTI) of a debt security held for which no such other than temporary impairment (OTTI) was previously recognized.",
        "label": "Other than temporary impairments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payment of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r71",
      "r73",
      "r193"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r486"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from sale of common stock sold in equity offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoans": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from principal payments made on loans related to operating activities.",
        "label": "Proceeds from loans"
       }
      }
     },
     "localname": "ProceedsFromLoans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r71",
      "r72",
      "r193"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Maturities of marketable investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Matured marketable investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r72",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.",
        "label": "Proceeds from Sale of Held-to-maturity Securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r384"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Net proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r224",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r227"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r229",
      "r486",
      "r549",
      "r559"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net of accumulated depreciation of $1,144,077 and $1,143,697 respectively",
        "totalLabel": "Property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets",
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r229",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r8",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r8",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r185",
      "r187",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Agreement with Spriaso, LLC"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Debt repayments"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r395",
      "r520",
      "r590"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Contract research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r7",
      "r88",
      "r91",
      "r528",
      "r555"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r313",
      "r389",
      "r486",
      "r557",
      "r575",
      "r579"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r107",
      "r108",
      "r109",
      "r113",
      "r121",
      "r123",
      "r211",
      "r385",
      "r386",
      "r387",
      "r421",
      "r422",
      "r450",
      "r572",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r172",
      "r177",
      "r178",
      "r182",
      "r183",
      "r184",
      "r328",
      "r329",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenues",
        "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r62",
      "r99",
      "r160",
      "r161",
      "r172",
      "r177",
      "r178",
      "r182",
      "r183",
      "r184",
      "r210",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r458",
      "r542"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalties, commitment amount"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r155",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Pretax Income from Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r356",
      "r380",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMalpracticeInsuranceTable": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance coverage used by the entity to manage the financial risk of malpractice claims (including general and professional liability).",
        "label": "Schedule of Malpractice Insurance [Table]"
       }
      }
     },
     "localname": "ScheduleOfMalpracticeInsuranceTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Key Assumption of Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r316",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r405",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Reconciliation of the Beginning and Ending Amount of Total Unrecognized Tax Contingencies, Excluding Interest and Penalties"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Warrants outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "strike price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility",
        "terseLabel": "Volatility",
        "verboseLabel": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate",
        "verboseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Warrants, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Warrants, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Warrants, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Warrants, Issued",
        "verboseLabel": "Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Number of warrants exercisable, shares",
        "periodEndLabel": "Warrants Outstanding, Ending",
        "periodStartLabel": "Warrants Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based compensation arrangement by share-based payment award, number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based compensation arrangement by share-based payment award, number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of options exercisable",
        "periodEndLabel": "Number of shares, Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Options exercisable, Weighted average exercise price",
        "periodEndLabel": "Weighted average exercise price, Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of shares, Options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Number of shares, Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Number of stock options issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares, Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average fair value of share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding, Aggregate intrinsic value",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r363",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of options outstanding, shares",
        "periodEndLabel": "Number of shares, Balance at end of the period (in shares)",
        "periodStartLabel": "Number of shares, Balance at beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Options outstanding, Weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Weighted average exercise price, Balance at end of the period (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, Balance at beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r355",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, Options cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Fair value of common stock",
        "verboseLabel": "Stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r375",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years",
        "verboseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Options exercisable, Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable, Weighted average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options outstanding, Weighted average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Share issued exercise price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r92",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r100",
      "r400",
      "r427"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State and local"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r96",
      "r99",
      "r130",
      "r131",
      "r136",
      "r139",
      "r141",
      "r147",
      "r148",
      "r149",
      "r210",
      "r246",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r296",
      "r297",
      "r300",
      "r304",
      "r311",
      "r458",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r43",
      "r58",
      "r59",
      "r60",
      "r107",
      "r108",
      "r109",
      "r113",
      "r121",
      "r123",
      "r146",
      "r211",
      "r311",
      "r313",
      "r385",
      "r386",
      "r387",
      "r421",
      "r422",
      "r450",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r572",
      "r573",
      "r574",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r146",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r311",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock sold through ATM offering, shares",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r311",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Vesting of restricted stock units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r311",
      "r313",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Option exercises, shares",
        "negatedLabel": "Number of shares, Options exercised (in shares)",
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, exercises in period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r311",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Common stock sold through ATM offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r16",
      "r17",
      "r311",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r311",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r99",
      "r186",
      "r210",
      "r458",
      "r486"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r313",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r469",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r469",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r469",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Description"
       }
      }
     },
     "localname": "TaxCreditCarryforwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r203",
      "r204",
      "r207",
      "r208",
      "r209",
      "r283",
      "r309",
      "r447",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r42",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r42",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r42",
      "r314",
      "r315"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock at cost, 5,710 shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r103",
      "r341",
      "r348",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized gain (loss) on warrant liability"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r396",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfReconciliationOfBeginningAndEndingAmountOfTotalUnrecognizedTaxContingenciesExcludingInterestAndPenaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrant liability",
        "periodEndLabel": "Balance at December 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets",
      "http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r129",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average common shares outstanding, diluted",
        "verboseLabel": "Weighted avg. common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r127",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding,",
        "verboseLabel": "Weighted avg. common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "http://asc.fasb.org/subtopic&trid=2289226"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r591": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r592": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r593": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r594": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r595": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r596": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r597": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r599": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r600": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r601": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r602": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r603": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r604": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r605": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r606": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r607": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r608": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r609": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r610": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r611": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r612": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r613": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r614": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r615": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r616": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r617": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r618": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001493152-22-006353-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-006353-xbrl.zip
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MV1)4\LJ)Q)+&@<$^K]_;?'B]Y*4DU>79BIQ($NHTD]^-$M%N\,<#<1*9E8Q
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M]^D^E2T2+C&$XFSN,F Y,3336GWKWI#&>"EKC)QCLD]M,I4:]TEJA+W$K?6
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M7QI54/*NHN_.;S=/*&_VKB:LY4K,:W3L6)&+=I4VGWU5:3PZ 1#R-Q'FC6&
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ML*<VRY\,N&C,Q?L3<1US^GL-HQA*.5FND%JR1O9M3>42C7OLWENG%T1_3TM
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M$4[I'_#S\]P=BC@&R,9D2P:(&=J,, &FS'@_A]ED^\.)+[76+A5?'M8>HL0
M@HM.K:N' NOA_5]>$OZ TFHE5^AO<_\(>0[&#9H=%+,7%U2=\[AICV)^^BE
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M*9_ZC4.;F#)D'[G*[=&/#NI4)6K./KDY(N,@)#=T#[R;!1S1G(+GK*KAEC#
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M$C2M()C >ZI+76 &#<,FJ%DTSPE)KQ&@YKI\E-J+'O$%O'TR3G#3[/5@AZV
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MK=(1*Q8#'DF)D,D\,Q6==-[X]).M,G+3.?F72X6MUETNU.QE4=-E)FE,_5\
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MHH"^MXHZ66[ 14C"P]?:H/0JUN,ZFYTK#>9M<Y.DZV,.RU#M'CY)I=\*J8D
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M'4_3DY8RK >_;;$!7TW\+U!+ P04    "  <0&E4X<"T +,!  "E!   "@
M &5X,C$M,2YH=&VU5,%.XS 0O2/Q#T.DY42:=J7ED)A("<EN+06(FK""HYNZ
MJ5G7SCH&=OEZ[#8NL-H#E^009\:>>6]>QH/F]541'Q^A>9YD9@7[H!K711ZC
M8+^:W6#81NE-=@]5?5_D%]Y:"AW";-IIJ-F6]G!-GV$AMT2<[1UG4%'%UIX)
M-*&EB]L2U3(1PM2+3\6R[R(4E/\<^6SJ" [)(M#TC_8)9ZTQ%6LWVHM1&N=W
M<YSB&K[.)C,4I/$(8 T5FJH=6G6;5CC#R0+GU?AH3KY1<!X>>\W6?[VX8)UL
MF*!PTU%%-!,M8-%,QH1$Z<(E;3@E*H2EU!MOUXH#ZHGOPW=&^2J$DK0T,JE_
M/U+14,,@,E0UDZ(/H2"]!M\?6AME^.?'-O2U[ R/3CM2OD'2<AO"N?4MI5I1
M=?"EG#2_8#;Y9DKL)6<K0[5.TB*'R[PHRB3+\/6/"V_J[>RJ3"Z=/8 .^1K)
M.>EZP]5]1?#,5GICY9M^B<!*Z??LA>[UM# '19ZHTJPAW*EF*O@H(Z?K743F
M(MZE?KMS=69O^,*^; 5F->(XG=ZI&UAYK83C_.C_-7%@Q\Q^[MCQ] I02P,$
M%     @ '$!I5#+^>R=D P  0PH   H   !E>#(S+3$N:'1MU591<^(V$'YG
MAO^P9::9NQD<C"'D !\S@)V+IPXPX+2]1V$+K,9(CB0NE_[ZKFQ,P^4>^N*'
M^L%>2:OOV_U6DN7>1P_AI-EP[_VIAU\PCQL%4>A/W$[YQ='.:=B=+;VOL(F^
MAO[GUDYP/8*NG6N(V($J6- 76(L#X>VRHPT;*MFNA1-QZJJ:=R!RS_@([-;D
MBF]5/G8[JQ]<_BOT&,Y@8]#TN[9(QO;8E&R?ZM;$G4W\/^^#61"!T[ONNIW9
MI%:R*I]::&+*-94%SWRYV/B+")9W$"P\?^7C"YMK_TNPB?RU[\'J<18&<YC.
MY\O'110LOC0;=\'ZH>;0:JOG7T>EV>ZU-8E2"C-!9 )B!QZ3--9"*G>V1L:0
MY2)FG$+ X^M1G5'4G^<?%&+!%>H*6H#&K!F/A<R%))H)#MM7D'1')>6Q&3(>
MS8:D>Z;TR4-IHND! 11\6 AU#;U>SW)N;/O6:1=V=VA_&MZ6MM.WNV?;&0P&
M_9/=[?>'9__;OM,%PI-3LSL8WGP$I+H3\J!@8_7,8+.QL3Z9ZER4PW2(H\2@
M,04-"<:6P .1<0K#-CBVX\ +TRF.JQQK6B5M-! 9*]VW)",F7952BEF]HR"F
MK]GP:$P/6RJAURV0RY#1L-N%97 ES0K("_PWBIEH<UHJJ8I9L3CDDJ:4*_:-
M0B84UC)."=]CE9E16\1/J<@2*M655,]',6XVZ/.1Z=>2-28JA5TF7A3LA"R"
M>*5$*F-QH#RAR?OPN- (_R$668:B('&&:,;A*DL,Q47X.\91'D:R-XE<R<+O
M8[O9>$E9G%;ZDSPOR,N5 S^3C!\1Z>1^JC&N;.NW=[K_+S?:^3 -)AW5@0CS
MQ?3#<.YV@CI.R'-&&Y)I",D3A7FQ-AXU2>ODN]AC]?W\?BC4+Y8%=XQFR0A6
M9$_'"/)\-&<5<HUAF1?[:H0Z* V6=;IXN%[P^^4EP=(B1\9<5_365F@M#B,8
MF+ZMD+C?SGVSC,1/T+V^P62*;8'EC::ST(>Y'X:KJ>?A?_!SRVX5[<UJ.J_:
M)](3GMEN)%<8:V6-\7!*=&J$LG\=@Q'-4NQO6BIG:-85QC<J-8M)5NF#&5P*
MEM%=,<.K9KR!_E?'R#/WK[5YF0SPB^)4.KU1MV/D-1+6L79^?J/IF$M@>2LT
ME\=_ %!+ P04    "  <0&E4S)RJYDH'   !*P  "@   &5X,S$M,2YH=&WM
M6EUOVS84?1^P_\ 9Z)  <IRDS8#%GH%\N*NQM E28]@>:8FRN5"B2DIVO5^_
M<TG)5FPW==88R0;G(8DH\MY+ZIQ[+BEUW@W>7W6__Z[SKG=VB;^,?CJ#_N"J
MU^VT_%_<;96W.^?7EW^RCX,_KWJ_-&*=YJ?LZ##+V4 FPK(/8LIN=<+3P#<$
M[*,P,FY@((;>/'9<FR7<C&1ZR@[;+!>?\R97<H3+OPJ;RWC6Z/Z8#FW6[K1N
MGMJ#D:-QWNAVSKN]/][US_L#]OKHX*C3.N]NP5DHTEP8Y^VB=SOHO^U?G WZ
MUQ\^;MG?$ZY>H]L/V'L^%G;,?C]@-SP7*H C0\^)Y6.>GSZ1GZ6@!V?G5SUV
MT;NZ^GAS=M'_\.LOC<.&N[XYN[RLKA_M<"JC?$Q=#U\U'"LZ@]O*RH1F%7)5
M+6>NLT;)G,[@LNI56C@\.#Z1*9[MV^L/@WH<S9@G4LU.OQ:)ZVOEW\('WN@>
M'71:9(SH>;GP^X0>^FS,)X(9,9%B*B(\/FD93]."*S1FVN1,I^RM-@D&-']C
M.F97,M.A3 7KI^%!NQX@?MWZ%6RY9]7=(>!;G\_Q>@14MM=FRJ?S?LXM, $
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ME01S/H^G]AUEBSYA]=^TTJ>O_P!02P,$%     @ '$!I5'JV,94[!P  /BH
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MFP'I.EHJ2W))71]53I:Y\OU5"VRXJS,/=Z=&:Q'AAE+HLUUQQE5S\XJF\3'
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MTN]Y(^EW0D=('Y-\WY[D>_Y'DWP/. T7AM^B7^5U/]-+O^;[?U!+ P04
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MTJ$PE<^#^!$5'D+5!>!2M:24(F.(-@YKU?G[&-#8GY^>_O/P]"I\ E2$MK!
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M\&,*Z^!<=+A]0JA+\*\).']+@4C3T5P"D2:Y10I$!5D79/U<!CQ,GPLR9=:
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MG*VLKE;V1_/VZ]GEE[NKR]+ZVG'EJ,+JU>W&?DY7HX_)JP$_#_.4XY5MT08
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M?>\[V\Z.8AL[6]7O_V[_?=/^XZ'>NSIM;[  TR-^V9!O,ODJHW<C1G)*#CL
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M/;+9Z< DD':N/?=QP*AN&]GP4')#VQ="I>_J"R%(<(4!;X>DGJE2 $@M* ?
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M 1,="\##1ZMIB/\._<!J#Q9X!OLD] #@_U4NPS4H;/. 7?..^ 0#_!.B)?>
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M$8D]NE<K[.31$'#[ Z%YH(  3S59:\!XOV_#XD'F7E^S^4.)/0C)I1$BYK9
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MKI;6\?:Z;*W8ZB>@R".+@)O?U;5^D2N@R!&9$0(468K#7ASV8JOS?-A!_);
M!:#NHZ3?CNT4+<O&SL@!JMYD,4V8#4%5]]Q[X "H@;>Y'P!#0+\K_.5Z_2Y
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M7A]_.VU^*)3]Y92EFE&.."B#5I\J92>5)>5'/V#GUT>7K%9K[&EAAJIB 9N
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MO8 JE(R;ID=7OVP*(&/58/TFG60,68MF@8E1@""/XS^A9?RP$\YBC/*CT%T
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M"*A'N<8IK%@7<U2FE>TZ+7!82%3E)X>C5$1$5I(8: R9DH 1]3KD'2U>*L!
M;0V1KN69(T$QM(5NOTSR:KU1)FSK&*#T</0\AJJ$)*Q&@394(C(QZ%;^8@]6
MAF/^)@9HNE W&^P'5:@&,2/._4Q3D$HNBD/,HI>U,0YN5ZP]$=VA*I=BPJW,
M-N,CH0X5'M/DJ<(!/J*9S3<L.HO1?>]_*+'X@$838A)L=)<G3K V BK%GFHO
MDRF"/HO J, )5>Q$<H5X5>KK'JAH)=9R3>5-]U5=V=[ E2E'*!YMJH?;/, T
MJ= Q5$M/@Z-G WC+\.@ISH-< GG9YOGI&:972QZ-F>O *"AJ3F%\\_KF"E&
M"&Y9KM'%@"3DB&@P2KE7X1> S0!E51DLX4FN8J0Q/;85]BP'%H^F4+@LX6Q_
M_&&9CAA$T$O\Y.Z@SA D--V_N%/X%S/U+^X4_L7WX%]<B<@\6,2Q]/"MKUW!
M[E(&-EFT:Y]B8\J"5K@W52?,=*7IO<J]3*,:.: BB+*(7E%FX\-- "_:*,,8
M%'V4BDNGX&4XV%BJ0^H@" 3;KE9+U6J5]84+HC=>^)2X.^K 346X1T4:2(9"
M&4)E.*-L$0S2E:PH<A'U31=E;(P+,V7E/_1ORO(@IB[4@5+ L-6CPG;J/TD]
M@'0W.?V(;63S_.Y#K-D@EE&_5"D%H#RX&!7="H&?.NMKFU1\XI&:I ,P_[-7
MJY< %1_C\3X@V%332]I5I'7>E[X6Z9JML!,.<M( @ZEX"\0?!K)A6VLLZ1EJ
MNXCF]36%9\ AX4\MYOPNAIR"ICMI45&:I1R8"(;:HOW2%BMA4>BU:5$Q>4Y]
MW7LN5>/0DC(-VQ*DU5'X_ !T-2^JS1.X+O,MD Y2\JGNKL%RQR'SFBV5?PYW
M/ASD@;$HHFUA32DNF4 7:#&JAS=4S= 3NF#!/?9.,$.;5!&/,C!@"%#CVU;+
MPSC,%AQ*OZ(NNU3(1S#HX]@8WZ'*^^'Y],NVB]6-X!CA>>+^H-<'J9=L)3*R
M87,LL_N@RM  +]3<2NE$2O](QFJ0I8B,)HRRZC$AJ4>U$:GH@-*7HF)(8V"8
MP'*Q>!<>S,B;/)$U^U+)(EQ%JK#4:%-&'JFRED;L1'_S$)FQ*&GE]IY[\"?6
M7P"N M. ;%<9<M]$QDBIZ!*'YJAL@QAH8^Q0@"$H=;D/E?6U([?7HSLJ5)?4
M</B2UN7C6R5UGY2>OG$V+YNGY\>@@AI=ST738EQQX[/,.3LJ178\=.WCOV,
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MJ&P.?$7 40 '4 \YZW'NJ*PTQI-^DEB-BB0"R7_$;ZA((D:"T"JILR0-@ C
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M-L^,!N+0[Z2'=.Q0DC-N=Y]Z7D679-: 9H/HQ'(OE<JLB!5AKU]?&? M^7>
MOJCRN] 2%<N83%\Q=$(2Z\"UO@9V821<JH:@U#3WE/]*ETKB/0;Y%Q'Y1/J
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MON+B;%Y5^^VG$-B+/+TD1U^[Q9J:36Z:PZMLN*?GX$IHPF#DB)[I=L@8.Q[
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M[;/"+@IDB,&8BYY'.XBQP&#//Y*SF56[3"-;IUS"F*%9WA\H7]@Q>Y.]'I#
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M8PW1UI"+32[5;K/=UW;.SH[/=\D6FDCOPY^BUS&"YH,BSO#QJXP]A,MXEY7
M?V1&7IED,J6QTX-G<?K#7YU!G/SU_2_G??1S?/PS^1$\QY^JZ.^_'OZX_S3:
M^7L"?N76OF,X[ :=FY).5(+2H)TW\:A()B2=[=6_F=#-%Z@NJSB_[EL]DV#4
ME&+!$M#!"IH02@P.#AK;UJLUPK7'W&I%1]]]#'C]/\D+'9+%GPY[T;/<3 $O
M(T7RBOX[G9IDUNV\G U(,^A1[?-1C>2D1B<2&.S1'S)@;ML[R8>8/EW,XF?Q
MHB$3/?WLM$9,AQY0D'T?2XW%2PT3-7[0[<@/Z$.T-VR_Z74UH@]?S69U0:Z
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MIVO1%'YRY/)2*ZV&9B0 ;8M"+TUJ?$FF^4AV/D^:[&.&-_<$E2&<'079(X"
M:S45<UBA)DTJ]OPS6<'L1<]C^*(ZE^O!1\EX:1%B(=,@C>(7C0:BT"-]F/\1
M_")66NLS72]/SAINS5[T0HJ[>I&)EW2&>X<$\\PH".<!'S*  Q?A:$ %28=P
MAT'W57V#/"Y&7/7VZOP9_R\Y/\F0\W*\#JS$L7H0..8+X<$$#\,7Q(%?WMQN
MA_5BN!2 M.-E*]]%7OMP"F=?V<>P/1  K7 @GVD<*R&+<JU!IG@]&,H_3.CL
M5RZYQ^5U):O<;H<D9E:RYS4U*J5@;"L_L,#02I&G.ZJQ?>Y1E3A]*R8F)P,G
M?48*0Q>_P&[$99ZQ=9HH::EB*Q ,XV?R[M#!'">5^JKK5H/O7]W24GE:X( :
MF1PV%7^5R\;*@[KY0I2S0F[L,8!'.DU8Q6 QA-&A,)SYS*J8#1^..."Y]@RM
M,!Y(526I33O3]FZ$YM\@*_<7! VZG57BJ[4&4HKJ%54U+4CXM):*CQ8"=IHN
M@UV($A=RH" Z?+)G@R0SHQM'_F^MF!L+VF(#NYT#?[V'U@Q_&AVLU'!U6;.
MC).BQ!C[B$#)YST.X8I^^F@!Y. XQ<5YE6M5BZUR,QJ(C)$P:-1 J^"Q1U'.
M8IC1]6S V'AG$DGD2U57,W[*6=NBGKA[U,=0R^&4#(I47DQ6AO%Q5+7'\M$B
MHV4=(EKY2WYE+G';6H6/5:$QD&EE^C@3(%;"A3 B Q\'HJ<>6@DS;HA?BHI.
M^-#85;4EZ%I= \IIO,&9=<X6T,=*W!0NA/H?[I#R<BO75WM9\70;X*6[V?*0
MTM>D+%W79#.T\R:?T</KSNCATAF%ZW[-,61-OO8@@AZB@-N0UY6</S%8+ND1
MW8Z<13:@1XR0",ZED]Z=6"!<L;(8R#B/=MG@C8 Z(\=DR-:5A)ZU3FVU.T3F
MB#W7FK(P*9=$%@E&I) QFS%AZ+2@K\8+RUUK6@6/<MPUJ,#67L\F1$9&O'(Z
MY?.*\S.B(\"Z01:X9%UZ2ZI",CWX*L((<)R,,_3*:3)GHRXI-<W%-IR>3!J+
MX[^P0^+L  \1>+-R]91@$M+^E-.\J/H8= 3+MML)IRB6+"]["@NZB"9%7L_#
MW=I;*T9ECI+Q69 $*^B9.=FVSHMU#]F( [=!!I[7'4?7Z8ZCY<C6LM[ O<UD
M@I?KU(8+=7!U&RN-&6Y!E;EY/M<\7;?3T!,E[E:$#\E]5EUA_ZF:YG7)E[)^
M>Y<N5I)L@::BWI7).3D'+*Z/'"(MSN9+,Y([TR98K=FBTMSMK!5G*2Q*$PF6
MT@>#''YG^&DCJ!(Q9"R?%/%\JO<RC6$.C2-D.HHMVYFAK*XOR15=\=WVW<X6
M%L()V(HLI&)TY@WI&28O<IO7R!<'I2(Q,SMJS<=234G.2YVREGB@WB=6A98C
MJ"T1,E0A?6!3 K7W%A8[B)%4!UC$?M/2+>U%+ZU!UV,1"FMFE@IFVN+HHB;B
M/R\7+H];M$-:EP"LLK*AAS19[6\'M$P!R<!6B]VQJ9PU:;9<;IMV4P3F85M_
M]:Q)'53/<H+&6N"-G?=%\H&:$ ]'SLM$*'G=_2P%^$A@=CM>"<$+$-Z&0(6H
MP^!/7\!]Y2T?9Z</5HLY8"*A<AO[86_$#F^2L!9T 9 I"MX:P(3+R 7"+:&=
M@D]6A@Z78\TQ5V.74+Z9W%P^^BSVZE6!;TH*RUJS^FX\#B'%]86SEN+9WV)C
M">D*RV^&H+8CV';V\Z5MV,@J-4,00&Y).0YL )#H!W IA?X@(,_IK\E$:N C
M(+7@",1HC4)7$#^RZ=1;X_2@YZQ4#&R=\8*#9'-^-O8(?QPX2&&\DQ0KK/6%
M=430 HWSJ]R9"=G)5(DS7LB%$N1"Z*_\+>B''E=4LJD>W+@!%2"'T94_1W)^
M\5(D/$R&TOFV',L3IG4L>P&**78K[<I=''C.Q4#"U!#TV,!P</ZC0(4XX$R[
M&@]!%,+Q:(FED,C2^N]%%^17D<W&-'SKX_%#WJ 56<S&?=P.":.)*\N&SQ$D
MS9.@=SX</ME$S51?GRVA4;HHSXK1NL\:X#"4PUZ7@^MV2,)H!'2VR+_,APD[
MG_S.X%#8LX)'L&>Z]8;NYE1.\DS+JY%[JMKI#_HEARNRT$OP#HZ__EN(39<)
M87]>633"[P?0P(@48BW'U@%%)6@@65@@+DB.XB%2F+0HP_+Z+'$#20I*L93F
M"_A%P"S<Q"F&YGR2\0DQQ9"U$-GEJ%93*M?V*>-JNV82\OU2M:!]K\MRQG-6
M,/E8<FYE)7!N&0%^82O<!G%%*U*R:_A967'NN;<JL\SOMMM@2_K&K*)*ERYT
ME7FKB^VZ':FVLZL_%NZME6-:HBX-&.4<UZR_V#EMK6E!C A7"/MKE4776L%R
ME[?7?AR:L@CHH.3QDZLURHWH4_8I)WE3_W.X*\DM+@%4_]#2Y=2D$N3>8%WV
M"23HHRT2]&:1H(^V2-"-1X)N$LWNWL5>M]-BUSWW57+'UMK=2';=C4RGT9>[
M'>;$/?9A/XF'_S9GLLP&BUMRR92@2]ZF+PL)/$/DH69T:,N(,V2KJ5=[36JX
M1A&R)'V0RA6SJUWQL<S0X'E<?=6)>."-#'K#YOQ$A5#/%Y;80&[ Z5^0"8/V
M5.V:EY%&&<A\K!IA!E]P(O%9I4@/(+A%LP0E*:5HQ0'8-!86D/P.\M&B&=!U
M'//ALMN$FQ[.9L:\C RRX?#6JRGG,Y <17*#_BP]#F#[^S  O'AF=#4A4ZT&
MG=657.;BPW M*I']<=AA90P:#\ZP%OI<(1 .' <O(EHHI!O@$H/!!NQ%SR\-
M.].,/%CU%;C4+@[D>:7Q\H#G;V2&".\[TQ)3L]9CMR/#EMUP<PJW@3NMQ2'3
MKF& YPI^YIY=+]D_C7\BJZNFKLL16UB%16N@,9IBKDT01A4S'[O#4"2LU140
MU_ZIS;:FH-XMDF%E"ZW4$XJ08#&MW$< N:P:TN *7=&F32'F0N\;#,QQ$4MP
M!OS#M8QX8&PFRK&J+N50[NG5N1'W_[N"=&2F]\4IUY7&VDQI@^[Y#8KR_.:Q
M\+)W0G]_C%LM/+F3(F:.;?X*(Z%&P>XJ.JILY$TYQ0,H#)2XZB0FY[:9&:M>
MPEX>X"5?]5W1L+'"-,9TS6DWZ,/]_=[^_GX#=KR*II(38#.IV_F<GSG">*U&
M]LCLPDBT-80H2W@S]B,5'5GR-:ZVC#4+9C'S"O@"UY7TT#&O:+?#H1A<RG09
MLY9=N3H6'([./)?<"(53"V@^L'HY),2#D>(U>W;SEW96 S'(SY#KB?B+K3_2
MNU%F)7;*,6<-K=BPR)3K9*;7""S9ZR-,^(&L7?LNT&/FEJ4&-QD_$3>7BM8P
M9>MK7@_(F$#E6=",:=W,7(R'5O'2+*3HV#82Q9HAL0.<D)'E&]6-0A37:0%W
M]"H>$#6B-C@6=#^G\FH,'6.M!CX"R%NL4VV^&4:Z\/:91#D+.AL-%HZQ&EGV
MC'J]D<A;Q-H,3H&6W 2P/9R'5#2HCLE^JE4[ LE5IE^#0B2G<:RVYO(Y9V\O
MFKS78DDU[']8JC/C2*Z5S6 66HL]O!Y4^70R2,,LG.4Y3(IA/4.5)+=]DGPH
MC&N&/37/7V,&4PL3%O,2^8!N9Y#FPP]-2Q>-2[)VZ[BR_2+.0[(S2KXH*BRD
MV4G9>(Z;EV!YD6U&YXD&>@#E'(F\B[\54#*4'NEH.TW!=HWY[ZX0U02C<)FT
MD%1VQ>J&"*Q[9_I]1>7PPSU:%K&(&8YS[. XYV%&=6L4W\VI'&=DAZ[KT.1U
M^I6Q%T+C%ECJ$AG01*UL&!D@%E;FZ&!JA T7&WG%GN^<*"3;BCEQH*N@,"*,
M5Y'1:[-[&+RDZ><CSMFOXLT.HU>>&X?4V-S%NQK]?9IC%"::Q(;IK.?/V;TB
MS\C:DRDJR)ROQ]JC&&?&UR*&#Y+;DXD""MM<BXTPWX6R-1!+D,0QA,9JE]S(
M*AO%A29 1_2K8=6O<F NRWJ&&S3L;DFOG"8#MK\17LGL&!!DO$9V:D1F@*5P
MI2L!UE?O<AOV:G0H7)^YM+<,&39:MNH#D3L?LOP*B S;QC ?C_O\*4:BG0EW
M(8*C&K'.OL9F(0;#A/'SL,4A"O2JV";U@V:L86NSQD=HW0B,L\LB(RF6F>K:
MSEU"JQ?L.I SW(HI,Y.8BRFY9%,284VTC\J^N %L8S2Z.VEC*X^$YK,WPYX+
M'+HHE*<BE!_A=)O5F3.=)-*<#P7%#*&\IN_41BA$1V;!H(TP_LI-78-FI;8%
MGI,ZBSEUGS!JS5-5B4N<,)Z.[6W.U4^L9)5U<6G(N8VEN:EK&\O[9ZLVPMYF
MQG7KY=@ALZ(Y/UEP]ED0!><XY')XLZ'*-$K:BG#>;3/M:UME-YEQ.CSX[[*>
M_Q5P#AH^_>F$I+HFE^,$G :(3=W/_-I&V4BL$MQ.R3Y%2QL5[9RQ,HY>QU?1
MVWPO.GCXL'_XZ-%N=!7#UXUMONV4#"FNB3LXZD6'^P>/-1557JG-DZ*#LYI.
M,\Y&!5#8;F=(/N9$JKZ8WR!>R-GVAAFB/>8J:.H],R/)(9K+A/M)'J\AW@A?
MS9T0,6 \6&P[YD; L\D:6<R%G4-X[&Q5J[WGO5&F7T!+'>!APX;'+G DW:V"
M=TL%'/Q/^QN?VE2V#E)8P+1U.YBJ&TT+52KQAU)B7"-; YO"%G.TS;88>,VP
M.,Y;:2=M%[U3@E-OCK"=60K7H%SWY=PH073HEW]B8WX/>"8^+7*%85P?!VE(
M;4]R!E)SA%0X/&Q^-Q[E<QO1PPB"MK&2A9KG)+J+:%(G@NQ;8ET-VEW;=? $
M'MIL$F$?V'(+4_&"2*(8!B#XCFZ>YN$K9Z8^ 0A[O 6$W2P@[/$6$+8%A-T+
M0TX2PE#<W<XO7#(QQ"5 ED"I[;4=4_8V*G8/IK*FX3H"Y6$X@)U"S=6EBS .
MU@Q^V;*=M7W-PUK4H**0O<!5D3/RUOBB=> 5M05/6/=*\.4-FQ9*?"5_24:8
M,5L: 6H+6>$R1)&UFO>ZYM0]1#EL!(*_"#8SVU'^I!DYP%\%Q"66Y:D!U,N6
M0<HAX4$PUY ;5\\_N/F+OV'GA]I1SZ>RY:O'=%\6F8%5,DYL'%!-NY6/<<CZ
MQC;XJ8)(#=5"'Q'T,U+Y)4:BSU\A5IG,!C57<=,NVP7ON=7N>626Y:1&)H??
M.O5J8H[*P'BF G;"I2:+,-J#?^;\=B^L3\W"L-6#(&35[0B$P3^W&?M;2Y@=
MC"DEU76=R)'$R5;9WQ[3./J_)L,/ U@U%V(>H]TYF:2HX8J36:E/E1@2#<E4
M,9FS+H"D'P>C&!=Q+041\AA>.MNCWIG;B,?"EI\7R:4K<C=#J=/P7^QVA(4/
MHU;Y>Y65=<%J^2POJI#$'&RA=>;^B4$BM'>_O#H[/I:)GUEV1#)9%CRFBQI<
M'IF1;TL3WP6#+_,)CC^/OMO!+!4,UY*H:+5 1>XT0Z1HED.[_X49<#&);O32
MSG(5D,<=RL#MHR"__/-FZ9OH@'>S+!G0F)_5([#HGQMPJ]):B$X[%G+V@Z=/
M]Z,=#;:^>W9^[&.LMH+4S>&L\'A5 =Z\FK&OJNWHH:3 &9-9O@5]Q^'^_M%J
M?Q4OM&-?YR3..7XW8$7&8>M@$.*%P5'C ^F7Q2TGAX)G\_R*"0%%'=+W,S/)
MJT16SC^Z':X6;::Y:QZ&I8^5SUA)XV2/:X[_N\@Y._/PX<#^_L&D G[,'0Q(
M(G.BYD G"*"JAS1*+KA=>L0"JZ[YF?(C:D#R>#Q&.1<,X!-L%-8=4C,3=--@
M(5>0GI@3>Z,\M_IFC6P<[A^0;*BOS>Q /1N6/SYQ@A+V_$!1G0UM:%PC4 70
MMRBVRH9R.)ARPRML;=G$*H!;"I0L TW)8922IK'YQ,Y,7 IY*(W)LU^8\B<.
MG7)==0],PB.HUPJ\.C0*8R2VNH@4T:,D=T[V).DQDTIKFP :@$Z$0[9+,LAT
M(DE.:L)B@<J?M7VF/S\ 2I]&C'FBKY".C^>,!X*:LAK@9]$Z_$MM*R&#(T5>
M&"7D\V(;-PZ,: ^<&*\GG=W )_9<],69O(S#(T"X0KHU\6<4*Q!@E24.@%RA
M$![Y]K:%829*:W7@(@\VO%R4I.L=LYJ<DAZS#OG@@\2SE0 %YX4N)[=&JB)5
MI5H+(-2YHH<;_R(<G3%X3!QJ#9!NL=#^D-ZXA=.3UOJY0,_S172A['&N6E%)
M3KS===R@^NV%*Y5:=Z&AD)E4&P_?C/S*!GD)#17KVF/0*R%IDMR40%D#S,.R
M#3IWIMVR;#1\C MA)E>\>^!.E%)X[[X=2$H0P^,C(<?197VYLW,FD*5>6(+0
MRF8U4\?>]/066$SF@.DUC"P2XJP$C1N"?VS6W%/7?2/B#V>MDIT358,]=%ER
M)N-Y0Q]N Q!W<RHK Q *J<:1E8R&&C70'%QO)AAH3A$OFDB,)13/BJH;V]/-
M%KO@:<UD N,XBLHE%<+.3US(']R[CLZK>0$K("$I1GT\:@%[@YU2KW*\4:?F
M0(,>_Y+&%(1+.!L1@_O;NM*7S-_=<Z:@/L-:A$'@(R\FL74W2NZ>L2+F<\UC
MZ)*W#DEK.K0:P%);1K36$N3A;: LCFP;#.+2E^2E@-(W>=*#E=FIID5>3Z8"
M:5WE*3JO<-=322X/A/-VCJ%*:"C;DQ&6.#8@N7T&AT62S$:!-(>%1!RR9M:#
MAK'==_U0,FTU:!->JQ>@&?O"TY-B)41+.!["CAZ-%*EK"HA681^YF5OL$J;7
MF(><U2LU298N/,XB .N+I C=.QTAS_W;$AS>F.<U6;^&E )]J/Z6R$PC;A@0
M'=GC;9W#)<(&>G(@!F'@4%SN5;O'<3N_?7%%AO7<6N)B,^>%50G&.YB?W+!>
ML ZI5%UF6AR09!DI%888V9^*ER]+F7CG&%E#<8X%_"6N;JR;5)I4^ZY)@K11
M;&?=&G;3I\PUR#EST0BA][BVWB5WMI<UJ*S;$H990B%Q#<#UH:T]9H4YKZNF
M#V2D%7GN(>[Z@EX01IS9*I!:^!M]\$#Q7M@\/E$K @>J_66\CDJ,1E98!?>>
MD\1V+ (WD\XST,HTCMH^P"5[\8B&YFQHVX8"[='=.$J&DG4?!K&YAI.^RG(5
MQU!PYBZ(:I5:(M9GL)?B-O;:$9?F*G(^VV/V9"]IP[3Z:B\Z+J6])"U4;\W-
M%1RF]B8%3&+>36R=6:$<EZ*INI2L@-+P9 TNF,+0/F:0#?Q:.-=FTGW#<W@I
M]E#8IX*2\:U7>,>FPF@AK3=9K\6;5IG$!]=;9J$1%MP63-J-:Y KV/,5VE_Q
M*20Q6N^"D!",12C\5+J<6AWO"Z6MQ;%TEUB#9OT5:C$S@K!UY2$VF=4J:F;K
MHS$JMIM2$X]X0J/\*KL"2YX]P5YY+8=<'4<7'>ZTY/3$T@1\G3[[ZY:X.@[N
M,1>HXR43'9\4[;5KUI$[0*6%/_D]B9O/NP)[01RA\UL?%A+*0%DGH7$KN>"T
MVQRGLGDCTGJD/.4>I=O-*1LV0NP-TT/_N1C 36[>LC3OH/33&S5E8Q?;"HZM
M3V2D.)PL3'N?MNXQ0B8K5!RYO4!EIAY7];N)KCAR%]*:^G:S:,_;P&-[:HUZ
MCJBJJRU2L&K@[[@6-LNK4"(3*%P&G/;*<K!R: )(XC7NP&%T+*ZR ):+2\\J
MM\ 62)R6J\VU#ZLE?D=,/)_1\'VC8(] :S)UF36F<GB5, ET0%<A<<\1W9M2
M6J'Z1IF[M%'O<O3ILQ206P39.;R(0>FQ@Z5;$GE[9:DA4J!$K;9VE1@>'%IB
M:X1W?4W3O35##/I ,?+0M+T*6I978XQ?2+%ML%;V;(W$SC5;)Q)^K8I>YZL&
MC=&P<&Q!=SO3_$IHS0&BY@CZ%4.NPZ)!;-9"3<1"*QZ8Y$0]7 F[ST38'%4G
M7C)B7AB>WKPF@R#FAH%FIN!1K"09$> FX0I#;R5:!QUAQ)#JU'OZ,$F:(4K8
M[Z1,AVYGQHE-A?966Y>]2)(SW!K25;UK@VL1#WW[!ALLGP (/MD"!&\6(/AD
M"Q#<>(#@IGD&S8ANBXB$W$72W[BS)%$;^'FL;GU]N8N>M%LX"!6)9MI#/I*R
M0:-1:@9>"&\UDH$2>RVN9!X.KFI(]LP>;.G<=JC5NV4%,0DZ6N39:A:.76WB
MXW$[FB%EO('$J/PL:#]F/AAEG>!>8T$:%!32\CX 4,@Z-!9@K['<(66/[[5#
MIJ<2MK&):-N-N'!=9+LP_A3M'.Q:=K?2YNP8>,74S[Y:O]%/(J %T,X#[:)]
MV>2^94XP"G=3L(6C70ARUC]'.X?!4#!E.PY.JE?Q1W@ZF,"E&G[.H+9+2\\X
MVK65@IXPF^%T7O1<-6S9V(EASG%8EFA/.DZ&[T(+,&!G)V("2=39CE7S\3*H
MQF8)E&'GX:[R\8QK;4V-401VN=C3XX(Q".K/^MZVOAQ$:O*V"<IOF: $DW""
M8)K29-[?[.-&W4M+^\)N?,@,(\T<F/%/VZ4(QPLSX*_L(,'GF9^VIZ2H<L;I
M$:*AO'Y#:L8D'.W0:^M"B]/='96[C^Q8]_2SZ#BRWVYRV9A*KE!I 14QJXDF
M.)G#$Y$)9D>?N[K:D-O(SJ-2!JN,@=_<H2J+GN[_E[9:\20S>D]:*AIN0.^8
M:7:1QSLXM'R2L2./$K*5BDL$_3IR23ZKQ<#S16)EEJ>&@U3D@5M&=KX&Z>G[
M_]G3\ZS?>$-D7[!'2VQ7?6F))4O=7F.[>+)DT9H5HT$W6#9EW 'YYW^V((_7
M/O>F%B )2.!DVCGBBDT[A-P%Q"RC.IN9RF73$$#Z-I[PX4/XD_?40K_Y.^EX
M2$X<=ZHD.\M1-F\OICMQ,:W>'#II%_6 @2B_>)9MOK,4\K!,)O*V6>^JH-@F
MB2-*K9G>0\@P&O@9M#J(@GZ^W8YGGG7Y/P5N2,\[TG8&/H7&8GW - ;1 XT3
MRI+>/<\3QN\F.8>&F7DF#2+$S=:#UOV 3G*/T713(6N@F&9-( 8N%9#6:*WC
M=;2SCL/?<,:7-"89S#W7[806 \S3;CC@JDAXV:'>AX N+Y3J-FFH546P2U_6
M49@B<3-Y'U9(VT=8!\:W:[-/C+T/B1BU3Y$!*&1;7C%',UT>/*.P'66;I%M>
M**O.',<^,M\>Z">.U "8SKNGYCY+'=S1L9-^/A=H0+=SQA'X]T"<BEFQ)<;X
MYOKY'9VSO]5T; Z%R>*(X<L<WF756W&"C4:$8_B +#^#OL<-Q%<\*8P"W?D$
M7P 3@>0M#3&LKD@08OD7VV#]_$IY#-_$4U-.H[^C#P/R>KWH95Z,IER2Q7_]
M6S[-HM_WHE^223V<)KWHM-B+?D_2-*%+XE7P[VKR)P6B6US* KO//5^>AT$@
M'X)2)F9SE=K>:6+&T?./9#5*;NP=!TT*_3!."M0W:A[N&?=\H[^<,N-6C@J5
M-X4;B-7@MF7VZI_PDQLSY7\Y]<_I,9DN:+SDU_)$Q Q!Z<OI4?VGZ]Y2>2>"
M 8G!_H7;QH\,]GR#$SSW<RH!\;4_CGX+^=#*![;[%+3LV!2:E=<SR?ZRBDL!
MQPT@1Q"X*MY/; :V"!C&1'*)VJ]::X ,]/<XUX$,&;PJ&694\" -T<(TV-?"
M>_7#2U-]N629!ZFR:96:<PUSN8UHL9VN6@JP$/KA%V!09J;@09B/4HG&2^.0
M"B%?K4N6!Z'A84S*HL@7<2IXZ$-Q>C'=S%22NR>WS_Y6:NN<PJOG A>9Q1^3
M6<UE47^!4P]MA2X.?A?HOZQYQ,6V(,,I66%J<-F?54GZ3M?L1N6ZT@5>:UY7
MT&ZN#^G*C7J_1I8DM6T^SD&85L_5(N:_.]M1Q4CGXVEC)2_?[81[BJB0D8VU
M49F5#POT$^?-63/Y'_O50]2*4PH<>4# RK6G;)Z/;J<E,4?[I H7I6NJFN5
M2#*J@>$1G_748*7<ZCC;-$W^#?J=@"2WS-/:]47WDI*E#"Y:]^0D."_2T]-=
M:I% OI&'SXM@%[8Z^XY-)=#9R[:2:&S\+41-1>,85;@N!B8*Y< K(?<@U&I8
M6E*2O7QAI+#9'A(.]VK76_HR#8,&JX?>25GP8O=@.?CL=1_N(SKKB*^3RKIR
M7!\'GY0/@#U-_KE>*!4*3=9=LYC9#3.!,@9#F/"3<Z\=O/G@H9;?EPWA'UF+
MDE[Q.IGGPR0S/#)NYXWE0OHM,WU,EZZ=Y%*L,!1\1F,#ED]9F1+.8C0@5<M8
MK: ]@!^,-"JVO&(VZHE5 U7_?8R6V=-U/_-/SZV@@VGQ/D;V-EO?'4N#5\>-
M>'308Q7"JFX:CZ*#HPBX-6F%[;66@C+9*%)&P&5=!RQJ6DF+CHSS/!-!^B)2
MMQ<]YUO;> &)V:.9<*%#XAHE!+9DDQ)XS(:@5)EH?8%"#L-2;V2PAY6KB@B,
M:3^;J[SX  .,E2X^NB!;,GJ-P.0)%)=J^,5>U%AY6('2$AR@H[SX"=B0RC#B
MQ/+)V I]#G,I)ZVB3)PB8UBK@#>!LJTS3@HR.T&<"GZ1ICC-:\NZ727J#Z*=
M+VB(Q52""4FC!U/#ZJ_M@<,0_993J7AV/PCY()::H?/J()C7!B\T"U'D37J_
MM6A!M.9)VG -&Z0-<,7U*+T-FC $HL805\ VX>T"';R0/O9DD F@I8AL2YK!
M(O+4%[1Z-#Y!40>.LXJNH]5DO\K8"+4N9-&\H0$QR?.;9U+<JJ__;"J_ [-.
M8@H_(.>*!?()>+]!K\54W96)V:EKZBX(E6U&S\:<T6;36A%;VK)!"+]0/,L#
M<8HV8NG^#)+VQRV2]F:1M#]ND;0;CZ2]]R;\L<VT=CNO?(N.K35_]Z;RKB[(
M7#,#NJ6,0\ D9-1<7>VEZGGOT;7'T3/.NP=5M(5AXVLX!:K()M5?<54L65CG
MSD+B5C"Y2ZWHZ^C>+!KOZ(DE+61>VD%&:,U!/G6PW_^U!\!H09J4VYXM??Y_
M]Z*A6*M+G_Z('_,U#K8T,>L8!)=S4:!\6<(4"'R/ZR(#O1C:]Q5E'4L4Y4+)
MV Z.=N)=&)$'CW9&NS9H<R%$AO UGFM4VM/O'3U$C*/,<^X_X9HT+FP!-R^H
MX)^0F',M:*3]) 8FX6%T^&6^="$-S%'2Q4.5ALV]]DB8 ,Z.QC-]2HCHXOD)
M/3#)M"=9YIJAV"V*M!6%? .5A[Q0W&;FXT*S";XYL2-]+'L!@4+X#6',,[S2
MK5FZOKXTC@&0#[6@PZ95-?_IP0,(9&F&>Y/\\L:M*?[O1X_V'I+5\3FGL*_?
M_6HZ_XNNXL]?A,;-'!H ^TM6UW[CIO[\5ZRXTW_X*V8T^M/#9=.);_G_Y"%[
M3VZZ*_U 'Y:,_N>'>/;_[>\?_F W\M7[YV_$ /G<_QP@\A@(PI^=[NW?]>>O
M+G[]LKF].#YY_^[\(EJ:8&BUW=\KM54$L %& LT(;C,GSZ0Y+I=L,-DCF?GY
M%1</)^4'36<X3A\'VT)&04N3W0WFNL(U*I1MB&MUF:HM:>40I*]IC8+BU4F1
M7U53W% "&-^+W@6/U3+I 4*5Q4SB/[Y9"&P!3$.NQW4S<IA%E+?0[%UG-,E*
M,->#8<K7<3S4;$Q5Q"-'CF,-(803^-I$>U%;*"[%PR,AZ%P>FMRLB[R6@F;&
M,7.$LE#&KS$^#,E))%E?EF!\$B(H_RP\IYRZ5J=@7)#"=Y[*TO7M&XLR6A.%
M9V*LG;-AP)#[P%AK\F(C? :/GO,[?G.]T: <%<(P0^MI.,[WE<[0UG];NLC"
M.,8(G1!9"'X2^ :D](>_GI,8=3LO8L$A7=0S&NK"S?@>3OY67+M##/WSM??#
MV_#QG (,M6:S)6B&=I*@/U?E,(X]B*VA <.3+1Y4 $71HP[BK5X4M+)CVA/U
M\ 3=8ND))%HN^CA\M.C?PDSBPC4R</?-3UO1^GK07FP$:LX\*S3NU&=6I" @
MKY1(Z%XJ[-5;X[VNT,MJ>V'_F=>U-F[Z T<L;]+GXOCG4NQT?^_P1E'29,<O
MO>I/>&?_T:!6[O#3QT^>WM0P;UD<F9 2@T,*'1>M _\V$ZWESTONTRT)31A<
M_]/K%NS"+2P_(PZ9W)(LR@E?12U2AM=G)V^C@X.'/_;L'P$_LG\\D#]V.P<'
M^T]8I66F+G*!$*"A"=V-R:C\>;O6G[/6DB(/&!$; %[ENQ7$@C)E&<N+*LZ)
MP$$<)]UVV779@WY5C>8#Z]FQOL+2W87+XS^ZPN[CY;""?K)G(<,]Q8%[XK X
MS,!X '9;6NCUKX_?GK[[>C?+W9"=VSRVM[#W\[PL$TL7!Q_K?;\P##H1Q*]E
M;O;A+LFG %'%I;$]P4#IA^02:J%#\ 7E46<O['L3A^_4\(RS12A?R/'&25H7
M(5>CHV=L$#VWV>I#EL*M\&SB/1089S)(+>!_?_Y>6;2:82*NRBHLXZEETGW?
MGQ@F:->8L_QR*S'?A;K)$9C$X-0><4W:0RK4)ONI6">V0D5;7&[%91,5C.?
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M',U'49O4L\_BII)Y)4UV/7&_M)+(3+H5KDT4KE$"<:E3X#Y=G'^&WJ+6X57
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MM[<<MUX#]>A0)B,SY%ZP6UM](VUUE_P1/D=RV(1N;.R:#*(@RU*#1:BE"%@
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M)_=H=!+_>/'XV>G)Q<47WV2%AEEIFW<9W;RD=]L.6\"(,H$,@3'*6S/Q$-=
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M0;'_Z(1R];V_LD?7A;L3(TA _^B1ML8FN?\Y9Q\9 -!V!Y$4>1T.DB >'^#
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M_NY1O>^E?:?LKYZ#YTZ3[]PH]\Y(!_9>Q?T!H.]4GVBZ3MMM6U(7[5+J_\P
MH"/\P:C#?N_S[JAP)0UU=U>8]F<\[>U;[>TQ: I/TS4HGAZC]H$F02DSGW=N
M2N*V'["ZM-(/$?-T! ]X'A5W#S"B]PWU,4$+M%SQQ3X )C\$P3#$+W^;GNJ'
M4T_UN^VI?CCU5+_?GNK;#\-D5MZMV^%(S4I_67A_K6BEG\77K4OOW$Q+N&<9
MOC[SQ<PHQT*(E1E!$_*B]+J9K(W)DISV]D@M28[OYIQ7U@*ENEGEE57"6)Z[
M<1P+XFAMQ?4+!\S.+G\MK3 (NM=]UQ8+%TC/.)9LO>8"7X;\#Y,,#U'X)TTS
M:9II;^^/IHE9.9:%QI(Y$\0%XB, #Z-A=?3H%\SN.1H@RR.8DL.)9-5]<79*
M\G!7KG)+=)N1ZKIQQ6K-K6>:/4.QTJ2#)ATT[>VQZZ#4%?)-\EN8.>;I!-4D
MJ;2W4T_:#&-EG&8_J4]EILZ@2W22NTFG3'M[Y#J%N</G3/#(JL,J=Q>H_MYW
M9K*VZ-QT\J>3/^WMD9W\8BECPYD&>@P@])0=G+NJ6ZV/DP0:O?1R<5VTJ$UZ
M7&_X0VZ6%-+XKEGK"LK:^=HM^E)JT4:^;R!%,I#Q;FE&Z![Y)ELG7!.%\CVP
M,+9=4L;'$'D1Q;DW:>Q+OA(!$U!+9Z:F3<M(*<;3B'(DSQ,2F3UCUE2]%^[1
MVJ)<@TE5(*^UXCQ&)2P X7;56RF@#*07WBOZB\2BIL,X*=II;X]+T>Z96.95
M#9HF\NSG'WYZ>8ONF01D.OS3WMZ3PZ_ R(!I"@:%P21KC9,"_+(?IDU%WK8H
MZZX-S0<,]^:_:IVV4]YITA_3WMXO_5&@-X!>PB"/2"#-(ZCH"*F*>[:]"CG<
M21$@VUL&R8IICAC1-NZ&DJ&$AGKZ?-2?E0GRD19W&WB-  ?J9SQ<HN7KD\>G
M2?O/%([K\4_/%7;K<VGR9\:NPC6M>FOHZK?VLV8AF3,78<$#;*LK!+:C2'HS
M&4Y:^+_F:U0&I.O4?H?A3R=KTIK3WAZ5UD0^S)>8;[6%6AGBHO9R-)['$2S$
MOE?,[I +!\C9SN5-YGZ;EWV+9LN=8O)XE%SX:J]<V]7<WUZ)8FGZJ-TR$2Q?
M4_Z'6\7X?[_XYOS;+[?=V_0OGEU\??[%EUQ&? ^Z,1]QV?N[G,N+N!\RI?&#
M]8UN_'K9.5P7+9(CA;8V 0= X>*CQ&NKL 5YN6.L)(%KK781N0/?3APR10S0
M73-0LBO\W</DE'9)*UH4*!UR;8.J&:I+"$[>*J6KN*&5H]>4@#)0L.C0?HIC
MD/0]\H \L.($&#"BPP8D8-'TWKN2>U8#+JSMI4U8T5<,LYJ$RU"$8OR V+H;
M _H1//^Z,[R)&K5$)+0N V%/AD T_7I =4/#B+ENK%@@YRC[(%V8( & U;?I
MJ_U* LBU;X[&T%!^&7VJJ!@\C>TWFD;.;"/@$3;&GEF HD;K,0V,9D>V\LY:
MBW$0P=7&<B[X-3<@6W"OQ];E//N)IE\S"X+T H]@)"T5$^[T1)X'D'+ V_2H
M#M4SIB"V*$4ORF%>0(@K%@IKVQMBE3R-5Y4AY]2D-6RZ :62F?@1EI9^(8"O
MUXV']Z.%;K&]-W M&*B!%-N&A@,0.GI]6=8WHM\*[OT.S5,P]I=[3+C1RA@4
M.G=K,^'4AE9 5B'(CX';!2%C_.2<RV@9'ZL"T,K"$%S9Z6A=QX#(C/EK;PET
M4%%#^B[$2"2=Q8)2-[H^G)H*('ZO0.HE(Y+>- 4PUS65MM;0.>86'T0C3NA5
MHY/X!7")@I(#(>BX"IO<8F#L<DA="50"GC5<NR'T8_"%9VHASE*=  :3@J]G
M:2"Y=A%>E:<QX+L3Z'>*PBK&I'Y720T.(*M=N5O 51<?%NSJ:"[?CS\5$19&
MG]*;%EJ>>6#*W4AWNQI\K3''>#J7(0-,RYB=S\G$ R/8PP</+QC*@_LB66-K
M1_R M_KTQ!-7BRK6O].5T#<M2,V9OL[$FOT<>IP]A>$TQ,^AD]#4N[SL=F<
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M^PX4:'HE<7VKK<"!:X8KJ@._LPWG+9&&<8&=GMP<OL'>#)/\-C#$QU="<<_
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MCK/;X3ZR[G=R0N. "C297CK\9^8)C2ZN%K>&,$;$*E)L(=)(Y.<TN!B-R6Z
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MNYL9P=I.JNG%=B\JZW)18(5ZPR!7R(/[QA2AP$67*3<0B&$AKT*8#:$WMA1
M-VV@0=Q98Y^:**;O^%103Q_(-D6-EVY5M*6*@E9%<^DV@RAY&BIIPJJYI[8M
M$#1"K3*HH%Q%MP=*LY]7V66_0DKV(?-\7$B-]_?] AT\CZ76G<LVZB5S9]('
M$-WLF*US)+2KJ,P25/5%\8W49Z)B&K19]#7 2YUGE]G?D?:ER9>HS0^L4G65
M/>&L;4='1[]+0V.V:&T:\G01 GOE.X,7^CW_3LX3&QCTGR[.'P)GKBSCY*Y
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MWY #)B@39>MNA/U 8=LV^:\CO@F7Z%2,:<AM8TRO,8A)1)^Y*FJ/IT_&:-$
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M+$MTL%*F2F7,+'M:S<_OGS3>#>&[PXIITD-W8%A'I(>^%]H!U4 VYG?V>#2
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M!<+NYE20<63G)9*>B%ZFO;6F0F03;/)>U7LVOW(G"LW'JH0\3S+OD?3J9<.
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M^([TNDHT6S.IED8;:]*>3OITTC^YC3RBDQZWBNM17QXPU1/;/G+01ZUW>@;
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M,8$7:#/<@E$4#099?-*63=XO%'B@5_)%Q9F*0)*DXWN^T^XL$@&<2'X6#T.
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MFELR&5F4@R-2WC=#L8 I@= .>)"JJ-Z7-UN;CN TJ>U1EM+ 0Z(%$67HR$C
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M.'J!X*$S^<8*<D2'W_B1/*,/HF%O9Q/ZXL'$)O1.V82^>#"Q"7VB;$)':<K
M_ XHC*(HM>^?S&XKBNN0=&LUNT(6+I> !-Q#A4&-(:P4]ZC= T(5$_W*N<HP
M>H7S\?1D:+\,[DV,S:M[LX/.L\O6%PS'X+F<ZBSJAB;VOXK*E3S WZ481&1T
MT"6YV;J%\Z *&[KE+*+!%<>P+<80*F9AN6R-1F:DQ@F2>@%VJ:\,#B).U<$5
MX#M+DIC#I\_>PL/UH!.P>_!.;V?=8 ]*QFR66@--R2^:>GL&L+3&O!9QC *9
MIWY24QFA("#SH]U;!U^G$-F!<HFG)A&@UG2%)>F+E&3R"9$2CN$SVM?0"K5
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M#Z)M!1BQ#9^E]X2WS.A%^'_\S[\PE']%'Y7X??3I^#%HQ4-[OO3; DG(@++
M\4,+8F %IR=A'OD5W!W&3;*'QB\4R[&^L6^?^X\MDADTB>E'<[62/;:LN/9'
MV4DV2;,CB/]J\4\7:*LMKGJ/,R50V45>I:A(@9=Y@#=%_JB^M4EWC6&2XF>T
M C)_Y12%BIE_\NB%!K&M/=^-6Q:\P0'BNBU^0\JT6]/DEYV* L(N9F[73;%B
M=-5D\'#?_3.63)/$DBU@FV@1K-Q-D%,_HGML'Q[G5'Y0BI'3$Q:E!@!V'3.H
M53T'1CP&%PY#(O>QK,N_&4W=(.$8GJQNC.))^&,]8Y"@C\V#S@FG\/STY&D
MTI_YEVNLH0VT*"1\B_+@<V2TZ@,W;EZC'$ 8%4J<!<:MF]&2E*08,AK\G,EF
M+)4HN'IT7;X6O@%]_4;"*XJZ!!R1Q#-O#;5MX_*62=>5=Y"&YUWKI!1I? V,
M1(F]+!VB!!GB<2!*.HZP7UP7I04GZ-1NY @[^E_/N+"M&21P)[@R]A0 UES7
M$BP1+#?6^"(8$N "(ZN!Q&6&7.:=Z_&] (;AN:!UW_()>F$'F,2B:6C<'E4Q
MOYEE:V&@!,:^A+88M4)?SHR[VYPA^7^E]6\7FNAEZ=D)AHRI4H]_8U\I=^2K
MKR$4+:,UZ4-[\L)RMM/+Z-NYPMEY\#J(YJ+&35C/ LZB/D3@C4U+-_2 3?Y:
MD],Q6*1@Q@UH7IBF?J_E>U*A=VPJ+SP2LT)T']9(D$//'2'(2?I)*(0=$U<;
M8M1,S[L75\\J)7B$H= A\&I;541%.O2E!_C_<8!.RFI)^*T""@B$4/$O^4V,
M QK!6D>HAO7F"N$EP*X(R#HH2' D$96DB? _EQP7\I@2]SDR="PNJF5F+!ZY
M8%QZ9C$Q'%5%[C%T",T+U&5OUT$H>_^PG GW:&/?]U04.):-NI@ 9(PX@P'>
MVXR)/N0J@CV0MX(Z2S[-_/6Z+ADKC=D<G3(8Q7;'LBFNZQ+Q=%SA/>(1<HVQ
M"DD*-.$DS+A$<S>+I(YUD6>,PLT/7Q;I%;R4X]\29=;\"^DK3[G7.O>:]!09
M17+Y+PKE$-JX!>.ND5T*.&2DH4PG&<SBWPIX;7+#S\QT8VYZ^+>F\H+(,[Z2
MF"B,KS1,F>0*'[=3BXV5,QTFI&F<K;^B'3/' 0,O<0#'O_L\^SYA^(Q8&_8P
MZF*ZQ)Y^XH,=@S[%)B%OIE(KT'[1A#3MQ%P9P'4!J+ \$R 1RK'ED0%Y Z+C
MC[OJQL6M,>FJF2S4GLP(3&F<)5K"9U;2"V6D:==L\\!:8QHEV.@+#F$(Q&&2
M; P=.7L75.LW!>D.,<5H]9Q*\2S*\<2/DSQ&C,9C\\2M'MBJC*<M)CA+.-J"
M4.M;A-T*#'&H7HJ8N3Q+EHO N!4J1S)?2O!V73=#E^B&K=5!_BMO:-L;1=N^
M5E=>!H_MPS%BRT21B"3FP^+J>R TM1,?S29AR#T]*1B>5L"\%PGENB%UTUH:
MF'5T=$(::P]+$GA2)5G[]#I9K59-GY'A&)M<0N3#K[=EC--1!FH^R/</PJ 1
MPQZ4(H]Q,E<.3N41IO/V4_KB7=,$T9%\!LX<8.]?? &^QHMO$W&6B$/ -Y1T
M,3/#0V4A+9IO@-[7JAK)%8,4:(L-P@)0G4%KC"JV&2UD\?^^)"6] 5//54ZW
MS?5Y]H]B2V)-VOYI-3_/@&I?PDXZIV'^Y>+;L_GUV8,'WS[XZNS%3[_,1,D-
M[N4GA2*</>:$L >)MU_3?/[9Y6L)QG). "$.0QZ-B&JBJ3$:ZI(<!&<A ;H1
M<7TSSZZ7>?LCD@Y&]]C.R[I5=$$Y*Z6BUN(=SYY<1E1,K!\4AM_HBL (Y"1S
M/+? 0PR+FX[4R(?B,5VAT"=ARN,FK: _>4?][**I<03GSUP=/G^-_5;F<T[W
M7=$-QYM^7=2ECW98R"&R!21RP5SILO-L<K0I"8/,*9&3SYAT/4B41LT99)>4
M&9D22C<_IHBC]_.]\1,'S1Y^+=+N*X/\.?A&_O#Y3$#%JU8XY!?Y)H=02&%&
M7VF0"X,1#3E37B3_!TXB24*42S1^[2LF_(-]6+@E%S4(<+Z_>+1\"1ZL&6@\
M*]1^L+/Y\73I=[3-\]<HRZD62-G6S5]P=W;NSBO9.S;')_Z( IVQ<P)C?%VL
M:O#4!RA$DN7-  M1KO(\H$;.Z"1W=#.S\JD'9*CC1E@V9H.1#+][(RPUP-CX
MLE(C+>G*%#)MP]0O<JM(K'A!UN3<%Z-%Q_I3/ !O*)=Y-)7+O-MRF4=3N<R]
M+Y>Y1T&J2^^X Y$;%O2V*<KLH9GS-QH"( O*S"Z[4!Z7>=.WX^&L@?5,GWGB
M2M19Z@TD08W<'N+MK;]?OOKAV?\\IP7^^HOO A"RA2I:SI,#6ES->__%HF5*
M "[$D/A&^Y?LV]F#1U_,OOGRF^_HGP\??#E[\.77^.<7WSR8??7M _SSZR^_
MGCW"/[^:??D5_>6K1]++]-7LVX>/9M]^\XV0&C2]T#3F57LC%1&QU6^.M-QM
M3%CJFF"" 7H[#;9PC?0U[?2""1M0Q&T/'BQ(\K!X@[Z5'3K/GE?9C^ZJZ=%K
M?7&!WSY\P/MV79?TW9P^O;/@&_8QA8T>BP4MN0IBRS$97M 7\J%G-1G@?IWD
MKO7KI+:ML"%QO+ C+;;AB!L6BS=H+^0@]L12PH/;OG-BX8O4K!T*ZBWEI]D<
M!F)';3*M1+^B0W)Z<O&E26NN!<$H76':=@X6NIS9'.J1A5+4ZK;?;/!K7T\=
M?>?O>25?X;<\O$#6E?R '?]@_FX/7M85\*Z'6YA)XRO/\:6^YN_Z&FYG6%B
M+PB0EYP],8_E>UR\3T\B^<;LO(R;R/%0HH(V\E&*=BD%(C?D[""LNHAJ3*)$
M-\;TZ$L>Q>/S#&J0)GAQ\?#<E 'I+"ZT7B!3;9SU.A^YS\*"L>C^O2?IO'@T
MT]4$(5<EY O,Y)9G?RWK*S(E+U>-DR%P(82^3N+;G!FY%MF&X<B, >'%'-QE
M-RB.FO[3%UR!^\ [@"$\QH/)\5H?F=2W_NF+T$. 5HD=7\1YJ]%F4CQ_>GC^
M9>@RV&S<HN#\]NSTY$\740-"G2[ 0]ZP/WWYX,'LP8,'P[\^DK,1A?5X4H%"
M+ZI0UP^%0-Y>"(^.K\7PLF$(3Y85-ON0MSLM5SS2_-N]J'-]O&-J0U_G(MP^
MYO!$Q]N7WK 6IL.UXL]SQ0M[1;/,T3U6[QR'&E8]:O,6>9=K^0,33%@2B'^/
MKN!9$IIGOCQKRIA%Z#V&@1O:JJ)42(D4*/EOBRF%>4>G@DPU' 6GI="A&8RS
M<[YG3*_*D5:H+/XZR+ +1&Z;E9@G& TS3W1YG$,S>DIP[V!F)"]0L0AY,+^,
M7DN@/! U?Q"M-6A'KC"+@I<<#VS3W-V2.PD5&E(RHU(EQU$%X982ZH4AX8P,
M*3S33D#25F<6@;4]Q;.),HWMKNW<II6+<";UJ3AP8J1(F^Y"Z^90>DOCPP**
M&5FVT8D_L([)BT-<U[2 1EF#JM :.V,MU3#,XZ'VT%6QS6!5@11UR%H-BMVU
M=S$J]$WRI*;9Y/7%-:B!HBK@64Q*%!?C">MC*U6O$:UL^.XYV6]%5"($FE,.
MH5J1)1I0P<DF]8:A\%@6/J[[,[4&BJ!BCN"9UOI"6)5>EQ?W-R[*;-EZ# E$
M%.]4#H4_TN>)L="-7&#TO( B#$K=Q'M2B;L&N>7;N=/^O]"OVKA2WMM8XH +
M&/6@[35>TH.79.U JW.2N,E[5-C)4_N*W#80E6@QT>B=D>YY7#L'_3ZX"F8@
M?FJ;?MOMV1V^D5>RX6PVE3'Y,;P%-IJ=HLU(;OLH#1&[)H[3 OD9YL;IR<^*
MPDEG%]V>3Y2!2ORS5WQ;O-#;X@/>[Q\@UOK1+,D/.#NK4^.+2)FUB[D4I)D[
MYI.5D3' R4!MCXK,!4NA1A?I'G%;'M\PW&<1\"=0? &?IV9JZOAMT1T^\Y@$
MH15WQD_S0P<MU2KR)2\1)/D]XV-5*JG6F>_N#9Q.L[B7-VKA51<,%WB=EB!Y
M< !Q0ELWG+IO(+&2P;QD[E%>I3<NY[;,E>8\)C>>C.X[.A52I'1%0@#BK:5M
M6S7Y9F\?8RGA+G?/(19E\*+RK'G>KKE:$!2HP2KYQ3?.=]F.9)*<P%P)+V'7
M[>(3=YT<HK0=:WB Q*;9/]_*#8DXG/[SBR_"/[^9!?)(DG*9,+,7/KM\&0:;
MA(K^?_;>M;F-(]D6_<X(_(>.N;XW[(@6AZ3>HW-.!"W),YIC2]JBO'WW_7*B
M 13('C6Z,?T@A?WK;^7*S'HT&J1D4S((]8?Q4"3078^LK'RL7$EOUJ/\LYQU
M'S4*T!$X]/93*S$ZW[][[X+8A_QTGUI5B!7J/V1B/!I8) .;,!@/5Z64*;,&
MG6!FB*"'!80\UJ:3;'X .@^>/SG +G.O1^=T]:,[A\D_N$Z#2R%JQ+KZ;#];
MI&AH JEC5I#QDUA$VG-C57FQA=H 8R[R#Q1)*JKJ WW"B9A?E>8B7['(W'.4
M@9L*F\+,H7@.PC+7OA-GQB1EC&9- TEVBM@]3B-KZ"MMA8M.3/!ED#)TU/MT
MXP.3 _E$Z;AA^DMRG=BXYL;PX "FI27R-^\UYR^03/L\\M@_89<I3DI%4QM;
M[?DRT"4ZJF8B3$N;*XJ91NGJ'J3N*G)XV2,4#&%L'P#/2(Z7^<B1!:L3[W'S
M1]$DCG^#O>]JUM%LW3KU+E?_Z=Z+N'_DS*PX72K!WIIA9O36@LJ2RI*."@&%
M""E6H-DDY >@)MJ[F?5&W<VNU[#]G?4BBR&MMZ5J"+;#]H.G:+ES0]I^=0%P
ML3ULW4P*K6;67U+[B 6SBDI0""0$O-+VKPV,"18"HWPWG%9[<[A"%50I TY^
MHX[W(TD$LD9'0BX<;>9I"CD:^EHV::+WZEWU.6\T.8Y9C@)FE,.(M$N4/U;.
M_LCJ!D\.2@G["TU6=(%"UX91<I7%2RL+*I =GMN7O%#&]L)8V2.[Z[V@)NU+
M<-48(>)!MA;B.H\T,NH+K ) Z@5@YU IRTVUCIV@M'\90I/ 54$V%,5J]A H
M;%PXG$1#"N(S*!-2.*C>G[Z6Z#-LL6%U9-VM-V7R9M96'N [E**[WNX*;824
M J1-1S<)M1U6PB9-F]K?Z7/HAF=.J$NBX:JKM367UO>FG)6E4.B4W3F<K#I'
M\0=R$/S^^$:,S9Z4FZHO4(FK)7N)\^@X(R;H6?8<^0\>C7"3 ?G^VA7!!2\E
MRTUL/MEI5ROV6,U'&C#/CVMQ.'TZ.6 (ZGU.8)^ QTVG+3/X?]\=$HM$ ^Q1
M2R4U/1O3E3Z2?,:TKI]F(U/3=%+1KDT\I_T1S-<9;9B;ZC%79-[R\OLF[E0,
MT(BV)79)-?'1?[UW/A(]'HJ>O?Y\^"6&W1R=C\8-_4NIXYTBQWHPHOUN%^WW
M8$3[[1?:;Z\L&D22AO1^K/-[,))K/,VAT,-0AI/?J74FHF$10O%A4FO\K$Q-
MB4A&+*#  :ZAP]QH.FXI=T\<O6T.W>UZ8S@Z+S6=5[GH6LALS/9;PQ?E-N.%
M L^E]4():B]X"QCZ80H94]&BT[_MQ9T2J)Y0U?15T6?/+-)$6S767[X4^?CO
M&#"E6>[1&MCQE=65=="#AO:/O^Q>_#%N\>N'_D=&?L=8T-51XA'"Q PC7)0O
MKXT&N.:&G'9&"816KM(Q!$8FZ&V@'JT]6ZPWS,N( BS0>WDM_14\-3/I(8J
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MUO8A:*]$Y;B W-?V@GEU5"2C(AD5R5[BOO(%C\W3N; 'U3B^B*F1FB-N+!0
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MF#L2R% :N_9"2GOI*Y>4.*\AMUFQ5D;HT'H('#M&=3;9TF66VKHSP)]<5%=
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M;"^&-:JC7=R5;U8=":"!!PC2W'-R^5 W%]/1;B?D%<;>(>YBK\Z:"]1>9YL
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M7KB%*KDP2=^#L3)SG0L3>"X_V2NRNI+/Y=4<8Y:VK+EOS='W7C)YQEK,Z";
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M/3HZFAP\QXUSBCN.U#GY4B:SFCG\ WPT>[_)&A&)&:O@H07+XE_)^D7+-_
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MB\J'8H(<7AHNEE]'6=<H_Q?LNMV@X*30!$I@B,/:&>#--X1?4%54'=,M[=Q
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MHW;:0O 31&R)(CJZ!+UO',R+(6+G&?/PB9Q%K'\;K/RTJZ&8NFWU0W-2-2S
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MRE!<EU7=2JY@N^RBLS+IO$#7]?DWPZ1S).=D7! Z($LH@1^TQHB$GP.> @2
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M(GQ+'IE\B#(JUNQI&<J"Y!"XD0(T(3$EFH4I7<N%QLAD[!UV3E3/;5"1O0[
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MM=T:ZTI88LV%Z1<$UX-A7V6_X*(>T"',UKYPE4KE!5ND[.M4NL/#  *IQ^K
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MK'D=9_DJXVR]#S5U;O6C4B!7I].N5P:OG=?=>9/&9..(%=%]WA69XSJ7RDP
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M0.R+I*F3M2MI]"VMK:1PS(ZGYURF;Z2-\%V9Q#!=?UBB%VE!UMQ7=56>L_Q
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M4+\?KA5B,<(XGH+NCSV[E5MB"O1SP.XU]BAD+JK7U$C<"9((PX_"+X/(JKY
M"A4!3;$)L$Y-,)<Q(NG!KA"%X$L5G-S<\=NY(I)C ]<QA@]];*&0LJYYX^G]
M4[O&*\'<;NZ.D<7D4"3[Q41>E%OV7F^91G/6W;]@;!,?F4""Q08Z+L(?3YS
M8WU:Q6\3L[4)$C'V"%$8RK11:/2,O##*DMR%M7E_L<,\ 1*/9]-H%(4. L(2
MY"W1*F'[S6V!K98/$Q'16;(!Q-3'#CK;",\ZT&?]5^8$U M-&$/D+T2D;6=
M3N_0==#SJ1L#DU-)#&FTG]&#2"A9/JH"F9-;'>:!OP&S:,2E.E%<_!VU]R7_
MKDFI&:P]$)GV4U_0O@@UR/N*E#@%&H/;8K21-NYX&:PF0A(8;$4W:]!\"(E=
MM'7.R1J21G /PP0]G3_ Y8;1!PYF]?R"J)I?(R$_):]GOF.TFC.1H5LMN"W7
MXAQQ,QTXBWB2YT[4BF6 WD19UB2]I'V$#38VI8#N+1"+#7S*8PDF;(PI;6B&
M_15O(<(_([S?9GXHVAW'2F^C S '::?0S66-(@X/^()O)4AZTB 5F,'DQ51%
MT7(V7$G"_.LRUGU>F/5]3( MO/4XD/3B\O7'MZ<O*P-SJPW,O3V0OS<;1_?Q
M"S[-F9RZ+)?(#^=/*0!HN(ID .0'"[$[K&:S<RQ52JJJ (8.J@RI$'C_"CJF
MG=<X R>+<]KF.ZU]2:5YHAJWDR\<5%0)>(^MI?PX'D>)G_RHIM/1"K(Q"9A_
MC#*49,TT19\3Z#@4Q%0C&1X\;@K&;P>>3_]R@D$T1F<C1I'AE]'80U=A"OJP
M4@].K_ZE!0&Q;F3+Y$GT<+Z$G6NU:!=@N]2LFTWKA:GD6__Y\!+[?X5PUJ+4
MC,47+@LU"J&B$1K+ G4^C?T2??XZ+Z@(Y#<BH'[4BU E1BGA.M0 +J(S+5O(
M96$A]9I820,DDWIAP 6Z()2H !=&&,_@'+[,R 7JR9D.'/BG.<M_79ZI:>K.
M>52YZ[DF./$-=Q@0H!<<-T?W,4%86'T_AB5J0.I7FKK*UN3@@CW5PTR%O%&E
MI8ZP\%X0=%BS%TF/Y9A J+U0 P_'<,8A2$5V@;-HI(2IF52Y./)*#E6'>RW0
M1OANCI#4!O"%PQF)+>YVA$LX23&?(YO .#)F"S+N\O5+[B)%/V\U&TUNSC<%
M>3Y-U@B3_[1U=M4J*C&^@;7LA3)R'0$#(L^1[!X]S"B%@R)T.D&8@U-^H,-:
M!-'E!*1G4V>8F=&;Q@9&TY>NJY"\MQ2'DA_*EV33 ["PN>$+)1?8F/"4>*2W
MXTQ$LQ[I*Q%]? *47J&GGF(SW? 2B)&#P.G+@FLGCAW1MM,(A5&*"4M-PL*?
M&5E&]%(I5!*RQRGT-(;QR2WU15IN\@U&'\#BC'3[/GZ3<LS0SHLZSODWXG;0
M?*R2V60AU9FKH43FWES03OZ0T][0UE66]EX0\;=$GUI5]&F]T:=6%7VJHD^[
MPS,P'".ZE8EF6-@ABJQ6,/C ")F!$,+>V^0*R[#/#YJ#U&SL-.'NW@5(+"%#
MJ:6*,Q# 6*K-G0 S.FH='JFV9>0?! N!O?P\_C#(,),1A G. &4!_M<V)##H
M\!Y+1M'A*Z1>:BQ8L0?+B*T<(4:+" +<_4L\;H21P$)4$H,S4D(OI5E1#YKG
MO7:'&N%*HXJFQ_F>)5O!N$SL8'S>,OOL+GF^7A,O:&!^;!_]Q,(X1.>RQ%EB
MK03F+W:,\SC1W$-!B#(TY(,4!\O53*%7*&::DY/F+E%F$:7>V*)#C-Q-M,,X
M]1PW5H*[$"*.$3RY\;CYN&T89:K1LN[%;!==^@6]:X_E\VXNA:*X2DN3"=>4
M%(;D9J8::THTVE)JJI778!Z3@QMT_[ 7^U651:]4%KW977]8:;.:9.MAM=O_
M]_].>D<GZYK5AO.0,>A*,A$G.,QBLJP*N:C+3"Y[WAG7.29&H+S/N9W0U=9/
M3Y=;2HE;.JW'3HFOB.7QI[5;C(M4$IYA3G7UAJ!KI$E%2GLQK8KO;..I?+=\
M1W(9GF&NUC;B5+E,6CW(E+PO/O=%EK^J"&TOIE5QI6T\E>_%:IL@G /\L7F*
MWI<I^>6P!BW&]@&I\.2F7A!X7"^.Y7]  C-=$D=)%Q6![<.T*FZTC:?RW>I(
M D>&)[@D<H"5KPBW(Y4E'0^X(YQP6$Z):T:V[1Q3;Y.5D&V;QX?MJ@_*LNP;
MS'*1CO\@"D<'E)!8?N3Y',R2HC#N."!\DV5>R5N/ZVVP7)NP/QR$_G",3%X!
M8L.I^\XDRB3HN(HLBLG*]!Q1\R'AGX) !"@QO#@A  !&+S$7(I%R1#&&+G&Q
M#<@@S'TQ7LU +RG&2Q,%+PA+D&DT!M90[CGCI_,>V[)B>ZYX$>NE_$@3-!%?
M$?+%,Q\6SA6[<$:D@IBXC!*RJ7Q@_2 5%Y7]AFN/'%$<!8N2*4_&D0NP/#]V
M"<>+$K)H7EBGQI'H&R?&&I92<BH&.8DQ>8R%H,*5]9J*5Y8C%A#\$V_]W;R.
M,K(,&'NJ,)+$FGC>9UP1794\0\1J#DXEFU+Q'!J;T]B_P7>(K+0HYKPS 2Z%
M./N1) .!TV0S>H]C;H?85IMV,.3JLI*L,EE>AN5HGRC]7;0[D>A?M!(38$I?
M-CTE7B<\9:!$1-AO!./ES@V,1A\A]))--6)T+Q.8]I#+OU*Y/TP>)OO PBJJ
MSCJT3H-T3)LED_V,4B;*389MP(*L88:PG%;4QQ7@]/1$"]O-NG5NOW46(*;A
M#VGGY.U=FJ"GME*V+X3-Q#T)(X)0BZDJ*4<8N&%BK]P(#E,!.#UB;X,]"IZO
M&9GH3':GJ=>NF(/,*DRB+6C+2Q5T/LF(OL?I1U;@.228[P_CD\//N0>:#]7H
M%,:Z/YJ/ >:#^LIG;T83CD(2_4+F"ODU(Q2=-'J<S(J* A?QA5>9'[A4NXQT
MDOA#'V$70<'R#X#/(_:B+":CZBHL$F.8 I^ZZO5_RO?3\2;3((*S!94FR+P#
M%Z012C)YY@J.LTBLFCSKM2GH*5AGFT,N-!+GRI*J%=;1G;1I*+YG\&[4A-Y[
M\0VJ7U>S)/4F]=J+L_=7+XTGJ%Z:5"_,!94 24I-65#;5N@T1+<(EUXR>RE'
M^[#3WHTG0*YR2%"V0(M*8<8#B0>%M;Z)Z #GNC&EE5N# '/Y& AJXKETE]G"
M$*.@)'?<&Y+@H"4,/@=&23BJ+]3.#)59&)@1Q;!<6#&+I^GA>?*H75EV]CZ?
M\L&JPK[.,18D9J'_5^8MKZQT1A&: ER6C\6;!LV_R-'X2P$5IDA=W@ENYO!)
M$7)A%G?4F X(]EX3LIF^5T+.6-GG$.8; QT7[B%-$2QH-4=GP-+3E]F=DRP9
M!)ZZY^H^@\X<(20":,]./ #M/?2=0^M*_9VRDK'81A>:JHG . SL0/(<JQ_)
M_*9+1:"?N?Q2A(?39K1F3 *P ;<H\(<>&>L(\$GYRVJ1J*<+F&,Y=:YM'5B8
M[0_B'"ZLDXYGYO.P%V3MPV1<4=TO.(C^S01L0)X LFWB8Y(SZ?0IA'2%%>8
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M7CTJK(VVJ*C75NE1\1B-)^HUU7G"6JFOS](@3ZYGSWWZ[:"0_^:&.]9:^NT
M68JBC4+3G.(Q%!OH7"_=$;HN0F%)U._XRH4B)&G#L>"$>7W80Q'HC8TTT1M#
M,/F6;5:2B'G^Y\.A]9'\0E0/0WV?!<DMG)9-=TPU["X7.G!Q=8&)P6)D3K\
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MA:$F[]@.L059<<&05:^-DHL\V''%\+:$X<7(M^[&@4<&>'1XI/@?_O#YB?[
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M?IQ1,_9FSS@&9\+N6](SEXPG8Z>P#AM=0^CUH,N*3J@1>8XG,#[[=PNK$GN
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M7@-S)8YND?TKU679Z'URQJDB?:R%YT:O"/H12$Y_"0JK9WW SZ<!09U0I'U
M1=;4<"+,0,/B6<N7U6M^@@VY2;<%*9*.@QE/E]0W$*M<-1Y:OV3POJ9N&B[+
MQ47_:%K]!&O6>5+B7;K9-^&?2NT-GU?K&2+\! <=)HX?4KDHW#J!)\ 3Z7M
M1/053.5]=,,.29Y.0V,'"@%/3=CU:(BK&D_$/J#L12GH?^$Y)OK=U/+Z%)X+
MU)LEIL(%"&7#!=H Y8!$[-G%[^>O#YHGA$)"5? 4X>_G]P4V@9;RO-=MD(+R
MEIJS"TW8.@.]&VQ!0H!(Z?!W4B[O"]^_Y" <:%L&QZ^8^W8NY1,<$S%R9N,#
MH5VQA/:3)/-D4!5A' C'1*+N1?$$X3Q A68=7N*4,K=7.4$J+2J*1TXHT(<X
M7IG/&Q(H!.I#[KB=[P<[*_24)4:*P]V X "UGUYK-N)6H\\#+LD&LP8^4.+%
M-[["0U#H&/A2G5T&^X&H&@HE2.^9R.T*9M*^XJBLA[E*#N.VA(A0@Y8$Y7\!
MLQT@'D\@D(/T?:DXV!,N0J4%UVOO$+>DXEY;NI1S4$U/LQ$,!EI%HU.BEH8:
MZYCU2V)D&?D)&"L(V-D5*$#6.U2^SN 3V_J8.F.\UHF <4)'P7 H;ZW UL(N
M/NA*]U@EK->0>2 W2817 ;@$:9ECSW%!IXMA6L S+D(=:^NP.LB01Y'K#WWT
MR" ('B*$H7N&%#B:L]2DM/?PF)YN[R2GV'$?!.;N#- 2.1T,L)<*$LEE%/@#
M*4ZN-$XM:/[N2+LHWL"$T-OV>.Z)BI^L;NIF,?H(0X?!\ 0@6H) 6H.,$HI%
MRWDGF %SD!Y$$1 A;4A@7M+O.'S./U,YXZ!5"><EZ@.YIY,4"$/ LBO<8X(%
MX]87G"'G ,W%+JH-K/I\/+PZ-%0/Q-6<ILA(-&T*6PXCZ"]P4:W&CS^?GE[2
M7YL_OCRTSD/=72,_*70ARUG9BXU62=6\/Z W3H0+E['G"'%.9,9A,KTGNQ#1
MYC!>&3-7WVB#3<"@L/5!E( 9+:(_PL.7+G@*S4!Z#EFO,('+=EB![Y5-2$ 4
M)H(9B_1]UTCPX:=H;\DF9AQ-.BN$A$N9E]/@"L3)/!#)+"0(9-\#5?1&[2SZ
MY0EP3V!JSM,DT"FV11$0>>BQ_E/R&0P#@?P0[Y(@FZ%7?E[]*.,=\_B0:+04
MA94XNQ@S*-$Q0)C;&=!=S*"IL#<39U:O@74 )X*D";-)**:=ZFVY0%P^[J\B
M[P-L0X! EACZ4O& I$A%Y&CG'Q&^H7BLC_" V//3":J U)8MY=/8#SP!+&E(
MP#+"1[)RO600^WUF:P23ZWI 6H0D^3Y*L;1$<%ATOB&F;=E%%OB8+ANFP%U%
M<R!"[97W:H6;2&ZG@1#MTBOX9TYX:P*5Z<KI6#)G=5<7\?2=5-3VQ:3[P!R]
M7OO@#2*@3#RLRJK;SJ6@5?>;@_D1S0XK 6_5=3(4[JL4KJ03NXGU*H+_*,WF
M[>G5*ZG9L O++7_LXY24!/G<Z=5']=C[Z)"&/VB< !_1],/22L8@A:OK#+8E
MFJ# ?'$=3?V!U6OT7EI(7?2U [??E:P*W]JU7L!8]+>#9N>ER 9N]M3'O0.P
M[=3?FPWZ1[W&_^+H@?JVU7@)TSNDX3#ND-&B,,>*EXGJI@/"_Y;*:&)OC)C/
M-QJ%.=;W 6U0+V"I+_201/TN%5YY^O57K#-$%0 5DY !8E-@WK!XQ(!&2&/L
M%S3DKARC*'()8E:ZUZC-D#40VT8!F5!VI12C#[$G&[^*#'%7J,^DC0U25F7Z
M'E9=$NXY,6/OBU!%N!@"H6_GQN;HS B1<E&#IG"#6JQ6-G'A(]@^I3U1),<6
ML\QU^%4:4<H [7+'R'^I<3E!MZ;"%**@09Z"Y%:P%NFX$2GP),RF<11&. 27
MDI*.AN<GG0@44&D>T8/FZ<A98*)NLW?8-'.!**&#8V>Z$Q3/Y#1,*8GI<NS$
M$\<&PV!PR!8MV! .[-6[=V><OQY&:J6B#F:/U;$[\F1;59[L>O-D6U6>;)4G
MNSL\XY/'75-DV&<A%("2@,Q]<YT:\FT84$2Z-R2CN#^*?@FP]#\CGZQQ[$&@
M U6']9J0 K$KLM>$ZX+A[H5W.?;\21^C=N2"<JBPH^^@/\L/%T]=O&N/F?QN
M+N64TZ)+JLRXWP5VQ""_%#8C<%AY*-"=U@% @_*FJ>A=D ^=2-HFTEM()AP&
M825/1"Q4N*--JDH7-3!42G5V$.:;).@P8+5.JAH.^4IE#XJ<LX"\ Z *2]5=
MO@ML?DHUXC?8J*T(G9Y]@3X%<R>P=0>_5O;X$RX"#+(X0SWU@TE(KPU^\T;P
MKLI*W\ZEL,S+^9*ELX[/UL"]H:\\!TZY[P0DTY*Q!U*'[&]_<1A$!TK(?Z<2
M4P9^/,@F:.)2LL;G$.2@Z,7D"!,2YN2Q\UE,@Z<%]AZGG@@#3#$R6W\TGV(2
MB2XXX@>*Q:$34TZQ7LMM!$W8H\4G$2P+#3KB3>IALZ1&V+GT>NYM8^3*',I,
M-ZDV)& KRC$,2Y+C#X(%DO=<-'!"RYP;DLGT>-4'!_Z+3;Z&66!Y80QB06H8
M4QB;@PF)3X?DI[ZC(EL\\F0:>-+K6<   IJ"[8A"CWHOA;SYU!*)ET][P_%Z
ML6OL-L <3)EE")JR2+=4>T8I@GT%@204&HZ2 ^L@,J.^9L)?P1 ))#.PFPUN
M";V<&O9,(Q ZU*OGUI.=X'SL&C_AA6H/0!;V86#TJLB)N#ZH6:B!&>$+N31Q
ML&C-_RNZA7G%1E,CM,QU\,Q<O'Z#&2 47>KUK K-QV3K(:(,]3I,6+HQ_HT[
M)(JU9M38R:,DIP)I.I0E-3/<)9PL.P*=(83M0L&//F\X)!NT4V0T2EF]&_U*
M-'727>7@5=PKJEY3T:(K'4%B7PXII?IF3;@7$H)K"/\3AX(L'812+ CN>B7C
MGW 15UA1<_ *29E*-9 .G,KQOKU+^<3^5/8A<D'4 7.B@7%Z2J .94,^$GBY
M*C#G%CWLMFK01@YI_#X#.9+(Y(CB5RC;\/:>A^A)\E&678*Z0(Q2=G:VP: )
M=9]G]D2J#ZP)&4%*%>E39 #^P?P:)5].I:#I'Y :,G3\F-H9"M&*WF->!DBP
MZV6_=<1ZT5K1>1C:&8MRMG0#2<(1:\;'5;8)"0B2NDJBL-!B22KZU=DJ.80F
MAFX %HJH%(EC*SF3\KT?B<)7%K<(=604V-%.XM23X8P2(&0&@#&@T>T5U)4(
M&UQR/HRQ;&QH9\,).>A@SQ\!:8*VQ# 4P=?$RXT@BP*%#F"0*KX+VX$/V3.-
MK5N+J@5GA22%M^!"54F'01KP!I*[MSKZP"T?^6'9*-&8'7;=5.UN6?< -:#/
M:;U#K(&&#>,^M*23%E5%W<-\_A0C,Y5&S5OI0K%WXR?83M(?UFM*NMH+\C'V
M@E'M&<_-$M;0*"QP<#481YBI):)Q$5VB3"AQDG#< @\JN>F'UD?17MD7+[/-
MA^!#4-<'&=^X/DMI?-A(WB*M4& *X4Q>^"]U .XFPE+9@#NCSE?24L&L#8_
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MH*LNFXA\)EFQ84(>P!7"P@F*YR4,V<)5#+ UG-E.D3\1P)1)?AB&', I9V&
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M?AO%5[ FC:[^VNNG^E_":BWGCDF8M1I1\FOXO\[F74T/W*7?G/BSEPHH&JR
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M7Z___/G?D_&&6B:L<3OTRJS$2]. 6[!)C^2,AWY2AESE?!7OZ2)JW+@2O4T
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MMIC #K*;5/W3Q!YIM)VYXY9C(V(FBB_KINT!VUI J7-UN8%<OS@_;4XRM[]
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M_3Z[!ES9NCRT82_>3^^%!TUU^GA Z:^0$Z\(8CKF,#3.$,Y/"L&TFYGEX-D
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ML7$FP=#28$WXL_^<0Y2^8>IF;WPLW, + D?+E-[;AP?P%9 -0SB!Z541XZ;
M&'-G' !L,'/'>R'(F1$M-:9[(H\:R]FAFSD6/+AZF[?ISLP'@SX@*' N:MW9
M"''-\1\#F,S_W1 ZI"_K73PJ/FPPE1@49;;)!\WIPT?6$#\@H(5;C@$@G3FF
MT)=AGR,#)S6XQX.]*J9-P:4!70)1^<.] N^_!RP!XHAA$U$ RB.V8\*IW,81
M+HXP"MEC\E3T7](E@%@ 6(^.?IQ^CMCSQORZPWRGP2;Z8N])]#_.G.+P ! "
M6/+.J@IX(D80NOQ@XROQ9RK>\9<S A_+%CF.B7== 12_K/EGYH;^$,.%W0+!
MHW6!@PVGJBCF""OJ>U?(M("69==PL)-@M!>T)U;1E%K:KU+F:R$=EVMV>Y?K
M27MR4FW)=_;=Z!(S!@<#F8FX '"%*70%#[Q;N6W7]W3M4 ^]M4FS6P/1/$!A
M.DN^^6 IY.R#[4DKIWP9]4_O\[*<?#*=@>:&253[\%8&#M ^Q,<%VCPC%$OM
M2:=:>S!SA<;]1^W-AULV2-C'SY3@9_:U>:+/EX\K>Z!B;D/#A(L:M2@""HCL
MF0-AKFNFP=""?KS\J?IR>]PZ%GK$0(T!%!%94<@0[W=Y*NM<_0PT$- \0&\
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MR>8R[<G/4S.GGO6&?ZKJ4ZEZJ]^^@3:,1P4_FZ.XD&YWO#07"#T\.FX7H;8
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MQ]57;7#FX+*OM"?:[W)^T/WSY;K#1Y/TMGZ=EMN3S/F7_L?[L\O^&!#(\"0
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M@XO>$-S-X>CP(( _+S)_CY?NG/H[VX^*&E!NGYZ9_DC3V<K'PI6)O7[8!.4
M%%CBB:^TF&ZC$'H*JL&+<Q7>\SVUADSUH0KSC$/0T[E8?!*=LK/ FC8'\7RO
M]O1UU*#5<%HY?3'"(-"*Q2]C]R8]!M\['4WM:CXAX'"M*'\.(]*/@^"CE>IA
M?4,.#Z;[]6R'$2U=A-\6<3U_#G9&_RP!<-WCF,[Y08> Q^GP16^:8;R^R,07
M,^5X,=-FBYERO)B)%S/Q8J9TG"[EV]]I,1,O8>(E3+R$B9<P)?A^W+X/8F2[
MGG.J)Q^UE+ZITUY"*M'1/'*S3N<2R6=M[A"+]EBX=;/3-?=E8O!+F,8NZ\K(
M=1K[AIQLVZ.!;THZ?2^TASMYJP4R6NY-['OF9=F$>1O@]P&\L47W-@3#&DS8
MMQJ\8^H(9R:<-O",?V98KO)VS'DX0CP:\T$Z *<7IO2,0;]',7DDE@)VG_!V
M^@UB#?X6#P]@I\'C@KZ)X2U5&*.F*4S-?_^(S+Q^J]W_+5B:?7?4Q9QBWUE/
M8WG'[,E57B;:^]*+XV&QBH_S@-D]D%7BA348]+K,W2$NFL2N?X.:O2'Q2[ 7
MND1S6- 27NVMQL*.S"8^/(A@%*/A+"O.2-:]=V+ZK!L^%;J6.7"=2+[YO@(:
MZ QA6_8G*GA5,ACQ<4LNW-@U:_@\=#NRVFZ AYWP/_/IV*6 _[VJZR;FG*G4
MHTL=ND&7?(VMV!X:N:$4FI0]^='O7I]\N;VI3;I/=7R)MMB&QZT<Y9:W>2E*
M^27#FI@K&ZEY 7RU=<!7,(JLCXX//K>/SJCY[6O]N_1=OIU6D*RDB1B!+/FI
MZF&==%: N."#N+@PW.8X;(H1 R_<'#H>(-@_QU[:C<O38>FX$79$]*.R/O#V
MN_G;<//1+F_0:+-;<^5QBSECPR'M(L*=:>MY(J^HJ* QKF7#<8-COF);LSUY
MO'/JA<J7VR\WY4T-U(U!QYD-1)WDVY/^I/5P<W;B#'_GHHR$]> FN( 3*.1<
M[@K"3A2FT&/C2GWO,0.@0"'HT]DR.V2C@U^?=D!5 E->V7Q8JL!%G/*Z='#7
M"S+:9D=6T1?-#H3=X$(A@V.+\]Z[I5/A%K:V41/VS8>?(,_8!FLHTW8"H)DA
M<*^-%+*)(06\8W:#?PY^!G[IU;)?[%A.\'Y?^_$CD]^:(Z9=):18#IVKO?9)
MKHD-=R>6 QG8>.*>Z&:PV<B*J>BQ('LN+K?9L_YG_E"^J5F6UC U:=?6U>73
M+'V_Y3D/+ERE=ZYLVL-!U5#/IAAPU_'JI[O#T]Y .F_>WDYGF'M@RBX9)[\N
MH.)V+H24:$> 0?2IK\N\$-FR)&;*Q65F\K,FV<>C.>PK?YV_A+_F73GQ\)>9
ML6[4S.#+STQZ^6O!K[1=_BJ4<V(VDTT<?[WH;IX?NQV6GO/"+7]DF8OT#I95
M' -CTZ;G]XLSN6,4"L\?$;]A&9B0Z]C%!G!*=087<P+CZN3C[]/KPHE<T2);
M7ZD0(LLOZ4B0>;D8R65S8JFX-%CP]*CVY)H)26:ZDUW>T1&9KI[-*(/O_;M2
MN;Q?3+?\YMX2TY7*%;%22@C3Q65,ITDR;,ODV"1[1%XH=7*:8V-W&G>:Z"3T
M,LK2<@35''5TLBV+>YW<$W59ZLGYI%;0OMW5S]75M^[R@R;VXET_WV7%95J4
M<F(E']G1E&K)F!B*S[Z XA>RA1I K[F;\Z_YVR<4S122_+K91RL(/B/F2CDQ
M4X[L^]G2]>.G'(=4Z0<R@:J%]J12SYXT3:?U\4;;4)8.;WN]7I*R9MLCLMC<
M-MBW<TE2UG2X^\EX^HA;-U_%Y-0FR\K]2&NKZP;+-XKD/&+?K!LJ>23JC5G'
M35HV-H%UPGKA^EEDF&+(ONL9L9,?U4?YDER/OV>?XO+-GO.9[IZE1WB1O*#[
MM5%D9*3BRJ308**Y'=KO^"16DE"?\&QLCB)Z5>?7^?!C_]3I^+FI#3^K>A8.
MC#L20#C+718;()P0<LD5I6>0BSJRO'[Y$;-=#P^FG<7T,9^%L/-+X0L9T]:O
M?HW(*#"X0B58/*$9LI=%NM@[=)8@O!8-M(G>\FSFE*'Y7\W'=&S3W+<VI[[F
M=]*[ =SBB=ZQ[G;!>AGL]@J,2FLQYGO2L5*-:4Z_UV]CL13%'#G8#1CSAX^%
MLQ%M8:AK RQ.$?H:O,-"7\7A 7[-TFB)/%(4/*'+EM^#Q5G8',X'#D[@\&=V
M:" 3M:Y&5&]@!] Q]G*T5-JE@I8_T>-@?SR;M9'H"BU'[G8/#P*U=R<C72?P
MD_ 6:Y^RTOM6]83^E'G_M] PCP&:)5$ 8++LZYG.02*"E!8!N("AJ]+:%M6=
M&:/C#F=;G[@]6*8G.#QPCZ"2KF9XK=AFP.!U L;VR#V_D2]>(I9;M\,><X?6
M8'<,/)R+2_?Q(/\>"^=SVPZTWS@\F#;Y$-V7TG(>-O]F<5WL\RO3)BK+VX6(
MX5]%!*,<XO=#$B0&#@4_.K<(D$#=JWZ[!G*>RHXEY7'L+D%D^M6(;JMKR@&L
M\(Y.13(<?1SH/ D/WAZW@"4LVCW'M59<FI0--HH%KB"L5K/(0-8,*@* =#C%
M)(%BIG?,F5ME&7+/^ 684^UCI@,1K"4S-=HO0'5IQ7T'TTKD#EPSH>6JH(IH
MBC9D];#^:D/:BV^V$Z-JP@FQ-^7T*Z@IPRV$=.5]U?;4(FS)8A-"297U[N5D
MERRR^^;7,D\)+U#?W)6QLGA*;;:IT]:@1B@=P=V$*HRKLNRGT?*,;E%YWBUJ
ML]VB\KQ;%.\6%>P0XAT[O=UM]KYI5(./D.?]ER*?D/=?VJ_^2UMLO[1;"R#.
MMA/AH9% .,/^YHVWJ$[]TS<(W^?UFMC$0NU)MW*5N[BQ&H:RL0836[&+SG$N
MQ[Q_'@S9N2XD,WU^_3Y2(0Y_(BM]KS$5ZV7LFDW3P [M;FS[/8RF'MK# Q81
MP%]9D3+ZCUW_92 ($5? 8 LM/<KMR>_NSVZQ61K_^-.+TM+C"QD+4[K#3\X1
MX-\\@+-V6RZE"A\9!I/6MZ.\J;X=RTVM="1LK=$N(.[6#!QNZ_542$ZR;H32
M]0WF>M6"42:>__U<#7,N?:8\GS[3>3IAI#.OK."-0"^$@(+BH0G#N)FVZOP,
M3RO6>G^N>K?-Q]JO\IMUI^:$S._&?(\%W2ZVX[WY4#@NYY8,^V9T%/5_W+'A
M^Y<CS+GGY=RSD*)\JI#SA\GGR0B+)9[FGM59OYQWDE'K,N=KWGB[E_!H^#YV
MHWBJW'4CZ<1A%(XPQI0$+R$!\Q':0TUMJ\/VZ&IDD?#+L*<8O^JWYM?BEVE_
MTB7HVG&#BMBAM>%"G7KCW,]$/LH&<DL1&=@X55K:.74[+2O^>HW\5]@M_RU<
MI_:5^=VYU4]S/TNODK_6K0IZ@KNDXTHN2=R51F-WMA_\7BGN4WF0BTL>>&#T
M\KT"\D!:=2'_T#JW-[F+:M?4_0MY"4K>;-X V:J0" /1>I?PA%BF*MO]9T@(
M&L3*OD]&Y>#^\%-IQ_RT<,$V?S0_E[+G7\Q!\=7PRQ.7:MJY)>F-U7QQ?1](
MNMQ+;H]-F_9 .$U;C6C/5K\;E<\GA7X/RP?GK\\I/O9%%,S"9\L6K)0]SI1W
M(!+F#==]X:;JKKEIX?+L?1PKQ='M[==&Y15Q3$PV:4:2CG.[:%6QQ!0-=*EX
MHD]%I3WYULW^N/\ED6ZMP/M4;#UCJ=HZF2G';&$1*2U*/#55FJI'V<<KSJRV
M3OWBS%*FS HS:=+,S$ <6I=)1\];;CFEE^_DF-/AZC,CJEAI*DYQ\X8Z#4W+
MR]+Q<JI"![%AL26M,;)H2OYL?I4\9 5P@>%__H U-E?.'6H.WP:&L[1[K&FA
M$]>F9;/^4#TA6*/=(7WY7C.M8Z'.ZCO=LLKI^+C%66YVV# W5>B, R58HH#Y
M1+@$%NS**J*=C6IS!QHNS+T;R&,VAIT"G*:<L5JIV(>N<TZ+>H2J?7@ )+'0
MKX&2*V *2S<7)L8%[^U(8[P:IH'L0%1Z6]DWIB/KP;_C(*J&Z?PDSG1(55NK
M!^;,N=KN./MX^>?KF6P-I]&;6\-GW37&R\6V_]F;MFHWN\\?]??".718X(U;
MA:^N A%PJ)OJ:<*3[*""'9@J-O,->:J. .UXZ:1@<!(KM'9N9H[I4)<-%(H@
MVNC*.)URMF- 8*,X/U20%]-$I^7K\X29VP9ALEXMYZ;E?H3/K<B^^5TO:GKO
MI-K\F/5)]OOR(RV *^Z4G>W"Z<V'[/&R3 267( #4E7A 4@8R8'=,^Q^#$XH
M5?I(A+0>-^P.=9LI+)#.7.>2I31.3SFE[F=WN:%R$RYYRWRD>]/'BU)4BJVK
MDD=>579J^L<SV(5O)BP)C5_>?QHJ-^7,A;J<4J-!<+M]DYX\;QQ^@J XOO+:
M)TG'E=)2L0Q,S@ 6/H=U(=%IR_2P8 Q?E\9W=_G"IUQ9>0WT\"(K> DUE)::
MOU-J$(4M-L2*7_V=E^V;+R#RT7A)>X-0^J"U6F/V_Y?4!N6+ 0:+_([V1'G\
M<I/OC^0?)^MWK&0EV!+:)'.5[U*,.!$V6C4'-O5;[6_6 ,LO?MOX$G/5-,52
M>W)W\TEJ_JY7M$_9-Q^FE3'^#F9W%.AGP,W)G388':';<0+?O_>*ZV!YI6]H
M?T:>?V,@@WZ$/A=4K48VO4/,#C;&HF5,FC$<.:PG)<YDF']R9"P^"U8$ZY/E
M $<?'@Q-V];@SW/=7MRN=K"-P/WE]YT)-L-SMVG=$4<8RA9K#H->CP=SI*MT
M)Z"##D&VH88HTR_#HZ"MZIK<H7Y7?[P]/&7@UW7\\P#M'UF]AY?!'66.;'>5
M8^%[GZ!A9M@:>G[@K8O+SVP1_2K34PRF LUMG>97W!T>!)[K:W Y6DH?H*'1
MMF CS>X#0#K$>2"P@0!H$?XAL!:%A[Z&,PU!H\$>R3W3HG8;[,<T_&YDTWH_
M'2=BQ=T*D%>(QU,A7MQPA7B$2%0"ZMC_[W\KQ5)E4]N,6?A>('^Q[66$.F71
M=\+7D8GJ.@HHE';8\T@E!J418%0;]"OFQ*5]$FGI+I,V >?LDA2$71%EO%FZ
MZ=K%9FDJ:O))ZC ?K_SA D<0LBL$CM?.=:6X$84_*R35\K>X7V>[\ -QM),?
M?3]K5#HP5:(?N8&T@#X*+W!U&%V'%:9M0 *:9_!CICJI^!J+-;R=T8K8+K@<
M3=TNN!SE<C01<C3GRU&_(XWM)0"P('VH,>W+,6IXH7%ID3!Y1N7H*G$6-/.6
M2*[]:G#TC+:7!=[V<K-M+PN\[25O>[DE]R?O=_E2WWRZM]_@[3IYN\Y]<<;R
M=IW/;-<I;+%?9]IORNWDG>HZ33P-RQCL:H9L*-J<@QJM$VJO>/-^9OU%"PXE
MM'7\B)Z)V:R+D44Z[N;P0%84:T0#5V[W#\U0S $1X=UD*&LJE9_L%=[\"1KE
M@_/)C/YLT#S'^&+F;O)>Z&9"NW$X1;:L,8T2#MAW @EB-()W>. &(HDBNR%.
M.J"G;UH8@W1&%HXN8)_2N*,/'1;>G(;:F%B<'> $U@B-"OHS+,)B@?!R=C26
MAN?%,#42R')W(XQP3&<F_0<P@.F; "'< L!>L_&1Y5ER"Z' &'-%JO14;K:'
MVC2NO8V>X#Z7M9,]#4L9B?BJ]F1R\O%W][IS<G.E;JIA;/SM2T_:D_)YL_:0
M_=4W[S)1VI=.4S)$@<%&\("#1.&#1Z#P25K?TDIN0WU+4U$@'])D<Z---%'_
M#/#[PK6[<3#-O(CE^R)N=#4FQ[(/P,R"PV!IF]*%O6VX<^DYO3MPAXLI("B!
MX1;#HB4<9,1F<L&/.P%C]$KV^/AJ9P03O:WM Y;L'Z'<(RAO'RQY&#\1A;0-
MWA)1I (G<8.?Q@#8GC/L/TQ%Y2A) DJR'"5)0TEN]RA)P&T6.^83O%]^?'[\
MUWO\N#HLKK])9ON_VPJ20FS7='0\?\9"O.T>QP;'!L?&:\1&G-W^<X7-=CX^
ME>V^,)U'[^8B'PD#TR!CKWBK"_M;9J:DN@'Y?Z+U=V/*@1]#.=-L13=MOZTA
MK3AO^T\C2*N&BO^I30%;?=3LP$.7"-]+"MYSA.XE=3NWAT-I*"WT%L]MM;?X
MTM.NZ@KCG:P=?K"(Y>B2WS-&FN\9DQ6E<D4L%3*[[12^4JSL*R\4=L(+[<7H
MY<G8__&3%_:E;I6Y-_I/L81D^DAF)8MMMWU_'"SF_WG%X3D;IID-B_O AMGM
MLF'PB]A)ZDA[/.IKJDK@Y0#5K/;8L72IF"V\^7 T']WGA!P3(9?V@9!SR23D
M8G((.45S5#YBOSZ#9I@Y%LU & L=3=?GK9YTF]E3#LQ&XD#L8HG4O3XKWK9N
M7'"V,).*)N.Y?#/Y^?%7\7/]IW+WL;>#?M4O4\&6G^OE*E9!+&0*8@4SWI,P
MP&%_B/YD]T0?DTTSN1E5?GXDY>:-')X;ETY>VHY)P_DM)GX[WSM^\XR72>O>
M(;_/[NJ=R5UD?IO)0G;33=9-?_95O-CUR<H"GCE/O( GHKF5T\03GATT^6S?
M?V[H)_T?7[K[S1,Y*0D\D?3!6J?F8$ L6@HUE(?$VE.&CJ94KLW'4RA>(1!#
M?0YI4?1"S_)R_0V4MURY(!9SD4<T\\LJP;2]E;#/+EQSN>R3KCE.F-$(L[P'
MA!D>"$FU+%]IKV>YO$\Z6U7V@*W"PS([D??Y'<O[%,5?3DUK:.+L.+9(QS14
MUL#2,!VRU2#,4U5"6V3'S-KL>.YUH:C[;188ZR@C&XZ%K.C"^P0A#8!N()Q#
M6><Y $GBC<6.W%YUX@VDQ63%4KDD%J/GQ:3Z3DH0DZR?I[E1\R*9O)=.]UHQ
M">ZUU\-!9[OEH&RB.6C7MU<$BXK?</O-GZ>[Y<]<HODSG3=<.0DWW$8#2*GG
M[2QM=:V:HXY.MI4'&RT+;\K9$5AG^3$2>+N]_%;*%\12J2Q6"L77>ROM@G+S
MR;"Z]HTAMI/P!EJ<5!"+I5>LR>V"9]:OHHLQWK3G/+.QH%.N+&9*.3%;+G"F
MV2;3K)^"$&,T:=M,$]&LR.\ZP2!Y;7WV,%P;0T23=R[AV.#8X-C@V$B^N^QB
M.M6 =ZM++K5P;'!L<&QP;"0?&RG*$OPN6Y9L.&P);[S/>.=^D7C"PBN<(L'T
M]X ^\.+L0/\)%] )SZA8??1(/L.9@Y;*E0+\DS;@8:\4Q%+E%<>D=I,I\5*^
MV')"8/+8+:JC<=>9[:^'I"L)(.EG9.BEEZ2?;@#'27KS&=N[(NEG)+4ECZ3C
M5HI6 2Q4<=HSA2DAGKZ$"(E=1'W/HXN(D%8IDS-IU+GX-+@>_RPG,]%A?2;=
M0,I<42R4\F*ID$T&M[T6FGZ&<;*R_<]F&\=5KD\'#_U36SLI[!NK\&2Z/>:F
M9]A%\7.3WQ9N<EVQ?SBUYH]/W5?%33S-CK-3#!WE5+FGV;6+[&4E\ZK8*;?'
M9A7\1P8LP4_P\]![-9MA_TZ0 (W2YI8=LF7HBH)"='THJZIF]"BH\'=X3O%^
M#RS'*L)6+P;&'R-%,/QT>6B3=X+WTWO![;%>P<D][&Q'"% XX'%!,]Z\3O-R
M%X'9%T[M#:D2_+?SX8PHE$$/#W(9\=]_.KNZFV9>M(6ARA&=70O;V8)[T1]\
MFHGNE'MBG[&0#HI[!M"H_W./EX,PH,U<";HE;4%V!(L,39 91D]098<((QM^
M7*#$V%N$,A#YXBY7V.RDDB=6#<'?EB:F;(2R_-UF8H/:4_M\0!P?X25(L(+Z
MP9*'S]Y\#G<_=Y$?.>:07N;^[>=M@?$!O9B?PP11_N>YF]@D6X-B)\VPW_!I
M(;TCFN"<% <G/7.?+P!K. %2NX&=(,/^HU%[8H5VDA30<H+<<X+,<H+D!)DD
M@LRE@B!?;1B:)W!S;'!L<&QP;.P9-I+7'X"UE."%E,FE&8X-C@V.#8Z-Y&,C
M\0/99+LOD.ET#N%(&."D=+;F@,Y+%[HX,#VE1+8BOZ7V_+&+T@9'ST]^/'1O
M+ZY[RNU5*?&C?J2Y#)7P,VU@CD]9S%4J8N&5Y'HEJ5]:;(0>6YIRL5B[-<B7
MUI<]89_M)"=S%HN!Q:+U\4064Y//87[JLM4[_Y*YO?ES07([G9I5R.UW(>9V
M:#3:S("4T*B?#]S/?^E4^KK2N]9W2Z.[KG]/4<^678Z!3E#1<[2&Z2_7R\)G
M+$X&)\W3TT;Y_ J,S'6@DV0%*Z:QTOE\1:Q47G&19)*G4;WXYMKJ[.G)W:??
MVME)#T[02707C$)QOY6O!-%Y;J<70EQ6Q)5L*Y7&]\?/0_UUW#/;*8OD=U'"
ME;;DWT6^$77;O!ETOWX?_SB_2_9=5$ZSD<7S[UY-W(]C@V.#8X-C(_G82%[^
M74+4RUVTW"BN:P!.>J-"\]RY&8Y.$MH68RT[:R/1SC(82H52Z?4:2LD=!KK2
ME;%9=]MYUCJ[.+V_&&O]/6(0GC*PSTRT 7_@9EUYS1^-<O=K_C*3U,Z FV<B
M[J]+,P=%3WU;YJW;L*/M=O+YZT.AT%&?"/KL?G)H,=630[FO[=58L!P;'!L<
M&QP;R<=&\GQM?')H*@B'8X-C@V.#8R/YV$AZP2L?%\H<(Z4UF[LON$>>.2)K
MXERKK1]?C-/^UQVEO6ZZ>?N\$W%Q?&BED-N #U[,E"11*KSBF2*[3_B+P"FQ
M^A%?/DAT4BN>-$\N[[/W3J(S_8J[+J=Z/01^FB "?_E8T<GO"^GCR/AZK5_(
MR:9P/EUT6Q3^C.FB\0=37SYF=))KZ+?%^_L?E?,GPK!IU:%V,&TT8?I5\ER%
M"9$@NX@B2R^2'Y/[;_E<Z>/D0?NF)3-K8GV.?3G?98'I,A6QF"TG@_%>"TV?
M).E.]+/TROWZ=ZUL/5Z6<OO&*CQ5C[/3MO/UKJX>C.').;E\++XJ=N))>VGF
MI8WYIC>:NO=C\KMR=?OPN?#I";_"GO'2Q@:/)M7""@X?=7?6 "/<TA2<8>:1
M9;F::T^Z-^>CHOHC._C86V,VZ,Q 4^_?+(7\'MF.UAVO?=*0,2=S1V?C3^&H
M<%+RJ.@CE7SX]W^.CH1SC>CJ.^%*[@'5MLB?$3%P ERY^%Z@)/%.R I'1Y[8
M4+7[U9X'R@2N[V%NU%J13E]YU@#6I\>J9B3IK[ A+\OM9\<<ADJTU4-_ LN]
MF0&<![+WPLUX".M7+6!'Y;W0 "9E8&V8",!R,?BM?[ROX9^FA.D1Y;__ *##
M8&X1^>ZH0X GX>5#BK/@A+O4@'@&G!ZIKH1"$'@(50:X #7/3A%.)7O&M/U8
MII=>U*^:I_5&[?"@WC@]%JJ-,Z%U>]*JG]6KU_5::VX"XC9.ET(@-IHWM=;A
MP4U3.&TV6LV+^EGUIG8FG-<;U<9IO7HAM&[@@\M:XV87 -WD2<]JI[7+D]HU
MG9,LX/!S0394(618YB9/EJ_@?13W\<)Y>2J%@U)W7BH_^Y@SDG/.51S]+2$2
M.R0!Y]F[DHZS=*;Y1DGG;?;O^<%L:^]TPUMKC09 =F[;?+,KM "86A< :SA"
M55',D4'G,E^!/J2 ?B[\W_^6LYG,>^$M*N6:,2+JW\+R4<V^AAHG.Z3N;CL&
M"HO]"#=]<GC0!4W(?$ $#HC3-U6;BBS9MD>#(1HPMO! +!RX351@(+"&0*X,
M-(,(3I\(7;"IW('=0!A$5OJ"HL-W\3>9EJ31M^E3ZTVPB(+*F(I#O:=?/SS0
M#/K&CJS+J#':?3(SJ"AEE\$>4 ?V\#H\",S/>"<L3-086F :6_!Z-,!MS780
M\7VMUX=/+-D!+-.)&S/#-BA%.!:=[SX6@"YT(#'-Z0NFI<%191V>=D86HQ;'
M/#Q LC@U!W"N,;[>Z5N$X'N=/M"9!6JW[=(LD.EP9"E]&6E5E7%;0&1#V2-1
MNHH]!'N^J\$38U2TZ3;MX\6C642G!\ =1#L$KD^IG[T>5P.BIGX&(<-V/L,Q
M?<]=(W2((@.#X0-C^AKZ@,JFW M_1B9L!';!U@>8*X2>O&.9=\3"GU0"N[;H
MDS)C6C">!%L#S,/I&2<>;U']X/(V[ @?3=!(#$R!.#SHF!X5&8!=X*V; )4#
M+<#?@!PT2ST"^G7&%.M(##:Q[@'_*(H9%0'- .5HQCVQ'7PUT/*MH2'EMAPD
M;6%NI3DR/3S8,)T*LV2*=*BIL"]4Q()W@D6&IL741\>25<+I<^?T>6I:@!,@
M&I<\148Q(L67,M?7?*,4ZZ\L!!<^/ A;>*6<S;Z ?IDX_2<@2_'L'4UU-V)V
MN\3"3XBA])'*V0W"R%FQB*HY<+O G>!^9,(R()T[" !*YVS^,J?S7=.Y7R?A
MUT@P8GY@GT]+)X2W#WT-=%JF"Z VXCU#?_:4#5!6@9BHTHO$:N(N3>7N;T&S
MF314CQSSR)6+5$EFP@^)#@A:,UTI3 D7WFCTD%:").PKS; J(RO-@*6(\)8\
M#HEAD[\%5W^6P2"C+$E9#V\ RF*X-Q/6<K4#--ET^KQ_'C@!:'N/R&F@/HD"
MO%@##@'QS1;LRHHKN17-4D8#>+>! EX'>@^^*0 ]V&R'[GW*K/ 1A4W?U%5@
M)FHJEMY3Q<L9'U,LX+$/#WRC(OS5 %F0'J!\.C[[RLP[?]12X.6(#6J^''EB
M:&"J1&<KV $#-FCH4!L'X @\#"(,OL1T3_8B8>9%]%[#/>(GX5N4*=#/B$)#
M3(+G$1(1=>C+%=YJ?POW)E 6>QX>9B3N!PNE;"!8V$(:.T'5%F4NX)RBLHJK
M]BB.3\;31Z[D,<VTA%VI?MRK.CUJ#:A& =!]\Y>_!DBVAYK:5H?MT16&'S'J
MF)'@?]MM_&DN_MCR2*M&48=[ B5YL=?O7'9GIM+7/X\^E:UOY*F0WQ8./!LW
M/+?, 9[T2,+_HS^MJ'Z)&#.L-\[]J.%1-A V1!B_^9"1I.410_:?C8F]OT0,
M F[XI6\UH&)+L^^$+IIE&AK2P)G4K HCZ9.X2/H:]G .6ZB[.Z $#<0<"QD/
MZH6SQD.W5-/TK9)QV"%W3\32<65%!\(8J!B(#JC.=BSMCC!# TGM/_.TEHE/
M?+)K\@J7IGD:(#B5S9&7]L4R,OGN92%WMV4I&3A7:%+%\Z@)Z<2E(LU8(*A@
M!L45W:2-M%18E(@!P;5Y^77_]YP;,ZC#A=+5PK4<%QV,G2^__I^]=VU.6VG6
MAK]3Q7_0F[W7KJ0*^^9\6+F?5&$;)R0V$!O;2;ZXA#2 ;"$1'6S#KW^[9W0$
MB8,M@6SKV4^MVP$TFNGIZ=-T7_U5KTX>"VL39-QY/&??-MF9PT9C9X<\QSRN
MC[ WQ-+<8%D- S7*R>)N#-:?AL$V-D.?:)/"K6C\CD>7E)5^0:SWKCHG-6>3
MK1R=J"0[5FK]*YK:C/#P10#CQ$*R#U^*AXW%K*/X3C(N3M^_@9_?QL O[]C
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M9Q!AK*BR.IH=9C/=*4):T=0_]FZ8F$: V^!/D-E8X*?3!#]5H5_"2X >U%B
MD766?_@XEF"".IGR,!;,2-(%C< ?0SO"! MQ>).NW8:5H(^3!W"JZ7?9S&#&
M4@K'$AERJC,Y#*OH^/"$OR<:T@7^\'ZA Z%&O(86!)),-37P(WD9Y!5[*5*/
MUW6B4]K N'0^X&P><OWE]V4S"R^<\"+LC@FK=%_H#@E4\HS(\8:3%HE[+>.F
MY9".0$.;S(<Q\?(;4F;'0&0,FM -7*W#O#<2JQZ[G<\5N<K?#<X>?Q3>O>J2
M=ZZZCF_G)U*A.;AX.NKVA0]?>IH$\F$J$RI8?#N7JK"$JC#!V25,2W8DO&[
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M3QP9#HE@Y&P50STD4 ;FQ*2_R694>$*CIK=&QD31L9Y&HG!VW$<<^Q,^H7M
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MHZ%>3-PVC'0N,'&8K&'/AI.<$?5EC53?_4J6#@+?Z;9:C[IPXND&L<%*5AZ
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M H^="]6O77T^>?K9*'LP6]UG[0Y,:ZN3O ^M EOUI\:_.)5D!5XJDFY-.[-
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M];=S*2KPG$A+OS<%.&1P1^1)D$V1?/GO_W=PP)U*1!;_Y7K\"'CPDOPUB2+
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M73/)XFF[M HONL,K12.".E+P@@G.X)%5.G.ARK)E(?4Q*Z$/;SR25>'^@Z^
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MY=<.\J6#?,7YJVK[[X'+M:\7/<O:WILO+V&DYM<G^E' *1V>MY)3 TYE;JD
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M0K2^&EV:1I%3;-9$8K,6RX?E,#M^Z6JEC$;9V[#N7Z4GT5:R&2O8DK.=9O)
M$7!LEW6%XY]C[7=H.)2&;QBHT*,5HJ"!AZ6(" WP6!%*BC#$6)G"/X9&)9UF
M04[<ED)RT==;%0H+C:MRWKYXKF.[78@RM\KI9]!NO(VRR/J5X$\>,82)/[3C
M71P-=_GAXSAI:!6=>T(R(<&D;,:F]T?^DV\*DFYY_0P%$R9#M!$+G+":="?"
M!(,.+"0E&I#Y./C$5?)+X8!%T#,,\QH6=B3],YOA!5K]CO3"8/C"(+BCA-<4
M"L.K/F(C)QL,+0?&-E #_M<.ZHC.1!]QXPSK0@)7\Q';%WI@Q;Q@F9]RB(ZI
M8LR1PNWI%*1WS -C#0@#]=15UN>*\J;=U6IHWUAP'U6KO1;/>'Z9LW$=3H3&
M0JNT0S3LGTZ_1'O:A$7<-8(QK\<QANNMH";L*?A<W(,J@2QF$Z4_9 PPYA\8
MO[";BL!SX,9V!%6;JIJUD4.K4]="9#7'%J\L=A0.CNP$#VZ%U1:A1VDPT=T+
M*^Q&E^ _"C19+?0LI#&D),'!49F,#>.86*9P<' ("9FX0I<B*.WH5F:I/';^
MXP<OU^_4R5%O=?),A+<R=M&JH6Z=7[.JI>"ZKIA,0'D!Z)Q(OG,0@VX:;#V-
M)Y3>J(!@PJZ"]B&W-Q&%,0,H1JQ>Q?N=!V#:2>&CD79V&VO]>%%%'%OZ]X*
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MY_(+[_:WIBQ>A7=^#E4;18"<&)<\DULUPZY$U=H& 8P0HT(C.0-6T\D*<X9
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MDB(W=DE0%#(B7TR'UMH?[!)+*[5U,QX;&T4M3Z6SRO#;P.K77Y;Q&'WT=P/
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M(_ %8E4@/FYH^)B$[KV\=T_&^)$2-\#'3@+F2]KQD8W_9%$ZR>V#B3 #4?A
M#"4+%AV\YIJ_>'A0[2'^A 6%".ZBO#<[1VKI(<PEI(>PDBVG3LG2RQ;T*&L3
M!7WZ^%_9+'<.W3_><U?2+08$7;RY"$,H> C_@2/P^#TG<MFLBW(4]7XYEB<
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M[S#'1[?(3$YD9T0UG\,@DAM,8.8*9QI320/@R)$FAP\DJD-;Q*DD9 2X<AJ
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MP!^Q)B89Z$)DAJ1"6S/1B>,C70(M3[]M(H@\$*;1?&/7R^M/.>SL3TC<@"2
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M>2>YP9PTL8>&J3Z1FQSJN1P?.<\B)%G(MMV+-,OM/NPZ!V, 8R.:#^%^:0R
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ME*:<6'PN+: ]1O <_=;'L%UY^""93]S54#)'$O[H2(7GO<6BPEW73_&#]<D
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MKR,A6GI'JJ)H*%9WRXVZ^S4J)/0>$>'U7>L7A'^=)TNJ.8)R->K&G1J2J23
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MIG9@B%0$0DDJE5N(W>_SO-^[UOWN_=:Z_USXXU0E5:=J#V?O_=M[GZC>JH3
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M;$>'@S_;-\0VXM2]BQ ]-;;S3L;$2O.0!KU7+VO- <(G"#,]K@)F_J4",E6
M,@&G90TV$QH-<T8=>)CV2Q7@K (4!BI ? B=I0(^#')O<Y'+%O)C^/5_(;AJ
MQ+6+<'%:X#3,=63\"8[1(5,NS*?;J8"_)@$LSQ";3<&GQT7S*)I1+Q%@1@5"
M9Q!GF79+)F;Z[:M>%; :?S+&@CLI,^S"FE'FYC>1?NQ@[' 3NIB@6 ^U?J%?
MQ 565XJ$.K^7CSJCV_%/SS2CMA9-+'032Z]R;$B.9?0H ]4G7R-1BO.,!M9"
ME/*(OA5Q51S#7E$,L*7();:DA:X/JP!Y#.(J(2P:$IQH7U>6*'E$H_+(EAWC
M0R/#RDV-(P>XFS81W@>55T3<F[$Y@>CY3=>XMU0 8I&"&E7#1$R[3W&"ODCY
MU(&H.(QZ(_%B,":<L>'Y$SC\&GV!4&KFU-E\G6%">U%C" 5WC$5*H$!K!6EA
M'Z5Q_Y$7_-C&KIG088M,#)R<=9^P1B9H;(YAS:$6A@H2* L91BBY8]S>+S+K
M+4W2Y&L(IW_(])=?"I"_LCQ#]6S/F'PE=7Y%,OUKCND/CGGJR3CK*Y2W&13D
M97//$&NRD*O'^$T%-.Q')CY%7ONZ4?Y1!5P.1$ARB:SBLL,9,3,A8S5LTGS9
M@02)0KR)A""CPWG42(W/+Y0E\H*G].TSRW?6WFCY:"Y%$K%E(XC3%ZC1$=TE
MP;)(.BK@"Y5Z>@RM 4^"HL>@_U;NE_.LDBX[Z.4IY'R["I@-=6^6.J,V3<,Y
M%=C>\_*()K>O:P5Z$9#(;?*C28&L"5L&([@:.1-D9KC@OTWH;X$ZBN#$ /0W
ML)[!&EM-\\O!-"4Y)E&?U.4.6#=8_,M?6#NKY"U1[L58 HWN_S9]%C['%L56
M%2 :0,ZI@-=.C,TJH)Y,G"5C(H%0PN(F"O)CU0:6TDH%#"D^IOJI@-IJ%3#K
MG@\D>H"9GU<!!UBQ*H#P-4HZ^"]&J9I2+6@R-ONI?T#>0'?Y9%Q:;F^OX"WE
M[5'O_A[?(T<OG0\)#SH?<JNRA%N^IO7WV,[VH!VB*_%_$9!5MM+83$8-ZZD*
M:(3X'RGPX3P980]B<S^(/SX14QKEU>O8:3/>27?,I)T?+H\H>G\G,^!D*Z<P
M->;ICMG\TT"*S3@Q&B5I7:HB"$<TO'V:H3-"%:#[R=2PG)/^8[CA!6Q)F]3Z
MUO-*]=F+NUHVJC7NJCT^2OP=0C93>'P5< VW;LFL\N9X=..#(5.S[C"2&N)K
M:6+ FSSTH:+ YQVI'M)\I\QH=WE2\JM\Y/V!?]T863+O^>]+B86LV57G"/4J
M &>"+F>E5X]K5B_J!&O%H.'4K'=_K&3MC6DTTKPGMCQ#_O!)PSMA+4,@MZ75
M$*[' G_)^+92&\5F6HKX<!Y,X;%*M6I](B4+D\P'"ND6K>35B,$A).61\='$
M&_G(PF:?F_6I%_<6R94;=GS<;+:48<%XQ84/NT4+2L$:*!YZZERC0^%OK!.4
M4:^J /]T9Q'$2W)K@DJ<&REJB-EVY*EPI =3%H[8,*\R5L'EZ2+E&IYK-YUL
M9*]T=M>GI'D#L9R^Q=2/U!JNQAAS'J.)^ 0:]H,MY>;(!%R!Z=C -^5U,)3(
M^($>V$E6HTWP..9(Y/E,Y,NH)W)/)A$;2HF1#PD$!#=>UZM6R]V&BT#,(-UC
M3R>GD2#?U9BBS%=3#M RY6G*-/IB21[9$.')+R-F(DI"U^2/V/)*Y)P8O-:O
MWH*>UXJ76J4.CM0;("Z'NZT<ME6:W$ZO[AQ.S0RZ,9"G^^*/MKR?DHB)E,76
M;G&0&F,%G?XDF62$4$4C=:Q%=*^R"AC+"3(GKVFM6B8*&3%,]+'P<)/J.N#6
M;KO?"0,7CFGP^A>QW6:IV$PPQ%5+^+$6[ G'=)APC/RE\A9F1IO 9FO+[.5W
MD5;936%STT5,#6$USNVGZW5^1NW#X0FQ12P8J/ A[(='+C-,Z/9/V^B',<L6
M9@*Z_FX5%[[45N8:L/_,"JB(JN;9'PS".RASW@[<\;"+5:H =%Y__YLFMW;I
M60M.90<)]&\NYN-_GNG=*47T0SMR7YX]=_E(- ,*A.!S%@UIE)[N6FYY13T3
M6>$L-18VO\VLY[XU>ER@V/Z)M8 SC]9H0JC%EG>G\#;UKR9KE5:UTYVB_)05
MH;E_"GI.JE\^3ZGN7Z]\ OI3X^?29D )W-+XFN;8F_3]+6,J0)].;L-6H8=@
M(J\ZI&%R4]&9H/!LGT CY^MA?:1]78E%TMP9M9Z''F\[7=Y*J0UCH0:.DG@>
M"UEAB!J\DK_L<O!1^#$ZB"6L*^M00S&SUQ'33A*K@ 2602%J' Z_HWV!==U$
M3-Z([NZ<8*-UZ<+J'3UA2K\:+V:\#56Z+$I9[.W:9MWG%OX8MRF>:$ AHXU%
M!$/8<VB@G%H!:\72W14$^BJPV/8Z?37NU"9DSE);&55>"L>5"3<6>M$H/,%"
MFQ<F;G7$XO)8^//DB (\S(4_QH5RYP^ )[CJAXT:4U>I*])DW5(#6$<46]3W
ML9Z9S-+B$#V/T"+=9&<S(R74A P=N*@ZY8I-8O.3(,;J2I9/=^AX:8N-92?6
MW&[3?3Q[T.A2H"C\W*4O1*F;"M!8B00I[&@Y\MEM#AL?>J)GX2;I1\5.6K@<
M@L%Z0CQFVT)"+>]77)7J]K&OQQ6<#-MJ7\\GGK!^O9NV6*]&AK[!:L$22AP4
MZ(:LXJ(&#"J?(+R$% E!G2G+2E&SKMZ''D&B\FC,6CED@-J(N?H(U:.MRC%$
MG*:)^UIT)69J&,'YC7\A,\E[C^%O<W<4HUI"9L]'^6\R-]2 A<T:A9G" 20&
M=A$GW\9?.!Z1/D2,F[Q8O!&#$#]A5%R16->KJ8[A4 U+I;^F61%X@M-&=VZ%
M$8:5&^[1.@T__ ) #^-B9#HU&6N[4!<16X?67D<VEQ%BSCXHEB7'WJ<E.G79
M<'4H1T]Z>R&)/SVM3AW]L?KF\ 3YJ-TUIV7>SFL*?S_$<,4]93*#7TE"#9KE
M6Y$2Q=$A3*V3LW* ,EL,EW9GZ+2&I;D2W+O<$NC^#Y"=/59EWD,F.^M:WO8-
M#3#>2WY/;GGXI)D83X%=V/PTD3,Z3R$G(0GX$F4CJV7J(A4@U8$=Y;\_1;04
M3DAOG:FV#+Q>1N&3Q%J-@OG!$UR<F\$FWHVF*ZNQ%IEM++;T4\KA5$:!V,2Q
MOC(7?EP0I+Q9XM(69F6VAU+.%?Y%TD42&XFP,X'?SN/,:QEO-@A)@=%5WKH6
MO C?G,=#X:=9BQTT?GX5DG7DR*!A=Z&5^N?9T0%;U@ 'U&[";IB.HZ2(*D]1
MIJF 4P*^!--6R)KE-L^53Y9U2Y3I##-:21-Y!I(HA(R01)ZO*66>#\+X,E%K
M&UOJ+75QJVI]<\M<S_A UVFS8R>.YQ/:N7QC/*2]Q?6W9^L.<(D,>W0K$B9V
M,QKR<HZO,A8FN5-*64W]I"Z;@E[OK>NZZ_HUG]IB5MTN?>]F>K27/E^;J=?O
M-^-G00JK. #5I]3X+D(2%0Y8)PX6P& 6_Z/\"9(&0Z+.4I:ZM1M?J\F+42"B
M7,*]8")J%N)7&,(Q@#\S[P\L#?&*BFV2,Z[S8T"Y1\]I\[=A6S?NOKGW:XXP
M!34PD#^?"H;H$55($UPBHM80$'R1QI.7TD1LNH_,37*1&J\"X'U@W*3SU3+7
ME.X(L-'-B$)W@E/JK;1X%SRN&^YH3ZFQ>UR4Y:EKY:'A&[WUE1P/P&(N88OH
MZHA ]JHN(F"X0O91G#/<K5A!=X&A.@)?(G\&![5P17C\CUR2Z!2XS&^+CZ<R
M47/R#\7P^_'.]/A$TMA#5L^O/N^=7V=#P5@=U@:5$>LH/>?E@<AMA0?]I\[W
M;E<@'53MG(SHT3$6XI[7/\C?55%6V79F3,>IJ9=4M3W\HM_Q1ZMI]95)TM02
M#7.FV%'.:B5OHFL@X?AZ*L;)/O)288VU0'/!0#QRF9 ^/R-CRG^2&5[F&(6D
M5M0U7Z40,$M:<TUJPX<7%V4SWKPZ@"_<.+?+I^GZ%_%@[5CWN+]/-VM#VYOT
MO%0E&Y_O1F#E1ZD_;N/ZE,\@X6WN3/IBF7T]M[1YF*WX 7M#[+4">:^*+&H$
M!F6ZQ!TPD7EZC'@%6UO5H1&?,-[GX@:/=_TF-SH/U9<<KO19 95>G*G>!_FS
MD77@);(5PFOB:"ISH%/4),H3W#ZC6Q7K<615SKI4A*U[_6"HG&@ GB+J#82G
M-EVM"G_D2SMYZTD7NC7'JNAS@7!HS*BXZ*_8'T(G-..' W#R.V&*U$DF$.;@
MH.TJL3BEB=H3SP/+FJY4A4M&WE:(FQIV5Y% /!H*I.B@FTNKN^A.H5:A(3)(
M6#"*!\EN<S]-GLU2YIGF9/6_O9%/D%JM&H02,M:V8*NAV@#R5BZ.E@($E\ E
M#&,:14A ]</E\<H[Z/$B- 0)8M/MGKY0YI(WH79==)M'=*,6K8335?;*LJ@L
M0?\&/#C,B6V[8[GUM?*6C<FFG7W*ZV'-"<1RIG0!SED"8BAJ[N')HY%S>;BE
M7<%90-_[1%E&=Y*%B*!K="(>+<Y$,O<@NT7<&,P$/GNS8&B3W84T<>3(XA 6
MP0F[8RWOV!,4T:*KS+:NI@1JC3!K0,2*,-R@. #5_DAW5J@SFN<.0O.7P\PZ
MB@'J+--J4A(.5( Z*[M1HCB2H!="UH&OJX 3-S$#\_;/([,ZJGRR!LUV&14]
MSGJT@W\SZ(U$[C@-LKEI11N%4A:O&=FR4<1%+4=B89JQ:-T-_ TSNT(MM1V(
M0BJRDV,2%-'PL4DP3W T:%.%UXH[+-'0UI_'?(J^%K_L>.=#?=/('C#\&_$[
MV6 #*'@W9Y^Z?4Z+"ECFELW"(Q72^[WW-;^G$/+!KT$8].+ /G7H?\D8,+]G
M ?ZGQ,2]/BSFJU&4==2';]>L <+FN[M_9C9]3<6/&KXA^* QH.D3F=O2/L!L
MB8(>Y+3,A-"?TU$B3!S W83DUHCPVZU[@/]*N%C\6^KE;I_[D-+I^P"0'PZS
MW-$&E_T7W/*P$]%+E%K=DT91?R=S_,+<V./S)[\/0)#BE0J8@1T$OV5IB-](
M=E2V(]"&;5K_GH+YGI>9O@P8_/NV?PZ O_,JMXEHJ0H ^^YKK^;^9R[GO^=V
M[*)Q7':']5%1M@*':59@\T0P3N#T=]\OA:88W_HMD[--+U<%O,_YBDEW_Q=K
M4\FC4 UTV^[["-BELD(9X)_M>7D3SA+T]=]/M/B6</DV6<NW"UJ _[S1+GI1
M-65(Z4J^.SU$+THG=$_.I@9,,C\$O6Q10O>SY5 N=BIZQ=]9G._C-D*VA>,X
M=IGU/?,R)94<2 M_D#N$]-DCH!!LBS96 4VK/0J44-ZC*6$6=&+<CA;U@82I
M>7/:#1[@$VW?IHW#N@'!/WD>RI1K.,!$2-1A'URKBY$FD=LEJ)093]X4S-D@
M8_'2" FI1W%$15]\'V'^:*3[N;J(=F'6.AR\+$#._8I2:!'H F_-_8N+7\UM
M"M3ZK*4"EN19?EV+FZ27N(+>!L?,&5T@$E*%OUSS<B9RO0#3=E<!.RA2'+_&
M\6JYZ)=5ZI,MWZBR0$MPB?:S_ZJ%A%_PZ-9-J0V618\W\0A:^HA$3 [$)_T#
M-\KVT%][E(7G!G!LSJM]B^* V4^R&(W*59]LQ@4-?51T2%KQM:2<Z?'%7PLU
M=<+I*GIV9U%*+5@6]_6O+_@22CPN;'^GI@)LEDQLU8Q(Q?+I&]D]M!*>E]:U
MT/I[H2/S/E7NY1Y+T;][5B.Y),>SOU>9M]O<)]$EZZOCDKF&^1^B[8(#/['B
ML<LAH_;8;)P2C7W*W[C"V\0Y9%/42_DHE)K@Q8UCK$ FJ?%>,R%=ARW9M,1#
M,;XX'F*+W<EY9PI#^HU=0DA//DU0''[>%?XKT-C2KZ_PQ,UA&.3'>MLD]U'>
MAD*@:Y@)TAH.\^0UK=)Q0:R<80#?N91/RW[3-5K'AZ[/I^6X5,E\[QW/Z8N*
M/U3VKMSH3M[HK^>?S*@AE@J^-..<B6!^#<"@:DHBL3P%-721.RBO,&9@+UFE
ME$:(0 ^LAHG2&T*)!(R]@.G &;$%(>65VV!N3-717Y#B+D5#ZLD+AIE[99Q?
M%Z\EC6__$/7BYA/#-+D4]Y,?&4T"V(T43RRN:" D,TR0U[E(N)P#;Q4D8X8Y
MT546]X=2Y!%;,^*%;OIE[$0K=M6AK#3C]N,R+6<-Z]%\3$;=\>LASQHPD'4?
M5TM'-W8#%UEEBQINE&_%9S_S"2RIN,HA(Y$2TRP_Q5[:QGVR)IX*0#RP>2UA
M+PO'$HW=]'S*N%<YO>+7JWHH/] >_WZZ/3D_\\SG=[<7AZ/S73"=>PI3J/:'
M<7;T)%&J?A]'RE0PD*GY#AFM<18)KH1:75AEG>92O?RUM&PT%ZG@-3:.7F"?
MVO&CS=+,+6OM $8S)/LC',87;59 3Q\ORC\@ZBSQ956<SK/KOQ%7#ENU;!Z8
MV+5H>// -<06FYTN4XAMAW'MG0DK'W,#N3$3DQ=29"!N36NY<Y&F6J/DIUF]
M(1$^&=R39Q:VB4=V5X''J[>=35LCO.P=TP PHB%9I<>48>Y^Q2T.:/ )$4/#
M5,5&^CGD=E[0D!@D8G]RM3B6-,619,LHBSU&W8F<10BUT=2RD_''K"=/GBBB
MWDLG[NB]MEN[M/[D-52,0+A*?E5>(9NAVV'G^,(S# <D4D1J@*YU4V8R"%@7
MF838BG6UY+Y(GHS<]E</00=Q%_M+;I_JP"U_BW6ZBWM;Z6N+@^#Y@[ZS@"&&
M-4X(@7L22N;\@.04(9EB0VF4J#F>9>+@#29Q;!AO? %E'L<"\9"?1AZ(+8>R
MJCNI#H?@_*9]BAG.;$%4QJA'^YAQGX7K'6^G92?VCS*>T0+PQ789W2(:F47S
MWO6TQ6&C*,K8#1Z)&]NZKL,S*)4<D\GW[@GR\L]ZLM;J]&EKA7?(_&W/#AWZ
MZG$?O8Q\Q,EK429RU%$OY#W,.]K"#82,/U&*QP3'E(^PC702LDS,,J$O1!:+
MH6+C5Q1-Y&/#Y!9!"-O>V$7+CG$O+\C.-R_"P+,SM'GXM>?82/48FV_+XQJ"
M?G'*?([N40%49R-QB_:J:*3$I51B=[L,L^M&:RHR5L#OWQ0\\C7INKZK+.BT
M3X+9XT.] /'0= F"+=Q8!\)>7&2U!FO8X '6G\I%%YAAVK+'R&1;VQ"%)=>2
M:=6^GL$3"ZZQ=B$WHD0$9+N&(!8]Z["C\N/5,?O]8A-+A?U/[6YRG[Z;5(VX
M7#";E 3"1P2QQ!)F++;@E<Q2SE#F.U D@GF,U[[SE=FX&"G"G!H5,)<F<4$T
MA%$4I[+.\<CFA$JE\L.-G$"_;5RCZL0CSKG!$8\SK",;.TNE6W9L )0WOSET
M,M>XZAS.2:[R&MT*]WT\S"!&PFSD&F'M*J"D(5YJ!>O4L#3)<Y&<1FP-CE2P
MB8/5Q9M2=][T8SZA9=>&)D7NZ[)NGIN^9BO)M97*.MR1:7D-:9)XH N']B)%
M.5#M&FP=UH#]8&18R^5#V&PMJF(]H]4KH &<Z15$7@-W,46O'7QI'VOYKS.>
MWQ2^/N^J&Q*EK,X>A+[,KO)XHYVT#8SB;*#K(139Z"XX)YZQ%CGNX"<2:*';
M8'9].HE7,<&_S8D_+R',\O'QH7DIZNT.)8TGIXNC0!?."Z-!6GC][KP@8N]"
MHY6/^>[!J:?NRA2VH9/$ORPEI!X#N019IO@YB#47I2CL54!=@)@99PK(&E0
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MCA.U_[@QKP/XN[7DGQ:3;[M)W"/!#FCCWF^I'=L2I?.HM9K5A@AN]V1JU/0
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M[F)BU[2[%#=N$.IJX^-QJ(1=#0F+*3AT2F+![L0$5C'S6Q.TK<R,-SE2[T/
M,9?V6+,VXK68;@D7T0GWD5,C3=""*GO9-@$M?]2UXW35V4I!HL/J;# :IVI.
M0W[014)!?OY=RU%W.:N+LQ7QPW3,"K$F;FE%?"9L-2'=+IMJMXFUDA#+D-E-
M=96&== \6N:15LS IP>)Y"VT"ZK&6I^VA::#"K#>+B,E'PJ6='B\H)MW,39-
MU7^@,U&;% V68FX,@PQ7"V*LF<E4X6O+V@S+M 8\I%Q7M3V3UNR.N(6'X^:V
M;K=H1$J8ZYFX=;=;?-A6TN$Y:D:<.X$SB(B?"D </F+)(?4@$H7-@KXD%Y=Q
M+T,PS;GFM;$'TBEA)6/+9.&7.(0C/JB;+/Z*E&.-FG=]E)%B4;73=$_QUID#
M1BNO\['BL#[B[LKVG>E9DH,=J2.G;C_+ #G$*\0%#I8RKHAYB6-%6^[Y <ZI
M)\P)Q%:W</H,>ZB9[>.)3B_*X[XT7PRQ+]-[<+OXY\UOYO_S,S+@739B88$N
MZ5:L9'3UKT(\%%L9+79[7RAL&5T,\R?=#V18K%A*Q.8*8OH-9<G7J9_/H*0
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M(WTG]WM1?Z"CPEUB?>X#QG4.MYG.X3>=TB)T$+]H>$P7"SJD?^E#S-/X]])
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M- \Q7\QI80//SU;83:G!N(T-$V9Z!]636\?>F*W\4&,_\QI.]49U"Q2ELCC
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M*?R(C=?P,FBENW3-^-);%5K2DGK)>6$A\X(Y_.DY/9%,JES+6F7SOC 0IHO
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M^=GB&(;L&NPLYUYB"^;Z#XHW]J;?/\4WZE[#QV*.!K+NH8_;N@6G;U]*>(D
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M:[>'6VZPV_7HY7STS21!3QNE?@84BRCXHUQC7/C3)Z:<3?X\/D#W1O"?PD7
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MBM!<&? #<H76HR+(7/&]]$V)LP%3#[[/!N43WCGV==+B2=Y,04F;@YN4/4]
M+1PR]BZ/GRQ_6>.S)7_8*'S6OEZ/#G_/Y(D,9Q]X8/_5#0T:WRRA*=F0PA4!
M,=WWRNO@N3'=86PU3)6UXP^J5PL;C68J*)GN7X?I)F!]0362+*'-^X#N>E'U
M\L-C4W7@B*Z*4(+:Y#"2$V>$%MN[S]/??SMA<D Q%WO-FJ6\#IQ)C1:6YO,+
M?".)8G+LA-)013BF]\W6;"T<)VM\7R)-73P8IVF4M1(^*N=P2M_\IM/=63IS
M Y!JWYH\W=L$+,6G<!\@>@%H,]>*%6"_.B8[%K)M()42T87O^!J[RF-?&?O=
M6O^T'-1%DJ1 0K7=^2:UP,5\L/[XE<B<H9'<S"U'.QVH^?Y_!D/]IT"YF;(0
MH*M?:3;A"VW+, E?*\&M220N.PIW@1RVM@UHB-(0&NSI:(>3J<VP[L?7->UC
ME"7S[/TK*"3Z@H 9O-+>_6Y'ODS_);.CY.?FW9TQN1%I*<([NH4G^D+49YJY
M_8!URH/PYHL1\U>#Z[L<;-=76NQI8SE4W"EF7'&&*;?/[W8"GS"$_/#&^(**
M8QZT&[+JX$[KC[31\]_C";!%H$BJ<,T\C.FH"P?\V%&M+>=+UF=M0P[0%!N.
MG0_M*Z;*=HK)H[YA(5?9)9(!FMVYO[2?=1'F40XK>TG_%QH2."V(?3*IU.[$
MYDH5.[\8V0W>#N($^JQ$R*%Y7WH]DXMK'Q<X!<!^?%+@\[+.X[4#5Y_,[SBR
M>"IT6>$%Y0__357!.Z@8K/N#!KD)XX1Z@!_=0"T[9$,S8SJ5(_D04 =JU<Y'
MKHB5R8.I./60'F[GLI/2V8%=DU['K<>?@N=O2^^_,GYW6 N+S?]ZZ(%TVO'_
MOG+A_[ELB.9_9DE\;\WB[TL(Q/_IUOT/YOQOXJA_9X+?[\>ROV5<#@%H7];6
ML(>!>P^T OXSN>+_38VKH\,J FTX $ ^KOL[%(<P??KO=B?^.:Z>"?[K_-_V
MWTGU:S3^>BD5HGH>F%:"P@T] M.;QE)XI6&QU2#LVFP$T9#\1D'JC>K(4Q%%
M)P2>@F.YC=UY29(:6[?UZV4+].2$^?LWW>&<4>=J9@A+2*.6D5(W%_DA1$L\
M%CO%UEM?/,%;<L)?P+L92I,I=%QC0X/H(4RWIX$#.TY?DB][<#*&"E;A9NWC
MGATD$KI,&0>>)463B"PRTP)QA:[\ -'Y8RD"3N)D:I*924D75Y$$+!ZF;"JK
M[JC>=2GB$E@L',3WNG_ 5+K[>NM^Z_%*^ZNUQK4+Z8BM'S:WK3F"Q<^::84;
M?GKC3)"Z5%K#ZOY[T-.^*X-KCH.*$ZQZ#_!90B*FQQK@E4W)3& 7$6D4OVD6
MBARR41&6L.I ;1S&6-1"GQN+ 7Z&BG"+N:<PM2((T)N0;1LV6Z8B7"_MW']*
M8FI[5$.Q_-J??B(02?:5+U81LD\J"P#(2(PO#%L#92+"KL]: C<GA++G(N_X
M HND:BN)I4[F%F_H<Z+U2[<K.[LG!AXF96YQ[PC5\7A66WH^JB>]_?G)C6^U
M>]_AKGK6D#**!2+UU'[[BDL*!Q1G+Y\.^#G6.!9H_$E*H4''23'@3)[H-S4.
MS1%,\8'$Z>;ZL61\LHFCUD0-?Q@YP9#N8TL ^?,.'K>V]^F&*+",5[I!1> F
MIQ0TZ/\E.N/N@BX28CH'(5M,ZQJ4)H] 7L*^8K"19/J%76Y_(G5>'T.7299_
M6.K) )WA)7:O>B9;-H'2=^X5KTK^V/+&,7UBY(2273N;<5_<DPI%-+#G4 Q&
MA-K66M9CHZ3XC-8H)ODQHN%LO,DW)]FBWB,CPM_08O_AY/7'AMY:\],,.S-2
M);31<4A'ZISVX NPF#4778/D/V+0K,21YA*<8N@P>O="GX+=?P=]CS/2G;M&
M)RZNEQ5GM\0X7[SQO._)"8UOORI_ T1?J7V]\CL(#*6)C.)4!#] X.($$YN(
M9HP(,994-'(;W6;G?J\ 23VB,,CLR;-RN-@K]#6)7NX<\6R9L;(04>>%K$5H
MD!#3)D,T3.OE$\2\V4-%T,>VHEMZ*&O\*=LZ>6*2F6;'1"1)X?\A(*-2,)G;
M^_X!*":]!+[8>1787B5HC.M_]5F*^\K35,V@<)>;3'/%,M;O/HMAY^@(^A-_
MLV5ME%GHQH[0%I-#9:_*NR:2/=_5CX"GP+,OKOKTO4W1&G:>J7#.A4#Q?@ZL
MLPMY4<C<#,W/A[WXX6<$M@FL58%F>FV<:O"A_Q3K5%5G",?PC[[*&R$RQY:6
MMS7)*3DEMH)CP6:G9FE\^X!;0MQKU;6!I:FHOE">CZ0JUJ"[$5WX<Y/91N2"
M-2BC+F!0@)FD^?BEYX>NAC<6E-OUWIR0N=RWK+V2;^9\>;_E%WI_NI0SBKMQ
M30O6:Y^5+Y%,A0VCV0<QASY+0^^4H0"2*S%UJ>^]@OX M<:[#K'6E-4@KM(:
M.U30_Z667%MB&#;]ZW%#F<#;=L4Z)1EI5<QE-0/E\[(V=&%D['?VS.I+$MI2
M_][P#3PIN != ZTNEA;>(%O795L)T553 @-Y;>5TZ&WSO;58FV_^F<T+%J5]
M4TMYI/0 9VG]^O)F90E/E :4\EZ-W?"9B?.V5W V>@:V:* O9K1B"PN)BT<H
MJRJ@][?ED>MZ1]?)O<Y?*-[Q[2>#\I.BWTYJ3(2I#RHB,"T%SHA.(JX*(]19
MF5F>JH_]#LZ<9-BTQM&T<:+;,*)#FAMDZ%Z[HKR\A@O/3Y5& DVVHQ6L]?!"
ML$'1(+AYNR!S^'?S=4QU.?D#8!U L6>]Y^'6^<Q8$JGL:9J4W#\FTO!\ R6(
M&YM36&L"KK)T@QPWC+N4;\W DJ3)6QJK7GA3IC^]!NMW2AP/_/)BU9M50=]$
MR#@^[B$((&(W@K< 73_E3>8E#O$Z6W^2'>_A600N*']G(O,)7C'F41Z\OW6W
MW7*>H:[R=@C>B<6=+8/L3W.P=H/I 7RTU&+TK5]HT"%B/UU^7YD[D1J%62!>
M=(7MKJ(WH6(W7R]N-YUY5'E;Y.W5I"NW?^B;E_2#QYZ@>3\YC^2NU,@@3+^3
MAJ$+04QK2N'"U$*,%#;,\\K?)D!3Y@)E1HC"E"Q*B-Y038>=]I1!J]EG'WHR
M GMZ6H]"K<D3F>#Q8^7V]MX.Q 7#X27^TOFN]D8!H#\-645&]54$>1&R"]HB
MHLEF*QR& #W,@-5BMZHR@347^6&JF:1?OLU!*UO@;VQ[77;>*I2*6P)^E9QC
M_(5BUF'=;;8<YTAKSQ5YYUE9,K.A=YB.U2/F'O44,''\&_/(";)HF-Z?!GUA
M5&VG+*06#;@]'?;C^ZQM1VVQI$*=V1(T\%W!O(#F%=UW?IGO!>61$$>+NBT#
M@^_9S_P:0EQU=H:N>8XDY#I9\V57KSJ-QBKF*3GWBV[7B?1OWXH"#]#*.>C"
M-#E!R4$U(9J8+3-5V >0]%&BPOX+CH#FH(X1TM3$Z444[3:PS#IX2<A+5Z$V
M(N4+XI_&[H?DMT\"XN5=-DX5+<?O7V)6RO/4T$7]X@;'G-XZHJEX'LY&^@?V
M(L4/F3.@/W&^M#-OV,P6R18+$:=J(.*L^)UERX:>D3K65NC3P\+L/L1UQR&F
MTX9"%I_JOO#"SVY"&U8W&SKFK2\_K8P!SI$&?IX2A=UT\,['.NRFZI.-!\0]
M[*(!IT+&$71WQ]/)4Z%7KIY_^R'9YOSKDPOFO'98,/"<@UCVHH8#._&>'6*$
MR:_UAJ;V*QJ!)8>EC2E<,)C^($A>Y8*:)SB7MW_%6J^ZQ3^4YYD?=7BH<_^0
MQ\I/493WRB>@Z [[&5'V(A2Z.R)_I,RRYMR<(FF@CL!US("+ Y+:-0PZIF<U
M<T1A%I&YM=]AB92N&UEMV!:2-Q[:W<75DU.6+K\L4S[!\?<O.*<DR2HEG/BL
M;<H"GE^PN:3R)F4!([RW'H?T7*\Q$R85^J/6&%+F?I9S:^\$!(EX)LB%^F^S
M582Q*X_S<@82-AP1@QJ@+QFQ)]8)N6,R%\A)[E^JO$59P5CQ64I-F4C5J).\
M4Q$,!3Y]7_0#O^D4?!"X/,SV+C"/FY<3_?/%/[#!$1YT*).LUI7(10!,ZQX.
M2[-I+[JKO2%/A706S4#:;<5[=OY!62>= SZ+ORVW&G@[=&9+YN&5'RS/>S_T
MUZA1XL!;=(?WS%:6#;N*A4T< 5T>WL%:B[HAU.PA8R)_;%&@F0V2*7Z#VF9_
M$7P0)EH7V@>1YC &^.$&DJ'ICQ\'<_(/=7(M!OM.'WB2SNH (5>PCRQ_B8Q
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M/W^NL\T_8!S\,='U?JM.[3WP6F!/6.5:N='E%TM>?4LF,'%*3KRMC *^<((
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MY&/3IMD4L449)WGGJM/5.5F\(.G=LQ#EKKTJ0JY0MNMCPJ06Y(+-#548,.?
MK8W41,R@BT49$2YD.3 UX(31<?A=,VT!RX:1WUR[ BD3<TP%230]!KNQDK7:
M+I%B>[("[/=,N:?,S!FR/'NFZES*PXOAQ9K8W&;%(N3**]ZS9GZQ_6[DIUIU
M6<*KS%W=M6M8+>TM\,RO$2,D@Q'CR?Q$S@8'[S#Y J;K6277?W' V-(=\\[\
M_(I _'1?OD#Y"PX.9X)U;CP1+VMC&\6>U?&F&'O+(L%S'HM=DU*3/']1$:"L
M0,I&Q!ZVBA,VQJQW05=79LVK?NDE3,C)W(8<+1J]>%5$;K$%*ZFR*T5@W5)
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M.T$AAO&8V3 &:Q4RFT4E?E>L(LQK.U(Q!\M9RP'L3;P@I1C"W8T^RQX]HNK
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M:-[HM8M)=ZX'+MM?OV#*@^>1@#5Q-G"<.Y/9"8 'FH2;4<TX:$Q6+B<%*TE
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M^2<=MA_[I'_),[.^JK/0+ZH^</>DI= \[<;DSLJ\MB\[+*=\J<F8[OS? 15
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M@&G6>D,O:V!E@6!DC,JC(0;?#N^$\(@>']6N*X']0H]=D!;ZR6A#;B3>%$F
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MKPDN45/W<JQ$A,/TQG4GWW9:5N37Y%I6.IF07OD/'3^(0^W&<4'!Y@I/U2/
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MXH "MJY 4$(<6H1%F[]H6"17NJ7FHA.8XL<QHQ.5@ZJ:.#),"2Z,$$^O)4M
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M7RUN#AH7<;^KK\?.'!!]B47AX779TO.!>]M J1TT'BK?AM<4@+D!Z'J&&Q(
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M7K +NE!3X,2_Q"G+2&1XA!%FEQMU'PQ4G8(NOV+,A>V;7>O<H+>JHK,R@L&
MK=K7VV;Y*R85WOHB7_-[VYH"+\(OM_7SA'G2YSCPQ^@A:K3:!UFFN<\Y1)V"
M*8*+;IKU-)>.(XDRX24GOLA(M4)329H2%,'2YQS5XN+?#33S9.',JPR[$D'M
M^J/!#PYH<1&=L'<C:2;$BX\*SO7O.A'IZM]U?X!UDKY1<Q,,96'V$341"#P
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M][)0O0^4/G@)?/HIYY\^O(L?@/],*0;M,;6:5X68LM!XB@@+PHU=+FIQSYL
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M"T0TCI1]9 \7:,/SQE?<F;.]%Y?5QLZ[=VFZW:D?+WQQ\9G'$<DXTJ1V9(B
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M-BZ%>?W,N+WE:%38N<O\_O2%X;L;*(N[N59\LS.%.^;<;R5!KF Y^QFR2L[
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MZO="F)$T6:KPMMS77F.<U3=J8XK_M+LK)JU^IKA(RWV6KS?C]Q=%><MH*>K
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MM55=)5;&/38)^9FV' RG#M#4]]%8N+JATN*2!]WJ0,$P<'.69%'CC  *0_C
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M%OA#(^]'[Z>;XZUNFKB1!P96WI4J"J+0?L*?%<(%_"MEI&IKN!$'&5FK?,W
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MH UW9<+O7BB"N+(RIKBR0F[\6HI3YN=#.^LQ@"?"VF[]CP#['5>U?\25(09
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M)*=L7Y?2UW/QB;\R(^=VURZ]B1>U!EX%X,]5M1FM*HVZ>I767=#9&+:X&S.
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M)XUE,+\$" HK_R^OC/Y1P(C%_P-02P,$%     @ '$!I5 IB6D,N+0  <S<
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MR=YJ"][Z*J]7$=)&!8+J:$ B3A)C,_()U#+B9+_V/ X-!*>1Z%GQ: UZ,6[
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M':MA:57:_ RW97_(SS*&&_3)ZR^79.S!CZ5PJ>)9,D(CU*4(93GE\]+(W!F
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M&<NZ-P X+Y4^+#9;;"3 *(=4.5ASN/)]YI9% GF>L$_\=,]KZ8$DLX0>I'&
MWEE["L/8C2+VUR%6L@R;\P#S4_+N6XIKC!]LQ2$A$6T27.6C!-+9/<DW#;56
M"<NN4]=!(A\\S!3NYGW?SU_="+AC'^^V\=J9@@^C@_CN?Y ..R'J>%+62>N
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MZ6D/'><V4Z"].65D83XKP%T!V$[CB(\.Y^;;8EL)T4B/%/9BGA>6T[/['O"
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MVCP]WCBP^OAD;.968'%BC5"*X@LP^:;;(>SH3FL)?;R9/"^D=(].2F[4C(?
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M]N;H^/DR+483E?!@UO^_\^4<_BTM7WR(C3N**+/ :]J6QRF97/!-Z[7^!W"
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MI .\2QSXNTV>:&Q(14NSY Y.<B1V.;ZR^_:*%DN7J66'2XOK!+X_ZZ@/]*M
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M8]_,DA4&L%[;0T_DE+,.73RY5,.BM5+9RDIF(UN*%S;<^2G!M[-527!]RUG
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M7MIT^O3'&^L-@QB@.2Y*AMU.>=IW\3K?2G54!I._:&+&,"?9ILST2#<R1@+
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MOVDB^NE#%#JD; OG:I,-*1YF5IRW>_RD)I14&W#4TTBA=4SE\%_>'?]NG='
MO=2&]WF5V;'>"3[Z!F-LCD3Z%DP-/[UDB"4 VH7&NCS:.RE'2T^:FDECOX][
M1=JHZ+^8\0N\_Y6Q#E6A4H#P*4#73N%7I8/Z%3 Y7,\G?PJCA(U3W$!5LC>H
MZ,%?7N'AYR/ T./-! KIXL+#T>8C@Y_2!OF7PW4WU^_=[6$#O@VUO-OP9@Y"
MCH1 S14?,5H_RN,@WPF)#7-D>4MBBVA] ]4SAPHR@^4DM"=&*DOOIQ#?X&?6
M>[I;R*"ZWHGW#N\_<<<@8=&W7WA8P<=?A+Y^,P>,9 RS'<Z.1)E)IULKPZ13
M:A(+"U7!7Y@BWZH7)M%CC7E3GQ:I:SJ)OZD=<0@MT#Y=V_\ZM^W?7C).MC#D
MB)N^$(;Q)21\J3&[*63B >4#=EBEI(6\02?:@;VG,\1>)+4LLT]ML*V(ZD%)
M\W'A,&>*;,)%G4=Q(PE '37HW0A8G3';Z"I_+?&6/A+6V7[,1]G,ON"&A!S;
MAS/0A.8.I$3;A_FW=@KA;BEP$C2;*#P<Q!G3S&14D);6AS"40^F=6UI6FG2W
MY#XZBU[')2LB5^T['0RPVCN/P,&L (J$A).$-8IZAA@5= *M\1?**G'8>J8)
MO:ODO#LHZ5*#HN93 /NR<RGQ!0]XG7-#^(8R!:#>N[=IPK8-T4NIFUV1_85#
M!]#=FJP,+"$FF%4W"=%++WD;^+7Y?E:Q<(A-$_540O*!XUJD:H1Y8Q04\2W5
M#,S2F]L"4 &)Z3-\CLJC<"J99DJH"T_/SHUR,60+,SC24QSSF#0#\EW0K0\.
MFB_9=\'-_6;J!4*CI:T20],,)P8DG^=90G='Q::H- KMD&(4]B5'1K2?>8-*
M#8?/GDQR5%!YGP)(G;\:V631+W GK06,T$G1;]FW.8R=WA&3C"TRAWQ'.)LF
M;>0 70[-C %IN04\$0O2*S&-1<S$I/5=*_GW?15)=C[.<V@E^Q4F R6:\DA'
M>!;A$Y/N2T2%G%IR[(C\F* L.'*O+\\7M;=)4.'US%IBC'HS;>\;EB?6/@60
M.6T2\B8)?DUVJEOWUC0RZ\@-^Y403:_9TBQ-H_I)1;0)8;T9?E3IOO^SKA\]
MPWHR[_1:!=J<+Z\MF6+*$>^F(WPF!7C24U&7DIRX'\6DF!" /82=XQ8:&NW@
MNQB7QH]ESZKX /9[F.B =^(!31L'K3'H3DR4>PDF=QCST.B]^K )4)O;H%8L
M ]9E  -[37:[T&O"9Y7>7I;WB7?(] W]8,U0]M@\3F\J;Z2]$\^=GQXNL;P
MEP%&OS*^CK Q\QU5D3P0@1>V=TU7@)3+5Z H9E_2^))_:2'_SRT$F^'P*+_]
MCX0^F]M,0RI-5M.P=&;NIHI%A_R'P9981(GXV.N6^@45P?<N, \#"1Z#C%AX
MEM+[\6W\\F"]_GG'OKC(@AVXD\WE>@(_Y03Y3! NRCU%.F1U9 Q>6 "U>,CK
MJ>JK_O+IG)Z9G\!D]J0&0 _=FA-5ND-T<,4$")'EG<A$5)I29IY&U]E&>U+'
M'@,+I5:#6&)TZ;/2E6:P\T[^E16:)&+9^\D@?A;^[I[J=IS6BI#)9K:+>E]*
MIGOEM,\@?_)R2:G_BHXC7R5S>GI]AJ![8-7J(*+$1^B=NIC+YVBB0:23;&/,
M$(]F#VXQS[UN!B'A0H.XP<1F&HLNMB8C<.<S&01-A/CBP"FKX+0FV2S-@X8N
M 2U-[;HDL<F@+Z;^1:G((:37'D\MV>Z\U/K*&'O1Q#45[P-#3KF-VA42PY3:
MQT!"AU?_(-4QM[MDI^8FXKWC%-ZAQH(.V4H023H_WG<.S?Z4X-7HD^BC]2KN
M8V-1])(W26]#^4*+SYFJ:=L-''=F+293W'/0;3'!V6>S K9.$VN<9A,!2<H'
MN^I$\0@&<X]H]F=Y/T0XCS1'56T*(R94<8%\2HK5[6(\[FF;37X;Z5 )P>F6
M'YXF7FTF<DI*"Y#W_+/Z)R%F3+#.W$R@#700'J'Z H=QOU)TW]AL!ORU1*!]
M9N+6J^FR*LX&S>QF<%DFVA+"'TB^IFBB;ALL@F PU6_+5:Z;3W=26PI'._ED
M(7+F23*TS+A)HX(%Q)Y\7.Z*1:SNYRZX>D;H7-SS44EJMZD6!3J.<$*;C#-0
M(FT>X$*#M;B%+1'WG9 D2?M%%?%0>KWEW_ZU?45HR0,T#^ZP2JP\5[NE]R]T
MDQLY%!Y]F+@Z>9.T1?IMBY>9Y4.-P8K[&R_Q"2I3BC1DP8BC'=:/F^^=IG&1
M>_ZKE06>=LS7C65^"!UVM"/)'8E4#?NQO#0#0_)$-ZQ]1X#D*&%SI#\J(G+$
MX&M?,PV".$(-XA-%+)I0TC:QS>0L'BT@]R,!=V==F(!]G)H:]MA\N$Z5L$)Z
M_R?]Y,LRI'SB@W7,@Q].GGQ \(>7=F):CN;>^##(5Y(Y9]:O?B'?SVQU(($"
M2N_KO\R5RH3_7&D<$7(Q3:@L<C]#5>PEFY-T"#77IP>%H8&))>72A2,17C=:
MU1!<?7[*)>?/+/C!Z%[K]B&@%F)X-)]$P9>MBGTE4$G?:ZAT>Q1ES"%O,43Y
MJ8'K6RIY_F*P8']JJ8AQC ;KZ5IXVJ& 1OY6CUYJ.MP9N&7""M#[2?\P8\1#
M)>6S,3,&>)20<I>-XT TSLJ)PFQ(@3[W;YL??7BY\/B:^_%"B':$DO7L]>L/
MWVA_W*-\T9;USQ5*B[8CS[<@G:.)=PQAI?KJL#&-SRZ&MX NK,*/QDX7Y!*%
MQXP/;_=[W2.IG"?AB7#D6'%HM=< Z]5Q<FA/?(4R@*]K4SIO^L$^VZWRB1Y%
M!I?S+C#FE=[>PB>?1TZ38QEE@VHY3Z->)WS#-Y[]G^'[/WS"(]+UWA7;K>M;
MS''X*Z9S[5V/F:)GR7(_G%.9!6V^_!9]_+(9V/\C[[::G0XVJ%_:SJ-E\\M*
M6DI[48YE (G"'B>!BND=.7M3?MSPR\K%321\&^'FS$-KU=8Z)36%20K((RB1
MG&J\=U<S!9JHX&*@UIR3!++,6-UL++996__ JVK/0.U8QJ>-:_'?_[8P]%I
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M0G)>,A(Z,.&5W%\(J-*R=7*'N'#0D956H*P)\D7HEOLQL3P.^^_578[%U,/
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MF:U<^/.9(\SIO;,0&(]T(67VEK@W1UYSKV@.47CM+H?2\YW0A1:XB]Z&IF0
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M@"Q+-E]B2#(;J:-34YOA$RG-29J3M*-)&S'V995UTHS+[H+G)@%!VI9>(G_
M)Y?=/1%*23GCI#$(CTZM*U+2J1_N4WW;P?FK7_"W2)5;O@?8.Y8XFS&HMIFV
MJ]OJMEU A>+\^HQW.$ZDJZXD<;PX965,'8)4+TL,6"[61&U_*]#4N\*U892\
M^F!(3+YL@'YA8</+X'UD[ 8R'3<,V_%HCTISWI=5PN6[\!1E,H9O<(E+L)J%
M%+A36NH+$_ZZ:UKPP\'0+ZJHMCG=X&1NF3WZ-<Y.D5=_RR-OZ[F!%R'@.T;I
M-!PO6B:4^DH%,UW2$V&C^$?MT)E,,Q10;;4K]LG>WK.A$[-:K"D'ZMQM"MN9
M5[6_L]Y%-0WUEB9]!U_R\Z8%,GUW-LJ #S47UB[!"K[[M[S_HNS./:;5<?^]
MJ9+;20,8 M:D(/)!1JXEEDJ-=2"ISQZ/\[=UT!)%PHN7XC#I3H#DSU^Y@.?&
M7^-.M8@]KKEG2?_F8_DT^K4_ZWJ_Z?K;?Q6N7GW(6HHWQ><HV4+W!45P:4!Y
M(VE[7?6:*I1X#Z2T3[=7!JY_N,#:RC/F4H1D\]2NY"C084V9E8A,TYM1G;P2
MKH)"FQE<$-^@M!&M_*8>=<K4LYHFYE>=WU5:;#"2V@Y&^AK6WBA$WZ3*7C\
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M3?>/'?KX;JE>."%U>;Y%;&WM3QU"&$=!)I]WVK?KD_?0%.B<#FU$YA2!XZH
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MP*8MJ#/@W@O2%"XETZK"_1*:2?TI"&,/XULAWWC"&\18&#9@+8:;750VP0>
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MT*:8;L&6\"0DF@.BIIO^'#V-ENM7WBY8ATS]HI@N>"I*.6*O\EG*;^CY;<8
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MZ^7[Q\]&U^_]SVR 2IZ_/6_WBX(F(TU3(/=[XP7KWR9L#W-84?FZ;_V/ $$
M$?88IKBT&>R[ J@\Z7>18TF?<%7IU6:M_RQ60UN_?/URCK^OH:ZI/2A$YM
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M+_HJ?- T M^O&(S01I!Q@^)['WZZ3B@,FE;$T)H[DMO?D^3F;&:8QJM4F*1
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MEH0T?:/Q?H<]J"^64T>13(:;%14NH8UT8/)5*H?NCR$F=J3J/P*:3%=J"(Y
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M<\X)WBM^$>0U91V5=C4AD@Q\LEK(;\.=A8K*Y/I&TBM(^>#(FX69$;2B+IG
MI?WT!26][[[9;C%4[2@M>0K:U^@5,$B121N!P]D(WKW@,NXP9%* .M4T/('N
MM4\5?=\#T9'%A#2*/JHE;:I?6A,:FLI;;\)'C#GZE9&HS[VOTT@U2=F:<_BV
M(S8_+'!8)LQJ$CON;@0*(5?8-1?#/!"S;W&/K>*&/TH^E1^Q._(UZL#K2CD:
M3QT[T@0E<:@=54Y1%197L7TZ[]7\Y0S+E.HF[>M".B4A-0GKS6AEI%] HG5;
M%AJ.RVT+*VV%[N8ILR>A(]ZL?M.Y!@G;5*+"NERNF"N*@NF]=>C'"Y -85FQ
MY:5975%Q98_4!W-+ <@'(^[C?EKAUK^*@.LO((&MQHB"/1M#TA?R@QP-4$.*
M?J=?\9I=WB/RO(<;CWG/V0A>;CB(/GFQ.,>[(Z.ZT&<FA"3IS@;9JKD+'F:S
MV2TVY1&%=IZ\+[:N'@!49*JNLI] Z8RGM% ;O"4)JC:V.S;KB:G.>6\M2/DR
MW ]>#6<@HZ$#V7J3/1A*KE0N44IVG>1'F;EU;(U5*:R\/.Y1#W;W.J?TR^HH
M'?PB2FF>O;.12'D4@(CRL?*=[6&+9L.]/7 ]=[ZM89!HH">*K5JMJCC94P3I
M:TU<H>'Z<D2X<9D^MR$Q(^G"6U;@0&AEUJV,:O9']T-2RRLX+Y@S6ODF#Y^@
M1IHJ\PS =TS56H(GN5'TL$9<L.F&V!D[\&1@D9UE^I<4'-"]FB<%9OB<.4DT
MD_8E=UY:5G-&HTM#5R!;GH^\+.PV@TH(CI=^P=P_OA_].6JAZ!Z-)R]C>F5Q
M2$VV:H6OQ#3@;A1R,\;KW(J5%#4<!2@]#.=A?]6G,D"R,&2>NBN$DW4J>:N!
MA.FE5C;>$D=,'$Y&W;;EMOB1KJ6UMSXZ6KCT N*<O/LN/+I\'=MN\\( J^K
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MP'Z?T^06HF2WWF[-;;M\85X%119\7Z2Y]T)+QV#CR%Z]/>*>+UWI"-8N3V*
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MC0W2YS"%L2*R7><Z@<0HW404M#05)K=)&,JR1;#'5C*A-8AVHU%>0$E&\.G
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M3IG/FTV#PZ]#_Z[$8WY]HZ9S7PJYA=;\J/E18N_(?6:92ZTT+E5G0$=H27D
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M2617\"FS#Y^F].65M(1],DKJNV.<I3/FUD<:#3_:YOX:?HZZ [?YVEJOGUC
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M <)0>>WBK!$04Z@@"6$"9Q=GK[]RU*WCZ<V;> 8]1G<3+\NT_3D(*%5U^^6
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M:"F5ADG;U^-8F6$#I&LWEZ\7#Y;\<LT<MYY(NWP_+S6@45&&RI$'!YEBU4R
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M/BHE,X0 LV9;Z9LH0Q'1NC9*Y7$G!Z4]+U'19LKI\P@H_+! L0]?R-5B5&1
M!*Y%Z=Q;BJ.N'23$E=DS-0;P]"B,&_ACYA:(+08:HYG:SW,J]/$MH!>8+8U3
MSL;]GQAH.(@/D.#AV25%O$PVC;705UG+87H3/+]1;-Y3'2JVQX4\2*'^M-S)
MDA3N"C/$#8!YT:-VWOX4E&;H[JX;3[$(LZ7KQZGT8#11Z/J5@_+-:J*G.#;T
MFLC*DXX9TQ/+87U:!YL3 _U*0JW"%K'$WPB/NWDAVXU&?()P$35J>\IF2ZMW
MP09Q^R2%1O;'Q&!]2<I)!X\-"Q_X8!H2%#"W\7%N/>,M/[A?,.:/B5-B*=JD
MQ:Z%XK.,/"8"/L12B5A""H[[%0$U\3ESB/1M\#:1#T2-@-'KO9(]8(J/)<12
MA+,!IJC0C/[%O!;L*C>RN92JO%4N1G -G+'R.7V./ $Y_D:I';I7?E6CYK"'
M@>5MY5(B8B^37:5$+];]G";4M+B0(MB+H7 9E ,2AXG3\-+5>=Q&O%3CV_M#
MI?F(WRCS.WY,SVYH"BW@W8!UAEC68$@/M(15G'D&55V+0#&7M-%@Z[59*L0W
MER!/;/  U>+??Y1Y^3>?^JY8.V\ADK%J*(-S]!U( P\;)D#H:AIOGJ%.XK)_
M"8KT%PK5'7L$Q36ODUQ]K'HOQF:(?SX#OQM%89.3,Z ?0"E&>6T1$?:E^+5%
M;63BWV=F_6= 2]]_H[G 54>\I2-D,!ZK0ZE_EC8^I%3 $NZ'*;&0*1A@QJ11
MQM3J9OKBWHRV[D)0ND2L;SAQ]-55++/FPC"_K53P%)274CA[;[XN$TWSWE0E
M+)#9+E,Y$FDJRMN(SYO?_T\JZO[R6T')%I%]-%O^-Z:Q\WD+3-\R&:6#>6G(
M =^;ONB[(Z(^\A0M)D6S2K%=#=Q,/>^'F?N Z39J2-GV8%!P84Z6 R_^Q V)
M32A_'&NWH.46/;=03-6Z(,5GM7N_VVBFK-*-#VC^;)[M=+SK"&A[H'9=>G0U
M[.&KUGLZ86PER#1_K2C9H@8K\Q5+:%^_&=(7N)N__^%:V1WY =R[[BE%L$"P
M@(D!PL=WQQO.^SMR@#YSL4KF/R@U:+8[T3_7/;S1HE,3#"+- 2.RXCV/USPQ
MSR9MRKIM@;NCW7IHA7XSH4I<0QOGG28!)>9.6\_4I^I_(*$P&!A9W)NX642-
M*4K-X76>[W0FY/WP""A-L[8A;\'$?&D,FJ2:(KN3T[0%S.M]6!_]<=;4*)32
M);QH-,>:*6$$P'C)R5@(F?/6U7BMC#0U )+;Q(BPB![_1M&(5D8@O0:\3CC9
M%0J\S+MR8W-+FDFT4SCYN!P(2-DTAV#@J3S1E)0S7J':U5 $$+24FWP0+:!O
M$JSTY;\0$XOU%RK79&3_4+0P177C;Q2%]R)CFP[9B0L3^5G/05N1K\#53F4L
ML$<EE9131HX(\5@*L?&D6S>)!;S7\!\O%1D*!;[RK<FL_]% ];=7':5Y/^^T
M7#%\<UQ?EO^0;(C<"KW_A-+QZ]%6[9!#/N<]FUYOO@"C:&_H,5RVTYCIF7PF
M2,-@XEAQ8^810QZ842NY#CT5Z^"AFQQ*__[K9YKW&HNW9WP**:46</77*0$C
MNVJM8O_ZEKVL&%ZH[WJ?&IMHYJ<O5;,>O6@M44%1$6F]G>GL5O.,01\3XD>4
MT01.O>)_H]@RK33BW/D%PI&;ZSL8)581VB*!ZXR*2V543A\9.=ZHHV$6?^$Q
MED']@O5& P4?_X\N_D^4RL5N^MJ 1#ETE/*C^.=%(>T#@^DHJ&B37H.K$EM6
MN@A'T@1@=A+'"4HS%#:]^UHS(?(REG.==YY-]=?<8H%([K?F3.&:NFU6(7B-
M#W6-,P]W_M T3GG&/@=^"G4R_K;-!%49L1>[[75F<6%,\Y;H.<M6L18Y=BV7
M?0M,LTI?CV(+(PJPD/3!T*=PYTSSR:E'V;3@A!Q_$OVM3@LF5ETFD:+!&WE5
M %KR=;7#O>*/B1NZ^5G6D(2^J9H>-@AZ:XY3N&9#_V@Q,A2?<AY*78Z)KZX-
M:V9LKH;**FM.XN%78W$VVNQ&,<*!M1RDNZ).: 6FQ0>ORS-\M.!VA+=P!>K<
M] B/#_+WC*T::#+K=\Z-N%8&+O4AEIQ1RE>4P(QN9:93600U+E>(UNZ+Z+M)
MNDZOQK_RTR2-R*1VM? 2HK!%0U('S94X90 ^M1/Q]"MRQ@P?@V7^DS?Q64@K
M6C!D)"67TZ.L\D7J90=2OV3?(&68@?="4S(7@&K=F*KY  /TGK]L[7+V<9AP
M.DJ5G@U^J5?RO*ZE3-"M!590HW@\\J%P6.2#<=0\JOL_'OS_8-A12;@7M._Y
M1#N7>QSWL?9#/_F(>>Z3;"&XW]6TCK?YU-4\==@=KW]XM>51?)>A@,3+#4II
MN ?2NZXF7HSJKE^V8K?'=YT^SO]&T=E=7-\\$]ATV9Y^AT^-Q;<B7P/)^G5+
M?Z0T)^SW:?SSQF^40O&TF(>BA]\H3U08P3'UY9\* <UFM\;;<IKR! GRM$DM
M-8Y%+\"1CQM7]]\G!16';XV\O]?4=C@;[+"G3E;N+[(3YV.^*]K[.AE.IUJO
M; +A9&-C&;"CXV**_\E'+='G9Q*V>8"$^7QF+NUR$FRT<Y7W>H*T>D6/H:#A
M$WH6"RH%3E=X0VO516&&M VX7J06B%-*C4ZK=+YN&?]$,6_9>Y_C:-O2)I]M
MO91PH IT,:)@%B]QEA^@"T*337!W[C_NZ3Q-7/=&#)0^\K3[3B,'B(_.8QW%
M# S'W8B,G@**M(33 9"M["GY((N;4PHC$@J#"UD^L,X=M/O#[1XPWT%_FY(I
M[4.JG %_ZZ42P>V<8$!82!!')I$Q<Q;/JMA!QU;J:<.26G/RAF=X]W8%;!/:
M@+2!Y!.H!S 4,(!#([*]6E8_Z?U;=/ _D2AI^HX>(X1;A=XP6&K4DFFC.A[5
M<7>9]E=VX%6'$:-KD_(>IHL.U90B6)1E4=?I(V]+J38Q)TBF!_@0)7[S,\50
M$!;YXK/*''QD2_W"8.M8*+F_^QRII)HY0MP:$X-'<,1':YL*DP;IASIO23-;
MI#N=YZU./*>LY'3#=J?&IB86B C2YOM#4@FD!*&C0CQO1SM7U'[EIOB5/+SW
MMFP@T.%,D1H"9PV1%%N#?BBF\]$#1-<Z%!6E=/4U%1ZW8XFV#'[!Q#11_O4#
M=>@_&N4K&3<-2<GO;Z&L(Y+U0E59\#(2IP_J9'YL=8;ZLU@<*@M%'\U+!C,:
M$=GF&Y9G8J4\T!DXY!<;@>?(85R*(XV:)[C<PGAPLJ+84OA35#,O@B#V&V.%
MK%2NU;H();,F$,$QV1CK(\AQ%6#="OTY2;$ +V(0CLF<YJAQ"8."W[F(<>8P
MM,]N/>0GOHLCM6C&]"2H&M,J;=*>9YE/R*KSN/Y27ZU97%SBO9NFVG[(!K-R
M*)ZPDBL@\5<G"*5-A?=="]HTL@4SLB>(.(&M.+OT?@Y'+WQP\D/?/W_FM_BN
M@I3Q^U_C6W9E4DIS'L](7@YZ];L5<#$Q1+V8KX&LV,Z/XM"4<:B/RE<:>)RS
M\4^Y"AA<">]1([=OLHKL?DF*]\_*XWF'I4PDN.VL=(*+YY+W"WEV7V<!]W<H
MVIULW/IOF-]V>J/R5;JMYZ829.=:WW#L"O1P\]]H>A3W%1!=K]H.;L"M!QO
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M9T%HXW4FM'(& W?O<#@$F=\!B[JA[<K5,> 8]DM[0YKL7/IT4 G>$><TOC,
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MN.%'::FJP0R) F+4 &OUGK@+[Y\K)VIFRL!$NV'.8!#0#$.]?L55]<?V895
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M]H@?^=EC>;$#W>1?&\YTAM22[K]+7F@*X%"B:\2_AZKF:B(Y%"N@TX5$_[K
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MU#)P"&P,Y?I@4H__<3%"2CN#J8?'J1]+2O"[Q:NTGT%5FJ\.R>0K_B%8XTG
M((>"-'^DYB.M$^'E&4;%KWG2VIZ%"#;5%":I!0SE&Y? OGW[';!ESOXJGEO
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MV-@DW(\I'G/_CQ_X=P /#<'AP3 B BWP  \!$0\!W@Y0 P ",L)O#_#[@_
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M#F<O>CB@!S48@_)4=QXUQK5"F/-)[H$5N"\(O9YY04>HP:$/@7K;F%-"<(=
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M2(_KWRCNX1LH>M _;L\>R:3)\40@Q^#I1#5RWGLD&=_5@6] \L-VE[>;=U;
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M[/5%'CR9&?0O)07)(W3\I6A<"\ERLN^^GO/J-&R5[*LOT,]'*,N;^CT( &,
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M%OW]Q8TJ'"_\V\&H)N['1YQ!J<+W!#/.0;^'BU2A?\T2W0?>?TTC.4]>1D#
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MG2ISAU@NN2)KS]*V;"D\PH?F ITMA;/YGXY1+93_-F&>]+_+:*$S$RJ(9,Y
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M -@N*,78:J&JJ5/*F1DPPT[@:)Q+FKH0EP@"V?00[?.AG [SKT"JEYY,UV9
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M'ILD18JA*M<TJ_]8#Y-QJ)KKKI55M:<7]/GHU+<G1F0ZT"T]'P#R?T>]SIH
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MQEBJ8_KR^@!9WBKNPCF='F/5N7;JA^ZP&LBBF^>;I@I/A4HHBLU-GQ^!K'5
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M&I5I:>Q^HNFNCXM+P0XF7KX'*-8XPC:J\H]4)C]03-BV19QK6]4%JG$S8HP
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M4@^#2YDH_689F67=>7C=Q1S\KNY2Z2X'<G=^#[1"X$^1#(VDB%04A8&L'!F
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M7:C0H$H8C7V38/7-3YL:.Q=_3E! 9BCCWX$8#D];XWL.V*_FKT7G&SJNW$-
MI5*#RWX/TK"4_<EF]N4NCW5]X4^U5AK32W1<'EJL2: 5"FX_(#&(/+NY8 T3
MM*A7/(W)\*?9;)$Z\TB,3=1D1H &<;IQ4(I7-G*1!^2MR:L3P9H8S)L%=MQE
MI[7!69C5PZSABWWHD[HP^A-,G3MU(6!225(=!5S899N7,;H;,!=KHSKP(<UX
M )KHG/CDY#YGYL_GS*3G=2:=V=1+&W9'"N#T0W7:'1',WKO6X?V3/IL%+.W[
M%6T;:2JBWN-P7T20ZO,G/5(U5;._T+'I\[5AX3DW>,P7_PDP:/=8)_$$R)@1
M++"<KJEF+]YY&U'HY&+>XYQH\00PCQIK0=2G;&^YB7@"S#"V7 AM=@.-]B!!
MCU([4P[.#NZ$.F'UKO?3X<?/O2&<N_^OC1,A;,REUR.6/8'G>9?X8YJ81IPU
M+0'B?[I]@T./P,>U=GA[J_J"=JAV<5.^>=]_J"H7#=8_US+#]_;_)>*]GP"G
M7IU#A?"H.WHTL3&>)T""W\XXM!&"!4WS*LWS3K9-</-Y2\JZ:J7@\PV\5>!"
MB07F!LU%!$VGN0 )/0ZRSY7*!6F[[Q_E]7[4>17R+UQP-;KBHGY7[6RPRDVZ
M&WPE/! A>@9LD-$A#4EQE&Y2NYT.@\/T8]A>[ZDBU^G_#FK_1D13=D&KW@+_
MF'QB.\8KQ_K)];MA7\KC0S,W'%>KIMYG*XWSV]4TV /UI#](<5^/(%[Y&L^!
M"&31HJ"<M+!\$U?=4 C";9_Y_2-/71L7Q*'L)_(-0*;A@Z=6O;2M9T1TS]PS
MVG*V;_9,C,_-UTY5=LX3($F7_?8B^ D@44+G+6KT>*UZKW@NJD*)?;F%IZ:I
MR:D])^<D;!-*Q]8SJPD"&>>.MQ_?4=P=7$>:8,8O1+YZD>-F&E.9#B1Q9E;3
M#&BY=)#--FD0:@ '5]7*K(MQD3U(Y;@I]5>TQV;TUR)IQNV*TE9.TVF5C'6F
M:*=R&D9CI=V,U.3Q[OB2I_;E59J>XW[VP19;-Y3O2"A4[I1[I:I@YK+7,N0K
M!8WZ:H&L(H(9RIC9/'KV#_WZVUONX0</:?#TJS \QJ.Q(@*54O1H/-SH5N<2
MZZ[3+Q'80<<Y*NO&*'3LR!F -W%;T(9'"8").\%QNX-/D<+)Q@R7],&,*O%:
M/&XLZI(+&1;@184O#TXS>DB ^)VQ\RVOU;U [-'ZQX;Z]+M#)7EGG07R#X<E
M.,A*:GU^0@$.\[SCUO5\T%*=5_JR4VR?,<AHMHG)X;>3:F'Q9,H3@24D^*L:
MLKO"4&YW+BE1WC%_5YI#A^MK6,%^6M4)0]!!Z5I]]5C)>CH]-FGI00$YMLY.
MD1!>&L^$,/<7'Y"-='^R=?_<[7.8ZJ8K_57"-5/O/TU?>F&ZM=>;IQ2GT;/*
M;DD?L2%9S@+8L(<Y%V:R-+'784@#:XN0#NY&C0JK6Y_.* _,GM,LA%:B[1R
M/;?[<J<CW/=V85_,RD:L4V-:V=JUG^9.[9/"BNM]WJ]A$?"HRQ,@I!SN>&98
M X=HRG,1)Q+STN"$B#, _'3I'#W]I<)!^ ]9JVG"TJ.LQ0=K59.?ZS@1-G]]
MI*T&D(.#3H/;[7#< U6G<[1Y]F%5"QY7-4F:7-\_?PI_GR_Z3F0'L652E$IW
M'AYJ0Z@X=BFB U;Z=B;'V,%:Z_NSCUA@^T6^]1. P-F&0:VQFL\MB: :)\3.
M[NV?WX0B95K<)J 5,K4/[8^L8]ZZA<MPWW4YL(AIYS7*N>^=A<2<K)_HE_ 3
MZ6(Y6-!M&BSD4C=,GJ9#IZDTR]E6PT>=<JB&]3H)7=3L"$4"(,<0=>QL&&+
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M*X\-X/'"IH=XDD2H@YFC_THZ-VG!T<LN"6FGKL[A8I%L,B\H=6%%F;K*8 \
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M6F=XT\)^!CHVP>JT?U\]/?8N*/2C/UYY7RO1QHSBZOQ:_Y<-4/XBY41M,7*
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MI?_U^6\;YWWPGNYQ=U'ZNJ1WDW9?3$)D6*?JY&/.P\FBG29J//>!H?#:5][
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MC:I%Z6S-4TK*3.D%):@'G0WD"\B_[PQWG4_'/!0YWG4VW]KNC((O[N!J>A7
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MW4$#Z3VE5Q=H8#Q[!QL%XVW>7T<#T"]9.<5=7[3C<J+2K^4/2MN@7 WQ@VC
M=BHRQB JA=!]^\*Z)M$BYCZ>&TAQN; N#G0@<EK]F_ :902;'T A=.H/;N(N
M=QOPG<&;^;HH\YKUP$](HTCJ1#_CLC?2FMF@\:9$IQ!I\C<S[C45$P'W#"L/
MWH2:NMG9T+*-$;E=+%7H<WA8J_(FO 2M^U.TS#%.S#S %[0./TV2_7[+1##
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MY+LL+:'AF>4/"VO]W+SP[46VYCP\55@UTV&=W924O/9#MNQ(04EZ2,N-TPG
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M?K)I1:FV1X(PTD3+;BO\!UMMI[C,N\A)13_W9>MCK#V9.TC5<L<UYJQB LU
M7O9^>1^K-<6M6VNKL6HHKY@]XT_ZJV4!Y<B958 D<V5GG8PSL85#H>/IAY6Y
M.;,%S_Q:@LM6Z9Z)CZGH[,]P:/OR(&X1G[L0$U/ZV?[ZA8M\V3] BW2PRZQ8
M9=4T..FX+($MZ3@:6F8-R7?J05E1Z17@C&]=WJ],\'P[=\1*+9W^<Q;[X8]J
MU2F95@*4X'[XL[TJG>,PH\*O'A-/E E4)UK[>U7D35.]JL8)L+N+H23 HPM%
MG3S$@L"DZ#"J3'EZ@A@\KVV*1U1@POL^@=ZJ_2LA]Z?1NQF) '/WX=/]NU=
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M:T+0Z!4AS:SR>6]Y8LQ]E0A9)"FEW^(9R^'4= 31##W+AF=/7O:]C85U-!&
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M+8$<2!S-FO>-_R)LVJL1%=/P7E.#I:7A'"O*Q,9R=\IR0LY&U<G&\WP"3)K
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M"@KWDT\+L_0IG58@4SJ][$ 'KHH[$9$*_Q-6$->'X:]#DA2"QOT#G"/PF ;
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MT6VEU9\WU9LEI*!:M#AB+XC+?=I#=<6(TY$M:02B8QY%(=+7+4IU3>IR%20
M:#; MS*%&K9]JM!O:318[W1HDM9]9'#O<&I 4:.ISE]*S^%C2K_V>@6L>\5[
ME@X7>IN91Y?.RJU(@C"*O[CF].+XY=[LIWK2;+6A70TX/#ZR-S1]7#GP5XH.
MT@H1IK4D9EP>C/)V _0(?++:.0_ 8TL/@4VX.) MN)_0#?R%@>M\X1<'!M@
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ML;,);E_^6T6'-Z7ZA3ARPQIY!82^7]/#BFVGGA?CR RDJ1O+C.0#'OH@'JN
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M7WDW<P+>^R%@@8P9>!M/ /&5<D;M_T%,:@"#(D:&2IMS5A%LS1J%<<@!43'
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M4*YLZE92)%+6FB:T+Q4.U <H4\M7AB\4[$#"5OUB^E0B<7(=.\YR[Y['8=U
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M8^&:S7P$Z(]V)992*8/LHWI!#GE-T1:^$%NL1_<I[SV83-]'+MJ W1\X 45
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M:1\6<)M1-$/M?IX?H<H$@"OD:SDV6R(!Z.\SL>O<7;<0QXX \]H8<Q#X)6T
M81Z-MR66/1N1W3DW:T.NG=BN>N! *MG7W\U6/YK_/XPC/QQH52'6QA_M"^(T
MTGBMAC:R/0330)!!0!AVB!"ZDZF-2Z_"O*Q&U_?L/1!>]*"QU%OY[#X*^4@*
M3T0H[FI;WC7W=J._PR.T[[=9[+81(H79MY_\RGQH?TWYJM4L[X!NP7[=290
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MLGXZT5U1K2UWCH>R\A ]PPTFC;'H^F(62Y54TL<F#P>2\W2N;YG#>)2K& Q
M:;F.3B'7-QIP8)X#>M#%7RL.<RN [B/@_ J38S!,M(HQ*P:AQ/M&BF _ #]%
M^O=AZ-KF&!SX >B#Y<V?U(>9^>>L; H=G8#A@'L/'&A_='A"?7%9BG *#.#
M4B2HFVWYW^J&Z CK@F@]-TD; 9*$5.K/L>>NK4)^'J=H3=/_CN/_O^,(_5,"
M OESG()(HI6S3^E*+(&&**3M)G%^)N,L_Z$<A'Q*:ZVZ0?/\@OE!T4%M2=I@
MV9*/%Z?%;S_@D;SL,5>QR_H,!XRF-R(<9W7&S>H&@BKGKLK?V"[MK?$?I^<B
M5Q[(A)'W$9332YM]I^@(J]X)G<=HQ#H2HKO-(V I"7L\L/0!<W*C)K:72 35
M2VEWZBBQ0C8^))[B0+TJQ%-T)ZK[Q0Y_)Q?;#DEWV#V/,J_QAB?T>OP?>*^4
ML>  (.MJB).[232ZSVQ:A*URZ*C;'=_M7V<^*X )F4TG8!-B.Z>Y#O)U :>_
MCI&F+VY@V>U)/8),$X<:(@'43Y\_1TDV$Y4&+]X@'[]^.YS.1,'"Q\?$N*UI
MQD.#4DYS=QC?TS^/VFM-2^0S>+VG:A,Z^33%?0\UG8D6,D['0+-TE!LCB!R\
M)2WUF.O69-E9Z*[:%]EDF@@!Z,?"IW.3,2(G7*#6JOM3?DD'D:0N8>0B-*&=
MY18ZS(7;4<N6'1L2NHL];(JCM^(-#KMV3&,>,[;,@NC,VGN"\;[/;8S=SS&>
MO<,=,:$IP1(G;6YC1KX]NINF,\/Y]M[@T[Z>A"L]RDUI_*:C=:= CE97BB\!
M.L7=04C8XV$SDHG3T'R:9:K$W*J(_G+;12EG'?S)]2!LKZPWL8WD=.](TJCM
M[E92RUJ"E+NTS^\S3<5_7QMF)9:/V^7+-E"GO]NZLC.>27,%0K*,Z)QV4E65
M,'U6(:\>!_M2111Z]G^H^\JPNI)ET14@$#PD$%P"!'=W#>Y.\. 2W"$$)[AL
M @1WM^ ."2X!@@=W=_?-VV3F3&;FS;USSKGW?N^^'_N#WGMU=75UK:ZJ[I+=
MQW%OHCK1NQ\;S<H_Z?)Z\";Z57UN,)U#$P*OJ@P3)_%WPP]B+N\14!^@\#GQ
M>G7EF$)G9Y0[>IC+\$GANELP.[JZ[7QJ'WXTL:KX]54@QX(;@=RR*HN'+*V)
M>/7H:[&7R>QO/!MST^%F'HL .C^XK^Q&K+@_;;/T;:R4/;KXL*3&HOY4 ;-W
M:F/7IUL18<\ERB*ZRMLKPX#>,_6T5U\+\'5D4QNVO>=3>%$H-+R;1/1=(MH_
MN3@A.H'@Z5ZDR(>@&T)A$C$GG2C4OB-%.:WY;ZE3I_;@4%/WO=10Y2WC*=N(
MIG*#N,XF5J$(0O(P TFDK?<= %5B+3D*V1"PWI+5^+YL 6TKC)2*5"V&;W2\
M6*&00WR^*D6IE%H,N.-C+'%-3\[?4(RQ:G.=MSNI7?'T6QW,;#UQC91J@B9Y
M/,_QH):<UZ)^@H@ [4*[J.>UK3-IU&0/58^]S3&'?NW &ND"1 $U+BI)C_*E
MW!#LSBYE&/)+4 N[P<[Z8DL%D8JM/.L]*$+BRV8S8D)NJ9V%@DL6Q<QM_(_I
MWXW0'.?4\&8'5\2V?1)YJ2N 78_J!IQRNW^D6WRJ*8<W]$3 98:AFX.$9"ZE
MI#2Y"!<.#HZ#=:W^H5\SWN$=\/Z&%Z,]8PH5E1-$M&[0MQ8V("8-DN,[S5VT
M/^,/2F$>R5B:!?>YH3N\PD>HNW&"%L#O9^&J8"J$4LN#RW:M5#V^Z%O"#'I#
M?^HA.3 O?D1265U>Q^"Q,F-DV>*>$K]4UU.5^MA%3?-PKC"G*J:C.&PLO1[S
M=6A%!"7F*I6 TH#]X+ 7;WWP49/GDFQACDO/FQW0U+:TU+2[1.MDK[2H3!TR
MFQ-<GR$=*OZQ3&+7'$6 ^_4B2JQ#(K[[->TR!=@A4(M"S]Y+=/'T+ U5-:,Q
M!S60[_DHF"@G2.]*S]N1DC:WBNV(9^@+5L^'6KTTMD<$?N&5@\@W$H=\+273
M/!I(Y:83:D^$L&FRH3 4/W,F)8?U'C$PIIH#IPG4?@?LP:?)UBK-GR9BIX;/
MT(]A4VBS@M7CG)CK@EZA'Q[3.CO\.U'*_\QUX<^/_3OV0]HN_TIU>EK+]-H$
M]]IB%9/(3J^Z3@G@@)I9Y"+$TO9U7E^Q"$96-7M&=Z*8Q8?:R%#O9V,S7=^1
MOL%9B]A&NQS-63JW?=LL%Z%+SKLMTA+?Z",51>_!E46(M(\4-9M(?5*)Q>*A
M>O6L+E:&:WX7]<W9</M>UJ(X4N8J>=@LG)( ?AA&.V'@E(LEUYE$9LT('<NE
M]8M7KQ,'M?T%B2R_*#1$S^<M59?R&*6I2]C$X?CDU]2$KTF3,, _;S6 !G5E
MA,ME U9#ZF=\Y,-5M%3["M6U!@]3[H#*HB@6:S2%V@!1P#?<%:-';#GBJ;:+
MQGY[V0:;C1G9@$6B*FBC,HT*%+KIQ? =#SHJ 3C1H 8=G+?3HFH,3UE7/["W
M-(YCMPTDQ17$BX$Q"K#CTQKM.X1N$Y-I:(F]7 @84%^JPWQV)'K(G$2V:@0#
MG5+; 3B<J+'"132RVV</YG6\ZT=Z6ER1&T44W6]=G\';$,3[B3.'O)T>N2?W
MQ9'VP% /MV:6_K 2=7<F#8R[,YXSD9X\G(*(O5M+</'B05-)38[V9%-3^T&6
MW0"A 76M4JN/L'VX&%PQ&W\@'U:TAO9S1_J3-IOQ!FDZ=$EX7$0#4W(XO./[
M"[$!\V9R+KF0DR;BI8?/XLY&NFM>U*D%PE)'R-3Q^]OCL'>HC;_E?'BBH9^]
M<U7I9J?)\GZO&8O/]K95\R -53*CEA_^K<3(:6+LB"/VLJ^RQ72(:89X$@F,
M0:454<E2)D?_FZF+[;::^L_#Q:?(Y[+[>":]MGCAJ:ZJ0FQE6!O(@(.#&GS:
M6_&RN%8NX_R2WN>-C4]KHBU@0*])8B*;QY"$O& EEBH;-9<.TR[,!]5&AJ=V
MK>F( C!CM:/TA=MB@<,Y+ZX$ZI A/J*IF0VW@,QBFF<2!DZ6.)JNTH>R,P:]
M1$9'L@RP]FIWP"+_P<092T+^*,)T%T>UHRGIDZ (\9NFAAIW?2\N#>K @Y9V
M*5HK]\ ]XW!&NGS:\!15<@+3ETCL)IEZ*2A<#H5N$.6(%F+9PY@3D S'6(.&
ME1XAUV$DB9-8B6_ \X1SI*&4!Z_0WIC2L&37'SZN#I? ;ZP:#JT)*1-X\;'@
M;>T@YUDVX>,3YT/5Q P!LF1'1$%[Y%%;[N=(HD.M)T3KO'!OY>&T16S 1!=>
M4Z@1#KM04@_=J3^$]O^N0K4)[^:GMR^?WKRL/]@H5WAMC9Y=6@.2CJ*JR--R
MP/U\Y2N /X;QM6WY#D#NM_3@; *AEX49)VEI2CR%,?#7*TK[1.[MY9K;OQR&
M,C<U;J9SJ+&9K/^C4+3)'!EO@Q<V7E2X*71F1I0Z5P#^H^[L_YIW6MVMA7:J
MW*C&W"R)D:]L;?-'=H^/CS)'2)-NJ=.*>)4$+875I9(7]6([+7 C47 M%O)U
M'G43G8)/R=^ECD><XE2=@JMTTV.R7&;F$]'K*AB^?I,]CVPOI6X_O'1!*(#7
M:Q5H@^8@+MGFHP!-MSG7Y\2]9NDWSTZFUXL=?0B ;#80';J@\[>HA!?ZGU>Y
MG))+$(B47R-V?N6I4PI7-XB]%!C$>X?EN._GL!WV9%NB@LDL]OS5T\07H<P^
M#()S1?S/4]UR+39O+< ONR#::#'_U[Z)F]>.61?!(S+AN-;S162D<4[7H/TJ
M'X9+-;TOE_5K-0XRDA"=?1?+"LKU3 VD62;HI18@? >\+5^?9TUT7*BU?A&5
M,V8]:Q).L?<AL.4="6F)N-R'XQN.&U36[ PST.8=,/5DAHGE/ ZDQ=8J#NTO
MV U>*O$XEGA0"-EV&7[<FV0_[.^(%C$]ZZ,D ?.]9DK'WE!F KN6*'I":TFD
M)=-:G0R7]["4-R:X6K]8T7<6X/FRNLSCN ['.JT@H+5^J@VUK?#I601;HET0
M\<?F>7WC[^ELZ_NAU7;V77!8^QI<=#$H[S.FS&)7/A9G/H('3$87;)CL;-4V
M,A;U[L.U4=NG7G0V&=*2>/"(?O'U*/\ZH!SEU7-<,HYW!<90 J,52S@F\^V8
M'\A8&B"(H+.KAI% P1+(+(G@?K>MS>_BV+(?^7%*3UU\0>MXD2#5)+G$O::
MG3!33AY;O@]MO-<$:]\#G'4X/FI 4R/=Q>K#BS[-51 :4F<?_:<NQX,MNJ-"
M&PK"XPV" <?_[+R2;*B(?+RXRM7R?'[ZY:$PI=,E1ED#8I+A@GWHN#;$Z+IA
MSY=S91U/ZM3L ;E.TKT(K0S.5@D8QY6%QS/@/=;&1W_@UXQ\<'5A98U*EQ"2
M_=59"J'!9_UY^6!R^PJ*Q""&I^KPPE@E=S_5FT Z/5-<?%\ZJE/T![VYWB>W
M4FUNHLE+XL3-]2/IZL-KY"X?'T.MOA)_'0DK:D9^0)"$*5PYTNZD81SO8HTS
M]+@FE0C.S)B<$V:=G/106QO]P>!V,_PW'@E/Y+-\$](:^4Y]"8/ZV"=/.;NZ
MVWA&WO(NY@R=)MLKI1C%6DJ:GCT<W%L,@^KT2Y&X;D]UV\A+0W'7..!_SR/X
MKN8J-H&T ;YB(-R,V%A7E*+-YHPSE]^GD?=%;+;QE,TU7^[J;3%,"4^_%]6)
M=1R \K'XB@+Z8^.%^Z*VL#I7\< '@I-N4#S,$07=QZEIX8<S#)R=<F[58-1O
MAE5UU19(;8YN]&NZK&"S-MCYY$D\[\_+4S44::AT(V#,K7$^!IR";5LQZ]NT
MB8$#>)!9S,>RH+BO1]5)"Y'QK./3%XAMSQ(:S"/-]+ESG")W$P2QC&&8'YV_
M@5DY@G/;I$A#XD7],H4:L$=6.US$$[\J'T$B><3VS;X2T\!_\+6WYH=__D3Q
M7\S>@*YL/R/XQGL]@2,R"3;*)_3*7N4.J*J<OWH$,<+G5^\ '#/V<HQA.@7E
M/WW-_X?6V_(=O+ZZB&5=)/;@DT2IQP=^P5>X\<^,9DH")XVZ:DMDCQ<MYR?7
M*S\U5H5W(BLXXG.-W72H'V5)/$4G*EA9P>!1R_"T,&LY>0Q1_UOZP"Q_:-CU
M?;*G6T>&:YO>R!FVHETK&\FM9"\EGY0.Y^E9_EZ"")* @;(/SLZY81P;<S3(
MWW+:IP4'7QE(@F2H,<GY++#AMT>]O;C5,O]N!%S+!6W1K67Q:(W:\BA:EOB3
MGN4:Y/=J4^AA\SNE?*<19@<)-RZB5ZW7J@$>JIHA9L2U4U]X&AP1G[ Q?/_,
M25+7[Z9V5IUX!P@BZE[?M"R+_:%!TP#'M*?GXM[J^7J(E1OWVH)"4X&&_!H/
MU+Q*6?,BBS0Z%!P39+8P_^S+HE0$0E^AF>*FE EM<6.S<-"D9(S S2Y6]V;2
M4D/IKB4[V.=9R_FE9V?$[_X/?^6$8C2SM/<6KA ;QP)9@YO;>_%D.#.!81HD
MHN<<(=C)*VI!Q>\_53AIOLF[F]"7)V= ]TPB&WZ%3Y/V.8T=?W>I!'A\Q'/C
M.62K]XR[,?U#8S5.;TU[D.%PWM^1VV34$5&)-"AO^YDS;G%&U-PD<6B^W=/U
M[7"EA!"9 ^/LT@TWE6'UMM=\<<YV91UV$VC%*W8&3&6S:X5/HWM8MU*GIJQO
M86@]]X_N@##"WS?P?K!0G^X%F68IE/K&LSO H *$^-$*2Z2QG:V75*\AR,IU
M>ZX ]?V$STS76=_;U*>>EB9PMSKOUJ_GLYW^#F[_C?"!QWS(2:)ZY?;WG=+B
M'+KH;O@'V-CX+J?(5ZJ6J6W&98>G.17(,\*2-0%,-&?)G0Z![:6;8;G')=/7
MFA#S(LV_]!:L>YCYAT:LMF^\,T<A__N:V/$I:1E7*YG8!K:\%>ACDOW6B+/F
MUY?*7&)MLSH#ZV+E]:-O4D6']@T;JXZ67]N2L"VE]RP\:#S9UI[_&YYQ_: +
M?XHHA4_85U=67UM1G3)NFNN:&?P29!SY>"AR$O>3X,*$S!+_P\&""WKI(9KF
M-NCO_=8,X2^-O2Y-7C""G%*2SDI2_V8*/(=\6%N49L[V^&>IUOD2^8)Y7ZRM
MH5\DR3TFHIM97^OI.>V0XF_K-W>(4[$4^FRQ6]A1\!"M9=([#.'1'= 4^L1^
M@G7^[]ZNC]M@Y+&3^0?;]HVMVUK1*MJJ_47/WV2UIWW6D>4[N++7QECW-JR]
MD,/THUT+YFP,C%F)?)+=5EC'<<K=PK7-_Y]L/IQ&WSGC[,,/4;U,:H-[)]H&
M37+--EY@LIDU/UHUD8=YWTM4IN7 @V,<M6"I*=)R4#76M!M='9^;S'=HJ'KY
M+5)*+/S&N63D;TC$28]^@2#WQ/PJ>UI;#,_93: \4&\OW"CZJ]@5%%R3XL@[
M/',NVQ&R$-4P:\L=>N+:>@2IIJ\K[ E\?LXG&+-_1YRDS53DJA"G49-1LA'Z
MU8814/]R+<A54?45]#,G?75#D[UE."P\Q9FW'!/&![,YJ;?IQN>1,C21VHT5
ME['/ Z<^U7)_!!@#MKNRW>C_AIW4?=B#YRA6(GLWO#6$./7AR _SJ5+_IH]6
M1OX=\)_/8+67$FW\I9HH4BA3$8H@0645R;_LY/+O?OXR@Z:%ST70XJZ)9MU(
M]LAS=D08I0?81Y*D_35]SJ\$'XIBX;>P\ZBYBP#$5M\;NFG#Q3<32J$'>72,
M3[1 C!6\\ 15QG^H@ JWFWKOWO4C)./-'7#O/!8!;KJOW%7M>>_K]<-5_?Y*
M1?D77W5:] ?/)N^ >^>Y>X_G^_L5I5_<N"OE831-?G'@NP]#F.:_.97[X9E^
M']IH^;]R%!%[F]CJ?68?%3$1O.COJ'8N:= _^^'^'&8KOJ7.;[^NQE\?!NYH
M;69H/?VU=]?E6J4I%.U/<"<_1[_/*U+]$^FAG\/?!T3_Q%GTYQSOTU3\]=@:
M%/^;1AF)%&=N&FMBJ 577OV7REXZIQZ>YD+@?[D#AA15>G-=[P!"#<_;MX2W
M&"^T<LZ$-#_]75X$Z@^'[\I*-C$U%#<])SNIM[,J^<W")F.F;6>//BU#9SLZ
M2LD/%[.*5EKD]25*^=>]1Q(EE1?@<=QR24,QWE]Z$9!TKJ#]:A:SJDZ3/%[E
M"24=0@!5]D<#WZ0D@'LMBQ_-(>H6!);IBL[_H)Y%QEB5? :H.2T?(SUY0'":
M[;B(3[R'^W$E6(5YSJ.V!Z^HI,(2L4F<$P_IG2/,'.P0G;7EWII4/KG72VC6
MD62PYK[0S4W[$[>K;["\->U5;*4OQGWSBG*.UJ8HTK^OWH"F(^:P/BNEOHO/
MCUX*"'UC5 \:/T-"M$>0#@PP2N33I*3U0AF_;C? *";T.5$O)=C43W278;F6
MWE'14:%^KC( :^?FS(I[@2GH;HLZN2K_:;HUO(+!\/$3 RK!;A+;]693:":Y
MH"LAS3:;6 V_,MZ6*4/39<7GH>(&^O/LQO@5*9/%UB@NL=I.YQH^,ER:RB,E
M_?6].]E&G^%X\'P'WOFY+XZXL(O5!8CO/7%M[-,M:^CA9F9Q/U\ V2?/W@$(
M%7#OW]#FC+WPDWVOM+;XLK_&:3;[@PF">!?)-WE8.-^W=G-DXU74E 8UXM]<
MSVB?KO3 GDG7\.#E\8MB3(V_>._GP$MWU+O7VLIM5K3 =E@I;+5"!(5+Z+X7
M+F/Y[8%636A5F+4HCD."VG<D9S5;#89Z,7T<T<^O*\/ALAU9I10A*ZQ<(U7;
M5]S4JM450(+RGLKE/ W%?'L)(R7NQ6S3:7:?E!&ITX@<3D'K<:TBFA0['B//
M <#)(G%(+AX^(M/ H'6;<ME*'8U%,6<2Y]-0_MUJZU$7:['S(BWQ*;VJNB'L
MWBK=BD-,3*PR0)T/1R6@,%PPZX(JW!0[IQG3$"N.9C W(2OE[\GH?'S\NF[-
MBYGH(N)82\PV;0M*(:_OM34>-][7[J*NBP .I9298/5WE*;E9D<Z$A8>,/I8
M)G[2P3F.,<&4NHG0:S#V$3HQ582^)RZGPGDT2JZ=FZ50\1\S>KL5/M+9,&&M
MI?%!'5Q62EF7=S_A-BW.)#9&"L+%%$*QPV(<</L&:]B"SO)QE[@VO$L^7@/>
MBA2-F#T:3ZYL,GSG,6J.'9=JM?>2*VN3KD8YE\,WD=RO95D[O:KR"IIIG'!)
MMXSSP0[-R,/D_IFUFD%]DSWZ@[1M%2R*#,8PT1-$]E,EWS?8N*RR73W,R[-J
M7L/TK96)4J4+3B=!>\%ZY$%''J!&E-XHY7G$7B&:WO3Q5XGJBX7Z-N9K\<_O
M.--#<Y0*%2&C?DF@?U_RS/V1\3%)8!M:PN+*42:YK3*2N+PX7/!\&H*;W(UW
MT:\)4GISL^Z ;IQ_9$C1^O<SI%!''3I%&[@67KR36)@[U@TTY Z<29$NKEPX
MZ88[**G/GS./=7K:A?QU&G\9I/"%B!AX%9&&3?@QLP*5)'#4L=^X<UH^A7H(
MOU(C8[.[@42D)@3!.<Y&=">YSOJ#H8UY2NXRK6*7=(5!_LN)=!SKF1YH81L?
M2U_:T I+O,!#W^@NJ";8:=61TN'1Z5EA+IV7PU\J5R1]L4FFUPB3N15&'6X)
MOLZ98S)H3'=UQ5,BP+JC>KX6&O&DW[[:P]V]]=1-;],TY\I2BW-BV!YF;9\Z
MUF3JCFJ8;E?XB*%EFX1D0A+^/JF51VZ)FY9ACG=8I^]%V':1KHG*H[.C FK;
MGF[23P.\C-H=XTU9W[?0)F>TN_"_3C,T2%QWP==Z^_<L&(:FQ)CW7LW+!ZW4
MV/6"&F4?$1468N@)GJ/'SD^DZ2H%E(^?]LV7:70535<ZJX'%Z_W3:Z,,CO"[
MN6$_.U-TX:,2G3O[LUK<"K<?-*<75F]6MAM5ME));I,6?"T,75]%LMW>#-X?
MPX#%$(H08!14H<'RCOJVG*VFX,!3?K73=DBP"EJ:'Y31F>3)JG_M,,2"YE.(
M*4R@7O'T.[NM3KX(>FS0\Z8],9Z#J=81+2D\!?HY5RRJB'R6]L:J6)@4[H\Z
MF-R*(C8JX;9>[L<=QBX%4U/[0B#J?)-@>C;R^8=ER=YJJH1$JMV]H8>A:L_S
M6.+X<(=S6X9+C.IKQM"*->:EXYPCH_.9L,;D8B61CA[P+-B)(-YXWP'Q&\[L
M3N,*\'0EQ#Y,-CAJ",R;T8IBQ%(X/;B%F4B%E-TDHSBKC;)G;F%5#9)3_@VO
M9H)('(=7DIBQ J\3440)2_.Z%#3Y"&///%&_2^5ITE9-"^6HJSCY<6S6U(S4
M2&+*&\>@*P@\UM;54"]@G1U]MCAM'F\(7WN%=,I*(H73'561YSPP1A[;I85R
MVGMQ^\P#05,%A3P%VT!4FW&O#ZJ6 L'W4PU>JIQYMDV9\%($PBQ?C"O^E.:'
M6I==LOC7R 082,'9-EA)QWNF&K=WP!JJ<$5M4V6E"VAM"TO#>!JGATAQ_9M)
M?O[VP(V9!5GNNIQ>-.OLKE\LX[26F;VX'=YB3">,&,]J[6?5W<&TUJ)(T9+I
M9&58OEQT6I4O&SM\_TP \R*8V#0!7/$P[DQQNO]A8SZUP%$YLSBI%CO@ [6W
M<+4.>NB,+@^%M&""O1^<;TQVS3 UM&QO0.79Z+'UI]PR[7? 7 3XDG]9E!Q\
MXGG> [&#[O66IW> &__U"L3NQ4J]'H(82.0W]Q5*:>1N-^Z _6@PB[[GOAA$
MF4D]O%=9ROC/(8I)L]S%4!#$CB.\/?+LO->*_A8VW""^SO,[X '_LN(X1E]Q
M9ZXK]-1MR=(+T8 YV<?IG9KDH2LU+7T"N+_A8/H;2.633D':&7F^:],9F#9#
MRJZO:5>H(QS%./\VZF.\\C&?/"OE\,1?V2S"3TT'C(1>+56:)S#/Z%; U@9S
MO\TD(8*G)'K\^;P#,+H#C,V=$88&SS@T5)5L>8CV/J+XPMAVX5L(44_>M >L
M"%NSA&^C&Z[4ZBS#C21\RY' Z<XB0'F$Q!5Z13 *S/S?J!3XKPXOO3B7,D*2
MA'X[+-V?9+_=275!=)+VZ/#?I.W_Y+K]2[!'HK^NNRIM5NJG_D<%LH;^"<=+
MV6,P7^4=<'7!?T4E6:>\S[^\+0=1MWWO@(RL^W3F4DZ_^%VJ,2[N8XDM$3XV
MKW=@L\1O2B!IL],E7GR5+/4@'';E#=[QN!>7&W74\(V5(_WC#CV'98SDKS4,
M4[.NG^,)8-M6&8]\!U!D;:?JW1NVI1[YU<3)3W?*?AOA$)#+D1OVHG()EGA]
M,%!(0]-#]:JWN]=&\)&-6).K:C)F(,NT)ZJY\SF[T,#:WISX@GM<G8U(4:<8
MYSJ24W+\KDYO$4BT)!0;R_"QW2.66CP;CDT! BFC0T+UNA$K0^:I(J&M<=86
MT R,#Z5*"'-&'1X&]+Z-9DK,6Y=!C=I#P6&0)F85/,X>D>@$Q<$^LUC<['DX
M (1"1R><% =5EHQ]V6*4*K-#&8KZS)&&BG$P'^[81X@D8A7W;,+VBY&YSFKQ
M_.W#% 5<UQ;V0?_+:X>3D@CY0Y3LO!OJB;V56':7;- X=Y\#145;DUJ_0G0X
MH@/',G$3%K&7@(+O1'@5QFQ,U6GHN!I#4>R(J &(>>A#*)H  ?,2LI3N4.GI
MIB5=*:%4[!D^+QI^RY Z#5UH<_#G^B2WX!/T,<=X1QFA>7FU\N$AXX[O58P?
M%)(8(NOP.0?F>^L#T\.Q%-&UB"GD47E0X#0B0T-Q@$,)QUO5]44JX9P9<W:K
M4A>K_>(L>A:JT%TLXP'1G5S^6;A1-8-%J9[LP[>?+[_0L4AQQX-T"NFT[3S@
MH4]*5JB\!.0?[#Q4]96KK&FN:PI^7,,N"#-L"/HBBN[^('IDW(OV1V[NB*T[
M8)HK(#>/+#Y/SBRO;XD9BJD.H%'U7Q8EG"&%$GN;<(90")ML9NGJZ(STG+S>
MR.SCT^,87,$NZ>5@X#@"Y2*WW?F*=NPV.[E-BBZ7JP=FO)_1%Y&PF\_Q,W*M
M<^%^D1A<!ZZX5560O%QFS[H&2X,BI3T:0+0Q[9QBYW:LXP?@PU*R45I.BWK8
M"A"\@,VVO8U?8O<YT_2K;!Y9*W?9)ZT+9(P25(FZI+%SIA=,.-LJ=,Z9G.]"
M=V:@"4+OXZ(7P)=5/IR 2S$?^QD:NX+3,VY]2BO#TB_D+B,JAX;H8&@'B.\Z
MBQ;QU\J1.O>4ZA9\,AN/G:A1BVQ]XIZ18P)SLRKZX)<9>:*Z0&8T)3)[6WP_
MHVRF'IAJR(S,Q8Y0DVV@K4Z+X1W]?)<<_=@UVO-,AK..=W&T\]%;&JB@G/39
M"?YB1L\@,XI;"B)JBEVDV6>YW$GA[J'35V,"5 S?2;$?T@M&Z<RJT+-,<U]D
M!*\]!''D2(RY(6_9Y8;7\ARK;OR2U3'Z#B"R^$?\DUW^)O\1[&^N=FJ4_W[\
MTPJ/B"7+'(E+E#/K6I"CI14\@&V752('1(K='GE0EV9$JXU<3:;G6GH6C]RB
M<I<?A)<9%0MCU!>YF9R][2 <H++<(STZS^W^4@WR]U;Z0MN]5&*> )L/Y\LJ
M]<#JJGAUF$F@;(;[8X\0NU7=QP7[B _G&Q:U&?D-=X".,[I#V>?M!++T0JVE
M@1&5"O?3&DSWJ>^M&>R#7^V^8B$=)+NLYQ?/(T(=6]10@S,\%(4QTQ'R0L5N
MD''J<2B?W]=[@?VG@J3_<H.=>'J(@!N2/;R[6W3*%I6+,A&K8^ 1@Q$3-)4;
M^\82&PN;7WA:0>"A4L53CX^6+I]GOO=&WXC-Y=0U5%<(G*NA"?@ML)2@/]WL
M5Q@^U>9:(@U %AI_]2KQ430UX\H9;/)'K1:(^%C/\KS/WX7#R']S$@&^@(CT
MM4)DH;$4&(F8KZM^1GQZTVY''%DP'U/!;O="@O"PX'"NBZ83:]]20Z'S"T3&
M?"NH6NU8G4L$AQE1P2NT[5N&?]STGDE(YVWKR_X"(V= VJ#^:!&&"?(DS5GX
M]V7.S6!@X[?!1,GO@)0HB$R"NS%OQ/&IF5RN#=K=>Q':$MO&+; -XB@TW:2B
M[NSM;GO^805-  DBX8Z'^>\394%DV3\0^D5J_0'@?9XOLYTO8N0I;757*@]P
MS<N,'8@[30,L5X3*80?L9-\ER0-D#?4?LFAQLNRPUHY?&Y$:7,BZ;G&FF3$B
MFNI1/B4E,<=4I8&[GJ[0(-+3#P9Z*:849,*L,>*?/Z,HCI@WWOZRJ?$[#,2[
MB?,UK*NLRSDBV[W>U"8(= K9B9]VIR'^?"83(H8'Q2$"UQ?,>G]R]W/BIK^;
ME92,L_JRB1-",+PQN==#0+G!O3*01A)4$9FMMOI<XLN;]2J^N3E-"],%"958
M5@1$G_9;"9X16@/,IXF;3V83'UJN!H*DQ> 2&@30]#TO-PEO#SP[0R'REI?D
M1V*O^X-!]9\+&=!IFFUFF1, 39HAT1W"9X+511X^,^Z/+P+H"^:;8RIDA9QQ
M)*C0HS]9?QO('T)T>$E0Y3:^,SLMS&+?%A3MYM.XW/)N#&%2^W,A$MEDIH B
MIZ&B#BMOV?PQ_D/UFA%:VHP:$7_X&J&H,CPO-[## XKCP.Y88M0,PL/LW\U8
MF"#>!+Z&4;AB9]%/@+$U8%OB62(2H3%:#X>F78=RK[CEK+-):4TV(/=7O"HO
MHG^(:$-OA?7R:W^3]S%S"M9RVB"ZF*63#V =?R;>_]RT4UO6IOG[<JHY )(@
M0)^G.2".6#+Z#'989:H/D'AMQ/M(4?#6@K"W'CPEZ,I;^?$R\YCD,V5LM\Z[
M@TLF#\HW)(V8YU#PQ?ZU'S#1TJ?>G2G;MQE8R14#;_Z2O 0BA]#L@8]2/=%0
M#,#K.LTGN)H9*-8S[^Z KUAA+G*7ZR?GVP)/E_ZJ*[(1-1SLU8+51TE&[TK4
MA<US4P\>C@^XA4D25'WM'Z=#WV;>IG"Y?X->CY4RU3 S"B4.C5Z-OC4OGY^!
M$^1!AA(7*JR'8G*##N 8;,*<DJ^MKE4&"1UU@[R&\:"R'L.E<608U[:(U%SC
M?<IW-",0J@4>VS#(RJ$_</[)E2R_3>E77?(?*\0)X\L]*9<SUG6:._1?JA30
M"#%@BOG!S:C@8%")"O?@Q=7('; -&6(CGVJ5O?S)K#^Z@K@^TWNA(J8B!A&[
M:D_4DV2JJZUC<="Z7.P25MIM>SQ: =]^G)/;"=\LX[WG0+]9"F+9".O@+L=>
M2=:CXQ[K-ZMO:W$,ZH5JL5>NHD,3-E: SDGLA9'\4G!Q<X 7\UOV.X"X&O+:
MZ<A#1H6JHJ9O\SRB-B,\744%>U$K0J1-04+R^9E5(N_Z9&X=(]U+!KIU^PVX
MRPY ,Z.<!=_QK>!BB(SYW/A+3(;+?&B&V?G50=FQKS*'C$5&8\2C-]SN9F3)
M;^*>T"?CI7JT$H-R$60EUM-@OL%YB+QVT6W/7]*4JA/)G.HQLQD?3H\R5/P,
M'>.X^)ZUX5^*'T(_2;V$5O]'[%*,G,0=$,GZC\BFNO\5Y6&DM##;6<;F7)YU
M."H&]"[OK,L=<S3UNI+)I+:=@\_[MK5WT1^L$!(T#EZ(L'B3(=X6KG65M.EH
M'S2VW-"$88E5\B=\GQW98_7@+M4T/=I4TK*(=:IA<PH<^53K;_@(_8DX#(%M
MPK'SMT;>4C.YO$T<ZLVX>L.6EG"*)_!CZM9JBO&X7D3A[H\]J.O]78[<R<?7
M>26M$Y-.7"HG,X^P9\E L,;A$J]"D"<')WR#*]#9'W>2!-$:" ZIB$,?E)@(
M'(IT-'541R_!DS!K4;!Q!2.7Z=);GQN>ZMP6EI5PBG1,)N:D='B>#*KSD\B@
MS<+2//QD,+K+R6I>MO-6ZG6>2\"U2,U3EC-3 @F$")J5!7_.%=\OR]C+>:PD
M].6SY3'6%9&BCXB.53PK]M!B=N<H)(7TPY2<.N":Y^(Q<D4 H[BQ8OW+<<0/
MX4AQ L+=RY]TDF[-?;;=_ Y8J@^%AFGT5:J^=XH*V:!JH8[7<RWO-TH1!"WA
M>J**U:4LY'0Q0CT_QO(G='F&#7GC\4VA=8:I"U?"]Q:FN_N>NZA$^L)?9[OP
M1-KWF]X!.6Y?+G$\JNJGIK.HI!YN=14^[2'?LC/7 $K!\=MP*Y GI$]]CUCU
MR_<<I]VUW:;%7>BDSQ]+L%B5W?B1L2.MEW[E@&X"M'Y]#+FCJN.ST*;Y/JYU
M:'UTU7MAE4K^Q]/;Q1YX3A.J(Y/2SU-P8^1[.X11Z\6)?+AO+72\F(NMK++-
MB,PL4Y:0"]E&]:#14IA5/4=X]6["V Y)']"1F$VFS<Q)OT1E#W_/JJ0R47SB
M+F41DD>',,AB@_8DX&CR.\7L - #V<%NF<=1N\>X@ZQ?U$MQK'F3?H[YXA^O
MP;,0>K)^7&#KTB97-V%=&:*^FK+6C]53EKGZ 4J9TG+EB',Z]#!IO"/I362<
M&9D]-39;?VB.ZW37:X%'A4[!&.\&T)$ ] 7%7PE5)J^C596=%5U<.4'C&Z@'
M-"0M0Y.B?O46@/\#M;Z*'.**IB!R+OE<9M2^!(FB(6E2B^LKD??/?B&DVXO?
M['<\>:#[ ]^A'_W,.YYSP%RYR<,0;J9\>B<:\8.IM'::^8=W=QPU0PHU+TA'
M#,57JUWB^NWZZIR =KQ27E& LY,ZNZI6JD'<R@"&-*^<PJJ6A(0%&/S16>S*
MI(@PJA!=_J'G[]I%Q5(=3FZR9<^272U<4M[82>!_#F2Q+F,O#\6?1-P-G^SG
M;WM'7G$H4C3QS%8.IW412QHS*4]/4%7/A:19S(8"ZN2;G$TB6?CP2_!V.LEI
M+JDS(Y'X^.1C!Q5%H%#Y3T/M/W8!3;?9M+'.5HU^ZEZ4^ESPTI4(2E!/CH9#
M7JZ*MC2P>.^M&%_ >(V-M@AJ2C$5 .IJL%HEB@Z]\DX9?9#^1^X+_A,[$N3F
MT<7E]CA]D^&0?K>'WQ#!O_L8;DE$;_JMP%#)7F6A*<PN6_83*1S.,"3S=B]U
M9BA7./\9ET%)8*/E!VO]0N<B!0&,.^#'%Q*8R8-)!F??44]S09"-!;"3*)'@
M(]YDGFH\&Z_W_X));XVGT-ZP.HWUH7[5:_)3 $RDK)N] +[C;U(PT< 5-O.U
MM?N;ZX7:,*.PLM!"I(AUV?^^,Y*"=Q3EP7> 0 IV,5TIR<-7Q<4FC#QI! )$
MH8<IS .,,CM^-<89@T_K1&*PNU20X#%>N/171R_22K6?G>'(^65<XS)E:K>=
M!980OS$*TF/PEX-AACW;3#4(> Z#UEZT@R84X#33!8T7/3J,=75O:5G< 876
MZ;E*NK>:'LB \84U6,22!-R8#E'S'YJKZ@;< 2NJP_S;O82W@&HV@"&G+#7I
MT+,\\A5J,\X<-W1GO<1V4'J</=@Q65BZ_E/ EP4Y7B,3,WWZ<R<#K->WR^JI
M!Z +7_"[(L\#C):+^CDLUWY[$DK54.WX[$5>U'8=PF\G'F06R:P+%<827TVO
MLT+,IFMX<6W7JZG\P#"C=&\YEQZ1CC['J:YP7N]G0/[4B67I=S[]R9)_'\?D
MAO0^XU=J(>'-0VLP7<2%Q'VH-K\J_P7"_(VVVI@YXO9C-AZTQ9 ()/6Y-N[I
M#"VM^(S*JMF5:2B *K%NQ<?=SB*OE/\.\(MK)SP^-;@#O(KO@([QW/>LLY!-
MX)4%]R9M5L3.+M7'= I!I,P&PGWE/E2.$F..\=#DJ'$%$0SOO'\V%/E/ EOY
M#^+\P_^S4.3?*7-5GUTFE$<5N1_!-XW0DS:T,[_J(2VCD>Q]M?HH"<24CN)J
MW>Y\(O]06[0564VJ?F1/D$%;Z%M/Y<*NGF#7NOH<YC?9( N[/IMS>ZV>^E=[
MCY"^B'9@J4![\2<[..IT@7DQ;]<@[!0&V,5IR#3:2RS>2DY1.B2+A$RM!AX9
M;:G(\BG=2%V,T+)ZR+6JR6_J//^@I2XY37-JPGLMQMB%O#$+D7S):C(A*B,K
M59$QY&L2F$56G*H$"V/(7.JGLW3KTF.[RZ E^AD=@66JN5"X3!2(M:-1SUF7
MZ7P,X8ACIJKDN-,5B[VD4/\0\!7_HA8X?F$;GZ2=V>(9(U9.PM.G8F?O#2^3
M&AC@.$A3<]<LR*2F!]]+JE[,Z%[H>1;4 HWC.H&WD]RP6UPX?F]-#\Q(;JFV
M4^[/E2.,R(M4AK0VK=/GC#WW((OK07B0R7P'./%?;]P!_N*/B-"^#8^+1/WV
M8XF)TH&A6VY0\6F=E:'$:T:&,,FHCSTD2&IVOM&1629-C@[R,*]2K^]#<,5N
M*+[> ;,1]PC?^W#\!J.(5ZSM/ Y,7#XVH02:+5H"42R&R>>CAK6#_%9V=6Z;
MJ[Z-6<R*#LJ&Z1RM46!\)XY[8PA"?U<$MRR !<8Z..T*V,FNOG:?"R)EBDNB
ML.N*U5<1U/>0=5-=,P'O>)X/W0$(;ES=P1M?H@)4( ;X%N7H@V>__;+2:)"-
M_0:3/5.VBIW:GED@?256Y7DT[H?P O@K-2/ETHS(/FM;/!TSO^2A%2-O+(Y!
M[/N4J7#XV2Y6),O0>;5)&,X-_@3*",9ZSX00Z.2 MUD+AH?: [_!3[<&0&O0
MR(D:7Q ;<VT0M+^C?2,\"R*]AFP\(O%W0 /A[8EG:YZ%F^5X6::V68_#F>@B
M&_;N/$HFSS+1*39AF+F" )[:#?7I:_-RW5Y%B@P?]2&#ERD<*TRB652VE:F+
MG6(:.\S\YY!WO3GB0KGR=\2FQ-U]* [%(+Z%=7BE/"H/AXS9%N(\;/6&%;=G
MOWV8IX\GG"3FA:.1R4QP=A!R1"()@!(SMCENG;-9/<Y0\+%X23VRT0\$=)$&
M-XG\#M70P=OO$$LK\T=Z\][Y"]%E^<.'G057Q:WPQ6&ED=F,3S"^?.]@IR0'
M"6[!O5:ZT&WM6[2P""Q>.VX\5[/\HB"*3M&:X<6!EV284C7T>R;X'9=)B0#V
M[R@.2F]>J!Y,SVIAO1:2>N3SQ!4OP/ %*KZRKVC,8D,R<SM.0)$C-IW&R<V0
M]&,_Z+V"3]K3RH8/DNSDE!(V*=(>5?R#* J_X0XQ"9E.P]@\=*5CN[LC@QAC
M$<I14&Q41O,)%;3Z6]HTN4W*CO9R&:=I)#<&<@>.LIAR9+^68$<@>H=SJ3G^
MAT1079LMI36N3J%(P8[L(MXGL8ORX2"(Z1$YF)"K8>8-FYT-+>:,)Z!\V^K5
M3FP()2"*$%': M7@1@'5Y/^!RRK9TN!-MEY-D'[HTR2J4-15N?]"9O(YSZ[Q
MU#M %^X.$)%XE<)" D;3;"<[515 ;TI"9D[KYJ3*8M1AL!V +_X+LS5%</'6
MH!5'<IJWI#A/:QNM6RH[(-4&QX&<3TGT2Y#"M&WWCICD:;?A<5JX=@3!*7)9
M)[8=%]JVCF/F6YDXQ8F 9-HF4 _KBDT'C/VS> -K#D;;R;A>13$!G";BR-9@
M>.")"U3=+F(GEW4@?<KP./?'Z5[FUF.Q*I- 1J$-^^[N?=_N-)2 A#M@:WK#
M JJM4\,JLZ0Z!LF9:G4MG'*.1X3YI4"4\CHHZQPZO<.ZY:KZ"@?H/YB_"9X2
MNW45AL@@A-&B%N0[H+LXRW/B _\54"P)+/-8W@'/9:C!=5J>'(6P-8U_:#9)
MLQ]$?=%=?BV"KKHFJ-&,?@=$I4$DV(?4*SS'F#^UPSP7*R3Y<;A[*3(:,[_]
MLT>^E'\\.Z;ZT]'R?VN=N+_]_ <.7(W7G><$3.X6]@:Y$NB/9PHKS"8:LC[
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M2MY_GC(*6P_6P$U4SPG94:SNP;3I=OG,P7O)G_QZ0N[@&BQZ=E\OS?/$4"6
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MNF#L]%] 5^?LI?MX(V!#\A:S;AXYUGI2WB, 8RSL#V!.-W@$K$@\ M:LR[J
MJ[4SHO:L)]DJ/_1/#CLDKI<;2F]O+>0? 1GQZ?=_ME)D!K;A)R0DI(PAGKV9
MR-4\#+.Q_]3NZ==^/90%I.X#V=11C3X'0C@@89[^],7W#I2O?32B-Y&=U2OU
M@5M<M'A]K!9??Y<;7X?&_'6W9A'H)LU.8O_F52!E:V>P]':-6G9L%I""G>??
MSO=ALOM3(ZU.P(2,-YW)YKOP,J?P^E%@'\7M0[.*@S I2WAL+W)@C?&MGPIE
M1*/[Q?=9)2L:=,D8SGD4 &H!.D.X>;'AU4GO:$^>/,LUO7SP&R^+.I=H#0U8
M63BE\/I4N(/E0QL9RO1O;5R/9(5X%+S^4KN9H2&/1#T%":,<V?Z5;3$N=8YF
M&7>B\+?C*_+$WP+H7X)Y:/2>='-W ZCC41GV!"DL]XUVG7,SR^$]249M-EP7
M4&.:=CI=-Z[FPIPD/ENC6I3U*=S9T$A9)*@T;Y4?B38SRP]%]D[(57[L+LP?
MH/FJ95*/#PZ*'E?1JO2HDHKPZE=<L0*)1O)]!M*,4LN$8SM'3\Y492*S(; +
M'6>=(1'],>=723"F%S*;P"ITEMFI,PI/4E'_G-'2T$UOEG5!OAW0F_H(6?N\
M"!FJ>I=0Q1^!<R-=)C2BER6Z8Z_FY_8<YA:DW *U">E2X&VQ+:U[1[W<GIX6
M$=5NJ!JA&V>1^ ;6I(LU<>7M%8,W?C$9&SYI9C]$+K&<CR8)?O/G&"6\M+NL
M'1)>=S'_C,43;FHAUK?]89K^:2%ST9X&KD+Y@)=M996MNI4ZE[T$SRRL2*;,
M:KAT8J'O">,' RL"]4.TK]@.GJ2 R<Q*>+>P=<[J[8>$:BS38$[V#U^!J$(T
M:35N+'#M[9CGI<8QEH^ &>E23(8I5WP4,8+!Y:L)M!G;ZGWBS;BA?$RA7"_W
MDV\O>N(-?QE)W/M@4Q1X;/4IE4_EWE)<IPW.ET(Q0&DTW*CAI3(*ZPSD%H)9
M.7\,[[X*7)="BB# >:V)C$60_;"DYGE&/&ISX*AB>8'@4(IW\X/@=H[=N)S[
M"Y8H)%&$VH?I925" 9[&'DP[>;"678SR5S/EB.1( ]D^'1@2NXP^,IMOI*:^
MH2EZ@LR2I/8Z1@20D>(@-'#Q+/ZL_F9N.K-A2)R [=3#I<>.WWJ7YIWN3^W7
MCH9.SZGOF5E^6'3C7M6R48J(<7:Q<CC%5)\\PRTJC))>;CG%L6,N*?DSG9FA
M?J.'(ON.HO+,N5MZ\F0T9D#T0, Z39EOS8?U;GZWQF8=%Z1^[ZGLVPCS.D=,
M(?T.R76T%2J[^3'\KS.9#?(XI)VB8B8%UM!+C.U?8+.Z6K= W.92[88^)549
M@WAPLV%V:;'+XBRE90/A#X;YY4'MX*?*K5PQS_L> 7K*SQ $0Y%DNS,7T6*_
MH58;VAL8%B#:]*;0#^'+[C3$)&.K:<S3?>&\7F 5A2H@2820@>4O\PC:V$,B
M(\Z,1P#[IZ>8^M]V&UJDS&U(-VM#GB=M80[0O!@]LK<]>3[M6?5*D*HL8ZWJ
MR-OQUYR>J.J00Z<XQPB4Q8I2\*X=R^LGEO<\P"L)L+-3ZBE. --OR:ACPXTY
MFQ\AF.(@#^[DCR5S[&A'3^/TL:KU%1HO,P%K@->^ZM2LC8@U]<9\K%\8E-TF
M(>G+S\"."-TH:X;DP:SJB)@L?"?;C=ELV*KZW@#)K.N?^AX9=IOXV2AX9';4
M4!V<AYZ7?L=TI+6Q>L-%\T3Z4)#!BG@_C4N"3%U3U-LJN\]>M.[)R6(&E#&-
M!*0GGXA-T[G.X+@;*?<9"84>?T#F[(^PC@%J="U.X\?-.A1,C5Y!<,/_;.LO
M6")JD8G"6]4)-K0:_#PYV5QA3%A5<H/?C:O\@+9/,2=?IFB$(--B\.!/$'GU
M4%G5>5#*(*V"O6K]RE?G,>*M@'R*IP1!'&&\0S8-B,.>Q;)X_"IP+%R8)AOB
M74"3@NW31\,;N=9$C"C9M %)CM2SOJV]9;DNQ7^BQ?YN!\WY**+Y;Q/YH4^[
M?"J<RC0Q^S4\[.><]!\!5\BCPV]=+XK._LT1'9V3)>UA'*P"LB[Z8WU,_Y/*
M=4#DD6_<&(?J(R"]R?#NF?V#D"9CGJ-6WN:>X>FES2/@Z\@CH(_QY)SC^K;F
M$=!N_@A8CW<*%?+K$?_G]\@D%$#&%LL>4 4> >1%<2K#A$S7G@EW][ _5HD'
M@AP4;9%_\$5 CDG:KC;U,B.,*I2&IMJV#V?_V/+D1T"$RE]&8][$=WX:ZFOP
MY\\N[M9VA;5\YQ3Y5P&S?K*J_46D./ _'ZU!BKSC2_H_%RGK+\-]'F3<PL2_
M^V<R4?[SP4I59#C_MP+^TPIX4_45-O_>SA <RJ<XU^O E>)6D)\9Z_X?SKW7
M$ AKVY"?A1Q0.3X",F&U-B+=A,[6E*33MB53O)>$SE+$#("J-ZCI!1E8. 'I
M)XHNAC=;CX ;KL*RGD? -3TL\A8)V?E2(2J&T]V&;<G?*%7KGSWTLOR-@7SD
MS\TPY\ ^SXK2.8^C'E^\:=X1)=E)Q":$$1[,0,6%C6D*%5Q11B/5O(MOP7SH
MV7CX/'F5T$Y(R3A%N':J,I459(FGT^7P4=7D%_4V58!R^7%O 7HW!8=F##ZA
MVXTP3';)J#\*^^?^U2Q8@E(?R2#IW_5 .EY6G<PGKX]W36<9!4$1C=WO)[^=
MS=8RU-WS]"::B<%@VY;86:_GHYLN)JJMA"UT5W8PQT43FW**28$+/91Z'C#J
MHZ[>[9'=,\VU7;CN.Y.(+]I&;HEU9. HE7%=A7#O+W$?]P4@'&D'W-@/W4XW
M,V]N')O."DRG?1GW;"YL?#"5)H8<[$Q_OAMSX(9$EXP]NZ*DPB(Y*BTU5)ZQ
MNZYOCBTX"AA[?[>#FGJEZ-2HV-NPRI)5>3**W)2RPXI.P8KLI[IZ5:94RM+[
M#O5AL25(9X*#3'$6U#:]4":#FF&//%O9JER?\672RIL_%!7*6^YOQ@S>>D&V
M\&-Y7!D]8]EP?A=:XNKC3%#]0H);;E7=(H^^.58EC24]>(DK#8-0-OL8WBB<
M$OB,ECITSK_#X"W2/.?I983=*F$4_U5UD=J)Q7W6\BG#@OKLPZMI,V1>"!\Q
MVSJA>R./-ASW;7B_BCJ6&[GRLX3.<IPN?5K<*)43G%N$WM[V:E!$;4I9(%^#
MX /B;PFJ$*5+FXICRFAPQA6'TJ3];]4] J.]8F*L"C&9BJ(EVG$V4<5?>KON
M82=R;2SK/Q=<C ]? L!'WUR\7OKN]^GX9CU/FU T#J-?XPER$D*?TI1Y!+Q(
M[C \0Z>Z?%!Z8"X7)5B-)/+@D9CY8^7KA.-F<:LQ6=NS0S&PNC=P.\;X<NZ+
MD/(/ 2-$CX G.(\ (@D*Z(_,W0>JR02E2>H3MO@PM 5=M)0TX(BE)DV&X=7>
MNH;L^2*58DTY,SRG+MG9/T)PP6M6_R^<'01'JGOR0,)!CXP&P7G:"A)\\DOE
M]S1U*GJZ=^(-"</Q1P?AL8LU(SUU<\D'X0K&S]Z>OCON/8AQ JY/-B1IK00"
M<XRB>W,2(R4  WP]'>M#(=XL!7LQ5KZ?IY.EERVL,"@5OFG3?7DF 9NW1?U1
MLBNO*"U/U74E'>6R:S^_!B+AS=1XE;=)>YVJ5+9XL2^;AA'/:Q.F-1IIXW8"
M'R*?T7$,)@SHBN0$?R^G=4$SH4]005(VF:W>^F@LB>%=,-%%B'-C%KP03WR;
M61F5%YF<YJ4)-/GCMU[(SW4N97\ >L<[8V-0@YP #!$R*I]+EL^W/J7/+CB7
M7WEN/M! K!7(#GYKTT;6N/71S;^D/$>+C::461,J2J,]1EP&R]9XP07/UI#]
MGTLPE<A84']N+#V)C6AR$MK7V$2^2P<5\,4/+NI&T;*PSHQ&#U2X\\_0I "4
MZM%)\G5[2:VM9F8KI;Q#7!D#%U]F'26&$ND7/I.EIH2(JNJ+M@W;EYV/_\KS
MH!<3Z<9;SK1RZKQ4U4>']@DPCL5()/AR8@B*.$>([2M)C&].-(O?1X)%!1SH
MK]99<#]\$5JM[&.([6^_R$_O%?ZR"RQ@U3R!/YR.<,%D>W%85^\Z(N/\<-#3
M!$>D"CS@BI7R2#1-S5AMN$^FE!\Z,W[N^="W;_400[E/@_Q>+_5;!+AYRP)#
M\O2M> :*@ X73CP+=D%4UJB4LO;)D1S6-]L417)4&'K:2W.+.GNX]G7-3:G=
MY7B4(D%+@YQ=6(* $['"+H_>7@KNF8>M295 C"P\D60A_DZ,7KWU;^F3:7$=
MZ_*T4S7)ND5>^323+YZE=&Z:+A !C%SIO@),TZ8_[<['9FE2Y%RIW?+N!"%:
M+2[TG/-NBL&MYD+[O5Q'23D%'O3Z\MU=GV,>4$D7WSL3Q\PU5X"](&Z1;2]*
M_#X1"3&4V.\V3I<6O.SJK.JCJSI((S$VB^'YVDZPY_2<AF34.NB.7D=5=VG$
MB1TA%=-[2M=3E/7=C3F<B(0Z2J:,?&*^C..*ZAB]I=<J#?]A=#JC]=8^<9-O
MW_:D(KU:KM)U[!C1U^K<0S<6H'.D EWS.AEOB OVX^P]@]\C&BB<\*G4@#@1
M+F [Z$+)F2IXWYX:.OKQ5=.ZD9,TD9OTN\QH;PN3EZE5"]=5>GID_N1N&B>R
MVE]B31S#PQU3;M>@_2;FQW$3?2\@5M'53''7"J(#:('2=N38P!UX!2S)FXHQ
M@"9,C2EXAK];@?M)_.CG#@H?Q[V76HW(VC 0OFH(.T,  HK(KJL#$S+J'O9?
M43$*BH%7D#V2?WS[F52*I0J**0%.7:LT@]LRNGER3CW<;WM=%$Y"N;/OV=<U
M.R9\?I10J4@2DO_2M>5T"QL:$&D@'NBC:%@KW34@)S7/OC2TMM*\3-/AORN]
M6/!L,&@-%3O]^,!261.QI)NL+_T\%YY(6Q6MP392XY[B&'MM^CI\@B'L+)%/
M):](#QRX6N(]:;?VAMM/SKZ7YZNBR!Y[H).'\#G?\]J]WZ6IV-DW<0Z8ADOV
M/CUQK7<F[-W>#7>% 7E=[A$LT_53O\#L+KO%I)8(N0'Z$YQD&B(1>*3Q61&L
M+P)/_"6%$K"VP9GVN .M<KZ_OU/F!3F*7Q=)>_] ^R&+- [![MH6"U-V8NY2
M[8D>IJ:L]TE3K>FVC9?I>JZSVN0-XD&#^6;Y9OEN&.3<7O?PYN.M6Y[Y,.AI
MT]9(XA>C[NMHIMC-+\_14M+C3 BF=M-A=$<Z=](5R7YL*H[1KP!/NMUIN2[0
M7HS4(2/2P3FE618V!0MPH7MXC\F;):Z8K@C_7!]/\[P:Y*=DB+N]O;E%_>E*
MQ H0'TL%MX-1;WUS=/+:.3039,+S^9BNMF0-?3JWI5[U1)<KQ"P*ZZ/6>A!J
MS/O=7L&-6!W/Y2#CV3+>RZ:T]S;F8PS19+QF&RPUNI[E-)9L?3Y+4XWVH;R+
M&N>@DB2?"1H@6LR'_MC"*.(LW$! ]/6&XXCMQ$[0=(JI+WKC9%Y-K.QTYC<0
M^W9]7<3A_.$3UD+4-^^L*Z[K^)WOM$JF?V^"?"<UTW9)M6S3IG^_92[5C@[#
MJFB_%G:>+2,HD0*\MZ 8UKBU.\0#NW,M15^;H,4\X_;$PMI.,6^P24>3=UW+
MF:%K"YCFP#L4N^C)E2BH&\1I>Y&JA#DU:_SWC]3@\Z,NH-W9%>NG(LP.BKSY
M1P#$4J\7/G_7WWM,$+&"(;0J95<7($ R!H?,[/VVANPUVLZ?N!Y5E;7)[3+^
MLKJ'Z'_;__,SJM/5L6P<K8NXO8 MZIH,]-WL-B_<'RYR+9=1L(B]H^A[NO&:
M:>*PO;;.S[YN]\%Q6([(B6+=3H*<?"5\UED*4_%;TZ'3$MMQ7"M]#*N!1%0P
MW;=?]74\U!R12XP+61X=@)3SW/2GYA,G. B<JVL;_L6-^^6J@T> 32I<'.NR
MM#24,!EU:FNYT^O<K>W6CJ? I\TB_A'PZ4%Z>/OA:7H7Q5Y<&DJ$#VF78H+R
M%VBC>J/;>=C3NFL/WV:3H=U1YYDF4L9RUX8^?0\1Y:G5UF25:="R<MH2BX=I
MX%2V8_#&*0JS'I2N\41P=U^'H:N.N[5,-"DAP;5 6\9V0K=;;<!5DVR654FS
MGV2=PB8C,ZBPG V;2NG*&T0*I#R9II0/ \Z#0%A6/XGKW&FA8[3IH\762R^2
M;F WQ/9L^(M++7,Q-AI6;//1RKP*E4P:9, Q[W7*E@!\L?>63J1!WZ W$Q<"
MS4#3M!NR#0'^AR_/(G@C;4JECS^DG-TN3=LH'F=4-DZR.QO;S8!$>/GYTQ2<
M2)Z$KSMN@,@O+TJAH4_Z<$$K(L%\>5/)RM5)QA=1D6S1[E'RXW*]2HF:7_&-
MC-P*UU>[GB.R;7X(6X$VX[-JTP:RJR.$GCP)(8EE\?L62$;"$$YZM//+$D>-
M2KZZK:))7HE]@H)]Z3<NX=(;TNH&D=#23].HY'B>MQH]_Y$0(L'00/X^:6N%
MET7VV--BPH\T0\SV[ \_#YBST-^:T;W.SRQ?G;&8K#9V7'L.77)D@*(9"B1Y
M$:"*^3#]]LCZ!)TX=-[NGO%W&1\BT<9W$[&Z%7+1Q$OQ3%;7?"=JEIT,J7[M
M4'Z=2;U%$TC[NB]_K1CFD?"I23Y31]>M1O^4KMN,1'.6,FZ1J62<.=J+QR"T
M=_).*6]/P,K6SR,[7EYRNUM93DP]K0;+EVO"#*JND8[[C%LH&*'?XN3CPWBA
M!OL;"?)R9KDQ4C]\S56+?1TJJ+!/7AYO]7K:Q[HU>1T37$T[Q6'BL6$E6D'N
M&-L2(HAQ?\AXP7- .4$QFA2:E6L]TUC-+=9Z;@DWC1X,T,?Y1?#-JV#_M4?:
MZ:?*ENK:T.=0"0N%;6KW3-X-N*X6^82F,(PE;E+4Y-5OJ:62[\9.,_!5U<_]
M)/T7194>=9\B,,&B3;7@J<;.J%AJ95E6&>..W)T1$2VY8IV%I<R*;21_*D%)
M,3*QU'<&(U#$8Z@)93;26G+-A]/*!M*J_X,AKN+:8ICC?K&UYMVH3^AVI+-Y
M:"\EP^2G!+%;W@)R;#S+)6Y*?@9BEJM)T)U:WL(8+V/"6]DU'N9F.H5\D;(2
MRE$?_S2QD4:6A(D[LY>CT1=#_71 K"4=&7P%^  #BL\G=-[&H'#0VOBA/8@Z
M/B_P_6M)7C,YKH?C _'[SP:].8@OG[7XO%+%"+Z!2FIF*DQ>Q?7A7Y0P!<K*
MU;ZG$1)#IV R0?K&LTUTDQJ3#6S2#00')[:@JEZH'8A;D1ELG1,$N*\M\H]Z
M_=2WTT<DXUT[0)^+ 7>>VL+'**:;G3OAF=&269[^$SF=0/U?!?0'B70$0?E[
M[OQ+#!.V-&:O](H#)31COT7[RXKJYB;W^(/ZI1,&=/TQ3L)N[ K5-R:L,*9"
M03QNH9U-2+MD"[%A]CKVBY$0[WIY-,KLLR>E/27:BC[V5F150$=T&,T;#Z;]
M)(-1MY:@,3+85@!!^!+#9$"8/H[0U"?0-!ZW_H(;:@N?]^?<5/ZU\[NKB<5N
M9QE:4V$N45.5@^TYH?4%>&:%;;-:GJ%>!]H75ZMY*'V,V*^+\!2J7T4SPJFM
M672#<*A]U> 7-Y:O6JY])=AXNAEJ8?,)C*62FC.BDGD^F?>9-:&#3-V.[7<#
MW+'A?CB>?(:OK)?MIX@4=5V#% /,4A2R$V@M4"D$B]1-#R8-I]M&\/:R$?<0
M'0H?@J'%O:3-Q69W3VM=76V?.#W>2RK^]7 $\>YY3J3Z;(T^AV*R4IT?JD/
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M>ZBRG"M6SY"W0N3@\\+!@RGV0U-%S D^]$@YXD'2WKZ2ULP%E)\<@7)RLUW
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MS"=Y]94HQX@%17IF$TW0/9MR^$,J]5Y6T\"<U]F$P+B?[;S!-Z,4/KZ.'[N
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MNA.3\D%H4'T1"1BB[<&]T@P:ELI,5L(FZR>XTJ''U5/:V%I+D;'VGNV6C!L
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M"Q(Z;!/H UO(LO MSE=YQW'0;83&GS5*.:PO%/UZ1S:#GW[9$+I5E*3N9"-
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MF\DBGSOTS!*#1!@'O>7F46#OM-];!96VE14NJQ\LVZW]B#NI-A&Z%0!@#.!
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MI&X8=L8,.J/G>$4@T[5'9]E4^TU<K%ZS-::P:D>/>?CFE@J7L.CE)X3;-U"
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M\0:+H<M?>X^;I6O5'1U<6<3:0NH]%U=UIIZ'L:E7"SX0HKF"64,<]X;:4I%
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MCBZ< X+1LF++>\QR;98WT;S6"7-:J9:;\(2?4X3\ILKLI(9(P.">=W*M-"!
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M/8XG :[+:O$S*A[%ONRV5SB/,=[^+>WPTMJ*H*S&V-M/<E1A7%$7>.HT!D_
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M]5'_38S=W-E#BJD?/^AY[ZN=S]'83<A4FSF-WS,RO:V]R4];?%Q=W:IHC.1
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MJ65;1ZHD<T)IGC1ZQWUBSS8LO4A(3!;M%2V#!Y>:NP^3#N3IL9Y&>9=.H]V
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M[Z,/KU/\HU)]K/@?A>JX_RQ4-\0J+SN X4<8V>C(V</OQ:%:4+T(4HL; -(
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M/Y'B<J$I-4,2<(4MOLY 2&B5Q)"S!"^$2+CR<8%W<^&OG2NFO6-86>!L+B[
M)2K9!^8@&N8%TD0&K#4%6CGLM%7C,YO(G:TI^C?B$P4U5A$LW4<B;^0!?'>^
M:C^Y"S&%CI/"N**LDQ_83N ][YP7_J;H+$OB,F!?-U+9,>S^W<&A$56<:8)Z
M2ULVGV\.ZEFW&_L#G=X=G5%W,GVEW*$YNYMT&R#^:'$8*PT1<[[!*XJA%VK.
M&=%'2ZC>;)/J"%>DD?%8LJI]FA\R4=HO(;QZ7T< -AI:[S2]C],)X-M_S51X
M14\2X%WI(S9XSKHT_>BN?[6)"BBO4OK!&#FTC]+12<"DPZ+%#QYMC-J :$[U
MR=V<AT FC8U,+T(6V:/,'H?[%S>]Z!JL*_<BJ<.KO_B=#8H)\:'L#VZ?6O^\
M!K17#!U>6("'!&_[(7<-S6E$@%GLT0(J7>P\S&[1PD4R.]=[7 J+7XG,DI9#
M-0GY%:UF+-*D##+Y@PAP:!D?)6R8A+V../)XI><9SKVU9%+VKI-%.:/7O?#/
MU,!:X90U7U4,/SIJTQUQ#%QDE[AY@>SKO\/+-F5";;%M,DLR?%W,=:!- S$U
MDUN2*?MSD3=DG-L_6OC01=0WP)L#7%B)]RFT2@F J3LLOB*IWPZI!%)]#\,P
MMPMF:<?NO'S:<,AG K:&K.7GD2&SN-O'!652BU156E\*<[R0'X&W4?G^ 3J.
MK*PK 2G%Z*2I<LEL&W,D"\94P9>D<E^":Q%B(KC3!P54LJ3,"Q8I>@Q&UIDN
M>08_-ZJEK$V5Z!)'SEI[+X,'-OV\2\;7S.?,=PG8N)C-QG.OY$H5F +_3W2\
M]LU7?@=P_.RN1F49^ESZ2!]A.K<N?M#FBMS^G-02X5:9 =-JACCW$;2T2%&M
MZ?^G;NV/+'SH6G&!=.BAI2=1B#[UM\4>I?KGQKL.%O^5=V(PJL&DSSTDGU-K
M][K V,F58?;LFR9Q04)1*DRKL3ZMS7L<[7*WAC<=W"],..N#[G'T0JGO\&.C
MB/I"9#L:N#L)5B6IIK>NC"##K3(W*RN+11FP7)NA+X0/977B7IAG&48^PG_6
M&#X@"3Q(,2_=J!D&+Q'SGKCW@XM%WZ:.U%9XSI5_; ':9E1LL>-AN=[=M"^Y
M.H)5E?F8YNK1;WQ@%]&SB _NL>J0L-K(7M9&7^3M.8$5[=8%"ASS)IR_-&7H
MT=Y4!0@JJ?N>_\0EJW2U<+K?&/*?0P/X<W5G5T0HCW1AMU@-*$O?N>V3^&>:
M9J00H:^BC33PDV=IJP:_@XOO;(H)"V0SP.R/8J2?4<#BN:WF6:_1,L-5^HT;
M0^:?H$N^0;>^O96AX8=EPPT.3\)::D&&K2K15DD""@,?\[A*B+VFKWP&XZ*;
M;^[;Z8UN#]^.T2IV SI[#\/7N'8AAO&ZN/;[MQ=QB>MH.2O3"+XY,; G0/H9
MP^-O/;51O&7_ H]0P.>YFHC,3P1?7 %AG$<A&,T]T]RB64@_D5[;YBT>7BH.
M+&+V(*:^"<#Q=5*?^=\ZV3]S\[\J&K#LHE[^(S4%0-;V_P5EV)&LFLJ612HG
MDE]\207=?=-I *5S" P-AKN8>%Z1O6VS%Z5:>\4YR/S"3T-B[:[*_I;F-15:
M85X=S _UK<UJ>U6<N^B]B^8)'OIGRZ6Q5.[A]3**/QR%K=ZL=.(-FV V).DT
MURU;\:L%?J-:NWH,"9<BPK\WC8:G+_$YD3<5F7]28:N%BZCWA6CE]7RL8/RH
MEG(:O6JZ=II;&BEVD\)>?II:.JSRJ'SJ34?VPVIAKC>QLV:XSO?/9X6GF@3_
M.0H"'S##3J=?YC_E%M3PR4]:]<7'OU\E3U<O5OTO<*(8TKRZ6C%\:%<- 8J.
MQ4_-&ZN+EHEP%+^JV$5DBS_B(6R1=4D;Y8I,,PGH @\7\Y=>*\ECEM!J:NA8
M@>3U?6H-XGV")>3LW 7GR[FZXA+;74KZ^6?"RM')?"JK<$.6$4<F48'\BE4=
M7F7\.&?A 5YYRL0QO+>N1]+M>D:>J#7W]\J\C]=6R@G8]F.3M-U(]%-LJNTK
MK@9R^2IHS^HX?-M2/!!6%D5?88&7Z<%K@O)?I'W5N;G-)JG1+C3C-JBNM+O;
M\(1D;<,?^YYK]==2.BGG6IIU735_)4FQ?Y8Y /[@)JOTKJ7W2B*$#SX8#!['
M-OVWZ([:GW5O.N36ON%RO_>I%:=O%>@<27B[1><J+98&_LW%&*T-\'?+-*5$
M5'.V#4$,C*,LF1,*DE$@RN9#B+0Q$RWO:;:]DW\N)LNZ;N_;.^T^\JXFS=[>
M)K6_K;[;H ![7FIV\%YPPG##55-HW#!HQ(\%+ZP02O>JU7WVF/6Z:LF8>3$9
MKZLQSK$^%T[TGF'UYVEOHYR[AM^C @DE:U2R4P7F%CEQD9;$EW%DYG*AI6S1
MR8?_+")$X:3ONL[Q5V=82?P 3'[YF@JTP[LO^=)V8.?N<=)\ ]:E@\54S>^#
M?7]L@D2$EM;!FT6>@K/&7DYN"@R)_[M6,S.A73HM_Z+8/V/N1?$66V5CS7.E
M''5:/2C;@ @A5I>SPG%)PA6D9P&4B6FH4K78U%<&J5D ^J)*_SB7#;AJMDE@
M+;F:H$!SUUZ.%>VN.[:9=LHOLOWM$7]N%LB-. Z7@)P19-X?SEQ(EA><#/L!
MB.1PVKR^U0C*[X&Z4?4@=M1&]*#+EKR40'/J*245!]9]:<%'/XM].7_6T*;H
M!J/K=KM!9UF7*$6[R2N!&2$/2Z>SU= 1*O5+<LAU9$_1MXT-F;?:=_W?2;%X
MO<EER1'\HM2+4'H&()E@T, Y5T890TVQDD^)U58X5);D875A%+I$ZX0B(M>T
M0YYQ"Z\9C\Y'.@V\*0JTWM"V]Q0?-DP2NY[,X17_#FO1D)6 GKC!7[@QQ%\&
MTDL(OG__LK<)O9RJUG],M%<$UPW%]D299KAK:MM5CTDW!5?4UA/2(J3N,D21
M:+;!Z[:S@D0L]L#+PG8]^= C3R\?GRX6? VF>Z"[X5!#:C-<\9U7& ;'HHW
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M:K'JUDNZ0_>;;M/ K63 P*M^<YPY$GK+@5WM%O//,DC<[C6,Y8T"E9]ZH=J
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MH7'C@PA-'.21@0-AV3VL\(-?-F)2W]:^_%WN]*46?P!(VA;'Y=1?>!"B#*=
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M%Q8GFV"T0<3,R6HV+I:R<W7M;6#_8\ GF>,J\KS7-;:!<7B)BDC>SF'RNR2
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MSA=GAD-R]/O?7E8^6F,6$AI\.CIY_>8(X<"E'@D6GXZ^W4^F]^>7ET<HC)S
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M?Q_ED'9['][:B>VWZB>VT:L:OA\'/&J^0V_>&E?O9%R5R!&=HQ(]<@(/U09
MR0@F]YCS&X/9&2])I;;E4</GG#&?$7#"]P*OL4^3#?V,-EF DX*9=HU"?31/
M.7=S;U]42QOG^YSJJ;<B 0FC],I+I]HZ 4W[?%7%*4K /M45#):IL(*OJ#YL
MUELDG>:DMQ_R)ZSQ 4U)-[Q G2L[TR%U?L23R+X5=;)&O*$!K7/7Z<FZX,Q>
M3<B[)*5$Y0?WQ=R((8S/(B7]-&XJR 5@GUO.*>RTN\:#QMW";@IJ9=="__#5
M(4'2 A&'L^#S"S 8DW )MI5VPY(D.]V@INO7.RE/623V33/HB./XT \'F  >
M9L$%9F2=)&^2M*(3T'2]>R=-*HK#/CV6.]OW..(+>J4UHQ3(='U[)_TIB,%"
MEUKFCZ)N96=X3AFN='WB7H8Y7 <D<-CFDLLQ.6<.]S>H[U>:6,GBYH"#FDZ2
M1I"H*,5O60Q8N7HQ("*U&6V=;[W!D4IM8.LQTU.@E>I&UCF\#5BGSNT.EV<X
MP'/9WJ$0P/045E>QD%L+HV'+_G3W]KT4R/145.!H2VOMFK5N*HG.$Y1I]']3
M'X[!EMET>2UXRDC(O[J(X4T"Z7LANO4\W(BF)[.^D0PM?9MV9W5?VEG;U'RO
MOJF9X48D0%7L_^D\T? WM'W08%@V&V_\K#'ULP93'!-*49E-HX"06T;7A$OD
M;/,MQ-YE4"3.63=2Z:T:'1S_2AEWR"<T-7288>L"<Y?IIKU'8<-R15E$_DI^
M%>M*"F0Z>.RM.061V*?'I-/OV7:C7[$*1<^;+CKOK3VY(.Q3'-R-QD!B9XFR
M^:3INO+>RA(Q;Y^:;-CJ&:[ O+<B]]GV,;W(+M_MYOU?G.X,ESVJQ6KM #-]
M@GIOE2J)Q;Z)6KB4:MQ.7DN9M@J!5UDPO"+Q*BQ/ LA:R.V(3TW_O]BK__T$
M:>$\Y^DX7.?!%SC]_S+(^I(T>U=*FV3IXE&SA%_MM83=!'<0%I!UO\Q?*=3:
M!5/'$M3PJ5G$AT.R"!U!'H1E;+66TG0'=5#%8L:;0U*X0#[V)01"[Z74NT8-
M6E'!%I>K=*34HXZ;+]" 3V1'>&9!VUP$J"X@12796)E28<_6^2?@.LT9]ZMU
MM^(PVN,C>T_; YVZ_XP)P\*NI&)>=7!86B67Z':[4XBVP"Q,'AI,R+M!:ZB^
M"Y&EM?8]]*\F.AN-@%$78R\Y/02$<]O-WHV\J;QWO,&5Q!AV16AI"5_#*/83
MY<&$P"\D< )WOQ#8BL.6>7 9AC'<_>ZJD,M@+ UQ$MU)K+E=(/89[!U?S&^R
MLQ=RU36?M#0FJ2M,Q+SM0:?R2M?\Y9F>8GAI![4TD.PV]:3BL6\&MGN-2ALW
M76]: [5TXWA?I]HB'KLUFVVGY?:HF TVH2S=/]Y-GR*A#%]VXFQLYYXUHWI8
M,AHOEM.':T$)2@>!I1O$"CK3Y=36F0CL;[TYLO%FR?H'E2?3<\+-LJGKQU[2
MW<!-CL_>.1'^/)]C5_;"I)'I,)U2FY%[\WRF;C'6RKMK-@M3MN3?0YC#99PV
M"U/FF"VZG7"!0Y>1I_2PR%D<\B]%#=9^@5>/D]#U:1@S#+^4L'!6OX0>[I(!
MV 7;S.;W9!&0.7&AZISN;,)=$.H3MRKG&OF_;I.?(0/2*^A0B0^5" ?CZ-IA
MWW$$!;+R5$Y+C:S&R8=M3DHDJ,2"VHJ,O=.?OW@O=OSI@F%</U54)?ODS3;9
M%5A4!1Z,V"OJP!'Q3#";8LQV>D^VZ07PI&%@C@!5, Q&=+[%TKJ[4B/X=)O@
M'#0ANF4?JG=:*[=MVTE\NTUB"H$RD.$T#[Y=0-.[AIZSAP>\*Z5T^^OD?<-E
M52]V_?#KZ<DO(]SL^@,V]]H)_'F;P'=O3EY]_Q&E$ ,ZG=6*I <8D_Z@B;?&
M@=#WGS1"5P5#U@*TAF,PR@N' 2\JO7]BQ GIE>^V4]V(6 4T>N;@*(/_"5U=
MG0])<QE@&0WXCZ[,RS>"4S6>;L$;SA.D^<)I(URIYPOH5?[3H USE9A\@+1
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M]G^RKF1L7B-A4XG5Q@AAYK(#NFHTI_2RHT4:\4V6$=LG5'_"88B_(U<D!;)
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MH+(N5ZO84)/(*C4";VMIN$Z2>(%#[@UOJ/PHUT&(;>,NV33)%9M(VVKH7/A
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MY!'/VQ"+UM?C+I&"1@Y5T_TBPP!KI'4Q%/A&'PY]7C[Y>$4F.#JU9?SP#HG
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M"@X=0I\"!@!T:JE=P@?N$@[^K,4-P:P>*D[J%[X,G:XE]7?T8U:V.^]1T\&
M@5DY^8$MC 0Y:NB]O*CDD+2BIO/[CI(M045%! ,&!LV4#R<=( %%-P-0D!6F
M@A>#W_WY?85:G<OO_0BC?Q4:R37.&<FANW-9B;K7]HA/1^GOJJU1U>ZFK9(,
M1K<;=9/NV=Y_:HJ2^PKOF"]Q].UA7;N+9P?KV-W].MR\PN67B"26N[0C&I\;
M1$KU^IM" X+@T#!I);D%1K//B[$Z7\#VEBYH2^>L],<-U8&N-']G< I&>G_>
MP4'MSDT8B(.#PE5#^=B;;0JV/(@QL5V"WQW\ELN7XOZIV+*R@Q\S_(QS49]M
MH+WA!LP$;G^W8R:;U-V<<6:%@;3)^HYQ1R'VMBG)-T(?@"N4]>N@^CMUP]^]
MW:E3J=7>J>O_&!PE.HUT[[ >>B%:K-=%SIW=X(UZY7)+2^NQY*)9W5Y]135A
M\/YWT4Y5T[K(ZW.JFN'0P/@I*QZBS&$9HR'T!@FCHBT>E%0PP&!237H?D--Z
MW*?*(K(M[Y\PB39X6Z6QN9*8D=SGZ85-Z?XYAHX6!CKL"BK.-B@'ZK,L?)07
MN]N0-"J+R\M3P_)&HO&WI-&HURUC1@0P^E^CE;1<$62(TAVZFS%Y3F.G#2X-
MI;\N-ZK:=;R2#$CWFW230""(#[W?Y59>]+1XQF3YP-ZOC:N1:8K??9465:K5
M%!8=_!@< #J-Y/#PF=7,;JA"=/99$?-+_VQ#36'%\&=?7:U2JNGI_F\@.EJA
MD%1@H2;AVY8!.GE)/YXP!<ZSZ%%APNAW7]VL5*OIY\&/(#I:I9&T.]W0($84
MLJO/<!F3E#\>8;)E0.:]XQ5*2OW?HX$% UDQ/1IZM &=_"U^K)^E9WL8==*M
MP:5IZ'U/ T:UQ_."DA@$<%PTU,X<?2;4<@7$TC+/MU%VBS<%,4%H2.8;.2HE
MQX#ITX#"B4(Q+3P$+1+$ 5'Q_VXC4F&2O5J!(5'ZQH9&U3$\1F2@$*+630N2
MECP\3NY)E)<I<V96H,BDWI<A&F6E)<F(#A16-,KIERHM?7BTW#WA+#LMUILH
MMSL6%;%OQ.@5'F-&I@2%&JUZ6MQP#E2SP((.+X=^1D,G1X-[]"$!)*EMPE!+
M#!9&8PT=D21JV3.^@&BZP20M$AI^$QN.)$K?"-*H.L;.B P4:M2Z:?$BR!&G
MAP&4CWGB!).6+@Q(1FJJ(5(3 03(4#,;/"AU:'"<IV4<94*?<_HWU0MN!EK?
M(-&J.P:*1 @*+#KMM( 1# UN.$MPT/PGCH@;9'J480 CJ:J&2TL&$"QCW6Q0
M8?3!@'*Z)62@N7[VT9-Z.\RU*-N>ZVKH0(#%HIQTVBO(!V ).!M]Y&]9GJ<9
MOMHJ$D'4)+[PH5.NP<7X=Q!XT"@UQH$@0XP."<)@O=^<*N05*[BM-6E,YA<%
M:B6'2!C2 $*#4C$-(CI:7O\\&"I.J9<B47:1)_CEW_&KUC:)SB\N-&H.@3$B
M H0,M68::-3$B%,C2AX,'#<D7;/R@6ELF39D0K_PT"DZQ,>8"A! -*II$%)3
MH[N+T]"SRGWT<I%0P*:K-.8'UA:D:.G] L:B]A W&F) \#%KJ$$1*U$]Y H-
M)E8[FVR*7KK$:;&ESO#UM$CT$8N%RR^PG$P8PLO( @AD+GIJH#9@78B<%E00
M5 M 3$(PU"V3A#966?_C,LWQ6VT;*&G](LR@[A!7"D) :-)KI\%03;EH_@4Q
M'G2=0P+.NPGFO@L/G'>NP'D'&CCOY@#G_DL!"#CO)YC[/CQPWKL"YSUHX+R?
M!1S:^<%]SBG]UVMR7WQ1)7QK*8/ 1E95"9J.#!YD)-UL@&$,++YA+*&APH.M
M:W)#BN<TC_5AM(X\"&@T2BN1,Z*%!Q^U@C8,M4%RPQ<:2'6P;ATL#5D8;S-4
M4NUJ! T\H P5LSH901T:%C=%6479_Y=NC(MT-7$0B"@55@)E0 D/+BKU;* 1
M/(@RA5ITU[!E!R#*ZVJCW_U=.5:HU5TY[OT( @@JC>0KQV)W11"%Z&J&58(C
MC6<8_NRMHQ5*M?W<^PU&-\L*2;W,QS>E"36@^8MS-T]%KD\ND$E\];9.N:;'
MQ[^#Z'6-4O+;[#QGC=$%W+E_J7!>JEUY[S=O,_U8G79B;WX T<-C;:1IN_D]
M0(_^0M**?IW5,]OF]<F0*@=10^>KIXUJ-KVN) *! )-F8S34M&A('  :=T66
MQFG%RGG3Q2E)(Y5E*B)?H- KV"!"I@ !!ZU:4OF@EA UE & <$,P R.FG<$O
M'.(\P827;E?89B+V!0R[P@U ])0@@&)53_%PRDG<XT""113:#P^=B[+<8C()
M0 J60##2*J\!DT0/$5(Z):W $HRA\76'XRU[=/WMNX?[M,I4"T^9Q-O\I%&N
MG9U&OX/ AT:I,1[X;^RIQK?OOGWX#C5< 2!P5=R3**%3Y-WK^J'(-)6PE%2^
M@&!0L<&"@@0$'/1ZR0_WH9H4"=I0E;(&"BM,&OWN"P1*M9KN'_P(HN-5&DE.
M8-#? =W_QY?XB2J&-9<=U&2^IP&5DN.IH$\# @8&Q>1:IX(4-;2A+CMT4]BC
M/2AX#!84/%J"@D>(0<&C:U#P&#0H:#XMRI10'W7]D*6/D:9HHI':-S ,*H\Q
MHB %!1>]?EK?T;*@CB=$M4U>=NTB7Q5DS74XI_^BL%1#YZW>IDG-MN"FB@@$
M3DR:224W12&\'C%BU"&PL4W2"B="H?,TC_(XC;*V=*-J]]S.X@TQCLJWX+'0
MP\"1FY(2I 1;4V.Q9>S*<(;8=A=)'+_@+/OWO/B2W^&H+'*<B/T6U>F2F=YO
MUHU%[6'BC888!*1<--2DWS"FD]\8%VK8ZMVR8&CZN<BV>141?H>=J#R4ALXO
M>C1J#E$S(@*$%K5F&I2TQ$A0A[L4+JI7M($7<W[*,C1F<L]7Q(U*CVZ**VD!
MX<:HH.[>>%USI(N7!5? ZYP59F]=I,_X+*JB6C^MS3IRWQ<X34J/;VZJ: '!
MR*B@]JYFR\/*U40-KH*6K2&G-/QZ+ S9YR,J_\5K)!7E^C4M"2"(J/0R5+$A
MJ*$-AH>[=91E'[9EFN-2/RF-J/SB0:GB$ \#$D!X4.FEP0,G10UM,#Q\7&/R
M2*>[GTCQI7JJ:\AJ[=-0^\6'4>4A3I2D@/!BTD^#FX8%"9ZF[&\X +UT!=!%
M!4B]M0I2S]#1*CO"C40'"30ZY23$9#AF^S%7187N"_2YQ*AZPHBGQR;T[[W*
M]4).R%=2XIA=N!#1>IY$1 4C$['W%U.T"DOOIDB4(,!D54__ADK+@1J6 ,BY
MIE@F_34>5^2BPFOM30H[BR\4N2K?8,E&#P)1CDJ.<<79A@MOSH@89^BJ2OV"
M_/JP;T#D.5I6*#@*EGL4('"B54L7*O??-PA7SV_[D*7Q>59$^EV8 8WG*GZR
M>J,"?AT!(!3(6NG*]G%"Q"F#8>!#E/]&MILJ?KTA18PQR]8J6\]EVZ-SY/:+
MFTDF#1'EQ H(:U/TU:"P$X%Z,A:]V2OTAA]+1F<5YHKXM[NGB#;B];8JV8Q*
ME=/OF!N9/!]%.!@P.I P< ""GX.:NL,)SHDXZP()9M3C#KAN*[OJA#CY\'J+
M5YBP.PWW^*7Z0#_VFV'EX<#K>U7G;,YXD6=E! '$J=KJEH EZ@M 'UB>62TB
M !8OXA7AN2<%6585IJ."YSZI+RZ8B'VAS:YP R\])0@\6=4; ^CB]/P6U1RH
MQQ+L%7"ARGE*UA>J':?1[UZSRL9J#5+(FA]!P$"ED3(YC'8Z(T(79^'Z6G.G
M8?"KYWY6W6#H_02ICPWW%9H>#G1+H?X\J^NA24N7*#QW\UBU45<W/T/J[I%.
MNBYOR/;:[:NH?.#:;LN3QRC:\+[_ 6=5V?R%0^#DS=N3]V\Y#.H__]KFFUZO
MVB34FT(<=2P?V,LA\7B5/HW5!W#F&,,0-84O.-1F*"M==6A8V469+N>XX49_
M;OC_"P@ZEV6)J]*"PS&13\2I%>QC:T@!!D5*M22?Q8E 8:'>,W*"A$3K'QD:
M=66 C B!X42MG>XQNHCS_!$(;DZC\FF9)^P?'_^R39^CC*W*E]5I1,AKFC_^
M'&7;<90[D=<GKB:9T\>9$R,8W$W15L(A94)1GJ"8_0ONV($@\I8NY4G*\DW4
M5FJ:Q,[F$X>N1O0A:.,!@SY'1<? Z]@X](# ;?D<I52'#)\7Y([J7U]X37%Y
MAA^J[K_49W*SI7B=;.>9.)B&IXD  ]5Y>H^1^RDBO^&*B4%I_DQAS%<)9<L-
M!,K\S@#5[A;'F(Y%JJX9M 9ZG_"TJMT'HI88#.1L&DK+B#@F6^H3TYJ/_DM<
M['GC:SZF;@C>1&GR\66#\Q)37\^3K 9QKZ8=G#A]XFR"*7W$.;"!P9Z[KHHR
M<HR3!X8%SZ.+!^L5('!T 5Y B%G!% XV55%%V:7K6E971X8) 8H,QYG^BO;B
M7D*YOB"(T9QLZ)R KI/B%:W/F#P4)3;B=:X%1QK=G18YWU[Z):V>3K=E16,$
MX=FOZ/_90.W*['6O9I)!@\T:)TXPL_(D=>7G0P2S\+9 L'A#B@TFU>L-5;6B
M809;_&_8L*$6:4,3$XO?.-"N_#  U-.#P9B#DG+()UAXS(<;^@7*,3\!B^)X
MN]YF/"\KP1N"XU1DV-#?_M?;Q=O?_6[QY@]_X,S\/]\O?O_C'Q"U:X/YM?5L
MOQGV\\':BX&M?E)#ZQ.>1G7[N%02@@&D23OUQ1U8X217QA@JAUA:Z-<4$!<3
MQE4$J.Z^3*.'-./A'G6>/#_ZJ<@23$KF2*M7RXFJ.[M/R$PUJ@\J5UXP_F:B
MPM(K3AT[G]+Z O[^[_[IW=L__ D)0? 0ZW;J;V((A$J'\W\]-43D3<L$R#I&
M*.D ]8WL\B9ZM9\?Z(B]3HM&A0?3I)(2#(J,ZBG.##@QV@AJ..AA1QGR@-#;
MK*/WC"&SVB,8J8DA(<FHH>X "HM3 R@A&=O%,\-G0.$3, K5^A#I_0P&%+).
MTI4L2H%.VLU]?@T53"+V)<6QJ#E^BTM,GBTSDY[<;Z1C5GH8YZAIP0#(HJ <
M3S?DB"[SJDPD5C<1SRM@H#G.7:$G+;?9*O T9=TG<)ZDAB>/O<@9"FZ*_/$>
MDS7SHM9=1AVQ5_P8%1Y@2$D)QS&9U--,<GF1G\#T/[]$A$0LES=/;M/'I\I0
M=<&-Q2>F7)3O(\M$#P9?#DI*+P4+EFZZ P(N:0ZW>RH31]!8RN*S].1@@&77
M<7I0!=>Q]69Z>RP0+)2RQ%!@@R=CU 0O6F)U:%*>9\/<*DMQH,X4Y[$>'$8.
MOUDK5M6'J2I:<C".R*ZCG)32<HBK1'T>]&U>5/0?_[A _\1_??OV.R"XFWRP
M!^4H;]KAW1$<UTT^H%,=R&'.".7LY(:PTD4$B\-'T\5)):7G5'B=JJ/4]S$9
M& #I=5.DM@M*5(JZ9YN(H&?&@/[7F^_?O'GS%FTP026KAK9 ;]\LZ)_8_Q=_
MH0YN6ST5)/TK3OZ$_HI)@5+V9E2=*G^@VFF[3:UU<3CCW5V)S/<DJE)R/'/V
M:< @3Z.8:HYD@;H3YHR@^Z=_6KS[\?>+][]_PS'W!TKXN[>+'W__ASX2.=&;
MQ>__L2-Z__O%NW_\ T",+I.$E]2(LILH32[RTVB3TD!5=YZEH_9Z1FA6>7!"
MJ"8%@U^S?M+I8$N-V 6ADS1'L6   J9[@J-R2UZM+D]%Z!-">D7[Z)&I_ #G
M1P&<'#^RC%_3LE.KH?P*O2 4/A!%%5TGE-6"+@S^\+9Q=$! M.R2G7DR*JL1
M3O 3SLOT&5_P"YF715E>X>IZ=1^]Z$_>ITGQG.4PQ\11[L,4$7 \WBR]%7D2
M;4)\?46R+P=EQ9Z?7]JEAD85I3E./D8D9W6E>ZJ?X54:I[KUK@NCWSH:KH8,
M*VG8N,! TUE5$QH300D$?/+2WGD/(/2FBMMF"JQ=8*U^ZLW@4KN/ @0^MD1N
M^V:XA@U2ZKWEG$') PMVCMI:3R3X:A4\* =NN;L+1_\]P[RT9)XLU^R\[:_\
M[]K;>/8 94?Q@2+*O32*)M3<23:8B7[/!IG"@;[\!6J_P$=:_QL+U'R%_AO[
MSH*3M)]"W]+%?E)D641**"<XPVW?FXA<$UZW->$+T1M,^*,63GO&>N9P6_$V
M@_2[\SI., -@DKKN>_@@<2E>5EFV>[A.32(SA<.AS@ ]_L8<0'&G4=.*-VE;
M'C#N+OBIP(3F:!A"XVVHN UK@AHTS@8JNF),'.H QI<])=7*%1IIEL14"PMH
MS-G34W7 @W=0V#MJG1CJ.7$&.O*>$N0YL(%!H[NNCF?E\%#H&-@9.0*ASB6D
M,Y!#1)EC,#=$%]1(3K++&,9IJ8.B2Q_ :4CAHLH8NBD1!2INF_!ZJQM+4%Q9
MPC70[[9.4-()9O"BM$%"B+#-)76DH0R6@S-459N$(\C X$BOFSG_9@$KXT:D
M7;1O;EGR\+74?@O5&U4>EJE7DH(!D5D_Z;%53HVZ!]+ /85VBY]QOM7ZG>YG
MO\DK0Z6&*2KB-S"(&"DD/]XB?@;2W]<;3")VY:@N=6][!<] [[6VITWM07U/
M'3$8S-@TE.I\-O1MK2$H=W?8#5S:B.PQHS.*]*S@!Z"U6=H18^3Q_-R47?W1
M6U-Z!C#X<M%2\<H4Y^%'V4G'!01H/^&<CH&,G?8GZS1/V7AAU9+-4+-R^02;
MHPE]N%E8P #.3<\QY&HNCKAHP <$=)*?=O7G@6='IUD15EJ<3CUU'EPA38C0
M$--EQ]L,[E,&08VLJA(W'1E0Y$@*ZL,H\508^I9=/8"2H755Y,70E.8Y*G.(
M[L#G$U;.9O1!9F4",].Y:JHNU=_@KO9:4*!WT3[?(TQJGN+3;H+HR/WN*IF5
M'FXKJ6G!P,JBH+RQ5+]YR$*GWN-+H)Y ;)0TA^@258@G- TA^(@$VJ52M7I:
MO-2.!PA"?HK2O&03-BZO\X\OS*=NT_*)0?EZQ4H.ZI8;=CZO"SM7,P9+.QL3
M&-_DJJFTO*-\J,@IYOHL[!FDA#(!@>#GG. H8^D,3%UFY75^ADGZS->ANN#=
MRN43?HXF],%G80$#/3<]Q\#KN- CPZ (\QD4OX O,'G7UB<T3YM&CC %)K6J
MJPM,2N30IE:[JDYU)H% C"] M*L7W=K:PN3]?3>K =)#;UH.8+L8+KIJ-L/X
MTK*.[/@SA$ @UVW(G-.>%/41M]2T>A^FR,L/>%60NI+$??2"2QI>D*@@29I'
MY/6BPFO^"!Y[RK/(,MXJEI7I ;_H/V7BH$TGIUT<Y'.PAMGA#97F!/HM],"%
M-ML_5?0";"'6FEO[FP\XQRMML1,MM?\1HE591K=$"BW>,*NIR2V"AZ4K7%D/
M/T8T7O>G5>H-]J+[!+"\ETJU,2XH#:2*2DU]GN8BRX>H3&.->1I:G^@PJMM'
MB9(0S+K9I-T8,/PW#IFNM":*JHJD#]N*/9*'JH)5[&HSJH$@ZQ?,7I7 R?*9
M3MV/^&J[?L#D>B7EB)L0-U&&US=!YI@W>"1DB@ PR)VCM?2,2"T#14)(BU[I
M(L "");'X_4LS;:5]@Z3ECJDIQRI;/*5-2D8S)GUDYY"$K]^/1ZS-LCUNM-D
M*0"\ILU$![^I$P$&Q?/TWL%WHD2(!H)N17'2IC"I)8/&B=/S/3Y74T;7^6QL
M8-#JKJOB<M^H>*PQ&1[.4O(=F,97ZP5\):FK0-R=]OUKD3''U!T5WN%X2T2I
M19*6]*<S^I_Y(YWGTR*QU*0^W.>\'YH<L-&DXY8#? O,L#FP@89C[)P.Q=%1
M=O0<I1D+-D]6!3DI(QIUENW'@ Q9@Y.?/BV F8(G3KVPMA#MBMKG6R#H:J_5
MWK-AH+%W3.2W3K9*P6&-[#X%&$>G5$M^6*R]U<S)H%QI;O6Z3'/,S^ML5O8(
M@\!#4E0)D98*'DS&JAF@PD@1IS7BY:#-/K-ZO=_X?<-#!-IRI#+Y<X.>TD8_
M?DQSMM&%'B+Z0XP7H*J%N>X_!=YA<MI#"KM+Y H=QRVA#PU:['50_F<E8P[T
M_;J09TP>BA);T\X.::EE4<,WT>EJ9AV1W[#8.^]=9]G?@B;;Q#EW/&_?U6Z'
M_6506XK:>?]$BNWCD_"CUZL5)K(;FL#GPRU--H/AW)DI>*@Q55-3)3!44F94
M">[ZF0Q4U/P! ::L_#69&Q38Y IA$UF/!WC&2F+.\-M7D3$-#+D)HC)CWUOS
M$K._B#L1Y<<73.)4+G(P1X W,,XRK,7C)&X8D)RCLA&5]5.XJX*TMV-PP^\7
MC6(D[0)'K830>+289@.DAATT(LTZSX8DL&J,R^2_MR)8+>\+S0/!O"4>HA(G
M+-"F439/-+]E,T"95O@.D^<TQJ+5;G%</.9<BNE)WL-_UN\;T7X:<?C8]&&_
M&7QL>C94WO*C(_F$R^3/O39"#S2E.%G97LF[7M5^J7F,[_4ZK_]BG'8.\15O
M4]/AFJB=OO;_B>##Z+!V2:.F%<*NR4NWE?M7F/<6I.WMV$4?F-[BLB)I7-7O
MK2RI#<E/1'\]9*8L[V_@SC57.FB8*BCXL-B']F/P_TSIV>D$13YI6>N0<$MG
M'.!(%P'OGJ!N%08 ZXX&.X#=(@DZVMW4GPQW8$L=TU"_PE_X+W,<>H\7 *C5
MYK@Z[)81.F25VKKO7B[O/^UMY]R'5YZ)3XD9 $ U!CE[V:.!J%K=>1@](E?*
M?[O>\%H$S7)!=Q%LAAP "+:;Z>INE4*@X]JJN5RVEE<4.I(%GQBV>T"Q41
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M( 5D@>"T5RV?K5/JDCC5:V^E;"L@[R[ [VG.5,.&ISRNW&!P.UEE^52H%;!
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MF)1"QZNBPNX!S@1^KTDZ4\T:Y.FX,H.!X%2-I6R='O_?_]T_O7O[AS_5^0Y
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M"-"PMNL-:"M1GM?DO2?5JMV-S^-=?'<S>K?O[4S!D3954[<-0K#>T7JIRC8
M#0*"^L1)M\7<N8/C<[;*T@VB]B)J>WL(*DC53IYOV^PV3]0B $[> ^-FS-R<
M'RY8[4HK-^E0MRN-*KS>%.05)>F*"L>TX<$Z6=.=:1UQ4$QJ[TBK*6$E91MU
M5&9DBUO0K$(39^3S=L19X2&J.7])\2YSMYN40!B<8J(&G"XBH)Q,[Z;^\4WK
M[8E-STI+DZA9@MXE4BAOO$C4HP\!O'M7KVE0V-EW9ATK,.Q-0AT$O+DC[8@P
MYH0NMF5_/*@2D4;/*E.!;PM7T-!/;8(Q!ARR  \&E<KJ+DIVD> /2BA"26N9
M?X$(W VAF5> P-SQF17O3;S+PROTP+W&(QDVP1>&=X"N7@^^J]/[-VEN!;7:
M_9P3'!>/>?I7;HSE2%M+[1-%%I7[0-*0>L72AK]<<5=%I#(ARJSJ&%0?HHPY
MH05ZP(]IGK-$BV*%7G%D?) 9=J?XK3<@NN5C;IPV;*IJNP7GB4N'>!SH^IP>
M4W%>*Y?/@>]H0A]K%A8PF_9N>DK[]&V6%6-# SY@=7?U!EY:"N\Z<<* H62*
M&Q0OP=7>===U&B0OW6KO'K#S]E 7YSV8;K)I*#^3R:]H4P94<Z!O:Y[O@/@)
MEQLS\^KC[$6R3S^SQZ;HPWH/8L$,@/W9(J5<M@\@]P8-HT=#Z0L45:C^ &J_
M,&9:H/H)VT!>[X ;/7ZC]DF)#P9MM9N0K,<$]P*U_&@);-='MFQL?%/$1GD=
M=;X8G_YOKI%]!$^5 0;,,Q4?XUH!X062P<Y>@J^?R_RV>73SNP5:[N7=3$UV
MKAQCGK<QYCJM1!G/Z_QSB?57JJ?+\):U.]>\-H-WJH#@T-U%:Y=E!&K7$3U1
MZ#I'5%@HJ-X07'S),2F?THT8D'/ JI<" *XV$QT JQ,!';(6O:>!E@H[::6A
MND2</]A2FQYI.$NUN)X%6"M_&*@ZFJ4&J849(#S=-+8 LQ82 )'*5.0ID)PH
MP!LF9QG6@G(2-PQ4SE%9RFFCX:<0,M@G/"0N#[Z;/7E#%<K>];0MZ^ @=%9Q
MR@8U$'0IQY9Q(6_D\(DO!]7[ #.0@T&874='OQ9L/?WQ99.*9S'.H@J_G18#
M2\P EB0:@QQ6(B/.X"";I>ZT=4<G W$AD)W<&2YCDFX,KYC9V8*[.X415I_7
MXPF.R8F*.GN_'JOG8Q!QSSPMXZPHMP1?LNW-<OE05B2*%5?G-82>CSILM06M
M:DIUJ.I7GM'U"IUO*\J(ZM?MT2W.V?62F^B5W6'B*T34\RI</A"_P?)Q,>Y<
M)M.MK9/8&'"VQ5?XI;K_@K-G_*G(JR==8#Y?G$\_LZO1??\S5Q84\._)CO'H
MH'![=V00_T\<D?LOQ8[MTTJ!".B1B7-P7(L ,ZW.TUL!U_='!M<=VP,F0'=!
M)JPK#1.U5E]07=<!1<;/DC<U%Q"@#FVK,^"L^TH#VC![=0IUU=MT/4(P_LZD
MG6$ERV/.!8],FV1%,# 2KZPE^(7=P[THRRTF):L54+V:<^FM?'[AY6C&$&H6
M)D"P<]-4AB#?*JD9454@P?H/)1+,P!+KU8_/+%E)^$?,O.^'UXZD=N-+MB 7
MAI;7VZJLHCRA@^YJNW[05GDZP'>\/JI\J&8:O+:\[X] O*AV*".E>Y/\1W:+
MJF3BZ%Q0WZYB&;>#:V_5$PTUN/+HVS2OR:$DM.^QN7[!Z>-3A9,E71U'CW0J
MQ21.2WQ#4NV5<V]?/]*Q[-*D!QKAID]_Y>/>P73ID9.:!46"!^&:"6T8E[-S
M2(HLBTC)_B0<Q=?B)WYB;\"4%_D-M]54!>\@7SJF\6]HJGV.=<5GP$3'A[/-
M/HW7(M CDX&/<LXN)S7/(>;M?6H :NSNOVDGC>G]??YXQOK>;9X\>:M<PK29
M^I"09>_W\$V Y&Q+:%@AVH$W6<E_K-5OFB)1(F^R%%_GS>Y5E':PP7U::+#Q
M54X,3<,$G1LF*G%4T\.L!M[K##%)@Z]GDIAC]NQY8N@COMHUW7E!5CAEF3IM
MJQXHGE=^"=3 G]]4^US3*3YS/$-XMFWND_=*R/@Z)V]% X68OB>K 6H<'ZB1
M]SJ%3]3A>#S 80R?/8T/O<57.XUW&?B'GL:57P(U_.<WU3ZG<<5GP*VU#V:B
M^VP>LQ.5+/LZ9W-% X59C$]4 ]1P/E C[WE!/DF'KV<VGV?X[-E\Z"W@;-\>
M9^8/P&K(AS-R4NY/75MY>M;/<8 ,:DK*UPU()]-W24I1H_8K7O/PEF"9L@=-
M*U5\!U2 -+>9]KO:&7WDZQO).A,G'SLR"<>XVG%OGP!9I,Y?/]*AZWO*=OST
M5SW,/1POMKX ["R]C./M>INQO23^9C-K58*?:,.V-;%921#3K:1I(GP.T#G&
M]4?9%'XPB_X92H]AWA.!Q$O> R%-;?)OF9SO@-UF<C3_TO)FR'0Q ($M&3D#
MW)?@GA:9J?B.(+\,_O#(D6Y#P7GLY'"VZ1<)11T0%!WOHEX9 '&8W.0'>ZL\
M3-X"N<7K*&6W:$Z+G!<6VD;9/2;K=Z;^\:V)]P5#F*:6QKA?-6#Y@""VJZ^)
MCSR#M, @C504=V)1EJ[HS,3JN_S/?O7A-FV_RIG+R>)Y6!TNAF&O>_?8HA=T
M7*8T9HS94RD>KE&/OW=,6U[69CO0.!]^[&L<UTH+G<;Q\O&1\&PBE#8R^'/E
MQFHY@#$6Z$0$6(QS$-OLZYS>QB<D3[]#Q*??,=9%?./ZV$$U.:;US0Y-O<_U
MS0PU8(W](+;KYIJ>1_A;6M\<P>'>5SECS4K#<</J<'WS]4UOPQ#2PRPF??!(
M)RM-PQUH3AI]#=8@/J2)3J-VUFKF&#8>KHI<&"R*2%[D946V/(G[X 48)WWZ
M*+8C9C3F7F;H"=^%-:[]&*M?7U)YO(;,<+##.TB;TTYR\[#CZ/NG*)]]Z+#W
MRFV'T?$H?,4ANV<O3N40"AZ_]SE@JUC3 O6KV@,]W;9_'STAR3>(!MX>D0O3
MM.U;4GX_'WS8A[-Y<JYO>Z8)*?Z8L_ZR>LIV335<E_4<Z+Z7A'M1Z2AV$_;8
M^'O9;]B#/L&="*!&D+).H6]/;!_*-$DC\GI-1"M\PM53D5SDS[BL,+Z+,GR]
MXI4::>-)Q V9Z;[ ?C_A=9 ?H'$&@W:/\N$,POT;);U+V7*A@C2/K(BOH(9_
M@=B'V%8"_Q1Z>$5*MH8>V+6&3M=>>UU:+C'8F,*,'9,!ZM&@X@"(;X.:>L2.
M<0GEHL&<:?,\2@F?!Y=EN5VW)41P3,/H_9_66[_F.8&SPL3\WJ@'2\<X:ZC$
MB7J:HU=VIGYL1^HF^\_2YS3!>7)+8ZJ][JJY?A3.H\[^31[#K2%"KRG.DJ\)
M9C\7&17#'K+T"K3A9T$Z-$\FCZ'6D86$F3F')T2:C:M_,"?$B%C$FN=RP.;]
MI3[P6U*7PS;B2LN&AXD^2.4AZW-83AJ/.Z97#^@,QY@?C[Y_NT!TV?#F0&<+
MR^2_MV7%QN[UJM'YO"!WN*HR+/[<OO)[G=<4S0ZK:GMW1X'>=O[W8GB[D;^3
MM."KG;V9('F:EIFM@3+.3I?A1=X<^;?[[H$<43=7*:Q7>2(C [S9P$W=<;>=
M/K$YGJTH5I1?;&&R#HR+]9KV7<GGCR9IXVN80OR&7DZU<)STG3"!O#VV@/T8
MLKA AAY>+9<.5IM4KNO^+;0/S9.;GD'X-WC&#PJ2(1M >^1?<Z&&#=W4Y;TF
M(_88\@_U@YJ_VX?W_M: PP>/(C/0N>$./.O47PN^2/!FHFY*62#QMF"H+#MM
M/75U0D%%@^CZXBRW;\8K H#T@I.1Y[$;W.=P#TH%=P#06F+R!+\?]P%W0I<>
MF#V\Y^Y]\L@G=?/KO ?\WE?SLI"[K?H9OJ6$EDIO2QIL%?>66K\GC>!,[%Z:
M?O=E^5[4.9+)W$<;3)[&]^8C(,_D[=-,/KUT[Z-'/YM+#7CP^;S]8O#![=5,
MTV1.:8]Q*N=J YK('?3Y&J9QYV;W,8E;E0D^RJ&TP(P)'*1?T#N]T^;I0C_'
M&_WOP1_7$YKM@&=BW<>.?%RZ6ZB?>%M*:$/,YG1:Q<%,OHX:P1^F>VWZPT_
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M_4G$O\D R3_%*PTVW^5%,?B7%4#L_^F2_AO]<_,G^C_L&_0O_S]02P,$%
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M-!4?2I'6/\ CK?.Q!UXP*([^G\XRC/XTR#]"HTQ"NP*/H.ZXU6OR*3[+URD
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M2X)>#Z*#[$<ZN N/MLPB@G5!,U9.F'+:;EH\WT]B-K%7#98#'MR%R(ZL(R<
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MQWXMKP<$M8PA M[F^'FQVOSX5X]Q>7N]&LF[:[UA!.U/8Z_<Q4B"4EIP[I$
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M:&%R=%\Q+FIP9U!+ 0(4 Q0    ( !Q :53AP+0 LP$  *4$   *
M      "  >%Y  !E>#(Q+3$N:'1M4$L! A0#%     @ '$!I5#+^>R=D P
M0PH   H              ( !O'L  &5X,C,M,2YH=&U02P$"% ,4    "  <
M0&E4S)RJYDH'   !*P  "@              @ %(?P  97@S,2TQ+FAT;5!+
M 0(4 Q0    ( !Q :51ZMC&5.P<  #XJ   *              "  ;J&  !E
M>#,Q+3(N:'1M4$L! A0#%     @ '$!I5&FA"LL7!   A@T   H
M     ( !'8X  &5X,S(M,2YH=&U02P$"% ,4    "  <0&E4!W9EL@ $  "N
M#0  "@              @ %<D@  97@S,BTR+FAT;5!+ 0(4 Q0    ( !Q
M:53P_RSY2Q   -17   )              "  826  !E>#0M-BYH=&U02P$"
M% ,4    "  <0&E4]D XY-MN P"<LB( #               @ 'VI@  9F]R
M;3$P+6LN:'1M4$L! A0#%     @ '$!I5&3HI3UZL@$ #_L! !
M     ( !^Q4$ &9O<FTQ,"UK7S P-"YJ<&=02P$"% ,4    "  <0&E4SE>2
M;)TY  "M/P  $               @ &CR 4 9F]R;3$P+6M?,# U+FIP9U!+
M 0(4 Q0    ( !Q :5073SI((RX  *LU   0              "  6X"!@!F
M;W)M,3 M:U\P,#8N:G!G4$L! A0#%     @ '$!I5 IB6D,N+0  <S<  !
M             ( !OS & &9O<FTQ,"UK7S P-RYJ<&=02P$"% ,4    "  <
M0&E43)+SH/W/ 0!9.@( $               @ $;7@8 9F]R;3$P+6M?,# X
M+FIP9U!+ 0(4 Q0    ( !Q :50ORX[)<'<  )2(   0              "
M 48N" !F;W)M,3 M:U\P,#DN:G!G4$L! A0#%     @ '$!I5#J@CH)[:0
M^W$  !               ( !Y*4( &9O<FTQ,"UK7S Q,"YJ<&=02P$"% ,4
M    "  <0&E4[TW761\6 0#N4@$ $               @ &-#PD 9F]R;3$P
M+6M?,#$Q+FIP9U!+ 0(4 Q0    ( !Q :51D+Z&+L)L  +>Y   0
M      "  =HE"@!F;W)M,3 M:U\P,3(N:G!G4$L! A0#%     @ '$!I5%#]
M"NQJ$@  [+L  !$              ( !N,$* &QP8VXM,C R,3$R,S$N>'-D
M4$L! A0#%     @ '$!I5)*3GR81%@  !0T! !4              ( !4=0*
M &QP8VXM,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( !Q :506_O=V#C$
M  PO P 5              "  97J"@!L<&-N+3(P,C$Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    "  <0&E4+C'W=MUR   #B08 %0              @ '6&PL
M;'!C;BTR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ '$!I5->3DS+>30
MLB(% !4              ( !YHX+ &QP8VXM,C R,3$R,S%?<')E+GAM;%!+
4!08     %P 7 ',%  #WW L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
